Document 914927

WHO REPORT
2011
GLOBAL
TUBERCULOSIS
CONTROL
1109_0319_P_001_248 i
23/09/11 07:19
WHO Library Cataloguing-in-Publication Data
Global tuberculosis control: WHO report 2011.
1.Tuberculosis – epidemiology. 2.Tuberculosis, Pulmonary – prevention and control. 3.Tuberculosis – economics.
4.Directly observed therapy. 5.Treatment outcome. 6.National health programs – organization and administration.
7.Statistics. I.World Health Organization.
ISBN 978 92 4 156438 0
(NLM classification: WF 300)
© World Health Organization 2011
All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press,
World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]).
Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO
Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html).
The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the
part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the
delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.
The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health
Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are
distinguished by initial capital letters.
All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the
published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the
material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.
Cover design by Tom Hiatt, Stop TB Department. The image depicts the remarkable decline in TB incidence, prevalence and mortality in China between
1990 and 2010. See Box 2.5.
Designed by minimum graphics
Printed in France
WHO/HTM/TB/2011.16
1109_0319_P_001_248 ii
23/09/11 07:19
Contents
Abbreviations
iv
Acknowledgements
v
Executive summary
1
Chapter 1. Introduction
3
Chapter 2. The burden of disease caused by TB
9
Chapter 3. Case notifications and treatment outcomes
28
Chapter 4. Financing TB care and control
42
Chapter 5. New diagnostics and laboratory strengthening for TB
54
Chapter 6. Addressing the co-epidemics of TB and HIV
61
Chapter 7. Research and development
69
Annex 1.
Methods used to estimate the burden of disease caused by TB
75
Annex 2.
Country profiles
87
Annex 3.
Global, regional and country-specific data for key indicators
111
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 iii
iii
23/09/11 07:19
Abbreviations
iv
HBC
high-burden country of which there are
22 that account for approximately 80% of
all new TB cases arising each year
WHO African Region
HIV
human immunodeficiency virus
AIDS
acquired immunodeficiency syndrome
ICD-10
AMR
WHO Region of the Americas
International Classification of Diseases
(tenth revision)
ARI
annual risk of infection
IPT
isoniazid preventive therapy
ART
antiretroviral therapy
BRICS
Brazil, the Russian Federation, India,
China, South Africa
CDR
ACSM
advocacy, communication and social
mobilization
AFB
acid-fast bacilli
AFR
IRR
incidence rate ratio
LED
light-emitting diode
LPA
line-probe assay
case detection rate
MDG
Millennium Development Goal
CPT
co-trimoxazole preventive therapy
MDR-TB
CBC
community-based TB care
DOTS
the basic package that underpins the
Stop TB Strategy
multidrug-resistant tuberculosis
(resistance to, at least, isoniazid and
rifampicin)
NGO
nongovernmental organization
DRS
drug resistance surveillance or survey
NTP
DST
drug susceptibility testing
national tuberculosis control programme
or equivalent
ECDC
European Centre for Disease Prevention
and Control
EMR
WHO Eastern Mediterranean Region
EQA
external quality assurance
ERR
electronic recording and reporting
EU
European Union
EUR
WHO European Region
FIND
Foundation for Innovative New
Diagnostics
GLC
Green Light Committee
GLI
Global Laboratory Initiative
PAL
Practical Approach to Lung Health
PPM
public–private and public-public mix
SEAR
WHO South-East Asia Region
TB
tuberculosis
UNAIDS
Joint United Nations Programme on HIV/
AIDS
UNITAID
international facility for the purchase of
diagnostics and drugs for diagnosis and
treatment of HIV/AIDS, malaria and TB
USAID
United States Agency for International
Development
VR
vital registration
Global Fund The Global Fund to fight AIDS,
Tuberculosis and Malaria
WHA
World Health Assembly
WHO
World Health Organization
Global Plan Global Plan to Stop TB, 2011–2015
WPR
WHO Western Pacific Region
GNI
XDR-TB
extensively drug-resistant TB
gross national income
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 iv
23/09/11 07:19
Acknowledgements
This report on global tuberculosis control was produced by a core team of 14 people: Annabel Baddeley, Hannah
Monica Dias, Dennis Falzon, Christopher Fitzpatrick, Katherine Floyd, Christopher Gilpin, Philippe Glaziou, Tom
Hiatt, Andrea Pantoja, Delphine Sculier, Charalambos Sismanidis, Hazim Timimi, Mukund Uplekar and Wayne van
Gemert. The team was led by Katherine Floyd. Overall guidance was provided by the Director of the Stop TB Department, Mario Raviglione.
The data collection forms (long and short versions) were developed by Philippe Glaziou, with input from staff
throughout the Stop TB Department. Hazim Timimi led and organized all aspects of data management, with support
from Tom Hiatt. Christopher Fitzpatrick, Inés Garcia and Andrea Pantoja conducted all review and follow-up of fi nancial data. The review and follow-up of all other data was done by a team of reviewers that included Annemieke Brands,
Hannah Monica Dias, Dennis Falzon, Christopher Gilpin, Christian Gunneberg, Tom Hiatt, Jean de Dieu Iragena,
Fuad Mirzayev, Delphine Sculier, Hazim Timimi, Wayne van Gemert, Fraser Wares and Matteo Zignol in WHO headquarters, and Suman Jain, Nino Mdivani, Sai Pothapregada, Lal Sadasivan Sreemathy, Alka Singh and Saman Zamani
from the Global Fund. Data for the European Region were collected and validated jointly by the WHO Regional Office
for Europe and the European Centre for Disease Prevention and Control (ECDC), an agency of the European Union
based in Stockholm, Sweden.
Philippe Glaziou and Charalambos Sismanidis analysed surveillance and epidemiological data and prepared the
figures and tables on these topics, with assistance from Tom Hiatt. Tom Hiatt and Delphine Sculier analysed TB/
HIV data and prepared the associated figures and tables, with support from Annabel Baddeley. Dennis Falzon analysed data and prepared the figures and tables related to multidrug-resistant TB. Christopher Fitzpatrick and Andrea
Pantoja analysed fi nancial data, and prepared the associated figures and tables. Tom Hiatt prepared figures and tables
on laboratory strengthening and the roll-out of new diagnostics, with support from Wayne van Gemert. Tom Hiatt
checked and fi nalized all figures and tables in an appropriate format, ensuring that they were ready for layout and
design according to schedule, and was the focal point for communications with the graphic designer.
The writing of the main part of the report was led by Katherine Floyd, with input from the following people: Philippe
Glaziou, Charalambos Sismanidis and Sai Pothapregada (Chapter 2); Dennis Falzon, Mukund Uplekar and Hannah
Monica Dias (Chapter 3); Christopher Fitzpatrick and Andrea Pantoja (Chapter 4); and Haileyesus Getahun and
Annabel Baddeley (Chapter 6). Chapter 5, on new diagnostics and laboratory strengthening, was prepared by Wayne
van Gemert, Christopher Gilpin, Karin Weyer and Fuad Mirzayev. Chapter 7, on research and development, was written by Christian Lienhardt and Katherine Floyd. The contribution to Chapter 3 of a case study about the engagement
of the full range of care providers in TB care and control in Nigeria by Joshua Obasanya, manager of the National TB
Programme in Nigeria, deserves special mention. Karen Ciceri edited the entire report.
Annex 1, which explains methods used to produce estimates of the burden of disease caused by TB, was written by
Philippe Glaziou, Katherine Floyd and Charalambos Sismanidis. The country profi les that appear in Annex 2 were
prepared by Hazim Timimi and Tom Hiatt. Annex 3, which contains a wealth of global, regional and country-specific
data from the global TB database, was prepared by Tom Hiatt and Hazim Timimi.
We thank Elizabeth Corbett and Jeremiah Chakaya for serving as external reviewers of the report.
We also thank Sue Hobbs for her excellent work on the design and layout of this report; her contribution, as in
previous years, is greatly appreciated.
The principal source of fi nancial support for WHO’s work on monitoring and evaluation of TB control is the United
States Agency for International Development (USAID), without which it would be impossible to produce this report
on global TB control. Data collection, validation, analysis, printing and dissemination were also supported by funding
from the government of Japan and the Global Fund. We acknowledge with gratitude their support.
In addition to the core report team and those mentioned above, the report benefited from the input of many staff
at the World Health Organization (WHO), particularly for data collection, validation and review. Among those listed
below, we thank in particular Amal Bassili, Andrei Dadu, Khurshid Alam Hyder, Daniel Kibuga, Rafael López Olarte,
Nobuyuki Nishikiori, Angélica Salomão, Marithel Tesoro and Daniel Sagebiel for their major contribution to data col-
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 v
v
23/09/11 07:19
lection, validation and review.
WHO headquarters Geneva
Pamela Baillie, Victoria Birungi, Reuben Granich, John Kirkwood, Tracy Mawer, Paul Nunn, Yves Souteyrand, JeanMichel Tassie and Diana Weil.
WHO African Region
Diriba Agegnehu, Shalala Ahmadova, Ayodele Awe, Gani Alabi, Joseph Imoko, Kalpesh Rahevar, Joel Kangangi, Hilary
Kipruto, Bah Keita, Daniel Kibuga, Mwendaweli Maboshe, André Ndongosieme, Nicolas Nkiere, Ishmael Nyasulu,
Wilfred Nkhoma, Philips Patrobas, Angélica Salomão, Kefas Samson and Neema Simkoko.
WHO Region of the Americas
Marcos Espinal, Mirtha del Granado, Rafael López Olarte, Rodolfo Rodriguez, Yamil Silva and Alfonso Tenorio.
WHO Eastern Mediterranean Region
Ali Akbar, Mohamed Abdel Aziz, Samiha Baghdadi, Amal Bassili, Philip Ejikon, Sevil Huseynova, Ridha Jebeniani,
Wasiq Khan, Aayid Munim, Syed Karam Shah, Ireneaus Sindani, Bashir Suleiman, Khaled Sultan, Rahim Taghizadeh
and Martin Van Den Boom.
WHO European Region
Evgeny Belilovskiy, Pierpaolo de Colombani, Andrei Dadu, Irina Danilova, Masoud Dara, Jamshid Gadoev, Gayane
Ghukasyan, Ogtay Gozalov, Sayohat Hasanova, Gulshat Jumayeva, Bahtygul Karriyeva, Olena Kheylo, Mehmet Yavuz
Kontas, Kristin Kremer, Dmitry Pashkevich, Valentin Rusovich, Bogdana Shcherbak-Verlan, Javahir Suleymanova,
Vadim Testov, Gombogaram Tsogt and Richard Zaleskis.
WHO South-East Asia Region
Mohammed Akhtar, Erwin Cooreman, Puneet Dewan, Khurshid Alam Hyder, Partha Mandal, Ye Myint, Eva Nathanson, Rajesh Pandav, Sri Prihatini, Kim Son Il, Chawalit Tantinimitkul, Sombat Thanprasertuk, Supriya Warusavithana
and Namgyel Wangchuk.
WHO Western Pacific Region
Cornelia Hennig, Woo-Jin Lew, Catherine Lijinsky, Ngyuen Nhat Linh, Nobuyuki Nishikiori, Giampaolo Mezzabotta, Yamuna Mundade, Katsunori Osuga, Daniel Sagebiel, Fabio Scano, Jacques Sebert, Harpal Singh, Marithel Tesoro,
Catharina van Weezenbeek, Rajendra-Prasad Yadav and Liu Yuhong.
The main purpose of this report is to provide the latest data on the TB epidemic and progress in TB care and control
of the disease, based on data collected in the 2011 round of global TB data collection and previous years. Data are
supplied primarily by national TB control programme managers and their staff. Those who used the online data collection system to report data to WHO in 2011 are listed below, and we thank them all for their invaluable contribution
and collaboration.
WHO African Region
Oumar Abdelhadi, Jean Louis Abena, Juan Eyene Acuresila, Francis Adatu-Engwau, Sofiane Alihalassa, Inacio Alvarenga, Omoniyi Amos Fadare, Géneviève Angue Nguema, Claudina Augusto da Cruz, Fantchè Awokou, Boubakar
Ballé, Swasilanne Bandeira de Sousa, Adama Marie Bangoura, Marie Catherine Barouan, Jorge Noel Barreto, Frank
Bekolo Mba, Richard Betchem, Mame Bocar Lo, Frank Adae Bonsu, Marafa Boubacar, Mahamat Bourhanadine, Miguel
Camara, Evangelista Chisakaitwa, Nkem Chwukueme, Amadou Cisse, Catherine Cooper, Cheick Oumar Coulibaly,
Victor Manuel Da Costa Pereira, Isaias Dambe, Serge Diagbouga, Aïcha Diakite, Awa Helene Diop, Themba Dlamini,
Saidi Egwaga, Justin Freminot, Louisa Ganda, Michel Gasana, Evariste Gasana, Boingotlo Gasennelwe, Ntahizaniye
Gérard, Sandile Ginindza, Martin Gninafon, Nii Hanson-Nortey, Adama Jallow, Abdoul Karim Kanouté, Nathan
Kapata, Biruck Kebede Negash, Hillary Kipruto, Aristide Komangoya-Nzonzo, Patrick Konwloh, Jacquemin Kouakou, Felix Kwami Afutu, Egidio Langa, Bernard Langat, Llang Maama-Maime, Angelo Makpenon, Farai Mavhunga,
Momar Talla Mbodji, Marie-Léopoldine Mbulula, Azmera Molla Tikuye, James Mpunga, Clifford Munyandi, Lindiwe
Mvusi, Ronald Ncube, Fulgence Ndayikengurukiye, Thaddée Ndikumana, Antoine Ngoulou, Emmanuel Nkiligi,
vi
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 vi
23/09/11 07:19
Ghislaine Nkone Asseko, Joshua Obasanya, Jean Okiata, Davidson Olufemi Ogunade, Augé Wilson Ondon, Hermann
Ongouo, Maria da Conceição Palma Caldas, Martin Rakotonjanahary, Thato Raleting, Bakoliarisoa Ranivomahefa,
Gabriel Marie Ranjalahy, F. Rujeedawa, Mohameden Salem, Charles Sandy, Tandaogo Saouadogo, Mineab Sebhatu,
Joseph Sitienei, Nicholas Siziba, Dawda Sowe, Celestino Francisco Teixeira, Médard Toung Mve, Kassim Traore, Modibo Traoré, Dawit Abraham Tsegaye, Mohamed Vadel, Fantchè Wokou, Alie Wurie, Assefash Zehaie and Abbas Zezai.
WHO Region of the Americas
Marta Isabel de Abrego, Christian Acosta, Sarita Aguirre, Shalauddin Ahmed, Xochil Alemán de Cruz, Raúl Alvarez,
Mirian Alvarez, Alister Antoine, Cecilia de Arango, Fabiola Arias, Wiedjaiprekash Balesar, Stefano Barbosa, Draurio
Barreira, Maria del Carmen Bermúdez, Jaime Bravo, Lynrod Brooks, Violet Brown, Marta Isabel Calona de Abrego, John Cann, Maria Lourdes Carrasco Flores, Martín Castellanos Joya, Kenneth Castro, Roxana Céspedes Robles,
Gemma Chery, Jesse Chun, Sonia Copeland, Clara Cruz, Celia de Cuellar, Ofelia Cuevas, Dy-Juan De Roza, Richard
D’Meza, Roger Duncan, Rachel Eersel, Mercedes España Cedeño, Clara Freile, Victor Gallant, Julio Garay Ramos,
Christian García Calavaro, Jennifer George, Izzy Gerstenbluth, Margarita Godoy, Franz Gonzalez, Yaskara Halabi,
Yaskara Halabi, Dorothea Hazel, M. Henry, Alina Jaime, Ronal Jamanca Shuan, Hector Jave Castillo, Carla Jeffries,
Sharline Koolman-Wever, Ashok Kumar, Athelene Linton, María Josefa Llanes Cordero, Marvin Maldonado, Francisco Maldonado Benavente, Andrea Y. Maldonado Saavedra, Raúl Manjón Tellería, Belkys Marcelino, Ada Martinez
Cruz, Maria de Lourdes Martínez Olivares, Zeidy Mata Azofeifa, Timothy McLaughlin-Munroe, Mery Mercedes,
Leilawati Mohammed, Jeetendra Mohanlall, Ernesto Moreno, Francis Morey, Alice Neymour, Persaud Nordai, Gisele
de Oliveira, M. Perry Gomez, Tomasa Portillo, Irad Potter, Bob Pratt, Edwin Quiñonez Villatoro, Dottin Ramoutar,
Leonarda Reyes, Anna Esther Reyes Godoy, Paul Ricketts, Adalberto Rodriguez, Maria Rodriguez, David Rodríguez,
Jorge Rodriguez De Marco, Myrian Roman, Katia Romero, Nilda de Romero, Joan Simon, R.A. Manohar Singh, Jackurlyn Sutton, Clarita Torres, Zulema Torres Gaete, Maribelle Tromp, Christopher Trujillo Garcia, William Turner,
Melissa Valdez, Reina Valerio, Daniel Vazquez, Eva de Weever, Michael Williams, Thomas Wong, Oritta Zachariah,
Nydia Zelaya and Elsa Zerbini.
WHO Eastern Mediterranean Region
Khaled Abu Rumman, Nadia Abu Sabra, Naila Abuljadayel, Khadiga Adam, Shahnaz Ahmadi, Mohamed Redha
Al Lawati, Fatma Al Saidi, Amin Al-Absi, Abdelbari Al-Hammadi, Samia Ali Alagab, Issa Ali Al-Rahbi, Abdul Latif
Al-Khal, Rashed Al-Owaish, Saeed Alsaffar, Kenza Benani, Abrar Chugati, Ahmad Chughtai, Walid Daoud, Sayed
Doud Mahmoodi, Suleiman El Bashir, Rachid Fourati, Mohamed Furjani, Mohamed Gaafar, Amal Galal, Dhikrayet
Gamara, Said Guelleh, Kifah Ibrahim Mustafa, Assia Haissama, Dhafer Hashim, Kalthoom Hassan, Ali Mohammed
Hussain, Heba Kamal, Joseph Lasu, Stephen Macharia, Alaa Mokhtar, Mulham Saleh Mustafa, Mahshid Nasehi,
Onwar Otien, Ejaz Qadeer, Mtanios Saade, Mohammad Salama Abouzeid, Khaled Sediq, Mohammed Sghiar, Kinaz
Sheikh, Mohamed Tabena and Hyam Yacoub.
WHO European Region
Elmira Djusupbekovna Abdrahmanova, Tleukhan Shildebayevich Abildaev, Rafig Abuzarov, Aynura Ashyrbekovna
Aesenalieva, Natavan Alikhanova, Avtandil Shermamatovich Alisherov, Ekkehardt Altpeter, Nury Kakaevich Amannepesov, Peter Henrik Andersen, Delphine Antoine, Margarida Coll Armangue, Analita Pace Asciak, Gordana Radosavljevic Asic, Rusudan Aspindzelashvili, Andrei Petrovich Astrovko, Ewa Augustynowicz-Kopeć, Elizabeta Bachiyska,
Ana Ivanovna Barbova, Venera Lazarevna Bismilda, Thorsteinn Blondal, Oktam Ikramovich Bobohodjaev, Olivera
Bojović, Stefanos Bonovas, Eric Böttger, Hamza Bozukurt, Bonita Brodhun, Noa Cedar, Ismail Ceyhan, Ana Ciobanu,
Nicoleta Cioran, Radmila Curcic, Edita Valerija Davidaviciene, Liliana Domente, Manca Zolnir Dovc, Mladen Duronjic, Connie Erkens, Jos Even, Jennifer Fernandez, Akhmedov Tura Gafurovich, Viktor Gasimov, Catherine Guichard,
Larus Jon Guomundsson, Ghenadiy Lvovich Gurevich, Weber Guy, Walter Haas, Efrat Haddad, Hasan Hafi zi, Armen
Hayrapetyan, Peter Helbling, Sven Hoffner, Daniela Homorodean, Elmira Ibraim, Djahonhir Dkurahovich Ismailov,
Vincent Jarlier, Maglajlic Jasminka, María Soledad Jiménez Pajares, Jerker Jonsson, Iagor Kalandadze, Kai Kliiman,
Maria Korzeniewska-Koseła, Mitja Kosnik, Gabor Kovacs, Olga Vladimerovna Krivonos, Tiina Kummik, Aliya Kurbanova, Arutiun Kushkean, Jean Lorenzi, Turid Mannsåker, Merja Marjamäki, Fauville-Dufaux Maryse, Wanlin
Maryse, Rujike Mehmeti, Narine Mejlumean, Donika Mema, Vladimir Milanov, Vladimir Milanov, A Mirziyat, Zohar
Mor, Nicolae Moraru, Gjyle Mulliqi-Osmani, Anne Negre, Joan O’Donnell, Vibeke Østergaard Thomsen, Dimitrijevic
Pava, Elena Pavlenko, Branka Perovic, Edita Pimkina, Monika Polanova, Bozidarka Rakocevic, Vija Riekstina, Elena
Rodríguez-Valín, Tom Rogers, Karin Rønning, Kazimierz Roszkowski, Sabine Rüsch-Gerdes, Petri Ruutu, Eugeniy
Romanovich Sagalchik, Branislava Savic, Aynabat Amansahatovna Seitmedova, Hasia Kaidar Shwartz, Aleksandar
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 vii
vii
23/09/11 07:19
Simunovic, Elena Igorievna Skachkova, Girts Skenders, Ivan Solovic, Dick van Soolingen, Petra Svetina Sorli, Olga
Mihailovna Stemlah, Janos Strausz, Silva Tafaj, Stefan Talevski, Odorina Tello Anchuela, Turaev Laziz Temurovich,
Medina Nazirdjanovna Tuichibaeva, Uzakova Gulnoz Tulkunovna, Aigul Sultanovna Tursynbayeva, Piret Viiklepp,
Ludmila Viksna, Cveta Vragoterova, Gerard de Vries, Maryse Wanlin, Guy Weber, Aysegul Yildrim, Maja Zakoska and
Hasan Zutic.
WHO South-East Asia Region
Sunil de Alwis, Si Thu Aung, Arjin Cholapand, Kim Jong Guk, Ashok Kumar Gupta, Emdadul Hoque, Jang Yong
Hui, Ashaque Husain, Kim Ting Hyok, Kashi Kant Jha, Suksont Jittimanee, Badri Nath Jnawali, Neeraj Kulshrestha,
Thandar Lwin, Dyah Erti Mustikawati, Fathmath Reeza, Chewang Rinzin, Aminath Shenalin, Paramita Sudharto and
Asik Surya,
WHO Western Pacific Region
Paul Aia, Cecilia Teresa Arciaga, Susan Barker, Christina Barry, Iobi Batio, Connie Bien Olikong, Nguyen Binh Hoa,
Kennar Briand, Richard Brostrom, Risa Bukbuk, Nou Chanly, Phonnaly Chittamany, Cho En Hi, Kuok Hei Chou, Jiloris Dony, Jane Dowabobo, Marites Fabul, Rangiau Fariu, Louise Fonua, Anna Marie Celina Garfi n, Shakti Gounder,
David Hunsberger, Xaysangkhom Insisiengmay, Noel Itogo, Tomoo Ito, Nese Ituaso Conway, Narantuya Jadambaa,
Mayleen Jack Ekiek, Seiya Kato, Pengiran Khalifah bin Pg Ismail, Khin Mar Kyi Win, Leo Lim, Wang Lixia, Liza
Lopez, Henri-Pierre Mallet, Faimanifo Peseta, Serafi Moa, Suzana Binte Mohd Hashim, Dinh Ngoc Sy, Fandy Osman,
Nukutau Pokura, Waimanu Pulu, Nasanjargal Purev, Yanjindulam Purevsuren, Marcelina Rabauliman, Bereka Reiher, Bernard Rouchon, Oksana Segur, Temilo Seono, Cheng Shiming, Tieng Sivanna, Ong Sok King, Grant Storey, Phannasinh Sylavanh, Kenneth Tabutoa, Markleen Tagaro, Cheuk-ming Tam, Mao Tan Eang, Ulisese Tapuvae,
Faafetai Teo-Yandall, Kazuhiro Uchimura, Rosalind Vianzon, Du Xin, Wang Yee Tang and Byunghee Yoo.
viii
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 viii
23/09/11 07:19
Executive summary
This is the sixteenth global report on tuberculosis (TB)
published by WHO in a series that started in 1997. It provides a comprehensive and up-to-date assessment of the
TB epidemic and progress in implementing and fi nancing TB prevention, care and control at global, regional
and country levels using data reported by 198 countries
that account for over 99% of the world’s TB cases.
The introductory chapter (Chapter 1) provides general
background on TB as well as an explanation of global
targets for TB control, the WHO’s Stop TB Strategy
and the Stop TB Partnership’s Global Plan to Stop TB
2011–2015. The main fi ndings and messages about the
six major themes covered in the rest of the report are provided below.
The burden of disease caused by TB
(Chapter 2)
In 2010, there were 8.8 million (range, 8.5–9.2 million)
incident cases of TB, 1.1 million (range, 0.9–1.2 million) deaths from TB among HIV-negative people and an
additional 0.35 million (range, 0.32–0.39 million) deaths
from HIV-associated TB.
Important new fi ndings at the global level are:
The absolute number of TB cases has been falling
since 2006 (rather than rising slowly as indicated in
previous global reports);
TB incidence rates have been falling since 2002 (two
years earlier than previously suggested);
Estimates of the number of deaths from TB each year
have been revised downwards;
In 2009 there were almost 10 million children who were
orphans as a result of parental deaths caused by TB.
Updates to estimates of disease burden follow the completion of a series of consultations with 96 countries between
2009 and 2011, including China, India and 17 African
countries in the past year, and much greater availability
and use of direct measurements of TB mortality. Ongoing efforts to further improve measurement of TB cases
and deaths under the umbrella of the WHO Global Task
Force on TB Impact Measurement, including impressive
progress on TB prevalence surveys and innovative work
to strengthen surveillance, are summarized.
At country level, dramatic reductions in TB cases and
deaths have been achieved in China. Between 1990 and
2010, prevalence rates were halved, mortality rates fell
by almost 80% and TB incidence rates fell by 3.4% per
year. Methods used to measure trends in disease burden
in China – nationwide prevalence surveys, a sample vital
registration system and a web-based case notification
system – provide a model for many other countries.
Other results reinforce the fi ndings of previous global
reports:
The world and all of WHO’s six regions are on track to
achieve the Millennium Development Goal target that
TB incidence rates should be falling by 2015;
TB mortality rates have fallen by just over a third since
1990, and the world as well as five of six WHO regions
(the exception being the African Region) are on track
to achieve the Stop TB Partnership target of halving
1990 mortality rates by 2015;
The Stop TB Partnership target of halving TB prevalence rates by 2015 compared with 1990 is unlikely to
be achieved globally, although the target has already
been reached in the Region of the Americas and the
Western Pacific Region is very close to reaching the
target;
There were 3.2 million (range, 3.0–3.5 million) incident cases of TB and 0.32 million (range, 0.20–44 million) deaths from TB among women in 2010;
About 13% of TB cases occur among people living
with HIV.
Case notifications and treatment outcomes
(Chapter 3)
In 2010, there were 5.7 million notifications of new and
recurrent cases of TB, equivalent to 65% (range 63–68%)
of the estimated number of incident cases in 2010. India
and China accounted for 40% of the world’s notified
cases of TB in 2010, Africa for a further 24% and the 22
high-TB burden countries (HBCs) for 82%. At global level, the treatment success rate among new cases of smearpositive pulmonary TB was 87% in 2009.
Between 1995 and 2010, 55 million TB patients were
treated in programmes that had adopted the DOTS/Stop
TB Strategy, and 46 million were successfully treated.
These treatments saved almost 7 million lives.
Alongside these achievements, diagnosis and appropriate treatment of multidrug-resistant TB (MDR-TB)
remain major challenges. Less than 5% of new and previously treated TB patients were tested for MDR-TB in
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 1
1
23/09/11 07:20
most countries in 2010. The reported number of patients
enrolled on treatment has increased, reaching 46 000 in
2010. However, this was equivalent to only 16% of the
290 000 cases of MDR-TB estimated to exist among notified TB patients in 2010.
Financing TB care and control (Chapter 4)
In 97 countries with 92% of the world’s TB cases for
which trends can be assessed, funding from domestic
and donor sources is expected to amount to US$ 4.4 billion in 2012, up from US$ 3.5 billion in 2006. Most
of this funding is being used to support diagnosis and
treatment of drug-susceptible TB, although funding for
MDR-TB is growing and expected to reach US$ 0.6 billion in 2012. Countries report funding gaps amounting
to almost US$ 1 billion in 2012.
Overall, domestic funding accounts for 86% of total
funding, with the Global Fund accounting for 12%
(82% of all international funding) and grants from other
agencies for 2%, but striking contrasts between BRICS
(Brazil, the Russian Federation, India, China and South
Africa) and other countries are highlighted:
BRICS invested US$ 2.1 billion in TB control in 2010,
95% of which was from domestic sources;
In the other 17 HBCs, total expenditures were much
lower (US$ 0.6 billion) and only 51% of funding was
from domestic sources.
Most of the funding needed to scale up the treatment of
MDR-TB towards the goal of universal access is needed
in BRICS and other middle-income countries (MICs).
If BRICS and other MICs fully fi nance the scale-up of
treatment for MDR-TB from domestic sources, current
levels of donor fi nancing for MDR-TB would be almost
sufficient to fund the scale-up of MDR-TB treatment in
low-income countries.
Donor funding for TB is expected to reach US$ 0.6 billion in 2012, a 50% increase compared with US$ 0.4 billion in 2006, but far short of donor funding for malaria
(US$ 1.8 billion in 2010) and HIV (US$ 6.9 billion in
2010).
New diagnostics and laboratory
strengthening (Chapter 5)
The fi rst data on the roll-out of Xpert MTB/RIF, a new
rapid molecular test that has the potential to substantially improve and accelerate the diagnosis of TB and drugresistant TB, are presented. By 30 June 2011, six months
after the endorsement of Xpert MTB/RIF by WHO in
December 2010, 26 of the 145 countries eligible to purchase GeneXpert instruments and Xpert MTB/RIF cartridges at concessional prices had done so. This shows
that the transfer of technology to developing countries
can be fast.
2
The continued inadequacy of conventional laboratory
capacity is also illustrated:
In 2010, 8 of the 22 HBCs did not meet the benchmark
of 1 microscopy centre per 100 000 population;
Among the 36 countries in the combined list of 22
HBCs and 27 high MDR-TB burden countries, 20 had
less than the benchmark of 1 laboratory capable of
performing culture and drug susceptibility testing per
5 million population.
Overall, laboratory strengthening needs to be accelerated, as is currently happening in 27 countries through
the EXPAND-TB project supported by UNITAID.
Addressing the co-epidemics of TB and HIV
(Chapter 6)
Progress in scaling up interventions to address the coepidemics of TB and HIV has continued:
In 2010, HIV testing among TB patients reached 34%
globally, 59% in the African Region and *75% in 68
countries;
Almost 80% of TB patients known to be living with
HIV were started on cotrimoxozole preventive therapy
(CPT) and 46% were on antiretroviral therapy (ART)
in 2010;
A large increase in screening for TB among people
living with HIV and provision of isoniazid preventive
therapy to those without active TB disease occurred in
2010, especially in South Africa.
Impressive improvements in recent years notwithstanding, much more needs to be done to reach the Global
Plan targets that all TB patients should be tested for HIV
and that all TB patients living with HIV should be provided with CPT and ART.
Research and development (Chapter 7)
The topic of research and development is discussed for
the fi rst time in the global report. There has been considerable progress in diagnostics in recent years, including
the endorsement of Xpert MTB/RIF at the end of 2010;
other tests including point-of-care tests are in the pipeline. There are 10 new or repurposed TB drugs in clinical trials that have the potential to shorten the treatment
of drug-susceptible TB and improve the treatment of
MDR-TB. Results from three Phase III trials of 4-month
regimens for the treatment of drug-susceptible TB are
expected between 2012 and 2013, and results from two
Phase II trials of new drugs for the treatment of MDR-TB
are expected in 2012. There are 9 vaccine candidates
in Phase I or Phase II trials. It is hoped that one or both
of the candidates currently in a Phase II trial will enter a
Phase III trial in the next 2–3 years, with the possibility
of licensing at least one new vaccine by 2020.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 2
23/09/11 07:20
CHAPTER 1
Introduction
Tuberculosis (TB) is an infectious disease caused by
the bacillus Mycobacterium tuberculosis. It typically affects
the lungs (pulmonary TB) but can affect other sites as
well (extrapulmonary TB). The disease is spread in the
air when people who are sick with pulmonary TB expel
bacteria, for example by coughing. In general, a relatively
small proportion of people infected with Mycobacterium
tuberculosis will go on to develop TB disease; however,
the probability of developing TB is much higher among
people infected with the human immunodeficiency virus
(HIV). TB is also more common among men than women, and affects mostly adults in the economically productive age groups; around two-thirds of cases are estimated
to occur among people aged 15–59 years.
The most common method for diagnosing TB worldwide is sputum smear microscopy (developed more than
100 years ago), in which bacteria are observed in sputum
samples examined under a microscope. In countries with
more developed laboratory capacity, cases of TB may also
be diagnosed via culture methods (the current gold standard) or, increasingly, using rapid molecular tests.
Without treatment, mortality rates are high. In studies of the natural history of the disease among sputum
smear-positive and HIV-negative cases of pulmonary TB,
around 70% died within 10 years; among culture-positive
(but smear-negative) cases, 20% died within 10 years.1
Treatment using combinations of anti-TB drugs developed in the 1940s and 1950s can dramatically reduce
mortality rates. In clinical trials, cure rates of above
90% have been documented; the treatment success rate
among smear-positive cases of pulmonary TB reported
to WHO reached 87% at the global level in 2009.
Despite the availability of highly efficacious treatment
for decades, TB remains a major global health problem.
In 1993, the World Health Organization (WHO) declared
TB a global public health emergency, at a time when an
estimated 7–8 million cases and 1.3–1.6 million deaths
occurred each year. In 2010, there were an estimated
8.5–9.2 million cases and 1.2–1.5 million deaths (including deaths from TB among HIV-positive people).2 TB
is the second leading cause of death from an infectious
disease worldwide (after HIV, which caused an estimated
1.8 million deaths in 2008).3
WHO has published a global report on TB every year
since 1997 (Figure 1.1). The main aim of the report is to
provide a comprehensive and up-to-date assessment of
BOX 1.1
Goals, targets and indicators
for TB control
Millennium Development Goals set for 2015
■ Goal 6: Combat HIV/AIDS, malaria
and other diseases
Target 6c: Halt and begin to reverse the incidence of
malaria and other major diseases
Indicator 6.9: Incidence, prevalence and death rates
associated with TB
Indicator 6.10: Proportion of TB cases detected and
cured under DOTS
Stop TB Partnership targets set for
2015 and 2050
By 2015: Reduce prevalence and death rates by 50%,
compared with their levels in 1990
By 2050: Reduce the global incidence of active TB cases
to <1 case per 1 million population per year
the TB epidemic and progress made in prevention, care
and control of the disease at global, regional and country levels, in the context of global targets set for 2015
and WHO’s recommended strategy for achieving these
targets.
The 2015 global targets for reductions in disease
burden (Box 1.1) are that TB incidence should be falling (MDG Target 6.c) and that prevalence and death
rates should be halved compared with their levels in
1990. WHO’s recommended strategy for achieving
these targets is the Stop TB Strategy4 (Box 1.2), which
was launched in 2006 as an enhancement of the DOTS
1
2
3
4
Tiemersma EW et al. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIVnegative patients: A systematic review. PLoS ONE 2011 6(4):
e17601.
These deaths are classified as HIV deaths in the International
statistical classification of diseases and related health problems, 10th
revision (ICD-10), 2nd ed. Geneva, World Health Organization,
2007.
http://apps.who.int/ghodata. These HIV deaths include 0.4
million deaths from TB.
The Stop TB Strategy: building on and enhancing DOTS to meet the
TB-related Millennium Development Goals. Geneva, World Health
Organization, 2006 (WHO/HTM/TB/2006.368).
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 3
3
23/09/11 07:20
BOX 1.2
The Stop TB Strategy at a glance
THE STOP TB STRATEGY
VISION
A TB-free world
GOAL
To dramatically reduce the global burden of TB by 2015 in line with the Millennium Development Goals
(MDGs) and the Stop TB Partnership targets
OBJECTIVES
• Achieve universal access to high-quality care for all people with TB
• Reduce the human suffering and socioeconomic burden associated with TB
• Protect vulnerable populations from TB, TB/HIV and drug-resistant TB
• Support development of new tools and enable their timely and effective use
• Protect and promote human rights in TB prevention, care and control
TARGETS
• MDG 6, Target 6.c: Halt and begin to reverse the incidence of TB by 2015
• Targets linked to the MDGs and endorsed by the Stop TB Partnership:
– 2015: reduce prevalence of and deaths due to TB by 50% compared with a baseline of 1990
– 2050: eliminate TB as a public health problem
COMPONENTS
1. Pursue high-quality DOTS expansion and enhancement
a. Secure political commitment, with adequate and sustained financing
b. Ensure early case detection, and diagnosis through quality-assured bacteriology
c. Provide standardized treatment with supervision, and patient support
d. Ensure effective drug supply and management
e. Monitor and evaluate performance and impact
2. Address TB/HIV, MDR-TB, and the needs of poor and vulnerable populations
a. Scale-up collaborative TB/HIV activities
b. Scale-up prevention and management of multidrug-resistant TB (MDR-TB)
c. Address the needs of TB contacts, and of poor and vulnerable populations
3. Contribute to health system strengthening based on primary health care
a. Help improve health policies, human resource development, financing, supplies, service delivery and information
b. Strengthen infection control in health services, other congregate settings and households
c. Upgrade laboratory networks, and implement the Practical Approach to Lung Health
d. Adapt successful approaches from other fields and sectors, and foster action on the social determinants of health
4. Engage all care providers
a. Involve all public, voluntary, corporate and private providers through public–private mix approaches
b. Promote use of the International Standards for Tuberculosis Care
5. Empower people with TB, and communities through partnership
a. Pursue advocacy, communication and social mobilization
b. Foster community participation in TB care, prevention and health promotion
c. Promote use of the Patients’ Charter for Tuberculosis Care
6. Enable and promote research
a. Conduct programme-based operational research
b. Advocate for and participate in research to develop new diagnostics, drugs and vaccines
4
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 4
23/09/11 07:20
FIGURE 1.1
Fifteen annual WHO reports on TB in 14 years, 1997–2010
1997: First report:
epidemiology and
surveillance
2002: Added financing and
strategy for 22 high-burden
countries (HBCs)
July 2009: Online data collection introduced
December 2009: Short update to 2009 report in transition
to earlier reporting of data and report publication
2003: Financing
and strategy
(all countries)
strategy. DOTS was a five-point package that remains the
fi rst component and foundation of the Stop TB Strategy.
The other components of the Stop TB Strategy highlight
the need to address the challenge of drug-resistant TB
and the co-epidemics of TB and HIV, the importance of
engaging all care providers in TB care and control and
of contributing to strengthening health systems, the role
of communities and people with TB, and the fundamental role of research and development for new diagnostics,
new drugs and new vaccines. The Stop TB Partnership’s
Global Plan to Stop TB for 2011–2015 has set out the
scale at which interventions included in the Stop TB
Strategy need to be implemented to achieve the 2015 targets for reductions in disease burden.1 The plan comes
with a price tag of US$ 47 billion and the main indicators
and associated baselines and targets are summarized in
Table 1.1.
This 2011 edition of WHO’s annual global TB report
– the 16th in the series – continues the tradition of previous reports. It is based primarily on data compiled in
annual rounds of global TB data collection in which
countries are requested to report a standard set of data
to WHO.2 In 2011, data were requested on the following topics: case notifications and treatment outcomes,
including breakdowns by age, sex and HIV status; an
overview of services for the diagnosis and treatment of
TB; laboratory diagnostic services; drug management;
monitoring and evaluation; surveillance and surveys of
drug-resistant TB; management of drug-resistant TB;
collaborative TB/HIV activities; human resource development; TB control in vulnerable populations and highrisk groups; TB infection control; the Practical Approach
to Lung Health; 3 engagement of all care providers in TB
control; advocacy, communication and social mobilization; the budgets of national TB control programmes
(NTPs) in 2011 and 2012; utilization of general health
services (hospitalization and outpatient visits) during
treatment; and NTP expenditures in 2010. A shortened
version of the online questionnaire was used for high-
income countries (that is, countries with a gross national
income per capita of *US$ 12 276 in 2010, as defi ned
by the World Bank) 4 and/or low-incidence countries
(defi ned as countries with an incidence rate of <20 cases
per 100 000 population or <10 cases in total).
Since 2009, data have been reported using an online
web-based system.5 In 2011, the online system was
opened for reporting on 15 March, with a deadline of
17 May for all WHO regions except the Region of the
Americas (31 May) and the European Region (15 June).
A total of 198 countries and territories accounting for
over 99% of the world’s estimated cases of TB reported
data by the deadlines, including all or almost all countries in five of WHO’s six regions (Table 1.2). Data were
reviewed, and followed up with countries where appropriate, by a team of reviewers from WHO (headquarters
and regional offices) and the Global Fund. Validation of
data by respondents was also encouraged via a series of
inbuilt and real-time checks of submitted data as well as
a summary report of apparent inconsistencies or inaccuracies that can be generated at any time within the online
system. The data contained in the global TB database on
21 June 2011 were used for the main part of this report.
The detailed data in Annex 2 and Annex 3 reflect the data
available on 2 September, the fi nal deadline for receipt
1
2
3
4
5
The Global Plan to Stop TB, 2011–2015. Geneva, World Health
Organization, 2010 (WHO/HTM/STB/2010.2).
The annual data collection form is designed for collecting
aggregated national data. It is not recommended for collection
of data within countries. WHO recommendations for recording and reporting within countries are described at: www.
who.int/tb/dots/r_and_r_forms/en/index.html
The Practical Approach to Lung Health (PAL) is a patientcentred approach to improving the quality of diagnosis
and treatment for common respiratory illnesses in primary
health-care facilities.
http://data.worldbank.org/about/country-classifications
www.stoptb.org/tme. Countries in the European Union
submit notification data to a system managed by the European Centre for Disease Prevention and Control (ECDC). Data
from the ECDC system were uploaded into WHO’s online
system.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 5
5
23/09/11 07:20
TABLE 1.1
Summary of main indicators, baselines and targets set in the Global Plan to Stop TB 2011–2015
BASELINE
(2009)
TARGET
(2015)
5.8 million
6.9 million
Treatment success rate (in annual cohort)
86%
90%
Number of countries with ≥1 laboratory with sputum-smear microscopy services per 100 000 population
≥75
149
Percentage of previously treated TB patients tested for MDR-TB
7%
100%
Percentage of new bacteriologically-positive patients tested for MDR-TB
7%
20%
18–21
36
PLAN COMPONENT AND INDICATORS
DOTS/laboratory strengthening
Number of cases diagnosed, notified and treated according to the DOTS approach (per year)
Drug-resistant TB/laboratory strengthening
Number of countries among the 22 HBCs and 27 high MDR-TB burden countries with ≥1 culture laboratory per
5 million population
Percentage of confirmed cases of MDR-TB enrolled on treatment according to international guidelines
36%
100%
11 000
60%
~270 000
≥75%
Percentage of AFB smear-negative, newly notified TB cases screened using culture and/or molecular-based test
<1%
≥50%
Percentage of TB patients tested for HIV
26%
100%
Percentage of HIV-positive TB patients treated with CPT
75%
100%
Percentage of HIV-positive TB patients treated with ART
37%
100%
~25%
<1%
100%
<5%
≥50%
Number of confirmed cases of MDR-TB enrolled on treatment according to international guidelines
Treatment success rate among confirmed cases of MDR-TB
TB/HIV/laboratory strengthening
Percentage of people living with HIV attending HIV care services who were screened for TB at their last visit
Percentage of people living with HIV attending HIV care services who were enrolled on IPT; among those eligible
100%
Laboratory strengthening (additional to those above)
Percentage of national reference laboratories implementing a quality management system (QMS) according to
international standards
AFB, acid-fast bacilli; ART, antiretroviral therapy; CPT, co-trimoxazole preventive therapy; HBC, high TB burden country; HIV, human immunodeficiency virus; IPT, isoniazid
preventive therapy; MDR-TB, multidrug-resistant tuberculosis.
TABLE 1.2
Reporting of data in the 2011 round of global
TB data collection
WHO REGION OR SET OF COUNTRIES
African Region
NUMBER OF COUNTRIES
AND TERRITORIES
REPORTING DATAa
46
45
Eastern Mediterranean Region
22
21
European Region
55
42
Region of the Americas
46
46
South-East Asia Region
11
10
Western Pacific Region
36
34
High-burden countries
22
22
216
198
WORLD
a
NUMBER OF
COUNTRIES AND
TERRITORIES
Countries that did not report data included Comoros (African Region), Libyan
Arab Jamahiriya (Eastern Mediterranean Region), Timor-Leste (South-East
Asia Region), Japan and Wallis and Futuna Islands (Western Pacific Region).
Countries that did not report in the European Region were mostly in Western
Europe.
of data from countries in the European Union.1 Besides
the data reported through the standard TB questionnaire, the report uses data about screening for TB among
people living with HIV and provision of isoniazid preventive therapy to those without active TB that are collected
annually by the HIV department in WHO, as well as data
and information that are available to WHO through separate mechanisms.
The report is structured in six major chapters. Each
chapter is intended to stand alone, but links to other
chapters are highlighted where appropriate. The six
chapters are:
Chapter 2: The burden of disease caused by TB.
This chapter presents estimates of the numbers of TB
cases and deaths caused by TB in 2010, estimates of
trends in cases and deaths since 1990, and an assessment of whether the 2015 targets for reductions in
cases and deaths will be achieved. This is done for
the world as a whole, for WHO’s six regions and for
1
6
Countries can edit their data at any time. After the global
report is published, the most up-to-date data can be downloaded from WHO’s global TB database (www.who.int/tb/
data). For most countries, there are few updates after the
global report is published.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 6
23/09/11 07:20
each of the 22 high TB burden countries (HBCs) that
have been prioritized at global level since 2000.1 The
chapter also puts the spotlight on China, highlighting new evidence on impressive reductions in disease
burden between 1990 and 2010. Progress in improving measurement of the burden of disease under the
umbrella of the WHO Global Task Force on TB Impact
Measurement is also discussed, covering efforts to
strengthen TB surveillance and to implement national
population-based surveys of the prevalence of TB disease in around 20 global focus countries.
BOX 1.3
What’s new in this report?
• The absolute number of TB cases arising each year is
estimated to be falling globally
• Evidence of dramatic reductions in TB cases and
deaths in China between 1990 and 2010
• Estimates of how many children become orphans as a
result of parental deaths caused by TB
• Better estimates of TB mortality due to the greater
availability and use of direct measurements from vital
registration systems and mortality surveys
Chapter 3: Case notifications and treatment outcomes. This chapter includes data reported by NTPs
on the number of TB cases diagnosed and treated,
both overall and for multi-drug resistant TB (MDRTB) specifically. Numbers of cases diagnosed and
treated are compared with the targets included in the
Global Plan to Stop TB. Progress in engaging the full
range of care providers in diagnosis and treatment is
illustrated, and estimates of the proportion of estimated incident cases of TB that were reported to NTPs
in 1995, 2000, 2005 and 2010 – the so-called case
detection rate (CDR) – are presented. The last part of
the chapter summarizes data on treatment outcomes,
both overall and for MDR-TB.
Chapter 4: Financing TB care and control. This
chapter presents breakdowns of funding for TB prevention, diagnosis and treatment from both domestic
and donor sources for the 22 HBCs from 2002 to 2012,
and for a total of 97 countries for which trends can
be assessed since 2006. Breakdowns are provided for
categories of expenditure and by source of funding.
Funding gaps are quantified, and available resources
are compared with both the funding requirements
set out in the Global Plan to Stop TB and levels of
international funding for HIV and malaria. Countryspecific estimates of the cost per patient treated, and
how these are related to levels of average income, are
also featured.
Chapter 5: New diagnostics and laboratory strengthening for TB. Laboratory strengthening including
the roll out of new diagnostic tests and policies are recognized as top priorities for TB care and control. This
chapter describes laboratory capacity in the 22 HBCs
as well as 27 high MDR-TB burden countries (a total of
36 countries, given overlap between the two groups).
It also assesses progress in efforts to strengthen laboratories, with particular attention to the EXPAND-TB
project 2 and the uptake of recent WHO policy guidance on diagnostics. Following the endorsement by
WHO of a new molecular diagnostic test for the rapid
diagnosis of TB and rifampicin-resistant TB at the end
of 2010 – Xpert MTB/RIF – progress in the roll-out of
this test is assessed. New policies on TB diagnostics
• An important update to estimates of TB cases and
deaths in the African Region
• Discussion of how synergies between the work of the
WHO Global Task Force on TB Impact Measurement
and the new grant architecture of the Global Fund have
the potential to substantially improve measurement of
the burden of disease caused by TB
• Better data on the contribution of public-private and
public-public mix (PPM) to TB notifications
• Analysis of the funding required to scale up diagnosis
and treatment of multidrug-resistant TB (MDR-TB) in
BRICS (Brazil, the Russian Federation, India, China
and South Africa), other middle-income countries and
low-income countries, combined with assessment of
how donor funding could be better used to support this
scale-up
• Data on the roll-out of Xpert MTB/RIF for the rapid
diagnosis of TB and rifampicin-resistant TB following
WHO’s endorsement of the test in December 2010
• A chapter on the latest status of progress in developing
new TB diagnostics, drugs and vaccines
in 2011 and the evidence on which they are based are
also summarized.
Chapter 6: Addressing the co-epidemics of TB and
HIV. Besides diagnosis and treatment of TB among
HIV-positive people, WHO recommends a range of
other interventions to jointly address the co-epidemics of TB and HIV. These include HIV testing among
all TB patients, provision of co-trimoxazole preventive
therapy and antiretroviral therapy for HIV-positive TB
patients, intensified case-fi nding for TB among people
receiving HIV care and isoniazid preventive therapy
for HIV-positive people without active TB. Progress in
1
2
These countries are (in alphabetical order): Afghanistan,
Bangladesh, Brazil, Cambodia, China, the Democratic
Republic of the Congo, Ethiopia, India, Indonesia, Kenya,
Mozambique, Myanmar, Nigeria, Pakistan, the Philippines,
the Russian Federation, South Africa, Thailand, Uganda, the
United Republic of Tanzania, Viet Nam and Zimbabwe.
www.who.int/tb/publications/factsheet_expand_tb.pdf
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 7
7
23/09/11 07:20
scaling up provision of these services is described and
discussed.
Chapter 7: Research and development. The most
commonly used diagnostic test for TB is over 100
years old, the anti-TB drugs used in fi rst-line treatments are around 50 years old and the BCG vaccine to
prevent TB is almost 100 years old. In the past decade,
efforts to develop new drugs, new diagnostics and new
vaccines have intensified. This chapter presents the
current status of progress.
Annex 1 explains the methods that were used to produce estimates of the burden of disease caused by TB.
Annex 2 contains country profi les for the 22 HBCs and
also highlights additional profi les that are available for
all countries online.1 Annex 3 contains summary tables
that provide data on key indicators for the world, WHO
regions and individual countries.
1
8
www.who.int/tb/data
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 8
23/09/11 07:20
CHAPTER 2
The burden of disease caused by TB
KEY MESSAGES
There were an estimated 8.8 million incident cases
of TB (range, 8.5 million–9.2 million) globally in 2010,
1.1 million deaths (range, 0.9 million–1.2 million) among
HIV-negative cases of TB and an additional 0.35 million
deaths (range, 0.32 million–0.39 million) among people
who were HIV-positive.
In 2009, there were an estimated 9.7 million (range,
8.5–11 million) children who were orphans as a result of
parental deaths caused by TB.
Globally, the absolute number of incident TB cases
per year has been falling since 2006 and the incidence
rate (per 100 000 population) has been falling by 1.3% per
year since 2002. If these trends are sustained, the MDG
target that TB incidence should be falling by 2015 will be
achieved.
TB mortality is falling globally and the Stop TB
Partnership target of a 50% reduction by 2015 compared
with 1990 will be met if the current trend is sustained. The
target could also be achieved in all WHO regions with the
exception of the African Region.
Although TB prevalence is falling globally and in all
regions, it is unlikely that the Stop TB Partnership target
of a 50% reduction by 2015 compared with 1990 will be
reached. However, the target has already been achieved
in the Region of the Americas and the Western Pacific
Region is very close to reaching the target.
Dramatic reductions in TB cases and deaths have been
achieved in China. Between 1990 and 2010, prevalence
rates were halved, mortality rates were cut by almost
80% and incidence rates fell by 3.4% per year. In addition,
methods for measuring trends in disease burden in China
provide a model for many other countries.
Between 2009 and 2011, consultations with 96
countries that account for 89% of the world’s TB cases
have led to a major updating of estimates of TB incidence,
mortality and prevalence, particularly for countries in the
African Region.
Estimates of TB mortality have substantially improved
in the past three years, following increased availability
and use of direct measurements from vital registration
systems and mortality surveys. In this report, direct
measurements of mortality are used for 91 countries
(including China and India for the first time).
The burden of disease caused by TB can be measured
in terms of incidence (defi ned as the number of new and
relapse cases of TB arising in a given time period, usually
one year), prevalence (defi ned as the number of cases of
TB at a given point in time) and mortality (defi ned as the
number of deaths caused by TB in a given time period,
usually one year). It can also be expressed in terms of
the years of life lost or, to account for illness as well as
mortality, the disability-adjusted life years (DALYs) lost.
WHO publishes estimates of the burden of disease by
major cause and risk factor using all of these metrics.1
The fi rst three parts of this chapter present estimates of TB incidence, prevalence and mortality (absolute numbers and rates) between 1990 and 2010 and (for
prevalence and mortality) forecasts up to 2015. These
data are used to assess progress towards achieving the
global targets set for 2015: that incidence should be falling (MDG Target 6.c) and that prevalence and death rates
should be halved by 2015 compared with their levels in
1990 (Box 1.1 in Chapter 1). Key aspects of the methods
used to produce the estimates are provided at the beginning of each section; a detailed description is provided in
Annex 1.2 Section 2.4 focuses on multidrug-resistant TB
(MDR-TB), providing estimates of the number of cases
of MDR-TB in 2010 and a new analysis of trends in such
cases at global and regional levels.
There is uncertainty in all estimates of the burden
of disease caused by TB (Box 2.1). The fi nal part of the
chapter profi les efforts to improve measurement of the
burden of disease caused by TB under the umbrella of
the WHO Global Task Force on TB Impact Measurement. These include efforts to strengthen surveillance
of cases and deaths via notification and vital registration
(VR) systems, and national surveys of the prevalence of
TB disease in global focus countries.
The chapter also puts the spotlight on China, where
considerable efforts to measure the burden of disease
1
2
World Health Statistics 2010. Geneva, World Health Organization, 2010 (WA 900.1).
Methods were fully updated in 2009 following 18 months of
work by an expert group convened by the WHO Global Task
Force on TB Impact Measurement. Improvements included
systematic documentation of expert opinion and uncertainty
intervals, simplification of models, updates to parameter values based on the results of literature reviews and much greater use of mortality data from vital registration systems. For
further details, see the Task Force web site at: www.who.int/
tb/advisory_bodies/impact_measurement_taskforce
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 9
9
23/09/11 07:20
FIGURE 2.1
BOX 2.1
Uncertainty in estimates of TB incidence,
prevalence and mortality
TB incidence has never been directly measured at national
level, since this would require long-term studies among
large cohorts of people (hundreds of thousands) at high
cost and with challenging logistics. In countries with a
high burden of TB, prevalence can be directly measured in
nationwide surveys using sample sizes of around 50 000
people and costs in the range of US$ 1–4 million per survey.1 Relatively few countries with a high burden of TB have
conducted prevalence surveys in recent years (although
this is now changing), and sample sizes and costs become
prohibitive in low and medium-burden countries. TB mortality among HIV-negative people can be directly measured
if national vital registration (VR) systems of high coverage
in which causes of death are accurately coded according to
the latest revision of the international classification of diseases (ICD-10) are in place (and sample VR systems covering representative areas of the country provide an interim
solution). Mortality surveys can also be used to directly
measure deaths caused by TB. In 2010, most countries with
a high burden of TB lacked national or sample VR systems
and few had conducted mortality surveys. TB mortality
among HIV-positive people is hard to measure even when
VR is in place, since deaths among HIV-positive people are
coded as HIV deaths and contributory causes (such as TB)
are often not reliably recorded.
For all these reasons, the estimates of TB incidence, prevalence and mortality included in this chapter are presented
with uncertainty intervals. When ranges are presented, the
lower and higher numbers correspond to the 2.5th and
97.5th centiles of the outcome distributions (generally produced by simulations). The methods used to produce best
estimates and uncertainty intervals are described in detail
in Annex 1.
1 Improvements to the estimates published in
this report compared with previous years are profiled in
Box 2.
2.2 and Box 2.
2.3.
1
TB prevalence surveys: a handbook. Geneva, World Health
Organization, 2011 (WHO/HTM/TB/2010.17).
caused by TB have been made over the past 20 years.
The impressive results and the methods used to produce
them – which provide a model for many other countries
– are highlighted as a special case study.
2.1
Estimates of the incidence of TB
The incidence of TB cannot be measured directly (Box
2.1). For 96 countries that account for 89% of the world’s
TB cases, estimates were thoroughly reviewed and updated between 2009 and 2011 in either regional or country
workshops (Figure 2.1). This was done using a framework
(Figure 2.2) and associated tools developed by the WHO
Global Task Force on TB Impact Measurement. In-depth
analyses of the available surveillance, survey and programmatic data were undertaken, and expert opinion
about the fraction of cases diagnosed but not reported, or
10
Progress in applying the Task Force framework for
assessment of TB surveillance data, as of July 2011a
a
All countries shown in orange participated in regional workshops held from
April 2009 to June 2010, with the exception of the United Republic of Tanzania
where a country mission was undertaken in October 2009 and India where
three country missions were undertaken between April and July 2011. As
follow-up to the regional workshop held for countries in the Western Pacific
Region in June 2010, a national workshop was also held in China in June 2011.
Further details about these workshops are provided in ANNEX 1.
not diagnosed at all, was documented. Reliance on expert
opinion is one of the reasons for uncertainty in estimates
(Box 2.1); strengthening of surveillance and better quantification of under-reporting (i.e. the number of cases
that are missed by surveillance systems) are needed to
reduce this uncertainty (efforts to do this are discussed
in section 2.5).
When the 2010 global report was published, 78 countries had been covered by regional or country workshops. Between November 2010 and July 2011, a further
17 countries in the African Region as well as India were
covered, and a national-level workshop was held in China
as follow-up to a regional workshop held in June 2010.
Major revisions were made for most African countries
(Box 2.2); these explain why the global estimates of cases
(as well as deaths) that appear in this report – not only
for 2010 compared with 2009, but also for the time-series
dating back to 1990 – are lower than those published in
previous reports. For countries not covered in workshops, estimates are based on extending previous timeseries (see Annex 1 for details).
In 2010, there were an estimated 8.8 million incident
cases of TB (range, 8.5 million–9.2 million) globally,
equivalent to 128 cases per 100 000 population (Table 2.1,
Table 2.2, Figure 2.3). Most of the estimated number of
cases in 2010 occurred in Asia (59%) and Africa (26%);1
smaller proportions of cases occurred in the Eastern
Mediterranean Region (7%), the European Region (5%)
and the Region of the Americas (3%). The 22 HBCs that
have been given highest priority at the global level since
2000 (listed in Table 2.1 and Table 2.2) accounted for 81%
1
Asia refers to the WHO regions of South-East Asia and the
Western Pacific. Africa means the WHO African Region.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 10
23/09/11 07:20
FIGURE 2.2
Framework for assessment of TB surveillance data (notification and vital registration data)
DATA QUALITY
TRENDS
Do surveillance data reflect
trends in incidence and
mortality?
ARE ALL CASES AND
DEATHS CAPTURED IN
SURVEILLANCE DATA?
• Completeness
• No duplications, no misclassifications
• Internal and external consistency
IMPROVE surveillance system
• Analyse time-changes in notifications and
deaths alongside changes in e.g. casefinding, case definitions, HIV prevalence
and other determinants
EVALUATE trends and impact of TB control
•
•
•
•
•
UPDATE estimates of TB incidence and mortality
“Onion” model
Inventory studies
Capture re-capture studies
Prevalence surveys
Innovative operational research
notifications ~ incidence
VR mortality data ~ deaths
If appropriate, CERTIFY TB surveillance data as
a direct measure of TB incidence and mortality
BOX 2.2
Revision of estimates of the burden of disease caused by TB in African countries
This report includes improved estimates of TB incidence, prevalence and mortality for countries in the African Region, following
consultations with representatives from 17 countries during a five-day workshop held in Zimbabwe in December 2010. It was the
first such workshop held in the African region for more than 10 years. In the interim, country missions were used to review and
update estimates for Kenya (in 2006) and the United Republic of Tanzania (in 2009). Participants at the workshop represented
the following countries: Botswana, Burkina Faso, Burundi, Côte d’Ivoire, the Democratic Republic of the Congo, Ethiopia, Ghana,
Kenya, Malawi, Mali, Mozambique, Namibia, Nigeria, Rwanda, Uganda, Zambia and Zimbabwe.
Before the workshop, estimates of TB incidence were mostly based on assessments of the fraction of incident cases captured
in notification data in the late 1990s. With the analysis of detailed national and sub-national surveillance data undertaken in the
workshop, previous assumptions were found to be overestimating cases (and in turn, prevalence and mortality). Estimates of
the proportion of cases being diagnosed and reported to national TB control programmes (NTPs) were heavily revised, mostly
upwards; that is, fewer incident cases were assessed as being missed by NTPs. Following the workshop, the number of incident
cases in the African Region was estimated at 2.3 million in 2010 (range, 2.1 million–2.5 million) and the number of deaths caused
by TB (including those among HIV-positive people) was estimated at 254 000 (range, 227 000–282 000).
As with previous workshops in other regions, considerable attention was also given to assessments of surveillance systems.
Recommendations for strengthening surveillance to move towards the ultimate goal of directly measuring cases and deaths from
notification and VR data were defined.
A full report of the workshop in Zimbabwe can be found at:
www.who.int/tb/advisory_bodies/impact_measurement_taskforce/meetings
of all estimated cases worldwide. The five countries with
the largest number of incident cases in 2010 were India
(2.0 million–2.5 million), China (0.9 million–1.2 million),
South Africa (0.40 million–0.59 million), Indonesia (0.37
million–0.54 million) and Pakistan (0.33 million–0.48
million). India alone accounted for an estimated one
quarter (26%) of all TB cases worldwide, and China and
India combined accounted for 38%.
Of the 8.8 million incident cases in 2010, 1.0 mil-
lion–1.2 million (12–14%) were among people living with
HIV, with a best estimate of 1.1 million (13%) (Table 2.1).
The proportion of TB cases coinfected with HIV is highest in countries in the African Region (Figure 2.4); overall, the African Region accounted for 82% of TB cases
among people living with HIV.
Globally, incidence rates fell slowly from 1990 to
around 1997, and then increased up to around 2001 as
the number of TB cases in Africa was driven upwards by
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 11
11
23/09/11 07:20
TABLE 2.1
Estimated epidemiological burden of TB, 2010. Numbers in thousandsa
MORTALITYb
POPULATION
c
BEST
Afghanistan
31 412
12
Bangladesh
148 692
64
Brazil
194 946
Cambodia
China
14 138
1 341 335
5.0
8.6
54
LOW
8.6
47
3.1
6.2
PREVALENCE
HIGH
BEST
LOW
INCIDENCE
HIGH
BEST
LOW
HIV-POSITIVE INCIDENT TB CASES
HIGH
BEST
LOW
HIGH
16
110
51
180
59
49
71
–
–
–
85
610
280
1 000
330
270
400
0.7
0.3
1.1
92
34
160
85
70
100
8.3
18
12
93
42
150
62
53
72
52
56
1 500
1 300
1 700
1 000
910
1 200
18
4.0
18
15
3.4
10
22
4.7
28
DR Congo
65 966
36
27
45
350
160
560
220
190
250
Ethiopia
82 950
29
23
35
330
140
520
220
200
230
1 224 614
320
210
470
3 100
2 000
4 600
2 300
2 000
2 500
239 871
64
42
91
690
300
1 200
450
370
540
18
110
49
180
120
120
130
50
45
55
17
110
54
200
130
87
170
77
53
110
Indiad
Indonesia
Kenya
40 513
Mozambique
23 391
Myanmar
6.9
11
4.9
7.0
9.4
13
–
110
24
–
75
9.9
–
160
29
47 963
20
12
31
250
180
310
180
160
210
37
21
57
Nigeria
158 423
33
11
68
320
110
690
210
99
360
51
25
87
Pakistan
173 593
58
39
84
630
270
1 100
400
330
480
1.2
0.7
1.9
Philippines
93 261
31
21
43
470
410
530
260
210
310
1.0
0.5
1.8
Russian
Federation
142 958
26
16
42
190
70
330
150
130
180
8.1
6.8
9.4
50 133
25
16
38
400
180
630
490
400
590
Thailand
69 122
11
16
130
55
210
94
78
110
15
13
18
Uganda
33 425
64
32
100
70
56
85
38
30
46
30
28
32
South Africa
UR Tanzania
44 841
Viet Nam
87 848
Zimbabwe
12 571
High-burden
countries
5.1
5.8
29
3.4
7.0
3.3
4.7
19
2.1
7.3
6.9
43
5.1
300
240
350
82
39
130
79
75
85
290
130
510
180
130
220
51
23
80
80
61
100
60
47
76
8 500 12 000
7 200
6 800
7 500
860
780
950
7.6
4.6
11
4 321 967
860
730
1 000
10 000
AFR
836 970
250
220
280
2 800
2 300
3 300
2 300
2 100
2 500
900
820
980
AMR
933 447
20
17
23
330
260
410
270
250
280
35
31
38
EMR
596 747
95
74
120
1 000
670
1 500
650
580
730
12
EUR
SEAR
9.8
15
896 480
61
48
75
560
430
720
420
390
450
20
19
22
1 807 594
500
370
640
5 000
3 700
6 500
3 500
3 200
3 700
190
140
230
2 500
2 200
2 800
1 700
1 500
1 800
35
12 000 11 000 14 000
8 800
8 500
9 200 1 100
WPR
1 798 335
130
120
150
Global
6 869 573
1 100
920
1 200
26
1 000
45
1 200
– indicates no estimate available.
a
Numbers for mortality, prevalence and incidence shown to two significant figures.
b
Mortality excludes deaths among HIV-positive TB cases. Deaths among HIV-positive TB cases are classified as HIV deaths according to ICD-10.
c
Best, low and high indicate the point estimate and lower and upper bounds of the 95% uncertainty interval.
d
Estimates for India have not yet been officially approved by the Ministry of Health & Family Welfare, Government of India and should therefore be considered provisional.
the HIV epidemic (Figure 2.5). Since 2002, the incidence
rate has fallen at around 1.3% per year and if this trend is
sustained, MDG Target 6.c will be achieved. It should be
highlighted that in previous reports in this series, incidence rates were estimated to have peaked in 2004; this
has been revised following the major review of estimates
of TB cases and deaths in African countries in December
2010 (Box 2.2). The absolute number of incident cases
has also started to fall very slowly since 2006, when the
decline in the incidence rate (per 100 000 population)
started to exceed the rate of growth in the world’s population.
Incidence rates are declining in all of WHO’s six
regions (Figure 2.6). The rate of decline varies from less
12
than 1% per year in the Eastern Mediterranean Region
to 1.8% per year in the African Region and 3.7% per year
in the Region of the Americas. Incidence rates peaked
around the mid-1990s in the Eastern Mediterranean
Region, around 2000 in the European and South-East
Asia regions and around 2004 in the African Region.
The incidence rate has been declining since 1990 in the
Region of the Americas and the Western Pacific Region.
The latest assessment for the 22 HBCs suggests that
incidence rates are falling in 10 countries, approximately stable in 11 countries and increasing slowly in South
Africa (Figure 2.7). Estimates of TB incidence have wide
uncertainty intervals in Mozambique, Nigeria and Uganda; the prevalence surveys planned in these countries
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 12
23/09/11 07:20
TABLE 2.2
Estimated epidemiological burden of TB, 2010. Rates per 100 000 population except where indicated
MORTALITYa
POPULATION
(THOUSANDS)
PREVALENCE
BESTb
LOW
HIGH
BEST
LOW
HIV PREVALENCE IN
INCIDENT TB CASES (%)
INCIDENCE
HIGH
BEST
LOW
HIGH
BEST
LOW
HIGH
Afghanistan
31 412
38
27
50
352
161
578
189
155
226
–
–
–
Bangladesh
148 692
43
32
57
411
188
671
225
184
269
0.2
0.1
0.3
Brazil
194 946
Cambodia
China
14 138
1 341 335
2.6
61
4.1
1.6
44
3.9
4.3
82
4.2
47
17
80
43
36
51
660
296
1 070
437
373
506
23
6.6
23
6.3
23
6.8
108
93
123
78
68
88
1.7
1.0
2.8
DR Congo
65 966
54
41
69
535
250
850
327
281
376
8.2
6.0
Ethiopia
82 950
35
28
42
394
173
623
261
240
282
–
–
–
1 224 614
26
17
39
256
161
373
185
167
205
5.0
3.3
7.1
Indiac
Indonesia
239 871
27
18
38
289
123
484
189
155
226
Kenya
40 513
17
12
23
283
122
448
298
286
311
Mozambique
23 391
49
30
74
491
233
844
544
374
Myanmar
47 963
41
24
65
525
381
643
384
328
7.2
4.0
2.3
11
6.4
41
37
45
746
61
60
61
445
20
10
30
25
24
25
Nigeria
158 423
21
43
199
70
438
133
63
228
Pakistan
173 593
34
22
49
364
154
611
231
189
277
0.3
0.2
0.5
Philippines
93 261
33
22
46
502
438
566
275
226
329
0.4
0.2
0.7
Russian
Federation
142 958
18
11
29
136
49
233
106
90
124
5.3
5.2
5.4
South Africa
50 133
50
31
75
795
364
1 260
981
806
1 170
60
60
61
Thailand
69 122
16
10
23
182
80
300
137
112
163
16
16
17
Uganda
33 425
15
10
22
193
95
306
209
168
254
54
53
55
UR Tanzania
44 841
13
11
15
183
87
281
177
166
189
38
38
39
Viet Nam
87 848
34
21
49
334
147
576
199
152
253
Zimbabwe
12 571
27
17
40
402
185
639
633
486
799
75
75
76
4 321 967
20
17
23
231
196
268
166
158
174
12
11
14
AFR
836 970
30
26
34
332
277
392
276
256
296
39
35
44
AMR
933 447
36
28
44
29
27
30
13
12
15
EMR
596 747
173
112
246
109
97
122
2.2
1.7
2.8
EUR
896 480
63
47
80
47
44
50
5.0
4.4
5.5
278
206
360
193
179
207
5.4
4.1
6.9
139
124
156
93
85
102
2.1
1.5
178
156
201
128
123
133
High-burden
countries
SEAR
1 807 594
WPR
1 798 335
Global
6 869 573
2.2
16
6.8
27
7.5
15
1.9
12
5.4
21
6.6
13
2.5
20
8.3
35
8.5
18
4.3
13
2.9
12
6.2
2.7
14
– indicates no estimate available.
a
Mortality excludes deaths among HIV-positive TB cases. Deaths among HIV-positive TB cases are classified as HIV deaths according to ICD-10.
b
Best, low and high indicate the point estimate and lower and upper bounds of the 95% uncertainty interval.
c
Estimates for India have not yet been officially approved by the Ministry of Health & Family Welfare, Government of India and should therefore be considered provisional.
should help to improve estimates of disease burden (see
section 2.5).
Estimates of the number of cases broken down by age
and sex have been prepared by an expert group as part of
an update to the Global Burden of Disease (GBD) study.1
These indicate that women 2 account for an estimated
3.2 million incident cases (range, 3.0 million–3.5 million), equivalent to 36% of all cases. Estimates of the
numbers of TB cases among women and children need to
be improved through more reporting and more analysis
of notification data disaggregated by age and sex.
2.2
Estimates of the prevalence of TB
The prevalence of TB can be directly measured in nationwide population-based surveys; WHO has recently published comprehensive theoretical and practical guidance
on how to design, implement, analyse and report such
surveys.3 When repeat surveys are conducted, trends in
TB prevalence can be directly measured as well. If sur1
2
3
The expert group is convened by the WHO Global Task Force
on TB Impact Measurement. The GBD study is an update to
Lopez AD et al. Global burden of disease and risk factors. New
York, Oxford University Press and The World Bank, 2006.
Defi ned as females aged *15 years old.
TB prevalence surveys: a handbook. Geneva, World Health
Organization, 2011 (WHO/HTM/TB/2010.17).
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 13
13
23/09/11 07:20
Figure 2.3
Estimated TB incidence rates, 2010
RUSSIAN FEDERATION
CHINA
INDIA
PAKISTAN
AFGHANISTAN
NIGERIA
BRAZIL
DR CONGO
ETHIOPIA
UGANDA
KENYA
MYANMAR
THAILAND
INDONESIA
UR TANZANIA
ZIMBABWE
SOUTH AFRICA
Estimated new TB
cases (all forms) per
100 000 population
0–24
MOZAMBIQUE
25–49
50–99
100–299
≥300
No estimate
Figure 2.4
Estimated HIV prevalence in new TB cases, 2010
HIV prevalence
in new TB cases,
all ages (%)
0–4
5–19
20–49
≥50
No estimate
14
WHO Report 2011 | Global tuberculosis control
BANGLADESH
VIET NAM
CAMBODIA
PHILIPPINES
FIGURE 2.5
Global trends in estimated rates of TB incidence, prevalence and mortality. Left: Global trends in estimated incidence rate
including HIV-positive TB (green) and estimated incidence rate of HIV-positive TB (red). Centre and right: Trends in estimated TB
prevalence and mortality rates 1990–2010 and forecast TB prevalence and mortality rates 2011–2015. The horizontal dashed lines
represent the Stop TB Partnership targets of a 50% reduction in prevalence and mortality rates by 2015 compared with 1990. Shaded
areas represent uncertainty bands. Mortality excludes TB deaths among HIV-positive people.
Incidence
Prevalence
Mortality
Rate per 100 000 population
150
100
50
250
25
200
20
150
15
100
10
50
5
0
0
0
1990
1995
2000
2005
2010
1990
1995
2000
2005
2010
1990
2015
1995
2000
2005
2010
2015
FIGURE 2.6
Estimated TB incidence rates by WHO region, 1990–2010. Regional trends in estimated TB incidence rates (green) and estimated
incidence rates of HIV-positive TB (red). Shaded areas represent uncertainty bands.
Africa
The Americas
Eastern Mediterranean
350
120
50
250
100
40
200
Rate per 100 000 population
140
60
300
80
150
30
100
20
50
10
20
0
0
0
Europe
60
40
South-East Asia
Western Pacific
60
200
50
40
150
150
100
30
100
20
50
50
10
0
0
0
1990
1995
2000
2005
2010
1990
1995
2000
2005
2010
1990
1995
2000
2005
2010
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 15
15
23/09/11 07:20
FIGURE 2.7
Estimated TB incidence rates, 22 high-burden countries, 1990–2010. Trends in estimated TB incidence rates (green) and
estimated incidence rates of HIV-positive TB (red). Shaded areas represent uncertainty bands.
Afghanistan
Bangladesh
Brazil
Cambodia
China
120
300
250
100
250
200
150
60
150
100
100
40
50
50
20
0
0
0
DR Congo
Ethiopia
400
100
200
50
0
0
Indonesia
200
200
350
150
100
200
150
100
100
50
50
50
0
0
0
Nigeria
Myanmar
250
150
100
100
300
200
150
Mozambique
Kenya
250
250
Rate per 100 000 population
400
250
300
0
150
Indiaa
300
200
600
80
200
50
0
Pakistan
Philippines
500
1000
300
500
400
800
500
250
400
400
600
300
400
200
200
100
100
50
100
0
0
0
0
0
Russian Federation
200
300
200
200
100
Thailand
South Africa
300
150
Uganda
UR Tanzania
1000
150
1000
800
150
800
100
600
50
200
0
0
Viet Nam
200
600
150
400
100
200
50
100
400
50
250
0
0
1990
Zimbabwe
1995
2000
2005
2010
0
1990
1995
2000
2005
2010
1990
1995
2000
2005
2010
250
800
200
600
150
100
400
50
200
0
0
1990
1995
2000
2005
2010
a
1990
1995
2000
2005
2010
Estimates for India have not yet been officially approved by the Ministry of Health &
Family Welfare, Government of India and should therefore be considered provisional.
vey data are not available, prevalence can be indirectly
estimated as the product of incidence and the average
duration of disease, but with considerable uncertainty
(Annex 1). Although the data available from prevalence
surveys allow for a robust assessment of trends in the
Western Pacific Region (especially in China and the
Philippines) and are becoming more widely available
for countries with a high burden of TB (see section 2.5),
TB prevalence can be estimated only indirectly in most
countries.
There were an estimated 12.0 million prevalent cases
(range, 11.0 million–14.0 million) of TB in 2010 (Table
16
2.1). This is equivalent to 178 cases per 100 000 population (Table 2.2). Globally, prevalence rates have been falling since 1990, with a faster decline after 1997. However,
current forecasts suggest that the Stop TB Partnership’s
target of halving TB prevalence by 2015 compared with a
baseline of 1990 will not be met (Figure 2.5). Regionally,
prevalence rates are declining in all of WHO’s six regions
(Figure 2.8). The Region of the Americas has halved the
1990 level of TB prevalence already, well in advance of
the target year of 2015, and the Western Pacific Region
is close to doing so. Reductions in TB prevalence in the
Eastern Mediterranean, European and South-East Asia
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 16
23/09/11 07:20
FIGURE 2.8
Trends in estimated TB prevalence rates 1990–2010 and forecast TB prevalence rates 2011–2015, by WHO region
Shaded areas represent uncertainty bands. The horizontal dashed lines represent the Stop TB Partnership target of a 50% reduction in
the prevalence rate by 2015 compared with 1990. The other dashed lines show projections up to 2015.
Africa
The Americas
Eastern Mediterranean
400
120
400
100
300
80
300
200
60
200
40
100
Rate per 100 000 population
100
20
0
0
0
Europe
South-East Asia
120
100
Western Pacific
500
250
400
200
300
150
200
100
100
50
0
0
80
60
40
20
0
1990
1995
2000
2005
2010
2015
1990
1995
regions have been considerable since 1990, and appear to
have accelerated since 2000. Nonetheless, current forecasts suggest that the 2015 target will not be reached.
In the African Region, estimates of TB prevalence rates
are far from the target level, and halving the 1990 rate by
2015 appears unlikely.
2.3
Estimates of deaths caused by TB
Mortality caused by TB can be directly measured if a
national VR system of high coverage with accurate coding of causes of death according to the latest revision of
the international classification of diseases (ICD-10) is in
place. Sample VR systems can provide an interim solution, and mortality surveys can sometimes be used to
obtain direct measurements of TB deaths in countries
with no VR system. In the absence of VR systems or mortality surveys, TB mortality can be estimated as the product of TB incidence and the case fatality rate.
Until 2008, WHO estimates of TB mortality used
VR data for only three countries. This was dramatically
improved to 89 countries in 2009, although most of these
countries were in the European Region and the Region of
the Americas, which account for only 8% of the world’s
TB cases. The use of sample VR data from China and sur-
2000
2005
2010
2015
1990
1995
2000
2005
2010
2015
vey data from India for the first time in 2011 has enabled
a further major improvement to estimates of TB mortality
in this report (Box 2.3). The total of 91 countries for which
estimates of TB deaths are now based on direct measurements represent 46% of the deaths caused by TB in 2010.
In 2010, an estimated 1.1 million deaths (range,
0.9 million–1.2 million) occurred among HIV-negative
cases of TB (Table 2.1), including 0.32 million deaths
(range, 0.20 million–0.44 million) among women. This
was equivalent to 15 deaths per 100 000 population. In
addition, there were an estimated 0.35 million deaths
(range, 0.32 million–0.39 million) among incident TB
cases that were HIV-positive (data not shown); these
deaths are classified as HIV deaths in ICD-10.1 Thus in
total, approximately 1.4 million people (range, 1.2 million–1.5 million) died of TB in 2010. This estimate is
considerably lower than the estimates of 1.3 million
TB deaths among HIV-negative people and 0.4 million
deaths from TB among HIV-positive people that were
published in 2010,2 following a major revision of esti1
2
International statistical classification of diseases and related health
problems, 10th revision (ICD-10), 2nd ed. Geneva, World Health
Organization, 2007.
Global tuberculosis control 2010. Geneva, World Health Organization, 2010 (WHO/HTM/TB/2010.7).
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 17
17
23/09/11 07:20
BOX 2.3
Estimates of TB mortality are increasingly based on direct measurements
Estimates of TB mortality published in this report are much improved compared with those of previous years, following a major
increase in the availability and use of direct measurements from national or sample vital registration (VR) systems as well as
mortality surveys. In the 2010 global report, 602 country-year data points from 89 countries (including 3 high-burden countries
– Brazil, the Russian Federation and the Philippines) were used. In this 2011 report, direct measurements from China and India
have been used for the first time. In China, the data come from a sample VR system covering all 31 provinces. In India, data from
6 mortality surveys were pooled to obtain a national estimate for 2005, and to derive a complete time-series for 1990–2010. As
a result, direct measurements of mortality from 91 countries with 720 country-year VR data points and 2 mortality survey data
points were used; the proportion of global mortality due to TB that is measured directly has increased from 8% to 46%. Estimates
for 2010 and trends since 1990 are now more robust, with narrower uncertainty intervals.
Deaths caused by TB in India were estimated at 408 000 in 2005 (range, 290 000–546 000), higher than the previous indirect
estimate of 291 000 (range, 177 000–437 000). In China, TB deaths were previously estimated at 155 000 (99 000–226 000) in
2009; the updated estimate is 55 000 (53 000–57 000).
Measurements of TB mortality among HIV-positive people from VR data remain scarce and are often unreliable. HIV deaths may
be miscoded as TB deaths, and TB deaths among HIV-positive people may be impossible to quantify because TB is only recorded
as a contributory cause of death. About one third of countries submitting aggregated VR data on causes of death to WHO do not
report data on contributory causes. Estimates of TB mortality in HIV-infected individuals thus remain highly uncertain.
Further efforts to implement national or sample VR systems are essential to strengthen TB surveillance and improve assessment
of progress towards the 2015 global target for reductions in TB mortality.
BOX 2.4
Parental deaths caused by TB have created
large numbers of orphans
Globally in 2009, there were an estimated 14 million
(range, 13–15 million) children aged <15 years who were
orphans as a consequence of a parental death caused
by HIV/AIDS.1 Of these children, an estimated 3.1 million
(range, 2.7–3.5 million) had been orphaned as a result of a
parental death from HIV-associated TB. There were also an
estimated 6.5 million (range, 5.5–7.7 million) children who
were orphans as a result of a parental death caused by TB
among people who were HIV-negative.
In total in 2009, there were an estimated 9.7 million (range,
8.5–11 million) children who were orphans as a result of
losing at least one of their parents to TB (including HIVassociated TB).
1
UNAIDS. www.unaids.org/en/dataanalysis/epidemiology
www.unaids.org/en/dataanalysis/epidemiology,
accessed 27 June 2011.
mates of the numbers of TB cases and deaths in African
countries (Box 2.2).
The number of TB deaths per 100 000 population
among HIV-negative people plus the estimated number
of TB deaths among HIV-positive people equates to a
best estimate of 20 deaths per 100 000 population.
Globally, mortality rates (excluding deaths among
HIV-positive people)1 have fallen by more than one-third
since 1990, and the current forecast suggests that the
Stop TB Partnership’s target of a 50% reduction by 2015
compared with a baseline of 1990 will be achieved (Figure
2.5). Mortality rates are also declining in all of WHO’s
six regions (Figure 2.9). The Region of the Americas and
the Western Pacific Region halved the 1990 level of mortality by 2000 and 2003 respectively, well in advance of
the target year of 2015. The Eastern Mediterranean and
European regions appear to have halved the 1990 level of
mortality by 2010, and the South-East Asia Region is on
track to reach the target by 2015. It is only in the African
Region that the target of halving mortality rates by 2015
looks out of reach.
Among the 22 HBCs, mortality rates appear to be falling with the possible exception of Afghanistan (Figure
2.10). Even allowing for uncertainty in the estimates,
five countries have reached the target of halving the 1990
mortality rate by 2010 (Brazil, Cambodia, China, Uganda
and the United Republic of Tanzania), and several other
countries have a good chance of achieving the target by
2015.
1
18
Trends in TB mortality rates are restricted to TB deaths
among HIV-negative people, given that TB deaths among
HIV-positive people are classified as HIV deaths in ICD-10.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 18
23/09/11 07:20
BOX 2.5
China has dramatically reduced the burden of disease caused by TB
The past 20 years have seen major efforts to reduce the burden of TB in China and to measure trends to demonstrate impact. In the
1990s, a World Bank loan was used to fund the introduction and expansion of DOTS in 13 provinces of the country; this was followed by
nationwide coverage. After the SARS [severe acute respiratory syndrome] epidemic in 2003, surveillance of TB cases was strengthened
as part of wider improvements to surveillance of all infectious diseases, and reporting of cases and treatment outcomes from all
providers – notably TB dispensaries – improved dramatically. National prevalence surveys were undertaken in 1990, 2000 and 2010.
Following discussions with WHO during an epidemiology workshop for countries in the Western Pacific Region in June 2010, data on TB
deaths recorded in a sample vital registration (VR) system covering all 31 provinces were analysed for the first time.
In June 2011, a workshop to review and update estimates of TB cases and deaths based on the new data was hosted by the Chinese
Centers for Disease Control in Beijing. A team from WHO participated in this workshop. The main conclusions were that prevalence was
halved between 1990 and 2010, mortality rates fell by almost 80% between 1990 and 2010 and
that incidence rates have fallen by 3.4% per year since 1990. Further details are provided below.
Incidence and notifications (black)
National surveys found a prevalence rate of bacteriologically-confirmed pulmonary TB of 177
(165–189) per 100 000 population (all ages) in 1990, 160 (142–177) per 100 000 population (all
ages) in 2000 and 119 (113–135) per 100 000 population aged ≥15 years in 2010. Adjusting for
age and accounting for extrapulmonary TB, the estimated overall prevalence rate per 100 000
population fell from 215 (200–230) per 100 000 population in 1990 to 108 (93–123) per 100 000
population in 2010.1 The rate of decline was 2.2% per year between 1990 and 2000, and 4.7%
per year between 2000 and 2010. These estimated reductions in TB prevalence are likely to
be conservative, because screening methods were improved over time (for example, full chest
X-rays were taken in 2010 compared with the use of less sensitive fluoroscopy in 2000) and
thus cases were more likely to be detected in successive surveys.
Rate per 100 000 population
TB prevalence
150
100
50
1990
TB mortality
2010
2000
2005
2010
200
180
160
140
120
100
1990
1995
Mortality
20
Rate per 100 000 population
MDR-TB
2005
220
TB incidence
If TB surveillance performs to very high standards, TB incidence is best measured from routine
notification data. Since 2005, a web-based and mandatory TB reporting system has been fully
operational and directly covers almost all health facilities in the country. In some remote areas
where facilities are not linked directly to the system, reports are provided to the nearest facility
that is linked to the system. In 2009, the TB surveillance system was assessed to capture close
to 100% of all detected TB cases. When combined with measured trends in prevalence and
mortality, incidence rates were estimated to have declined by 3.4% per year since 1990.
2000
Prevalence
Rate per 100 000 population
Data on TB mortality are available from two sources. The first is a series of two national mortality
surveys conducted in 1989 and 1999. The second is a sample VR system in which mortality data
are recorded for 161 counties with a population of about 76 million representing all 31 provinces
of China. Standardized coding of causes of deaths has been in place since 2004, using a national
coding scheme derived from ICD-10. The data from the surveys and the sample VR system are
remarkably consistent. The ratio of TB deaths (excluding HIV) to TB notifications fell from 24%
in 2000 to 6% in 2010, as a result of (i) a likely decline in case fatality rates associated with
improvements in the quality of TB care and (ii) improved reporting of TB cases at the time of
diagnosis, particularly after 2005 (see below). Overall, TB mortality has declined rapidly, at an
average rate of 8.6% per year between 1990 and 2010.
1995
15
10
Two sources of drug resistance surveillance (DRS) data are available: (i) data from surveys
designed to measure the magnitude of drug resistance that were conducted among samples
of notified TB cases in 10 provinces between 1995 and 2005 and at national level in 2007; and
5
(ii) data from the TB prevalence surveys conducted in 2000 and 2010 in which all diagnosed
culture-positive cases were tested for drug susceptibility. In the 2000 prevalence survey, 7.6%
1990
1995
2000
2005
2010
of culture-positive TB cases were found to have MDR strains (standard deviation (SD), 1.6%),
compared with 5.4% (SD, 1.6%) in the 2010 prevalence survey. The difference is not statistically
significant. However, the estimated number of prevalent MDR-TB cases in the general population, obtained from taking the product of
TB prevalence and the observed proportion of prevalent cases with MDR-TB, fell from 164 000 (99 000–250 000) in 2000 to 78 000
(41 000–126 000) in 2010.
Trends in the proportion of notified cases that have MDR-TB in China cannot be established with confidence due to the highly heterogeneous trends across provinces in which surveys of drug resistance have been carried out. A second national drug resistance survey
will provide a robust assessment of trends in the proportion of MDR-TB among notified cases.
1
This is despite rapid aging of the population which, other things being equal, increases the burden of TB because TB is more common among adults.
The proportion of children in the population fell from 28% in 1990 to 26% in 2000 and 20% in 2010.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 19
19
23/09/11 07:20
FIGURE 2.9
Trends in estimated TB mortality rates 1990–2010 and forecast TB mortality rates 2011–2015, by WHO region
Estimated TB mortality excludes TB deaths among HIV-positive people. Shaded areas represent uncertainty bands.a The horizontal
dashed lines represent the Stop TB Partnership target of a 50% reduction in the mortality rate by 2015 compared with 1990. The other
dashed lines show projections up to 2015.
Africa
The Americas
Eastern Mediterranean
40
8
40
30
30
6
20
4
10
2
0
0
Rate per 100 000 population
20
Europe
10
0
South-East Asia
Western Pacific
50
20
15
40
15
10
30
10
20
5
5
10
0
0
1990
a
1995
2000
2005
2010
2015
0
1990
1995
2005
2010
2015
1990
1995
2000
2005
2010
2015
The width of uncertainty bands narrows as the proportion of regional mortality estimated using vital registration data increases.
2.4 Estimates of the number of cases
of MDR-TB
In previous reports in this series as well as WHO reports
on drug-resistant TB specifically, estimates of the number of incident cases of MDR-TB have been presented.1
For the fi rst time in this report, estimates of the number
of prevalent cases of MDR-TB are presented instead. The
reasons are that MDR-TB is a chronic disease and without appropriate diagnosis and treatment for most of these
cases (see Chapter 3), there are many more prevalent
cases than incident cases; calculations of the number
of prevalent cases of MDR-TB are more readily understood compared with the complex calculations needed to
estimate the incidence of MDR-TB; and the number of
prevalent cases of MDR-TB directly influences the active
transmission of strains of MDR-TB.
The estimated number of prevalent cases of MDRTB can be estimated at global level as the product of the
estimated number of prevalent cases of TB and the best
estimate of the proportion of notified TB patients2 with
MDR-TB at global level. In 2010, there were an estimated
650 000 cases of MDR-TB among the world’s 12.0 million prevalent cases of TB. Estimates at country level are
20
2000
not presented for reasons explained in Annex 1. However,
estimates of the proportion of new and retreatment cases
that have MDR-TB are summarized in Table 2.3.
A recurring and important question is whether the
number of MDR-TB cases is increasing, decreasing
or stable. A reliable assessment of trends in MDR-TB
requires data from Class A continuous surveillance3 or
data from periodic surveys of drug resistance that are
designed, implemented and analysed according to WHO
guidelines.4 There has been substantial progress in the
coverage of continuous surveillance and surveys of drug
resistance (Figure 2.11). Unfortunately, progress is not yet
sufficient to provide a defi nitive assessment of trends in
MDR-TB globally or regionally (Box 2.6).
1
2
3
4
In the 2010 WHO report on global TB control, it was estimated that there were 440 000 incident cases of MDR-TB in
2008.
This includes new and retreatment cases (see Chapter 3 for
defi nitions).
Class A continuous surveillance refers to data from ongoing
surveillance of drug resistance that are representative of the
caseload of patients.
Guidelines for the surveillance of drug resistance in tuberculosis – 4th
ed. Geneva, World Health Organization, 2010 (WHO/HTM/
TB/2009.422).
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 20
23/09/11 07:20
FIGURE 2.10
Trends in estimated TB mortality rates 1990–2010 and forecast TB mortality rates 2011–2015, 22 high-burden countries
Estimated TB mortality excludes TB deaths among HIV-positive people. Shaded areas represent uncertainty bands. The horizontal
dashed lines represent the Stop TB Partnership target of a 50% reduction in the mortality rate by 2015 compared with 1990. The other
dashed lines show projections up to 2015.
80
60
20
0
0
80
50
5
0
0
India
40
40
30
30
40
20
20
20
10
10
0
0
0
150
100
50
0
Myanmar
0
Philippines
70
100
60
80
50
60
40
40
30
20
20
10
0
0
UR Tanzania
Uganda
Thailand
100
40
80
30
60
20
40
10
20
0
0
1990 1995 2000 2005 2010 2015
1990 1995 2000 2005 2010 2015
1990 1995 2000 2005 2010 2015
50
50
40
40
30
30
20
20
10
10
0
0
1990 1995 2000 2005 2010 2015
2.5
5
Pakistan
Nigeria
Zimbabwe
15
10
0
35
30
25
20
15
10
5
0
0
20
20
0
20
25
40
50
40
60
60
100
60
Viet Nam
30
150
80
Kenya
Indonesia
a
200
South Africa
Russian Federation
70
60
50
40
30
20
10
0
15
0
60
200
150
10
50
140
120
100
80
60
40
20
0
20
100
50
Mozambique
200
5
Ethiopia
DR Congo
Rate per 100 000 population
10
40
20
China
Cambodia
15
60
40
Brazil
Bangladesh
Afghanistan
80
a
1990 1995 2000 2005 2010 2015
Estimates for India have not yet been officially approved by the Ministry of Health &
Family Welfare, Government of India and should therefore be considered provisional.
Strengthening measurement of
the burden of disease caused by TB:
the WHO Global Task Force on TB
Impact Measurement
The estimates of TB incidence, prevalence and mortality
and their trend presented in sections 2.1–2.4 are based on
the best available data and analytical methods. In 2009,
methods were fully reviewed and updated, and between
April 2009 and July 2011 consultations were held with
96 countries accounting for 89% of the world’s TB cases. Nonetheless, there is considerable scope for further
improvement. In this fi nal section of the chapter the latest status of efforts to improve measurement of the burden of disease caused by TB, under the umbrella of the
WHO Global Task Force on TB Impact Measurement,
are described.
Established in mid-2006, the mandate of the WHO
Global Task Force on TB Impact Measurement is to
ensure the best possible assessment of progress towards
achieving the 2015 global targets for reductions in the
burden of disease caused by TB, to report on progress
in the interim and to strengthen capacity for monitoring and evaluation at the country level. The Task Force
includes representatives from leading technical and
fi nancial partners and countries with a high burden of
TB.1
1
Partners that are actively participating in the work of the Task
Force include the Centers for Diseases Control (United States
of America), the European Centre for Disease Prevention and
Control, the Global Fund, the Health Protection Agency in the
UK, the KNCV Tuberculosis Foundation, the London School
of Hygiene and Tropical Medicine in the UK, the Research
Institute for Tuberculosis in Japan, the Union and USAID.
Many countries with a high burden of TB are engaged in the
work of the Task Force.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 21
21
23/09/11 07:20
TABLE 2.3
Estimated proportion of TB cases that have MDR-TB, 27 high MDR-TB burden countries and WHO regions
ESTIMATED % OF NEW
TB CASES WITH MDR-TBa
Armenia
Azerbaijan
9.4
22
Bangladesh
Belarus
2.1
CONFIDENCE INTERVAL
7.0–12
43
38–49
19–27
56
50–62
28
25–32
24–28
60
58–63
Bulgaria
2.0
1.1–3.2
24
18–32
China
5.7
4.6–7.1
26
22–30
2.2
0.1–5.3
Estonia
18
Ethiopia
1.6
9.4
1.9–17
13–24
44
32–58
0.9–2.8
12
5.6–21
27–35
Georgia
9.5
8.2–11
31
India
2.1
1.5–2.7
15
13–17
Indonesia
1.8
1.1–2.7
17
8.1--26
Kazakhstan
14
11–18
45
44–47
Kyrgyzstan
14
12–17
39
35–43
Latvia
10
8.0–13
24
16–33
Lithuania
11
8.8–13
52
47–57
10
6.9–14
Myanmar
4.2
3.1–5.6
Nigeria
2.2
0.1–5.3
Pakistan
3.4
0.8–6.0
4.0
2.9–5.5
21
14–29
17–22
65
62–68
16–19
46
Philippines
Republic of Moldova
19
Russian Federation
18
South Africa
1.8
1.4–2.3
9.4
21
6.7
1.9–17
7.3–34
41–52
5.4–8.2
Tajikistan
17
11–24
62
53–70
Ukraine
16
14–19
44
40–49
Uzbekistan
14
11–19
49
42–56
Viet Nam
2.7
2.0–3.7
19
14–25
High MDR-TB burden countries
3.8
2.0–5.7
21
14–28
AFR
1.9
0.6–3.3
AMR
2.1
0.7–3.4
12
3.8–19
EMR
3.4
0.9–5.9
21
7.5–34
8.6–16
37
33–41
EUR
12
9.4
3.0–16
SEAR
2.1
1.7–2.5
17
17–18
WPR
4.9
3.6–6.1
23
20–27
Global
3.4
1.9–5.0
20
14–25
Best estimates are for the latest available year. Estimates in italics are based on regional data.
At its second meeting in December 2007, the Task
Force defi ned three strategic areas of work:1
strengthening surveillance towards the ultimate goal
of direct measurement of incidence and mortality
from notification and VR systems;
conducting surveys of the prevalence of TB disease in
a set of global focus countries that met epidemiological and other relevant criteria; and
periodic review and updating of the methods used to
translate surveillance and survey data into estimates
of TB incidence, prevalence and mortality.
The third area of work is discussed in more detail in
Annex 1. The following sections focus on the fi rst two
22
ESTIMATED % OF RETREATMENT
TB CASES WITH MDR-TBa
1.7–2.5
26
DR Congo
a
CONFIDENCE INTERVAL
strategic areas of work. Full details of the Task Force’s
work are available on its web site.2
2.5.1 Strengthening surveillance
In 2008, the Task Force defi ned a conceptual framework
for assessment of surveillance data, as a basis for updating
estimates of the burden of disease caused by TB and for
defi ning recommendations for how surveillance needs to
1
2
TB impact measurement: policy and recommendations for how to
assess the epidemiological burden of TB and the impact of TB control.
Geneva, World Health Organization, 2009 (Stop TB policy
paper no. 2; WHO/HTM/TB/2009.416).
www.who.int/tb/advisory_bodies/impact_measurement_
taskforce
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 22
23/09/11 07:20
FIGURE 2.11
Progress in global coverage of data on drug resistance, 1994–2010
Year of most recent
representative data
on anti-TB drug
surveillance
1995–1999
2000–2004
2005–2009
2010
Ongoing in 2011
No data available
Subnational data only
be improved to reach the ultimate goal of direct measurement of TB cases and deaths from notification and VR
data (Figure 2.2). Tools to implement it in practice were
also developed, and used in the 96 country consultations
illustrated in Figure 2.1.
Building on progress and lessons learnt in the past
two years, the Task Force’s four priorities in 2011 and
2012 are:
defining standards and related benchmarks that must
be met for notification and VR data to be considered a
direct measurement of TB cases and deaths;
development of guidance on inventory studies;
development of guidance on patient or case-based
electronic recording and reporting (ERR);
institutionalizing assessments of trends in disease
burden and related efforts to strengthen surveillance
within the grant cycle of the Global Fund.
The mid-2011 version of the Task Force’s framework for
assessing surveillance data implicitly defines some of
the standards required for notification and VR data to
be considered a direct measurement of cases and deaths,
respectively. For instance, notification data should be
complete and without duplications or misclassifications.
However, for some of the elements that are assessed,
standards and benchmarks have not been explicitly
defined. For example:
the framework states that data should be internally
and externally consistent, but it does not defi ne what
this means in practice;
the framework states that no diagnosed cases should
be missed by notification systems, but it does not
specify how this should be demonstrated or at what
level “under-reporting” would be considered acceptable (understanding that even the best surveillance
systems do not capture all diagnosed cases);
the framework states that TB deaths should be recorded in VR systems, but it does not specify the standards
of coverage and accuracy in coding that must be met
for VR data to be considered a direct measure of TB
mortality.
In 2011, the Task Force convened an expert group to
develop draft standards and benchmarks, and to fieldtest these in a variety of countries (including those with
both strong and weaker surveillance systems). The aim is
to reach agreement on a set of standards and benchmarks
(and associated surveillance checklist) that can be used
as a basis for efforts to strengthen surveillance in many
countries (including all those with Global Fund grants –
see below) as well as to determine the countries for which
national surveillance data can already be used as a direct
proxy for TB cases and deaths. By July 2011, field-testing
was planned or underway in Brazil, China, Egypt, Kenya,
Thailand, the UK and the United States of America.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 23
23
23/09/11 07:20
BOX 2.6
Global and regional trends in MDR-TB
The Global Project on anti-tuberculosis drug resistance surveillance was launched in 1994 with two key objectives: (i) to estimate
the magnitude of drug resistance; and (ii) to monitor trends in drug resistance. Since 1994, significant efforts to promote the
monitoring of drug resistance through national surveys and continuous surveillance based on diagnostic testing have been made,
with coordination at the global level by WHO. A total of six global reports on drug resistance and four editions of guidelines on
the conduct of drug resistance surveys have been published. The coverage of data has improved considerably (Figure
Figure 2.11),
2.11 and
about 60% of countries now have at least one direct and representative measurement of the level of drug resistance among their
TB patients. For some of these countries, data reported for successive years have allowed the analysis of trends.
The latest available data were used to conduct an analysis of trends in MDR-TB among new (previously untreated) TB patients
for WHO regions and the world as a whole.1 Data from 74 countries and territories with measurements for at least two years
were used. There were on average 7 measurements for each of these 74 countries (range, 2–17 per country or territory). Missing
country data were imputed from a pooled estimate for countries with similar epidemiological characteristics (these groups of
countries are different from the WHO regions shown in the table), assuming that levels of MDR-TB as well as efforts to control
MDR-TB were comparable among these countries. The annual
change in the percentage of new TB patients with MDR-TB was
WHO REGION
ANNUAL
ANNUAL CHANGE
ANNUAL CHANGE
CHANGE
LOW ESTIMATE
HIGH ESTIMATE
calculated for each country or territory and then combined
(with weighting according to the total number of new TB cases
African
5.6%
–7.5%
18.7%
in the country) to produce regional and global estimates along
Americas
0.2%
–17.1%
17.5%
with their uncertainty bounds. Results are presented in the
Eastern
table.
–0.7%
–23.5%
22.0%
Mediterranean
The best estimates suggest that levels of MDR-TB among new
Europe
3.5%
–4.8%
11.9%
TB patients are relatively stable at global level and the Region
South-East Asia
–1.3%
–31.4%
28.8%
of the Americas, falling in the Eastern Mediterranean, SouthWestern Pacific
–4.5%
–12.7%
3.8%
East Asia and Western Pacific regions, and increasing in the
African and European Regions. However, there is considerable
GLOBAL
–0.3%
–14.7%
14.1%
uncertainty as illustrated by the low and high estimates of
rates of change. Despite rapid increases in the coverage of
data on drug resistance, this means that a definitive answer to the question of whether the proportion of TB cases with MDR-TB
is increasing, decreasing or stable at the global level cannot yet be provided.
Coverage of surveillance of anti-tuberculosis drug resistance must improve further and be considered an essential and fundamental
element of TB surveillance. Recent technological advances now make the diagnosis of drug-resistant TB easier, quicker and more
accessible (Chapter
Chapter 5),
5 and offer opportunities for rapid gains in global surveillance of drug-resistant TB. For this potential to
be realized, anti-tuberculosis drug resistance surveillance must be prioritized by national TB control programmes and funding
agencies.
1
Data on the prevalence of MDR-TB among previously treated TB patients were too limited to allow assessment of trends.
Inventory studies with record-linkage are used to
quantify the number of TB cases that are diagnosed but
not recorded in notification data. They allow a much
better estimation of TB incidence because they provide
concrete evidence of the gap between notified cases and
diagnosed cases (which may be especially big in countries with a large private sector), and under some circumstances allow estimation of the number of undiagnosed
cases as well. They are also an essential part of the evidence needed to demonstrate that surveillance meets the
standards required for notification data to be considered
a direct measure of TB incidence. Unfortunately, inventory studies have been implemented in very few countries
to date, and the lack of such studies is a major reason
for uncertainty in estimates of TB incidence (section 2.1).
Examples of countries where inventory studies have been
implemented include the UK, the Netherlands and several countries in the Eastern Mediterranean Region (for
24
example, Egypt, the Syrian Arab Republic and Yemen).
To facilitate and encourage much wider implementation,
WHO and its partners (notably the Centers for Disease
Control, United States of America, and the Health Protection Agency in the UK) are developing a guide on how
to design, implement, analyse and report on inventory
studies. As this report went to press, the guide was due
to be published by the end of 2011.
Assessment of various aspects of data quality is the
fi rst and most basic of the three major components of
the Task Force’s framework for assessing surveillance
data (Figure 2.2). It was clear in all regional and country
workshops that many aspects of data quality could not be
assessed because of the absence of patient or case-based
ERR systems. For example, it was not possible to assess
whether notification data included duplicate entries or
misclassified cases. Electronic datasets are also needed
to facilitate analysis of data; for example, to check for
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 24
23/09/11 07:20
internal and external consistency. In 2011, WHO and its
partners are developing a guide on ERR (Box 2.7).
The Global Fund is the major source of international
funding for national TB control programmes (NTPs),
amounting to US$ 0.5 billion in 2012 (Chapter 4). More
than 100 low-income and middle-income countries
receive grants for TB control from the Global Fund. In
2010, the Global Fund took steps to streamline several
aspects of the grant cycle. These include transitioning
from multiple grants within the same country to one
consolidated grant, and periodically reviewing the performance of grants, including in-depth assessments of
trends in the disease burden caused by TB using surveillance and survey data. These assessments of trends
will in turn be linked to recommendations for strengthening surveillance; their implementation can be followed through the Global Fund’s standard monitoring
and evaluation processes. This new “grant architecture”
offers an excellent opportunity to institutionalize assessments of surveillance systems and related efforts to
strengthen surveillance in many countries (Box 2.8). The
secretariat of WHO’s Global Task Force on TB Impact
Measurement is working closely with the Global Fund to
make this opportunity a reality.
2.5.2 Surveys of the prevalence of TB disease
Nationwide population-based surveys of the prevalence
of TB disease provide a direct measurement of the number of TB cases; repeat surveys conducted several years
apart can allow direct measurement of trends in disease
burden. Surveys are most relevant in countries where
the burden of TB is high (otherwise sample sizes and
associated costs and logistics become prohibitive) and
surveillance systems are thought (or known) to miss a
large fraction of cases. A good illustration of the value of
prevalence surveys is provided by the results from three
surveys in China (Box 2.5). Before 2007, however, few
countries had implemented prevalence surveys (Figure
2.12). From 2002 to 2008, there was typically one survey per year. In the 1990s, national surveys were confi ned
BOX 2.7
New guidance on electronic recording
and reporting
Surveillance systems depend on countries keeping good
records of all TB cases notified to national TB control programmes (NTPs) and of TB treatment outcomes. This is
a data-intensive activity that is increasingly moving away
from paper-based to electronic recording and reporting
(ERR).
Advantages of ERR include:
• Better management of individual patients, for example
by providing fast access to laboratory results;
• Better programme and resource management, by encouraging staff to use and act upon live data. This may
help to prevent defaulting from treatment and assist
with management of drug supplies (including avoidance
of stockouts);
• Improved surveillance by making it easier for facilities
not traditionally linked to the NTP, such as hospitals,
prisons and the private sector, to report TB cases, and
by reducing the burden of compiling and submitting
data through paper-based quarterly reports;
• Greater analysis and use of data, since data can be
readily imported into statistical packages, results are
available to decision-makers more quickly and it is possible to detect outbreaks promptly;
• Higher quality data, since automated data quality checks
can be used and duplicate or misclassified notifications
can be identified and removed (which is very difficult or
impossible to do nationally with paper-based systems).
It is also easier to introduce new data items.
WHO is coordinating the development of a guide on how
to design and implement ERR according to best-practice
standards. It is due to be published in 2011.
FIGURE 2.12
Global progress in implementing national surveys of the prevalence of TB disease, actual (2002–2010)
and planned (2011–2015)
8
Nepal
Other
Number of surveys
6
Bangladesh
GFC, Asia
Global focus countries (GFC)
selected by WHO Global
Task Force on TB Impact
Measurement
GFC, Africa
4
Indonesia
Lao PDR
2
Philippines
0
Thailand
Gambia
Myanmar
Cambodia
Ghana
Kenya
Philippines
China
Nigeria
Malawi
Viet Nam
Mozambique
Pakistan
Rwanda
South Africa
Cambodia
Malaysia
Indonesia
Eritrea
Thailand
Viet Nam
Bangladesh
Myanmar
Ethiopia
UR Tanzania
Uganda
Zambia
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013–15
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 25
25
23/09/11 07:20
BOX 2.8
Periodic reviews of Global Fund grants – an opportunity to improve measurement of trends in
disease burden and strengthen surveillance worldwide
In November 2009, the Board of the Global Fund approved a new grant architecture.1 This includes the introduction of a single
grant agreement per disease (HIV, TB or malaria), in contrast to the old model in which each newly-approved proposal generated
a separate grant agreement with its own budget and performance framework (such that some countries had multiple grants and
multiple performance frameworks for multiple time-periods). The new grant architecture also introduces periodic reviews. These
will be conducted at least once every three years and include an in-depth evaluation of how funds have been used, programmatic
performance and progress towards the proposal targets, including targets for reductions in disease burden.2 Results will determine
funding levels in future years.
Periodic reviews replace the previous model of reviewing each grant agreement after two years, prior to the approval of Phase 2
(years 3–5 of the standard five-year grant). Existing country-led review processes (such as National Programme Reviews and Joint
External Programme Evaluations) will be encouraged as inputs to the periodic review process.
With the introduction of periodic reviews, evaluations of progress in reducing the burden of TB disease will be closely linked to
decisions about future funding commitments. The indicators that will be used to evaluate progress have been defined in consultation
with partners including WHO. For all countries, assessments for TB will include analysis of trends in the case notification rate,
after careful assessment of its suitability as a proxy for trends in TB incidence. Assessment of trends in notifications will require
analysis of trends in case-finding efforts, the quality and coverage of surveillance and risk factors for TB. If data from national
or sample vital registration systems are available, trends in mortality will be assessed and used to inform the periodic review.
In countries that have conducted at least two surveys of the prevalence of TB disease, trends in TB prevalence will be assessed
and used to inform the periodic review. In addition to case notification rates, the treatment success rate for new smear-positive
TB cases will also be assessed. It is anticipated that analysis of trends in disease burden will be undertaken prior to the periodic
review; to facilitate this work, the Global Fund will allocate the necessary resources within the monitoring and evaluation budget
of grant agreements. An indicative budget of up to US$ 100 000 may be allocated.3
Periodic reviews provide an unprecedented opportunity for regular and systematic assessment of trends in the burden of disease
caused by TB in more than 100 countries, using the framework and associated tools developed by the WHO Global Task Force on
TB Impact Measurement.4 If this opportunity is taken, periodic reviews will substantially improve estimates of trends in the burden
of disease caused by TB and provide a foundation for strengthening surveillance of the disease worldwide.
1
2
3
4
New grant architecture. Geneva, The Global Fund to Fight AIDS, Tuberculosis and Malaria, 2011 (also available at:
www.theglobalfund.org/en/grantarchitecture).
www.theglobalfund.org/en/grantarchitecture
Operational policy note on periodic reviews. Geneva, The Global Fund to Fight AIDS, Tuberculosis and Malaria, 2011 (also available at:
www.theglobalfund.org/documents/core/manuals/Core_OperationalPolicy_Manual_en.pdf)
www.theglobalfund.org/documents/core/manuals/Core_OperationalPolicy_Manual_en.pdf
This is separate from the dedicated budgets required to undertake TB prevalence surveys (cumulative investments amount to US$ 25 million)
or other studies that will feed into the assessment.
The tool used to date is available at: www.who.int/tb/advisory_bodies/
www.who.int/tb/advisory_bodies/impact_measurement_taskforce
impact_measurement_taskforce. Additional tools including a
surveillance checklist and associated standards and benchmarks (see section 2.5.1) will be made available on the same site as they become
available.
to China, Myanmar, the Philippines and the Republic
of Korea. Before 2009 and with the exception of Eritrea
in 2005, the last national surveys in the African Region
were undertaken between 1957 and 1961.
In 2007, WHO’s Global Task Force on TB Impact
Measurement identified 53 countries that met epidemiological and other criteria for implementing a survey. A
set of 22 global focus countries were selected to receive
particular support in the years leading up to 2015. Many
of the global focus countries had already developed plans
to implement surveys and had sought funding from the
Global Fund at this time, but in most countries experience and expertise in such surveys were limited.
Since early 2008, the Task Force has made substantial
efforts to support countries to design, implement, analyse
and report on surveys. These efforts include close collaboration with the Global Fund to help secure full funding
for surveys through reprogramming of grants (several
26
surveys were initially under-budgeted); workshops to
develop protocols; expert reviews of protocols; training
courses for survey coordinators without prior experience of survey implementation, including an opportunity to observe field operations in Cambodia; training
courses to build a group of junior international consultants who can provide technical assistance to countries;
country missions by experts from the Task Force; and
the facilitation of Asia–Africa collaboration in which survey coordinators from Asian countries provide guidance
and support to those leading surveys in African countries where no recent experience exists (which should
later develop into Africa–Africa collaboration). Besides
WHO, those actively engaged in these efforts include the
staff who have led and managed surveys in Cambodia,
China, Myanmar and Viet Nam; the Centers for Disease
Control, United States of America; the Global Fund; the
KNCV Tuberculosis Foundation in the Netherlands; the
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 26
23/09/11 07:20
London School of Hygiene and Tropical Medicine, UK;
and the Research Institute for Tuberculosis, Japan. All
of this support is underpinned by a new handbook on
TB prevalence surveys (also known as “the lime book”),
which provides comprehensive theoretical and practical guidance on all aspects
of surveys.1 The book was
produced as a major collaborative effort involving
15 agencies and institutions
and 50 authors in 2010, and
was widely disseminated in
2011.
1
As a result of these collaborative efforts, there is now
major global and national momentum behind prevalence
surveys. If surveys are implemented according to schedule, between five and eight surveys per year will be implemented during the period 2010–2015. These include
surveys in 20 global focus countries – 9 in Asia and 11 in
Africa (Figure 2.12).
A landmark achievement in 2011 was the successful completion of the fi rst national prevalence survey in
Ethiopia. This is the fi rst such survey in Africa following
WHO guidelines in more than 50 years. Results will be
featured in the 2012 global report, alongside results from
surveys undertaken in Cambodia and Pakistan.
TB prevalence surveys: a handbook. Geneva, World Health
Organization, 2011 (WHO/HTM/TB/2010.17).
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 27
27
23/09/11 07:20
CHAPTER 3
Case notifications and treatment outcomes
KEY MESSAGES
In 2010, 6.2 million people were diagnosed with TB
and notified to national TB control programmes. Of these,
5.4 million had TB for the first time and 0.3 million had
a recurrent episode of TB after being cured of TB in the
past. Besides a small number of cases whose history of
treatment was not recorded, the remaining 0.4 million had
already been diagnosed with TB but had their treatment
changed to a retreatment regimen after treatment failed
or was interrupted.
India and China accounted for 40% of the world’s
notified cases of TB in 2010; Africa accounted for a further
24%, of which one quarter were in South Africa. The 22
high-TB burden countries accounted for 82%.
Public-private and public-public mix (PPM) initiatives
to engage the full range of care providers can help to
increase case notifications. In 20 countries for which
data were available, PPM contributed between about one
fifth to around 40% of total notifications in 2010, in the
geographical areas in which PPM was implemented.
Treatment outcomes are most closely monitored
among new cases with smear-positive pulmonary TB.
Among cases treated in 2009, 87% were successfully
treated – the highest level reported to date. Treatment
success rates remained low in the European Region, at
67%, with high death and failure rates.
There has been an increase in the number of TB
patients diagnosed with MDR-TB in the last five years.
However, patients enrolled on treatment for MDR-TB
in 2010 only represented 16% of the MDR-TB cases
estimated to exist among reported TB cases. Outcomes
of treatment for MDR-TB are available for a small number
of patients. The numbers of TB cases tested for MDR-TB,
diagnosed with MDR-TB and successfully treated for MDRTB lag far behind the targets set in the Global Plan.
In most parts of the world, less than 5% of TB patients
are tested for MDR-TB. Laboratory strengthening and new
diagnostics are urgently needed to improve the coverage
of diagnostic testing for MDR-TB.
Between 1995 and 2010, 55 million TB patients
were treated for TB in programmes that had adopted
the DOTS/Stop TB Strategy; 46 million of these people
were successfully treated. These treatments saved an
estimated 6.8 million lives compared with the pre-DOTS
standard of care.
28
The total number of TB cases that occur each year can
be estimated for the world as a whole and for regions and
individual countries, but with uncertainty (as explained
in Chapter 2). This uncertainty reflects the fact that in
most countries – especially countries that have the largest number of reported cases of TB – surveillance systems do not capture all TB cases. Cases may be missed
by routine notification systems because people with TB
do not seek care, seek care but remain undiagnosed, or
are diagnosed by public and private providers that do not
report cases to local or national authorities.
Routine recording and reporting of the numbers of
TB cases diagnosed and treated by national TB control
programmes (NTPs) and monitoring of the outcomes
of treatment was one of the five elements of TB control
emphasized in the DOTS strategy, and remains one of
the core elements of the Stop TB Strategy (Chapter 1).
Following the introduction and roll-out of the DOTS/
Stop TB Strategy in most countries since the mid-1990s,
data on the number of people diagnosed and treated for
TB and associated treatment outcomes are routinely
reported by NTPs in almost all countries, and in turn
these data are reported to WHO in annual rounds of
global TB data collection. With increasing engagement
by NTPs of the full range of care providers, including
those in the private sector and those in the public sector not previously linked to NTP reporting systems, data
are also better reflecting the total number of diagnosed
cases. The number of TB cases that are not diagnosed
is expected to be low in countries where health care is
of high quality and readily accessible. In other countries,
the numbers of undiagnosed cases can only be estimated
with considerable uncertainty, using relevant data sources such as population-based surveys of the prevalence of
TB disease, inventory studies including record-linkage
and capture re-capture modelling, and indicators on the
coverage and cost of health services (for further details,
see Chapter 2).
This chapter summarizes the total number of people
who were diagnosed with TB and notified by NTPs in
2010 as well as trends in notifications of TB cases since
1990. It is assumed that notified cases were treated for
TB. Data from 20 countries illustrating the contribution
to total notifications of efforts to engage public and private providers not traditionally linked to the NTP are also
presented. The chapter then summarizes information
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 28
23/09/11 07:20
BOX 3.1
Definitions of TB cases1
Definite case of TB A patient with Mycobacterium tuberculosis complex identified from a clinical specimen, either by culture or by
a newer method such as molecular line probe assay. In countries that lack laboratory capacity to routinely identify Mycobacterium
tuberculosis, a pulmonary case with one or more initial sputum specimens positive for acid-fast bacilli (AFB) is also considered to
be a “definite” case, provided that there is functional external quality assurance (EQA) with blind rechecking.
Case of TB A definite case of TB (defined above) or one in which a health worker (clinician or other medical practitioner) has
diagnosed TB and decided to treat the patient with a full course of TB treatment.
Case of pulmonary TB A patient with TB disease involving the lung parenchyma.
Smear-positive pulmonary case of TB A patient with one or more initial sputum smear examinations (direct smear microscopy)
AFB-positive; or one sputum examination AFB+ and radiographic abnormalities consistent with active pulmonary TB as determined
by a clinician. Smear-positive cases are the most infectious and thus of the highest priority from a public health perspective.
Smear-negative pulmonary case of TB A patient with pulmonary TB not meeting the above criteria for smear-positive disease.
Diagnostic criteria should include: at least two sputum smear examinations negative for AFB; radiographic abnormalities consistent
with active pulmonary TB; no response to a course of broad-spectrum antibiotics (except in a patient for whom there is laboratory
confirmation or strong clinical evidence of HIV infection); and a decision by a clinician to treat with a full course of anti-TB
chemotherapy. A patient with positive culture but negative AFB sputum examinations is also a smear-negative case of pulmonary TB.
Extrapulmonary case of TB A patient with TB of organs other than the lungs (e.g. pleura, lymph nodes, abdomen, genitourinary
tract, skin, joints and bones, meninges). Diagnosis should be based on one culture-positive specimen, or histological or strong clinical
evidence consistent with active extrapulmonary disease, followed by a decision by a clinician to treat with a full course of anti-TB
chemotherapy. A patient in whom both pulmonary and extrapulmonary TB has been diagnosed should be classified as a pulmonary
case.
New case of TB A patient who has never had treatment for TB or who has taken anti-TB drugs for less than one month.
Retreatment case of TB There are three types of retreatment case: (i) a patient previously treated for TB, who is started on a
retreatment regimen after previous treatment has failed (treatment after failure); (ii) a patient previously treated for TB who returns
to treatment having previously defaulted; and (iii) a patient who was previously declared cured or treatment completed and is
diagnosed with bacteriologically-positive (sputum smear or culture) TB (relapse).
Case of multidrug-resistant TB (MDR-TB) TB that is resistant to two first-line drugs: isoniazid and rifampicin. For patients
diagnosed with MDR-TB, WHO recommends treatment of at least 20 months with a regimen that includes second-line anti-TB
drugs.
Note: New and relapse cases of TB are incident cases. Cases of TB started on a retreatment regimen following treatment failure or treatment
interruption are prevalent cases.
1
See Treatment of tuberculosis guidelines, 4th ed. Geneva, World Health Organization, 2010 (WHO/HTM/STB/2009.420).
on the diagnosis and treatment of multidrug-resistant
TB (MDR-TB)1 specifically, and compares the numbers
of cases tested for MDR-TB and the numbers of cases
diagnosed and started on treatment with the targets set
out in the Global Plan to Stop TB 2011–2015 (Chapter 1).
Finally, the chapter summarizes data on treatment outcomes among new sputum smear-positive cases of pulmonary TB, which have traditionally been the focus of
efforts to monitor treatment outcomes, and the available
data on treatment outcomes among TB patients diagnosed with MDR-TB who were treated with second-line
anti-TB drugs.
3.1
Number of diagnosed and notified
cases of TB
In 2010, 6.2 million people were diagnosed with TB and
notified to NTPs. Of these, 5.4 million had TB for the
fi rst time and 0.3 million had a recurrent episode of TB
after being previously cured of TB. Besides a small number of cases whose history of treatment was not recorded,
the remaining 0.4 million had already been diagnosed
with TB but had their treatment changed to a retreatment regimen after treatment failed or was interrupted
(for defi nitions of each type of case, see Box 3.1).
Among people who were diagnosed with TB for the
fi rst time (new cases), there were 2.6 million cases of sputum smear-positive pulmonary TB, 2.0 million cases of
sputum smear-negative pulmonary TB (including cases
for which smear status was unknown) and 0.8 million
cases of extrapulmonary TB (Table 3.1).2 Of the new cases of pulmonary TB, 57% were sputum smear-positive.
1
2
For defi nitions, see Box 3.1.
No distinction is made between DOTS and non-DOTS programmes. This is because by 2007, virtually all (more than
99%) notified cases were reported to WHO as treated in
DOTS programmes.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 29
29
23/09/11 07:20
TABLE 3.1
Case notifications, 2010
NEW
TOTAL NOTIFIED
SMEAR-POSITIVE
Afghanistan
28 238
12 947
Bangladesh
SMEARNEGATIVE/
UNKNOWN
RETREATMENT
EXTRAPULMONARY
CASE TYPE
UNKNOWN
RELAPSE
RETREATMENT
EXCL. RELAPSE
NEW AND
RELAPSE
7 085
6 248
633
1116
209
28 029
HISTORY
UNKNOWN
PERCENT NEW
PULMONARY
CASES SMEARPOSITIVE
65
158 252
105 624
21 420
23 438
3 231
2 989
1 550
156 702
0
Brazil
81 946
37 932
23 030
10 017
18
3 398
7 551
74 395
0
62
Cambodia
41 628
17 454
8 301
14 239
0
466
1 168
40 460
0
68
China
923 308
429 899
432 868
6 325
0
39 307
14 909
908 399
0
50
DR Congo
118 636
73 653
14 039
22 340
0
4 138
4 466
114 170
0
84
Ethiopia
83
156 928
46 634
54 979
50 417
0
2 664
2 234
154 694
–
46
1 522 147
630 165
366 381
231 121
1 508
110 691
182 281
1 339 866
–
63
Indonesia
302 861
183 366
101 247
11 659
0
4 387
2 202
300 659
0
64
Kenya
106 083
36 260
41 962
17 382
0
3 668
6 811
99 272
0
46
46 174
20 097
16 408
5 621
0
1 432
2 616
43 558
0
55
43
India
Mozambique
Myanmar
137 403
42 318
56 840
27 976
–
4 456
5 813
131 590
–
Nigeria
90 447
45 416
32 616
3 422
0
2 667
6 326
84 121
0
58
Pakistan
269 290
104 263
105 623
45 443
0
5 870
5 055
261 199
3 036
50
Philippines
174 389
89 198
72 440
1 610
0
3 075
8 066
166 323
0
55
Russian
Federation
170 904
31 416
67 894
3 513
0
8 737
17 741
111 560
41 603
32
South Africa
45
400 391
128 571
155 071
52 090
0
18 509
46 150
354 241
0
Thailand
68 239
33 450
20 927
10 135
0
1 885
1 111
66 397
731
62
Uganda
45 546
23 456
13 567
4 571
0
1 291
2 661
42 885
0
63
UR Tanzania
63 453
24 769
21 184
13 715
–
1 430
2 355
61 098
–
54
Viet Nam
99 022
52 145
18 237
17 651
0
6 834
1 574
94 867
2 581
74
Zimbabwe
47 557
11 654
25 157
6 061
0
1 337
3 348
44 209
0
32
High-burden
countries
5 052 842
2 180 687
1 677 276
584 994
5 390
230 347
326 197
4 678 694
47 951
57
AFR
1 478 356
597 364
480 665
246 997
642
53 603
98 872
1 379 271
213
55
AMR
226 669
116 828
52 169
32 184
2 130
10 410
12 135
213 721
813
69
EMR
421 384
168 563
137 256
91 947
633
11 201
8 598
409 600
3 186
55
355 258
81 155
130 897
33 314
387
23 683
37 943
269 436
47 879
38
2 332 333
1 046 865
615 258
328 353
4 739
130 714
205 286
2 125 929
1 118
63
EUR
SEAR
WPR
1 341 391
622 211
566 146
61 042
27
54 170
32 875
1 303 596
4 920
52
Global
6 155 391
2 632 986
1 982 391
793 837
8 558
283 781
395 709
5 701 553
58 129
57
– Indicates data not available.
India and China accounted for 40% of the 5.7 million
new and relapse cases of TB that were notified in 2010
(24% and 16%, respectively). African countries accounted for a further 24% (of which one quarter were from one
country – South Africa). The WHO European and Eastern Mediterranean regions and the Region of the Americas accounted for 16% of new and relapse cases notified
in 2010. The 22 HBCs accounted for 82%.
Among the 22 HBCs, the percentage of new cases
of pulmonary TB that were sputum smear-positive was
relatively low in Zimbabwe (32%), the Russian Federation (32%), Myanmar (43%), South Africa (45%), Kenya
(46%) and Ethiopia (46%). A comparatively high proportion of new cases of pulmonary TB were sputum smearpositive in Bangladesh (83%), the Democratic Republic
of the Congo (84%) and Viet Nam (74%).
30
Globally, the number of TB cases diagnosed and notified per 100 000 population has stabilized since 2008,
following a marked increase between 2001 and 2007
(Figure 3.1). Globally and in all WHO regions, a clear
gap between the numbers of notified cases and the estimated numbers of incident cases exists, although this is
narrowing, particularly in the Western Pacific Region
(mostly driven by trends in China) and the Region of the
Americas (Figure 3.2). Trends in the 22 HBCs are shown
in Figure 3.3, and for other countries are illustrated in
country profi les that are available online.1
1
www.who.int/tb/data
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 30
23/09/11 07:20
FIGURE 3.1
BOX 3.2
Global trends in case notification (black) and estimated TB
incidence (green) rates, 1990–2010
The start of WHO’s efforts to systematically monitor progress in TB control on an annual basis in 1995 coincided with
global promotion and expansion of the DOTS strategy. Data
compiled since then allow assessment of achievements in
TB control since 1995.
Between 1995 and 2010, a total of 55 million TB patients
were treated in programmes that had adopted the DOTS/
Stop TB Strategy; 46 million of these people were successfully treated. Conservative estimates suggest that these
treatments saved around 6.8 million lives, compared with
the pre-DOTS standard of care.1
1
150
Rate per 100 000 population
Achievements in TB care and control at the
global level, 1995–2010
100
50
Glaziou P et al. Lives saved by tuberculosis control and
prospects for achieving the 2015 global target for reducing
tuberculosis mortality. Bulletin of the World Health Organization,
2011, 89:573–582.
0
1990
1995
2000
2005
2010
FIGURE 3.2
Case notification and estimated TB incidence rates by WHO region, 1990–2010. Regional trends in case notification rates (new
and relapse cases, all forms) (black) and estimated TB incidence rate (green). Shaded areas represent uncertainty bands.
Africa
The Americas
Eastern Mediterranean
350
120
50
250
100
40
200
80
30
150
Rate per 100 000 population
140
60
300
60
100
20
50
10
20
0
0
0
Europe
40
South-East Asia
Western Pacific
60
200
50
40
150
150
100
30
100
20
50
50
10
0
0
1990
1995
2000
2005
2010
0
1990
1995
2000
2005
2010
1990
1995
2000
2005
2010
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 31
31
23/09/11 07:20
FIGURE 3.3
Case notification and estimated TB incidence rates, 22 high-burden countries, 1990–2010. Trends in case notification rates
(new and relapse cases, all forms) (black) and estimated TB incidence rate (green). Shaded areas represent uncertainty bands.
Brazil
Bangladesh
Afghanistan
China
Cambodia
120
300
250
100
250
200
150
60
150
100
100
40
50
50
20
0
0
0
200
50
0
0
200
200
350
150
100
200
150
100
100
50
50
50
0
0
0
Myanmar
250
150
100
100
300
200
150
Mozambique
Kenya
Indonesia
250
250
Rate per 100 000 population
100
250
300
0
400
a
300
200
150
India
Ethiopia
DR Congo
400
600
80
200
50
0
Philippines
Pakistan
Nigeria
500
1000
300
500
400
800
500
250
400
400
600
300
400
200
200
100
100
50
100
0
0
0
0
0
300
150
200
South Africa
Russian Federation
200
300
200
100
UR Tanzania
Uganda
Thailand
1000
150
1000
800
100
600
50
200
0
0
0
150
400
100
200
50
0
1990
Zimbabwe
Viet Nam
200
600
100
400
50
250
800
150
1995
2000
2005
2010
0
1990
1995
2000
2005
2010
1990
1995
2000
2005
2010
250
800
200
600
150
100
400
50
200
0
0
1990
3.2
1995
2000
2005
2010
a
1990
1995
2000
2005
2010
Estimates for India have not yet been officially approved by the Ministry of Health &
Family Welfare, Government of India and should therefore be considered provisional.
Public–private and public–public mix
(PPM) initiatives
In many countries, especially those with a large private
sector, collaboration with the full range of health care providers is one of the best ways to ensure that all people with
TB are promptly diagnosed, notified to NTPs and provided with standardized care. This is component 4 of the
Stop TB Strategy (Chapter 1); its two subcomponents are:
involving all public, voluntary, corporate and private
providers through PPM approaches; and
promoting the International Standards for Tuberculosis Care through PPM initiatives.
32
Efforts to engage all care providers through PPM initiatives, beyond those which fall under the direct responsibility of the NTP (termed “non-NTP providers” in this
report), are being introduced and scaled up in many
countries. Demonstrating this progress is not always
possible: it requires systematic recording of the source
of referral and place of TB treatment at the local level,
reporting to the national level and analysis of aggregated
data at the national level.1 However, this recording and
reporting is happening in a growing number of countries
1
WHO recommends that the source of referral and the place of
treatment should be routinely recorded and reported.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 32
23/09/11 07:20
TABLE 3.2
Contribution of PPMa to notifications of TB cases in 20 countries
WHO REGION AND COUNTRY
TYPES OF NON-NTP CARE PROVIDERS ENGAGED
COVERAGE
NUMBER OF NEW
TB CASES NOTIFIED
IN 2010
CONTRIBUTION TO
TOTAL NOTIFICATIONS OF
NEW TB CASES
AFRICAN REGION
Angola
Diverse private and public providers
Countrywide
15 676
37%
Ghana
Diverse private and public providers
Countrywide
2 032
14%
Kenya
Private clinics and hospitals, NGOs and diverse public
providers
Countrywide
7 706
8.1%
Madagascar
Diverse private and public providers
Countrywide
6 749
29%
Nigeria
Private clinics and hospitals
Countrywide
31 656
39%
UR Tanzania
Private, faith-based organizations and NGO hospitals
Countrywide
11 156
19%
Haiti
Private practitioners, NGOs and prison services
Countrywide
5 030
36%
Peru
Social security organizations and other public and
private providers
Countrywide
5 993
21%
REGION OF THE AMERICAS
EASTERN MEDITERRANEAN REGIONb
Iran (Islamic Republic of)
Diverse private and public providers
Countrywide
4 271
43%
Pakistan
Private clinics and hospitals
Countrywide
51 563
20%
Egypt
Health insurance organizations, NGOs and other public
providers
Countrywide
2 112
24%
Sudan
Diverse private and public providers
Countrywide
2389
9.4%
Prison and military services
Countrywide
1540
4.9%
Bangladesh
Hospitals, medical colleges, prison services and other
public providers
Countrywide
44 732
29%
India
Diverse private, public and NGO providers
14 large cities
(total population
50 million)
35 025
45% of new
smear-positive
cases
Indonesia
Public and private hospitals
Countrywide
48 391
16%
Myanmar
Diverse private, public and NGO providers
Countrywide
24 250
19%
China
General public hospitals
Countrywide
36 7607
42%
Philippines
Private clinics and hospitals
Countrywide
12 081
7.2%
Republic of Korea
Predominantly private providers
Countrywide
33 167
85%
EUROPEAN REGION
Ukraine
SOUTH-EAST ASIA REGION
WESTERN PACIFIC REGION
NGO, non-governmental organization; FBO, Faith-based organization; NTP, national TB control programme.
a
Private providers include private practitioners, private hospitals, private clinics, corporate services and NGOs and non-NTP public providers include hospitals, public
medical colleges, prisons/detention centres and military facilities.
b
For the Eastern Mediterranean Region, data are for the contribution of PPM to all TB cases, not just new cases.
and data for 20 countries are summarized in Table 3.2. In
these 20 countries, the contribution of PPM initiatives
typically ranges from between about one fi fth to around
40% of total notifications, in the geographical areas in
which PPM has been implemented.
NTPs have used a variety of approaches to engage
non-NTP care providers, according to the local context.
These include incentive-based schemes for individual
and institutional providers (in India and Myanmar); a
web-based system for mandatory reporting of TB cases
by all providers (in China); and reimbursement for TB
care delivered by private providers through health insurance, when care conforms with agreed-upon standards
(in the Philippines). It is also noticeable that countries
have prioritized different types of care providers. These
include general public hospitals (in China), private clinics
and hospitals (in Nigeria), social security organizations
(in Peru) and private and NGO hospitals (in the United
Republic of Tanzania). In general, the data illustrate the
relevance of PPM in both African and Asian countries. A
case study from Nigeria is provided in Box 3.3.
Typically, only a small proportion of targeted care providers collaborate actively with NTPs and contribute to
TB case notifications in most countries. For this reason,
it is not surprising that NTPs often give fi rst priority to
engaging institutional providers with whom establishing
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 33
33
23/09/11 07:20
BOX 3.3
PPM for TB care and control in Nigeria
Health services in Nigeria, including those for care of TB patients, are offered by a range of providers in the public, voluntary
and private sectors. Mission hospitals run by faith-based organizations have a long history of collaboration with the National
Tuberculosis and Leprosy Control Programme (NTBLCP), dating from shortly after the NTBLCP’s establishment in 1989. In 1994,
the NTBLCP introduced the DOTS strategy; DOTS was also implemented by mission hospitals, especially in the southern parts
of the country. The private medical sector is estimated to provide health care to up to 60% of the population, although there is
considerable variation within and across states. Private providers manage TB patients but rarely notify them to the NTBLCP.
To enhance access to quality-assured TB care and improve reporting of cases, the Stop TB Strategy was adopted by the NTBLCP
in 2006. Efforts to engage all care providers through PPM approaches began in the same year. After a pilot project implemented
in Anambra State with the support of the German Leprosy and TB Relief Association was successful, PPM was expanded
systematically following WHO guidelines and with financial support from the Global Fund and the United States Agency for
International Development. A comprehensive national situation assessment was conducted in 2007. Based on the findings of the
assessment and lessons learnt from the pilot project, national PPM guidelines were developed. A curriculum and training modules
specific to PPM were also prepared. PPM implementation was guided at the national level by a PPM Steering Committee; its
counterparts at the provincial level – the State PPM Steering Committees – are operational in 12 states. In scaling up PPM and
enabling productive collaboration with private providers, more than 500 medical officers, 1000 general health workers and 200
laboratory personnel have been trained. The number of private health facilities collaborating with the NTBLCP increased from
about 100 in 2006 to 451 in 2010.
The expansion of PPM in Nigeria has faced several challenges. Only a proportion of private facilities tend to collaborate. Private
providers have high expectations of incentives and enablers from the programme. An insufficient health work force and the high
attrition rate of staff in private facilities make it difficult to maintain the quality of DOTS implementation. Under-reporting of
patients managed in the private sector remains a problem. Despite these difficulties, PPM has helped to increase TB notifications
and to improve TB case management in the private sector. In 2010, PPM care providers notified 31 656 cases, equivalent to 39%
of the new TB cases that were notified in the country.
Further strengthening of PPM for TB care and control is planned. Current models of PPM will be evaluated and existing policies and
guidelines reviewed. Advocacy to relevant stakeholders to increase the number of private facilities collaborating with the NTBLCP
will be enhanced. It is anticipated that these efforts will improve access to care, save costs and ensure quality of TB services for
patients seeking private care, while also increasing TB case notifications and maintaining high treatment success rates.
collaborative links may be less demanding and, for a given amount of effort, will yield a higher number of notifications. At the same time, involving front-line health
workers such as community-based informal providers,
private practitioners and pharmacies – who are often the
fi rst point of contact for people with symptoms of TB –
can help to reduce diagnostic delays and the out-of-pocket expenditures of TB patients. The role of pharmacists is
highlighted in Box 3.4.
3.3
Case detection rates
The case detection rate (CDR)1 for TB is an indicator that
is included within the Millennium Development Goals
(Chapter 1). For a given country and year, the CDR is
defi ned as the number of new and relapse TB cases (see
Box 3.1 for defi nitions) that were diagnosed and notified
by NTPs (Table 3.1), divided by the estimated incident
1
2
34
The CDR is actually a ratio rather than a rate, but the term
“rate” has become standard terminology in this context of
this indicator.
It is approximate because of uncertainty in the underlying
incidence of TB and because notified cases are not necessarily
a subset of incident cases that occurred in the same year; see
Chapter 2 for further discussion.
cases of TB that year. The CDR is expressed as a percentage; it gives an approximate2 indication of the proportion of all incident TB cases that are actually diagnosed,
reported to NTPs and started on treatment.
The best estimate of the CDR for all forms of TB at
global level in 2010 was 65% (range, 63–68%), up from
54–60% in 2005 and 40–45% in 1995 – the year in which
the DOTS strategy began to be introduced and expanded
(Table 3.3). The highest CDRs in 2010 were estimated
to be in the Western Pacific Region (best estimate 79%;
range, 73–87%), the European Region (best estimate
73%; range, 68–78%) and the Region of the Americas
(best estimate 80%; range, 75–85%). The other regions
had estimated CDRs in the range 56–71%, with best estimates of around 60%. All regions have improved their
estimated CDRs since the mid-1990s, with improvements
particularly evident since 2000. Among the 22 HBCs, the
highest rates of case detection in 2010 were estimated to
be in Brazil, China, Kenya, the Russian Federation and
the United Republic of Tanzania; the lowest rates were
in Mozambique, Nigeria, Afghanistan and Bangladesh.
To close the gap between notified cases and estimated
TB incidence, action is needed in three broad areas:
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 34
23/09/11 07:20
Strengthening surveillance. This will help to ensure
that all cases diagnosed with TB are reported and
accounted for by routine notification systems. Establishing links with the full range of health-care providers through PPM, as well as stronger enforcement
of legislation regarding notification of cases (where
this is mandated by law), can help to minimize the
under-reporting of TB cases. Inventory studies can be
used to help quantify the extent to which diagnosed
cases are unreported (the “surveillance gap”). WHO
and its partners are currently developing guidance on
how these studies can be done, building on pioneering work in implementing such studies in the Eastern
Mediterranean Region and the UK (for further details,
see Chapter 2).
Better diagnostic capacity. This will help to ensure
that people with TB who seek care are actually diagnosed. It may require better laboratory capacity as well
as more knowledgeable and better trained staff, especially in peripheral-level health-care facilities.
Improved access to health care. For people with TB
who do not seek care, improved access (in fi nancial
and/or geographical terms) to health care as well as
improved awareness of how to recognize the signs and
symptoms of TB are important.
3.4
Diagnosis and treatment of MDR-TB
The diagnosis of MDR-TB (defi ned as resistance to isoniazid and rifampicin) requires that people with TB are
tested for susceptibility to fi rst-line anti-TB drugs. The
Global Plan (Chapter 1) includes targets that by 2015
all new cases of TB considered at high risk of MDR-TB
should be tested for drug susceptibility (estimated at
about 20% of all new cases) and that 100% of retreatment cases should be tested (see Box 3.1 for case defi nitions).
With the notable exception of the European Region,
drug susceptibility testing (DST) for fi rst-line drugs was
done for only a small proportion of notified cases in 2010
(Table 3.4). Globally, less than 2% of new cases and 6%
of retreatment cases were tested for MDR-TB, with particularly low levels of testing in the South-East Asia and
BOX 3.4
The role of pharmacists in TB care and control
Pharmacists can play an important role in delivering health care. Demographic and Health Surveys (DHS) carried out between
2004 and 2008 show that a high proportion of people seek care from private pharmacies: for example, in India, Nigeria, the
Philippines and the United Republic of Tanzania, 11%, 27%, 24% and 75% of people in the lowest quintile of income had sought
care from private pharmacies for fever, cough or diarrhoea.1 The figures were 78%, 72%, 45% and 36% respectively for private care
providers. A recent study estimating the sale of anti-TB medicines in the private sector found that in 10 high TB-burden countries
(HBCs) that account for 60% of the global burden of disease caused by TB, the amount of anti-TB medicines dispensed in the
private sector was sufficient to treat 66% of the estimated number of new cases of TB that occur each year in these countries. The
same study estimated that the size of the private market in India was equivalent to the number of full treatment courses required
to treat 1.2 times the number of patients reported and treated under the auspices of the Revised National TB Control Programme
(RNTCP).2
To strengthen the contribution of pharmacists to TB care and control, WHO’s Stop TB Department has been working with the
International Pharmaceutical Federation (FIP) – a nongovernmental organization (NGO) representing more than 120 national
associations of pharmacists that has an official relationship with WHO (www.fi
www.fip.org
p.org). In September 2011, this collaboration
culminated in the launch of a WHO/FIP Joint Statement on the “Role of pharmacists in TB care and control” at FIP’s annual global
conference in Hyderabad, India. This statement builds on WHO’s mandate in public health and FIP’s previous collaboration with
WHO on important public health issues including HIV/AIDS, good pharmacy practice and prevention of antimicrobial resistance.
The objective of publishing the statement is to stimulate national TB control programmes (NTPs) and national pharmacy
associations (NPAs) to work together on effectively engaging pharmacists in TB care and control. Pharmacists can contribute in
diverse ways: increasing awareness of TB among their clients, identifying people with symptoms of TB, referring them to a proper
place for diagnosis, supervising and supporting TB patients to enhance treatment adherence, offering anti-TB medicines on valid
prescriptions only and facilitating rational use of anti-TB medicines by prescribing physicians.
Some countries have already developed productive approaches to engaging pharmacists in TB care. In a project in Cambodia, over
a period of three years, participating pharmacists referred 12 577 people with TB symptoms to health care services, among whom
6 403 attended health centres and 1418 were diagnosed with TB. Collaboration between the NTP and the NPA in Ghana helped to
halt the sale of anti-TB medicines in private pharmacies.
Systematic efforts are required to enable NPAs and pharmacists to take on new tasks that could benefit TB control and potentially
other health programmes. A logical first step would be to sensitize NTPs and NPAs on the benefits of working together. Countryspecific models of collaboration can then be developed, tested, documented and scaled up. It is hoped that the WHO/FIP joint
statement will help to catalyse such efforts in many countries.
1
2
See www.ps4h.org/globalhealthdata (accessed 13 July 2011).
Wells WA et al. Size and usage patterns of private TB drug markets in the high burden countries. PLoS One, 2011, 6(5): e18964.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 35
35
23/09/11 07:20
TABLE 3.3
Estimates of the case detection rate for all cases (%), 1995–2010a
1995
2000
BESTb
LOW
HIGH
–
–
–
Afghanistan
2005
BEST
LOW
HIGH
BEST
LOW
16
14
20
42
35
2010
HIGH
BEST
LOW
HIGH
51
47
39
57
Bangladesh
21
18
26
26
22
32
39
32
48
47
39
57
Brazil
79
66
97
74
61
91
84
71
100
88
74
110
Cambodia
25
20
32
31
26
37
58
50
67
65
57
77
China
33
27
40
33
28
39
74
65
86
87
77
100
DR Congo
30
25
36
38
32
45
52
45
61
53
46
61
Ethiopia
25
22
29
59
54
66
61
56
67
72
66
78
Indiac
58
51
67
49
44
54
49
44
54
59
53
65
Indonesia
12
21
17
26
59
49
73
66
55
81
Kenya
61
56
66
72
67
77
80
76
85
82
79
86
Mozambique
23
11
Myanmar
11
Nigeria
Pakistan
9.4
8.8
4.5
7.8
78
23
13
53
31
20
55
34
25
50
8.5
14
17
14
21
57
49
68
71
62
84
2.5
250
12
240
26
230
40
23
85
3.7
5.5
3.7
3.3
2.7
4.1
9.0
39
32
48
65
54
79
Philippines
48
40
59
47
39
58
53
44
66
65
54
79
Russian Federation
53
44
65
79
65
97
83
69
100
73
63
87
South Africa
56
47
69
59
49
72
61
51
75
72
60
88
Thailand
56
46
68
40
33
49
64
53
78
70
59
85
Uganda
22
14
42
29
20
49
47
36
66
61
51
76
UR Tanzania
59
51
69
68
60
78
74
69
80
77
72
82
Viet Nam
37
29
49
56
43
74
56
44
74
54
43
71
Zimbabwe
55
40
80
56
45
71
50
41
64
56
44
72
High-burden countries
39
37
43
40
37
43
55
52
59
65
62
68
AFR
37
30
46
43
36
53
53
46
62
60
56
64
AMR
68
63
73
70
65
75
75
70
80
80
75
85
EMR
23
21
26
25
22
28
47
42
54
63
56
71
EUR
63
58
67
76
71
83
80
75
87
73
68
78
SEAR
45
41
50
42
39
45
50
47
54
61
57
66
WPR
38
33
44
39
35
44
70
64
77
79
73
87
Global
42
40
45
44
41
46
57
54
60
65
63
68
– indicates data not available.
a
Estimates for all years are recalculated as new information becomes available and techniques are refined, so they may differ from those published previously.
b
Best, low and high indicate best estimates followed by lower and upper bounds. The lower and upper bounds are defined as the 2.5th and 97.5th centiles of outcome
distributions produced in simulations.
c
Estimates for India have not yet been officially approved by the Ministry of Health & Family Welfare, Government of India and should therefore be considered
provisional.
Western Pacific regions. In the European Region, 51%
of retreatment cases and 30% of the new cases notified
in 2010 were tested for MDR-TB. Among the 27 high
MDR-TB burden countries, the proportion of notified
cases that were tested was relatively high in 13 of the 15
European countries that reported data, ranging from
3% of new cases in Tajikistan to 79% of new cases in
Estonia, and from 23% of retreatment cases in Tajikistan
to over 90% of retreatment cases in Belarus, Latvia and
Ukraine. While data on DST were not available for new
and retreatment cases separately, overall more than 20%
of notified cases were tested for drug resistance in South
Africa (see Annex 2). In the other 11 countries, testing
for MDR-TB among new cases was negligible or no data
were reported. The proportion of retreatment cases that
36
were tested in these 11 countries was slightly higher, but
was still under 5% in countries that reported data, with
the one exception of Ethiopia (10%). India and China,
which collectively accounted for almost half of the global cases of MDR-TB estimated to exist among notified
TB patients in 2010, did not report any data (Table 3.5,
column 2). Improving the coverage of diagnostic DST
is urgently needed to improve the diagnosis of MDRTB, and requires strengthening laboratory capacity and
introducing new rapid diagnostic tests (see Chapter 5).
Given low levels of testing for drug resistance in many
countries, and with only 9% of TB basic management
units worldwide providing curative services for MDRTB patients, it is inevitable that the number of people
who are diagnosed with MDR-TB remains low. Glob-
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 36
23/09/11 07:20
FIGURE 3.4
TABLE 3.4
Notified cases of MDR-TB (2006–2010) and
projected numbers of patients to be enrolled on
treatment (2011–2012)a
Diagnostic DST for rifampicin and isoniazid among new
and retreatment cases of TB, 2010
NEW CASES
RETREATMENT CASES
80
Number of patients (thousands)
Non-GLC
60
64
GLCb
53
40
30
29
20
2007
(123)
2008
(127)
Notified
2009
(134)
2010
(116)
NUMBER
WITH
DST
RESULT
% OF
CASES
WITH DST
RESULT
Armenia
471
Azerbaijan
493
9.6
–
–
–
–
–
–
152a
Bangladesh
23
2006
(103)
% OF
CASES
WITH DST
RESULT
54
48
0
NUMBER
WITH
DST
RESULT
2011
(97)
2012
(97)
Projected
35
220
Belarus
1 972
45
1 697
Bulgaria
801
35
165
47
47
China
–
–
–
–
DR Congo
–
–
100
1.2
Estonia
197
79
61
77
Ethiopia
42
a
Numbers under years show the number of countries reporting data.
Georgia
1 987
b
GLC refers to project sites monitored by the Green Light Committee Initiative
and known to adhere to WHO recommended norms in the care of MDR-TB
patients. Non-GLC refers to all other projects that are not supported by the
GLC mechanism, and include patients treated in all high-income countries.
India
–
–
–
Indonesia
0
0
324
4.9
5 214
33
4 655
Kazakhstan
Kyrgyzstan
ally, just over 50 000 cases of MDR-TB were notified to
WHO in 2010, mostly by European countries and South
Africa (Table 3.5, Figure 3.4). This represented 18% of
the 290 000 (range, 210 000–380 000) cases of MDR-TB
estimated to exist among patients with pulmonary TB
who were notified in 2010. The proportion of TB patients
estimated to have MDR-TB that were actually diagnosed
was under 10% in all of the 27 high MDR-TB countries
outside the European Region, with the notable exception of South Africa where 81% of estimated cases were
diagnosed. In the 15 high MDR-TB burden countries in
the European Region, the proportion of estimated cases
that were diagnosed ranged from 24% (in Tajikistan) to
over 90% of cases (in Belarus and Kazakhstan); no data
were reported from Lithuania. In the Russian Federation, which ranks third in terms of estimated numbers
of cases of MDR-TB at the global level, the proportion of
estimated cases that were diagnosed was 44% in 2010.
The numbers of patients diagnosed with MDR-TB and
started on treatment with recommended second-line
drug regimens in the high MDR-TB burden countries
in 2010, at just under 40 000, was less than the number
of cases notified.
Although the absolute numbers of TB cases tested for
drug resistance, diagnosed with MDR-TB and started on
appropriate treatment remain low, they are increasing
(Figure 3.4). The reported number of patients enrolled on
treatment for MDR-TB reached 45 553 in 2010, equivalent to 16% of the estimated 290 000 cases of MDR-TB
among TB patients notified in 2010. According to country
plans, further increases are expected in 2011 and 2012,
although these show very small increases compared with
2010. The scale-up of diagnosis and treatment for MDRTB falls far short of the targets set out in the Global Plan
Latvia
<0.1
510
10
45
558
40
–
–
613
–
74
51
–
102
–
94
Lithuania
–
–
–
Myanmar
–
–
–
–
27
<0.1
19
0.2
Nigeria
–
Pakistan
9
<0.1
306
2.8
Philippines
3
<0.1
297
2.7
Republic of Moldova
1 234
33
1 077
64
Russian Federation
35 862
35
13 405
51
South Africa
Tajikistan
–
–
223
23
9 194
29
4 840
95
Uzbekistan
2 845
18
1 180
26
High MDR-TB burden
countries
2.7
–
Ukraine
Viet Nam
160
–
–
–
–
–
61 124
1.5
29 739
5.5
AFR
2 732
0.2
4 294
AMR
10 229
5.0
4 182
EMR
2 323
EUR
74 820
0.6
30
1 250
31 272
2.8
19
6.3
51
SEAR
1 073
0.1
925
WPR
4 392
0.4
1 350
1.6
95 569
1.8
43 273
6.4
Global
0.3
– Indicates data not available.
a
The percentage may exceed 100% if notification of TB cases is incomplete,
especially in systems where reporting of TB and DST are not linked. In addition,
DST may be performed repeatedly in the same patients.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 37
37
23/09/11 07:20
TABLE 3.5
Number of cases of MDR-TB estimated, notified and expected to be treated, 27 high MDR-TB burden
countries and WHO regions
ESTIMATED CASES
OF MDR-TB AMONG
NOTIFIED CASES OF
PULMONARY TB IN
2010a (A)
Armenia
NOTIFIED CASES
OF MDR-TB IN
2010 (B)
CONFIDENCE INTERVAL
NOTIFIED CASES OF
MDR-TB AS % OF ESTIMATED
CASES OF MDR-TB AMONG
ALL NOTIFIED CASES OF
PULMONARY TB IN 2010
(B/A)b
260
230–290
177
Azerbaijan
1 700
1 500–1 800
63
Bangladesh
5 900
4 400–7 400
184
Belarus
1 700
1 600–1 800
1 576
93
Bulgaria
94
71–120
56
60
63 000
56 000–70 000
2 792
2 700
190–5 200
87
China
DR Congo
Estonia
76
61–92
63
Ethiopia
2 100
1 100–3 000
140
Georgia
68
CASES
ENROLLED
ON
TREATMENT
FOR MDR-TB
IN 2010
EXPECTED NUMBER
OF CASES OF MDR-TB
TO BE TREATED
2011
2012
154
160
160
286
500
500
339
1 558
2 597
200
–
–
56
60
65
4.4
1 222
6 706
7 061
3.2
191
220
–
3.7
3.1
83
6.7
80
64
836
1 218
680
620–740
359
618
550
550
64 000
44 000–84 000
2 967
4.6
2 967
7 800
15 000
6 100
3 900–8 400
182
3.0
142
600
900
Kazakhstan
6 400
5 900–6 900
7 387
115
5 705
–
–
Kyrgyzstan
1 000
880–1 200
566
57
566
–
–
87
125
India
Indonesia
Latvia
53
63
120
100
81–120
87
87
125
Lithuania
–
–
–
–
–
280
–
Myanmar
5 100
3 800–6 300
192
3.8
192
200
400
Nigeria
2 400
170–4 700
21
0.9
23
80
100
Pakistan
9 700
4 000–15 000
444
4.6
444
750
1 000
Philippines
8 800
6 700–11 000
522
5.9
548
3 500
2 372
Republic of Moldova
1 700
1 600–1 800
1 015
60
791
–
–
Russian Federation
31 000
24 000–38 000
13 692
44
13 692
11 400
17 000
South Africa
9 100
7 700–10 000
7 386
81
5 402
6 400
–
Tajikistan
1 400
1 100–1 700
333
24
245
700
300
Ukraine
6 600
5 900–7 300
5 333
81
3 870
–
–
Uzbekistan
3 100
2 200–4 000
1 023
33
628
972
1 080
Viet Nam
3 600
2 900–4 300
101
101
700
1 500
51 992
High MDR-TB burden countries
2.8
250 000
160 000–340 000
46 748
19
38 652
44 177
AFR
32 000
11 000–53 000
9 504
30
7 406
10 432
8 395
AMR
6 200
1 900–10 000
2 158
35
3 186
3 337
3 322
EMR
14 000
6 200–23 000
829
EUR
53 000
39 000–68 000
32 616
SEAR
88 000
68 000–110 000
3 779
WPR
77 000
61 000–93 000
4 222
290 000
210 000–380 000
53 108
Global
5.9
1 006
1 135
1 561
27 844
15 593
20 714
4.3
3 901
12 240
18 980
5.5
2 210
11 285
11 352
45 553
54 022
64 324
62
18
– Indicates data not available.
a
Calculated by applying the best combined estimate of MDR to the notified cases of pulmonary TB in 2010.
b
Percentage may exceed 100% as a result of notifications of cases from previous years, inadequate linkages between notification systems for TB and MDR-TB, and
estimates of the number of cases of MDR-TB that are too conservative.
38
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 38
23/09/11 07:20
FIGURE 3.5
Notified cases of MDR-TB (2007–2010) and projected numbers of patients to be enrolled on treatment (2011–2012) in the
149 countries included in the Global Plan, compared with the targets included in the Global Plan to Stop TB 2011–2015.
The numbers represent smear and/or culture-positive cases of MDR-TB.
Number of patients (thousands)
300
Projected enrolments
Global Plan targets
250
Non-GLC
200
GLC
150
100
50
0
2007
2008
2009
2010
2011
2012
(Figure 3.5). Approaching these targets will require rapid
expansion of diagnosis and treatment, notably in China
and India.
3.5
Treatment outcomes
When the DOTS strategy was introduced in the mid1990s, emphasis was given to the recording and reporting of treatment outcomes among patients with sputum
smear-positive pulmonary TB: that is, the most infectious cases. Although efforts have been made to record
and report the outcomes of treatment for other cases,
the data for such cases are still incomplete. Among
the countries reporting to WHO in 2010, 162 reported
data on treatment outcomes among smear-negative and
extrapulmonary cases.
As in previous reports in this series, the best available data on treatment outcomes are for sputum smearpositive cases of pulmonary TB (Table 3.6; for defi nitions
of the categories used to report treatment outcomes see
Box 3.6). Globally, the rate of treatment success for the
2.6 million new cases of sputum smear-positive pulmonary TB who were treated in the 2009 cohort was 87%
(Table 3.6). This was the third successive year that the
target of 85% (fi rst set by the World Health Assembly in
1991) was exceeded globally. Among WHO’s six regions,
three met or exceeded the 85% target: the Eastern Mediterranean Region, the South-East Asia Region and the
Western Pacific Region. The treatment success rate was
81% in the African Region (where there has been steady
improvement since 1997), 76% in the Region of the
Americas (where the rate has been relatively stable since
2002) and 66% in the European Region (where major
efforts to increase treatment success rates are needed).
Of the 22 HBCs, 15 reached the 85% target. The seven
countries that reported lower rates of treatment success
were Brazil (72%), Ethiopia (84%), Nigeria (83%), the
Russian Federation (55%), South Africa (77%), Uganda (67%) and Zimbabwe (78%). In Brazil and Uganda,
low rates reflect a high proportion of patients for whom
the outcome of treatment was not evaluated (11% and
16%, respectively) and high default rates (11% and 10%,
2013
2014
2015
BOX 3.5
Infection control to prevent the
transmission of TB
Outbreaks of MDR-TB and extensively drug-resistant TB
(XDR-TB) in health-care facilities have highlighted the
importance of proper infection control. Appropriate measures include personal protection (for example, masks),
administrative controls (for example, in waiting areas for
people attending outpatient services) and environmental
measures such as ventilation systems. The best indicator
to assess the quality of infection control in health-care
settings is the ratio of the notification rate of TB among
health-care workers to the notification rate among the
general population (with appropriate adjustments for the
age distribution of the two groups). This ratio should be
approximately 1. The data required to calculate this indicator for 2010 were limited, and collection and reporting need
to be improved. WHO is currently leading the development
of guidance material on how to establish surveillance of TB
among health-care workers.
Among the 149 low and middle-income countries from
which data on infection control were requested, 34 had
conducted a national assessment of infection control for
TB, 49 had conducted an assessment of infection control
in tertiary hospitals and 45 had a national plan for infection control (a plan was under development in a further 39
countries). Training related to infection control was implemented in 78 of these countries in 2010 and 79 had a focal
point for infection control in at least one tertiary hospital.
respectively). In the Russian Federation, treatment failure rates are high, possibly linked to MDR-TB.
National data on treatment outcomes for cases of
MDR-TB are limited. Data for cohorts of at least 200
patients are currently limited to 14 countries (Figure 3.6).
Rates of treatment success are variable, ranging from
below 50% (in the Republic of Moldova, South Africa
and Romania) to 74% (in Kazakhstan). Most of these
countries thus remain far from the Global Plan target of
a treatment success rate of *75% as a result of high frequencies of treatment failure, death and default.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 39
39
23/09/11 07:20
TABLE 3.6
Treatment success for new smear-positive cases (%) and cohort size (thousands), 1995–2009
a. Treatment success (%)
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
Afghanistan
Bangladesh
Brazil
Cambodia
China
DR Congo
Ethiopia
India
Indonesia
Kenya
Mozambique
Myanmar
Nigeria
Pakistan
Philippines
Russian Federation
South Africa
Thailand
Uganda
UR Tanzania
Viet Nam
Zimbabwe
–
71
17
91
93
74
61
25
91
75
39
67
49
70
60
65
58
64
44
73
89
53
–
63
20
94
94
48
71
21
81
77
55
79
32
–
35
57
61
78
33
76
89
32
45
73
27
91
95
64
72
18
54
65
65
82
73
67
78
67
68
58
40
77
85
69
33
77
40
95
95
70
74
27
58
77
–
82
73
23
71
68
72
68
62
76
92
70
86
79
78
93
95
69
74
21
50
79
71
81
75
70
87
65
57
77
61
78
92
73
85
81
71
91
93
78
80
34
87
80
75
82
79
74
88
68
63
69
63
78
92
69
84
83
55
92
95
77
76
54
86
80
78
81
79
77
88
67
61
75
56
81
93
71
87
84
80
92
92
78
76
60
86
79
78
81
79
78
88
67
68
74
60
80
92
67
86
85
77
93
93
83
70
76
87
80
76
81
78
79
88
61
67
73
68
81
92
66
89
90
76
91
94
85
79
82
90
80
77
84
73
82
87
60
69
74
70
81
93
54
90
91
76
93
94
85
78
86
91
82
79
84
75
83
89
58
71
75
73
82
92
68
84
92
73
93
94
86
84
86
91
85
83
84
76
88
88
58
74
77
70
85
93
60
87
92
72
94
94
87
84
87
91
85
79
85
82
91
89
58
74
83
75
88
92
78
88
91
71
95
94
87
84
87
91
85
84
85
78
90
88
57
76
82
70
88
92
74
86
92
72
95
95
88
84
88
91
86
85
85
83
91
89
55
77
86
67
88
92
78
High-burden countries
53
50
56
62
60
67
72
75
81
84
86
87
87
87
88
AFR
AMR
EMR
EUR
SEAR
WPR
60
50
79
67
33
80
56
51
66
58
31
72
64
58
73
72
29
91
70
67
57
63
40
92
68
79
79
75
34
91
71
76
81
75
50
90
70
69
82
74
63
91
73
81
84
74
68
90
73
80
82
75
79
91
74
79
83
70
84
91
76
79
83
72
87
92
75
76
86
70
87
92
80
79
88
71
88
92
80
77
88
70
88
92
81
76
88
67
89
93
Global
57
54
60
64
64
69
73
76
80
83
85
84
86
86
87
b. Cohort size (thousands)
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
Afghanistan
Bangladesh
Brazil
Cambodia
China
DR Congo
Ethiopia
India
Indonesia
Kenya
Mozambique
Myanmar
Nigeria
Pakistan
Philippines
Russian Federation
South Africa
Thailand
Uganda
UR Tanzania
Viet Nam
Zimbabwe
–
11
46
4.4
131
16
5.1
265
3.0
6.5
11
7.9
9.5
0.8
90
0.05
28
20
15
20
38
9.7
–
30
45
9.1
175
25
11
291
12
13
13
9.7
24
–
126
43
45
0.1
15
21
48
12
2.0
34
43
12
189
26
12
293
21
19
11
9.2
11
2.8
27
0.7
55
3.7
18
22
54
12
2.9
38
30
13
210
33
15
284
40
22
–
10
13
29
21
0.7
37
8
13
24
55
13
2.0
38
27
16
208
35
21
345
46
27
12
12
15
3
37
1.5
81
14
14
24
53
13
3.1
38
34
15
214
36
30
349
52
28
13
17
16
4.1
50
3.6
86
23
14
24
53
14
6.3
41
41
14
190
41
32
384
54
31
14
21
17
6.3
55
4.1
101
20
17
24
54
17
7.8
47
29
17
194
45
37
396
76
31
15
24
21
15
59
5.2
99
27
19
24
57
16
6.8
54
38
19
267
54
40
420
93
34
16
27
28
20
68
6.3
114
28
20
25
56
14
10
63
43
19
385
62
41
489
129
41
17
31
34
32
78
26
127
28
21
26
58
15
10
85
42
21
473
65
39
507
159
40
18
37
35
48
81
26
135
30
21
25
55
13
12
102
48
19
470
63
37
553
175
39
18
40
40
66
86
31
140
29
20
25
56
16
13
104
38
19
466
66
38
592
161
38
18
43
44
89
87
32
143
30
21
25
54
11
13
106
41
20
464
66
41
616
166
37
19
41
46
100
85
32
144
33
23
24
53
10
12
109
41
18
449
72
45
625
169
37
20
42
45
102
89
32
135
28
23
25
51
10
High-burden countries
739
967
879
912
1 044
1 119
1 186
1 260
1 450
1 776
1 965
2 087
2 132
2 181
2 179
AFR
AMR
EMR
EUR
178
129
46
34
233
134
51
94
268
125
60
24
235
111
89
48
323
110
66
22
365
111
64
41
409
102
52
50
452
105
76
54
491
110
81
60
552
121
98
75
564
119
114
81
566
132
132
98
577
116
156
108
591
109
167
114
602
122
167
91
SEAR
WPR
318
296
360
372
376
294
399
313
473
353
512
360
550
346
604
357
661
439
780
575
856
663
938
663
974
661
1 011
657
1 022
632
1 001
1 245
1 147
1 195
1 347
1 453
1 510
1 649
1 842
2 200
2 396
2 529
2 591
2 649
2 637
Global
– Indicates no data reported.
40
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 40
23/09/11 07:20
BOX 3.6
BOX 3.7
Definitions of treatment outcomes for
patients treated for drug-susceptible TB used
for reporting at global level
Cured A patient who was initially smear-positive and who was
smear-negative in the last month of treatment and on at least
one previous occasion.
Completed treatment A patient who completed treatment
but did not meet the criteria for cure or failure. This definition applies to pulmonary smear-positive and smear-negative
patients and to patients with extrapulmonary disease.
Died A patient who died from any cause during treatment.
Failed A patient who was initially smear-positive and who
remained smear-positive at month 5 or later during treatment.
Defaulted A patient whose treatment was interrupted for 2
consecutive months or more.
Not evaluated A patient whose treatment outcome is not
known.
Successfully treated A patient who was cured or who
completed treatment.
Cohort A group of patients in whom TB has been diagnosed,
and who were registered for treatment during a specified time
period (e.g. the cohort of new smear-positive cases registered
in the calendar year 2005). This group forms the denominator
for calculating treatment outcomes. The sum of the above
treatment outcomes, plus any cases for whom no outcome is
recorded (including those “still on treatment” in the European
Region) should equal the number of cases registered. Some
countries monitor outcomes among cohorts defined by smear
and/or culture, and define cure and failure according to the
best laboratory evidence available for each patient.
Definitions of treatment outcomes for
patients treated for MDR-TB
The categories used to assess treatment outcomes for
patients with MDR-TB are the same as those for patients
with drug-susceptible TB (see Box 3.6). The main differences are the definitions of cure and failure, which are
recognized to be too complex for routine surveillance. In
2011, WHO initiated a consultation on updating the defi nitions of cases and treatment outcomes in the context
of new diagnostic tests. It is anticipated that updated
definitions will be agreed upon by the end of 2011. The
definitions for cured and failed that are currently in use
are summarized below.
Cured A patient who has completed a course of anti-TB
treatment according to programme protocol and has at
least five consecutive negative cultures from samples
collected at least 30 days apart in the final 12 months of
treatment. If only one positive culture is reported during
that time, and there is no concomitant clinical evidence
of deterioration, a patient may still be considered cured,
provided that this positive culture is followed by a
minimum of three consecutive negative cultures taken
at least 30 days apart.
Failed Anti-TB treatment will be considered to have
failed if two or more of the five cultures recorded in the
final 12 months of therapy are positive, or if any one of
the final three cultures is positive. Treatment will also
be considered to have failed if a clinical decision has
been made to terminate treatment early because of
poor clinical or radiological response or adverse events.
These latter failures can be indicated separately in order
to do sub-analysis.
FIGURE 3.6
Treatment outcomes for patients diagnosed with MDR-TB in 14 countries, 2008 cohorts. The total number of patients starting
treatment in each cohort is shown under each country.a
100
Not evaluated
Defaulted
Percentage of cohort
80
Failed
Died
60
Successfully
treated
40
20
0
Kazakhstan
(2268)
a
Turkey
(263)
Uzbekistan Ecuador
(294)
(210)
Georgia
(417)
DR Congo Philippines Namibia Russian
(202)
(520)
(221) Federation
(1537)
Brazil
(444)
Kyrgyzstan Republic
South
(262)
of Moldova Africa
(522)
(4383)
Romania
(816)
Only countries reporting outcomes for >200 MDR-TB cases with <20% not evaluated are shown. Countries are ranked by the proportion successfully treated
(cured+completed).
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 41
41
23/09/11 07:20
CHAPTER 4
Financing TB care and control
KEY MESSAGES
In 2012, funding for TB control is expected to reach
US$ 3.3 billion in the 22 high-burden countries (HBCs)
that account for 80% of the world’s TB cases, up from
US$ 1.3 billion in 2002.
Among 97 countries for which trends can be assessed
since 2006, funding is expected to reach US$ 4.4 billion in
2012. This is an increase from US$ 3.5 billion in 2006, but
funding has levelled off since 2009.
Almost three quarters of the funding for TB control
in the 22 HBCs is accounted for by domestic funding in
BRICS (Brazil, the Russian Federation, India, China and
South Africa). However, in the other 17 HBCs, donor
funding increased more than six-fold during the period
2002–2010, accounting for about half of the total TB
expenditures of US$ 0.6 billion in these countries in 2010.
International donor funding for TB control has
increased by 50% since 2006, from US$ 0.4 billion to an
expected US$ 0.6 billion in 2012, but still falls far short
of funding for malaria (US$ 1.8 billion in 2009) and HIV
(US$ 6.9 billion in 2010).
Across 97 countries that reported data, the Global
Fund is expected to account for 82% of the US$ 0.6 billion
of donor funding for TB in 2012. Overall, donor funding
accounted for 14% of total funding.
Funding for MDR-TB has increased since 2009, but
large funding gaps constrain plans to scale up diagnosis
and treatment.
Funding gaps reported by national TB control
programmes for 2012 amount to US$ 0.8 billion, of which
US$ 0.5 billion is accounted for by the 22 HBCs.
Funding gaps in the 17 HBCs outside BRICS could be
halved, from US$ 0.4 billion to US$ 0.2 billion, if donor
funding for BRICS was redirected to these countries. The
US$ 0.2 billion per year of donor funding for BRICS is
almost sufficient to scale up the diagnosis and treatment
of MDR-TB in low-income countries according to the
targets included in the Global Plan to Stop TB 2011–2015.
Expenditure tracking and reporting need to be
improved; 3 HBCs have been unable to report expenditure
data for at least the past two years.
42
Progress in TB prevention, care and control requires
adequate funding. WHO began monitoring of funding for TB in 2002, and the global TB database holds
data from 2002 up to 2012. The data compiled to date
allow assessment of trends in funding during the period
2002–2012 in the 22 high-burden countries (22 HBCs)
that account for about 80% of the world’s TB cases, and
for a much larger set of countries since 2006. The fi rst
part of this chapter summarizes trends in funding for TB
in the 22 HBCs, quantifies the funding gaps reported by
these countries, compares levels of domestic and international funding, and summarizes estimates of the cost per
patient treated. The second part of the chapter assesses a
similar set of data for a group of 97 countries (22 HBCs
and 75 other countries). Ambitious targets for scaling
up diagnosis and treatment of multidrug-resistant TB
(MDR-TB) between 2011 and 2015 have been set (Chapter 1), but the costs of treatment are several times higher
than those for drug-susceptible TB. In this context, the
third part of the chapter gives special attention to the
funding needs, sources of funding and funding gaps for
MDR-TB. The fi nal part of the chapter compares available funding for TB with the resource requirements set
out in the Global Plan to Stop TB 2011–2015.
4.1
Funding for TB care and control in the
22 high-burden countries
The funding available for TB control in the 22 HBCs
has increased year-on-year since 2002, and is expected to reach US$ 3.3 billion in 2012 (Figure 4.1, Figure
4.2, Figure 4.3). Most of this funding has been used to
support diagnosis and treatment with fi rst-line drugs
(labelled “DOTS” in Figure 4.1). However, it is noticeable that funding for the diagnosis and treatment of
MDR-TB has increased since 2009, and is expected to
reach US$ 0.6 billion in 2012 (Figure 4.1). This may be
linked to increasing political commitment following a
high-level ministerial conference on MDR-TB that was
held in Beijing, China, in April 2009. The relatively small
amounts of funding reported for collaborative TB/HIV
activities (see Chapter 6 for further details) reflect the fact
that funding for most of these interventions (including
the most expensive, antiretroviral treatment) is usually
channelled to national HIV programmes and nongovernmental organizations rather than to national TB control programmes (NTPs).
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 42
23/09/11 07:20
FIGURE 4.1
FIGURE 4.2
Funding available for TB control by line item,
22 high-burden countries, 2002–2012
Funding available for TB control by source of funding,
22 high-burden countries, 2002–2012
3.3
2.6
2.5
2.2
2
1.6
1.8
3.1
US$ billions (constant 2011 US$)
US$ billions (constant 2011 US$)
3.1
2.9
3
2.3
1.9
1.3
1
2.6
2.5
2.3
2.2
2
1.6
1.8
1.9
1.3
1
0
0
2002
2003 2004
2005 2006
2007 2008
General health-care services: MDR-TB
General health-care services: DOTS
Other
PPM/PAL/ACSM/CBC/OR/surveys
a
3.3
2.9
3
2009
2010
2011
2002 2003
2012
2004 2005
2006
2007 2008
2009 2010
2011
2012
Global Fund
Grants (excluding Global Fund)
Government, general health-care services
Government, NTP budget (including loans)
TB/HIV
MDR-TB
DOTSa
DOTS includes the available funding for first-line drugs, NTP staff, programme
management and supervision, and laboratories.
FIGURE 4.3
Funding available for TB control by country,
22 high-burden countries, 2002–2012
3.3
US$ billions (constant 2011 US$)
3.1
2.9
3
2.5
2
1.6
1.8
2.2
2.3
2006
2007 2008
2.6
1.9
1.3
1
0
2002 2003
2004 2005
All other HBCs
Brazil
India
China
2009
2010
2011
2012
South Africa
Russian Federation
FIGURE 4.4
Funding gaps reported by NTPs, 22 high-burden countries,
2006–2012
600
Other
552
US$ millions (constant 2011 US$)
Across all of the 22 HBCs, domestic funding from
national governments is the single largest source of funding (Figure 4.2), accounting for 87% of total expected
funding in 2012.1 Nonetheless, the Global Fund has contributed a growing amount of funding since 2004, and is
expected to reach US$ 362 million in 2012. The Global
Fund is now easily the largest source of donor funding
for TB; funding from other donor sources is expected to
amount to only US$ 86 million in 2012.
In absolute terms, 60% of the funding expected for
TB in the 22 HBCs in 2012 is accounted for by just two
countries: the Russian Federation and South Africa (Figure 4.3). Brazil, the Russian Federation, India, China
and South Africa (BRICS) account for 83% of expected
funding, with 60% of all notified cases in the 22 HBCs
(Chapter 3). Funding expected in the remaining 17 HBCs
(which accounted for 40% of notified cases in HBCs in
2010) amounts to US$ 571 million in 2012, equivalent to
17% of the total funding expected in the 22 HBCs.
Despite increases in funding and 10 completed rounds
of proposals2 to the Global Fund, NTPs in the 22 HBCs
continue to report funding gaps (Figure 4.4). Since 2007,
these gaps have been in the range US$ 0.4–0.5 billion per
year. In 2012, funding gaps are anticipated for several elements of TB care and control, including fi rst-line drugs
(for which the gap amounts to US$ 48 million in 2012).
500
458
522
471
419
437
ACSM/CBC/PPM/
PAL/OR/surveys
TB/HIV
400
MDR-TB
300
DOTS, excluding
first-line drugs
DOTS, first-line drugs
200
183
100
0
1
2
Domestic funding includes funding for outpatient visits and
inpatient care in hospitals, the costs of which are not usually
included in NTP budgets and expenditures. The amount of
domestic funding for these inputs to TB treatment are estimated by combining data on the average number of outpatient
visits and days in hospital per TB patient reported by countries with WHO estimates of the unit costs of outpatient visits
and bed-days (see www.who.int/choice).
The fi rst round was completed in 2003. Round 10 was completed in 2010.
2006
2007
2008
2009
2010
2011
2012
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 43
43
23/09/11 07:20
TABLE 4.1
NTP budgets, available funding, cost of utilization of general health-care services and total funding required according to
country plans, 2012 (US$ millions)
AVAILABLE FUNDING
NTP BUDGET
Afghanistan
11
Bangladesh
48
Brazil
87
Cambodia
China
DR Congo
Ethiopia
40
GOVERNMENT
(EXCLUDING
LOANS)
LOANS
GRANTS
(EXCLUDING
GLOBAL FUND)
0.4
0
3.7
1.2
0
2.2
0
1.4
71
0
8.9
350
220
0
3.6
62
–
–
–
52
1.2
8.8
GLOBAL FUND
4.5
10
0.9
4.5
FUNDING GAPa
2.0
35
13
COST OF
GENERAL
HEALTH-CARE
SERVICES
(ESTIMATED)b
5.2
5.1
75
26
4.8
95
32
0
–
–
0.7
TOTAL FUNDING
REQUIREDc
16
53
162
45
350
63
0
15
15
13
13
64
India
210
43
87
0
80
0
84
293
Indonesia
102
16
19
121
0
0.2
47
39
Kenya
53
6.1
1.7
0.5
12
33
Mozambique
39
1.9
0.7
19
Myanmar
29
0.6
0
2.0
Nigeria
43
6.6
0
6.8
Pakistan
64
2.8
0
2.9
Philippines
Russian Federation
South Africa
2.8
15
8.1
19
13
5.7
17
53
8.8
10
2.9
24
5.9
62
49
32
67
70
79
24
0
0
24
31
58
137
1 204
1 204
0
0
0
0
35
1 239
–
–
–
–
34
0
4.5
3.2
–
–
–
–
Thailand
45
Uganda
20
0.1
0.2
2.4
3.5
14
0.3
20
UR Tanzania
42
7.3
0
6.8
5.2
23
2.4
45
Viet Nam
74
4.6
0
1.0
9.2
59
Zimbabwe
–
3.5
3.4
26
48
100
–
–
–
–
–
–
–
High-burden countriesd
2 653
1 654
90
80
343
425
383
3 036
AFRe
1 035
590
4.0
65
143
233
355
1 390
AMR
175
111
0
12
17
35
151
327
EMR
168
63
0
30
67
64
233
EUR
1 979
1 632
1 339
0
SEAR
449
105
87
WPR
595
309
4 054
2 517
Globale
8.9
2.1
1.0
92
51
240
347
15
147
95
108
557
14
121
149
183
777
117
509
819
1 209
5 263
– indicates not available.
a
Calculated as the NTP budget minus all the available funding.
b
See text for an explanation of how these costs are estimated.
c
Calculated as the NTP budget plus the cost of utilization of general health-care services.
d
These totals do not include estimates for DR Congo, South Africa and Zimbabwe and are therefore lower than those in Figures 4.1–4.5.
e
The regional and global totals include estimates for those countries that did not report data for 2012 and are in constant 2011 US$, consistent with totals presented
elsewhere in this report.
Trends in funding, funding gaps and expenditures
in the 22 HBCs as a whole conceal important variation
among countries, and differences between BRICS and
the other 17 HBCs are especially striking (Table 4.1, Figure 4.5, Figure 4.6).
The funding estimated to be required in BRICS has
steadily increased since 2002 (see blue line in Figure 4.5),
and the available funding has kept pace (see orange line
in Figure 4.5). In the other 17 HBCs, the amount of funding estimated to be required and the funding available
have also increased, but large funding gaps have persisted
and widened over the past decade. The 17 HBCs outside
BRICS have reported a funding gap of US$ 0.4 billion
44
in 2012, ranging from US$ 2 million in Afghanistan to
US$ 59 million in Viet Nam (Table 4.1). Funding gaps
in the 17 HBCs outside BRICS could be halved in 2012,
from US$ 0.4 billion to US$ 0.2 billion, if all donor funding for BRICS was redirected to these countries.
In BRICS, most funding (95% in 2010) for NTPs
comes from domestic sources (Figure 4.6), although India
was an outlier at around 50%.1 In the other 17 HBCs,
only 33% of the funding for NTPs was from domestic
sources in 2010. When the resources that are used to pro1
Further details for individual countries can be found in Annex
2, and in fi nance country profi les for around 100 countries
that are available online at www.who.int/tb/data.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 44
23/09/11 07:20
FIGURE 4.5
Funding requireda and funding available for TB control, 22 high-burden countries, 2002–2012
BRICSb
Other 17 high-burden countries
3000
3000
Funding required:
country-reported value
or best estimate
5−95th percentile
range of estimates
2589
US$ millions (constant 2011 US$)
2575
2000
2000
1000
1000
Funding available:
country-reported value
or best estimate
5−95th percentile
range of estimates
971
557
0
2002
2004
2006
2008
2010
2012
0
2002
2004
2006
2008
2010
2012
a
Funding required is the sum of the funds needed to fully fund NTP budgets plus the funds needed for outpatient visits and hospital stays (general health-care services)
if these are not already included in NTP budgets. The difference between the funding required and the funding available is the funding gap reported by NTPs.
b
Brazil, the Russian Federation, India, China and South Africa.
FIGURE 4.6
TB expenditures by source of funding,a 22 high-burden countries, 2002–2010
BRICS:b NTP
BRICS:b NTP + GHSc
2500
2000
2000
1500
1640
US$ millions (constant 2011 US$)
1000
2046
1500
Grants:
country-reported value or best estimate
5−95th percentile range of estimates
1000
500
77
0
2002
2004
2006
2008
2010
500
77
0
2002
2004
2006
2008
400
327
309
300
300
200
200
0
2002
149
2004
2006
2008
2010
Other 17 high-burden countries: NTP + GHSc
Other 17 high-burden countries: NTP
400
100
Domestic funding (government
including loans):
country-reported value or best estimate
5−95th percentile range of estimates
2010
309
100
0
2002
2004
2006
2008
2010
a
Total expenditures may be less than funding available in Figure 4.5, as not all funding commitments translate into disbursements and not all disbursements translate
into expenditures.
b
Brazil, the Russian Federation, India, China and South Africa.
c
GHS is the cost of resources used for TB treatment in the general health system that are not usually managed by the NTP. It includes the costs associated with hospital
stays and outpatient visits.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 45
45
23/09/11 07:20
FIGURE 4.7
Cost per TB patient treated with first-line drugs,a 22 high-burden countries,b 2004 and 2010c
10000
RU
Cost per patient (constant 2011 US$)
5000
2000
ZA BR
1000
The size of the orange circle is proportional to the
number of cases treated in 2010.
— The tail attached to each circle depicts the change in
cost per patient and GNI per capita between 2004 and
2010.
The grey area depicts the 95% confidence interval for
the prediction (= white line) of the unweighted log–log
regression of cost per patient on GNI per capita in 2010.
— The green line marks where cost per patient equals GNI
per capita.
TH
500
200
CD
AF TZ
ET MZ BD
KE
PK
Costs include all resources used for treatment (not only
first-line drugs), i.e. all items included in Figure 4.1 with
the exception of those for MDR-TB.
b
AF Afghanistan; BD Bangladesh; BR Brazil; CN China;
CD Democratic Republic of the Congo; ET Ethiopia;
ID Indonesia; IN India; KE Kenya; KH Cambodia;
MM Myanmar; MZ Mozambique; NG Nigeria;
PK Pakistan; PH Philippines; RU Russian Federation;
TH Thailand; TZ United Republic of Tanzania;
UG Uganda; VN Viet Nam; ZA South Africa;
ZW Zimbabwe.
c
Costs per patient treated are based on 3-year averages,
2002–2004 and 2008–2010, to minimize distortions
associated with non-annual expenses on items such as
buildings, equipment and buffer stocks of drugs.
PH
ID
UG
ZW
100
VN
KH
NG
a
CN
IN
MM
50
100
200
500
1000
2000
5000
10000
GNI per capita (constant 2011 US$)
vide TB diagnosis and treatment within the general health
system (that is, the staff and health facilities used for
outpatient and inpatient care) are added to the resources
included in NTP budgets, the share of funds contributed
from domestic sources increases in both sets of countries
(Figure 4.6). Nonetheless, the share still only reached 51%
in the 17 countries outside BRICS in 2010.1 Between 2009
and 2010 there was a marked reduction in expenditures in
BRICS (driven by the Russian Federation although there
were falls in spending in Brazil and China as well), and
expenditures also declined in Mozambique and Viet Nam.
The estimated cost per patient treated for TB with
fi rst-line drugs is shown for each of the 22 HBCs in Figure 4.7. The cost generally lies in the range US$ 100–
500 per patient treated. The exceptions are Myanmar
(under US$ 100), Thailand (US$ 830) and Brazil, the
Russian Federation and South Africa (above US$ 1000).
Between 2004 and 2010, the cost per patient treated has
increased in almost all of the HBCs, as has GNI [gross
national income] per capita, with the exception of Indonesia and Mozambique. It is noticeable that in all of the
HBCs, the cost per patient treated is less than GNI per
capita (that is, all values lie below the solid green line in
Figure 4.7). Besides GNI, a further explanation for variation in costs appears to be the scale at which treatment
is provided. Some of the countries with relatively low
costs for their income level (for example, China, India,
Indonesia and Pakistan) are countries where the total
number of patients treated each year is comparatively
1
46
Further details for individual countries can be found in Annex
2, and in fi nance country profi les for around 100 countries
that are available online at www.who.int/tb/data.
high (as shown by the size of the circles in Figure 4.7).
As in previous years, the cost of treating TB patients
with fi rst-line drugs in the Russian Federation is higher
than might be expected for the country’s income level.
The relatively high cost is due in large part to an extensive network of hospitals and sanatoria that are used for
lengthy inpatient care. Nevertheless, there is evidence
that some costs are starting to fall, with decreasing
expenditures on staff and gradual reductions in the use
of inpatient care. In addition, the number of dedicated
beds for TB patients fell from 103 000 in 2007 to less
than 97 000 in 2010, and the average length of stay for
a TB patient fell from 106 to 84 days. It should also be
highlighted that the characteristics of the patient population in the Russian Federation (such as high rates of
alcohol abuse and unemployment, and a comparatively
high proportion of ex-prisoners) may also warrant additional investments in some aspects of TB care. Examples
include patient enablers and incentives to support outpatient care, and psychosocial support.
4.2
Funding for TB care and control in
the 22 high-burden countries and
75 other countries
Besides the 22 HBCs, 75 other countries have reported
fi nancial data to WHO since 2006 that allow assessment
of trends in funding for TB control. These 97 countries
accounted for 92% of the world’s notified cases of TB in
2010.
Funding for TB control in these 97 countries has grown
from US$ 3.5 billion in 2006 to a projected US$ 4.4 billion
in 2012 (Figure 4.8, Figure 4.9); funding has levelled off
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 46
23/09/11 07:20
FIGURE 4.8
FIGURE 4.9
Funding available for TB control by line item and
funding gap, 22 high-burden countries and 75 other
countries,a 2006–2012
Funding available for TB control by source of
funding and funding gap, 22 high-burden countries and
75 other countries,a 2006–2012
5
a
4.7
5.0
4.6
4.3
4.2
4
General healthsystem services:
MDR-TB
General healthsystem services:
DOTS
3.8
3
Other
PPM/PAL/ACSM/
CBC/OR/surveys
2
TB/HIV
1
0
6
Gap
5.3
US$ billions (constant 2011 US$)
US$ billions (constant 2011 US$)
6
MDR-TB
DOTS
2006
2007
2008
2009
2010
2011
4.7
5.0
5.3
4.6
Global Fund
Grants (excluding
Global Fund)
4.3
4.2
4
3.8
Government, general
health-care services
3
Government,
NTP budget
(including loans)
2
1
0
2012
Gap
5
2006
2007
2008
2009
2010
2011
2012
These countries together account for 92% of the total number of drug-susceptible TB cases notified globally in 2010.
FIGURE 4.10
Domestic funding as a percentage of total funding available to the NTP, 2011
RUSSIAN FEDERATION
CHINA
INDIA
BANGLADESH
VIET NAM
CAMBODIA
PHILIPPINES
MAURITANIA
PAKISTAN
AFGHANISTAN
CAPE
VERDE
ETHIOPIA
UGANDA
KENYA
NIGERIA
BRAZIL
EQUATORIAL
GUINEA
MYANMAR
THAILAND
INDONESIA
UR TANZANIA
GABON
DR CONGO
ANGOLA
ZIMBABWE
SOUTH AFRICA
MOZAMBIQUE
>90%
51–90%
11–50%
≤10%
No data
since 2009. As in the 22 HBCs, the largest share of funding is for TB diagnosis and treatment with first-line drugs
(labelled “DOTS” in Figure 4.8); an increasing amount
is for MDR-TB. National governments account for 86%
of the funding expected in 2012, followed by the Global
Fund (US$ 515 million, or 12% of total funding) and then
by grants from donors besides the Global Fund (US$ 113
million, or 2%). International donor funding for TB control has increased by 50% since 2006, from US$ 0.4 billion to an expected US$ 0.6 billion in 2012, but still falls
far short of funding for malaria (US$ 1.8 billion in 2009)1
and HIV (US$ 6.9 billion in 2010).2
Funding gaps in the 97 countries amounted to
US$ 0.7 billion in 2011 and are anticipated to reach
US$ 0.8 billion in 2012 (Figure 4.9).
Global aggregates conceal wide variation in the share
of funding from domestic sources at country level (Figure 4.10). For example, in most countries of sub-Saha1
2
World malaria report 2010. Geneva, World Health Organization,
2010.
Financing the response to AIDS in low and middle-income countries.
international assistance from donor governments in 2010. UNAIDS
and the Kaiser Family Foundation, 2010. Available at www.
unaids.org
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 47
47
23/09/11 07:20
FIGURE 4.11
Cost per TB patient treated with first-line drugs (US$), 2010
RUSSIAN FEDERATION
CHINA
INDIA
BANGLADESH
VIET NAM
CAMBODIA
PHILIPPINES
PAKISTAN
AFGHANISTAN
NIGERIA
BRAZIL
DR CONGO
ETHIOPIA
UGANDA
KENYA
MYANMAR
THAILAND
INDONESIA
UR TANZANIA
ZIMBABWE
SOUTH AFRICA
>5000
MOZAMBIQUE
1001–5000
501–1000
101–500
≤100
No data
FIGURE 4.12
The cost of TB control as a percentage of total health expenditures by the public sector, 2009
>7%
5.1–7%
3.1–5%
1.1–3%
≤1%
No data
48
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 48
23/09/11 07:20
ran Africa the share of funding from domestic sources
is below 50% (the exceptions are Angola, Cape Verde,
Equatorial Guinea, Gabon and South Africa – all highincome or middle-income countries).
The cost of treating a patient with first-line drugs at
country level is summarized in Figure 4.11. In most countries in the African, South-East Asia and Western Pacific
regions, the cost per patient treated is under US$ 1000
(exceptions include Botswana, Namibia and South Africa in the African Region, and Malaysia in the Western
Pacific Region). Costs are higher in the Region of the
Americas and the European Region.
In general, the cost of TB control as a proportion
of public health expenditures1 is relatively low (Figure
4.12).2 In most countries, TB control accounts for <3%
of public health expenditures. Cambodia, Kazakhstan,
Kyrgyzstan, Lao PDR, Tajikistan and Uzbekistan stand
out as countries that have high levels of spending on TB
relative to total health expenditure. Part of the explanation is that these countries are among the list of 27 high
MDR-TB burden countries, 3 and treatment for MDR-TB
is comparatively expensive. Other reasons include continued use of models of care for all forms of TB that rely
extensively on inpatient care. For example, in Kazakhstan, 84% of smear-negative cases and 96% of smearpositive cases4 are hospitalized, with average lengths of
stay of 60 and 105 days respectively; 35% of cases of
MDR-TB are hospitalized for 180 days. In Kyrgyzstan,
Tajikistan and Uzbekistan, more than 50% of new cases
are hospitalized, for an average of more than 50 days.
Further details for all of the 97 countries that reported
financial data are provided in
regional and country fi nance
COUNTRY X
profiles that are available
online.5
1
PROFILEHIV201
burden
COUNTRTBYburde
n, high
High
Incidence (HIV
100
)
6.2 (4.6–8.9
0
156
106
98
Other
765
1767
32
ent
Total retreatm
Total )15 years
10561
Total new
Total )15 years
798
60
40
20
0
1990
40
12373
20
Yes
69
1995 2000
1990
–
ositive
ve
Smear-positi
ive/EP
Smear-negat
80
Retreatment
75
70
65
60
55
2000
50
2001
2003
2005
1500
2007
ESTIMATES
MDR-TB, 2008
MDR-TB
TB cases with
% of all new
MDR-TB
TB cases with
cases
% of all ret
among notified
Cases of MDR-TB
TB
of pulmonary
MDR-TB, 2009
for MDR-TB
cases tested
Number of
tested for MDR-TB
% of notified
cases of MDR-TB
Confirmed
treatment
started on
MDR-TB patients
88%
324
152
318
145
0.5
0.08
4
2008
0.6
35
82
4
6
In country
Yes
120
100
1995
1997
1999
2001
0
2005
2003
Government,
NTP budget
(excluding
loans)
99
2007
2008
MDR-TB
DOTS,
excluding firstline drugs
60
40
DOTS, first-line
drugs
38
30
2009
2010
2011
30
Gaps are relative to
country plans, as
opposed to actual
needs according to
regional or global
targets.
0
2006
2011
Funding available by
79.6line 88.3
item
83.2
88
2002
2005
200
484
27%
464
23%
2009
2010
2
2011
483
General healthcare services –
DOTS
404
OR/Surveys/
other
NTP budget
ACSM/CBC/
PPM/PAL
Available funding
TB/HIV
35
MDR-TB
DOTS
2011
2008
2008
500
General healthcare services –
MDR-TB
537
61%
64%
54
100
5
94%
93%
2007
Expenditure by line item
74.1
386
ACSM/CBC/
PPM/PAL
TB/HIV
2009
2007
2006
1
OR/Surveys/
other
108
400
General healthcare services –
MDR-TB
414
392
General healthcare services –
DOTS
347
300
OR/Surveys/
other
ACSM/CBC/
PPM/PAL
200
TB/HIV
MDR-TB
DOTS
100
0
2006
2007
2008
2009
2010
2011
2006
1
3
0
These 18 countries represent
95% of the total number
uncertain quality.
of cases notified in the
region
2007
in 2009. Data were imputed
2008
2009
when country reports were
incomplete or of
BUDGETS BY SOURCE
OF FUNDING AND TOTAL
EXPENDITURES IN SELECTED
countries; missing data
COUNTRIES (US$ MILLIONS)
were not imputed.
Data are as reported by
Australia
Cambodia
China
China (Hong Kong SAR)
China (Macao SAR)
Japan
Lao People’s Democratic
Republic
Malaysia
Mongolia
New Zealand
Papua New Guinea
Philippines
Republic of Korea
Singapore
Solomon Islands
Viet Nam
Gov. – government; GF
GOV.
LOANS
GRANTS
7.0
194.0
17.0
1.7
2.8
GAP
4.8
82.7
25.6
6.9
4.0
149.0
17.0
1.6
0.3
0.2
2.5
0.2
2006 – 2009
39.2
285.0
23.2
1.1
196.0
23.2
50.0
2.7
5.5
4.6
0.4
5.5
1.9
3.1
16.6
8.0
5.1
96.9
0.1
29.5
9.8
1.3
12.1
0.0
6.4
– Global Fund. Cells are
blank when no data were
TOTAL EXPENDITURE
GF
2011
4
5
BUDGET
TOTAL
2006 – 2011
7.8
0.3
5.1
0.9
reported. If a country has
1.2
4.8
10.3
225.0
22.7
0.7
12.1
10.7
0.0
0.1
9.6
3.5
0.2
20.1
new historic data to report,
6
57.0
2.4
2.6
2.6
67.4
it should contact [email protected]
t.
Improvements to the methods used to analyse fi nancial data, ongoing data challenges and ways in which the
quantity and quality of financial data can be improved
are described in Box 4.1.
Funding needs and gaps for MDR-TB
care and control
Of the estimated 290 000 cases of MDR-TB among notified cases of pulmonary TB in 2010, only around 50 000
were reported to have been enrolled on treatment (Chapter 3). China and India account for 44% of the estimated
cases (about 130 000), but reported only small numbers
of cases as enrolled on treatment (just over 4000). In
the Russian Federation, which ranks third in terms of
the estimated number of cases of MDR-TB among notified cases of pulmonary TB (about 31 000 cases), almost
14 000 patients were enrolled on treatment. In European
countries excluding the Russian Federation, there were
an estimated 22 000 people with MDR-TB among notified
cases of pulmonary TB (8% of the global total) in 2010,
just under 19 000 of which were enrolled on treatment.
Kazakhstan enrolled more cases on treatment (5705,
or 13% of the total) than any other country apart from
the Russian Federation. With 5402 patients enrolled on
treatment in 2010, South Africa ranked third.
The funding available for MDR-TB treatment in 106
countries that reported data increased from US$ 0.2
billion in 2006 to US$ 0.7 billion in 2011 (Figure 4.13).6
Second-line drugs accounted for 30–50% of the total,
depending on the year. In 2011, three countries account
for most of the funding: in descending order, they are
South Africa, the Russian Federation and Kazakhstan,
with a combined total of US$ 0.5 billion.7 Much of the
remaining funding is accounted for by China (US$ 35
million) and India (US$ 47 million). Although the
amounts of funding for MDR-TB in China and India are
small relative to the other three countries, they represent
a large increase compared with amounts of US$ 0.2 million and US$ 1.9 million respectively in 2006.
Much of the reported funding for MDR-TB is from
domestic sources, but the share varies from year to year.
Since 2006, domestic financing has represented 60–94%
112
80
20
FINANCING
600
(millions)
Total budget
e (million s)
Funding availabl
funded
500
% of budget
domestic sources
funding from
% available
Global Fund
funding from
400
% available
369
e funding
and availabl
NTP budget
300
2009
1.1
Global Fund
Grants
(excluding
Global Fund)
Loans
Government,
general healthcare services
(excluding
loans)
ART
2010
RETREATMENT
1548
30%
2007
LABORATORIES
ion)
100 000 populat
Smear (per
ion)
5 million populat
Culture (per
ion)
million populat
DST (per 10
e
DST availabl
Second-line
ce Laboratory
National Referen
0
13 (11–17)
3486
613
CPT
200
500
56 (41–61)
600)
2400 (2100–2
NEW
GAPS AND EXPENDITU
RES FOR 18 COUNTRIE
S IN THE REGION1
Funding gap by line item
100
1000
2010)
1999
US$ millions (constant
1997
Patients
1995
US$ million
40
Western Pacific
4548
HIV status
TB/HIV, 2009
39%
AVAILABLE FUNDING,
with known
TB patients
FUNDING
Number of
1564
HIV status
with known
Funding available by34%
itive
% of TB patients
source
that are HIV-pos
TB patients
itive
700
Number of
64%
that are HIV-pos
CPT
TB patients
started on
% of tested
87%
patients
TB
ART
HIV-positive
started
600on
% identified
95 780
TB patients
HIV-positive
d
HIV
559
identifie
with
%
547
34 845
of people living
500on ART
with HIV
489
Estimated number
3841
470
of people living
452
d for TB
Estimated number
2578
people screene
HIV-positive
with IPT
d 400
Number of
people provide
HIV-positive
Number of
TB patients300
itive
HIV-positive
for HIV-pos
CPT and ART
32
85
45
2015
2005 2010
Yes
Unknow n MDR-TB
, new smear-p
2015
2010)
Treatment success
75
0
49%
56
New MDR-TB
MDR-TB
Retreat ment
82
2010
TB CONTROL FINANCING
Regional Profiles
60
SUCCESS (%)
TREATMENT
ositive
New smear-p
egative/EP
New smear-n
Retreatment
2005
1995 2000
Mortality
80
11812
relapse
Total new and
notified
Total cases
Percent
80
204
NS
nt
DRUG REGIME
out treatme
(FDCs)
used through
combinations
Rifampicin
fixed-dose
treated with
% of patients
d
tions procure
Paediat ric formula
2005
Prevalence
100
2010)
failure
Treatment after
default
Treatment afer
654
Other
312
US$ millions (constant
8954
Smear-positive
Smear-negative
n
Smear unknow
Extrapulmonary
1251
Relapse
2000
1995
1990
RETREATMENT
NEW
notifications
200
67 (65–74)
ATIONS
in grey) and
300
27 (22–35)
16 (14–19)
2010)
CASE NOTIFIC
(millions) 668
000 pop)
Rate (per 100
37 (31–41)
US$ millions (constant
2009
0)
250 (230–26
0)
180 (160–21
)
110 (90–130
44 (36–52)
ion
000 populat
Rate per 100
OF BURDEN
ESTIMATES
ng HIV)
Mortalit y (excludi
(incl HIV)
Prevalence
HIV)
Incidence (incl
sitive)
Incidence (HIV-po
n (%)
Case detectio
US$ millions (constant
Population
Number
2009
4.3
7
Source: World Health Organization National Health Account
database (www.who.int/nha/en) accessed via http://data.
worldbank.org/indicator/SH.XPD.PUBL.ZS in July 2011.
In some countries in Africa, estimates appear to be too high
because of a denominator that is underestimated. A good
example is the Democratic Republic of the Congo; here, the
explanation may be a lack of data on expenditures by regional
governments.
For the list of 27 countries, see Chapter 2 and Chapter 3.
For case defi nitions, see Chapter 3.
www.who.int/tb/data
These amounts include the estimated value of resources used
for inpatient care and outpatient visits, which are not usually
part of the budgets and expenditures reported by NTPs. They
exclude laboratory supplies and equipment, since amounts for
MDR-TB specifically are not distinguished in the WHO data
collection form.
Financial data were not reported to WHO by South Africa in
2011. The funding available was estimated using data reported in previous years as well as a detailed budget developed
using the WHO TB planning and budgeting tool in 2007 (see
Box 4.1).
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 49
49
23/09/11 07:20
BOX 4.1
Improved methods for data analysis and ongoing data challenges
Improved methods for data analysis
Uncertainty about estimates of total NTP budgets, available funding and expenditures was more rigorously accounted for in
the time-series presented in this chapter, compared with previous reports in this series. Missing values were estimated using a
regression model in which the budget requested for period t in a specific country was assumed to depend on a combination of the
final budget requested for period t-1 and/or the number of TB cases in period t. One or both of these variables were included in
a stepwise regression, with forward selection based on p-values. In the absence of any significant explanatory variables, a linear
time-trend was fitted to the reported budget values and missing values were interpolated. For countries that have reported budget
data but have never reported expenditures, expenditure data reported by other countries within the same income group were
used to estimate the proportion of the required budget that was ultimately funded and spent. A full description of the methods will
be made available in a paper for a peer-reviewed journal.
Weaknesses in financial data reported to WHO
During WHO’s annual process of data collection, review and follow-up, considerable efforts are made to maintain and improve
the quality and completeness of financial reports. Despite these efforts, expenditure data are consistently less complete than
budget data. Examples of HBCs where there have been persistent difficulties with reporting expenditures include South Africa
(since 2006), Uganda (since 2005) and Thailand (since 2008). In Uganda, reasons include difficulties in compiling data from four
administrative regions and 111 districts. In South Africa, it has proved difficult to compile expenditures from the nine provinces
and 44 district municipalities. Wide uncertainty bands on the estimates of expenditures in these and other countries illustrate
the need for investments in financial management systems, especially in countries where responsibility for budget allocation and
monitoring of expenditures is decentralized to subnational levels (such as states and provinces), to ensure that TB expenditures
can be tracked at all levels.
Efforts to improve the quantity and quality of financial data
WHO continues to promote and train countries to use the TB Planning and Budgeting tool to improve the quality of the data
being reported (and to make it easier for countries to report to WHO). By mid-2011, the tool had been used to develop plans and
budgets in 13 of the 22 HBCs and a further 28 countries. An assessment of the tool by users in 2011 will help to make further
improvements; input can be provided via WHO’s Stop TB Department web site (www.who.int/tb). For some countries, specific
studies following the established methods of national health accounts may be required on a periodic basis to better track TB
expenditures.
FIGURE 4.13
Funding available for MDR-TB by line item, 106 countries,a
2006–2012
US$ millions (constant 2011 US$)
800
Other
Second-line drugs
600
400
200
0
2006
a
2007
2008
2009
2010
2011
2012
These countries accounted for 96% of the total number of MDR-TB cases
enrolled on treatment in 2010.
of the NTP budget; on the assumption that hospital
care and outpatient visits during treatment (typically not
included in NTP budgets) are domestically fi nanced, this
figure for domestic fi nancing increases to 79–96% of the
total funding available for MDR-TB. The value of grants
for MDR-TB from the Global Fund is growing, and
reached US$ 0.13 billion in 2011 (equivalent to 91% of
total grant fi nancing for MDR-TB). According to country reports, the biggest grants are for India and China, at
US$ 36 million and US$ 31 million respectively.
The funding that is available for MDR-TB is much
lower than the funding requirements set out in the Global Plan 2011–2015.1 The estimates in the plan are that
US$ 7 billion is needed over five years, increasing from
US$ 0.9 billion in 2011 to US$ 1.9 billion in 2015 (see
also section 2.4), for the cumulative treatment of 1.1 million people with MDR-TB, including 270 000 in 2015. To
reach the plan targets, substantial resource mobilization
will be needed. A new analysis suggests that most of the
funding required for scaling up MDR-TB diagnosis and
treatment could come from domestic funding in BRICS
and other middle-income countries (Box 4.2).
1
50
The Global Plan to Stop TB, 2011–2015. Geneva, World Health
Organization, 2010 (WHO/HTM/STB/2010.2).
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 50
23/09/11 07:20
BOX 4.2
Financing the expansion of diagnosis and treatment of MDR-TB
Funding needs in the three groups of countries are illustrated in the figure (right). BRICS account for more than 60% of
the required funding in each year and almost 70% of overall
funding (US$ 4.6 billion for 2011–2015). Other MICs require
US$ 0.2–0.4 billion per year, and US$ 1.8 billion in total. The
LICs require US$ 0.1–0.2 billion per year, and US$ 0.7 billion
in total.
Donor funding for MDR-TB amounted to US$ 0.14 billion in
2011. If prioritized for LICs, current levels of donor funding
would be almost sufficient to finance the scale-up of MDRTB diagnosis and treatment in line with the targets included
in the Global Plan.
US$ billions (current)
In a new analysis conducted for this report, the funding needs for MDR-TB set out in the Global Plan to Stop TB 2011–2015 were
estimated for three groups of countries: BRICS (Brazil, the Russian Federation, India, China and South Africa), other middleincome countries (MICs), and low-income countries (LICs). These groupings were defined with the rationale that BRICS as well
as other MICs should have the capacity to fund the diagnosis and treatment of MDR-TB from domestic sources, while LICs
will need financial support from grant sources. Estimates of
funding requirements for each group were developed using Funding required for MDR-TB, Global Plan to Stop TB,
projections of the number of patients that would need to 2011–2015a
be treated in each country to reach the Global Plan target,
2.0
and estimates of the cost per patient treated for individual
Total
countries that underpinned the analyses conducted for the
1.5
Global Plan.
BRICSb
1.0
0.5
Other MICsc
LICsd
0
2011
a
b
c
d
2012
2013
2014
2015
Total funding required is the best estimate from the range of plausible values
reported in the Global Plan to Stop TB, 2011–2015.
Brazil, the Russian Federation, India, China and South Africa.
Other middle-income countries (not including BRICS).
Low-income countries.
It should also be highlighted that there is scope to lower the
costs of treatment. The average (median) cost per patient implied by data reported by the 27 high MDR-TB burden countries
2009–2011 is US$ 8200 (interquartile range, US$ 6200–21 700). Besides the more expensive drug regimens that are needed
for treatment, a major reason for relatively high costs (compared with those for first-line treatments shown in Figure 4.7)
4.7 is that
people are treated for lengthy periods of time in hospital. The latest WHO guidelines on the programmatic management of MDR-TB
include a conditional recommendation for outpatient treatment, based on a systematic review of the cost and cost-effectiveness
of models of care in Estonia, Peru, the Philippines and Tomsk (Russian Federation).1,2 The outpatient models cost less than
US$ 4000 per patient.
1
2
4.4
Fitzpatrick C, Floyd K. A systematic review of the cost and cost-effectiveness of treatment for multidrug-resistant tuberculosis.
PharmacoEconomics, 2011 [accepted for publication].
Guidelines for the programmatic management of drug-resistant tuberculosis, 2011 update. Geneva, World Health Organization, 2011.
www.who.int/tb/challenges/mdr/programmatic_guidelines_for_mdrtb
Comparisons of funding available for
TB care and control with the resource
requirements estimated in the Global
Plan to Stop TB 2011–2015
The Global Plan to Stop TB 2011–2015 was developed by
the Stop TB Partnership in 2010.1 It sets out what needs
to be done to achieve the global targets for TB control
set for 2015,2 and the associated funding requirements
(Table 4.2, Figure 4.14). The total requirement over five
years amounts to US$ 47 billion. Excluding research and
development for new TB drugs, diagnostics and vaccines
(Chapter 7), which are not the responsibility of NTPs, the
total is US$ 37 billion. This rises from around US$ 6 billion in 2011 to US$ 8 billion in 2015 (Figure 4.14). Diagnosis and treatment following the DOTS approach requires
the largest single share of funding – US$ 4 billion in 2011
increasing to around US$ 5 billion in 2015. The second
largest component is diagnosis and treatment of MDRTB, for which the funding requirement is estimated at
US$ 1 billion in 2011, rising to almost US$ 2 billion in
2015.
A comparison of the funding requirements set out
in the Global Plan with the funding available in the 149
low-income and middle-income countries considered in
the plan is provided in Figure 4.15.3 Overall, funding falls
about US$ 2 billion short of the requirements estimated
in the Global Plan in 2012. This includes a gap of about
1
2
3
The Global Plan to Stop TB, 2011–2015. Geneva, World Health
Organization, 2010 (WHO/HTM/STB/2010.2).
For a summary of the targets set in the plan, see Chapter 1.
The total funding available in the 97 countries for which data
were available was adjusted upwards according to the fraction
of cases for which they accounted, to allow direct comparison
with the group of 149 countries considered in the Global Plan.
The Global Plan excludes high-income countries.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 51
51
23/09/11 07:20
FIGURE 4.14
Funding required to implement the Global Plan to Stop TB, 2011–2015
Implementationa
DOTS
6
10
5
8
4
6
3
4
US$ billions (constant 2011 US$)
2
2
1
0
0
2011
2012
2013
2014
2015
2011
Drug-resistant TB
2012
2013
2014
2015
2012
2013
2014
2015
TB/HIV
0.8
2.5
2.0
0.6
1.5
0.4
1.0
0.2
0.5
0
0
2011
a
2012
2013
2014
2011
2015
Implementation includes DOTS, Drug-resistant TB, TB/HIV, Laboratory strengthening and Technical assistance.
FIGURE 4.15
Funding required according to the Global Plan to Stop TB, 2011–2015, funding required
according to country plans and funding available for TB control, 2010–2012, 149 countries
Europe
Rest of the world
2.0
4
Required (country plans)
Required (Global
Plan)
DOTS
Available
1.5
3
bal
lo
d (G
US$ billions (current)
uire
Req
Required (country plans)
1.0
2
Available
ired
Requ
n)
al Pla
(Glob
MDR-TB
0.5
1
Required (country plans)
Available
0
Required (country plans)
bal
Glo
ed (
)
Plan
uir
Req
Available
0
2010
52
)
Plan
2011
2012
2013
2014
2015
2010
2011
2012
2013
2014
2015
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 52
23/09/11 07:20
TABLE 4.2
Summary of funding requirements for TB control
during the period 2011–2015, as set out in the Global
Plan to Stop TB
TOTAL FUNDING REQUIRED
(US$ BILLIONS) [% OF TOTAL]
PLAUSIBLE
RANGE
Implementation
36.9 [79%]
36.1–37.7
DOTS
22.6 [48%]
22.1–23.2
PLAN COMPONENT
MDR-TB
7.1 [15%]
6.6–7.7
TB/HIV
2.8 [6%]
2.7–2.9
Laboratory strengthening
4.0 [8%]
3.7–4.2
Technical assistance
0.4 [1%]
Research and development
9.8 [21%]
Fundamental research
2.1 [5%]
New diagnostics
1.7 [4%]
New drugs
3.7 [8%]
New vaccines
1.9 [4%]
Operational research
0.4 [1%]
All components
46.7 [100%]
US$ 1 billion for treatment with fi rst-line drugs (labelled
“DOTS” in Figure 4.15) in countries outside Europe, and
US$ 0.5 billion for treatment of patients with MDR-TB
in eastern Europe. These gaps reflect the funding gaps
reported by countries (as reported in section 4.1 and section 4.2), but also planning for the implementation of TB
control that is less ambitious than the targets set out in
the Global Plan (especially the targets set for MDR-TB,
as discussed in Chapter 3). It should be emphasized that
although funding for MDR-TB appears to exceed the
funding required in the group of countries outside eastern Europe (labelled “rest of the world” in Figure 4.15),
this funding is heavily concentrated in one country:
South Africa.
not estimated
45.9–47.5
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 53
53
23/09/11 07:20
CHAPTER 5
New diagnostics and laboratory
strengthening for TB
KEY MESSAGES
The landscape of TB diagnostics is rapidly evolving and
WHO has established a dynamic and systematic process
for timely formulation of policy. Between July 2010 and
July 2011, this process resulted in the endorsement of a
new test for rapid diagnosis of TB and drug-resistant TB –
Xpert MTB/RIF as well as a negative policy on the use of
commercial serodiagnostics for the diagnosis of active TB.
The Xpert MTB/RIF assay provides the foundation for a
revolution in the diagnosis of TB and drug-resistant TB.
Global roll-out of the Xpert MTB/RIF assay and
associated GeneXpert instruments has started. By 30
June 2011, 26 of the 145 countries that are eligible to
purchase instruments and Xpert MTB/RIF cartridges at
concessional prices had done so.
Conventional laboratory capacity remains inadequate
in many countries. In 2010, 8 of the 22 high-burden
countries (HBCs) that account for 80% of the world’s TB
cases did not meet the target of 1 microscopy centre per
100 000 population. Among the 36 countries that are in
the combined list of 22 HBCs and 27 high MDR-TB burden
countries, 20 had less than the recommended capacity
of 1 laboratory to perform culture and drug susceptibility
testing per 5 million population.
Implementation of diagnostics endorsed between 2007
and 2009 appears to be most advanced in the European
Region, where 51% of countries reported using liquid
culture and rapid speciation and 43% reported use of line
probe assays.
Laboratory strengthening must be accelerated to reach
global targets for the diagnosis of drug-resistant TB and
HIV-associated TB, as is currently happening in countries
that are participating in the EXPAND-TB project.
There were an estimated 8.8 million new and recurrent
cases of TB in 2010, of which 5.7 million were diagnosed
and notified to national TB control programmes (NTPs);
among notified cases, there were an estimated 290 000
cases of multidrug-resistant TB (MDR-TB), of which
only 53 000 (18%) were reported to have been diagnosed
and enrolled on appropriate treatment (Chapter 2, Chapter 3). Earlier and improved detection of TB cases and
expanded capacity to diagnose cases of MDR-TB are thus
global priorities for TB control, requiring new diagnostic
tests, clear policies on which diagnostic tests to use (and
which not to use) and strengthened laboratories in which
tests can be safely and effectively carried out.
This chapter has two main parts. The fi rst part highlights two landmarks in TB diagnostics in 2010/2011:
the endorsement of a new rapid test for TB and drugresistant TB called Xpert MTB/RIF at the end of 2010,
and new policy guidance on the use of commercial serological tests for the diagnosis of active TB disease. The
second part discusses the status of laboratory capacity in
2010, and recent progress in strengthening laboratories
including the adoption of policy guidance from WHO.
Particular attention is given to the countries that carry
the highest burden of TB and MDR-TB as well as to a
project in 27 countries called EXPAND-TB and the rollout of Xpert MTB/RIF in the fi rst six months of 2011.
5.1
The landscape of TB diagnostics is rapidly evolving, and
in this context WHO has established a dynamic and systematic process for timely formulation of policy. The process involves four main steps. First, the available evidence
is synthesized through systematic reviews and meta-analyses of data. Second, findings are reviewed by an external Expert Group. Third, the evidence and public health
impact of new tools and technologies are assessed using
the recommended GRADE approach.1 Fourth, detailed
policy guidance is developed, followed by dissemination
to Member States and other stakeholders.2
Between July 2010 and July 2011, this process resulted
in the endorsement of a new test for rapid diagnosis of
TB and drug-resistant TB – Xpert MTB/RIF as well as a
1
2
54
New diagnostic tests and WHO policies
www.gradeworkinggroup.org
WHO policies on TB diagnostics are available at: www.who.
int/tb/laboratory/policy_statements
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 54
23/09/11 07:20
BOX 5.1
Serodiagnostics: the evidence base for “negative” policy guidance
In 2010, a systematic review identified 67 studies on the use of commercially available serodiagnostic
tests to diagnose active pulmonary TB disease. There were 32 studies from low-income and middleincome countries. The results demonstrated that the sensitivity and specificity values from individual
studies were highly variable. Pooled results of the most widely used test showed sensitivities of 76%
and 59% and specificities of 92% and 91% in patients with smear-positive and smear-negative pulmonary TB, respectively.
For extrapulmonary TB, 25 studies were identified in a systematic review, including 10 studies from
low-income and middle-income countries. The results demonstrated that sensitivity and specificity
values from individual studies were highly variable. Pooled sensitivity was 64% for TB of the lymph
nodes and 46% for TB of the pleura. The pooled results for the sensitivity and specificity of the most
widely used test were 81% and 85%, respectively. In one study involving HIV-infected patients, the
sensitivity of the test was 33%.
negative policy on the use of commercial serodiagnostics
for the diagnosis of active TB disease.
5.1.1 Xpert MTB/RIF
Xpert MTB/RIF is a TB-specific automated, cartridgebased nucleic amplification assay based on the GeneXpert multi-disease platform. It was developed by Cepheid,
Inc. (Sunnyvale, USA) in partnership with the Foundation for Innovative New Diagnostics (FIND) and the
University of Medicine and Dentistry of New Jersey
(Newark, USA) with support from the US National Institutes of Health and the Bill & Melinda Gates Foundation.
Xpert MTB/RIF detects Mycobacterium tuberculosis as well
as mutations conferring resistance to rifampicin directly
from sputum in an assay that provides results within 100
minutes. Results from field demonstration studies found
that a single Xpert MTB/RIF test can detect TB in 99%
of patients with smear-positive pulmonary TB and >80%
of patients with smear-negative pulmonary TB (see Chapter 3, Box 3.1 for defi nitions of different types of TB case).
The demonstration studies also showed that while HIV
coinfection substantially decreases the sensitivity of
microscopy, it does not significantly affect the performance of Xpert MTB/RIF. Furthermore, Xpert MTB/
RIF can detect rifampicin resistance with 95.1% sensitivity and exclude resistance with 98.4% specificity.
WHO endorsed the Xpert MTB/RIF assay in December 2010. The test has the capacity to revolutionize the
diagnosis of TB and drug-resistant TB, since it can greatly increase case fi nding and overcomes several of the barriers to establishing diagnostic capacity at country level,
including human resource and biosafety constraints.
It should be emphasized that countries will continue
to require adequate laboratory services for microscopy
and culture to monitor treatment progress and to detect
resistance to drugs other than rifampicin. Moreover, several operational conditions need to be met for successful implementation of Xpert MTB/RIF, including revised
diagnostic algorithms, defi nition of the risk groups and
levels of the health system in which the test would be
used fi rst, and analysis of logistic considerations to optimize the use and benefits of the technology.
The use of technologies such as Xpert MTB/RIF must
be accompanied by rapid expansion and access to treatment services. WHO therefore recommends that health
authorities should roll out Xpert MTB/RIF in phases,
within the context of national plans for appropriate treatment and care of TB, MDR-TB and HIV-associated TB.
Global recommendations on the operational aspects of
implementing Xpert MTB/RIF are available in key WHO
documents on a dedicated web site.1
5.1.2 Commercial serological antibody tests to
diagnose TB disease
Dozens of commercial serological antibody tests for the
diagnosis of active TB disease are marketed in many parts
of the world,2 despite the previously reported poor performance of these tests. In 2010, WHO commissioned a
systematic review to synthesize the latest evidence on the
diagnostic accuracy of these tests, both for pulmonary
and extrapulmonary TB. Overall it was found that commercial serological tests provide inconsistent and imprecise results with highly variable values for sensitivity and
specificity, and high proportions of false-negative and
false-positive results. There was no evidence that existing commercial serological assays improve outcomes
that are important to patients. Following the fi ndings of
this review, WHO issued “negative” policy guidance that
strongly recommends that commercial serological tests
should not be used for the diagnosis of pulmonary and
extrapulmonary TB. A summary of the main evidence
used for policy formulation is provided in Box 5.1; the full
policy document is available from WHO.3
1
2
3
www.who.int/tb/laboratory/mtbrifrollout
These tests should be distinguished from interferon-gamma
release assays (IGRAs) which are used to test for latent infection (as opposed to active disease).
www.who.int/tb/laboratory/policy_statements
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 55
55
23/09/11 07:20
Laboratory capacity and progress
in laboratory strengthening at
country level
A total of 36 countries (see Table 5.1 and Table 5.2) are in
the combined list of 22 high-burden countries (HBCs)
that account for about 80% of the world’s estimated cases
of TB and the 27 high MDR-TB burden countries that
account for about 85% of the world’s estimated cases
of MDR-TB. In 2010, 20 of these 36 countries had less
than the recommended capacity of 1 laboratory to perform culture and drug susceptibility testing (DST) per
5 million population (Table 5.1). Capacity to perform
sputum smear microscopy also remains insufficient in
many settings: 8 of the 22 HBCs do not meet the target of 1 microscopy centre per 100 000 population and
at the regional level the Western Pacific and the Eastern
Mediterranean regions had only 0.5 and 0.9 microscopy
centres, respectively, per 100 000 population.
Globally, almost three quarters of countries indicated
the existence of a designated national TB reference laboratory (NRL). The African Region reported the highest
proportion of countries (87%) with an NRL, although
their functionality and/or performance have not been
fully verified.
The Global Plan to Stop TB 2011–20151 includes a
target that all patients who have been previously treated
for TB should be tested for MDR-TB using rapid tests by
2015. Given the slower, conventional methods for DST,
globally only 6% of previously treated patients received
DST by any method in 2010 (see Chapter 3).
The uptake at country level of WHO laboratory policy
guidance, with particular attention to the rapid diagnosis
of drug-resistant TB, is described in Table 5.2. Capacity to conduct conventional DST for the detection of
drug resistance exists in about 50% of countries. The
uptake of newer diagnostics is slower: only 38% of countries reported use of liquid culture and rapid speciation
in 2010, and only 23% reported use of line probe assays
(LPAs) to detect rifampicin resistance. At the regional
level, implementation appears to be most advanced in the
European Region, where 51% of countries reported using
liquid culture and rapid speciation and 43% reported use
of LPAs. Uptake in the Region of the Americas appears
slowest; only 23% of countries reported using liquid culture and rapid speciation, and 2% reported use of LPAs.
The availability of conventional DST and the uptake of
new, rapid technologies in the combined list of 36 highburden countries is better than the global average. Conventional DST is being rolled out in almost all of these
countries. However, the coverage of liquid culture is still
not adequate: 15 of the 22 HBCs (68%) and 17 of the 27
high MDR-TB burden countries (63%) had implemented
FIGURE 5.1
The EXPAND-TB project - progress by July 2011
Laboratory
assessment
• Laboratory
assessment
• Memorandum of
understanding
• Infrastructure
upgrade
• Creation of SOPs
policy reform
18–24 months
• Bangladesh
• Belarus
• Indonesia
• Kazakhstan
• Peru
• Senegal
• Viet Nam
56
The Global Plan to Stop TB, 2011–2015. Geneva, World Health
Organization, 2010 (WHO/HTM/STB/2010.2).
Routine testing
and monitoring
• Equipment
and supplies
• Procurement
• Training
• Quality assurance
• Laboratory
validation
6–12 months
• Azerbaijan
• Cameroon
• Côte d’Ivoire
• Djibouti
• Georgia
• Haiti
• Kenya
• Kyrgyzstan
• Republic of
Moldova
• Swaziland
• Tajikistan
• UR Tanzania
• Monitoring
and evaluation
• Impact
assessment
• Market
dynamics
Up to year 5
• Ethiopia
• India
• Lesotho
• Myanmar
• Uganda
• Uzbekistan
FIGURE 5.2
Cases of MDR-TB reported by selected countries
participating in the EXPAND-TB project, 2008–2010
3000
India
2967
2500
2000
1660
1500
1023
1000
Uzbekistan
654
500
1
Technology
transfer
liquid culture by 2010; the figures were 10/22 (45%) and
16/27 (59%), respectively, for LPAs. The slightly higher
rate of implementation among HBCs is due in part to
the EXPAND-TB project, a multi-partner initiative to
establish new and rapid TB diagnostic technologies in 27
countries.
Launched in 2008 and expected to continue until 2013,
the EXPAND-TB project aims to improve capacity to
diagnose MDR-TB in upgraded laboratory services in 27
countries, 15 of which are in the list of 22 HBCs or 27
high MDR-TB burden countries (Figure 5.1). The project
is a collaboration among WHO, the Global Laboratory
Initiative, FIND and the Global Drug Facility, and funded
by UNITAID and other partners. As this report went to
press, new laboratory infrastructure and successful transfer of liquid culture and LPA technologies had been established in 18 countries. Among these 18 countries, six were
routinely diagnosing patients with MDR-TB and rapid
increases in patient numbers were evident (Figure 5.2).
Number of cases
5.2
0
342
308
26
2008
57
2009
93
Uganda
2010
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 56
23/09/11 07:20
TABLE 5.1
Laboratory capacity, 2010
SMEAR
LABORATORIES
(PER 100 000
POPULATION)
CULTURE
LABORATORIES
(PER 5 MILLION
POPULATION)a
DRUG
SUSCEPTIBILITY
TESTING
LABORATORIES
(PER 5 MILLION
POPULATION)a
LINE-PROBE
ASSAY RIFAMPICIN
LABORATORIES
(PER 5 MILLION
POPULATION)
NATIONAL
REFERENCE
LABORATORY
HIGH TB
BURDEN
HIGH
MDR-TB
BURDEN
Afghanistan
1.9
0.2
0
0
Armenia
1.4
1.6
1.6
1.6
Azerbaijan
0.8
1.1
1.1
–
–
Bangladesh
0.7
<0.1
<0.1
Belarus
–
–
–
Brazil
2.0
6.5
1.0
Bulgaria
0.5
Cambodia
1.5
1.1
0.4
China
0.2
3.3
DR Congo
2.2
Estonia
Ethiopia
Georgia
India
Yes
No
0
–
–
0
0.7
0
0.7
<0.1
<0.1
<0.1
0
0.4
7.5
7.5
7.5
2.3
0.1
0.1
0.1
0.7
2.3
1.1
1.1
1.1
<0.1
<0.1
<0.1
Indonesia
2.1
0.9
0.1
0
Kazakhstan
2.9
6.9
0
Kenya
3.3
0.7
0.5
0.4
Kyrgyzstan
2.3
7.5
2.8
0.9
Latvia
0.7
8.9
2.2
2.2
Lithuania
0.4
9.0
9.0
1.5
Mozambique
1.9
0.4
0.4
0
Myanmar
0.9
0.2
0.2
0.2
Nigeria
0.6
0.2
0.1
<0.1
Pakistan
0.7
0.4
0.3
0
Philippines
2.1
0.4
0.1
0
Republic of Moldova
1.7
5.6
5.6
1.4
Russian Federation
2.8
9.5
–
South Africa
0.5
1.5
1.5
1.4
Tajikistan
1.4
2.2
0.7
0
Thailand
1.6
4.7
1.1
0.1
Uganda
2.9
1.2
0.6
0.5
Ukraine
2.2
5.1
–
UR Tanzania
1.6
0.4
0.2
0.2
Uzbekistan
1.1
0.7
0.4
0.4
Viet Nam
0.9
1.3
0.1
0.1
Zimbabwe
0.9
0.8
0.8
0
20
31
14
11
14
High-burden countries
1.0
2.0
0.7
<0.1
95%
High MDR-TB burden countries
0.9
2.1
0.8
<0.1
85%
87%
AFR
1.4
AMR
2.5
EMR
0.9
EUR
1.3
SEAR
1.2
0.7
17
2.0
12
0.4
0.4
0.2
0.9
<0.1
74%
0.4
0.1
77%
5.9
1.1
62%
0.1
<0.1
82%
WPR
0.5
4.6
0.7
0.1
72%
Global
1.1
4.4
1.0
0.1
74%
– Indicates no data reported.
a
The revised WHO target for both culture and DST capacity is 1 laboratory per 5 million population. While these processes previously had separate indicators, the
revised combined indicator is the result of the introduction of new technologies for which culture and DST are invariably performed together.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 57
57
23/09/11 07:20
TABLE 5.2
Implementation of WHO policy guidance for diagnosis of TB, 2010
Yes
CONVENTIONAL DRUG
SUSCEPTIBILITY TESTING (DST)
LIQUID CULTURE AND RAPID
SPECIATION TEST
LINE-PROBE ASSAY FOR DETECTING
RESISTANCE TO RIFAMPICIN
ALGORITHM FOR THE DIAGNOSIS
OF TB IN HIV-POSITIVE PEOPLE
HIGH TB
BURDEN
HIGH
MDR-TB
BURDEN
INCORPORATED
INTO POLICY
BEING
ROLLED OUT
INCORPORATED
INTO POLICY
BEING
ROLLED OUT
INCORPORATED
INTO POLICY
BEING
ROLLED OUT
INCORPORATED
INTO POLICY
BEING
ROLLED OUT
Afghanistan
Armenia
Azerbaijan
–
–
–
–
–
–
–
–
Bangladesh
Belarus
–
–
–
–
–
–
–
–
No
Brazil
Bulgaria
Cambodia
China
DR Congo
Estonia
Ethiopia
Georgia
India
Indonesia
Kazakhstan
Kenya
Kyrgyzstan
–
Latvia
Lithuania
Mozambique
Myanmar
Nigeria
Pakistan
Philippines
Republic of Moldova
Russian Federation
South Africa
Tajikistan
Thailand
Uganda
Ukraine
UR Tanzania
Uzbekistan
Viet Nam
Zimbabwe
High-burden countries
91%
91%
64%
68%
45%
45%
77%
73%
High MDR-TB burden countries
93%
85%
67%
63%
52%
59%
70%
59%
AFR
52%
48%
48%
46%
33%
24%
57%
54%
AMR
40%
34%
32%
23%
4%
2%
34%
30%
EMR
68%
55%
45%
36%
32%
18%
59%
59%
EUR
60%
57%
51%
51%
42%
43%
38%
34%
SEAR
82%
64%
45%
36%
27%
27%
36%
36%
WPR
50%
50%
31%
31%
22%
22%
42%
50%
Global
54%
49%
42%
38%
27%
23%
44%
43%
– Indicates no data reported.
58
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 58
23/09/11 07:20
FIGURE 5.3
Progress in the roll-out of Xpert MTB/RIF, as of June 2011
KYRGYSTAN (4)
TAJIKISTAN (8)
AZERBAIJAN (4)
GEORGIA (8)
CHINA (16)
NEPAL (4)
CAMBODIA (16)
PHILIPPINES (4)
PAKISTAN (4)
INDIA (14)
GUATEMALA (4)
HAITI (4)
ETHIOPIA (8)
UGANDA (26)
BRAZIL (4)
PERU (8)
MALAWI (12)
ZAMBIA (14)
ZIMBABWE (24)
BOTSWANA (4)
SOUTH AFRICA (361)
KENYA (32)
TANZANIA (36)
GeneXpert
modules ordered
0
1–4
MOZAMBIQUE (12)
SWAZILAND (20)
LESOTHO (4)
5–14
15–29
≥30
Not eligible for
preferential pricing
No data
As the newly endorsed Xpert MTB/RIF assay is rolled
out worldwide, WHO is systematically compiling and
sharing information on progress, including the plans of
countries and partners, information on sales of instrument modules1 and cartridges and reports of problems
from the field. Of the 145 countries that are eligible to
purchase GeneXpert instrument modules and Xpert
MTB/RIF cartridges at concessional prices agreed
between FIND and the manufacturer,2 26 countries had
ordered a total of 681 instrument modules by 30 June
2011 (Figure 5.3); 361 were ordered by South Africa alone.
In addition to equipping laboratories with new diagnostic technologies, implementation of external quality
assurance (EQA) systems is critical to ensure the highquality functioning of laboratories. Of the 36 countries
in the combined list of 22 HBCs and 27 high MDR-TB
burden countries, 29 provided information on the num-
1
2
3
ber of microscopy centres that participated in an EQA
scheme in 2010. Coverage was far from adequate, with
*80% of microscopy centres participating in an EQA
scheme in only 21 of the 29 countries. Similarly, of the
30 countries that provided information on the number
of DST laboratories that participated in an EQA scheme,
only 20 reported that all DST laboratories participated in
2010. More positively, all of the 36 countries that reported less than 100% participation in EQA schemes in 2010
had plans to increase the coverage of their EQA schemes
for both microscopy and DST in 2011.
In addition to advancing policies and initiatives to
accelerate the uptake of new, rapid diagnostics, two priority themes to strengthen laboratories in 2011 are promoting laboratory accreditation and laboratory biosafety
(Box 5.2).3
The most common configuration is a four-module instrument, which allows for 16–20 tests per day.
The list of eligible countries is available at
www.fi nddiagnostics.org/about/what_we_do/successes/
fi nd-negotiated-prices/xpert_mtb_rif.html
For the most up-to-date WHO policies and resources on TB
diagnostics and laboratory strengthening, visit www.who.
int/tb/laboratory/policy_statements. Resources of the GLI,
a Working Group of the Stop TB Partnership, are available at
www.stoptb.org/wg/gli
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 59
59
23/09/11 07:20
BOX 5.2
Priority themes for strengthening laboratories in 2011: accreditation and biosafety
Accreditation. The Global Plan to Stop TB 2011–2015 includes a target that more than half of all national TB reference laboratories (NRLs) should have implemented an accredited quality management system by 2015. Accreditation programmes for laboratories provide both guidance and an incentive for improving laboratory quality. While such programmes are required components of
TB laboratory services in most industrialized countries, they have been largely absent in resource-constrained settings.
International standards (so-called ISO standards) for clinical laboratory services have been developed by the International Organization for Standardization. However, because of the specific technical nature of TB diagnostic services and the corresponding
biosafety needs, these general standards need to be translated into practical guidelines and TB-specific requirements. Partners
of the Global Laboratory Initiative (GLI), including the Union, the United States Centers for Disease Control and Prevention, the
Royal Tropical Institute in the Netherlands and WHO have developed a guide to assist countries to implement a quality management system at the level of the NRL. This guide facilitates a step-wise approach to achieving relevant ISO standards, and will be
field tested in countries starting in 2011.
Biosafety. A combination of good laboratory practices together with administrative controls, containment principles, safety
equipment and laboratory facilities are essential in TB laboratories to minimize the generation of infectious aerosols and thus prevent laboratory-acquired infections. Different types and combinations of test procedures require different containment precautions, equipment and facilities. WHO has therefore developed a risk assessment approach to determine the minimum biosafety
measures required for TB laboratories based on the actual procedures performed in the laboratory. It is important to note that the
risk-based approach to laboratory biosafety moves away from the traditional approach of assigning different “biosafety levels” to
a much more focused approach taking into account the actual procedures performed in the laboratory.
The resulting three-tiered system is based on “low”, “moderate” and “high” TB risk precautions, described below; respective
minimum requirements are described in detail in biosafety guidance under development in 2011.
Low TB risk precautions. Procedures: direct AFB microscopy, Xpert MTB-RIF
Moderate TB risk precautions. Procedures: processing sputum specimens for primary culture inoculation on solid media, direct
nitrate reductase assay (NRA), direct microscopic observation of drug susceptibility (MODS) assay or direct line-probe assay on
sputum-positive specimens
High TB risk precautions – containment laboratory. Procedures: manipulating cultures for identification and drug susceptibility
testing (DST) with indirect phenotypic methods such as liquid culture, or for line probe assays
60
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 60
23/09/11 07:20
CHAPTER 6
Addressing the co-epidemics of TB and HIV
KEY MESSAGES
HIV testing of TB patients is now standard practice in
many countries, especially in the African Region. In 68
countries and territories including 22 countries in the
African Region, ≥75% of TB patients knew their HIV status
in 2010. Further efforts are needed to achieve similar
results at global level. In 2010, 34% of notified TB patients
(2.1/6.2 million) knew their HIV status.
The highest rates of HIV coinfection in TB patients are
in the African Region, where 44% of TB patients with an
HIV test result in 2010 were HIV-positive (range among
high TB/HIV burden countries, 8%–82%), followed by the
Region of the Americas (17%).
The global coverage of antiretroviral therapy (ART) for
TB patients living with HIV remains low (only 46%), despite
the large increase in HIV testing among TB patients and
the WHO recommendation that ART should be provided to
all TB patients living with HIV regardless of their CD4 cell
count. The provision of ART to TB patients living with HIV
must be enhanced, including the use of TB services and
infrastructure to allow decentralization of care delivery
according to national guidelines and the local context.
Implementation of WHO guidelines on TB screening
and isoniazid preventive therapy among people living
with HIV can result in a rapid expansion of TB prevention,
diagnosis and treatment.
The recording and reporting of the outcomes of TB
treatment disaggregated by HIV status needs to be
improved, using WHO-recommended TB registers (which
should also be used by HIV service providers including in
ART clinics).
People living with HIV who are also infected with TB
are about 21–34 times more likely to develop TB disease
compared with those who are HIV-negative.1 Starting in
the 1980s, the HIV epidemic led to a major upsurge in TB
cases and TB mortality in many countries that persisted
throughout the 1990s and up to around 2004, especially
in southern and east Africa (Chapter 2, Chapter 3). Globally, just over one in ten of the almost 9 million people
who develop TB each year is HIV-positive, equivalent
to 1.1 million new TB cases among people living with
HIV in 2010 (Chapter 2, Table 2.1). In the African Region,
which accounted for 82% of the new TB cases that were
living with HIV in 2010, an estimated 900 000 (39%) of
the 2.3 million people who developed TB in 2010 were
HIV-positive. Globally in 2010, there were an estimated
0.35 million deaths (range, 0.32 million–0.39 million)
from TB among people who were HIV-positive. WHO,
UNAIDS and the Stop TB Partnership have set a target
that by 2015, TB mortality rates among people who are
HIV-positive should be reduced by 50%, compared with
2004 (the year in which TB mortality among HIV-positive people is estimated to have peaked).2
WHO has provided clear recommendations about the
interventions needed to prevent, diagnose and treat TB in
people living with HIV since 2004.3 The recommended
interventions are collectively known as collaborative TB/
HIV activities. They include HIV testing of TB patients,
provision of antiretroviral therapy (ART) and co-trimoxazole preventive therapy (CPT) to TB patients living with
HIV, HIV prevention services for TB patients, intensified
TB case-fi nding among people living with HIV, isoniazid
preventive therapy (IPT) for people living with HIV who
do not have active TB, and infection control in health1
2
3
The probability of developing TB among people living with
HIV divided by the probability of developing TB among HIVnegative people is the incidence rate ratio (IRR). The median
value of the IRR in countries with a generalized HIV epidemic
was 21 (inter-quartile range 14–25) in 2010. A generalized epidemic is defi ned by UNAIDS as a prevalence of HIV infection
>1% in those aged 15–49 years old. The IRR was 34 (interquartile range 20–34) in 115 other countries with low-level or
concentrated HIV epidemics.
Getting to zero. 2011–2015 strategy. Geneva, Joint United
Nations Programme on HIV/AIDS.
Policy on collaborative TB/HIV activities. Geneva, World Health
Organization, 2004 (WHO/HTM/TB/2004.330; WHO/
HTM/HIV/2004.1).
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 61
61
23/09/11 07:20
TABLE 6.1
HIV testing, treatment for HIV-positive TB patients and prevention of TB among people living with HIV, 41 high TB/HIV
burden countries and WHO regions, 2010. Numbers in thousands except where indicated
HIV-POSTIVE INCIDENT TB CASES
BEST
HIGH
% OF
NOTIFIED TB
PATIENTS
TESTED FOR
HIV
% OF TESTED
TB PATIENTS
HIVPOSITIVE
% OF
IDENTIFIED
HIVPOSITIVE TB
PATIENTS
STARTED ON
CPT
% OF
IDENTIFIED
HIVPOSITIVE TB
PATIENTS
STARTED ON
ART
NUMBER
OF HIVPOSITIVE
PEOPLE
SCREENED
FOR TB
NUMBER
OF HIVPOSITIVE
PEOPLE
PROVIDED
WITH IPT
Angola
5.2
3.7
7.1
2.4
4.9
28
18
12
–
–
Botswana
6.5
5.8
7.3
6.1
80
65
79
45
0.2
0.7
–
Brazil
18
15
22
37
45
23
–
93
–
Burkina Faso
1.6
1.4
1.9
4.3
83
18
96
41
–
–
Burundi
2.5
2.2
2.8
5.5
71
23
95
40
–
–
Cambodia
4.0
3.4
4.7
32
77
6.6
65
45
–
0.5
Cameroon
14
11
17
19
78
40
–
–
–
–
Central African Republic
5.3
4.0
6.8
2.6
39
33
–
62
–
–
Chad
9.2
6.4
12
3.8
39
17
–
–
–
–
China
18
10
28
150
16
3.1
–
45
65
–
Congo
1.2
1.0
1.4
9.7
94
7.8
2.9
2.9
0.1
–
Côte d’Ivoire
6.7
5.7
7.6
17
73
24
80
26
31
–
Djibouti
0.6
0.5
0.8
2.2
52
11
–
11
–
–
18
13
24
29
24
18
24
9.3
3.9
–
–
–
–
67
43
15
69
39
44
6.6
DR Congo
Ethiopia
Ghana
4.9
4.3
5.6
10
69
23
86
20
57
–
Haiti
4.6
3.8
5.5
9.5
67
20
13
9.8
6.2
4.1
India
–
110
75
160
480
32
8.6
90
57
200
Indonesia
18
9.9
29
–
–
–
–
–
3.2
–
Kenya
50
45
55
97
91
41
100
48
–
–
Lesotho
11
9.2
12
11
84
77
96
27
–
–
Malawi
21
19
22
20
88
63
94
46
230
–
Mali
1.5
1.0
2.0
2.3
43
17
100
40
25
0
Mozambique
77
53
110
41
88
61
97
25
0.4
8.9
Myanmar
37
21
57
4.4
3.2
22
100
94
6.4
0.5
Namibia
7.6
7.1
8.1
9.5
76
55
92
42
25
14
Nigeria
51
25
87
72
79
25
59
33
57
1.8
Russian Federation
8.1
6.8
9.4
170
100
6.2
–
82
–
–
Rwanda
3.6
3.2
4.0
6.9
98
32
97
–
13
–
Sierra Leone
4.0
3.3
4.8
9.7
74
10
6.4
19
–
–
South Africa
120
300
240
350
210
53
60
74
54
760
Sudan
7.1
4.8
9.9
11
41
6.2
58
54
1.5
–
Swaziland
13
10
15
9.5
86
82
93
35
–
–
Thailand
Togo
15
13
18
53
77
16
71
53
25
–
5.4
4.3
6.5
2.3
78
20
–
–
–
–
Uganda
38
30
46
37
81
54
90
24
400
–
Ukraine
6.0
5.0
7.1
35
95
13
–
–
–
5.0
UR Tanzania
30
28
32
57
90
38
92
35
320
–
Viet Nam
7.6
4.6
11
42
43
8.3
62
43
–
1.3
Zambia
40
36
44
41
83
65
77
47
12
–
Zimbabwe
60
47
76
38
80
75
18
30
–
–
1 000
960
1 100
1 900
39
25
77
46
2 300
170
AFR
900
820
980
880
59
44
76
42
2 000
160
AMR
35
31
38
100
46
17
47
65
15
13
EMR
12
9.8
15
46
11
3.4
51
37
6.8
0.3
6.6
High TB/HIV burden countries
EUR
20
19
22
290
80
6.0
48
77
5.6
SEAR
190
140
230
540
23
9.5
87
57
230
0.6
WPR
35
26
45
250
19
4.8
55
41
69
2.0
1 100
1 000
1 200
2 100
34
23
77
46
2 300
180
Global
62
LOW
NUMBER OF
TB PATIENTS
WITH
KNOWN HIV
STATUS
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 62
23/09/11 07:20
6.1
HIV testing, co-trimoxazole preventive
therapy and antiretroviral therapy for
patients with TB
The number of TB patients who knew their HIV status
reached 2.1 million in 2010, equivalent to 34% of notified cases of TB (Table 6.1). This was an improvement
from 28% in 2009 and almost 10 times better than the
3.7% reported in 2003 (Figure 6.1). The coverage of HIV
testing for TB patients was particularly high in the African and European regions, where 59% and 80% of TB
patients respectively knew their HIV status. Impressively,
*75% of TB patients living in almost half of the countries
in the African Region (22 out of 46 countries) knew their
HIV status in 2010. This was an increase from 16 in 2009
and double the 11 countries that achieved testing rates of
*75% in 2008. More than three quarters of the African
countries that reported data (31/41) achieved *50% (Figure 6.2). Five African countries did not report data for
2010: Algeria, Cape Verde, Comoros, Eritrea and Gabon.
Globally, the percentage of TB patients who knew their
HIV status was *75% in 68 countries and territories in
2010, up from 55 countries in 2009.
Among TB patients with an HIV test result in 2010,
23% were HIV-positive at the global level (Table 6.1).
Among the 41 countries identified as priorities for TB/
HIV at the global level in 2002 (listed in Table 6.1), 25%
were HIV-positive. Much higher rates of HIV coinfection were reported for TB patients in the African Region,
FIGURE 6.1
HIV testing for TB patients, all countries, 2003–2010
The number of notified new and retreatment cases is shown
in blue and the number of cases for which the HIV status was
recorded in the TB register is shown in green. The percentage
of notified TB cases with known HIV status is indicated
above the green bars.a
7
6
5
Cases (millions)
care and congregate settings (the latter three activities
are referred to as the “Three Is for HIV/TB”).
Testing TB patients for HIV and providing CPT to TB
patients living with HIV are typically the responsibility of
national TB control programmes (NTPs). National HIV
programmes are usually responsible for initiating intensified case-fi nding for TB among people living with HIV
as well as providing IPT to those without active TB. Provision of ART to TB patients living with HIV has often
been the responsibility of national HIV programmes,
but should also be done by NTPs. When NTPs do not
provide ART directly, they are responsible for referring
TB patients living with HIV to ART services. The latest policy guidance from WHO recommends that ART
should be provided to all TB patients living with HIV,
irrespective of their CD4 count (and to all people living
with HIV with a CD4 cell count )350).1
WHO began monitoring the implementation and
expansion of collaborative TB/HIV activities in 2004.
This chapter presents the latest status of progress, using
data for 2003 up to 2010.2 The need for better data on
treatment outcomes for TB patients living with HIV, and
the recent and rapid expansion of TB screening among
people living with HIV and associated uptake of IPT
following new policy guidance in Cambodia and South
Africa are also highlighted.
4
3
34%
2
28%
1
3.7%
3.1%
2003
116
(42%)
2004
101
(48%)
8.3%
20%
22%
2007
175
(98%)
2008
173
(98%)
12%
0
a
2005
139
(76%)
2006
159
(88%)
2009
186
(99%)
2010
169
(97%)
The numbers under each year show the number of countries reporting data
on HIV testing followed by the percentage of total estimated HIV-positive TB
cases accounted for by reporting countries.
where 44% of those tested were found to be HIV-positive. The percentage of TB patients found to be HIVpositive in the 31 African countries in the list of 41
priority countries ranged from 8% in Congo to 82% in
Swaziland. Besides Swaziland, more than half of the TB
patients who were tested were HIV-positive in Botswana,
Lesotho, Malawi, Mozambique, Namibia, South Africa,
Uganda, Zambia and Zimbabwe.
In the Region of the Americas, the percentage of TB
patients found to be HIV-positive was 17%. In the Eastern Mediterranean, European, South-East Asia and
Western Pacific regions, less than 10% of TB patients
tested for HIV were HIV-positive. Among the 11 countries identified as priorities for TB/HIV at the global level
in 2002 that are outside the African Region, the percentage of TB patients who were HIV-positive ranged from
3% in China to 23% in Brazil in 2010.
Globally, the number of TB patients living with HIV
who were enrolled on CPT levelled off between 2009
and 2010, at just over 0.3 million (Figure 6.3). This was
equivalent to 77% of TB patients known to be HIV-positive (Table 6.1, Figure 6.4). Further progress is needed to
reach the target of 100% that is included in the Global
Plan to Stop TB, 2011–20153 (see Chapter 1). The African
1
2
3
www.who.int/hiv/pub/arv/advice
This chapter does not discuss infection control or services
aimed at HIV prevention among TB patients. Data for the
former are limited for most countries, but available data can
be accessed at www.who.int/tb/data. Data on HIV prevention
services for TB patients are not part of routine recording and
reporting in TB registers, and are not requested on the annual
WHO TB data collection form.
The Global Plan to Stop TB, 2011–2015. Geneva, World Health
Organization, 2010 (WHO/HTM/STB/2010.2).
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 63
63
23/09/11 07:20
FIGURE 6.2
HIV testing for TB patients, by country, 2010
Percentage of notified
TB cases with known
HIV status
0–14
15–49
50–74
≥75
No data
FIGURE 6.3
Co-trimoxazole preventive therapy (CPT) and antiretroviral
therapy (ART) for HIV-positive TB patients, 2003–2010
Number of TB patients (thousands)
500
Tested
HIV-positive
400
CPT
300
200
ART
100
0
2003
2004
2005
2006
2007
2008
2009
2010
and South-East Asia regions achieved particularly high
levels of enrolment on CPT, with 76% and 87% of TB
patients known to be living with HIV provided with CPT,
respectively (Table 6.1). Countries that achieved the highest rates of enrolment on CPT in 2010 included Burkina
Faso (96%), Burundi (95%), India (90%), Kenya (100%),
Lesotho (96%), Mozambique (97%), Malawi (94%), Mali
(100%), Myanmar (100%), Namibia (92%), Rwanda
(97%), Swaziland (93%), the United Republic of Tanzania (92%) and Uganda (90%).
The number of HIV-positive TB patients on ART
has grown steadily from a very low level in 2004 (Figure
6.3), reaching over 200 000 in 2010.1 Among TB patients
known to be living with HIV, 46% were on ART globally
(Table 6.1, Figure 6.4). In the African Region, 42% of TB
patients known to be living with HIV were on ART in
2010 and only a few countries (Botswana, Central African Republic, Kenya, Malawi, South Africa and Zambia,
at 47–62%) exceeded this level, despite the WHO recommendation that all HIV-positive TB patients are eligible
for ART irrespective of their CD4 cell count. Most of the
ART being provided to TB patients living with HIV is
accounted for by African countries, notably South Africa
1
64
In the annual WHO TB data collection form, countries are
asked to report the number of TB patients living with HIV
who “started or continued on ART”.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 64
23/09/11 07:20
BOX 6.1
Better reporting of the outcomes of TB treatment by HIV status is urgently needed
Percent of cohort
The Stop TB Partnership, WHO and UNAIDS have set a target of halving the number of TB deaths among HIV-positive people by
2015 compared with 2004 (the year in which TB mortality among HIV-positive people is estimated to have peaked). Earlier and
prompt diagnosis and treatment of TB as well as antiretroviral therapy (ART) and co-trimoxazole preventive therapy (CPT) can
cut mortality rates among TB patients living with HIV. To assess whether the goal is achieved, data on mortality rates among
HIV-positive TB patients during TB treatment are needed. In turn, this requires that treatment outcomes for TB patients are
disaggregated by HIV status; that is, outcomes are available
for HIV-positive and HIV-negative TB patients separately.
Treatment outcomes for HIV-positive and HIV-negative
TB patients, 2009. Numbers under bars indicate the number of
In 2010, a large number of countries (n=81) reported data on
patients in each cohort, which are slightly larger for a. because
the outcomes of TB treatment disaggregated by HIV status patients “not evaluated” are included.
(these data are for 2009, given the lag-time in reporting of
treatment outcomes). However, these countries accounted
a. Treatment success
100
for only 21% of the estimated global number of HIVrelated TB cases. The treatment success and death rates
75
reported for HIV-positive TB cases in 2009 were 72% and
20%, respectively, compared with 88% and 3% among HIV50
negative TB cases (see figure right); the remaining patients
had treatment outcomes of failed treatment, transferred out
25
of the district during treatment or their treatment outcome
1
was not evaluated. Among the 63 high TB/HIV burden
0
countries (see list below),2 less than half (n=28) reported
HIV +
HIV HIV +
HIV HIV +
HIV treatment outcomes disaggregated by HIV status.
(62 611) (1 689 075)
(56 998) (874 062)
(15 013) (124 005)
New smear-positive
data from 77 countries
The recording and reporting of the outcomes of TB treatment
disaggregated by HIV status needs to be improved, using
WHO-recommended TB registers (which should also be
used by HIV service providers including in ART clinics).
2
The death rate for HIV-positive TB cases cited here assumes
that those who were recorded as having defaulted from
treatment also died from TB.
The 63 high TB/HIV burden countries are a combination of
41 countries that were identified as priorities for TB/HIV at
global level in 2002 and that account for 97% of estimated
HIV-positive TB cases globally, plus 22 additional countries that
UNAIDS has defined as having a generalized HIV epidemic. The
41 countries are listed in Table 6.1.
6.1 The other 22 countries are
(in alphabetical order) the Bahamas, Barbados, Belize, Benin,
the Dominican Republic, Equatorial Guinea, Eritrea, Estonia,
Gabon, Guatemala, Guinea, Guinea-Bissau, Guyana, Honduras,
Jamaica, Liberia, Madagascar, the Niger, Panama, Somalia,
Suriname, and Trinidad and Tobago.
(Figure 6.5, Figure 6.6). The highest rates of enrolment
on ART were reported by countries in the Region of the
Americas, notably Brazil at 93% (Figure 6.6).
A substantial improvement in ART provision will
be needed to reach the Global Plan target of providing
ART to all TB patients known to be living with HIV by
2015. This could be facilitated by using TB services and
infrastructure to allow decentralization of care delivery
according to national guidelines and the local context.
Percent of cohort
1
30
New smear
negative/extrapulmonary
data from 63 countries
Retreatment
data from 53 countries
HIV +
HIV (59 381) (1 646 689)
HIV +
HIV (51 821) (821 502)
HIV +
HIV (12 695) (116 642)
New smear-positive
data from 77 countries
New smearnegative/extrapulmonary
data from 63 countries
Retreatment
data from 53 countries
b. Death rate
20
10
0
6.2
Intensified case-finding and isoniazid
preventive therapy among people
living with HIV
Until 2010, data on intensified screening for TB among
people living with HIV and provision of IPT to those
without active TB were requested from NTPs as part of
the global TB data collection form. In 2011, in an effort to
streamline efforts to collect data and improve the quality
of data, information about these two interventions was
collected by the WHO’s HIV department from national
HIV programmes. It should be noted that monitoring of
access to these two interventions at country level is considered weaker than for interventions such as ART, and
thus the reported data need to be interpreted with some
caution.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 65
65
23/09/11 07:20
FIGURE 6.4
TB patients with known HIV status who are HIV-positive and HIV-positive TB patients on co-trimoxazole preventive
therapy (CPT) and antiretroviral therapy (ART), 2005–2010a
% of TB patients with known HIV status
who are HIV-positive
% of HIV-positive patients on CPT
% of HIV-positive patients on ART
100
Percentage of patients
80
60
40
20
0
2005
a
2006
2007
2008
2009
2010
2005
2006
Antiretroviral therapy for HIV-positive TB patients by WHO
region and selected countries, 2003–2010
70
South Africa
60
AFR, other countries
50
Patients (thousands)
2008
2009
2010
2005
2006
2007
2008
2009
2010
The solid lines show values for countries that reported data. The shaded areas show upper and lower limits when countries that did not report data are considered.
FIGURE 6.5
40
30
India
20
Kenya
Zambia
AMR
EUR
SEAR, other countries
WPR
EMR
10
0
2003
66
2007
2004 2005 2006
2007 2008
2009 2010
The data reported indicate that TB screening among
people living with HIV and provision of IPT have steadily
increased, particularly since 2007 (Figure 6.7, Figure 6.8).
In 2010, 2.3 million were screened for TB (up from 1.7
million in 2009) and 178 000 of those without active TB
were enrolled on IPT (double the level achieved in 2009).
The number of people living with HIV who were
screened for TB was equivalent to more than half (58%,
2 302 680/3 956 326) of the reported number of people
who were enrolled in HIV care worldwide in 2010. The
number started on IPT was 12% (178 144/1 464 579) of
the reported number of people living with HIV newly enrolled in HIV care in 2010. Intensified efforts are
needed to approach the Global Plan’s targets of providing
screening for TB for all those enrolled in HIV care and
providing IPT to all those attending HIV care services
who are eligible for it by 2015. The examples of Cambodia and South Africa illustrate the major progress that
can be achieved in a short time when new WHO guidelines are adopted and implemented (Box 6.2).
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 66
23/09/11 07:20
FIGURE 6.6
ART provision and percentage of HIV-positive TB patients on ART, 2010. The area of each box represents the number of
HIV-positive TB patients on ART
AFR
AMR
South Africa
Zimbabwe
UR Tanzania
Mozambique
Nigeria
Brazil
Rest of AMR
EUR
Malawi
Uganda
Rest of AFR
Kenya
Zambia
Swaziland
Ethiopia
Namibia
Lesotho
Russian
Federation
Botswana
Rest of EUR
WPR
Côte d’Ivoire
China
India
% of HIV-positive TB patients on ART
Rest of SEAR
SEAR
Thailand
20
30
40
50
60
70
80
Viet
Nam
EMR
90
FIGURE 6.7
FIGURE 6.8
Intensified TB case-finding among HIV-positive people,
2005–2010
IPT provision among HIV-positive people, 2005–2010
100
200
Number of HIV-positive people without
active TB (thousands)
Number of people screened (millions)
2.5
Rest
of
WPR
2.0
1.5
1.0
0.5
0
150
100
50
0
2005
2006
2007
2008
2009
2010
2005
2006
2007
2008
2009
2010
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 67
67
23/09/11 07:20
BOX 6.2
Uptake of new WHO guidelines leads to rapid scale up of isoniazid preventive therapy
Recent WHO guidelines on TB screening and isoniazid preventive therapy (IPT) among people living with HIV were adopted and
implemented by Cambodia and South Africa in 2010. The guidelines recommend screening using four symptoms (current cough,
fever, weight loss and night sweats) and providing IPT if these symptoms are absent.1 This symptom-based screening algorithm
has been found to have a negative predictive value of 97.7% (95%confidence interval, 97.4–98.0) in settings where the prevalence
of TB among people living with HIV is 5%.2
An HIV counselling and testing campaign in South Africa in 2010 aimed at all sexually-active individuals aged >12 years included
TB screening based on the new guidelines. The guidelines were also reflected in planning and implementation of collaborative TB/
HIV activities in Cambodia in 2010.
In South Africa, the number of people living with HIV who were provided with IPT increased by more than five-fold in one year,
from 23 583 in 2009 to 124 049 in 2010. In Cambodia, the numbers provided with IPT increased seven-fold in one year, from 66
in 2009 to 491 in 2010.
To complement this large and rapid scale-up in the provision of IPT, emphasis on adherence to therapy as well as monitoring of
resistance to isoniazid are needed.
68
1
Guidelines for intensified tuberculosis case finding and isoniazid preventive therapy for people living with HIV in resource constrained settings.
Geneva, World Health Organization, 2010.
2
Getahun H et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource constrained settings:
individual participant data meta-analysis of observational studies. PLoS Medicine, 2011, 8(1) e1000391 (doi:10.1371/journal.pmed).
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 68
23/09/11 07:20
CHAPTER 7
Research and development
KEY MESSAGES
Progress in TB care and control is constrained by old
technologies.
During the past decade, efforts to develop new
diagnostics, drugs and vaccines for TB have intensified
and considerable progress has been made.
Several new diagnostic tests or methods have been
endorsed by WHO since 2007, including Xpert MTB/RIF
that has the potential to transform the diagnosis of TB and
rifampicin-resistant TB. Other new tests, including pointof-care tests, are in the pipeline.
For the first time in 40 years, there is a coordinated
portfolio of promising new drugs on the horizon. There are
10 new or repurposed TB drugs in trials, which have the
potential to shorten the treatment of drug-susceptible TB
and to improve the treatment of multidrug-resistant TB
(MDR-TB). Results from three Phase III trials of 4-month
regimens for the treatment of drug-susceptible TB are
expected between 2012 and 2013. Results from two
Phase II trials of new drugs for the treatment of MDR-TB
are expected in 2012.
There are 9 vaccine candidates for the prevention of
TB in Phase I or Phase II trials. It is hoped that one or two
of the candidates currently in a Phase II trial will enter a
Phase III trial in the next 2–3 years, with the possibility of
licensing at least one new vaccine by 2020.
Funding for TB research and development has
increased in recent years, reaching US$ 614 million
in 2009, but still falls far short of the annual target of
US$ 1.8 billion that is included in the Global Plan to Stop
TB 2011–2015.
Major progress in TB care and control has been achieved
since the introduction of the DOTS strategy in the
mid-1990s and the launch of its successor, the Stop TB
Strategy, in 2006 (Chapters 2–6). However, progress is
constrained by old technologies. To achieve the Stop TB
Partnership’s target of eliminating TB by 2050 (Chapter
1), a transformation in TB prevention, diagnosis and
treatment is required.1
During the past decade, efforts to develop new diagnostics, drugs and vaccines for TB have intensified.
Three public–private partnerships have been created: the
Foundation for Innovative New Diagnostics (in 2003),
which works on the development of novel diagnostics for
TB among a range of other diseases; the TB Alliance (in
2000) for new anti-TB drugs; and Aeras (in 2003) for new
TB vaccines. The Stop TB Partnership has established
working groups for new diagnostics, new drugs and new
vaccines. Although the total funding available for TB
research and development falls short of the US$ 1.8 billion per year that is called for in the Global Plan to Stop TB
2011–2015,2 funding increased from US$ 363 million in
2005 to US$ 614 million in 2009.3 Sources of funding
include the United States National Institutes of Health,
the Bill & Melinda Gates Foundation, the European
Union, the European and Developing Countries Clinical
Trials Partnership (EDCTP) and several other national,
bilateral and multilateral agencies and philanthropic
organizations.
This chapter presents the status of progress in the
development of new diagnostics, new drugs and new vaccines for TB in mid-2011, using information provided by
the respective Working Groups of the Stop TB Partner1
2
3
Abu-Raddad LJ et al. Epidemiological benefits of more effective tuberculosis vaccines, drugs and diagnostics. Proceedings
of the National Academy of Sciences of the United States of America,
2009, 106(33):13980–139805. The analysis in this paper indicated that TB incidence could be reduced by 71% by 2015 in
the South-East Asia Region with the combined use of a neonatal pre-exposure vaccination, a 2-month drug regimen with
high efficacy for drug-susceptible and drug-resistant TB, and
a rapid test to diagnose TB. To achieve elimination (defi ned
as less than one case per million population per year) would
require new delivery strategies such as mass vaccination campaigns, and new products targeted at people with latent TB
infection.
The Global Plan to Stop TB, 2011–2015. Geneva, World Health
Organization, 2010 (WHO/HTM/STB/2010.2).
2010 report on tuberculosis research funding trends, 2005–2009.
Treatment Action Group, 2010.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 69
69
23/09/11 07:20
FIGURE 7.1
The development pipeline for new diagnostics, 2011
Liquid culture and DST
Rapid speciation
LPA for MDR-TB
Non-commercial culture and DST (MODS, NRA, CRI)
LPA for XDR-TB
Distance from patients
10–40
Manual NAAT 1st generation
Rapid colorimetric DST
INTERMEDIATE LEVEL
70
Access after 5 years (%)
REFERENCE LEVEL
New SS+ case definition
Xpert MTB/RIF
2-specimen approaches
LED microscopy
Same-day diagnosis
POC test (detection of TB)
Prediction (LTBI)
Manual NAAT 2nd generation
PERIPHERAL LEVEL
2007
2008
95
2009
Technologies or methods endorsed by WHO
2010
2011
2012
Technologies at late stages of development
2013
2014
2015
2016
Technologies at early stages of development
Abbreviations: DST Drug susceptibility test; NAAT Nucleic acid amplification test; LTBI Latent TB infection; POC Point of care; MODS Microscopic observation drugsusceptibility; NRA Nitrate reductase assay; CRI Colorimetric redox indicator assay; LED Light-emitting diode; LPA Line probe assay
ship. It also highlights two documents fi nalized in 2011
that address the continuum of research from fundamental science to operational research.
7.1
New diagnostics for TB
The most commonly used diagnostic test for TB, sputum
smear microscopy, is over 100 years old. It is a relatively
insensitive test and it cannot be used to identify paucibacillary or extrapulmonary TB. Diagnosis using culture
methods – the current gold standard – requires laboratory infrastructure that is not widely available in countries
with a high burden of TB (Chapter 5), and results take
weeks. Conventional methods used to diagnose MDRTB also rely on culturing of specimens followed by drug
susceptibility testing (DST); results take weeks and not
all laboratories with capacity to perform DST for fi rstline drugs have the capability to perform DST for second-line drugs. New diagnostic tests that are comparable
to culture in terms of accuracy but which also allow rapid
diagnosis and can be used at the lowest level of health
systems are needed. The ideal is a simple, rapid, point-ofcare test that can be used to diagnose both TB and MDRTB outside the setting of a conventional laboratory.
The status of the pipeline for new diagnostics in July
2011 is illustrated in Figure 7.1.
Various new tests and methods have been endorsed by
WHO in the past four years. Since 2007, endorsed tests
and methods include liquid culture and rapid speciation for faster diagnosis of TB and MDR-TB, molecular
70
line probe assays (LPAs) for rapid testing for MDR-TB,
non-commercial culture methods for rapid DST, lightemitting diode (LED) fluorescence microscopes for better diagnosis using smear microscopy, and Xpert MTB/
RIF for the rapid diagnosis of TB and rifampicin-resistant TB. These are beginning to be implemented in
countries (Chapter 5), and Xpert MTB/RIF in particular
(a fully automated, cartridge-based, nucleic acid amplification test) has the potential to transform the diagnosis of TB and drug-resistant TB. It is suitable for use at
district and sub-district levels, and results are available
within 2 hours. As Xpert MTB/RIF is rolled out worldwide (Chapter 5), data are also being collected to evaluate
its performance in programmatic conditions.1 It should
be emphasized that countries implementing Xpert MTB/
RIF still need to establish conventional laboratory capacity to monitor treatment progress and to perform DST for
drugs other than rifampicin. The EXPAND-TB project
is helping to accelerate access to such laboratory capacity
in many countries (Chapter 5).
Tests that are in the late stages of development include
a second-generation LPA for rapid testing for extensively
drug-resistant TB in reference laboratories and a rapid
test for detection of TB in microscopy centres. Technologies that are in the early stages of development include
point-of care tests for TB and tests for prediction of latent
TB infection.
1
www.stoptb.org/wg/gli/xpert
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 70
23/09/11 07:20
7.2
New drugs for the treatment and
prevention of TB
The anti-TB drugs used in fi rst-line treatments are
around 50 years old. The regimen that is currently recommended by WHO for new cases of drug-susceptible TB is highly efficacious, with cure rates of around
90% in HIV-negative patients. Nonetheless, it entails 6
months of treatment with fi rst-line drugs (a combination
of rifampicin, isoniazid, ethambutol and pyrazinamide
for 2 months, followed by a 4-month continuation phase
of rifampicin and isoniazid). Recommended regimens for
MDR-TB require at least 20 months of treatment with
second-line drugs, are associated with multiple (and
sometimes serious) side-effects, and cure rates are lower
(usually in the range 60–75%). There are also interactions between TB treatment and antiretroviral therapy
(ART) for people living with HIV. New drugs are required
to shorten and simplify treatment, to improve the efficacy
and tolerability of treatment for MDR-TB and to improve
the simultaneous treatment of TB and HIV among people living with HIV. New drugs could also help to treat
latent TB infection in people without active TB disease;
at present, preventive therapy usually consists of 6–9
months of isoniazid monotherapy.
The status of the pipeline for new anti-TB drugs in
July 2011 is illustrated in Figure 7.2.
For the fi rst time in 40 years, there is a coordinated
portfolio of promising new compounds on the horizon,
some of which have the potential to become the cornerstone drugs of TB treatment in the future. There are 10
new or repurposed TB drugs under clinical investigation,
one of which is in a Phase I (safety) trial, seven are in
Phase II (early bactericidal activity and sputum culture
conversion) trials, and three are in Phase III (efficacy)
trials (rifapentine is being evaluated in both a Phase II
and a Phase III trial).
Two of the Phase III trials are evaluating 4-month regimens (in which a fluoroquinolone – either gatifloxacin or
moxifloxacin – is used in place of ethambutol or isoniazid) for the treatment of drug-susceptible TB, and results
are expected between 2012 and 2013. The third Phase
III trial is evaluating the use of rifapentine (a rifamycin
that has a longer half-life than rifampicin) as part of a
4-month regimen. The use of rifapentine in combination
with isoniazid for a shorter (3 months) treatment of latent
TB infection is also being evaluated.
Of the compounds in Phase II trials, two are in the
advanced stages of being tested for the treatment of MDRTB. These are TMC-207 (bedaquiline) and OPC-67683
(delamanid). Both compounds have been evaluated in
Phase IIb trials in newly-diagnosed MDR-TB patients, in
which either the investigational drug or a placebo were
added to an optimized background regimen. Final results
are expected in 2012.
Other compounds in Phase II trials include linezolid,
which is being tested for the treatment of extensively
drug-resistant TB (XDR-TB) at a dose of 600 mg (in the
Republic of Korea) and at a dose of 300 mg for the treatment of MDR-TB (in South Africa); PNU-100480 (a close
analogue of linezolid); PA-824; and SQ-109 (a derivative of ethambutol). In November 2010, the fi rst clinical
trial of a novel TB drug regimen (NC001), investigating
the bactericidal activity of a three-drug combination of
PA-824, moxifloxacin and pyrazinamide, was initiated;
results are very encouraging.
These major advances in TB drug development mean
that multiple trials will be needed in various high-burden
FIGURE 7.2
The development pipeline for new drugs, 2011
Discovery
Lead
identification
Summit PLC
compounds
Preclinical development
Lead
optimization
Nitroimidazoles
Mycobacterial
Gyrase Inhibitors
Riminophenazines
Diarylquinoline
Translocase-1
Inhibitor
MGyrX1 inhibitor
InhA Inhibitor
GyrB inhibitor
LeuRS Inhibitor
Pyrazinamide
Analogs
Preclinical
development
CPZEN-45
SQ641
SQ609
DC-159a
Benzothiazinone
Q201
Clinical development
Phase I
AZD5847
Phase II
TMC-207
OPC-67683
PA-824
Linezolid
Rifapentine
SQ-109
PNU-100480
Novel Regimensa
Phase III
Gatifloxacin
Moxifloxacin
Rifapentine
Note: This table only includes projects that have identified a promising molecule (known as a “lead” compound).
a
The first clinical trial (NC001) of a novel TB drug regimen testing the three-drug combination of PA-824, moxifloxacin and pyrazinamide was initiated in November 2010.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 71
71
23/09/11 07:20
FIGURE 7.3
The development pipeline for new vaccines, 2011
Preclinical development
Mtb [ΔlysA ΔpanCD ΔsecA2]
VPM 1002
MTBVAC01 [ΔphoP, Δfad D26]
M72
B PI
P B PI IT
Hybrid 56+IC31
P B PI
HG85 A/B
B IT
Spray-dried BCG
P
B
PI
IT
Hybrid-I+CAF01
P B PI
Hyvac 4/ AERAS-404
Prime
Boost
Post-infection
Immunotherapy
B
Hybrid-I+IC31
P B PI
Preclinical vaccine candidates are not yet in clinical trials, but have been manufactured
under Good Manufacturing Practice (GMP) for clinical use and have undergone some
preclinical testing that meets regulatory standards.
New vaccines for the prevention of TB
The Bacille-Calmette-Guérin (BCG) vaccine to prevent
TB is almost 100 years old. It has been shown to provide protection against severe forms of TB in children
(meningitis and miliary TB), but its efficacy in preventing pulmonary TB in adults varies among countries.
BCG is not recommended for use in infants known to be
infected with HIV, due to the risk of disseminated BCG
disease. Historic opportunities for the development of
new TB vaccines arose during the 1990s, following the
development of techniques for genetic manipulation of
mycobacteria and completion of the genome sequence of
Mycobacterium tuberculosis.
There are two main approaches to improving TB vaccination. The first is a “prime-boost” strategy in which
72
B PI IT
B
P B
countries. This presents several challenges. Trials are
lengthy and costly, since patients need to be followed for
an extended period of time after completing treatment.
New drugs have to be tested in specified drug combinations with current and/or newly re-purposed drugs; to
facilitate this, novel biomarkers for treatment response
and sterilizing activity, new approaches to the design of
clinical trials and increased capacity (including staff and
infrastructure) to implement trials in accordance with
international standards are required. The recent establishment of the Critical Path to New TB Drug Regimens
(CPTR) initiative, whose goal is to accelerate the development of novel regimens that will shorten TB treatment,
is an important step in this direction. The CPTR is a
broad coalition of stakeholders spearheaded by the Bill
& Melinda Gates Foundation, the TB Alliance and the
Critical Path Institute, and includes almost all pharmaceutical companies with compounds in clinical trials for
TB treatment.
7.3
MVA85A/
AERAS-485
AERAS-402/
Crucell Ad35
AdAg85A
HBHA
Phase III
AERAS-422
P
P
Phase IIb
Phase II
P
P
P
Phase I
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
BCG is given to neonates (as now) and then a new vaccine is given as a booster dose. The new vaccine would
be delivered to infants alongside other vaccines at 3–9
months of age and/or as a separate booster in young
adults. The second approach is to develop vaccines that
would replace BCG (i.e. new “prime” vaccines), such as
an improved version of BCG or an attenuated live Mycobacterium tuberculosis vaccine. It is anticipated that a booster vaccine on top of BCG will lead the way to replacement
of BCG.
The status of the pipeline for new vaccines in July 2011
is illustrated in Figure 7.3. There are 9 vaccine candidates
in clinical trials, of which six are in Phase I trials, one is
in a Phase II trial and two are in Phase IIb trials. Phase I
trials are conducted with a small number of healthy volunteers (40–90 people) to ensure that the vaccine candidate is safe, to assess immunological reactions, and to
begin to determine dosage levels. Phase II trials involve
larger numbers of volunteers (from a few hundred to a
few thousand) to continue testing safety as well as to
determine optimal dosage levels and the timing of vaccination. In Phase IIb trials, preliminary data on protective
efficacy are also collected. Phase III trials involve many
thousands of participants and are used to determine the
protective efficacy of a vaccine; the quality of data must
meet the standards required for a vaccine to be licensed.
Of the vaccines that are currently being tested,
MVA85A is at the most advanced stage of clinical development. It is being tested in Phase IIb trials in Africa,
including among people living with HIV. It is hoped that
one or two of the candidates currently in Phase IIb trials
will enter a Phase III trial in the next 2–3 years, with the
possibility of licensing at least one new vaccine by 2020,
either alone or in combination.
It should be highlighted that capacity (staff and infra-
structure) for large-scale trials of vaccines needs to be
increased in several endemic countries. At the same time,
cohort studies in infants and adolescents that are under
way in several countries need to be continued to provide
important baseline data about TB incidence and to help
determine the suitability of sites for large-scale vaccine
efficacy trials.
7.4
Fundamental science and operational
research
Besides the research and development discussed in
sections 7.1–7.3, fundamental science and operational
research are essential for improved TB care and control.
The former is required to better characterize Mycobac-
terium tuberculosis and to improve understanding of the
interaction between the bacillus and the human host, as
a basis for maintaining the flow of new technologies into
the product pipeline. The latter is required to identify the
most effective ways of using available tools.
In the past year, the TB Research Movement of the
Stop TB Partnership has developed a road map that sets
out research priorities across the continuum from fundamental science to operational research.1 A document on
operational research specifically has also been developed
in the last year by the Stop TB Partnership, WHO and
the Global Fund.2 This defines the critical questions to
be addressed by operational research, and the appropriate study methods to use.
1
2
The roadmap is available at www.stoptb.org/global/
research
Priorities in operational research to improve tuberculosis care and
control. Available at www.stoptb.org/assets/documents/
resources/publications/technical
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
73
1109_0319_P_001_248 74
23/09/11 07:20
ANNEX 1
Methods used
to estimate the burden of
disease caused by TB
1109_0319_P_001_248 75
23/09/11 07:20
1109_0319_P_001_248 76
23/09/11 07:20
This annex explains the methods that were used to produce estimates of the global burden of disease caused
by TB (measured in terms of incidence, prevalence and
mortality). It has nine major sections:
General approach. This section provides some background information about the methods used to produce estimates of disease burden.
Defi nitions. This section defi nes TB incidence, prevalence and mortality, the case fatality rate (CFR) and
the case notification rate. It also explains the regions
for which estimates of disease burden are produced
and sources of information on population estimates.
Estimates of TB incidence, 1990–2010. This section explains the main methods used to estimate TB
incidence, and the countries for which they have been
applied. Specific attention is given to estimates for
China and India.
Estimates of HIV prevalence among incident TB
cases, 1990–2010. This section explains the methods
used to estimate the prevalence of HIV among incident cases of TB.
Estimates of TB prevalence, 1990–2010. This section explains the methods used to estimate TB prevalence. These are national surveys of the prevalence of
TB disease and indirect estimates based on combining
estimates of incidence with estimates of the duration
of TB disease.
Estimates of the number of cases of multidrugresistant TB (MDR-TB). This section explains how
estimates of the proportion of notified cases of TB
that had MDR-TB in 2010 were produced and used to
assess the number of prevalent cases of MDR-TB in
2010. Methods to analyse trends in the proportion of
new cases of TB with MDR-TB among notified cases
1994–2010 are also explained.
Estimates of TB mortality, 1990–2010. This section explains the two methods used to estimate TB
mortality. These are direct measurements from vital
registration (VR) or survey data and indirect estimates
based on combining estimates of TB incidence with
estimates of the CFR. The countries for which these
methods have been used are explained. Methods for
estimating TB mortality in HIV-infected individuals
and TB mortality by age and sex are also described.
Projections of TB incidence, prevalence and mortality. This section explains how projections up to
2015 were produced.
Uncertainty framework. This section explains the
general approach to including uncertainty in all estimates.
1. General approach
Estimates of the burden of disease caused by TB (measured in terms of incidence, prevalence and mortality) are
produced annually by WHO using information gathered through surveillance systems (case notifications
and death registrations), special studies (including surveys of the prevalence of disease and in-depth analyses
of surveillance data), expert opinion and consultations
with countries. Two recent publications provide up-todate guidance about how TB incidence, prevalence and
mortality should be measured,1 based on the work of the
WHO Global Task Force on TB Impact Measurement.2
The methods used to estimate the burden of disease
were updated in 2009 following 18 months of work by
an expert group convened by the Task Force. Improvements to methods included systematic documentation of
expert opinion and how this has been used to produce
estimates of disease burden, simplification of models, 3
updates to parameter values based on the results of systematic reviews, much greater use of mortality data from
VR systems and systematic documentation of uncertainty (hence the uncertainty intervals shown on all of the
estimates of disease burden in this report).
2. Definitions
2.1 Incidence, prevalence, mortality, the case
fatality rate and the case notification rate
Incidence is defi ned as the number of new and relapse
cases of TB (all forms) occurring in a given year. Relapse
cases are defi ned as a new episode of TB in people who
have had TB in the past and for whom there was bacteriological confi rmation of cure and/or documentation
that treatment was completed (Box 3.1, Chapter 3). In the
remainder of this Annex, relapse cases are referred to as
recurrent cases, in line with expected changes in terminology that will be introduced by WHO in the near future
and because the term is more useful when explaining the
estimation of TB incidence. Recurrent cases may be true
relapses or a new episode of TB caused by reinfection. In
current case defi nitions, both relapse cases and patients
who require a change in treatment are called “retreatment cases”. However, people with a continuing episode
1
2
3
TB impact measurement: policy and recommendations for how to
assess the epidemiological burden of TB and the impact of TB control.
Geneva, World Health Organization, 2009 (Stop TB policy
paper no. 2; WHO/HTM/TB/2009.416). The policy paper
is available on the Task Force’s website www.who.int/tb/
advisory_bodies/impact_measurement_taskforce
For further details, see the Task Force web site at: www.who.
int/tb/advisory_bodies/impact_measurement_taskforce.
The review is also the basis for the TB component of the
update to the Global Burden of Disease, due for publication in
2011 (www.who.int/topics/global_burden_of_disease).
For example, some parameter values are now estimated only
at global level or for regions, rather than for each country
individually.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 77
77
23/09/11 07:20
of TB that requires a treatment change are prevalent cases, not incident cases.
Prevalence is defi ned as the number of TB cases (all
forms) at a given point in time.
Mortality. According to the latest revision of the international classification of diseases (ICD-10), TB mortality
is the number of deaths caused by TB in HIV-negative
people. TB deaths among HIV-positive people are classified as HIV deaths in ICD-10. For this reason, estimates
of deaths caused by TB in HIV-positive people are presented separately from those in HIV-negative people.
The case fatality rate is the risk of death from TB among
people with active TB disease.1
The case notification rate refers to new and recurrent
episodes of TB notified to WHO for a given year, expressed
per 100 000 population. The case notification rate for
new and recurrent TB is important in the estimation of
TB incidence. It is important to highlight, however, that
in some countries information on treatment history may
be missing for some cases. When data on treatment history are not available, recurrent cases cannot be distinguished from cases whose treatment was changed, since
both are registered and reported in the category “retreatment”. An assessment of data for patients reported in the
“unknown history” category is conducted with national
TB control programmes (NTPs) to determine the proportion of such patients that is included in the category
of recurrent cases.
2.2 Regions
Regional analyses are generally undertaken for the six
WHO regions (that is, the African Region, the Region
of the Americas, the Eastern Mediterranean Region, the
European Region, the South-East Asia Region and the
Western Pacific Region). For analyses related to MDRTB, nine epidemiological regions were defi ned. These
were African countries with high HIV prevalence, African countries with low HIV prevalence, Central Europe,
Eastern Europe, high-income countries,2 Latin America, the Eastern Mediterranean Region (excluding highincome countries), the South-East Asia Region (excluding
high-income countries) and the Western Pacific Region
(excluding high-income countries). The list of countries
in the fi rst six of these nine regions is provided in Appendix 1; the other countries are listed under the WHO
regions of which they are a part in Annex 3.
3. Estimates of TB incidence, 1990–2010
No country has ever undertaken a nationwide survey of
TB incidence because of the large sample sizes required
and associated major logistic and fi nancial challenges. As
a result, there are no direct measurements of the incidence of TB. Theoretically, data from TB surveillance
systems that are linked to health systems of high coverage and performance may capture all (or almost all)
incident cases of TB. However, as yet no standard and
widely-endorsed criteria and benchmarks for classifying
TB surveillance systems are available. The WHO Global
Task Force on TB Impact Measurement is working on
the development of such standards (Chapter 2).
In the absence of direct measurements, estimates of
TB incidence for almost all countries rely on methods
described in sections 3.1–3.4. The methods used to estimate TB incidence in China and India are explained
separately, in section 3.5 and section 3.6 respectively, following national workshops held in China (in June 2011)
and India (in July 2011).
It should be emphasized that incidence estimates are
no longer derived from surveys of the prevalence of tuberculous infection as measured in tuberculin surveys. The
WHO Global Task Force on TB Impact Measurement
has agreed that methods for deriving incidence from the
prevalence of infection are unreliable. The Task Force
has also stated that it is doubtful whether repeat tuberculin surveys provide a reliable estimate of the trend in
TB incidence.4
3.1 Estimating TB incidence from estimates of the
proportion of cases detected
Notification data for new and recurrent cases have been
analysed in combination with evidence about the coverage of the TB surveillance system and expert opinion in
six regional workshops and country missions held during the period 2009–2011, according to a framework
developed by the WHO Global Task Force on TB Impact
Measurement (Figure 2.2, Chapter 2). By mid-2011, these
workshops and country missions had covered 96 countries (Figure 2.1, Chapter 2).
For the 96 countries covered by these regional workshops and country missions, incidence was estimated
according to the following equation:
1
2
2.3 Population estimates
Where population sizes are needed to calculate TB indicators, the 2010 revision of estimates provided by the
United Nations Population Division (UNPD) was used.3
The UNPD estimates sometimes differ from those made
by countries.
78
3
4
Straetemans M et al. Assessing tuberculosis case fatality ratio:
a meta-analysis. PLoS One. 2011, 6(6):e20755.
High-income countries are defi ned by the World Bank as
countries with a per capita gross national income (GNI) of
US$ 12 276 or more in 2010.
http://esa.un.org/unpd/wpp/unpp/panel_population.
htm; accessed August 2011.
TB impact measurement: policy and recommendations for how to
assess the epidemiological burden of TB and the impact of TB control.
Geneva, World Health Organization, 2009 (Stop TB policy
paper; no. 2 (WHO/HTM/TB/2009.416).
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 78
23/09/11 07:20
incidence =
First, the variance for the distribution was taken as:
case notifications
1 – underreporting
V=
Expert opinion about the proportion of TB cases1 that
were not reported was elicited for three reference years
(1997, 2003 and, depending on when the workshop
was held, either 2008 or 2009). This was done following in-depth analysis of notification data (including data
from sub-national administrative levels), programmatic
data reflecting efforts in TB control (for example, data
on infrastructure, staffi ng, the performance of services
and funding) and (where available) data from inventory
studies.2 In addition, data on access to health care from
Demographic and Health Surveys and the overall performance of health systems (using indicators such as the
infant mortality rate) were used to substantiate opinion
on the proportion of cases with no or very limited access
to health care (Table A1.1).
A full description of the methods used in these workshops is available in a report of the workshop held for
countries in the African Region (in Harare, Zimbabwe,
December 2010).3
TABLE A1.1
Sources of information and data on TB incidence used in
regional workshops and country missions
a
POSSIBLE CATEGORIES OF INCIDENT CASES
SOURCES OF DATA
Do not have physical or financial
access to health care
Demographic and
health surveys,
KABPa surveys
Seek care, but TB not diagnosed
Survey
TB diagnosed, but not reported
“Inventory” survey
Reported cases
TB surveillance
Capture–
recapture
modelling
KABP = knowledge, attitudes, behaviour and practices.
Distributions of the proportion of cases that were not
reported in the three reference years were assumed to
follow a Beta distribution. Reasons for using Beta distributions include the following:
They are continuous and defi ned on the interval (0,
1). Since the variance of the proportions of cases that
were not reported tend to be large as a result of high
uncertainty, random draws of numbers from a normal
distribution would yield numbers outside the interval
(0, 1). The use of truncated normal distributions may
result in excess density towards one of the bounds.
The shape and scale parameters necessary to defi ne the
Beta distribution were computed using the method of
moments, as follows:
2
4
where l and u are the lower and upper bounds of the plausible range for the proportion of incident cases that were
reported (also referred to as the case detection rate in
Chapter 3).
Shape 1 (noted _) and 2 (noted `) follow from:
s=
E(l – E)
–l
V
_ = sE
` = s(l – E)
where E is the expected value of the istribution (Table
A1.2).
Time series for the period 1990–2010 were built according to the characteristics of the levels of underreporting that were estimated for the three reference years. A
cubic spline extrapolation of V and E, with knots set at
the reference years, was used for countries with low-level
or concentrated HIV epidemics. In countries with a generalized HIV epidemic, the trajectory of incidence from
1990 to the fi rst reference year (usually 1997) was based
on the annual rate of change in HIV prevalence. Incidence trajectories were derived from the series of notified TB cases using Monte Carlo simulations from which
expected values, 2.5th and 97.5th centiles were extracted.
All computations were conducted in the R statistical
environment.5
If there were insufficient data to determine the factors
leading to time-changes in case notifications, incidence
was assumed to follow a horizontal trend going through
the most recent estimate of incidence.
1
2
They are not necessarily symmetrical.
They are defi ned with two parameters that can be
estimated from available data using the method of
moments.4
u–l
3
4
5
Defi ned as cases of all forms of TB, including sputum smearpositive pulmonary cases, sputum smear-negative pulmonary
cases, and extrapulmonary cases.
Measurements from “inventory” studies can be used to quantify the number of cases that are diagnosed but not reported
to national surveillance systems. In some circumstances, data
from these studies can be used to estimate the number of
cases that were not diagnosed as well (using capture-recapture methods. A useful reference on capture-recapture methods is: Chao A et al. The applications of capture-recapture
models to epidemiological data. Statistics in Medicine, 2001,
20(20):3123–3157.
See www.who.int/tb/advisory_bodies/impact_measurement_
taskforce. The tools (called TISAT and the Workbook) used
in regional workshops and country missions are also available
on the Task Force’s web site.
Rényi A. Probability theory. New York, Dover Publications Inc.,
2007.
R Development Core Team. R: a language and environment for
statistical computing. Vienna, R Foundation for Statistical Computing, 2009 (www.R-project.org).
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 79
79
23/09/11 07:20
TABLE A1.2
Parameter estimates used to produce estimates of TB incidence, prevalence and mortality
MODEL PARAMETER
Incidence, high-income countries
DISTRIBUTION PARAMETERSb
DISTRIBUTION
Beta
a
Ī (1– Ī )
_=Ī.
V
` = (1– Ī ) .
–1
Ī (1–Ī )
V
–1
where Ī was set at 1.3 times the notification rate, noted N, and V is
defined by:
0.3
V=
HIV prevalence among incident TB
Betaa
4
_ = –x .
2
N
x– (1– x– )
V
` = (1– x– ) .
–1
x– (1– –
x)
V
–1
Where –
x is the expected value and V is given by:
u–l 2
V=
4
Duration of disease, non-notified
HIV-negative cases of TB
Uniform
l = 1, u = 4 (years)
Duration of disease, non-notified
HIV-positive cases of TB
Uniform
l = 0.01, u = 0.2 (years)
Duration of disease, notified
HIV-negative cases of TB
Uniform
l = 0.2, u = 2 (years)
Duration of disease, notified
HIV-positive cases of TB
Uniform
l = 0.01, u = 1 (years)
a
The probability density function of the Beta distribution is: ƒ (x; _, `) =
b
u and l denote upper and lower bounds.
x _–1 (1– x) `–1
t (1– t) `–1 dt
1 _–1
0
3.2 Estimating TB incidence from data on case
notifications and expert opinion for highincome countries
For high-income countries, the level of TB incidence was
assumed to be distributed between the notification rate
for new and recurrent cases combined (lower uncertainty
bound, noted l) and 1.3 times the notification rate (upper
uncertainty bound, noted u), as informed by expert opinion. The distribution of incidence was assumed to follow
a Beta distribution with shape and scale parameters computed using the method of moments, as described above.
In the absence of country-specific data on the quality
and coverage of TB surveillance systems, it was assumed
that TB surveillance systems from countries in the
high-income group performed similarly well, although
the model does allow for stochastic fluctuations. The
exception was the United Kingdom of Great Britain and
Northern Ireland, where the underreporting of TB cases
has been recently measured using inventory studies and
capture-recapture modelling.1 The results were used to
measure TB incidence directly.
80
3.3 Estimating TB incidence from empirical
measurements of disease prevalence
Incidence can be estimated using measurements from
national surveys of the prevalence of TB disease combined with estimates of the duration of disease. Incidence
is estimated as the prevalence of TB divided by the average duration of disease.
In practice, the duration of disease cannot be directly
measured. For example, measurements of the duration
of symptoms in prevalent TB cases that are detected during a prevalence survey are systematically biased towards
lower values, since active case-fi nding truncates the natural history of undiagnosed disease. Measurements of
the duration of disease in notified cases ignore the duration of disease among non-notified and untreated cases.
Literature reviews commissioned by the WHO Global
Task Force on TB Impact Measurement have provided
estimates of the duration of disease in untreated TB cases
1
Tuberculosis in the UK: annual report on tuberculosis surveillance in the UK 2010. London, Health Protection Agency
Centre for Infections, 2010 (www.hpa.org.uk/web/HPA
web&HPAwebSt a nda rd / HPAweb_C /1287143581697;
accessed 15 July 2011.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 80
23/09/11 07:20
from the pre-chemotherapy era (before the 1950s). The
best estimate of the mean duration of disease (for smearpositive cases and smear-negative cases combined) in
HIV-negative individuals is about three years. However,
the proportion of incident cases that remain untreated is
unknown. There are few data on the duration of disease
in HIV-positive individuals.
When measurements from two prevalence surveys
were available, trends in TB prevalence were derived by
fitting a log-linear model to available measurements.
When three or more prevalence measurements were
available, the prevalence trajectory was built using cubic
spline interpolation. If only one prevalence survey measurement was available, time-trends were assessed using
in-depth analysis of surveillance data, as described above.
In this report, the prevalence to incidence method was
used for only one country (Viet Nam), following a meeting in early 2009 in which consensus was reached among
national experts and experts from WHO and the KNCV
Tuberculosis Foundation.
3.4 Estimating TB incidence from previously
published time-series of incidence
In all remaining countries (n=57), previously published
time-series of TB incidence were extended by fitting a
log-linear model to the estimates for 2006–2009, to predict a value for 2010.
3.5 TB incidence in China
As noted at the beginning of this section, if TB surveillance performs to high standards then the best source of
information on TB incidence comes from routine notification data. In China, there is a web-based and casebased mandatory TB reporting system that has been
fully operational since 2005. It covers very close to 100%
of all detected TB cases.
During a national workshop held in Beijing in June
2011, incidence was estimated in two stages. First, the
plausible interval for TB incidence in 2009 was set at
1–1.3 times the level of notifications, which is comparable to most high-income countries. This plausible interval was justified based on the observations that (i) the
ratio of TB mortality to TB notifications in China was
close to that observed in high-income countries; and (ii)
the performance of the TB surveillance system is high.
Second, trends in incidence were computed backwards
in time from 2009 to 1990 and forwards in time to 2010
based on measured trends in rates of TB mortality and
TB prevalence in adults, adjusted for the rapidly aging
population. The workshop estimated that incidence in
adults declined by 3–5% per year on average, with an ageadjusted decline of 3.4% per year (standard deviation,
0.58%). This estimate can be considered conservative
given that the decline in TB prevalence is under-estimated (see Box 2.6 in Chapter 2 for further explanation).
3.6 TB incidence in India
Incidence for 2010 was estimated according to the methods described in section 3.1, including use of results from
two subnational inventory studies. The level of underreporting for 2010 was estimated at 41% (range, 35–47%).
National inventory studies will be needed to fully understand the extent to which TB cases are diagnosed in the
private sector but not reflected in the national surveillance system.
In the absence of any clear trend in case notifications and no survey measurements taken before 2001,
the trend in incidence was estimated to be flat between
1990 and 2001. This was also justified on the basis that
implementation of the Revised TB Control Programme
in India only began in parts of the country in 1999, with
no evidence of improvements in TB control in the previous decade.
For the trend between 2001 and 2010, data from
tuberculin surveys and notification data were used. Two
national tuberculin surveys were conducted around
2000 and 2010. Despite difficulties in interpreting the
second survey as a result of unfavourable distributions of
reaction sizes as well as systematic differences between
the two surveys (such as use of different tuberculins),
the estimated decline in the annual risk of infection was
estimated at 3.7% per year (95% confidence interval, 2.4–
5.1% per year). This rate of decline was the basis for setting a prior beta distribution for the decline in incidence.
In districts with early implementation (1999–2003)
of the Revised TB Control Programme, the average
annual rate of decline in case notification rates varied
between 0.6% and 3.6% per year. Combining the previous estimate from the tuberculin survey data with the
observed notification data led to a posterior distribution
of the annual rate of decline in TB incidence that had
an expected value of 1.5% per year (standard deviation,
0.071).
3.7 Disaggregations of TB incidence
In this report, TB incidence is only disaggregated by
HIV-infection status (see following section). The estimation of smear-positive TB incidence was discontinued in
2010, for reasons explained in detail in the global report
published in 2010.
4. Estimates of HIV prevalence among
incident TB cases, 1990–2010
The prevalence of HIV among incident cases of TB was
directly estimated from country-specific and empirical
data wherever possible. For the estimates published in
this report, suitable data (as defi ned in Table A1.3) were
available for a total of 544 country-year data points, up
from 440 country-year data points in the previous year.
For the 3905 country-year data points for which surveillance data were either not available or for which the
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 81
81
23/09/11 07:20
TABLE A1.3
Source of data on HIV prevalence among incident TB cases
DIRECT MEASUREMENT OF THE PREVALENCE
OF HIV IN TB PATIENTS
NUMBER OF
COUNTRY-YEARS
National surveys
31
HIV sentinel surveillance
30
Provider-initiated testing and counselling
with at least 50% coverage of testing
483
Total
544
percentage of TB patients tested for HIV was below 50%,
the prevalence of HIV was estimated indirectly according
to the following equation:
t=
hl
l + h(l – l)
In this equation, t is HIV prevalence among incident TB
cases, h is HIV prevalence among the general population
(from the latest time-series provided by UNAIDS) and
l is the incidence rate ratio (IRR) (defi ned as the incidence rate of TB in HIV-positive people divided by the
incidence rate of TB in HIV-negative people).1 We then
let logit(t) be log(t/(1-t)) and logit(h) be log(h/(1-h)). Using
data from countries where HIV prevalence has been estimated by UNAIDS as an independent variable, a linear
model of logit-transformed t was fitted using logit-transformed h according to the following equation, written in
matrix notation:
T̂ = X`
where T̂ is a vector of predicted logit(t), X is an n x 2
matrix in which the fi rst column holds 1s, and the second column holds logit(h). The vector ` holds estimated
model parameters.
Models were run using Monte Carlo simulations in
which h was drawn randomly from a Beta distribution
with shape parameters computed as described in section 3.1, (low and high uncertainty bounds are provided
by UNAIDS – also see Table A1.2). The model was run
50 000 times using country-specific distributions for H
and T (noted in capital letters to denote vectors or matrices) based on their uncertainty intervals. The uncertainty bounds for ` were chosen as the 2.5th and 97.5th
centiles.
The source of data used for each country is available
upon request from [email protected].
5. Estimates of TB prevalence, 1990–2010
The best way to measure the prevalence of TB is through
national population-based surveys of TB disease.2,3 Data
from such surveys are available for an increasing number of countries (Chapter 2). It should be noted, however,
that measurements of prevalence are typically confi ned
to the adult population. Furthermore, prevalence surveys
82
exclude extrapulmonary cases and do not allow the diagnosis of cases of culture-negative pulmonary TB.
When there is no direct measurement from a national survey of the prevalence of TB disease, prevalence is
the most uncertain of the three TB indicators used to
measure disease burden. This is because prevalence is
the product of two uncertain quantities: (i) incidence and
(ii) disease duration. The duration of disease is very difficult to quantify because it cannot be measured during
surveys of the prevalence of TB disease (surveys truncate
the natural history of disease). Duration can be assessed
in self-presenting patients, but there is no practical way
to measure the duration of disease in patients who are
not notified to NTPs.
Indirect estimates of prevalence were calculated
according to the following equation:
P=
- Ii,jd i,j, iD {1,2}, jD {1,2}
where the index variable i denotes HIV+ and HIV–, the
index variable j denotes notified and non-notified cases,
d denotes the duration of disease in notified cases and I
is total incidence. In the absence of measurements, we
did not allow duration in notified cases to vary among
countries. Given their underlying uncertainty, prevalence estimates should be used with great caution in the
absence of direct measurements from a prevalence survey. Unless measurements were available from national
programmes (for example, Turkey), assumptions of the
duration of disease were used as shown in the last four
rows of Table A1.2.
6. Estimates of the number of cases
of MDR-TB
6.1 Proportion of notified cases of TB that have
MDR-TB, 2010
Global and regional estimates of the proportion of new
and retreatment cases of TB that had MDR-TB in 2010
were calculated using country-level information. If countries had reported data on the proportion of new and
retreatment cases of TB that have MDR-TB from routine surveillance or a survey of drug resistance the latest available information was used. For countries that
have not reported such data, estimates of the proportion
of new and retreatment cases of TB that have MDRTB were produced using modelling (including multiple
imputation) that was based on data from countries for
which data do exist. Estimates for countries without
data were based on countries that were considered to be
1
2
3
www.unaids.org/en/dataanalysis/epidemiology/, accessed
15 July 2011.
Glaziou P et al. Tuberculosis prevalence surveys: rationale
and cost. International Journal of Tuberculosis and Lung Disease,
2008, 12(9):1003–1008.
TB prevalence surveys: a handbook. Geneva, World Health
Organization, 2011 (WHO/HTM/TB/2010.17).
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 82
23/09/11 07:20
similar in terms of TB epidemiology. The observed and
imputed estimates of the proportion of new and retreatment cases of TB that have MDR-TB were then pooled to
give a global estimate, with countries weighted according
to their share of global notifications of new and retreatment cases.
include assessments of drug resistance. In the absence
of direct measurements at country level, country-specific estimates of the prevalence of MDR-TB suffer from
much greater uncertainty compared with the uncertainty
that surrounds global averages.
7. Estimates of TB mortality, 1990–2010
6.2 Trends in the proportion of new TB cases with
MDR-TB, 1994–2010
Analysis of trends in the proportion of TB cases that
have MDR-TB was restricted to new cases. Data were too
patchy to allow analysis of trends in retreatment cases.
Countries or territories for which there were at least
two measurements of the proportion of new TB cases
that had MDR-TB between 1994 and 2010 were identified. A linear regression model of the log-transformed
proportion of cases that have MDR-TB was fitted for
every country, with only year as an independent variable. The restricting assumption of a linear association between changes in the proportion of cases that
have MDR-TB and time was made because of the small
number of measurements per country. The slope of
this regression model represents the annual change in
the proportion of new cases with MDR-TB. Modelling
including multiple imputation was then used to produce
estimates of the annual change in the proportion of cases
that have MDR-TB for countries that have not reported
data. Estimates for countries without data were based on
countries to which they were considered to be similar in
terms of TB epidemiology (see Appendix 1 and section
2.2). Finally, the observed and imputed estimates were
pooled to give global and regional estimates, with countries weighted according to their share of global notifications of new cases.
6.3 Numbers of prevalent cases of MDR-TB, 2010
The global estimate of the number of prevalent cases
of MDR-TB in 2010 was derived in two steps. First, the
weighted average of the proportion of new and retreatment notified cases that had MDR-TB was computed, to
give an estimate of the proportion of all notified cases
that had MDR-TB. This combined proportion was then
multiplied by the estimated global prevalence of TB in
the general population, under the assumption that the
proportion of all cases that have MDR-TB was the same
as the proportion of notified cases that have MDR-TB.
Country-specific estimates of the number of prevalent cases of MDR-TB in 2010 were not computed
because only a few countries have directly measured
the prevalence of TB in a population-based survey, and
even among these countries data on the proportion of
culture-positive pulmonary cases that had MDR-TB are
not always available. To date, direct measurements of
the number of prevalent cases of MDR-TB are available
only for China, although several upcoming surveys will
The best sources of data about deaths from TB (excluding those among HIV-positive people) are VR systems
in which causes of death are coded according to ICD-10
(although the older ICD-9 and ICD-8 classification are
still in use in several countries). Deaths from TB in HIVpositive people are coded under HIV-associated codes.
Estimates of TB mortality were produced directly
from VR data or mortality surveys, or indirectly from
estimates of TB incidence and case-fatality rates (CFRs).
The source of data used in each country is available from
[email protected] upon request.
7.1 Estimating TB mortality from vital registration
data and mortality surveys
Data from VR systems are reported to WHO by Member
States and territories every year. In countries with functioning VR systems in which causes of death are coded
according to the two latest revisions of the international classification of diseases (underlying cause of death:
ICD-10 A15-A19, equivalent to ICD-9: 010-018), VR data
are the best source of information about deaths from
TB among people not infected with HIV. When people
with AIDS die from TB, HIV is registered as the underlying cause of death and TB is recorded as a contributory cause. Since one third of countries with VR systems
report to WHO only the underlying causes of death and
not contributory causes, VR data usually cannot be used
to estimate the number of TB deaths in HIV-positive
people.
In 2010, 92 countries had well-functioning VR systems according to the following defi nition: (i) coverage of
at least 70% of the population, and (ii) ill-defi ned causes
of death (ICD-9 code B46, ICD-10 codes R00-R99) of
<20% of all registered deaths.1 In addition, mortality survey data from two countries were used (China and India),
of which one (India) did not have VR data. Countries
with mortality measurements included 6 of the 22 HBCs
(Brazil, China, India, the Philippines, the Russian Federation and South Africa). However, we could not use the
VR data on TB deaths from South Africa because large
numbers of HIV deaths were miscoded as TB deaths.
Among the remaining 91 countries, there was a median of 9 years (interquartile range, 6–11) of VR data on TB
mortality between 1991 and 2010 that met the above criteria, equivalent to 720 country-years. We assumed that
1
Mathers CD et al. Counting the dead and what they died
from: an assessment of the global status of cause of death
data. Bulletin of the World Health Organization, 2005, 83:171–177.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 83
83
23/09/11 07:20
the proportion of TB deaths among deaths not recorded
by the VR system was the same as the proportion of TB
deaths in VR-recorded deaths. For VR-recorded deaths
with ill-defi ned causes, we assumed that the proportion
of deaths attributable to TB was the same as the observed
proportion in recorded deaths. We assumed errors in
measurement (due to misclassifications) and assumptions (redistributions) to be binomially distributed.
TABLE A1.4
Estimates of TB case-fatality rates by case type and
country
HIV-NEGATIVE
y = (I – N )`1 + N`2 + ¡, ¡ ~ N(0,m2 )
where y is TB mortality from VR, I denotes TB incidence
excluding people living with HIV, N denotes TB notifications excluding people living with HIV, and parameters
`1 and `2 denote the CFR in non-notified and notified
cases respectively. Semi-conjugate priors were set with
an uninformative inverse Gamma prior on the conditional error variance:
POSTERIOR
DISTRIBUTIONS MEAN
(STANDARD ERROR)
Non-notified: highincome countries
0.1 (0.01)
0.1 (0.0097)
Non-notified: other
countries
0.4 (0.01)
0.32 (0.098)
Notified: high income
countries
0.04 (0.01)
0.074 (0.0026)
Notified: other countries
0.05 (0.01)
0.058 (0.006)
CASE TYPE AND
COUNTRY GROUP
7.2 Estimating TB mortality from indirect estimates
of case-fatality rates and TB incidence
For the years in which VR or mortality survey data of
sufficient quality and coverage were not available for the
91 countries defi ned above plus the 125 countries (as of
2010) without any direct measurement, mortality was
estimated as the product of TB incidence and the CFR.
CFRs were estimated separately for TB cases notified
to NTPs and non-notified cases and, within these two
groups, separate estimates were made for HIV-positive
TB cases and HIV-negative TB cases (Table A1.3).
For consistency with VR – or survey-based mortality
estimates, CFRs were estimated such that they gave the
best fit to the directly measured TB death rates (within
their uncertainty ranges) across the 720 country-years of
data from the 91 countries with functioning VR systems
or survey data), in conjunction with WHO estimates of
distributions of TB incidence in those countries. This
statistical fitting used Bayesian linear models and was
done separately for two groups of countries (high-income
and all other countries), to account for differences in the
ratio of reported TB mortality to TB notification rates
among these two groups (data not shown).
The models used normal errors and Gibbs sampling:
NORMAL PRIOR
DISTRIBUTIONSa MEAN
(STANDARD ERROR)
a
Priors and assumed distributions in HIV-negaitive cases were derived from (i)
pooled estimates from random-effects modelling of literature review results
and (ii) pooled estimates from the WHO global TB database of assumed
country-specific CFRs (2008).
7.3 Estimates of TB mortality among
HIV-positive people
A prior belief about the proportion of HIV deaths with
TB as the contributory cause of death was set on the
assumption of a beta distribution with parameters a and
b. The prior proportion was set at 30% (standard deviation, 3%).3 The likelihood for the estimated number
of TB deaths among estimated HIV-positive incident
TB cases was based on an assumed 50% CFR (standard deviation, 5%) in low and middle-income countries
and a 20% CFR (standard deviation, 2%) in high-income
countries, using the methods described above and from
literature reviews.4 Cases on antiretroviral therapy (ART)
were assumed to benefit from the protective effect of ART,
estimated at 48% (standard deviation, 0.45%) based on a
recent literature review. The likelihood was defi ned as a
beta density with parameters s+1 and f+1. By combining
the beta prior with the likelihood function, the posterior
is also of the beta form with parameters a+s and b+f. Posteriors were determined for each country-year data point.
7.4 Estimating TB mortality from disaggregated
estimates of TB deaths by age and sex
For countries with VR data, it was possible to disaggregate estimated TB deaths by age (with age groups defi ned
b ~ N(b i ,B i-2 ), m2 ~ IG (5.10 -4,5.10 -4 )
Priors b and their precision B were defi ned based on
literature reviews,1,2 and the country-year CFR parameters used by WHO for the years 1999–2008 (Table A1.4).
Convergence of Markov Chains was assessed graphically
and using two convergence diagnostic tests. Within each
case category 1990–2010, mortality estimates were computed by taking the product of posterior distributions of
the CFR, assumed to be time-independent (Table A1.4),
and country-year specific distributions of estimated incidence.
84
1
2
3
4
Straetemans M et al. Assessing tuberculosis case fatality ratio:
a meta-analysis. PLoS One. 2011, 6(6):e20755.
Tiemersma EW et al. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in
HIV negative patients: a systematic review. PLoS One. 2011,
6(4):e17601.
www.unaids.org/en/dataanalysis/epidemiology/ accessed
15 July 2011.
Straetemans M et al. The effect of tuberculosis on mortality in HIV positive people: a meta-analysis. PLoS One, 2010,
5(12):e15241.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 84
23/09/11 07:20
as 0–4 years, 5–14 years, 15–24 years, 25–34 years, 35–44
years, 45–54 years, 55–64 years, *65 years) and sex, in
line with the way in which deaths are reported. In countries with no functional VR system, the total number of
estimated TB deaths was redistributed into the different
age and sex strata according to the disaggregation of the
combined population of countries with VR data (with
standardization against the individual country’s age and
sex distribution). TB deaths in HIV-positive people were
not disaggregated by age and sex due to limited data from
countries with functional VR systems.
8. Projections of incidence, prevalence and
mortality up to 2015
Projections of TB incidence, prevalence and mortality
rates up to 2015 enable assessment of whether global
targets set for 2015 are likely to be achieved at global,
regional and country levels. Projections for the years
2011–2015 were made using log-linear regression models fitted to data from 2007–2010, with the assumption
that recent trends would continue.
9. Estimation of uncertainty
There are many potential sources of uncertainty associated with estimates of TB incidence, prevalence and
mortality, as well as estimates of the burden of HIV-associated TB and MDR-TB. These include uncertainties in
input data, in parameter values, in extrapolations used to
impute missing data, and in the models used.
We used fi xed population values from the UNPD. We
did not account for any uncertainty in these values.
Notification data are of uneven quality. Cases may be
underreported (missing quarterly reports from remote
administrative areas are not uncommon), misclassified
(in particular, misclassification of recurrent cases in the
category of new cases is common), or over-reported as a
result of duplicated entries in TB information systems.
The latter two issues can only be addressed efficiently in
countries with case-based nationwide TB databases that
include patient identifiers. Sudden changes in notifications
over time are often the result of errors or inconsistencies
in reporting, but may sometimes reflect abrupt changes
in TB epidemiology (for example, resulting from a rapid
influx of migrants from countries with a high burden of
TB, or from rapid improvement in case-finding efforts).
Missing national aggregates of new and recurrent
cases were imputed by cubic spline interpolation. Notification trajectories were smoothed using a penalized
cubic splines function with parameters based on the
data. Attempts to obtain corrections for historical data
are made every year, but only rarely do countries provide
appropriate data corrections.
Mortality estimates incorporated the following sources of uncertainty: sampling uncertainty in the underlying
measurements of TB mortality rates from data sources,
uncertainty in estimates of incidence rates and rates of
HIV prevalence among both incident and notified TB
cases, and parameter uncertainty in the Bayesian model. Time-series of TB mortality were generated for each
country through Monte Carlo simulations.
Unless otherwise specified, uncertainty bounds and
ranges were defi ned as the 2.5th and 97.5th centiles of
outcome distributions. Throughout this report, ranges
with upper and lower bounds defi ned by these centiles
are provided for all estimates established with the use of
simulations. When uncertainty was established with the
use of observed or other empirical data, 95% confidence
intervals are reported.
The model used the following sequence: (1) incidence
estimation, (2) estimation of HIV-positive TB incidence,
(3) estimation of mortality, (4) estimation of prevalence.
By design, some steps were independent from each other
(for example, step 4 may be done before or after step 3).
The general approach to uncertainty analyses was to
draw values from specified distributions for every parameter (except for notifications and population values) in
Monte Carlo simulations, with the number of simulation runs set so that they were sufficient to ensure stability in the outcome distributions. For each country, the
same random generator seed was used for every year, and
errors were assumed to be time-dependent within countries (thus generating autocorrelation in time-series).
Regional parameters were used in some instances (for
example, for CFRs). Summaries of quantities of interest
were obtained by extracting the 2.5th, 50th and 97.5th
centiles of posterior distributions.
Appendix 1.
Epidemiological regions used for analyses
related to MDR-TB
Africa – countries with high HIV prevalence: Botswana, Burundi, Cameroon, the Central African Republic, the Congo, Côte d’Ivoire, the Democratic Republic
of the Congo, Ethiopia, Gabon, Kenya, Lesotho, Malawi,
Mozambique, Namibia, Nigeria, Rwanda, South Africa,
Swaziland, Uganda, the United Republic of Tanzania,
Zambia, Zimbabwe.
Africa – countries with low HIV prevalence: Algeria, Angola, Benin, Burkina Faso, Cape Verde, Chad, the
Comoros, Eritrea, the Gambia, Ghana, Guinea, GuineaBissau, Liberia, Madagascar, Mali, Mauritania, Mauritius,
the Niger, Sao Tome and Principe, Senegal, Seychelles,
Sierra Leone, Togo.
Central Europe: Albania, Bosnia and Herzegovina,
Montenegro, Poland, Serbia, the former Yugoslav Republic of Macedonia, Turkey.
Eastern Europe: Armenia, Azerbaijan, Belarus, Bulgaria, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania,
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 85
85
23/09/11 07:20
the Republic of Moldova, Romania, the Russian Federation, Tajikistan, Turkmenistan, Ukraine, Uzbekistan.
High-income countries: Andorra, Australia, Austria,
the Bahamas, Bahrain, Barbados, Belgium, Bermuda,
Brunei Darussalam, Canada, the Cayman Islands, Croatia, Cyprus, the Czech Republic, Denmark, Equatorial
Guinea, Estonia, Finland, France, French Polynesia,
Germany, Greece, Guam, Hungary, Iceland, Ireland,
Israel, Italy, Japan, Kuwait, Luxembourg, Malta, Monaco,
the Netherlands, New Caledonia, New Zealand, Northern Mariana Islands, Norway, Oman, Portugal, Puerto
Rico, Qatar, the Republic of Korea, San Marino, Saudi
Arabia, Singapore, Slovakia, Slovenia, Spain, Sweden,
86
Switzerland, Trinidad and Tobago, the Turks and Caicos
Islands, the United Arab Emirates, the United Kingdom,
the United States, US Virgin Islands.
Latin America: Anguilla, Antigua and Barbuda, Argentina, Aruba, Belize, Bolivia (Plurinational State of), Brazil, British Virgin Islands, Chile, Colombia, Costa Rica,
Cuba, Curaçao, Dominica, the Dominican Republic,
Ecuador, El Salvador, Grenada, Guatemala, Guyana,
Haiti, Honduras, Jamaica, Mexico, Montserrat, Nicaragua, Panama, Paraguay, Peru, Saint Kitts and Nevis,
Saint Lucia, Saint Vincent and the Grenadines, Sint
Maarten (Dutch part), Suriname, Uruguay, Venezuela.
(Bolivarian Republic of).
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 86
23/09/11 07:20
ANNEX 2
Country profiles
profiles
1109_0319_P_001_248 87
23/09/11 07:20
Countries
This annex presents TB profi les for the 22 high burden countries that account for approximately 80% of all new TB
cases arising each year.
TB profi les for all countries and NTP fi nancing profi les for over 100 countries are available at www.who.int/tb/data.
Data source
Data shown in this annex are taken from the WHO global TB database on 2 September 2011. Data shown in the main
part of the report were taken from the database on 21 June 2011.
Notification data were updated by Bangladesh, the Russian Federation and South Africa between 21 June and
2 September 2011. As a result, their notification data in this annex differ slightly from those presented in the main part
of the report.
88
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 88
23/09/11 07:20
AFGHANISTAN
POPULATION 2010 (MILLIONS)
ESTIMATES OF BURDEN
Number
2010a
(thousands)
Mortality (excluding HIV)
12 (8.6–16)
Prevalence (incl HIV)
110 (51–180)
Incidence (incl HIV)
59 (49–71)
Incidence (HIV-positive)
Case detection, all forms (%)
47 (39–57)
31
Rate
(per 100 000 pop)
38 (27–50)
352 (162–578)
189 (155–226)
200
100
0
1990
CASE NOTIFICATIONS 2010
New cases
(%)
Smear-positive
Smear-negative
Smear unknown
Extrapulmonary
Other
Total new
Total < 15 years
12 947
4 479
2 606
6 248
633
26 913
642
(48)
(17)
(10)
(23)
(2)
Total new and relapse
Total cases notified
INCIDENCE (HIV+TB red), notifications (black)
(rates per 100 000 population)
Retreatment cases
(%)
Relapse
Treatment after failure
Treatment after default
Other
1 116 (84)
147 (11)
62 (5)
Total retreatment
1 325
1995
2000
2005
2010
2000
2005
2010
2000
2005
2010
PREVALENCE
(rate per 100 000 population)
600
400
200
28 029
28 238
0
1990
(99% of total)
1995
MORTALITY EXCLUDING HIV
(rate per 100 000 population)
80
DRUG REGIMENS
Rifampicin used throughout treatment
% of patients treated with fixed-dose combinations (FDCs)
Paediatric formulations procured
No
100
Yes
TREATMENT SUCCESS RATE 2009 (%)
New smear-positive
New smear-negative/extrapulmonary
Retreatment
86
TREATMENT SUCCESS RATE (%)
100
New smear +
New smear –/
extrapulmonary
Retreatment
60
20
1995
1997
1999
2001
2003
2005
2007
40
0
1990
1995
TB/HIV 2010
TB patients with known HIV status
% of TB patients with known HIV status
TB patients that are HIV-positive
% of tested TB patients that are HIV-positive
% HIV-positive TB patients started on CPT
% HIV-positive TB patients started on ART
HIV-positive people screened for TB
HIV-positive people provided with IPT
5 170
18
0
0
CPT (pink) and ART (brown) for HIV-positive TB patients (blue)
2009
6
MDR-TB, ESTIMATES AMONG NOTIFIED CASESa
% of new TB cases with MDR-TB
6.1 (3.5–10)
% of retreatment TB cases with MDR-TB
8.3 (1.7–21)
Estimated MDR-TB cases among new
pulmonary TB cases notified in 2010
1 300 (720–2 100)
Estimated MDR-TB cases among retreated
pulmonary TB cases notified in 2010
110 (23–280)
MDR-TB REPORTED CASES 2010
Cases tested for MDR-TB
% of notified tested for MDR-TB
Confirmed cases of MDR-TB
MDR-TB patients started treatment
LABORATORIES
Smear (per 100 000 population)
Culture (per 5 million population)
DST (per 5 million population)
Second-line DST available
National Reference Laboratory
a
New
4
2
0
2003
2004
2005
2006
2007
2008
2009
238
<1
13
34
3
6
272
<1
19
0
FINANCING
Total budget (US$ millions)
Available funding (US$ millions)
% of budget funded
% available funding from domestic sources
% available funding from Global Fund
2009
2010
2011
NTP Budget (blue) and available funding (green) (US$ millions)
1.9
0
0
1.9
0.2
0
1.9
0.6
0
Retreatment
Outside country
Yes
Total
2010
2011
2012
9
5
58
7
69
11
9
81
4
53
20
10
0
2006
2007
2008
2009
2010
2011
2012
Ranges represent uncertainty intervals.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_001_248 89
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
89
23/09/11 07:20
BANGLADESH
POPULATION 2010 (MILLIONS)
149
ESTIMATES OF BURDEN
Number
Rate
2010a
(thousands)
(per 100 000 pop)
Mortality (excluding HIV)
64 (47–85)
43 (32–57)
Prevalence (incl HIV)
610 (280–1 000)
411 (188–671)
Incidence (incl HIV)
330 (270–400)
225 (184–269)
Incidence (HIV-positive)
0.66 (0.33–1.1) 0.45 (0.23–0.74)
Case detection, all forms (%)
46 (38–56)
CASE NOTIFICATIONS 2010
New cases
(%)
Smear-positive
Smear-negative
Smear unknown
Extrapulmonary
Other
Total new
Total < 15 years
105 772 (70)
21 625 (14)
0 (0)
23 506 (16)
0 (0)
150 903
4 235
Total new and relapse
Total cases notified
Retreatment cases
(%)
Relapse
Treatment after failure
Treatment after default
Other
2 989 (38)
961 (12)
594 (8)
3 251 (42)
Total retreatment
7 795
153 892
158 698
INCIDENCE (HIV+TB red), notifications (black)
(rates per 100 000 population)
300
200
100
0
1990
1995
2005
2010
2000
2005
2010
2000
2005
2010
PREVALENCE
(rate per 100 000 population)
800
400
0
1990
(97% of total)
2000
1995
MORTALITY EXCLUDING HIV
(rate per 100 000 population)
80
DRUG REGIMENS
Rifampicin used throughout treatment
% of patients treated with fixed-dose combinations (FDCs)
Paediatric formulations procured
Yes
100
Yes
TREATMENT SUCCESS RATE 2009 (%)
New smear-positive
New smear-negative/extrapulmonary
Retreatment
92
89
81
TREATMENT SUCCESS RATE (%)
100
New smear +
New smear –/
extrapulmonary
Retreatment
75
50
1995
1997
1999
2001
2003
2005
2007
40
0
1990
1995
TB/HIV 2010
TB patients with known HIV status
% of TB patients with known HIV status
TB patients that are HIV-positive
% of tested TB patients that are HIV-positive
% HIV-positive TB patients started on CPT
% HIV-positive TB patients started on ART
HIV-positive people screened for TB
HIV-positive people provided with IPT
1 778
1
4
<1
100
0
347
64
CPT (pink) and ART (brown) for HIV-positive TB patients (blue)
2009
50
MDR-TB, ESTIMATES AMONG NOTIFIED CASESa
% of new TB cases with MDR-TB
2.1 (1.7–2.5)
% of retreatment TB cases with MDR-TB
28 (25–32)
Estimated MDR-TB cases among new
pulmonary TB cases notified in 2010
2 700 (2 200–3 200)
Estimated MDR-TB cases among retreated
pulmonary TB cases notified in 2010
2 200 (1 900–2 500)
MDR-TB REPORTED CASES 2010
Cases tested for MDR-TB
% of notified tested for MDR-TB
Confirmed cases of MDR-TB
MDR-TB patients started treatment
LABORATORIES
Smear (per 100 000 population)
Culture (per 5 million population)
DST (per 5 million population)
Second-line DST available
National Reference Laboratory
a
90
New
Retreatment
Total
339
4
339
339
<1
339
339
2009
2010
2011
0.7
<0.1
<0.1
0.7
0.1
<0.1
0.7
0.1
<0.1
Outside country
Yes
25
0
2003
2004
2005
2006
2007
2008
FINANCING
Total budget (US$ millions)
Available funding (US$ millions)
% of budget funded
% available funding from domestic sources
% available funding from Global Fund
2009
2010
2011
2012
41
12
29
10
57
48
14
28
9
75
NTP Budget (blue) and available funding (green) (US$ millions)
50
25
0
2006
2007
2008
2009
2010
2011
2012
Ranges represent uncertainty intervals.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 90
Data can be downloaded from www.who.int/tb/data
23/09/11 07:20
BRAZIL
POPULATION 2010 (MILLIONS)
ESTIMATES OF BURDEN
2010a
Mortality (excluding HIV)
Prevalence (incl HIV)
Incidence (incl HIV)
Incidence (HIV-positive)
Case detection, all forms (%)
195
Number
(thousands)
Rate
(per 100 000 pop)
5 (3.1–8.3)
92 (34–160)
85 (70–100)
18 (15-22)
88 (74–110)
2.6 (1.6–4.3)
47 (17–80)
43 (36–51)
9.3 (7.7–11)
(%)
Smear-positive
Smear-negative
Smear unknown
Extrapulmonary
Other
Total new
Total < 15 years
37 932
13 694
9 336
10 017
18
70 997
2 450
(53)
(19)
(13)
(14)
(<1)
40
0
1990
Retreatment cases
(%)
Relapse
Treatment after failure
Treatment after default
Other
3 398 (31)
122 (1)
3 208 (29)
4 221 (39)
Total retreatment
Total new and relapse
Total cases notified
120
80
CASE NOTIFICATIONS 2010
New cases
INCIDENCE (HIV+TB red), notifications (black)
(rates per 100 000 population)
10 949
74 395
81 946
1995
2005
2010
2000
2005
2010
2000
2005
2010
PREVALENCE
(rate per 100 000 population)
200
100
0
1990
(91% of total)
2000
1995
MORTALITY EXCLUDING HIV
(rate per 100 000 population)
15
DRUG REGIMENS
Rifampicin used throughout treatment
% of patients treated with fixed-dose combinations (FDCs)
Paediatric formulations procured
Yes
100
No
TREATMENT SUCCESS RATE 2009 (%)
New smear-positive
New smear-negative/extrapulmonary
Retreatment
72
68
42
TREATMENT SUCCESS RATE (%)
New smear +
New smear –/
extrapulmonary
Retreatment
75
50
25
0
1995
1997
1999
2001
2003
2005
2007
10
5
0
1990
1995
TB/HIV 2010
TB patients with known HIV status
% of TB patients with known HIV status
TB patients that are HIV-positive
% of tested TB patients that are HIV-positive
% HIV-positive TB patients started on CPT
% HIV-positive TB patients started on ART
HIV-positive people screened for TB
HIV-positive people provided with IPT
37 210
45
8 558
23
93
CPT (pink) and ART (brown) for HIV-positive TB patients (blue)
2009
10000
MDR-TB, ESTIMATES AMONG NOTIFIED CASESa
% of new TB cases with MDR-TB
0.90 (0.60–1.4)
% of retreatment TB cases with MDR-TB
5.4 (3.9–7.3)
Estimated MDR-TB cases among new
pulmonary TB cases notified in 2010
550 (370–850)
Estimated MDR-TB cases among retreated
pulmonary TB cases notified in 2010
590 (450–800)
MDR-TB REPORTED CASES 2010
Cases tested for MDR-TB
% of notified tested for MDR-TB
Confirmed cases of MDR-TB
MDR-TB patients started treatment
LABORATORIES
Smear (per 100 000 population)
Culture (per 5 million population)
DST (per 5 million population)
Second-line DST available
National Reference Laboratory
a
5000
0
2003
New
Retreatment
Total
22
<1
21
643
6
552
665
<1
573
573
2009
2010
2011
2.1
5.8
1.1
2.0
6.5
1.0
2.0
6.9
1.1
In and outside country
Yes
2004
2005
2006
2007
2008
FINANCING
Total budget (US$ millions)
Available funding (US$ millions)
% of budget funded
% available funding from domestic sources
% available funding from Global Fund
2009
2010
2011
2012
87
80
92
90
5
87
74
85
97
1
NTP Budget (blue) and available funding (green) (US$ millions)
100
50
0
2006
2007
2008
2009
2010
2011
2012
Ranges represent uncertainty intervals.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_001_248 91
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
91
23/09/11 07:20
CAMBODIA
POPULATION 2010 (MILLIONS)
ESTIMATES OF BURDEN
2010a
Mortality (excluding HIV)
Prevalence (incl HIV)
Incidence (incl HIV)
Incidence (HIV-positive)
Case detection, all forms (%)
14
Number
(thousands)
Rate
(per 100 000 pop)
8.6 (6.2–12)
93 (42–150)
62 (53–72)
4 (3.4–4.7)
65 (57–77)
61 (44–82)
660 (296–1070)
437 (373–506)
29 (24–33)
600
400
200
0
1990
CASE NOTIFICATIONS 2010
New cases
(%)
Smear-positive
Smear-negative
Smear unknown
Extrapulmonary
Other
Total new
Total < 15 years
17 454 (44)
8 301 (21)
0 (0)
14 239 (36)
0 (0)
39 994
99
Total new and relapse
Total cases notified
INCIDENCE (HIV+TB red), notifications (black)
(rates per 100 000 population)
Retreatment cases
(%)
Relapse
Treatment after failure
Treatment after default
Other
466 (29)
59 (4)
19 (1)
1 090 (67)
Total retreatment
1 634
40 460
41 628
1995
2005
2010
2000
2005
2010
2000
2005
2010
PREVALENCE
(rate per 100 000 population)
2000
1000
0
1990
(97% of total)
2000
1995
MORTALITY EXCLUDING HIV
(rate per 100 000 population)
200
DRUG REGIMENS
Rifampicin used throughout treatment
% of patients treated with fixed-dose combinations (FDCs)
Paediatric formulations procured
Yes
100
Yes
TREATMENT SUCCESS RATE 2009 (%)
New smear-positive
New smear-negative/extrapulmonary
Retreatment
95
93
79
TREATMENT SUCCESS RATE (%)
100
New smear +
New smear –/
extrapulmonary
Retreatment
90
80
70
1995
1997
1999
2001
2003
2005
2007
100
0
1990
1995
TB/HIV 2010
TB patients with known HIV status
% of TB patients with known HIV status
TB patients that are HIV-positive
% of tested TB patients that are HIV-positive
% HIV-positive TB patients started on CPT
% HIV-positive TB patients started on ART
HIV-positive people screened for TB
HIV-positive people provided with IPT
32 236
77
2 112
7
65
45
491
CPT (pink) and ART (brown) for HIV-positive TB patients (blue)
2009
6000
MDR-TB, ESTIMATES AMONG NOTIFIED CASESa
% of new TB cases with MDR-TB
1.4 (0.70–2.5)
% of retreatment TB cases with MDR-TB
11 (4.0–22)
Estimated MDR-TB cases among new
pulmonary TB cases notified in 2010
360 (180–640)
Estimated MDR-TB cases among retreated
pulmonary TB cases notified in 2010
170 (65–360)
MDR-TB REPORTED CASES 2010
Cases tested for MDR-TB
% of notified tested for MDR-TB
Confirmed cases of MDR-TB
MDR-TB patients started treatment
LABORATORIES
Smear (per 100 000 population)
Culture (per 5 million population)
DST (per 5 million population)
Second-line DST available
National Reference Laboratory
a
92
New
Retreatment
Total
5
<1
1
93
6
30
98
<1
31
38
2009
2010
2011
1.5
1.1
0.4
1.5
1.1
0.4
1.5
1.0
0.3
Outside country
Yes
4000
2000
0
2003
2004
2005
2006
2007
2008
FINANCING
Total budget (US$ millions)
Available funding (US$ millions)
% of budget funded
% available funding from domestic sources
% available funding from Global Fund
2009
2010
2011
2012
39
14
35
8
36
40
15
36
8
31
NTP Budget (blue) and available funding (green) (US$ millions)
50
25
0
2006
2007
2008
2009
2010
2011
2012
Ranges represent uncertainty intervals.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 92
Data can be downloaded from www.who.int/tb/data
23/09/11 07:20
CHINA
POPULATION 2010 (MILLIONS)
1 341
ESTIMATES OF BURDEN
Number
Rate
2010a
(thousands)
(per 100 000 pop)
Mortality (excluding HIV)
54 (52–56)
4.1 (3.9–4.2)
Prevalence (incl HIV)
1 500 (1 300–1 700) 108 (93–123)
Incidence (incl HIV)
1 000 (910–1 200)
78 (68–88)
Incidence (HIV-positive)
18 (10–28)
1.4 (0.77–2.1)
Case detection, all forms (%)
87 (77–100)
CASE NOTIFICATIONS 2010
New cases
(%)
Retreatment cases
(%)
Smear-positive 429 899 (49)
Smear-negative 430 580 (50)
Smear unknown
2 288 (<1)
Extrapulmonary
6 325 (<1)
Other
0 (0)
Total new
869 092
Total < 15 years
6 710
Relapse
Treatment after failure
Treatment after default
Other
39 307 (73)
2 662 (5)
1 103 (2)
11 144 (21)
Total retreatment
54 216
Total new and relapse
Total cases notified
908 399
923 308
INCIDENCE (HIV+TB red), notifications (black)
(rates per 100 000 population)
150
100
50
0
1990
1995
2005
2010
2000
2005
2010
2000
2005
2010
PREVALENCE
(rate per 100 000 population)
200
100
0
1990
(98% of total)
2000
1995
MORTALITY EXCLUDING HIV
(rate per 100 000 population)
20
DRUG REGIMENS
Rifampicin used throughout treatment
% of patients treated with fixed-dose combinations (FDCs)
Paediatric formulations procured
Yes
15
No
TREATMENT SUCCESS RATE 2009 (%)
New smear-positive
New smear-negative/extrapulmonary
Retreatment
95
92
90
TREATMENT SUCCESS RATE (%)
100
New smear +
New smear –/
extrapulmonary
Retreatment
90
80
1995
1997
1999
2001
2003
2005
2007
LABORATORIES
Smear (per 100 000 population)
Culture (per 5 million population)
DST (per 5 million population)
0
1990
1995
TB/HIV 2010
TB patients with known HIV status
% of TB patients with known HIV status
TB patients that are HIV-positive
% of tested TB patients that are HIV-positive
% HIV-positive TB patients started on CPT
% HIV-positive TB patients started on ART
HIV-positive people screened for TB
HIV-positive people provided with IPT
145 919
16
4 542
3
45
65 412
CPT (pink) and ART (brown) for HIV-positive TB patients (blue)
2009
MDR-TB, ESTIMATES AMONG NOTIFIED CASESa
% of new TB cases with MDR-TB
5.7 (4.6–7.1)
% of retreatment TB cases with MDR-TB
26 (22–30)
Estimated MDR-TB cases among new
pulmonary TB cases notified in 2010
49 000 (40 000–61 000)
Estimated MDR-TB cases among retreated
pulmonary TB cases notified in 2010
14 000 (12 000–16 000)
MDR-TB REPORTED CASES 2010
Cases tested for MDR-TB
% of notified tested for MDR-TB
Confirmed cases of MDR-TB
MDR-TB patients started treatment
10
4000
2000
0
2003
2004
2005
2006
2007
2008
2009
New
Retreatment
Total
229
1 669
2 792
1 222
FINANCING
Total budget (US$ millions)
Available funding (US$ millions)
% of budget funded
% available funding from domestic sources
% available funding from Global Fund
NTP Budget (blue) and available funding (green) (US$ millions)
2009
2010
2011
0.2
3.1
0.5
0.2
3.3
0.7
0.2
2.7
0.8
2010
2011
2012
285
278
98
70
30
350
319
91
69
30
350
250
Second-line DST available
National Reference Laboratory
a
In country
Yes
150
2006
2007
2008
2009
2010
2011
2012
Ranges represent uncertainty intervals.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_001_248 93
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
93
23/09/11 07:20
DEMOCRATIC REPUBLIC OF THE CONGO
POPULATION 2010 (MILLIONS)
ESTIMATES OF BURDEN
Number
2010a
(thousands)
Mortality (excluding HIV)
36 (27–45)
Prevalence (incl HIV)
350 (160–560)
Incidence (incl HIV)
220 (190–250)
Incidence (HIV-positive)
18 (13–24)
Case detection, all forms (%)
53 (46–61)
66
Rate
(per 100 000 pop)
54 (41–69)
535 (250–850)
327 (281–376)
27 (19–36)
(%)
Smear-positive
Smear-negative
Smear unknown
Extrapulmonary
Other
Total new
Total < 15 years
73 653 (67)
14 039 (13)
0 (0)
22 340 (20)
0 (0)
110 032
3 694
Total new and relapse
Total cases notified
0
1990
Retreatment cases
(%)
Relapse
Treatment after failure
Treatment after default
Other
4 138 (48)
713 (8)
796 (9)
2 957 (34)
Total retreatment
8 604
114 170
118 636
Yes
100
Yes
88
86
77
TREATMENT SUCCESS RATE (%)
New smear +
New smear –/
extrapulmonary
Retreatment
50
1997
1999
2001
2003
2005
2007
LABORATORIES
Smear (per 100 000 population)
Culture (per 5 million population)
DST (per 5 million population)
New
2005
2010
2000
2005
2010
2000
2005
2010
PREVALENCE
(rate per 100 000 population)
1000
500
1995
MORTALITY EXCLUDING HIV
(rate per 100 000 population)
40
0
1990
1995
TB/HIV 2010
TB patients with known HIV status
% of TB patients with known HIV status
TB patients that are HIV-positive
% of tested TB patients that are HIV-positive
% HIV-positive TB patients started on CPT
% HIV-positive TB patients started on ART
HIV-positive people screened for TB
HIV-positive people provided with IPT
28 997
24
5 273
18
24
9
3 892
CPT (pink) and ART (brown) for HIV-positive TB patients (blue)
2009
MDR-TB, ESTIMATES AMONG NOTIFIED CASESa
% of new TB cases with MDR-TB
2.2 (0.10–5.3)
% of retreatment TB cases with MDR-TB
9.4 (1.9–17)
Estimated MDR-TB cases among new
pulmonary TB cases notified in 2010
1 900 (88–4 600)
Estimated MDR-TB cases among retreated
pulmonary TB cases notified in 2010
810 (160–1 500)
MDR-TB REPORTED CASES 2010
Cases tested for MDR-TB
% of notified tested for MDR-TB
Confirmed cases of MDR-TB
MDR-TB patients started treatment
2000
80
TREATMENT SUCCESS RATE 2009 (%)
New smear-positive
New smear-negative/extrapulmonary
Retreatment
100
1995
0
1990
(96% of total)
DRUG REGIMENS
Rifampicin used throughout treatment
% of patients treated with fixed-dose combinations (FDCs)
Paediatric formulations procured
0
1995
400
200
CASE NOTIFICATIONS 2010
New cases
INCIDENCE (HIV+TB red), notifications (black)
(rates per 100 000 population)
Retreatment
Total
100
1
87
100
<1
87
191
2009
2010
2011
2.2
<0.1
<0.1
2.2
<0.1
<0.1
2.2
0.1
0.1
5000
2500
0
2003
2004
2005
2006
2007
2008
FINANCING
Total budget (US$ millions)
Available funding (US$ millions)
% of budget funded
% available funding from domestic sources
% available funding from Global Fund
2009
2010
2011
2012
64
<1
1
0
0
62
NTP Budget (blue) and available funding (green) (US$ millions)
75
50
25
Second-line DST available
National Reference Laboratory
a
94
No
Yes
0
2006
2007
2008
2009
2010
2011
2012
Ranges represent uncertainty intervals.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 94
Data can be downloaded from www.who.int/tb/data
23/09/11 07:20
ETHIOPIA
POPULATION 2010 (MILLIONS)
ESTIMATES OF BURDEN
Number
2010a
(thousands)
Mortality (excluding HIV)
29 (23–35)
Prevalence (incl HIV)
330 (140–520)
Incidence (incl HIV)
220 (200–230)
Incidence (HIV-positive)
Case detection, all forms (%)
72 (66–78)
83
Rate
(per 100 000 pop)
35 (28–42)
394 (173–623)
261 (240–282)
(%)
Smear-positive
Smear-negative
Smear unknown
Extrapulmonary
Other
Total new
Total < 15 years
46 634 (31)
52 457 (35)
2 522 (2)
50 417 (33)
0 (0)
152 030
3 190
Total new and relapse
Total cases notified
100
0
1990
Retreatment cases
(%)
Relapse
Treatment after failure
Treatment after default
Other
2 664
493
777
964
Total retreatment
4 898
(54)
(10)
(16)
(20)
154 694
156 928
(99% of total)
Yes
100
Yes
84
80
67
90
New smear +
New smear –/
extrapulmonary
Retreatment
70
2001
2003
2005
2010
2000
2005
2010
2000
2005
2010
600
400
2005
2007
1995
MORTALITY EXCLUDING HIV
(rate per 100 000 population)
40
TREATMENT SUCCESS RATE (%)
1999
2000
PREVALENCE
(rate per 100 000 population)
0
1990
TREATMENT SUCCESS RATE 2009 (%)
New smear-positive
New smear-negative/extrapulmonary
Retreatment
1997
1995
200
DRUG REGIMENS
Rifampicin used throughout treatment
% of patients treated with fixed-dose combinations (FDCs)
Paediatric formulations procured
50
1995
300
200
CASE NOTIFICATIONS 2010
New cases
INCIDENCE (HIV+TB red), notifications (black)
(rates per 100 000 population)
20
0
1990
1995
TB/HIV 2010
TB patients with known HIV status
% of TB patients with known HIV status
TB patients that are HIV-positive
% of tested TB patients that are HIV-positive
% HIV-positive TB patients started on CPT
% HIV-positive TB patients started on ART
HIV-positive people screened for TB
HIV-positive people provided with IPT
66 955
43
9 809
15
69
39
43 837
6 636
CPT (pink) and ART (brown) for HIV-positive TB patients (blue)
2009
12000
MDR-TB, ESTIMATES AMONG NOTIFIED CASESa
% of new TB cases with MDR-TB
1.6 (0.90–2.8)
% of retreatment TB cases with MDR-TB
12 (5.6–21)
Estimated MDR-TB cases among new
pulmonary TB cases notified in 2010
1 600 (910–2 800)
Estimated MDR-TB cases among retreated
pulmonary TB cases notified in 2010
580 (270–1 000)
MDR-TB REPORTED CASES 2010
Cases tested for MDR-TB
% of notified tested for MDR-TB
Confirmed cases of MDR-TB
MDR-TB patients started treatment
LABORATORIES
Smear (per 100 000 population)
Culture (per 5 million population)
DST (per 5 million population)
New
Retreatment
Total
42
<1
19
510
10
121
558
<1
140
120
2009
2010
2011
1.5
0.1
0.1
2.3
0.1
0.1
2.8
0.4
0.1
8000
4000
0
2003
2004
2005
2006
2007
2008
FINANCING
Total budget (US$ millions)
Available funding (US$ millions)
% of budget funded
% available funding from domestic sources
% available funding from Global Fund
2009
2010
2011
2012
49
40
83
20
40
52
38
74
23
39
NTP Budget (blue) and available funding (green) (US$ millions)
60
40
20
Second-line DST available
National Reference Laboratory
a
In country
Yes
0
2006
2007
2008
2009
2010
2011
2012
Ranges represent uncertainty intervals.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_001_248 95
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
95
23/09/11 07:20
INDIA
POPULATION 2010 (MILLIONS)
1 225
ESTIMATES OF BURDEN
Number
Rate
2010a
(thousands)
(per 100 000 pop)
Mortality (excluding HIV)
320 (210–470)
26 (17–39)
Prevalence (incl HIV)
3 100 (2 000–4 600) 256 (161–373)
Incidence (incl HIV)
2 300 (2 000–2 500) 185 (167–205)
Incidence (HIV-positive)
110 (75–160)
9.2 (6.1–13)
Case detection, all forms (%)
59 (53–65)
CASE NOTIFICATIONS 2010
New cases
(%)
Smear-positive
630 165
Smear-negative 366 381
Smear unknown
Extrapulmonary 231 121
Other
1 508
Total new
1 229 175
Total < 15 years
13 415
Retreatment cases
(51)
(30)
(19)
(<1)
Total new and relapse
Total cases notified
(%)
Relapse
Treatment after failure
Treatment after default
Other
110 691 (38)
18 463 (6)
72 110 (25)
91 708 (31)
Total retreatment
292 972
1 339 866
1 522 147
Yes
0
Yes
TREATMENT SUCCESS RATE 2009 (%)
New smear-positive
New smear-negative/extrapulmonary
Retreatment
88
90
75
TREATMENT SUCCESS RATE (%)
0
1995
New smear +
New smear –/
extrapulmonary
Retreatment
1997
1999
2001
2003
2005
2007
LABORATORIES
Smear (per 100 000 population)
Culture (per 5 million population)
DST (per 5 million population)
Second-line DST available
National Reference Laboratory
a
96
New
0
1990
1995
2000
2005
2010
2000
2005
2010
2000
2005
2010
PREVALENCE
(rate per 100 000 population)
400
200
1995
MORTALITY EXCLUDING HIV
(rate per 100 000 population)
20
0
1990
1995
TB/HIV 2010
TB patients with known HIV status
% of TB patients with known HIV status
TB patients that are HIV-positive
% of tested TB patients that are HIV-positive
% HIV-positive TB patients started on CPT
% HIV-positive TB patients started on ART
HIV-positive people screened for TB
HIV-positive people provided with IPT
480 752
32
41 476
9
90
57
199 732
CPT (pink) and ART (brown) for HIV-positive TB patients (blue)
2009
MDR-TB, ESTIMATES AMONG NOTIFIED CASESa
% of new TB cases with MDR-TB
2.1 (1.5–2.7)
% of retreatment TB cases with MDR-TB
15 (13–17)
Estimated MDR-TB cases among new
pulmonary TB cases notified in 2010
21 000 (15 000–27 000)
Estimated MDR-TB cases among retreated
pulmonary TB cases notified in 2010
43 000 (39 000–48 000)
MDR-TB REPORTED CASES 2010
Cases tested for MDR-TB
% of notified tested for MDR-TB
Confirmed cases of MDR-TB
MDR-TB patients started treatment
100
40
DRUG REGIMENS
Rifampicin used throughout treatment
% of patients treated with fixed-dose combinations (FDCs)
Paediatric formulations procured
50
200
0
1990
(88% of total)
100
INCIDENCE (HIV+TB red), notifications (black)
(rates per 100 000 population)
Retreatment
40000
20000
0
2003
2004
2005
2006
2007
2008
2009
2 967
2 967
FINANCING
Total budget (US$ millions)
Available funding (US$ millions)
% of budget funded
% available funding from domestic sources
% available funding from Global Fund
NTP Budget (blue) and available funding (green) (US$ millions)
Total
2009
2010
2011
1.1
<0.1
<0.1
1.1
<0.1
<0.1
1.0
0.1
0.1
In country
Yes
2010
2011
2012
139
139
100
44
49
210
210
100
62
38
250
150
50
2006
2007
2008
2009
2010
2011
2012
Ranges represent uncertainty intervals. Estimates for India have not yet been officially
approved by the Ministry of Health & Family Welfare, Government of India and should
therefore be considered provisional.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 96
Data can be downloaded from www.who.int/tb/data
23/09/11 07:20
INDONESIA
POPULATION 2010 (MILLIONS)
240
ESTIMATES OF BURDEN
Number
Rate
2010a
(thousands)
(per 100 000 pop)
Mortality (excluding HIV)
64 (42–91)
27 (18–38)
Prevalence (incl HIV)
690 (300–1 200) 289 (123–484)
Incidence (incl HIV)
450 (370–540)
189 (155–226)
Incidence (HIV-positive)
18 (9.9–29)
7.6 (4.1–12)
Case detection, all forms (%)
66 (55–81)
CASE NOTIFICATIONS 2010
New cases
(%)
Smear-positive
Smear-negative
Smear unknown
Extrapulmonary
Other
Total new
Total < 15 years
183 366 (62)
101 247 (34)
0 (0)
11 659 (4)
0 (0)
296 272
28 312
Total new and relapse
Total cases notified
Retreatment cases
(%)
Relapse
Treatment after failure
Treatment after default
Other
4 387 (67)
327 (5)
862 (13)
1 013 (15)
Total retreatment
6 589
300 659
302 861
Yes
100
Yes
TREATMENT SUCCESS RATE 2009 (%)
New smear-positive
New smear-negative/extrapulmonary
Retreatment
91
87
72
TREATMENT SUCCESS RATE (%)
100
New smear +
New smear –/
extrapulmonary
Retreatment
75
50
25
1995
1997
1999
2001
2003
2005
2007
LABORATORIES
Smear (per 100 000 population)
Culture (per 5 million population)
DST (per 5 million population)
Second-line DST available
National Reference Laboratory
a
100
0
1990
1995
2000
2005
2010
2000
2005
2010
2000
2005
2010
PREVALENCE
(rate per 100 000 population)
800
400
1995
MORTALITY EXCLUDING HIV
(rate per 100 000 population)
40
0
1990
1995
TB/HIV 2010
TB patients with known HIV status
% of TB patients with known HIV status
TB patients that are HIV-positive
% of tested TB patients that are HIV-positive
% HIV-positive TB patients started on CPT
% HIV-positive TB patients started on ART
HIV-positive people screened for TB
HIV-positive people provided with IPT
3 217
CPT (pink) and ART (brown) for HIV-positive TB patients (blue)
2009
MDR-TB, ESTIMATES AMONG NOTIFIED CASESa
% of new TB cases with MDR-TB
1.8 (1.1–2.7)
% of retreatment TB cases with MDR-TB
17 (8.1–26)
Estimated MDR-TB cases among new
pulmonary TB cases notified in 2010
5 100 (3 100–7 700)
Estimated MDR-TB cases among retreated
pulmonary TB cases notified in 2010
1 100 (530–1 700)
MDR-TB REPORTED CASES 2010
Cases tested for MDR-TB
% of notified tested for MDR-TB
Confirmed cases of MDR-TB
MDR-TB patients started treatment
200
0
1990
(99% of total)
DRUG REGIMENS
Rifampicin used throughout treatment
% of patients treated with fixed-dose combinations (FDCs)
Paediatric formulations procured
INCIDENCE (HIV+TB red), notifications (black)
(rates per 100 000 population)
New
Retreatment
Total
0
0
0
324
5
182
324
<1
182
142
2009
2010
2011
2.2
0.9
0.1
2.1
0.9
0.1
2.9
0.9
0.2
In country
Yes
3000
2000
1000
0
2003
2004
2005
2006
2007
2008
FINANCING
Total budget (US$ millions)
Available funding (US$ millions)
% of budget funded
% available funding from domestic sources
% available funding from Global Fund
2009
2010
2011
2012
91
43
48
31
68
102
63
62
26
74
NTP Budget (blue) and available funding (green) (US$ millions)
125
75
25
2006
2007
2008
2009
2010
2011
2012
Ranges represent uncertainty intervals.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_001_248 97
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
97
23/09/11 07:20
KENYA
POPULATION 2010 (MILLIONS)
ESTIMATES OF BURDEN
Number
2010a
(thousands)
Mortality (excluding HIV)
6.9 (4.9–9.4)
Prevalence (incl HIV)
110 (49–180)
Incidence (incl HIV)
120 (120–130)
Incidence (HIV-positive)
50 (45–55)
Case detection, all forms (%)
82 (79–86)
41
Rate
(per 100 000 pop)
17 (12–23)
283 (122–448)
298 (286–311)
122 (110–135)
200
0
1990
CASE NOTIFICATIONS 2010
New cases
(%)
Smear-positive
Smear-negative
Smear unknown
Extrapulmonary
Other
Total new
Total < 15 years
36 260
31 842
10 120
17 382
0
95 604
5 721
(38)
(33)
(11)
(18)
(0)
Retreatment cases
(%)
Relapse
Treatment after failure
Treatment after default
Other
3 668 (35)
245 (2)
1 502 (14)
5 064 (48)
Total retreatment
Total new and relapse
Total cases notified
INCIDENCE (HIV+TB red), notifications (black)
(rates per 100 000 population)
10 479
99 272
106 083
1995
2005
2010
2000
2005
2010
2000
2005
2010
PREVALENCE
(rate per 100 000 population)
500
200
0
1990
(94% of total)
2000
1995
MORTALITY EXCLUDING HIV
(rate per 100 000 population)
30
DRUG REGIMENS
Rifampicin used throughout treatment
% of patients treated with fixed-dose combinations (FDCs)
Paediatric formulations procured
Yes
100
Yes
TREATMENT SUCCESS RATE 2009 (%)
New smear-positive
New smear-negative/extrapulmonary
Retreatment
86
82
78
TREATMENT SUCCESS RATE (%)
100
New smear +
New smear –/
extrapulmonary
Retreatment
75
50
1995
1997
1999
2001
2003
2005
2007
20
10
0
1990
1995
TB/HIV 2010
TB patients with known HIV status
% of TB patients with known HIV status
TB patients that are HIV-positive
% of tested TB patients that are HIV-positive
% HIV-positive TB patients started on CPT
% HIV-positive TB patients started on ART
HIV-positive people screened for TB
HIV-positive people provided with IPT
96 930
91
40 069
41
100
48
CPT (pink) and ART (brown) for HIV-positive TB patients (blue)
2009
60000
MDR-TB, ESTIMATES AMONG NOTIFIED CASESa
% of new TB cases with MDR-TB
0.0 (0.0–0.70)
% of retreatment TB cases with MDR-TB
0.0 (0.0–6.3)
Estimated MDR-TB cases among new
pulmonary TB cases notified in 2010
0 (0–550)
Estimated MDR-TB cases among retreated
pulmonary TB cases notified in 2010
0 (0–660)
MDR-TB REPORTED CASES 2010
Cases tested for MDR-TB
% of notified tested for MDR-TB
Confirmed cases of MDR-TB
MDR-TB patients started treatment
LABORATORIES
Smear (per 100 000 population)
Culture (per 5 million population)
DST (per 5 million population)
New
40000
20000
0
2003
Retreatment
Total
706
7
103
817
<1
112
118
2009
2010
2011
3.0
0.8
0.5
3.3
0.7
0.5
3.2
0.7
0.6
2004
2005
2006
2007
2008
FINANCING
Total budget (US$ millions)
Available funding (US$ millions)
% of budget funded
% available funding from domestic sources
% available funding from Global Fund
2009
2010
2011
2012
59
30
51
37
49
53
20
38
39
59
NTP Budget (blue) and available funding (green) (US$ millions)
75
50
25
Second-line DST available
National Reference Laboratory
a
98
Outside country
Yes
0
2006
2007
2008
2009
2010
2011
2012
Ranges represent uncertainty intervals.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 98
Data can be downloaded from www.who.int/tb/data
23/09/11 07:20
MOZAMBIQUE
POPULATION 2010 (MILLIONS)
ESTIMATES OF BURDEN
Number
2010a
(thousands)
Mortality (excluding HIV)
11 (7–17)
Prevalence (incl HIV)
110 (54–200)
Incidence (incl HIV)
130 (87–170)
Incidence (HIV-positive)
77 (53–110)
Case detection, all forms (%)
34 (25–50)
23
Rate
(per 100 000 pop)
1000
49 (30–74)
491 (233–844)
544 (374–746)
330 (228–449)
500
0
1990
CASE NOTIFICATIONS 2010
New cases
(%)
Smear-positive
Smear-negative
Smear unknown
Extrapulmonary
Other
Total new
Total < 15 years
20 097 (48)
16 408 (39)
0 (0)
5 621 (13)
0 (0)
42 126
Total new and relapse
Total cases notified
INCIDENCE (HIV+TB red), notifications (black)
(rates per 100 000 population)
Retreatment cases
(%)
Relapse
Treatment after failure
Treatment after default
Other
1 432 (35)
234 (6)
235 (6)
2 147 (53)
Total retreatment
4 048
43 558
46 174
1995
2005
2010
2000
2005
2010
2000
2005
2010
PREVALENCE
(rate per 100 000 population)
2000
1000
0
1990
(94% of total)
2000
1995
MORTALITY EXCLUDING HIV
(rate per 100 000 population)
200
DRUG REGIMENS
Rifampicin used throughout treatment
% of patients treated with fixed-dose combinations (FDCs)
Paediatric formulations procured
Yes
95
Yes
TREATMENT SUCCESS RATE 2009 (%)
New smear-positive
New smear-negative/extrapulmonary
Retreatment
85
TREATMENT SUCCESS RATE (%)
100
New smear +
New smear –/
extrapulmonary
Retreatment
75
50
25
1995
1997
1999
2001
2003
2005
2007
100
0
1990
1995
TB/HIV 2010
TB patients with known HIV status
% of TB patients with known HIV status
TB patients that are HIV-positive
% of tested TB patients that are HIV-positive
% HIV-positive TB patients started on CPT
% HIV-positive TB patients started on ART
HIV-positive people screened for TB
HIV-positive people provided with IPT
40 554
88
24 574
61
97
25
433
8 904
CPT (pink) and ART (brown) for HIV-positive TB patients (blue)
2009
30000
MDR-TB, ESTIMATES AMONG NOTIFIED CASESa
% of new TB cases with MDR-TB
3.5 (2.2–4.8)
% of retreatment TB cases with MDR-TB
11 (0.0–25)
Estimated MDR-TB cases among new
pulmonary TB cases notified in 2010
1 300 (800–1 800)
Estimated MDR-TB cases among retreated
pulmonary TB cases notified in 2010
450 (0–1 000)
MDR-TB REPORTED CASES 2010
Cases tested for MDR-TB
% of notified tested for MDR-TB
Confirmed cases of MDR-TB
MDR-TB patients started treatment
LABORATORIES
Smear (per 100 000 population)
Culture (per 5 million population)
DST (per 5 million population)
Second-line DST available
National Reference Laboratory
a
New
Retreatment
Total
80
<1
18
251
6
130
365
<1
165
87
2009
2010
2011
1.9
0.2
0.2
1.9
0.4
0.4
1.8
0.6
0.6
Outside country
Yes
20000
10000
0
2003
2004
2005
2006
2007
2008
FINANCING
Total budget (US$ millions)
Available funding (US$ millions)
% of budget funded
% available funding from domestic sources
% available funding from Global Fund
2009
2010
2011
2012
34
24
71
11
0
39
24
62
11
12
NTP Budget (blue) and available funding (green) (US$ millions)
50
25
0
2006
2007
2008
2009
2010
2011
2012
Ranges represent uncertainty intervals.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_001_248 99
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
99
23/09/11 07:20
MYANMAR
POPULATION 2010 (MILLIONS)
ESTIMATES OF BURDEN
Number
2010a
(thousands)
Mortality (excluding HIV)
20 (12–31)
Prevalence (incl HIV)
250 (180–310)
Incidence (incl HIV)
180 (160–210)
Incidence (HIV-positive)
37 (21–57)
Case detection, all forms (%)
71 (62–84)
48
Rate
(per 100 000 pop)
41 (25–64)
525 (381–643)
384 (329–443)
77 (43–120)
400
200
0
1990
CASE NOTIFICATIONS 2010
New cases
(%)
Smear-positive
Smear-negative
Smear unknown
Extrapulmonary
Other
Total new
Total < 15 years
42 318 (33)
56 840 (45)
27 976 (22)
Retreatment cases
(%)
Relapse
Treatment after failure
Treatment after default
Other
4 456 (43)
1 495 (15)
514 (5)
3 804 (37)
127 134
302
Total retreatment
10 269
131 590
137 403
2005
2010
2000
2005
2010
2000
2005
2010
1500
1000
Yes
100
Yes
85
83
73
TREATMENT SUCCESS RATE (%)
100
New smear +
New smear –/
extrapulmonary
Retreatment
75
2001
2003
2005
2007
1995
MORTALITY EXCLUDING HIV
(rate per 100 000 population)
120
TREATMENT SUCCESS RATE 2009 (%)
New smear-positive
New smear-negative/extrapulmonary
Retreatment
1999
2000
PREVALENCE
(rate per 100 000 population)
0
1990
(96% of total)
DRUG REGIMENS
Rifampicin used throughout treatment
% of patients treated with fixed-dose combinations (FDCs)
Paediatric formulations procured
1997
1995
500
Total new and relapse
Total cases notified
50
1995
INCIDENCE (HIV+TB red), notifications (black)
(rates per 100 000 population)
80
40
0
1990
1995
TB/HIV 2010
TB patients with known HIV status
% of TB patients with known HIV status
TB patients that are HIV-positive
% of tested TB patients that are HIV-positive
% HIV-positive TB patients started on CPT
% HIV-positive TB patients started on ART
HIV-positive people screened for TB
HIV-positive people provided with IPT
4 362
3
961
22
100
94
6 417
514
CPT (pink) and ART (brown) for HIV-positive TB patients (blue)
2009
6000
MDR-TB, ESTIMATES AMONG NOTIFIED CASESa
% of new TB cases with MDR-TB
4.2 (3.1–5.6)
% of retreatment TB cases with MDR-TB
10 (6.9–14)
Estimated MDR-TB cases among new
pulmonary TB cases notified in 2010
4 200 (3 100–5 600)
Estimated MDR-TB cases among retreated
pulmonary TB cases notified in 2010
1 000 (710–1 400)
MDR-TB REPORTED CASES 2010
Cases tested for MDR-TB
% of notified tested for MDR-TB
Confirmed cases of MDR-TB
MDR-TB patients started treatment
LABORATORIES
Smear (per 100 000 population)
Culture (per 5 million population)
DST (per 5 million population)
Second-line DST available
National Reference Laboratory
a
100
New
Retreatment
Total
192
192
2009
2010
2011
0.9
0.2
0.2
0.9
0.2
0.2
0.9
0.3
0.2
Outside country
Yes
4000
2000
0
2003
2004
2005
2006
2007
2008
FINANCING
Total budget (US$ millions)
Available funding (US$ millions)
% of budget funded
% available funding from domestic sources
% available funding from Global Fund
2009
2010
2011
2012
31
14
45
4
46
29
11
37
6
75
NTP Budget (blue) and available funding (green) (US$ millions)
40
20
0
2006
2007
2008
2009
2010
2011
2012
Ranges represent uncertainty intervals.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 100
Data can be downloaded from www.who.int/tb/data
23/09/11 07:20
NIGERIA
POPULATION 2010 (MILLIONS)
ESTIMATES OF BURDEN
Number
2010a
(thousands)
Mortality (excluding HIV)
33 (11–68)
Prevalence (incl HIV)
320 (110–690)
Incidence (incl HIV)
210 (99–360)
Incidence (HIV-positive)
51 (25–87)
Case detection, all forms (%)
40 (23–85)
158
Rate
(per 100 000 pop)
21 (7.2–43)
199 (70–438)
133 (63–228)
32 (16–55)
(%)
Smear-positive
Smear-negative
Smear unknown
Extrapulmonary
Other
Total new
Total < 15 years
45 416 (56)
32 616 (40)
0 (0)
3 422 (4)
0 (0)
81 454
1 116
Total new and relapse
Total cases notified
600
400
200
0
1990
CASE NOTIFICATIONS 2010
New cases
INCIDENCE (HIV+TB red), notifications (black)
(rates per 100 000 population)
Retreatment cases
(%)
Relapse
Treatment after failure
Treatment after default
Other
2 667 (30)
748 (8)
1 650 (18)
3 928 (44)
Total retreatment
8 993
84 121
90 447
1995
2005
2010
2000
2005
2010
2000
2005
2010
PREVALENCE
(rate per 100 000 population)
1000
500
0
1990
(93% of total)
2000
1995
MORTALITY EXCLUDING HIV
(rate per 100 000 population)
120
DRUG REGIMENS
Rifampicin used throughout treatment
% of patients treated with fixed-dose combinations (FDCs)
Paediatric formulations procured
80
No
100
Yes
TREATMENT SUCCESS RATE 2009 (%)
New smear-positive
New smear-negative/extrapulmonary
Retreatment
83
85
81
TREATMENT SUCCESS RATE (%)
100
New smear +
New smear –/
extrapulmonary
Retreatment
75
50
25
1995
1997
1999
2001
2003
2005
2007
40
0
1990
1995
TB/HIV 2010
TB patients with known HIV status
% of TB patients with known HIV status
TB patients that are HIV-positive
% of tested TB patients that are HIV-positive
% HIV-positive TB patients started on CPT
% HIV-positive TB patients started on ART
HIV-positive people screened for TB
HIV-positive people provided with IPT
71 844
79
17 736
25
59
33
57 082
1 750
CPT (pink) and ART (brown) for HIV-positive TB patients (blue)
2009
20000
MDR-TB, ESTIMATES AMONG NOTIFIED CASESa
% of new TB cases with MDR-TB
2.2 (0.10–5.3)
% of retreatment TB cases with MDR-TB
9.4 (1.9–17)
Estimated MDR-TB cases among new
pulmonary TB cases notified in 2010
1 700 (78–4 100)
Estimated MDR-TB cases among retreated
pulmonary TB cases notified in 2010
850 (170–1 500)
MDR-TB REPORTED CASES 2010
Cases tested for MDR-TB
% of notified tested for MDR-TB
Confirmed cases of MDR-TB
MDR-TB patients started treatment
LABORATORIES
Smear (per 100 000 population)
Culture (per 5 million population)
DST (per 5 million population)
New
Retreatment
Total
27
<1
8
19
<1
11
55
<1
21
23
2009
2010
2011
0.7
0.1
<0.1
0.6
0.2
0.1
0.9
0.2
0.2
10000
0
2003
2004
2005
2006
2007
2008
FINANCING
Total budget (US$ millions)
Available funding (US$ millions)
% of budget funded
% available funding from domestic sources
% available funding from Global Fund
2009
2010
2011
2012
39
28
73
21
54
43
26
61
25
48
NTP Budget (blue) and available funding (green) (US$ millions)
70
50
30
Second-line DST available
National Reference Laboratory
a
Outside country
Yes
10
2006
2007
2008
2009
2010
2011
2012
Ranges represent uncertainty intervals.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_001_248 101
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
101
23/09/11 07:20
PAKISTAN
POPULATION 2010 (MILLIONS)
174
ESTIMATES OF BURDEN
Number
Rate
2010a
(thousands)
(per 100 000 pop)
Mortality (excluding HIV)
58 (39–84)
34 (22–49)
Prevalence (incl HIV)
630 (270–1 100)
364 (154–611)
Incidence (incl HIV)
400 (330–480)
231 (189–277)
Incidence (HIV-positive)
1.2 (0.66–1.9)
0.69 (0.38–1.1)
Case detection, all forms (%)
65 (54–79)
CASE NOTIFICATIONS 2010
New cases
(%)
Smear-positive
Smear-negative
Smear unknown
Extrapulmonary
Other
Total new
Total < 15 years
104 263 (41)
105 623 (41)
0 (0)
45 443 (18)
0 (0)
255 329
24 474
Total new and relapse
Total cases notified
Retreatment cases
(%)
Relapse
Treatment after failure
Treatment after default
Other
5 870 (54)
1 003 (9)
1 527 (14)
2 525 (23)
Total retreatment
10 925
261 199
269 290
No
100
Yes
TREATMENT SUCCESS RATE 2009 (%)
New smear-positive
New smear-negative/extrapulmonary
Retreatment
91
90
82
TREATMENT SUCCESS RATE (%)
0
1995
New smear +
New smear –/
extrapulmonary
Retreatment
1997
1999
2001
2003
2005
2007
200
100
0
1990
1995
2000
2005
2010
2000
2005
2010
2000
2005
2010
PREVALENCE
(rate per 100 000 population)
1000
500
1995
MORTALITY EXCLUDING HIV
(rate per 100 000 population)
80
DRUG REGIMENS
Rifampicin used throughout treatment
% of patients treated with fixed-dose combinations (FDCs)
Paediatric formulations procured
50
300
0
1990
(97% of total)
100
INCIDENCE (HIV+TB red), notifications (black)
(rates per 100 000 population)
40
0
1990
1995
TB/HIV 2010
TB patients with known HIV status
% of TB patients with known HIV status
TB patients that are HIV-positive
% of tested TB patients that are HIV-positive
% HIV-positive TB patients started on CPT
% HIV-positive TB patients started on ART
HIV-positive people screened for TB
HIV-positive people provided with IPT
6 289
2
22
<1
9
CPT (pink) and ART (brown) for HIV-positive TB patients (blue)
2009
40
MDR-TB, ESTIMATES AMONG NOTIFIED CASESa
% of new TB cases with MDR-TB
3.4 (0.80–6.0)
% of retreatment TB cases with MDR-TB
21 (7.3–34)
Estimated MDR-TB cases among new
pulmonary TB cases notified in 2010
7 100 (1 700–13 000)
Estimated MDR-TB cases among retreated
pulmonary TB cases notified in 2010
2 300 (800–3 700)
MDR-TB REPORTED CASES 2010
Cases tested for MDR-TB
% of notified tested for MDR-TB
Confirmed cases of MDR-TB
MDR-TB patients started treatment
LABORATORIES
Smear (per 100 000 population)
Culture (per 5 million population)
DST (per 5 million population)
New
Retreatment
Total
9
<1
9
306
3
306
444
<1
444
424
2009
2010
2011
0.7
0.4
0.3
0.7
0.4
0.3
0.7
0.4
0.3
20
0
2003
2004
2005
2006
2007
2008
FINANCING
Total budget (US$ millions)
Available funding (US$ millions)
% of budget funded
% available funding from domestic sources
% available funding from Global Fund
2009
2010
2011
2012
60
13
22
34
41
64
11
18
25
50
NTP Budget (blue) and available funding (green) (US$ millions)
75
50
25
Second-line DST available
National Reference Laboratory
a
102
In country
Yes
0
2006
2007
2008
2009
2010
2011
2012
Ranges represent uncertainty intervals.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 102
Data can be downloaded from www.who.int/tb/data
23/09/11 07:20
PHILIPPINES
POPULATION 2010 (MILLIONS)
ESTIMATES OF BURDEN
Number
2010a
(thousands)
Mortality (excluding HIV)
31 (21–43)
Prevalence (incl HIV)
470 (410–530)
Incidence (incl HIV)
260 (210–310)
Incidence (HIV-positive)
1 (0.51–1.8)
Case detection, all forms (%)
65 (54–79)
93
Rate
(per 100 000 pop)
33 (22–46)
502 (438–566)
275 (226–329)
1.1 (0.55–1.9)
400
200
0
1990
CASE NOTIFICATIONS 2010
New cases
(%)
Smear-positive
Smear-negative
Smear unknown
Extrapulmonary
Other
Total new
Total < 15 years
89 198 (55)
72 440 (44)
0 (0)
1 610 (<1)
0 (0)
163 248
965
Total new and relapse
Total cases notified
INCIDENCE (HIV+TB red), notifications (black)
(rates per 100 000 population)
Retreatment cases
(%)
Relapse
Treatment after failure
Treatment after default
Other
3 075 (28)
566 (5)
914 (8)
6 586 (59)
1995
2000
2005
2010
2000
2005
2010
2000
2005
2010
PREVALENCE
(rate per 100 000 population)
1200
800
400
Total retreatment
11 141
166 323
174 389
0
1990
(95% of total)
1995
MORTALITY EXCLUDING HIV
(rate per 100 000 population)
60
DRUG REGIMENS
Rifampicin used throughout treatment
% of patients treated with fixed-dose combinations (FDCs)
Paediatric formulations procured
Yes
100
Yes
TREATMENT SUCCESS RATE 2009 (%)
New smear-positive
New smear-negative/extrapulmonary
Retreatment
89
79
61
TREATMENT SUCCESS RATE (%)
100
New smear +
New smear –/
extrapulmonary
Retreatment
60
20
1995
1997
1999
2001
2003
2005
2007
40
20
0
1990
1995
TB/HIV 2010
TB patients with known HIV status
% of TB patients with known HIV status
TB patients that are HIV-positive
% of tested TB patients that are HIV-positive
% HIV-positive TB patients started on CPT
% HIV-positive TB patients started on ART
HIV-positive people screened for TB
HIV-positive people provided with IPT
1 356
<1
0
0
119
16
CPT (pink) and ART (brown) for HIV-positive TB patients (blue)
2009
1.2
MDR-TB, ESTIMATES AMONG NOTIFIED CASESa
% of new TB cases with MDR-TB
4.0 (2.9–5.5)
% of retreatment TB cases with MDR-TB
21 (14–29)
Estimated MDR-TB cases among new
pulmonary TB cases notified in 2010
6 500 (4 700–8 900)
Estimated MDR-TB cases among retreated
pulmonary TB cases notified in 2010
2 300 (1 600–3 200)
MDR-TB REPORTED CASES 2010
Cases tested for MDR-TB
% of notified tested for MDR-TB
Confirmed cases of MDR-TB
MDR-TB patients started treatment
LABORATORIES
Smear (per 100 000 population)
Culture (per 5 million population)
DST (per 5 million population)
Second-line DST available
National Reference Laboratory
a
New
Retreatment
Total
3
<1
2
297
3
232
300
<1
522
548
2009
2010
2011
2.2
0.5
0.2
2.1
0.4
0.1
2.1
1.4
0.2
In country
Yes
0.8
0.4
0
2003
2004
2005
2006
2007
2008
FINANCING
Total budget (US$ millions)
Available funding (US$ millions)
% of budget funded
% available funding from domestic sources
% available funding from Global Fund
2009
2010
2011
2012
81
55
67
55
42
79
48
60
51
49
NTP Budget (blue) and available funding (green) (US$ millions)
100
50
0
2006
2007
2008
2009
2010
2011
2012
Ranges represent uncertainty intervals.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_001_248 103
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
103
23/09/11 07:20
RUSSIAN FEDERATION
POPULATION 2010 (MILLIONS)
ESTIMATES OF BURDEN
Number
2010a
(thousands)
Mortality (excluding HIV)
26 (16–42)
Prevalence (incl HIV)
190 (70–330)
Incidence (incl HIV)
150 (130–180)
Incidence (HIV-positive)
8.1 (6.8–9.4)
Case detection, all forms (%)
78 (67–93)
143
Rate
(per 100 000 pop)
150
18 (11–29)
136 (49–233)
106 (90–124)
5.7 (4.8–6.6)
100
50
0
1990
CASE NOTIFICATIONS 2010
New cases
(%)
Smear-positive
Smear-negative
Smear unknown
Extrapulmonary
Other
Total new
Total < 15 years
31 416 (29)
66 595 (61)
1 299 (1)
3 513 (3)
7 081 (6)
109 904
831
Total new and relapse
Total cases notified
Retreatment cases
(%)
Relapse
8 737 (19)
Treatment after failure
8 197 (18)
Treatment after default 2 897 (6)
Other
26 149 (57)
Total retreatment
45 980
118 641
162 553
Yes
No
TREATMENT SUCCESS RATE 2009 (%)
New smear-positive
New smear-negative/extrapulmonary
Retreatment
55
73
34
TREATMENT SUCCESS RATE (%)
New smear +
New smear –/
extrapulmonary
Retreatment
70
50
1997
1999
2001
2003
2005
2007
LABORATORIES
Smear (per 100 000 population)
Culture (per 5 million population)
DST (per 5 million population)
2000
2005
2010
2000
2005
2010
2000
2005
2010
PREVALENCE
(rate per 100 000 population)
400
200
1995
MORTALITY EXCLUDING HIV
(rate per 100 000 population)
40
0
1990
1995
TB/HIV 2010
TB patients with known HIV status
% of TB patients with known HIV status
TB patients that are HIV-positive
% of tested TB patients that are HIV-positive
% HIV-positive TB patients started on CPT
% HIV-positive TB patients started on ART
HIV-positive people screened for TB
HIV-positive people provided with IPT
199 445
123
10 617
5
82
CPT (pink) and ART (brown) for HIV-positive TB patients (blue)
2009
MDR-TB, ESTIMATES AMONG NOTIFIED CASESa
% of new TB cases with MDR-TB
18 (16–19)
% of retreatment TB cases with MDR-TB
46 (41–52)
Estimated MDR-TB cases among new
pulmonary TB cases notified in 2010
19 000 (17 000–20 000)
Estimated MDR-TB cases among retreated
pulmonary TB cases notified in 2010
21 000 (19 000–24 000)
MDR-TB REPORTED CASES 2010
Cases tested for MDR-TB
% of notified tested for MDR-TB
Confirmed cases of MDR-TB
MDR-TB patients started treatment
1995
0
1990
(73% of total)
DRUG REGIMENS
Rifampicin used throughout treatment
% of patients treated with fixed-dose combinations (FDCs)
Paediatric formulations procured
30
1995
INCIDENCE (HIV+TB red), notifications (black)
(rates per 100 000 population)
10000
5000
0
2003
2004
2005
2006
2007
2008
2009
New
Retreatment
Total
35 862
33
6 218
13 405
29
6 169
49 267
30
13 692
13 692
FINANCING
Total budget (US$ millions)
Available funding (US$ millions)
% of budget funded
% available funding from domestic sources
% available funding from Global Fund
2011
NTP Budget (blue) and available funding (green) (US$ millions)
2009
2010
2.8
13.9
9.5
2.8
13.9
9.5
2010
2011
2012
1 216
1 216
100
100
0
1 204
1 204
100
100
0
1200
700
Second-line DST available
National Reference Laboratory
a
104
In country
No
200
2006
2007
2008
2009
2010
2011
2012
Ranges represent uncertainty intervals.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 104
Data can be downloaded from www.who.int/tb/data
23/09/11 07:20
SOUTH AFRICA
POPULATION 2010 (MILLIONS)
ESTIMATES OF BURDEN
Number
2010a
(thousands)
Mortality (excluding HIV)
25 (16–38)
Prevalence (incl HIV)
400 (180–630)
Incidence (incl HIV)
490 (400–590)
Incidence (HIV-positive)
300 (240–350)
Case detection, all forms (%)
72 (60–88)
50
Rate
(per 100 000 pop)
50 (31–75)
795 (364–1 264)
981 (806–1 173)
591 (488–704)
(%)
Smear-positive
Smear-negative
Smear unknown
Extrapulmonary
Other
Total new
Total < 15 years
132 107
64 692
87 080
52 095
0
335 974
50 474
(39)
(19)
(26)
(16)
(0)
Retreatment cases
(%)
Relapse
18 812 (31)
Treatment after failure
2 671 (4)
Treatment after default 4 921 (8)
Other
34 176 (56)
500
1995
2000
2005
2010
2000
2005
2010
2000
2005
2010
PREVALENCE
(rate per 100 000 population)
1200
800
400
Total retreatment
Total new and relapse
Total cases notified
1000
0
1990
CASE NOTIFICATIONS 2010
New cases
INCIDENCE (HIV+TB red), notifications (black)
(rates per 100 000 population)
60 580
354 786
396 554
0
1990
(89% of total)
1995
MORTALITY EXCLUDING HIV
(rate per 100 000 population)
80
DRUG REGIMENS
Rifampicin used throughout treatment
% of patients treated with fixed-dose combinations (FDCs)
Paediatric formulations procured
Yes
100
Yes
TREATMENT SUCCESS RATE 2009 (%)
New smear-positive
New smear-negative/extrapulmonary
Retreatment
73
64
60
TREATMENT SUCCESS RATE (%)
80
New smear +
New smear –/
extrapulmonary
Retreatment
60
40
1995
1997
1999
2001
2003
2005
2007
40
0
1990
1995
TB/HIV 2010
TB patients with known HIV status
% of TB patients with known HIV status
TB patients that are HIV-positive
% of tested TB patients that are HIV-positive
% HIV-positive TB patients started on CPT
% HIV-positive TB patients started on ART
HIV-positive people screened for TB
HIV-positive people provided with IPT
213 006
54
128 457
60
74
54
758 837
124 049
CPT (pink) and ART (brown) for HIV-positive TB patients (blue)
2009
150000
MDR-TB, ESTIMATES AMONG NOTIFIED CASESa
% of new TB cases with MDR-TB
1.8 (1.4–2.3)
% of retreatment TB cases with MDR-TB
6.7 (5.4–8.2)
Estimated MDR-TB cases among new
pulmonary TB cases notified in 2010
5 100 (4 000–6 500)
Estimated MDR-TB cases among retreated
pulmonary TB cases notified in 2010
4 100 (3 300–5 000)
MDR-TB REPORTED CASES 2010
Cases tested for MDR-TB
% of notified tested for MDR-TB
Confirmed cases of MDR-TB
MDR-TB patients started treatment
LABORATORIES
Smear (per 100 000 population)
Culture (per 5 million population)
DST (per 5 million population)
Second-line DST available
National Reference Laboratory
a
New
Retreatment
50000
0
2003
2004
2005
2006
2007
2008
2009
92 300
23
7 386
5 402
FINANCING
Total budget (US$ millions)
Available funding (US$ millions)
% of budget funded
% available funding from domestic sources
% available funding from Global Fund
NTP Budget (blue) and available funding (green) (US$ millions)
Total
2009
2010
2011
0.5
1.6
1.6
0.5
1.5
1.5
0.5
1.5
1.5
In country
Yes
100000
2011
2010
2012
218
218
100
100
0
400
200
0
2006
2007
2008
2009
2010
2011
2012
Ranges represent uncertainty intervals.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_001_248 105
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
105
23/09/11 07:20
THAILAND
POPULATION 2010 (MILLIONS)
ESTIMATES OF BURDEN
Number
2010a
(thousands)
Mortality (excluding HIV)
11 (7–16)
Prevalence (incl HIV)
130 (55–210)
Incidence (incl HIV)
94 (78–110)
Incidence (HIV-positive)
15 (13–18)
Case detection, all forms (%)
70 (59–85)
69
Rate
(per 100 000 pop)
16 (10–23)
182 (80–300)
137 (112–163)
22 (18–27)
100
0
1990
CASE NOTIFICATIONS 2010
New cases
(%)
Smear-positive
Smear-negative
Smear unknown
Extrapulmonary
Other
Total new
Total < 15 years
33 450 (52)
20 927 (32)
10 135 (16)
0 (0)
64 512
137
Total new and relapse
Total cases notified
Retreatment cases
(%)
Relapse
Treatment after failure
Treatment after default
Other
1 885 (63)
459 (15)
652 (22)
0 (0)
Total retreatment
2 996
66 397
68 239
Yes
25
No
86
80
68
TREATMENT SUCCESS RATE (%)
New smear +
New smear –/
extrapulmonary
Retreatment
80
60
1997
1999
2001
2003
2005
2007
2000
2005
2010
2000
2005
2010
2000
2005
2010
PREVALENCE
(rate per 100 000 population)
400
200
1995
MORTALITY EXCLUDING HIV
(rate per 100 000 population)
30
TREATMENT SUCCESS RATE 2009 (%)
New smear-positive
New smear-negative/extrapulmonary
Retreatment
100
1995
0
1990
(97% of total)
DRUG REGIMENS
Rifampicin used throughout treatment
% of patients treated with fixed-dose combinations (FDCs)
Paediatric formulations procured
40
1995
INCIDENCE (HIV+TB red), notifications (black)
(rates per 100 000 population)
20
10
0
1990
1995
TB/HIV 2010
TB patients with known HIV status
% of TB patients with known HIV status
TB patients that are HIV-positive
% of tested TB patients that are HIV-positive
% HIV-positive TB patients started on CPT
% HIV-positive TB patients started on ART
HIV-positive people screened for TB
HIV-positive people provided with IPT
52 753
77
8 544
16
71
53
25 278
CPT (pink) and ART (brown) for HIV-positive TB patients (blue)
2009
10000
MDR-TB, ESTIMATES AMONG NOTIFIED CASESa
% of new TB cases with MDR-TB
1.7 (1.0–2.6)
% of retreatment TB cases with MDR-TB
35 (28–42)
Estimated MDR-TB cases among new
pulmonary TB cases notified in 2010
920 (540–1 400)
Estimated MDR-TB cases among retreated
pulmonary TB cases notified in 2010
1 000 (840–1 200)
MDR-TB REPORTED CASES 2010
Cases tested for MDR-TB
% of notified tested for MDR-TB
Confirmed cases of MDR-TB
MDR-TB patients started treatment
LABORATORIES
Smear (per 100 000 population)
Culture (per 5 million population)
DST (per 5 million population)
Second-line DST available
National Reference Laboratory
a
106
New
Retreatment
9
2009
2010
2011
1.6
4.7
1.1
1.6
4.7
1.1
1.6
4.7
1.2
In country
Yes
Ranges represent uncertainty intervals.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 106
Total
5000
0
2003
2004
2005
2006
2007
2008
FINANCING
Total budget (US$ millions)
Available funding (US$ millions)
% of budget funded
% available funding from domestic sources
% available funding from Global Fund
2009
2010
2011
2012
45
42
92
81
8
45
42
92
81
8
NTP Budget (blue) and available funding (green) (US$ millions)
50
25
0
2006
2007
2008
2009
2010
2011
2012
Data can be downloaded from www.who.int/tb/data
23/09/11 07:20
UGANDA
POPULATION 2010 (MILLIONS)
ESTIMATES OF BURDEN
2010a
Mortality (excluding HIV)
Prevalence (incl HIV)
Incidence (incl HIV)
Incidence (HIV-positive)
Case detection, all forms (%)
33
Number
(thousands)
Rate
(per 100 000 pop)
5.1 (3.3–7.3)
64 (32–100)
70 (56–85)
38 (30–46)
61 (51–76)
15 (9.9–22)
193 (95–306)
209 (168–254)
112 (91–136)
(%)
Smear-positive
Smear-negative
Smear unknown
Extrapulmonary
Other
Total new
Total < 15 years
23 456 (56)
11 609 (28)
1 958 (5)
4 571 (11)
0 (0)
41 594
669
Total new and relapse
Total cases notified
0
1990
Retreatment cases
(%)
Relapse
Treatment after failure
Treatment after default
Other
1 291 (33)
264 (7)
1 209 (31)
1 188 (30)
Total retreatment
3 952
42 885
45 546
Yes
100
Yes
67
59
70
TREATMENT SUCCESS RATE (%)
New smear +
New smear –/
extrapulmonary
Retreatment
75
50
1997
1999
2001
2003
2005
2007
2000
2005
2010
2000
2005
2010
2000
2005
2010
PREVALENCE
(rate per 100 000 population)
1000
500
1995
MORTALITY EXCLUDING HIV
(rate per 100 000 population)
80
TREATMENT SUCCESS RATE 2009 (%)
New smear-positive
New smear-negative/extrapulmonary
Retreatment
100
1995
0
1990
(94% of total)
DRUG REGIMENS
Rifampicin used throughout treatment
% of patients treated with fixed-dose combinations (FDCs)
Paediatric formulations procured
25
1995
1000
500
CASE NOTIFICATIONS 2010
New cases
INCIDENCE (HIV+TB red), notifications (black)
(rates per 100 000 population)
40
0
1990
1995
TB/HIV 2010
TB patients with known HIV status
% of TB patients with known HIV status
TB patients that are HIV-positive
% of tested TB patients that are HIV-positive
% HIV-positive TB patients started on CPT
% HIV-positive TB patients started on ART
HIV-positive people screened for TB
HIV-positive people provided with IPT
36 724
81
19 836
54
90
24
401 973
CPT (pink) and ART (brown) for HIV-positive TB patients (blue)
2009
20000
MDR-TB, ESTIMATES AMONG NOTIFIED CASESa
% of new TB cases with MDR-TB
1.1 (0.30–2.5)
% of retreatment TB cases with MDR-TB
12 (4.8–23)
Estimated MDR-TB cases among new
pulmonary TB cases notified in 2010
410 (110–930)
Estimated MDR-TB cases among retreated
pulmonary TB cases notified in 2010
46 (190–890)
MDR-TB REPORTED CASES 2010
Cases tested for MDR-TB
% of notified tested for MDR-TB
Confirmed cases of MDR-TB
MDR-TB patients started treatment
LABORATORIES
Smear (per 100 000 population)
Culture (per 5 million population)
DST (per 5 million population)
10000
0
2003
2004
2005
2006
2007
2008
2009
New
Retreatment
Total
358
<1
15
356
9
37
1 623
4
93
10
FINANCING
Total budget (US$ millions)
Available funding (US$ millions)
% of budget funded
% available funding from domestic sources
% available funding from Global Fund
NTP Budget (blue) and available funding (green) (US$ millions)
2009
2010
2011
2.6
0.9
0.6
2.9
1.2
0.6
2.8
1.2
0.6
2010
2011
2012
23
11
48
3
76
20
6
31
5
56
20
10
Second-line DST available
National Reference Laboratory
a
In country
Yes
0
2006
2007
2008
2009
2010
2011
2012
Ranges represent uncertainty intervals.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_001_248 107
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
107
23/09/11 07:20
UNITED REPUBLIC OF TANZANIA
POPULATION 2010 (MILLIONS)
ESTIMATES OF BURDEN
Number
2010a
(thousands)
Mortality (excluding HIV)
5.8 (4.7–6.9)
Prevalence (incl HIV)
82 (39–130)
Incidence (incl HIV)
79 (75–85)
Incidence (HIV-positive)
30 (28–32)
Case detection, all forms (%)
77 (72–82)
45
Rate
(per 100 000 pop)
13 (11–15)
183 (87–281)
177 (166–189)
67 (62–71)
200
100
0
1990
CASE NOTIFICATIONS 2010
New cases
(%)
Smear-positive
Smear-negative
Smear unknown
Extrapulmonary
Other
Total new
Total < 15 years
Retreatment cases
(%)
24 769 (42)
21 184 (36)
0 (0)
13 715 (23)
Relapse
Treatment after failure
Treatment after default
Other
1 430 (38)
96 (3)
255 (7)
2 004 (53)
59 668
5 216
Total retreatment
3 785
Total new and relapse
Total cases notified
INCIDENCE (HIV+TB red), notifications (black)
(rates per 100 000 population)
61 098
63 453
1995
2005
2010
2000
2005
2010
2000
2005
2010
PREVALENCE
(rate per 100 000 population)
400
200
0
1990
(96% of total)
2000
1995
MORTALITY EXCLUDING HIV
(rate per 100 000 population)
40
DRUG REGIMENS
Rifampicin used throughout treatment
% of patients treated with fixed-dose combinations (FDCs)
Paediatric formulations procured
Yes
100
Yes
TREATMENT SUCCESS RATE 2009 (%)
New smear-positive
New smear-negative/extrapulmonary
Retreatment
88
88
83
TREATMENT SUCCESS RATE (%)
90
New smear +
New smear –/
extrapulmonary
Retreatment
80
70
1995
1997
1999
2001
2003
2005
2007
LABORATORIES
Smear (per 100 000 population)
Culture (per 5 million population)
DST (per 5 million population)
Second-line DST available
National Reference Laboratory
a
108
0
1990
1995
TB/HIV 2010
TB patients with known HIV status
% of TB patients with known HIV status
TB patients that are HIV-positive
% of tested TB patients that are HIV-positive
% HIV-positive TB patients started on CPT
% HIV-positive TB patients started on ART
HIV-positive people screened for TB
HIV-positive people provided with IPT
56 849
90
21 662
38
92
35
321 436
CPT (pink) and ART (brown) for HIV-positive TB patients (blue)
2009
MDR-TB, ESTIMATES AMONG NOTIFIED CASESa
% of new TB cases with MDR-TB
1.1 (0.30–2.8)
% of retreatment TB cases with MDR-TB
0.0 (0.0–5.9)
Estimated MDR-TB cases among new
pulmonary TB cases notified in 2010
510 (140–1 300)
Estimated MDR-TB cases among retreated
pulmonary TB cases notified in 2010
0 (0–220)
MDR-TB REPORTED CASES 2010
Cases tested for MDR-TB
% of notified tested for MDR-TB
Confirmed cases of MDR-TB
MDR-TB patients started treatment
20
New
Retreatment
Total
201
<1
9
246
6
22
474
<1
34
17
2009
2010
2011
1.6
0.1
0.1
1.6
0.4
0.2
1.6
0.8
0.3
In and outside country
Yes
20000
10000
0
2003
2004
2005
2006
2007
2008
FINANCING
Total budget (US$ millions)
Available funding (US$ millions)
% of budget funded
% available funding from domestic sources
% available funding from Global Fund
2009
2010
2011
2012
39
19
48
36
30
42
19
46
38
27
NTP Budget (blue) and available funding (green) (US$ millions)
60
30
0
2006
2007
2008
2009
2010
2011
2012
Ranges represent uncertainty intervals.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 108
Data can be downloaded from www.who.int/tb/data
23/09/11 07:20
VIET NAM
POPULATION 2010 (MILLIONS)
ESTIMATES OF BURDEN
Number
2010a
(thousands)
Mortality (excluding HIV)
29 (19–43)
Prevalence (incl HIV)
290 (130–510)
Incidence (incl HIV)
180 (130–220)
Incidence (HIV-positive)
7.6 (4.6–11)
Case detection, all forms (%)
54 (43–71)
88
Rate
(per 100 000 pop)
34 (21–49)
334 (147–576)
199 (152–253)
8.6 (5.2–13)
200
100
0
1990
CASE NOTIFICATIONS 2010
New cases
(%)
Smear-positive
Smear-negative
Smear unknown
Extrapulmonary
Other
Total new
Total < 15 years
52 145 (59)
18 237 (21)
0 (0)
17 651 (20)
0 (0)
88 033
112
Total new and relapse
Total cases notified
Retreatment cases
(%)
Relapse
Treatment after failure
Treatment after default
Other
6 834 (81)
595 (7)
385 (5)
594 (7)
Total retreatment
8 408
94 867
99 022
92
92
73
TREATMENT SUCCESS RATE (%)
New smear +
New smear –/
extrapulmonary
Retreatment
90
80
1997
1999
2001
2003
2005
2007
2000
2005
2010
2000
2005
2010
2000
2005
2010
PREVALENCE
(rate per 100 000 population)
400
1995
MORTALITY EXCLUDING HIV
(rate per 100 000 population)
40
Yes
100
No
TREATMENT SUCCESS RATE 2009 (%)
New smear-positive
New smear-negative/extrapulmonary
Retreatment
100
1995
0
1990
(96% of total)
DRUG REGIMENS
Rifampicin used throughout treatment
% of patients treated with fixed-dose combinations (FDCs)
Paediatric formulations procured
70
1995
INCIDENCE (HIV+TB red), notifications (black)
(rates per 100 000 population)
0
1990
1995
TB/HIV 2010
TB patients with known HIV status
% of TB patients with known HIV status
TB patients that are HIV-positive
% of tested TB patients that are HIV-positive
% HIV-positive TB patients started on CPT
% HIV-positive TB patients started on ART
HIV-positive people screened for TB
HIV-positive people provided with IPT
42 356
43
3 515
8
62
43
1 317
CPT (pink) and ART (brown) for HIV-positive TB patients (blue)
2009
6000
MDR-TB, ESTIMATES AMONG NOTIFIED CASESa
% of new TB cases with MDR-TB
2.7 (2.0–3.7)
% of retreatment TB cases with MDR-TB
19 (14–25)
Estimated MDR-TB cases among new
pulmonary TB cases notified in 2010
1 900 (1 400–2 600)
Estimated MDR-TB cases among retreated
pulmonary TB cases notified in 2010
1 600 (1 200–2 100)
MDR-TB REPORTED CASES 2010
Cases tested for MDR-TB
% of notified tested for MDR-TB
Confirmed cases of MDR-TB
MDR-TB patients started treatment
LABORATORIES
Smear (per 100 000 population)
Culture (per 5 million population)
DST (per 5 million population)
Second-line DST available
National Reference Laboratory
a
New
Retreatment
Total
101
101
2009
2010
2011
0.9
1.3
0.1
0.9
1.3
0.1
0.9
1.4
0.1
In country
Yes
4000
2000
0
2003
2004
2005
2006
2007
2008
FINANCING
Total budget (US$ millions)
Available funding (US$ millions)
% of budget funded
% available funding from domestic sources
% available funding from Global Fund
2009
2010
2011
2012
59
18
31
26
66
74
15
20
31
62
NTP Budget (blue) and available funding (green) (US$ millions)
80
40
0
2006
2007
2008
2009
2010
2011
2012
Ranges represent uncertainty intervals.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_001_248 109
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
109
23/09/11 07:20
ZIMBABWE
POPULATION 2010 (MILLIONS)
ESTIMATES OF BURDEN
2010a
Mortality (excluding HIV)
Prevalence (incl HIV)
Incidence (incl HIV)
Incidence (HIV-positive)
Case detection, all forms (%)
13
Number
(thousands)
Rate
(per 100 000 pop)
3.4 (2.1–5.1)
51 (23–80)
80 (61–100)
60 (47–76)
56 (44–72)
27 (17–40)
402 (185–639)
633 (486–799)
480 (371–603)
800
400
0
1990
CASE NOTIFICATIONS 2010
New cases
(%)
Smear-positive
Smear-negative
Smear unknown
Extrapulmonary
Other
Total new
Total < 15 years
11 654
18 341
6 816
6 061
0
42 872
4 371
(27)
(43)
(16)
(14)
(0)
Total new and relapse
Total cases notified
Retreatment cases
(%)
Relapse
Treatment after failure
Treatment after default
Other
1 337 (29)
135 (3)
157 (3)
3 056 (65)
Total retreatment
4 685
44 209
47 557
78
74
80
TREATMENT SUCCESS RATE (%)
New smear +
New smear –/
extrapulmonary
Retreatment
50
1997
1999
2001
2003
2005
2007
2000
2005
2010
2000
2005
2010
2000
2005
2010
PREVALENCE
(rate per 100 000 population)
400
1995
MORTALITY EXCLUDING HIV
(rate per 100 000 population)
40
Yes
100
Yes
TREATMENT SUCCESS RATE 2009 (%)
New smear-positive
New smear-negative/extrapulmonary
Retreatment
75
1995
0
1990
(93% of total)
DRUG REGIMENS
Rifampicin used throughout treatment
% of patients treated with fixed-dose combinations (FDCs)
Paediatric formulations procured
25
1995
INCIDENCE (HIV+TB red), notifications (black)
(rates per 100 000 population)
20
0
1990
1995
TB/HIV 2010
TB patients with known HIV status
% of TB patients with known HIV status
TB patients that are HIV-positive
% of tested TB patients that are HIV-positive
% HIV-positive TB patients started on CPT
% HIV-positive TB patients started on ART
HIV-positive people screened for TB
HIV-positive people provided with IPT
38 012
80
28 662
75
18
30
CPT (pink) and ART (brown) for HIV-positive TB patients (blue)
2009
30000
MDR-TB, ESTIMATES AMONG NOTIFIED CASESa
% of new TB cases with MDR-TB
1.9 (1.0–3.3)
% of retreatment TB cases with MDR-TB
8.3 (1.8–23)
Estimated MDR-TB cases among new
pulmonary TB cases notified in 2010
700 (370–1 200)
Estimated MDR-TB cases among retreated
pulmonary TB cases notified in 2010
390 (84–1 000)
MDR-TB REPORTED CASES 2010
Cases tested for MDR-TB
% of notified tested for MDR-TB
Confirmed cases of MDR-TB
MDR-TB patients started treatment
LABORATORIES
Smear (per 100 000 population)
Culture (per 5 million population)
DST (per 5 million population)
Second-line DST available
National Reference Laboratory
a
110
New
Retreatment
20000
10000
0
2003
Total
26
<1
17
27
2009
2010
2011
1.0
0.4
0.4
0.9
0.8
0.8
1.4
0.8
0.8
No
Yes
2004
2005
2006
2007
2008
FINANCING
Total budget (US$ millions)
Available funding (US$ millions)
% of budget funded
% available funding from domestic sources
% available funding from Global Fund
2009
2011
2010
2012
26
6
24
5
79
NTP Budget (blue) and available funding (green) (US$ millions)
20
0
2006
2007
2008
2009
2010
2011
2012
Ranges represent uncertainty intervals.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_001_248 110
Data can be downloaded from www.who.int/tb/data
23/09/11 07:20
ANNEX 3
Global, regional and
country-specificc data for
country-specifi
key indicators
1109_0319_P_111_246 111
Summary by WHO region
113
African Region
121
Region of the Americas
145
Eastern Mediterranean Region
169
European Region
185
South-East Asia Region
213
Western Pacific Region
225
05/10/11 09:02
1109_0319_P_111_246 112
05/10/11 09:02
Summary by WHO region
Table A3.1 Estimates of the burden of disease caused by TB, 1990–2010
115
Table A3.2 Incidence, notification and case detection rates, all forms, 1990–2010
116
Table A3.3 Case notifications, 1990–2010
117
Table A3.4 Treatment outcomes, new smear-positive cases, 1995–2009
118
Table A3.5 Treatment outcomes, retreatment cases, 1995–2009
118
Table A3.6 HIV testing and provision of CPT, ART and IPT, 2005–2010
119
Table A3.7 Testing for MDR-TB and number of confirmed cases of MDR-TB, 2005–2010
119
Table A3.8 New smear-positive case notification by age and sex, 1995–2010
120
1109_0319_P_111_246 113
05/10/11 09:02
Estimates of mortality, prevalence and incidence
Estimated values are shown as best estimates followed by lower and upper bounds. The lower and upper bounds are
defi ned as the 2.5th and 97.5th centiles of outcome distributions produced in simulations. See ANNEX 1 for further
details.
Estimated numbers are shown rounded to two significant figures. Estimated rates are shown rounded to three
significant figures unless the value is under 100, in which case rates are shown rounded to two significant figures.
Estimates for all years are recalculated as new information becomes available and techniques are refi ned, so they
may differ from those published in previous reports in this series. Estimates published in previous global TB control
reports should no longer be used.
Data source
Data shown in this annex are taken from the WHO global TB database on 2 September 2011. Data shown in the main
part of the report were taken from the database on 21 June 2011. As a result, data in this annex may differ slightly from
those in the main part of the report.
Data can be downloaded from www.who.int/tb/data.
114
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 114
05/10/11 09:02
7$%/($(VWLPDWHVRIWKHEXUGHQRIGLVHDVHFDXVHGE\7%±
Global
1990
1995
2000
2005
2008
2009
2010
Africa
1990
1995
2000
2005
2008
2009
2010
The Americas 1990
1995
2000
2005
2008
2009
2010
Eastern
1990
Mediterranean 1995
2000
2005
2008
2009
2010
Europe
1990
1995
2000
2005
2008
2009
2010
South-East
1990
Asia
1995
2000
2005
2008
2009
2010
Western
1990
Pacific
1995
2000
2005
2008
2009
2010
a
POPULATION
(MILLIONS)
5 283
5 702
6 097
6 481
6 714
6 792
6 870
507
580
656
742
798
817
837
723
777
834
885
914
924
933
381
433
484
538
573
585
597
846
862
868
880
890
893
896
1 317
1 446
1 572
1 694
1 762
1 785
1 808
1 510
1 605
1 683
1 743
1 777
1 788
1 798
NUMBER
(THOUSANDS)
1 300
1 400
1 300
1 200
1 100
1 100
1 100
180
200
240
250
250
240
250
55
41
32
27
24
21
20
120
130
140
120
95
95
95
110
94
75
72
62
58
61
570
630
670
610
550
520
500
310
260
200
170
140
140
130
(1 200–1 500)
(1 200–1 500)
(1 200–1 500)
(1 100–1 400)
(960–1 300)
(930–1 200)
(920–1 200)
(120–250)
(150–260)
(170–310)
(190–320)
(210–290)
(220–270)
(220–280)
(41–71)
(34–47)
(29–35)
(24–29)
(22–26)
(18–25)
(17–23)
(86–150)
(110–150)
(120–160)
(96–140)
(74–120)
(73–120)
(74–120)
(78–150)
(77–110)
(73–77)
(70–73)
(59–64)
(55–60)
(48–75)
(440–730)
(490–790)
(510–840)
(490–750)
(410–710)
(390–670)
(370–640)
(280–340)
(220–300)
(170–230)
(150–190)
(120–160)
(120–160)
(120–150)
RATEa
25
24
22
19
17
16
15
35
34
36
34
31
30
30
7.5
5.2
3.8
3.0
2.7
2.3
2.2
31
30
29
22
17
16
16
13
11
8.6
8.2
6.9
6.5
6.8
44
44
42
36
31
29
27
20
16
12
9.8
7.9
7.7
7.5
(22–29)
(21–27)
(19–25)
(17–22)
(14–19)
(14–18)
(13–18)
(24–49)
(25–44)
(27–47)
(26–44)
(26–36)
(27–33)
(26–34)
(5.6–9.8)
(4.4–6.1)
(3.5–4.2)
(2.8–3.3)
(2.5–2.9)
(1.9–2.7)
(1.8–2.5)
(23–41)
(26–34)
(25–33)
(18–26)
(13–21)
(13–20)
(12–20)
(9.2–18)
(8.9–13)
(8.4–8.9)
(8.0–8.3)
(6.7–7.2)
(6.2–6.7)
(5.4–8.3)
(33–55)
(34–55)
(33–54)
(29–44)
(23–40)
(22–38)
(21–35)
(18–23)
(14–18)
(10–14)
(8.9–11)
(6.9–8.9)
(6.7–8.7)
(6.6–8.4)
PREVALENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
14 000
15 000
15 000
14 000
13 000
12 000
12 000
1 700
1 900
2 300
2 700
2 700
2 700
2 800
660
540
470
400
360
350
330
1 000
1 100
1 200
1 100
1 000
1 000
1 000
780
710
670
610
580
570
560
6 000
6 700
7 200
6 100
5 400
5 200
5 000
3 800
3 700
3 400
3 000
2 700
2 600
2 500
(13 000–15 000)
(13 000–16 000)
(14 000–17 000)
(13 000–15 000)
(11 000–14 000)
(11 000–14 000)
(11 000–14 000)
(1 200–2 300)
(1 400–2 400)
(1 700–3 100)
(2 100–3 400)
(2 200–3 300)
(2 300–3 200)
(2 300–3 300)
(480–870)
(430–670)
(370–590)
(310–490)
(280–450)
(270–430)
(260–410)
(590–1 500)
(720–1 600)
(760–1 700)
(730–1 600)
(660–1 400)
(670–1 400)
(670–1 500)
(540–1 100)
(550–900)
(500–870)
(460–780)
(440–740)
(430–720)
(430–720)
(5 200–6 900)
(5 800–7 600)
(6 300–8 100)
(5 100–7 100)
(4 300–6 700)
(4 000–6 600)
(3 700–6 500)
(3 500–4 100)
(3 300–4 000)
(3 000–3 800)
(2 600–3 300)
(2 400–3 000)
(2 300–2 900)
(2 200–2 800)
RATE
263
256
250
214
190
183
178
331
325
358
367
342
332
332
92
70
56
45
40
37
36
266
258
248
206
177
175
173
92
83
77
69
65
64
63
457
462
456
359
307
291
278
249
228
201
170
150
143
139
(241–287)
(236–277)
(229–272)
(194–235)
(169–212)
(162–205)
(156–201)
(228–453)
(240–421)
(264–465)
(281–463)
(280–409)
(280–389)
(277–392)
(67–121)
(55–87)
(44–70)
(36–56)
(31–49)
(29–46)
(28–44)
(156–405)
(167–368)
(157–360)
(135–292)
(116–251)
(114–248)
(112–246)
(64–124)
(64–105)
(58–100)
(52–88)
(49–83)
(49–81)
(47–80)
(393–526)
(404–522)
(401–514)
(302–421)
(241–380)
(223–368)
(206–360)
(229–269)
(207–251)
(178–225)
(151–189)
(134–167)
(127–160)
(124–156)
INCIDENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
7 600
8 000
8 600
9 000
8 900
8 800
8 800
1 100
1 400
1 800
2 200
2 300
2 300
2 300
420
380
340
310
280
270
270
460
520
570
610
630
640
650
460
460
490
450
430
430
420
2 800
3 100
3 400
3 600
3 500
3 500
3 500
2 400
2 200
2 000
1 800
1 700
1 700
1 700
(7 000–8 300)
(7 500–8 500)
(8 100–9 100)
(8 500–9 500)
(8 500–9 300)
(8 500–9 200)
(8 500–9 200)
(810–1 400)
(1 100–1 700)
(1 500–2 200)
(1 900–2 600)
(2 100–2 500)
(2 100–2 400)
(2 100–2 500)
(360–490)
(350–410)
(320–360)
(290–330)
(260–300)
(260–290)
(250–280)
(350–580)
(470–580)
(500–630)
(540–680)
(560–710)
(570–720)
(580–730)
(390–530)
(430–500)
(450–530)
(420–490)
(400–460)
(400–450)
(390–450)
(2 500–3 200)
(2 800–3 400)
(3 100–3 600)
(3 300–3 800)
(3 300–3 800)
(3 300–3 800)
(3 200–3 700)
(2 000–2 800)
(1 900–2 500)
(1 800–2 200)
(1 700–2 000)
(1 600–1 900)
(1 600–1 900)
(1 500–1 800)
RATE
144
141
141
139
133
130
128
215
235
279
302
286
279
276
58
49
41
35
31
30
29
120
121
117
113
110
110
109
54
54
56
52
49
48
47
214
215
215
210
201
197
193
157
136
119
105
98
95
93
(132–157)
(132–150)
(133–149)
(131–146)
(127–138)
(125–135)
(123–133)
(160–277)
(189–286)
(227–336)
(257–351)
(260–313)
(261–297)
(256–296)
(50–68)
(45–52)
(38–44)
(32–37)
(29–33)
(28–32)
(27–30)
(92–152)
(108–135)
(104–131)
(100–126)
(98–124)
(97–123)
(97–122)
(46–63)
(50–58)
(52–61)
(48–55)
(45–52)
(45–51)
(44–50)
(187–243)
(195–235)
(199–232)
(194–226)
(186–216)
(182–211)
(179–207)
(132–185)
(118–155)
(106–133)
(95–115)
(89–107)
(87–104)
(85–102)
Summary by WHO region
MORTALITY (EXCLUDING HIV)
YEAR
Rates are per 100 000 population.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 115
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
115
05/10/11 09:02
7$%/($,QFLGHQFHQRWLILFDWLRQDQGFDVHGHWHFWLRQUDWHVDOOIRUPV±
INCIDENCE (INCLUDING HIV)
YEAR
Global
Africa
The Americas
Eastern
Mediterranean
Europe
South-East
Asia
Western
Pacific
116
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
POPULATION
(MILLIONS)
5 283
5 702
6 097
6 481
6 714
6 792
6 870
507
580
656
742
798
817
837
723
777
834
885
914
924
933
381
433
484
538
573
585
597
846
862
868
880
890
893
896
1 317
1 446
1 572
1 694
1 762
1 785
1 808
1 510
1 605
1 683
1 743
1 777
1 788
1 798
NUMBER
(THOUSANDS)
7 600
8 000
8 600
9 000
8 900
8 800
8 800
1 100
1 400
1 800
2 200
2 300
2 300
2 300
420
380
340
310
280
270
270
460
520
570
610
630
640
650
460
460
490
450
430
430
420
2 800
3 100
3 400
3 600
3 500
3 500
3 500
2 400
2 200
2 000
1 800
1 700
1 700
1 700
(7 000–8 300)
(7 500–8 500)
(8 100–9 100)
(8 500–9 500)
(8 500–9 300)
(8 500–9 200)
(8 500–9 200)
(810–1 400)
(1 100–1 700)
(1 500–2 200)
(1 900–2 600)
(2 100–2 500)
(2 100–2 400)
(2 100–2 500)
(360–490)
(350–410)
(320–360)
(290–330)
(260–300)
(260–290)
(250–280)
(350–580)
(470–580)
(500–630)
(540–680)
(560–710)
(570–720)
(580–730)
(390–530)
(430–500)
(450–530)
(420–490)
(400–460)
(400–450)
(390–450)
(2 500–3 200)
(2 800–3 400)
(3 100–3 600)
(3 300–3 800)
(3 300–3 800)
(3 300–3 800)
(3 200–3 700)
(2 000–2 800)
(1 900–2 500)
(1 800–2 200)
(1 700–2 000)
(1 600–1 900)
(1 600–1 900)
(1 500–1 800)
RATEb
144
141
141
139
133
130
128
215
235
279
302
286
279
276
58
49
41
35
31
30
29
120
121
117
113
110
110
109
54
54
56
52
49
48
47
214
215
215
210
201
197
193
157
136
119
105
98
95
93
(132–157)
(132–150)
(133–149)
(131–146)
(127–138)
(125–135)
(123–133)
(160–277)
(189–286)
(227–336)
(257–351)
(260–313)
(261–297)
(256–296)
(50–68)
(45–52)
(38–44)
(32–37)
(29–33)
(28–32)
(27–30)
(92–152)
(108–135)
(104–131)
(100–126)
(98–124)
(97–123)
(97–122)
(46–63)
(50–58)
(52–61)
(48–55)
(45–52)
(45–51)
(44–50)
(187–243)
(195–235)
(199–232)
(194–226)
(186–216)
(182–211)
(179–207)
(132–185)
(118–155)
(106–133)
(95–115)
(89–107)
(87–104)
(85–102)
NOTIFIED NEW AND RELAPSEa
INCIDENCE HIV-POSITIVE
NUMBER
(THOUSANDS)
320
630
940
1 100
1 100
1 100
1 100
280
530
760
930
920
910
900
35
40
39
37
37
36
35
1.0
2.1
4.1
7.3
9.9
11
12
3.1
5.2
11
17
19
23
20
35
110
180
190
170
180
190
4.1
19
24
32
35
34
35
(260–370)
(550–720)
(830–1 100)
(1 000–1 200)
(1 000–1 200)
(1 000–1 200)
(1 000–1 200)
(220–340)
(440–630)
(660–880)
(820–1000)
(830–1000)
(840–980)
(820–980)
(25–48)
(32–49)
(32–47)
(33–40)
(33–41)
(33–40)
(31–38)
(0.37–1.8)
(1.2–3.2)
(3–5.3)
(5.8–9)
(7.8–12)
(8.6–14)
(9.8–15)
(2.6–3.7)
(4.4–6.1)
(9.1–13)
(14–20)
(13–27)
(21–26)
(19–22)
(25–47)
(84–150)
(130–230)
(140–240)
(130–220)
(130–220)
(140–230)
(2.4–6.1)
(12–27)
(18–32)
(24–41)
(26–45)
(26–44)
(26–45)
RATEb
6.0
11
15
17
16
16
16
55
91
116
125
116
111
107
4.9
5.1
4.6
4.2
4.1
3.9
3.7
0.25
0.48
0.85
1.4
1.7
1.9
2.1
0.37
0.61
1.2
1.9
2.2
2.6
2.3
2.7
7.9
11
11
9.9
9.9
10
0.27
1.2
1.4
1.8
2.0
1.9
1.9
NUMBER
(5.0–7.1)
(9.6–13)
(14–17)
(15–19)
(15–18)
(15–17)
(15–17)
(43–68)
(76–108)
(100–133)
(110–141)
(104–127)
(103–120)
(98–117)
(3.4–6.7)
(4.1–6.3)
(3.8–5.6)
(3.8–4.6)
(3.7–4.5)
(3.6–4.3)
(3.4–4.1)
(0.10–0.48)
(0.28–0.74)
(0.62–1.1)
(1.1–1.7)
(1.4–2.1)
(1.5–2.3)
(1.6–2.5)
(0.30–0.44)
(0.52–0.70)
(1.0–1.4)
(1.6–2.2)
(1.4–3.1)
(2.3–2.9)
(2.1–2.5)
(1.9–3.6)
(5.8–10)
(8.5–15)
(8.4–14)
(7.4–13)
(7.6–13)
(7.9–13)
(0.16–0.41)
(0.78–1.7)
(1.1–1.9)
(1.4–2.3)
(1.5–2.5)
(1.4–2.5)
(1.4–2.5)
3 740 193
3 400 391
3 746 813
5 130 297
5 721 861
5 803 185
5 770 498
418 520
504 377
792 911
1 186 801
1 330 146
1 380 577
1 380 417
231 186
258 188
238 580
228 018
218 249
201 606
214 030
234 620
121 745
141 748
287 158
392 633
411 172
411 961
242 429
290 031
373 061
365 088
339 119
328 798
309 818
1 719 365
1 401 096
1 414 228
1 789 186
2 078 238
2 124 371
2 127 973
894 073
824 954
786 285
1 274 046
1 363 476
1 356 661
1 326 300
a
Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
b
Rates are per 100 000 population.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 116
RATEb
71
60
61
79
85
85
84
83
87
121
160
167
169
165
32
33
29
26
24
22
23
62
28
29
53
69
70
69
29
34
43
42
38
37
35
131
97
90
106
118
119
118
59
51
47
73
77
76
74
CASE DETECTION RATEa
PERCENT
49
42
44
57
64
66
65
39
37
43
53
58
61
60
55
68
70
75
77
73
80
51
23
25
47
62
64
63
53
63
76
80
78
77
74
61
45
42
50
59
61
61
38
38
39
70
79
80
79
(45–53)
(40–45)
(41–46)
(54–60)
(62–67)
(63–68)
(63–68)
(30–52)
(30–46)
(36–53)
(46–62)
(53–64)
(57–65)
(56–64)
(47–64)
(63–73)
(65–75)
(70–80)
(72–83)
(69–78)
(75–86)
(41–67)
(21–26)
(22–28)
(42–54)
(55–70)
(57–72)
(56–71)
(46–63)
(58–67)
(71–83)
(75–87)
(73–84)
(72–83)
(69–79)
(54–70)
(41–50)
(39–45)
(47–54)
(55–63)
(56–65)
(57–66)
(32–45)
(33–44)
(35–44)
(64–77)
(72–86)
(73–87)
(73–86)
Data can be downloaded from www.who.int/tb/data
05/10/11 09:02
7$%/($&DVHQRWLILFDWLRQV±
YEAR
Global
• 71
84 •
• 83
165 •
• 32
23 •
• 62
69 •
• 29
35 •
• 131
118 •
• 59
74 •
Africa
The Americas
Eastern
Mediterranean
Europe
South-East
Asia
Western
Pacific
a
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
NEW AND
RELAPSEa
3 740 193
3 400 391
3 746 813
5 130 297
5 721 861
5 803 185
5 770 498
418 520
504 377
792 911
1 186 801
1 330 146
1 380 577
1 380 417
231 186
258 188
238 580
228 018
218 249
201 606
214 030
234 620
121 745
141 748
287 158
392 633
411 172
411 961
242 429
290 031
373 061
365 088
339 119
328 798
309 818
1 719 365
1 401 096
1 414 228
1 789 186
2 078 238
2 124 371
2 127 973
894 073
824 954
786 285
1 274 046
1 363 476
1 356 661
1 326 300
SMEAR- SMEAR-NEGATIVE/
POSITIVE
UNKNOWN
30 046
1 175 290
1 540 720
2 413 732
2 656 275
2 662 565
2 652 481
24 064
212 910
367 831
550 004
595 394
607 257
601 149
1 542
138 932
131 294
124 840
119 862
110 613
116 864
1 587
46 851
60 959
113 765
166 558
168 013
168 627
0
104 444
94 474
96 145
105 160
100 468
88 378
2 769
357 882
510 053
857 371
1 007 382
1 028 656
1 047 013
84
314 271
376 109
671 607
661 919
647 558
630 450
22 393
1 811 850
1 614 819
1 722 343
1 979 978
2 010 610
1 998 265
6 137
191 477
221 715
364 785
446 400
473 217
477 516
516
72 312
60 392
56 056
51 818
45 033
52 223
12 394
51 823
34 289
102 274
137 780
143 633
137 301
0
146 592
208 218
157 299
159 328
152 438
140 984
3 241
939 945
741 471
594 185
635 427
636 755
615 463
105
409 701
348 734
447 744
549 225
559 534
574 778
EXTRAPULMONARY
4 237
262 728
399 615
686 566
786 191
831 388
804 338
2 067
72 689
141 156
208 979
233 576
244 806
247 020
723
32 991
32 037
33 285
33 218
31 422
32 226
754
33 382
40 754
64 612
77 247
87 726
92 070
0
29 866
35 118
49 788
42 899
47 199
38 930
656
76 865
120 708
242 332
310 700
329 338
328 421
37
16 935
29 842
87 570
88 551
90 897
65 671
OTHER RELAPSE
0
5
37
8 111
18 429
9 998
12 865
0
0
0
2 941
1 484
346
642
0
5
37
3 685
3 343
4 363
2 131
0
0
0
12
0
76
633
0
0
0
0
8 858
3 393
7 924
0
0
0
1 439
1 866
1 796
1 508
0
0
0
34
2 878
24
27
734
59 240
115 314
259 937
280 988
288 624
285 795
554
15 133
19 153
60 092
53 292
54 951
53 967
180
1 723
10 834
10 152
10 008
10 175
10 407
0
2 407
5 568
6 495
11 048
11 724
11 203
0
7 927
21 607
22 248
22 874
25 300
24 139
0
5 546
27 095
93 859
122 863
127 826
130 714
0
26 504
31 057
67 091
60 903
58 648
55 365
RE-TREAT EXCL. TOTAL
HISTORY
RELAPSE
RETREAT UNKNOWN
49
0
236 113
406 424
495 112
385 181
416 917
49
0
68 085
66 449
82 971
89 377
94 506
0
0
14 344
12 481
13 193
11 317
12 123
0
0
0
5 334
5 393
6 240
8 606
0
0
19 166
64 900
112 511
41 833
59 699
0
0
80 444
158 215
209 433
203 598
208 542
0
0
54 074
99 045
71 611
32 816
33 441
783
59 240
351 427
666 361
776 100
673 805
702 712
603
15 133
87 238
126 541
136 263
144 328
148 473
180
1 723
25 178
22 633
23 201
21 492
22 530
0
2 407
5 568
11 829
16 441
17 964
19 809
0
7 927
40 773
87 148
135 385
67 133
83 838
0
5 546
107 539
252 074
332 296
331 424
339 256
0
26 504
85 131
166 136
132 514
91 464
88 806
29
44
56
18 039
16 851
36 693
25 934
0
0
0
2 075
4 607
305
317
29
44
56
2 106
232
3 829
885
0
0
0
20
18
737
3 186
0
0
0
3 530
8 021
24 989
15 508
0
0
0
202
132
261
1 118
0
0
0
10 106
3 841
6 572
4 920
% SMEARPOS AMONG
NEW PULM
57
39
49
58
57
57
57
80
53
62
60
57
56
56
75
66
68
69
70
71
69
11
47
64
53
55
54
55
–
42
31
38
40
40
39
46
28
41
59
61
62
63
44
43
52
60
55
54
52
Summary by WHO region
NEW CASES
NEW AND RELAPSE
NOTIFICATION RATEa
1990–2010
Rates are per 100 000 population. Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 117
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
117
05/10/11 09:02
7$%/($7UHDWPHQWRXWFRPHVQHZVPHDUSRVLWLYHFDVHV±
% OF COHORT
TREATMENT SUCCESS (%)a
1995–2009
Global
• 57
87 •
• 60
80 •
• 50
76 •
• 79
88 •
• 67
68 •
• 33
89 •
• 80
93 •
Africa
The Americas
Eastern
Mediterranean
Europe
South-East
Asia
Western
Pacific
a
YEAR
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
NUMBER
NOTIFIED
1 175 290
1 540 720
2 413 732
2 586 522
2 656 275
2 662 565
212 910
367 831
550 004
566 988
595 394
607 257
138 932
131 294
124 840
119 838
119 862
110 613
46 851
60 959
113 765
155 572
166 558
168 013
104 444
94 474
96 145
105 271
105 160
100 468
357 882
510 053
857 371
972 441
1 007 382
1 028 656
314 271
376 109
671 607
666 412
661 919
647 558
SIZE OF
COHORT
1 000 581
1 452 991
2 396 387
2 590 608
2 648 749
2 658 344
177 567
364 804
563 750
576 752
590 866
605 932
128 531
110 642
118 840
115 636
109 007
122 391
46 318
63 749
113 742
155 658
166 719
167 317
33 823
41 480
81 410
108 175
114 234
99 224
318 410
512 286
855 962
973 507
1 011 353
1 022 380
295 932
360 030
662 683
660 880
656 570
641 100
COHORT AS
% NOTIFIED
85
94
99
100
100
100
83
99
102
102
99
100
93
84
95
96
91
111
99
105
100
100
100
100
32
44
85
103
109
99
89
100
100
100
100
99
94
96
99
99
99
99
CURED
40
60
77
79
79
80
46
59
62
68
70
70
37
60
55
57
56
53
60
69
72
75
74
74
58
47
59
59
54
58
9
44
83
84
84
85
67
85
89
89
89
90
COMPLETED
17
9
7
7
7
7
14
12
13
11
11
10
14
17
24
22
21
23
19
12
11
12
13
14
10
28
13
12
15
10
23
6
4
4
4
3
13
5
3
3
3
3
DIED
3
4
4
4
4
4
6
7
7
6
6
5
3
5
5
5
5
5
2
4
3
3
2
3
6
5
8
8
8
8
1
2
4
4
4
4
2
2
2
2
2
2
FAILED
1
1
2
2
2
2
2
1
1
1
2
1
1
1
1
1
1
1
3
2
1
1
1
1
6
6
7
9
10
12
0
1
2
2
2
2
1
1
1
1
1
1
DEFAULTED
5
7
5
5
5
4
12
11
9
7
7
6
6
8
7
7
7
8
13
8
8
5
5
5
4
6
7
7
6
7
2
7
6
5
5
5
4
2
1
1
1
1
NOT
EVALUATED
34
19
4
4
4
4
20
10
7
6
6
7
39
11
9
8
10
11
4
6
5
4
4
3
16
7
5
5
6
5
64
40
1
1
1
1
13
4
3
4
4
3
TREATMENT SUCCESS = percent cured + percent completed then rounded to the nearest digit.
7$%/($7UHDWPHQWRXWFRPHVUHWUHDWPHQWFDVHV±
% OF COHORT
TREATMENT SUCCESS (%)a
1995–2009
Global
• 86
72 •
• 69
70 •
• 72
50 •
• 75
77 •
• 40
48 •
• 68
75 •
• 90
86 •
Africa
The Americas
Eastern
Mediterranean
Europe
South-East
Asia
Western
Pacific
a
118
YEAR
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
NUMBER
NOTIFIED
59 240
351 427
666 361
767 155
776 100
673 805
15 133
87 238
126 541
134 133
136 263
144 328
1 723
25 178
22 633
21 038
23 201
21 492
2 407
5 568
11 829
13 898
16 441
17 964
7 927
40 773
87 148
148 613
135 385
67 133
5 546
107 539
252 074
310 029
332 296
331 424
26 504
85 131
166 136
139 444
132 514
91 464
SIZE OF
COHORT
COHORT AS
% NOTIFIED
71 395
188 509
546 182
533 643
594 939
592 460
5 756
44 147
114 838
113 504
98 414
94 342
1 104
15 302
18 603
18 975
15 483
19 146
1 860
4 217
12 860
14 372
14 990
16 332
480
10 739
39 497
69 300
60 077
57 419
3 271
59 337
254 378
227 767
323 436
332 286
58 924
54 767
106 006
89 725
82 539
72 935
121
54
82
70
77
88
38
51
91
85
72
65
64
61
82
90
67
89
77
76
109
103
91
91
6
26
45
47
44
86
59
55
101
73
97
100
222
64
64
64
62
80
CURED
82
60
51
58
50
49
57
47
35
52
48
50
61
47
38
35
29
29
61
51
60
60
57
56
20
39
32
28
30
27
62
57
49
63
47
48
88
83
81
79
80
79
COMPLETED
4
10
19
10
22
23
12
11
27
16
21
20
11
8
16
23
23
22
14
11
15
17
19
21
20
19
18
24
18
21
6
14
22
3
28
27
2
3
6
7
6
7
DIED
3
6
7
7
7
7
9
9
11
7
9
9
6
5
6
7
8
8
3
6
5
4
4
4
11
9
11
11
11
11
4
6
7
7
7
7
3
2
3
3
3
3
FAILED
3
4
4
6
5
6
3
3
3
4
3
3
4
3
2
3
2
3
4
7
4
3
3
3
8
14
13
19
20
23
5
5
5
5
4
4
3
2
3
3
2
2
DEFAULTED
3
11
12
11
11
10
12
16
13
10
10
9
11
12
15
18
20
19
12
15
10
10
11
10
32
11
14
12
12
11
15
15
15
13
12
12
1
1
2
2
2
2
NOT
EVALUATED
4
10
6
8
5
5
6
14
12
11
9
10
8
25
21
15
17
21
5
11
6
5
6
6
8
8
10
7
9
7
8
3
2
8
2
2
3
9
6
6
7
7
TREATMENT SUCCESS = percent cured + percent completed then rounded to the nearest digit.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 118
Data can be downloaded from www.who.int/tb/data
05/10/11 09:02
7$%/($+,9WHVWLQJDQGSURYLVLRQRI&37$57DQG,37 –
YEAR
Global
•8
35 •
• 11
59 •
• 35
46 •
•1
11 •
• 41
85 •
•2
23 •
•2
19 •
Africa
The Americas
Eastern
Mediterranean
Europe
South-East
Asia
Western
Pacific
% OF TB
NUMBER OF TB
PATIENTS WITH PATIENTS WITH
KNOWN HIV
KNOWN HIV
STATUS
STATUS
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
8.5
22
29
35
11
47
56
59
35
44
50
46
<1
6
11
11
41
77
83
85
2
4
14
23
2
11
12
19
470 128
1 380 408
1 784 325
2 150 116
140 713
664 034
816 338
876 918
84 032
101 487
108 010
103 557
2 582
24 280
45 408
45 969
178 349
353 550
328 648
317 466
31 847
84 113
318 237
540 660
32 605
152 944
167 684
265 546
PATIENTS
NOTIFIED
(NEW AND
RETREAT)
NUMBER OF HIV- % OF TESTED
POSITIVE TB
TB PATIENTS
PATIENTS
HIV-POSITIVE
5 554 760
6 233 824
6 225 059
6 196 595
1 255 325
1 417 724
1 470 259
1 475 117
242 605
231 674
216 752
226 859
292 512
398 044
418 149
421 626
433 518
459 651
395 620
375 562
1 947 603
2 287 803
2 328 230
2 332 779
1 383 197
1 438 928
1 396 049
1 364 652
103 683
372 092
465 978
488 446
73 332
312 218
370 245
388 137
14 232
16 953
18 148
18 157
330
1 158
1 625
1 565
6 543
12 611
15 643
17 182
7 025
18 601
46 089
50 985
2 221
10 551
14 228
12 420
% OF HIV% OF HIVNUMBER OF HIVPOSITIVE
POSITIVE TB POSITIVE TB
PEOPLE
PATIENTS ON PATIENTS ON
PROVIDED IPT
CPT
ART
22
27
26
23
52
47
45
44
17
17
17
18
15
5
4
3
3
3
5
5
22
22
14
9
7
7
8
5
77
72
77
77
78
74
77
76
22
33
36
47
18
42
41
51
26
63
51
48
50
59
86
87
32
55
64
55
36
32
39
46
29
30
36
42
85
67
61
65
16
43
41
37
16
32
62
70
31
37
50
57
51
28
16
41
25 938
50 883
89 083
178 242
22 211
25 553
63 290
156 066
3 727
11 728
5 390
12 804
0
702
464
253
0
12 003
17 826
6 575
0
208
467
581
0
689
1 646
1 963
7$%/($7HVWLQJIRU0'57%DQGQXPEHURIFRQILUPHGFDVHVRI0'57%±
YEAR
Global
Africa
The Americas
Eastern
Mediterranean
Europe
South-East
Asia
Western
Pacific
a
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
TOTAL
CONFIRMED
CASES OF
MDR-TBa
11 988
31 077
46 897
55 112
2 445
9 543
10 741
9 750
4 427
2 227
2 884
2 646
350
555
496
886
4 347
15 845
28 157
33 598
68
1 717
2 560
3 937
351
1 190
2 059
4 295
NEW CASES
NOTIFIED
4 830 752
5 440 873
5 514 561
5 467 949
1 126 709
1 276 854
1 325 626
1 326 327
217 866
208 241
191 431
203 444
280 663
381 585
399 448
398 631
303 232
316 245
303 498
276 216
1 695 327
1 955 375
1 996 545
1 992 405
1 206 955
1 302 573
1 298 013
1 270 926
PREVIOUSLY TREATED CASES
NUMBER OF
% OF NOTIFIED
NUMBER OF
NOTIFIED TESTED TESTED FOR CONFIRMED CASES
FOR MDR-TB
MDR-TB
OF MDR-TB
62 806
100 500
111 101
112 920
1 826
2 566
3 878
2 732
4 504
12 460
11 513
10 229
1 442
2 089
1 760
2 397
34 527
78 323
87 815
84 413
661
902
950
1 073
19 846
4 160
5 185
12 076
1
2
2
2
0
0
0
0
2
6
6
5
1
1
0
1
11
25
29
31
0
0
0
0
2
0
0
1
Summary by WHO region
% OF TB PATIENTS WITH
KNOWN HIV STATUS
2005–2010
1 909
8 856
12 879
12 686
277
177
372
248
212
352
992
226
30
92
80
104
1 334
8 177
10 328
11 646
9
22
10
19
47
36
1 097
443
NOTIFIED
666 361
776 100
673 805
702 712
126 541
136 263
144 328
148 473
22 633
23 201
21 492
22 530
11 829
16 441
17 964
19 809
87 148
135 385
67 133
83 838
252 074
332 296
331 424
339 256
166 136
132 514
91 464
88 806
NUMBER OF NOTIFIED
TESTED FOR MDR-TB
% OF NOTIFIED
NUMBER OF
TESTED FOR CONFIRMED CASES
MDR-TB
OF MDR-TB
23 497
41 559
42 294
46 737
3 922
9 614
4 340
4 294
10 498
4 286
3 056
4 182
94
1 555
1 274
1 257
7 024
21 098
27 618
33 696
420
2 823
5 069
1 264
1 539
2 183
937
2 044
4
5
6
7
3
7
3
3
46
18
14
19
1
9
7
6
8
16
41
40
0
1
2
0
1
2
1
2
7 047
11 742
16 284
22 875
2 073
957
1 191
1 359
3 052
1 517
1 135
1 216
46
334
395
575
1 711
7 173
10 463
16 522
25
875
2 538
705
140
886
562
2 498
TOTAL CONFIRMED CASES OF MDR-TB includes cases with unknown previous treatment history (i.e. not included under NEW CASES or PREVIOUSLY TREATED CASES).
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 119
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
119
05/10/11 09:02
7$%/($1HZVPHDUSRVLWLYHFDVHQRWLILFDWLRQE\DJHDQGVH[±
MALE
Global
Africa
The Americas
Eastern
Mediterranean
Europe
South-East
Asia
Western
Pacific
120
YEAR
0–14
15–24
25–34
35–44
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
7 491
12 387
18 414
20 221
2 910
3 625
7 635
8 393
437
3 464
1 520
1 050
2 010
1 339
1 546
2 316
553
201
298
138
165
2 453
5 064
6 737
1 416
1 305
2 351
1 587
48 816
115 250
242 358
268 684
16 754
29 522
54 066
57 146
2 888
18 564
16 410
11 456
6 796
8 135
13 558
19 526
3 588
4 636
6 172
7 124
3 179
30 093
94 638
114 806
15 611
24 300
57 514
58 626
76 799
172 897
329 719
345 525
28 172
47 654
94 388
98 636
3 443
21 869
16 671
14 246
8 673
9 002
14 609
19 993
7 046
8 323
9 150
12 868
6 467
45 720
120 560
136 683
22 998
40 329
74 341
63 099
65 678
156 274
312 528
336 494
20 240
34 435
71 072
78 660
3 157
19 787
14 369
11 297
5 475
6 525
10 798
14 908
10 157
9 862
9 152
11 995
6 508
47 107
122 256
142 080
20 141
38 558
84 881
77 554
FEMALE
65+
UNKNOWN
49 514 41 756 34 776
121 277 82 843 75 158
261 234 184 836 166 858
298 313 227 237 186 553
12 017
7 008
4 104
17 923
8 970
5 751
40 974 18 931 12 143
48 543 24 094 14 478
2 448
1 866
2 251
15 138
9 899
9 717
12 340
7 801
7 951
10 608
7 428
7 074
3 731
3 732
2 604
4 409
2 990
3 036
8 729
6 581
5 595
13 086 10 596
9 521
7 625
5 716
4 842
8 065
4 312
3 323
8 705
4 443
4 089
11 887
6 628
3 873
5 241
4 682
3 523
38 058 25 080 16 208
107 228 74 084 45 533
132 411 101 728 67 131
18 452 18 752 17 452
37 684 31 592 37 123
83 258 72 996 91 547
81 778 76 763 84 476
0
0
42
7 502
0
0
0
17
0
0
0
59
0
0
0
0
0
0
42
7 423
0
0
0
0
0
0
0
3
45–54
55–64
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 120
45–54
55–64
65+
UNKNOWN
7 730 41 378 50 102 32 741 22 688
14 749 94 642 110 307 74 706 49 823
26 178 199 700 220 530 153 503 106 029
28 792 210 567 225 765 163 084 118 438
3 167 15 873 19 005 11 339
6 643
4 315 29 530 35 386 20 037
9 402
10 023 57 115 75 056 43 213 22 855
10 287 55 537 76 051 47 070 26 299
431
2 293
2 434
1 654
1 109
3 535 15 305 14 961 10 323
7 294
1 718 12 405 11 563
7 891
5 933
1 136
8 401
8 490
5 808
4 874
1 881
5 035
5 797
3 679
3 047
1 711
6 710
5 780
3 922
2 851
2 766 13 529 12 098
8 386
6 245
4 377 21 108 17 151 12 183
9 776
548
2 906
3 636
2 594
1 549
290
3 507
4 406
2 946
1 798
422
4 667
5 101
3 161
2 242
269
4 800
6 344
4 052
2 930
250
2 187
2 834
2 404
2 003
3 222 21 518 25 653 19 241 13 019
8 591 71 923 76 779 54 000 37 709
10 923 84 006 84 704 63 272 48 470
1 453 13 084 16 396 11 071
8 337
1 676 18 072 24 121 18 237 15 459
2 658 40 061 39 933 36 852 31 045
1 800 36 715 33 025 30 699 26 089
17 816
33 696
72 023
86 190
3 655
4 581
11 047
13 522
912
5 038
3 788
3 465
2 742
2 039
4 383
7 532
1 560
1 243
1 337
1 961
1 866
8 142
24 289
34 052
7 081
12 653
27 179
25 658
16 686
33 830
65 717
75 169
1 734
2 578
7 163
8 685
1 311
5 894
4 751
4 060
1 902
1 893
3 399
7 032
3 289
2 491
3 176
3 207
1 480
5 468
12 975
20 004
6 970
15 506
34 253
32 181
0
0
15
2 595
0
0
0
9
0
0
0
22
0
0
0
0
0
0
15
2 561
0
0
0
0
0
0
0
3
0–14
15–24
25–34
35–44
MALE/FEMALE
RATIO
1.7
1.8
1.8
1.9
1.5
1.4
1.3
1.4
1.6
1.6
1.6
1.7
1.4
1.4
1.2
1.1
2.5
2.3
2.1
2.4
2.3
2.1
2.0
2.0
1.8
2.0
2.2
2.4
Data can be downloaded from www.who.int/tb/data
05/10/11 09:02
African Region
Table A3.1 Estimates of the burden of disease caused by TB, 1990–2010
123
Table A3.2 Incidence, notification and case detection rates, all forms, 1990–2010
126
Table A3.3 Case notifications, 1990–2010
129
Table A3.4 Treatment outcomes, new smear-positive cases, 1995–2009
132
Table A3.5 Treatment outcomes, retreatment cases, 1995–2009
135
Table A3.6 HIV testing and provision of CPT, ART and IPT, 2005–2010
138
Table A3.7 Testing for MDR-TB and number of confirmed cases of MDR-TB, 2005–2010
140
Table A3.8 New smear-positive case notification by age and sex, 1995–2010
142
Table A3.9 Laboratories, NTP services, drug management, human resources and infection
control, 2010
144
1109_0319_P_111_246 121
05/10/11 09:02
Estimates of mortality, prevalence and incidence
Estimated values are shown as best estimates followed by lower and upper bounds. The lower and upper bounds are
defi ned as the 2.5th and 97.5th centiles of outcome distributions produced in simulations. See ANNEX 1 for further
details.
Estimated numbers are shown rounded to two significant figures. Estimated rates are shown rounded to three
significant figures unless the value is under 100, in which case rates are shown rounded to two significant figures.
Estimates for all years are recalculated as new information becomes available and techniques are refi ned, so they
may differ from those published in previous reports in this series. Estimates published in previous global TB control
reports should no longer be used.
Data source
Data shown in this annex are taken from the WHO global TB database on 2 September 2011. Data shown in the main
part of the report were taken from the database on 21 June 2011. As a result, data in this annex may differ slightly from
those in the main part of the report.
Data can be downloaded from www.who.int/tb/data.
122
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 122
05/10/11 09:02
7$%/($(VWLPDWHVRIWKHEXUGHQRIGLVHDVHFDXVHGE\7%±
Algeria
Angola
Benin
Botswana
Burkina Faso
Burundi
Cameroon
Cape Verde
Central African
Republic
Chad
Comoros
Congo
Côte d'Ivoire
Democratic
Republic
of the Congo
Equatorial
Guinea
a
POPULATION
(MILLIONS)
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
25
28
31
33
34
35
35
10
12
14
16
18
19
19
5
6
7
8
8
9
9
1
2
2
2
2
2
2
9
11
12
14
16
16
16
6
6
6
7
8
8
8
12
14
16
18
19
19
20
<1
<1
<1
<1
<1
<1
<1
3
3
4
4
4
4
4
6
7
8
10
11
11
11
<1
<1
<1
<1
<1
<1
<1
2
3
3
4
4
4
4
13
15
17
18
19
19
20
36
44
50
57
62
64
66
<1
<1
<1
<1
<1
<1
<1
NUMBER
(THOUSANDS)
2.3
2.5
3.8
4.2
3.8
4.2
4.3
3.9
5.9
6.0
3.5
5.2
5.7
6.5
0.61
0.74
0.88
1.1
1.2
1.3
1.4
1.2
1.3
0.93
0.57
0.5
0.43
0.43
0.9
0.9
1.4
1.8
1.6
1.5
1.3
1.1
1.6
1.4
1.6
1.5
1.3
1.1
1.4
2.7
3.9
3.5
2.8
2.8
2.8
0.14
0.14
0.16
0.15
0.15
0.14
0.14
0.62
0.67
1.3
1.9
1.6
1.6
1.5
1.5
2.6
4.1
5.9
5.6
5.4
5.3
0.085
0.076
0.065
0.065
0.056
0.055
0.053
1
1.1
1.3
2.1
2.2
2.1
2
3.3
3.3
4
3.5
2.5
2.2
2.1
28
32
33
32
34
35
36
0.022
0.025
0.035
0.044
0.061
0.046
0.039
(1.2–4.2)
(1.2–4.7)
(1.9–6.6)
(2.1–7.5)
(1.8–6.9)
(2.1–7.5)
(2.1–7.7)
(1.8–7.2)
(4.4–7.5)
(4.2–8.1)
(2.2–6)
(3.2–8.3)
(3.5–8.9)
(4.1–9.6)
(0.24–1.2)
(0.5–1)
(0.62–1.2)
(0.76–1.5)
(0.86–1.6)
(0.93–1.7)
(1–1.8)
(0.34–2.8)
(0.64–2.1)
(0.57–1.4)
(0.36–0.85)
(0.39–0.64)
(0.31–0.59)
(0.31–0.57)
(0.57–1.3)
(0.59–1.3)
(0.98–1.9)
(1.3–2.4)
(1.2–2.1)
(1.1–1.9)
(0.99–1.7)
(0.63–1.9)
(1.2–2.2)
(0.99–2)
(1.2–2.1)
(1.1–1.9)
(0.95–1.7)
(0.84–1.5)
(0.57–2.8)
(2–3.5)
(2.8–5.1)
(2.2–5.3)
(1.8–4.2)
(1.8–4.2)
(1.8–4.1)
(0.066–0.23)
(0.11–0.19)
(0.11–0.2)
(0.11–0.19)
(0.11–0.2)
(0.1–0.19)
(0.1–0.19)
(0.26–1.2)
(0.41–1)
(0.88–1.7)
(1.4–2.5)
(1–2.3)
(1–2.2)
(0.99–2.2)
(0.77–2.5)
(2–3.4)
(3.1–5.3)
(4.5–7.4)
(4.2–7.3)
(4–7)
(3.9–6.8)
(0.045–0.14)
(0.057–0.098)
(0.047–0.085)
(0.049–0.084)
(0.041–0.074)
(0.04–0.072)
(0.039–0.07)
(0.6–1.6)
(0.74–1.5)
(0.88–1.9)
(1.4–3.1)
(1.5–3.1)
(1.4–3)
(1.3–2.9)
(1.6–5.8)
(1.9–5)
(2.6–5.7)
(2.2–5.2)
(1.6–3.7)
(1.5–3.1)
(1.4–3.2)
(22–36)
(25–41)
(25–41)
(24–41)
(26–44)
(27–44)
(27–45)
(0.02–0.025)
(0.023–0.03)
(0.03–0.043)
(0.037–0.055)
(0.052–0.073)
(0.039–0.056)
(0.031–0.049)
RATEa
9.2
8.7
12
13
11
12
12
38
49
43
21
29
31
34
13
13
14
14
14
15
16
87
80
53
30
26
22
21
9.7
8.5
12
13
10
9.1
8.1
20
27
23
23
19
16
14
11
19
25
20
15
15
14
39
36
35
32
31
29
28
21
20
34
47
37
37
34
25
38
50
60
53
49
47
19
15
11
10
8.1
7.6
7.3
43
39
42
61
57
54
49
26
22
24
19
13
11
11
78
73
66
56
55
54
54
5.9
5.8
6.8
7.3
9.2
6.7
5.5
(4.6–16)
(4.2–16)
(6.3–22)
(6.5–23)
(5.3–20)
(6–21)
(6–22)
(17–69)
(37–62)
(30–58)
(13–36)
(18–46)
(19–48)
(22–51)
(5.1–25)
(8.9–18)
(9.5–18)
(10–19)
(10–19)
(11–20)
(11–20)
(24–204)
(41–134)
(32–80)
(19–45)
(20–33)
(16–30)
(15–28)
(6.1–14)
(5.5–12)
(8–16)
(8.8–17)
(7.6–13)
(6.9–12)
(6–11)
(11–33)
(19–36)
(16–31)
(17–30)
(14–24)
(12–21)
(10–18)
(4.7–23)
(14–25)
(18–32)
(13–30)
(9.6–23)
(9.3–22)
(9–21)
(19–67)
(27–48)
(26–46)
(23–41)
(22–41)
(21–39)
(21–38)
(9–40)
(12–31)
(24–47)
(34–63)
(24–53)
(24–52)
(22–50)
(13–42)
(28–49)
(38–64)
(46–76)
(40–68)
(37–64)
(35–61)
(10–32)
(12–20)
(8.4–15)
(7.6–13)
(5.9–11)
(5.6–10)
(5.4–9.5)
(25–65)
(27–53)
(28–61)
(40–87)
(38–81)
(36–76)
(32–71)
(13–46)
(13–34)
(16–35)
(12–29)
(8.6–19)
(7.5–16)
(7–16)
(60–99)
(56–92)
(50–84)
(42–72)
(42–71)
(42–69)
(41–69)
(5.3–6.8)
(5.1–6.8)
(5.8–8.3)
(6–9)
(7.9–11)
(5.7–8.2)
(4.5–7)
PREVALENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
26
29
41
47
43
47
48
37
52
58
53
68
72
78
6.1
7.3
8.6
11
12
13
13
11
13
12
9.8
8.6
7.9
7.6
8
8.2
13
16
15
14
13
12
15
15
17
16
15
14
15
24
35
40
37
37
36
1.2
1.3
1.4
1.4
1.4
1.3
1.3
6.2
7.2
12
18
17
17
17
14
23
35
50
49
48
47
0.75
0.68
0.6
0.58
0.52
0.51
0.5
8.4
11
15
23
23
23
22
31
33
41
40
34
31
31
240
280
300
310
340
340
350
0.34
0.41
0.61
0.83
1
0.83
0.85
(9.4–48)
(9.8–54)
(16–76)
(17–87)
(15–81)
(17–86)
(18–89)
(14–75)
(24–85)
(27–95)
(17–93)
(26–120)
(28–120)
(32–130)
(2.1–13)
(3.3–12)
(4–14)
(5–17)
(5.6–19)
(5.9–20)
(6.2–21)
(3.4–27)
(5.9–24)
(5.9–20)
(4.4–15)
(4–13)
(3.5–12)
(3.4–12)
(3.6–14)
(3.8–14)
(5.8–21)
(7.6–27)
(7.2–24)
(6.9–23)
(6.4–22)
(5.1–21)
(7.2–25)
(7.2–25)
(8.1–27)
(7.5–25)
(6.9–23)
(6.3–21)
(5.2–31)
(11–40)
(17–58)
(19–67)
(17–59)
(17–59)
(17–59)
(0.47–2.4)
(0.6–2.1)
(0.64–2.3)
(0.63–2.2)
(0.63–2.3)
(0.61–2.2)
(0.61–2.2)
(2.4–12)
(3.4–12)
(5.8–20)
(8.4–29)
(8–28)
(8.1–27)
(7.9–27)
(5.5–26)
(10–37)
(16–58)
(23–82)
(23–80)
(22–78)
(22–77)
(0.3–1.5)
(0.32–1.1)
(0.28–0.98)
(0.27–0.95)
(0.24–0.85)
(0.24–0.83)
(0.23–0.81)
(3.4–16)
(4.9–18)
(6.5–26)
(10–38)
(10–38)
(9.9–38)
(9.5–37)
(12–60)
(15–58)
(19–68)
(18–66)
(15–55)
(13–50)
(12–50)
(110–400)
(130–460)
(140–480)
(150–500)
(160–540)
(160–550)
(160–560)
(0.085–0.59)
(0.12–0.71)
(0.21–1)
(0.34–1.4)
(0.38–1.8)
(0.29–1.4)
(0.36–1.4)
RATE
101
101
135
142
126
134
136
361
431
417
324
375
389
411
128
129
132
139
142
145
149
820
830
705
521
440
400
380
86
77
102
114
97
89
82
212
249
239
232
198
179
162
123
173
224
228
196
190
185
347
328
318
286
283
273
269
210
216
326
436
393
388
376
226
323
429
508
458
435
417
172
137
107
90
75
71
68
352
391
493
645
603
575
545
244
227
245
220
177
160
156
661
634
596
546
540
537
535
90
92
117
137
158
122
121
(37–188)
(35–192)
(51–249)
(53–264)
(45–235)
(49–247)
(50–250)
(135–724)
(201–704)
(194–684)
(102–563)
(142–642)
(150–661)
(168–688)
(44–264)
(59–215)
(62–217)
(65–229)
(67–231)
(69–236)
(71–241)
(249–1970)
(374–1516)
(336–1136)
(233–823)
(206–680)
(178–625)
(172–592)
(38–151)
(35–132)
(47–175)
(53–191)
(47–156)
(43–142)
(39–131)
(92–379)
(118–411)
(113–387)
(112–369)
(94–314)
(84–283)
(75–256)
(43–253)
(81–284)
(107–368)
(108–379)
(91–317)
(88–308)
(86–299)
(136–686)
(151–539)
(146–521)
(134–470)
(130–466)
(125–449)
(123–443)
(81–419)
(103–366)
(158–538)
(209–718)
(189–650)
(188–633)
(179–618)
(92–436)
(148–535)
(200–710)
(234–836)
(214–754)
(204–717)
(197–684)
(69–334)
(64–225)
(49–175)
(42–147)
(35–122)
(33–116)
(32–111)
(141–667)
(178–642)
(208–816)
(284–1067)
(268–999)
(252–955)
(235–908)
(98–476)
(105–393)
(117–408)
(102–364)
(77–288)
(68–258)
(63–255)
(303–1089)
(297–1037)
(282–962)
(257–873)
(253–861)
(250–852)
(250–850)
(23–157)
(27–159)
(40–200)
(56–225)
(58–265)
(42–205)
(52–197)
INCIDENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
17
19
27
30
29
31
32
21
27
35
45
53
55
58
3.7
4.5
5.5
6.8
7.7
8
8.3
7.4
14
16
14
12
11
10
6.1
6.3
8.5
10
9.9
9.4
9
8.3
10
11
12
12
11
11
9.8
16
26
35
35
35
35
0.61
0.66
0.7
0.72
0.73
0.73
0.73
4.3
7
11
15
14
14
14
7.5
13
22
31
31
31
31
0.37
0.34
0.32
0.29
0.28
0.28
0.27
4
6.7
11
15
15
15
15
19
27
33
33
30
29
27
120
140
160
190
200
210
220
0.3
0.35
0.52
0.67
0.83
0.81
0.94
(12–22)
(14–25)
(19–35)
(22–40)
(21–39)
(23–41)
(23–42)
(13–32)
(22–33)
(28–42)
(37–54)
(44–62)
(46–65)
(49–68)
(2.2–5.4)
(3.7–5.5)
(4.5–6.6)
(5.5–8.2)
(6.2–9.2)
(6.5–9.6)
(6.8–9.9)
(2.8–14)
(8.7–20)
(13–20)
(12–15)
(11–13)
(9.6–12)
(9–11)
(4.5–8)
(4.8–7.9)
(6.6–11)
(8.3–13)
(8.1–12)
(7.9–11)
(7.6–11)
(6–11)
(7.9–12)
(9.4–14)
(10–14)
(10–13)
(9.9–13)
(9.5–12)
(6.2–14)
(13–20)
(21–32)
(29–43)
(28–42)
(28–42)
(28–42)
(0.37–0.91)
(0.54–0.8)
(0.57–0.84)
(0.59–0.87)
(0.59–0.88)
(0.59–0.87)
(0.6–0.87)
(2.6–6.3)
(5.7–8.4)
(9.1–13)
(12–18)
(12–17)
(12–17)
(12–17)
(4.6–11)
(10–15)
(17–26)
(25–37)
(25–37)
(25–37)
(26–37)
(0.23–0.56)
(0.28–0.41)
(0.26–0.38)
(0.24–0.35)
(0.23–0.34)
(0.23–0.33)
(0.22–0.32)
(2.5–6)
(5.4–8.1)
(9.3–13)
(12–18)
(12–18)
(12–18)
(12–18)
(12–27)
(20–34)
(26–41)
(27–40)
(26–35)
(25–33)
(24–32)
(95–150)
(120–170)
(140–190)
(160–220)
(180–240)
(180–240)
(190–250)
(0.26–0.34)
(0.31–0.4)
(0.46–0.59)
(0.58–0.75)
(0.72–0.93)
(0.71–0.92)
(0.83–1.1)
RATE
66
68
87
93
85
89
90
205
226
250
276
292
298
304
77
80
85
89
92
93
94
533
855
918
733
596
545
503
66
59
69
74
64
59
55
148
165
178
168
147
137
129
81
116
168
202
187
182
177
175
168
160
153
149
148
147
145
209
302
363
336
327
319
125
181
262
315
291
283
276
85
69
56
46
40
39
37
169
245
353
425
393
382
372
150
181
198
182
158
148
139
327
327
327
327
327
327
327
80
80
100
110
125
119
135
(48–86)
(50–90)
(63–114)
(67–122)
(62–112)
(65–117)
(65–118)
(125–305)
(184–273)
(203–301)
(226–330)
(244–345)
(249–351)
(255–356)
(47–113)
(65–97)
(69–102)
(72–107)
(75–111)
(76–111)
(77–112)
(204–1015)
(547–1230)
(732–1123)
(665–803)
(538–658)
(485–610)
(448–561)
(49–85)
(45–74)
(53–87)
(58–91)
(52–77)
(49–69)
(46–64)
(107–197)
(130–203)
(148–212)
(144–195)
(128–167)
(121–154)
(113–146)
(50–117)
(95–140)
(137–202)
(164–243)
(152–225)
(149–218)
(145–212)
(107–261)
(136–202)
(130–193)
(125–185)
(121–180)
(121–177)
(120–175)
(88–216)
(170–252)
(246–364)
(296–438)
(273–405)
(268–393)
(262–381)
(76–187)
(147–218)
(213–315)
(256–379)
(237–351)
(232–340)
(227–329)
(52–127)
(56–84)
(46–68)
(37–55)
(33–49)
(32–46)
(30–44)
(103–252)
(199–295)
(297–414)
(345–512)
(319–473)
(312–459)
(305–445)
(95–217)
(136–233)
(156–245)
(148–220)
(134–184)
(128–168)
(120–160)
(261–400)
(267–393)
(272–387)
(278–380)
(281–376)
(282–375)
(281–376)
(70–91)
(70–90)
(88–113)
(96–124)
(109–141)
(105–135)
(118–152)
African Region
MORTALITY (EXCLUDING HIV)
YEAR
Rates are per 100 000 population.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 123
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
123
05/10/11 09:02
7$%/($(VWLPDWHVRIWKHEXUGHQRIGLVHDVHFDXVHGE\7%±
MORTALITY (EXCLUDING HIV)
Eritrea
Ethiopia
Gabon
Gambia
Ghana
Guinea
Guinea-Bissau
Kenya
Lesotho
Liberia
Madagascar
Malawi
Mali
Mauritania
Mauritius
a
124
YEAR
POPULATION
(MILLIONS)
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
3
3
4
4
5
5
5
48
57
66
74
79
81
83
<1
1
1
1
1
1
2
<1
1
1
2
2
2
2
15
17
19
22
23
24
24
6
8
8
9
10
10
10
1
1
1
1
1
1
2
23
27
31
36
38
39
41
2
2
2
2
2
2
2
2
2
3
3
4
4
4
11
13
15
18
20
20
21
9
10
11
13
14
14
15
9
10
11
13
14
15
15
2
2
3
3
3
3
3
1
1
1
1
1
1
1
NUMBER
(THOUSANDS)
0.19
0.53
0.17
0.23
0.47
0.56
0.63
7.5
18
27
33
32
30
29
0.2
0.2
0.27
0.42
0.64
0.82
1.1
0.34
0.44
0.47
0.61
0.74
0.75
0.84
5.3
4.8
4.8
3.8
2.8
2.5
2.1
1.4
2
2.8
4
5
5.6
5.9
0.19
0.17
0.35
0.32
0.36
0.39
0.41
5.1
3.4
5.6
6.5
7.1
7.5
6.9
0.23
0.22
0.32
0.3
0.25
0.29
0.29
0.81
1
1.6
1.5
1.9
1.9
1.9
4.7
4.2
6.3
8.1
9.8
10
11
3.3
3
3.1
2.5
2.2
1.9
1.7
3.6
3.8
2.6
1.1
1
1.3
1.5
0.36
0.78
1.4
2
2.4
2.6
2.7
0.014
0.014
<0.01
0.015
0.016
0.017
0.013
(0.14–0.24)
(0.37–0.71)
(0.12–0.23)
(0.12–0.48)
(0.21–0.89)
(0.32–0.89)
(0.37–0.96)
(4.6–12)
(14–23)
(22–32)
(27–39)
(26–39)
(24–36)
(23–35)
(0.084–0.38)
(0.12–0.29)
(0.15–0.44)
(0.25–0.64)
(0.38–0.98)
(0.54–1.2)
(0.74–1.4)
(0.16–0.61)
(0.32–0.59)
(0.32–0.65)
(0.42–0.84)
(0.53–0.99)
(0.54–0.99)
(0.62–1.1)
(1.9–11)
(2–9.1)
(2.5–7.9)
(2.3–5.8)
(2–3.8)
(1.9–3.2)
(1.6–2.8)
(0.56–2.6)
(1.2–3)
(1.9–3.9)
(2.9–5.3)
(3.7–6.6)
(4.3–7)
(4.5–7.4)
(0.088–0.38)
(0.1–0.3)
(0.24–0.49)
(0.2–0.49)
(0.23–0.55)
(0.25–0.58)
(0.26–0.6)
(3.7–6.7)
(2.2–4.9)
(3.4–8.5)
(3.8–11)
(5.3–9.2)
(6.1–9.1)
(4.9–9.4)
(0.13–0.46)
(0.12–0.42)
(0.16–0.6)
(0.15–0.63)
(0.17–0.4)
(0.18–0.45)
(0.19–0.45)
(0.38–1.5)
(0.79–1.3)
(1.3–2)
(1.1–2)
(1.3–2.5)
(1.4–2.6)
(1.4–2.6)
(2.5–7.6)
(3–5.6)
(4.5–8.4)
(5.9–11)
(7.1–13)
(7.6–14)
(8.1–14)
(1.5–5.9)
(1.8–4.5)
(1.7–4.9)
(1.3–4.2)
(1.7–2.7)
(1.6–2.2)
(1.4–2.1)
(2.3–5.2)
(2.7–5.2)
(2–3.4)
(0.9–1.3)
(0.91–1.2)
(1.2–1.5)
(1.3–1.7)
(0.2–0.93)
(0.5–1.2)
(0.99–1.8)
(1.6–2.6)
(1.9–3)
(2–3.2)
(2.2–3.4)
(<0.01–0.024)
(0.01–0.018)
(<0.01–<0.01)
(0.015–0.015)
(0.016–0.016)
(0.017–0.017)
(<0.01–0.016)
RATEa
6
17
4.7
5.2
9.5
11
12
15
32
40
44
40
37
35
21
18
22
30
44
56
70
35
39
36
41
45
44
49
36
28
25
18
12
10
8.7
24
27
33
44
53
57
59
19
15
28
23
25
26
27
22
12
18
18
18
19
17
14
12
16
15
12
13
13
38
49
58
48
51
50
48
41
32
41
46
50
51
53
35
30
27
20
16
13
11
41
39
23
8.2
7.1
8.7
9.7
18
34
52
67
73
77
79
1.3
1.2
<1
1.2
1.3
1.3
<1
(4.4–7.5)
(12–22)
(3.3–6.4)
(2.7–11)
(4.3–18)
(6.4–18)
(7.1–18)
(9.6–26)
(25–40)
(33–49)
(37–53)
(33–48)
(30–44)
(28–42)
(9–41)
(11–27)
(12–36)
(18–47)
(26–68)
(36–80)
(49–96)
(16–64)
(28–52)
(25–50)
(28–56)
(32–61)
(32–59)
(36–63)
(13–72)
(12–54)
(13–41)
(11–27)
(8.7–16)
(7.8–13)
(6.4–12)
(9.8–46)
(16–40)
(23–46)
(32–58)
(39–69)
(44–72)
(46–75)
(8.7–37)
(8.9–26)
(20–39)
(14–35)
(15–38)
(17–39)
(17–40)
(16–29)
(8.1–18)
(11–27)
(11–31)
(14–24)
(16–23)
(12–23)
(8.1–28)
(6.8–23)
(8.2–31)
(7.5–30)
(7.9–19)
(8.6–21)
(8.5–21)
(18–68)
(38–63)
(45–72)
(35–64)
(36–69)
(35–67)
(34–65)
(22–67)
(23–43)
(29–54)
(33–61)
(37–66)
(38–68)
(39–69)
(16–63)
(18–46)
(16–43)
(10–33)
(12–19)
(11–15)
(9.5–14)
(26–60)
(27–53)
(17–30)
(6.9–9.8)
(6.3–8)
(7.7–9.8)
(8.2–11)
(10–47)
(22–50)
(38–68)
(51–85)
(57–93)
(60–96)
(62–99)
(<1–2.3)
(<1–1.6)
(<1–<1)
(1.2–1.2)
(1.2–1.3)
(1.3–1.3)
(<1–1.3)
PREVALENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
3.8
10
4.4
4
5.6
6.2
6.7
110
180
260
340
340
330
330
2.1
2.2
3.3
4.9
7.2
8.6
10
3.2
4.2
4.8
6.1
7.1
7.2
8
46
45
44
37
31
28
26
12
18
25
36
45
50
52
2.3
2.4
3.5
3.7
4.2
4.4
4.6
47
43
81
110
120
120
110
3.5
4.6
7.1
8.5
8.7
8.7
8.7
7.7
9
14
15
18
19
19
41
43
60
77
91
96
100
34
34
38
34
30
27
26
30
32
23
11
12
14
15
5.5
8.6
13
18
21
22
23
0.55
0.55
0.52
0.53
0.52
0.5
0.5
(0.97–6.9)
(2.2–20)
(1.3–7.8)
(1.4–7.1)
(2.2–10)
(2.8–11)
(3.1–12)
(33–190)
(84–290)
(120–410)
(160–530)
(150–540)
(140–520)
(140–520)
(0.77–4.2)
(0.99–3.6)
(1.5–5.7)
(2.3–8.1)
(3.4–12)
(4.1–14)
(4.9–17)
(1.2–6.4)
(1.9–6.9)
(2.1–7.9)
(2.8–10)
(3.3–12)
(3.4–12)
(3.8–13)
(15–100)
(17–93)
(19–84)
(17–65)
(14–50)
(13–45)
(12–41)
(4.3–26)
(7.9–32)
(12–43)
(17–59)
(21–75)
(24–81)
(25–85)
(0.76–4.4)
(0.83–4.2)
(1.7–5.8)
(1.6–6.2)
(1.8–7)
(2–7.3)
(2.1–7.6)
(23–77)
(21–69)
(37–130)
(45–180)
(51–180)
(54–180)
(49–180)
(1–6.4)
(1.7–7.7)
(2.7–12)
(2.9–14)
(2.8–15)
(3–14)
(3–14)
(2.9–15)
(4.2–15)
(6.4–23)
(6.8–24)
(8.2–30)
(8.7–31)
(8.7–31)
(16–78)
(19–69)
(27–98)
(36–130)
(42–150)
(45–160)
(47–160)
(15–64)
(17–57)
(18–63)
(16–57)
(15–46)
(14–41)
(13–39)
(13–54)
(14–56)
(11–38)
(5.5–18)
(5.5–18)
(6.6–21)
(7.4–24)
(1.3–11)
(3.6–14)
(6–21)
(8.4–29)
(9.6–34)
(10–36)
(11–38)
(0.22–1.1)
(0.26–0.9)
(0.24–0.85)
(0.24–0.87)
(0.24–0.85)
(0.23–0.83)
(0.23–0.82)
INCIDENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
RATE
121
318
120
89
113
122
128
219
315
403
458
432
406
394
227
199
270
355
498
580
676
335
369
367
405
435
427
460
311
263
231
172
133
119
106
212
238
304
399
474
509
525
224
213
284
271
286
295
303
202
157
260
313
301
300
283
215
255
362
413
409
405
402
362
428
487
459
489
490
476
360
324
388
431
467
479
489
361
348
335
265
217
189
174
344
326
206
87
81
93
101
277
375
485
587
630
655
670
52
49
43
42
40
39
39
(31–219)
(69–612)
(36–213)
(32–159)
(45–211)
(55–210)
(59–219)
(68–383)
(146–501)
(189–632)
(211–716)
(194–677)
(178–643)
(173–623)
(83–449)
(91–332)
(121–459)
(165–594)
(232–838)
(280–960)
(326–1113)
(128–664)
(169–608)
(165–607)
(185–669)
(203–712)
(201–693)
(217–744)
(101–703)
(98–550)
(98–436)
(79–300)
(62–213)
(56–187)
(48–168)
(74–454)
(105–429)
(140–517)
(189–657)
(224–780)
(243–827)
(250–850)
(75–433)
(74–371)
(133–469)
(120–453)
(127–478)
(135–490)
(138–502)
(97–329)
(76–250)
(119–419)
(128–519)
(134–471)
(137–463)
(122–448)
(61–393)
(95–426)
(137–602)
(141–700)
(132–687)
(141–671)
(138–665)
(137–718)
(199–699)
(226–798)
(215–750)
(224–807)
(226–803)
(218–776)
(144–693)
(146–528)
(178–640)
(199–707)
(217–765)
(223–783)
(228–794)
(155–687)
(169–578)
(158–560)
(122–445)
(108–330)
(94–285)
(85–263)
(145–623)
(144–568)
(97–336)
(42–134)
(38–125)
(44–142)
(48–155)
(67–560)
(159–630)
(226–794)
(275–957)
(293–1034)
(303–1070)
(309–1093)
(21–102)
(22–79)
(20–71)
(19–69)
(19–66)
(18–64)
(18–63)
2.3
2.5
3.1
4.1
4.8
5
5.3
83
100
150
200
220
210
220
1.4
1.7
3.1
4.5
6.6
7.4
8.3
1.8
2.3
2.9
3.7
4.3
4.5
4.7
23
28
29
26
23
22
21
6.9
12
17
23
29
31
33
1.6
2
2.4
2.9
3.3
3.4
3.5
33
46
89
130
130
120
120
3
5.8
11
13
14
14
14
4.2
4.6
6.9
8.5
10
11
12
20
26
33
43
50
53
55
31
46
52
45
38
35
33
14
18
14
8
8.6
9.7
10
4.5
5.8
7.3
9.3
11
11
12
0.29
0.3
0.29
0.29
0.28
0.28
0.28
(1.4–3.4)
(2–3)
(2.5–3.8)
(3.5–4.9)
(3.9–5.8)
(4.1–6)
(4.3–6.3)
(70–98)
(91–120)
(140–170)
(190–220)
(200–230)
(200–230)
(200–230)
(0.91–2)
(1.4–2)
(2.5–3.7)
(3.6–5.4)
(5.3–7.9)
(6.1–8.9)
(6.8–10)
(1.1–2.7)
(1.9–2.8)
(2.4–3.5)
(3–4.5)
(3.5–5.2)
(3.7–5.4)
(3.9–5.6)
(9.9–41)
(16–45)
(18–43)
(19–33)
(19–27)
(19–25)
(18–24)
(4.2–10)
(9.5–14)
(14–20)
(19–28)
(24–35)
(25–37)
(27–40)
(1.1–2.2)
(1.6–2.4)
(1.9–2.9)
(2.4–3.5)
(2.7–3.9)
(2.8–4.1)
(2.9–4.2)
(28–37)
(42–50)
(83–95)
(120–140)
(120–130)
(120–130)
(120–130)
(2.2–4)
(5.1–6.6)
(9.5–12)
(11–16)
(12–15)
(12–16)
(12–16)
(2.6–6.3)
(3.7–5.5)
(5.6–8.3)
(6.9–10)
(8.4–12)
(9–13)
(9.6–14)
(12–30)
(21–31)
(27–40)
(35–52)
(41–60)
(43–63)
(45–66)
(21–41)
(38–54)
(43–62)
(37–54)
(34–43)
(33–38)
(30–35)
(9.7–19)
(14–23)
(12–17)
(7.6–8.4)
(8.3–9)
(9.2–10)
(9.9–11)
(2.8–6.8)
(4.7–6.9)
(6–8.8)
(7.6–11)
(8.7–13)
(9.1–13)
(9.6–14)
(0.18–0.44)
(0.24–0.36)
(0.24–0.35)
(0.23–0.35)
(0.23–0.34)
(0.23–0.34)
(0.23–0.34)
RATE
72
78
85
92
97
99
100
173
182
235
276
271
265
261
153
155
248
326
452
502
553
185
204
225
248
263
269
273
155
167
152
119
99
92
86
119
154
200
259
302
318
334
158
174
192
211
224
229
233
139
169
286
359
332
312
298
184
323
553
639
635
634
633
199
219
242
266
283
288
293
177
196
217
241
256
261
266
326
462
467
354
273
243
219
163
185
124
61
60
65
68
228
251
277
305
324
330
337
28
26
24
23
22
22
22
(44–107)
(64–94)
(69–102)
(78–108)
(79–117)
(81–118)
(82–120)
(145–203)
(159–205)
(212–259)
(252–301)
(248–294)
(243–287)
(240–282)
(98–219)
(127–186)
(201–300)
(265–393)
(368–545)
(410–602)
(454–662)
(113–275)
(166–246)
(183–272)
(202–299)
(214–318)
(220–322)
(225–327)
(67–280)
(91–266)
(95–222)
(88–155)
(83–116)
(81–103)
(75–97)
(73–177)
(126–186)
(163–241)
(211–312)
(246–364)
(259–382)
(274–400)
(106–219)
(141–209)
(156–231)
(172–255)
(182–270)
(187–275)
(191–279)
(121–159)
(155–184)
(267–305)
(338–380)
(316–348)
(299–325)
(286–311)
(134–241)
(282–368)
(483–628)
(533–754)
(552–725)
(551–723)
(551–721)
(121–295)
(178–264)
(197–291)
(217–321)
(230–341)
(236–345)
(241–350)
(108–264)
(163–233)
(177–262)
(196–290)
(208–308)
(213–314)
(219–319)
(228–441)
(382–550)
(385–556)
(291–423)
(242–306)
(227–260)
(203–237)
(112–223)
(142–234)
(103–148)
(58–64)
(57–62)
(62–68)
(64–71)
(139–339)
(204–303)
(225–334)
(249–368)
(264–390)
(270–397)
(276–404)
(17–41)
(21–31)
(20–29)
(19–28)
(18–27)
(18–26)
(18–26)
Rates are per 100 000 population.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 124
Data can be downloaded from www.who.int/tb/data
05/10/11 09:02
7$%/($(VWLPDWHVRIWKHEXUGHQRIGLVHDVHFDXVHGE\7%±
Mozambique
Namibia
Niger
Nigeria
Rwanda
Sao Tome and
Principe
Senegal
Seychelles
Sierra Leone
South Africa
Swaziland
Togo
Uganda
United Republic
of Tanzania
Zambia
Zimbabwe
a
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
POPULATION
(MILLIONS)
14
16
18
21
22
23
23
1
2
2
2
2
2
2
8
9
11
13
14
15
16
98
110
124
140
151
154
158
7
6
8
9
10
10
11
<1
<1
<1
<1
<1
<1
<1
7
8
10
11
12
12
12
<1
<1
<1
<1
<1
<1
<1
4
4
4
5
6
6
6
37
41
45
48
49
50
50
<1
<1
1
1
1
1
1
4
4
5
5
6
6
6
18
21
24
28
31
32
33
25
30
34
39
42
44
45
8
9
10
11
12
13
13
10
12
13
13
12
12
13
NUMBER
(THOUSANDS)
11
13
12
11
11
9.7
11
2.1
1.9
1.5
1.2
0.89
0.69
0.58
2.1
3
3.6
4.3
5.1
5.4
5.7
31
34
44
45
34
31
33
4.3
3.2
3.2
1.7
1.2
1.3
1.2
0.032
0.037
0.026
0.015
0.027
0.024
0.022
2.9
3.6
4.7
6
6.9
7.2
7.7
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
2.3
2.7
3.6
5.9
7.2
7.7
8.6
14
12
19
28
25
26
25
0.27
0.21
0.32
0.36
0.4
0.39
0.38
3.1
3.4
4.3
5.1
5.8
6.1
6.4
11
10
9.9
7.3
6.1
5.3
5.1
8
6
5.9
5.8
5.4
5.5
5.8
5
4.1
3.4
2.4
2.5
2.6
2.6
2.9
1.6
2.1
3.4
3.7
4
3.4
(1.7–33)
(3.6–30)
(4.6–24)
(5.1–20)
(6.3–17)
(5.8–15)
(7–17)
(1.5–2.9)
(1.3–2.5)
(0.99–2.2)
(0.69–1.9)
(0.71–1.1)
(0.34–1.3)
(0.45–0.75)
(1–3.5)
(2.3–3.8)
(2.7–4.5)
(3.3–5.6)
(3.8–6.6)
(4.1–6.9)
(4.4–7.3)
(1.5–120)
(2.9–110)
(4.1–140)
(6.3–130)
(9–81)
(14–55)
(11–68)
(1.6–8.4)
(1.4–5.7)
(1.8–5.2)
(1.5–2)
(1.1–1.5)
(1–1.6)
(0.93–1.5)
(0.015–0.058)
(0.028–0.048)
(0.017–0.037)
(<0.01–0.024)
(0.019–0.038)
(0.016–0.034)
(0.014–0.032)
(1.4–5)
(2.6–4.7)
(3.5–6.1)
(4.5–7.7)
(5.3–8.8)
(5.5–9.2)
(6–9.6)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(1.4–3.5)
(2.1–3.4)
(2.8–4.6)
(4.5–7.4)
(5.5–9.1)
(5.9–9.7)
(6.7–11)
(6.1–27)
(6.9–18)
(12–28)
(17–42)
(14–41)
(16–40)
(16–38)
(0.11–0.55)
(0.11–0.36)
(0.15–0.57)
(0.16–0.68)
(0.28–0.56)
(0.26–0.56)
(0.24–0.56)
(1.9–4.7)
(2.7–4.2)
(3.4–5.2)
(4.1–6.3)
(4.6–7.2)
(4.9–7.4)
(5.2–7.8)
(4.8–19)
(4.7–18)
(4.7–17)
(3.7–12)
(4.2–8.4)
(3.4–7.6)
(3.3–7.3)
(6–10)
(3.9–8.7)
(3.6–9)
(3.7–8.6)
(4.4–6.5)
(4.5–6.7)
(4.7–6.9)
(1.8–10)
(2.5–6)
(1.9–5.6)
(1.2–4.5)
(2–3.2)
(2–3.4)
(2–3.3)
(1.1–5.6)
(0.58–3.4)
(0.77–4.5)
(1.5–6.5)
(2.3–5.5)
(2.7–5.5)
(2.1–5.1)
RATEa
84
84
68
53
49
42
49
150
113
80
57
40
31
25
26
33
33
33
35
36
37
32
31
36
32
23
20
21
61
58
40
19
12
12
11
28
29
18
9.7
17
15
13
40
43
50
55
59
60
62
<1
3.4
1.8
2.5
2.4
2.4
1.7
59
70
87
114
127
134
146
37
28
43
58
51
52
50
31
22
30
32
35
33
32
85
84
89
95
101
103
106
60
50
41
26
19
16
15
32
20
17
15
13
13
13
64
45
34
21
20
21
20
27
14
17
27
30
32
27
(12–242)
(22–189)
(25–133)
(25–94)
(28–77)
(25–64)
(30–74)
(105–203)
(82–149)
(52–115)
(33–90)
(32–50)
(15–59)
(20–33)
(13–45)
(26–41)
(25–42)
(25–43)
(26–45)
(27–46)
(28–47)
(1.5–121)
(2.7–97)
(3.3–110)
(4.5–94)
(6–54)
(9.2–36)
(7.2–43)
(23–118)
(26–103)
(22–64)
(16–21)
(11–15)
(9.7–15)
(8.7–14)
(13–50)
(22–37)
(12–26)
(5.8–16)
(12–24)
(9.8–21)
(8.4–19)
(20–69)
(31–56)
(37–64)
(42–71)
(45–75)
(45–76)
(48–77)
(<1–1.1)
(2.5–4.3)
(1.1–2.7)
(2.5–2.6)
(2.4–2.5)
(2.4–2.5)
(<1–2.7)
(35–89)
(55–88)
(67–110)
(88–144)
(98–162)
(103–170)
(113–183)
(17–74)
(17–44)
(27–62)
(35–89)
(29–84)
(32–80)
(31–75)
(12–64)
(12–37)
(14–54)
(14–61)
(24–48)
(22–48)
(20–47)
(51–128)
(67–103)
(71–109)
(75–116)
(80–125)
(83–126)
(86–129)
(27–108)
(22–89)
(19–72)
(13–43)
(13–27)
(11–24)
(9.9–22)
(24–41)
(13–29)
(11–26)
(9.6–22)
(10–15)
(10–15)
(11–15)
(23–128)
(29–67)
(19–55)
(11–39)
(16–26)
(16–26)
(15–25)
(11–54)
(4.9–29)
(6.1–36)
(12–52)
(19–44)
(22–44)
(17–40)
PREVALENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
100
120
110
110
110
99
110
18
18
18
18
14
12
11
19
26
31
39
46
49
52
260
280
370
400
320
300
320
37
27
29
18
14
14
14
0.3
0.32
0.27
0.2
0.26
0.24
0.23
27
33
42
54
61
64
67
0.034
0.061
0.044
0.05
0.055
0.041
0.042
19
23
31
51
63
68
75
160
150
230
380
390
400
400
3
2.9
5.4
7.1
8
8.1
8.4
25
28
35
42
48
50
52
93
96
97
81
71
65
64
77
71
79
81
78
80
82
51
52
53
47
45
45
45
28
28
44
54
51
53
51
(19–310)
(32–290)
(38–240)
(44–210)
(50–190)
(47–170)
(54–200)
(8.3–31)
(8.7–29)
(9–29)
(8–29)
(6.9–22)
(4.9–21)
(4.8–18)
(7.4–36)
(12–42)
(15–51)
(18–64)
(22–75)
(23–79)
(24–84)
(21–1000)
(27–940)
(46–1200)
(74–1200)
(95–800)
(120–580)
(110–690)
(12–82)
(9.7–57)
(12–55)
(9.2–27)
(7.1–22)
(7–22)
(6.6–21)
(0.11–0.6)
(0.15–0.53)
(0.12–0.45)
(0.068–0.35)
(0.12–0.44)
(0.11–0.41)
(0.1–0.39)
(11–52)
(15–54)
(20–69)
(25–87)
(29–100)
(30–100)
(31–110)
(<0.01–0.06)
(0.028–0.1)
(0.018–0.075)
(0.022–0.083)
(0.025–0.09)
(0.017–0.075)
(0.017–0.074)
(7.6–36)
(11–38)
(14–51)
(24–83)
(30–100)
(32–110)
(35–120)
(55–300)
(65–240)
(110–380)
(180–610)
(180–640)
(190–640)
(180–630)
(1.1–6.1)
(1.3–4.9)
(2.3–9.1)
(2.7–12)
(3.4–13)
(3.3–13)
(3.3–13)
(10–48)
(12–46)
(15–57)
(19–69)
(21–79)
(22–82)
(23–85)
(35–190)
(38–190)
(41–190)
(37–140)
(36–110)
(32–100)
(32–100)
(38–120)
(34–110)
(37–130)
(38–130)
(37–120)
(37–120)
(39–130)
(19–110)
(25–84)
(24–87)
(18–78)
(21–69)
(21–70)
(21–70)
(11–59)
(11–51)
(15–77)
(22–94)
(24–82)
(25–84)
(23–80)
RATE
742
722
600
509
488
433
491
1287
1080
969
849
651
550
492
240
278
284
300
317
326
333
265
250
298
286
215
192
199
521
487
361
192
143
138
128
258
253
189
134
166
151
141
368
395
446
492
521
527
542
48
81
56
60
64
47
48
480
595
748
982
1122
1185
1282
429
352
524
788
792
809
795
350
301
508
645
697
697
704
690
685
720
775
825
843
865
526
461
399
285
227
202
193
303
236
233
209
184
183
183
646
586
520
408
360
355
345
272
244
353
429
409
427
402
(140–2255)
(201–1809)
(208–1326)
(212–994)
(225–862)
(207–748)
(233–844)
(586–2193)
(525–1760)
(477–1546)
(385–1377)
(311–997)
(219–939)
(210–779)
(95–467)
(128–456)
(133–464)
(141–491)
(150–516)
(153–529)
(156–540)
(22–1058)
(24–857)
(38–1003)
(53–876)
(63–529)
(78–378)
(70–438)
(170–1154)
(173–1021)
(153–679)
(100–289)
(71–217)
(68–212)
(62–197)
(99–513)
(117–416)
(82–316)
(45–231)
(76–275)
(68–252)
(62–235)
(146–717)
(183–646)
(209–728)
(231–800)
(244–848)
(246–860)
(253–879)
(11–84)
(37–133)
(23–95)
(27–99)
(29–105)
(20–87)
(20–85)
(190–909)
(274–975)
(346–1223)
(457–1605)
(529–1824)
(559–1918)
(603–2075)
(150–829)
(158–587)
(255–846)
(374–1270)
(358–1288)
(372–1287)
(364–1264)
(126–702)
(136–507)
(212–859)
(247–1085)
(293–1109)
(286–1118)
(281–1134)
(273–1305)
(305–1132)
(315–1192)
(347–1273)
(367–1365)
(377–1390)
(386–1418)
(195–1086)
(183–925)
(171–772)
(131–509)
(113–360)
(99–323)
(95–306)
(148–485)
(115–379)
(108–378)
(97–336)
(87–283)
(86–282)
(87–281)
(245–1351)
(283–942)
(232–851)
(160–681)
(166–557)
(165–548)
(159–534)
(107–559)
(90–436)
(123–619)
(174–749)
(194–657)
(203–673)
(185–639)
INCIDENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
54
76
93
110
120
120
130
9.8
14
20
21
17
15
14
9.7
13
17
22
26
27
29
130
150
210
240
220
200
210
29
22
23
15
12
12
11
0.16
0.16
0.16
0.16
0.16
0.16
0.16
14
18
23
28
33
34
36
0.031
0.03
0.029
0.028
0.027
0.027
0.027
8.2
11
16
26
34
37
40
110
130
260
440
470
480
490
2.3
3.2
8.5
13
14
15
15
11
14
18
22
25
26
27
110
110
100
87
76
73
70
58
68
80
83
80
79
79
56
70
73
65
62
61
61
31
56
91
100
89
83
80
(7.2–150)
(23–160)
(40–170)
(61–170)
(77–170)
(84–170)
(87–170)
(7.4–13)
(12–17)
(18–23)
(19–24)
(16–19)
(14–16)
(13–15)
(5.9–14)
(10–15)
(14–20)
(18–26)
(21–31)
(22–33)
(24–34)
(0.48–560)
(5.3–540)
(11–710)
(27–700)
(76–430)
(120–310)
(99–360)
(12–53)
(11–37)
(15–34)
(14–16)
(11–13)
(11–13)
(10–13)
(0.096–0.23)
(0.13–0.19)
(0.13–0.19)
(0.13–0.19)
(0.13–0.19)
(0.13–0.19)
(0.13–0.19)
(8.6–21)
(15–22)
(18–27)
(23–34)
(27–39)
(28–41)
(29–43)
(0.019–0.046)
(0.024–0.036)
(0.023–0.035)
(0.023–0.034)
(0.022–0.033)
(0.022–0.032)
(0.022–0.032)
(5–12)
(8.9–13)
(13–19)
(21–32)
(28–41)
(30–44)
(33–48)
(75–150)
(110–160)
(210–310)
(360–530)
(390–570)
(400–580)
(400–590)
(1.4–3.4)
(2.6–3.9)
(7–10)
(10–15)
(11–17)
(12–18)
(13–18)
(6.9–17)
(11–17)
(15–22)
(18–27)
(21–30)
(21–32)
(22–33)
(57–180)
(61–180)
(62–160)
(62–120)
(60–95)
(59–89)
(56–85)
(49–67)
(58–78)
(70–91)
(76–89)
(75–86)
(74–85)
(75–85)
(49–63)
(64–77)
(67–78)
(59–71)
(56–68)
(55–68)
(55–67)
(16–50)
(39–77)
(71–110)
(79–120)
(69–110)
(64–110)
(61–100)
RATE
401
478
513
524
535
539
544
696
862
1077
1028
793
682
603
125
138
152
168
178
181
185
128
139
172
175
145
130
133
405
394
286
162
123
115
106
135
124
114
105
99
98
96
195
215
237
261
277
282
288
43
40
37
33
32
31
31
207
279
377
509
608
644
682
301
317
576
925
960
971
981
267
337
803
1147
1227
1257
1287
308
339
374
413
438
446
455
624
542
427
304
244
226
209
226
226
236
213
190
183
177
710
788
713
566
500
482
462
296
483
726
799
716
668
633
(53–1091)
(144–1008)
(220–929)
(293–819)
(347–763)
(368–743)
(374–746)
(525–890)
(723–1012)
(938–1225)
(916–1145)
(729–860)
(637–727)
(563–643)
(76–186)
(112–166)
(124–183)
(136–202)
(145–214)
(148–217)
(152–221)
(<1–579)
(4.8–489)
(8.6–571)
(19–498)
(51–288)
(77–198)
(63–228)
(169–740)
(193–665)
(181–415)
(149–176)
(114–132)
(102–128)
(94–118)
(82–201)
(101–150)
(93–137)
(88–123)
(81–120)
(80–117)
(79–115)
(118–289)
(175–259)
(193–285)
(212–315)
(225–334)
(231–339)
(237–345)
(26–64)
(32–48)
(30–44)
(27–40)
(26–38)
(26–38)
(25–37)
(126–308)
(227–337)
(307–454)
(414–613)
(495–733)
(526–774)
(560–816)
(204–416)
(258–382)
(468–694)
(753–1115)
(781–1157)
(794–1165)
(806–1173)
(163–397)
(274–406)
(654–968)
(934–1381)
(998–1479)
(1028–1508)
(1058–1538)
(187–457)
(276–409)
(304–451)
(336–497)
(356–527)
(364–536)
(373–545)
(321–1025)
(291–869)
(256–642)
(218–405)
(191–303)
(181–275)
(168–254)
(192–262)
(192–262)
(206–269)
(196–229)
(178–203)
(171–195)
(166–189)
(623–803)
(718–862)
(660–768)
(518–616)
(452–551)
(433–533)
(417–510)
(156–482)
(332–662)
(570–901)
(630–988)
(554–899)
(510–846)
(486–799)
African Region
MORTALITY (EXCLUDING HIV)
YEAR
Rates are per 100 000 population.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 125
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
125
05/10/11 09:02
7$%/($,QFLGHQFHQRWLILFDWLRQDQGFDVHGHWHFWLRQUDWHVDOOIRUPV±
INCIDENCE (INCLUDING HIV)
YEAR
Algeria
Angola
Benin
Botswana
Burkina Faso
Burundi
Cameroon
Cape Verde
Central African
Republic
Chad
Comoros
Congo
Côte d'Ivoire
Democratic
Republic
of the Congo
Equatorial
Guinea
126
POPULATION
(MILLIONS)
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
25
28
31
33
34
35
35
10
12
14
16
18
19
19
5
6
7
8
8
9
9
1
2
2
2
2
2
2
9
11
12
14
16
16
16
6
6
6
7
8
8
8
12
14
16
18
19
19
20
<1
<1
<1
<1
<1
<1
<1
3
3
4
4
4
4
4
6
7
8
10
11
11
11
<1
<1
<1
<1
<1
<1
<1
2
3
3
4
4
4
4
13
15
17
18
19
19
20
36
44
50
57
62
64
66
<1
<1
<1
<1
<1
<1
<1
NUMBER
(THOUSANDS)
17
19
27
30
29
31
32
21
27
35
45
53
55
58
3.7
4.5
5.5
6.8
7.7
8.0
8.3
7.4
14
16
14
12
11
10
6.1
6.3
8.5
10
9.9
9.4
9.0
8.3
10
11
12
12
11
11
9.8
16
26
35
35
35
35
0.61
0.66
0.70
0.72
0.73
0.73
0.73
4.3
7.0
11
15
14
14
14
7.5
13
22
31
31
31
31
0.37
0.34
0.32
0.29
0.28
0.28
0.27
4.0
6.7
11
15
15
15
15
19
27
33
33
30
29
27
120
140
160
190
200
210
220
0.30
0.35
0.52
0.67
0.83
0.81
0.94
(12–22)
(14–25)
(19–35)
(22–40)
(21–39)
(23–41)
(23–42)
(13–32)
(22–33)
(28–42)
(37–54)
(44–62)
(46–65)
(49–68)
(2.2–5.4)
(3.7–5.5)
(4.5–6.6)
(5.5–8.2)
(6.2–9.2)
(6.5–9.6)
(6.8–9.9)
(2.8–14)
(8.7–20)
(13–20)
(12–15)
(11–13)
(9.6–12)
(9–11)
(4.5–8)
(4.8–7.9)
(6.6–11)
(8.3–13)
(8.1–12)
(7.9–11)
(7.6–11)
(6–11)
(7.9–12)
(9.4–14)
(10–14)
(10–13)
(9.9–13)
(9.5–12)
(6.2–14)
(13–20)
(21–32)
(29–43)
(28–42)
(28–42)
(28–42)
(0.37–0.91)
(0.54–0.8)
(0.57–0.84)
(0.59–0.87)
(0.59–0.88)
(0.59–0.87)
(0.6–0.87)
(2.6–6.3)
(5.7–8.4)
(9.1–13)
(12–18)
(12–17)
(12–17)
(12–17)
(4.6–11)
(10–15)
(17–26)
(25–37)
(25–37)
(25–37)
(26–37)
(0.23–0.56)
(0.28–0.41)
(0.26–0.38)
(0.24–0.35)
(0.23–0.34)
(0.23–0.33)
(0.22–0.32)
(2.5–6)
(5.4–8.1)
(9.3–13)
(12–18)
(12–18)
(12–18)
(12–18)
(12–27)
(20–34)
(26–41)
(27–40)
(26–35)
(25–33)
(24–32)
(95–150)
(120–170)
(140–190)
(160–220)
(180–240)
(180–240)
(190–250)
(0.26–0.34)
(0.31–0.4)
(0.46–0.59)
(0.58–0.75)
(0.72–0.93)
(0.71–0.92)
(0.83–1.1)
RATEb
66
68
87
93
85
89
90
205
226
250
276
292
298
304
77
80
85
89
92
93
94
533
855
918
733
596
545
503
66
59
69
74
64
59
55
148
165
178
168
147
137
129
81
116
168
202
187
182
177
175
168
160
153
149
148
147
145
209
302
363
336
327
319
125
181
262
315
291
283
276
85
69
56
46
40
39
37
169
245
353
425
393
382
372
150
181
198
182
158
148
139
327
327
327
327
327
327
327
80
80
100
110
125
119
135
(48–86)
(50–90)
(63–114)
(67–122)
(62–112)
(65–117)
(65–118)
(125–305)
(184–273)
(203–301)
(226–330)
(244–345)
(249–351)
(255–356)
(47–113)
(65–97)
(69–102)
(72–107)
(75–111)
(76–111)
(77–112)
(204–1015)
(547–1230)
(732–1123)
(665–803)
(538–658)
(485–610)
(448–561)
(49–85)
(45–74)
(53–87)
(58–91)
(52–77)
(49–69)
(46–64)
(107–197)
(130–203)
(148–212)
(144–195)
(128–167)
(121–154)
(113–146)
(50–117)
(95–140)
(137–202)
(164–243)
(152–225)
(149–218)
(145–212)
(107–261)
(136–202)
(130–193)
(125–185)
(121–180)
(121–177)
(120–175)
(88–216)
(170–252)
(246–364)
(296–438)
(273–405)
(268–393)
(262–381)
(76–187)
(147–218)
(213–315)
(256–379)
(237–351)
(232–340)
(227–329)
(52–127)
(56–84)
(46–68)
(37–55)
(33–49)
(32–46)
(30–44)
(103–252)
(199–295)
(297–414)
(345–512)
(319–473)
(312–459)
(305–445)
(95–217)
(136–233)
(156–245)
(148–220)
(134–184)
(128–168)
(120–160)
(261–400)
(267–393)
(272–387)
(278–380)
(281–376)
(282–375)
(281–376)
(70–91)
(70–90)
(88–113)
(96–124)
(109–141)
(105–135)
(118–152)
INCIDENCE HIV-POSITIVE
NUMBER
(THOUSANDS)
0.16
0.35
0.42
0.49
0.54
0.62
2.0
3.0
3.9
4.7
5.0
5.2
0.072
0.57
0.92
1.1
1.3
1.3
1.3
1.7
7.6
11
9.3
7.8
7.2
6.5
2.5
2.5
2.8
2.7
2.2
1.9
1.6
1.6
2.6
3
3.1
2.8
2.6
2.5
0.6
5.1
10
14
14
14
14
(0.081–0.29)
(0.18–0.59)
(0.22–0.71)
(0.25–0.81)
(0.28–0.89)
(0.16–1.4)
(1.2–2.9)
(2–4.2)
(2.7–5.5)
(3.2–6.4)
(2.8–7.8)
(3.7–7.1)
(<0.01–0.61)
(0.25–1)
(0.61–1.3)
(0.74–1.5)
(1.1–1.6)
(1.1–1.6)
(1–1.5)
(0.64–3.3)
(4.8–11)
(8.4–13)
(8.4–10)
(7.1–8.7)
(6.4–8)
(5.8–7.3)
(1.7–3.6)
(1.7–3.5)
(1.8–3.9)
(1.9–3.7)
(1.8–2.6)
(1.6–2.2)
(1.4–1.9)
(1.1–2.3)
(2–3.4)
(2.3–3.8)
(2.4–3.8)
(2.2–3.4)
(2.1–3.3)
(2.2–2.8)
(0.059–1.8)
(3.7–6.6)
(7.7–13)
(11–18)
(12–17)
(12–17)
(11–17)
0.034 (0.018–0.057)
1.1
3.5
5.7
6.7
5.7
5.5
5.3
0.84
2.4
5.6
9
9.2
9.2
9.2
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.38
0.6
0.93
1.2
1.2
1.2
1.2
3
9.5
12
11
8.9
8.6
6.7
9.2
11
12
15
16
17
18
<0.01
0.015
0.061
0.1
0.046
0.21
0.45
(0.47–1.9)
(2.6–4.5)
(4.4–7.2)
(5.1–8.4)
(4.3–7.3)
(4.2–7)
(4–6.8)
(0.33–1.6)
(1.4–3.8)
(3.8–7.8)
(6.6–12)
(6.5–12)
(6.4–13)
(6.4–12)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.016)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.22–0.59)
(0.45–0.78)
(0.7–1.2)
(0.9–1.6)
(0.89–1.6)
(0.88–1.5)
(0.96–1.4)
(0.9–6.4)
(6.5–13)
(9.1–16)
(8.1–14)
(7.5–10)
(7.5–9.8)
(5.7–7.6)
(6.2–13)
(7.5–15)
(8.5–17)
(10–20)
(9.2–25)
(12–23)
(13–24)
(<0.01–<0.01)
(<0.01–0.025)
(0.04–0.087)
(0.074–0.14)
(0.032–0.061)
(0.16–0.27)
(0.38–0.52)
NOTIFIED NEW AND RELAPSEa
RATEb
<1
1.1
1.2
1.4
1.5
6.0
16
21
24
26
27
27
1.5
10
14
14
16
15
15
125
478
604
498
402
362
326
27
24
22
19
14
12
9.8
29
43
47
42
35
32
29
4.9
36
65
80
75
74
71
NUMBER
RATEb
11 607
13 507
18 572
21 336
20 588
21 701
22 336
10 271
5 143
16 062
37 175
44 576
41 221
44 655
2 074
2 400
2 697
3 270
3 872
3 878
3 756
2 938
5 665
9 292
10 058
8 891
8 362
7 013
1 497
2 572
2 331
3 478
4 238
4 716
4 800
4 575
3 326
6 421
6 585
6 808
7 277
7 611
5 892
3 292
5 251
21 499
24 622
24 662
24 073
221
303
46
48
61
65
60
62
63
99
42
115
225
247
222
234
43
42
41
43
46
45
42
213
357
529
536
455
422
349
16
24
19
24
27
30
29
82
55
101
91
86
89
91
48
24
33
122
131
129
123
63
77
292
334
332
356
2 124
3 339
62
69
68
72
72
100
3 210
6 803
8 743
6 643
2 591
3 186
80
161
202
151
43
46
6 311
6 912
8 411
9 452
140
123
120
111
132
120
123
591
3 615
9 239
9 853
8 886
9 765
10 150
7 841
11 988
15 094
19 681
23 688
22 571
22 708
21 131
42 819
61 024
97 075
104 861
111 709
114 170
260
306
64
65
77
84
32
25
21
17
19
17
17
25
132
295
279
232
248
251
63
82
91
109
125
117
115
58
97
123
169
168
174
173
70
69
718
707
820
108
104
117
(<1–<1)
(<1–1.8)
(<1–2.1)
(<1–2.3)
(<1–2.5)
(1.5–14)
(9.7–24)
(14–30)
(16–33)
(18–35)
(15–42)
(19–37)
(<1–13)
(4.5–18)
(9.4–20)
(9.7–19)
(13–19)
(12–18)
(12–17)
(46–241)
(305–690)
(479–744)
(446–553)
(362–443)
(323–404)
(290–364)
(18–39)
(16–33)
(15–31)
(13–26)
(12–17)
(10–14)
(8.3–12)
(20–41)
(32–56)
(36–59)
(33–53)
(27–43)
(25–40)
(26–33)
(<1–14)
(27–48)
(49–82)
(61–102)
(62–90)
(60–88)
(58–84)
7.2 (3.7–12)
36
104
155
166
135
127
120
14
35
69
92
86
84
82
<1
<1
<1
<1
<1
<1
<1
16
22
30
35
31
30
29
24
65
74
59
47
45
34
25
25
25
25
26
26
27
1.1
3.3
12
17
6.9
31
64
(16–64)
(78–134)
(120–195)
(128–209)
(103–171)
(97–162)
(91–154)
(5.5–26)
(20–54)
(47–95)
(67–120)
(61–116)
(59–114)
(57–111)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–2.5)
(<1–<1)
(<1–<1)
(<1–<1)
(9.1–25)
(16–29)
(22–38)
(26–45)
(23–41)
(22–39)
(24–35)
(7.2–51)
(44–89)
(55–95)
(45–76)
(40–54)
(39–51)
(29–39)
(17–35)
(17–34)
(17–34)
(18–34)
(15–41)
(19–35)
(19–36)
(<1–1.7)
(1.6–5.7)
(7.7–17)
(12–23)
(4.9–9.3)
(23–40)
(55–75)
a
Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
b
Rates are per 100 000 population.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 126
CASE DETECTION RATEa
PERCENT
70
70
70
70
70
70
70
48
19
46
82
85
75
77
57
53
49
48
50
49
45
40
42
58
73
76
77
70
24
41
27
33
43
50
53
55
33
56
54
58
65
70
60
20
20
61
70
71
69
36
46
–
40
46
46
49
50
48
–
22
48
62
47
34
25
–
20
22
27
31
37
36
38
38
47
43
45
15
54
83
66
59
65
68
42
45
46
60
79
79
83
18
30
38
52
51
53
53
87
87
–
–
87
87
87
(53–96)
(53–96)
(53–96)
(53–96)
(53–96)
(53–96)
(53–96)
(33–80)
(16–23)
(38–57)
(68–100)
(72–101)
(63–89)
(66–92)
(38–92)
(44–65)
(41–60)
(40–59)
(42–62)
(41–59)
(38–55)
(21–104)
(29–65)
(47–72)
(67–81)
(69–85)
(69–87)
(62–78)
(19–33)
(33–53)
(22–35)
(27–42)
(36–52)
(43–60)
(45–63)
(41–77)
(27–42)
(48–68)
(47–63)
(51–67)
(58–74)
(62–80)
(41–96)
(17–25)
(17–25)
(50–75)
(58–86)
(59–87)
(58–85)
(24–59)
(38–56)
(33–50)
(38–56)
(38–56)
(41–60)
(34–82)
(40–59)
(18–27)
(40–59)
(52–76)
(40–58)
(23–56)
(21–31)
(17–25)
(18–27)
(23–33)
(26–37)
(25–61)
(30–44)
(31–47)
(31–46)
(39–58)
(36–53)
(38–55)
(10–24)
(45–66)
(71–99)
(54–81)
(49–73)
(54–79)
(56–82)
(29–66)
(35–60)
(37–58)
(50–74)
(68–93)
(69–91)
(72–96)
(15–22)
(25–36)
(32–45)
(45–61)
(45–60)
(46–62)
(46–61)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
Data can be downloaded from www.who.int/tb/data
05/10/11 09:02
7$%/($,QFLGHQFHQRWLILFDWLRQDQGFDVHGHWHFWLRQUDWHVDOOIRUPV±
YEAR
Eritrea
Ethiopia
Gabon
Gambia
Ghana
Guinea
Guinea-Bissau
Kenya
Lesotho
Liberia
Madagascar
Malawi
Mali
Mauritania
Mauritius
POPULATION
(MILLIONS)
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
3
3
4
4
5
5
5
48
57
66
74
79
81
83
<1
1
1
1
1
1
2
<1
1
1
2
2
2
2
15
17
19
22
23
24
24
6
8
8
9
10
10
10
1
1
1
1
1
1
2
23
27
31
36
38
39
41
2
2
2
2
2
2
2
2
2
3
3
4
4
4
11
13
15
18
20
20
21
9
10
11
13
14
14
15
9
10
11
13
14
15
15
2
2
3
3
3
3
3
1
1
1
1
1
1
1
2.3
2.5
3.1
4.1
4.8
5.0
5.3
83
100
150
200
220
210
220
1.4
1.7
3.1
4.5
6.6
7.4
8.3
1.8
2.3
2.9
3.7
4.3
4.5
4.7
23
28
29
26
23
22
21
6.9
12
17
23
29
31
33
1.6
2.0
2.4
2.9
3.3
3.4
3.5
33
46
89
130
130
120
120
3.0
5.8
11
13
14
14
14
4.2
4.6
6.9
8.5
10
11
12
20
26
33
43
50
53
55
31
46
52
45
38
35
33
14
18
14
8
8.6
9.7
10
4.5
5.8
7.3
9.3
11
11
12
0.29
0.3
0.29
0.29
0.28
0.28
0.28
(1.4–3.4)
(2–3)
(2.5–3.8)
(3.5–4.9)
(3.9–5.8)
(4.1–6)
(4.3–6.3)
(70–98)
(91–120)
(140–170)
(190–220)
(200–230)
(200–230)
(200–230)
(0.91–2)
(1.4–2)
(2.5–3.7)
(3.6–5.4)
(5.3–7.9)
(6.1–8.9)
(6.8–10)
(1.1–2.7)
(1.9–2.8)
(2.4–3.5)
(3–4.5)
(3.5–5.2)
(3.7–5.4)
(3.9–5.6)
(9.9–41)
(16–45)
(18–43)
(19–33)
(19–27)
(19–25)
(18–24)
(4.2–10)
(9.5–14)
(14–20)
(19–28)
(24–35)
(25–37)
(27–40)
(1.1–2.2)
(1.6–2.4)
(1.9–2.9)
(2.4–3.5)
(2.7–3.9)
(2.8–4.1)
(2.9–4.2)
(28–37)
(42–50)
(83–95)
(120–140)
(120–130)
(120–130)
(120–130)
(2.2–4)
(5.1–6.6)
(9.5–12)
(11–16)
(12–15)
(12–16)
(12–16)
(2.6–6.3)
(3.7–5.5)
(5.6–8.3)
(6.9–10)
(8.4–12)
(9–13)
(9.6–14)
(12–30)
(21–31)
(27–40)
(35–52)
(41–60)
(43–63)
(45–66)
(21–41)
(38–54)
(43–62)
(37–54)
(34–43)
(33–38)
(30–35)
(9.7–19)
(14–23)
(12–17)
(7.6–8.4)
(8.3–9)
(9.2–10)
(9.9–11)
(2.8–6.8)
(4.7–6.9)
(6–8.8)
(7.6–11)
(8.7–13)
(9.1–13)
(9.6–14)
(0.18–0.44)
(0.24–0.36)
(0.24–0.35)
(0.23–0.35)
(0.23–0.34)
(0.23–0.34)
(0.23–0.34)
RATEb
72
78
85
92
97
99
100
173
182
235
276
271
265
261
153
155
248
326
452
502
553
185
204
225
248
263
269
273
155
167
152
119
99
92
86
119
154
200
259
302
318
334
158
174
192
211
224
229
233
139
169
286
359
332
312
298
184
323
553
639
635
634
633
199
219
242
266
283
288
293
177
196
217
241
256
261
266
326
462
467
354
273
243
219
163
185
124
61
60
65
68
228
251
277
305
324
330
337
28
26
24
23
22
22
22
(44–107)
(64–94)
(69–102)
(78–108)
(79–117)
(81–118)
(82–120)
(145–203)
(159–205)
(212–259)
(252–301)
(248–294)
(243–287)
(240–282)
(98–219)
(127–186)
(201–300)
(265–393)
(368–545)
(410–602)
(454–662)
(113–275)
(166–246)
(183–272)
(202–299)
(214–318)
(220–322)
(225–327)
(67–280)
(91–266)
(95–222)
(88–155)
(83–116)
(81–103)
(75–97)
(73–177)
(126–186)
(163–241)
(211–312)
(246–364)
(259–382)
(274–400)
(106–219)
(141–209)
(156–231)
(172–255)
(182–270)
(187–275)
(191–279)
(121–159)
(155–184)
(267–305)
(338–380)
(316–348)
(299–325)
(286–311)
(134–241)
(282–368)
(483–628)
(533–754)
(552–725)
(551–723)
(551–721)
(121–295)
(178–264)
(197–291)
(217–321)
(230–341)
(236–345)
(241–350)
(108–264)
(163–233)
(177–262)
(196–290)
(208–308)
(213–314)
(219–319)
(228–441)
(382–550)
(385–556)
(291–423)
(242–306)
(227–260)
(203–237)
(112–223)
(142–234)
(103–148)
(58–64)
(57–62)
(62–68)
(64–71)
(139–339)
(204–303)
(225–334)
(249–368)
(264–390)
(270–397)
(276–404)
(17–41)
(21–31)
(20–29)
(19–28)
(18–27)
(18–26)
(18–26)
INCIDENCE HIV-POSITIVE
NUMBER
(THOUSANDS)
NOTIFIED NEW AND RELAPSEa
RATEb
0.26
0.86
1.3
1.5
1.6
1.6
1.6
(0.042–0.68)
(0.48–1.3)
(0.84–1.9)
(1–2.2)
(0.87–2.5)
(1–2.4)
(1–2.4)
8.3
27
36
34
32
32
31
0.14
0.46
1.2
1.9
2.8
3.1
3.5
0.014
0.045
0.13
0.31
0.51
0.72
0.54
0.95
5.4
7.5
6.3
5.1
4.9
4.9
1.1
3.1
4.7
6.2
7.4
7.3
8.9
0.057
0.21
0.46
0.69
0.81
0.85
0.89
9.3
24
47
62
58
54
50
0.26
3.4
8.1
9.9
10
10
11
0.035
0.33
0.54
0.56
0.33
0.52
0.91
0.59
0.77
1
1.4
1.6
1.7
1.8
14
31
37
31
24
23
21
0.77
4.1
3
1.4
1.3
1.5
1.5
0.11
0.28
0.54
0.83
1
1.1
1.1
<0.01
<0.01
<0.01
<0.01
0.024
0.021
0.019
(0.065–0.25)
(0.32–0.62)
(0.87–1.6)
(1.4–2.4)
(2–3.6)
(2.3–4)
(2.6–4.5)
(<0.01–0.1)
(<0.01–0.16)
(0.05–0.24)
(0.19–0.47)
(0.32–0.74)
(0.58–0.88)
(0.43–0.66)
(0.055–3.1)
(2.6–9.4)
(4.3–12)
(4.2–8.8)
(4.3–6)
(4.3–5.5)
(4.3–5.6)
(0.021–4)
(1.2–6)
(2.7–7.2)
(4.3–8.5)
(5.1–10)
(6–8.8)
(7.3–11)
(0.021–0.11)
(0.13–0.3)
(0.32–0.63)
(0.49–0.93)
(0.58–1.1)
(0.61–1.1)
(0.64–1.2)
(6–13)
(20–28)
(40–54)
(53–72)
(54–63)
(51–57)
(45–55)
(0.14–0.41)
(2.8–4)
(6.9–9.3)
(8.2–12)
(8.9–12)
(9.1–12)
(9.2–12)
(<0.01–0.086)
(0.19–0.51)
(0.36–0.75)
(0.4–0.75)
(0.28–0.38)
(0.36–0.72)
(0.72–1.1)
(0.29–1)
(0.47–1.1)
(0.62–1.5)
(0.85–2.1)
(0.99–2.4)
(1–2.6)
(1.1–2.7)
(8.6–21)
(25–38)
(29–45)
(24–37)
(22–27)
(21–24)
(19–22)
(0.027–2.7)
(2–6.8)
(2–4.2)
(1–1.9)
(1.2–1.4)
(1.4–1.6)
(1–2)
(0.045–0.21)
(0.17–0.41)
(0.35–0.78)
(0.54–1.2)
(0.66–1.4)
(0.69–1.5)
(0.73–1.6)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.011)
(<0.01–0.017)
(<0.01–0.044)
(<0.01–0.037)
(<0.01–0.035)
15
42
97
136
190
211
233
1.4
4
9.8
21
31
43
31
6.5
32
39
29
22
21
20
18
42
56
69
78
75
89
5.6
18
37
51
55
57
59
39
88
149
174
151
137
122
16
187
410
481
482
485
487
1.6
16
19
18
9.1
14
23
5.3
5.9
6.7
7.8
8.3
8.6
8.8
153
315
326
238
173
157
138
8.9
41
27
11
8.9
10
9.7
5.7
12
21
27
30
31
32
<1
<1
<1
<1
1.8
1.7
1.4
(1.3–22)
(15–42)
(23–51)
(22–48)
(18–50)
(20–46)
(20–45)
(7–27)
(30–57)
(71–127)
(102–175)
(140–248)
(158–271)
(176–299)
(<1–11)
(<1–14)
(3.8–19)
(13–31)
(19–45)
(34–52)
(25–38)
(<1–21)
(15–55)
(23–60)
(19–41)
(19–26)
(18–23)
(18–23)
(<1–69)
(16–80)
(32–86)
(47–94)
(53–107)
(61–91)
(73–106)
(2.1–11)
(11–27)
(25–51)
(36–68)
(40–74)
(41–76)
(42–78)
(26–56)
(75–103)
(128–172)
(148–202)
(140–164)
(129–145)
(110–135)
(8.6–25)
(155–223)
(352–472)
(397–574)
(420–549)
(423–551)
(425–552)
(<1–4)
(8.9–24)
(13–26)
(13–24)
(7.7–11)
(9.3–19)
(18–28)
(2.6–8.9)
(3.6–8.7)
(4–10)
(4.8–12)
(5.1–12)
(5.1–13)
(5.3–13)
(91–229)
(252–384)
(262–397)
(190–291)
(154–194)
(146–168)
(128–149)
(<1–31)
(20–69)
(18–37)
(7.6–14)
(8.1–9.7)
(9.2–11)
(6.7–13)
(2.3–11)
(7.5–18)
(13–30)
(18–39)
(20–43)
(20–45)
(21–46)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–1.4)
(<1–3.5)
(<1–2.9)
(<1–2.7)
NUMBER
117
668
181
79
60
57
55
183
46
139
167
178
183
186
99
103
2 512
4 540
3 073
3 473
183
313
208
231
1 023
91
2 031
2 107
2 145
2 070
6 407
8 636
10 933
12 124
14 149
14 892
14 607
1 988
3 523
5 440
6 863
10 025
8 357
11 038
1 163
1 613
1 273
1 774
2 117
2 171
2 183
11 788
28 142
64 159
102 680
99 941
102 997
99 272
2 525
5 181
9 746
10 802
12 019
12 213
11 674
135
129
128
120
43
51
57
56
61
63
60
35
47
65
76
105
86
111
114
143
103
130
146
146
144
50
103
205
288
260
261
245
154
289
496
523
565
568
538
1 393
1 500
3 432
4 970
5 918
6 597
6 261
21 616
67
53
108
136
154
165
56
165
18 993
22 034
22 758
24 432
12 395
19 155
23 604
25 491
23 929
22 674
21 092
2 933
3 087
4 216
4 704
5 989
6 611
5 291
5 284
3 849
3 067
2 162
2 698
2 640
2 461
119
131
160
125
107
115
122
106
113
113
118
132
194
210
199
171
157
142
34
31
37
36
41
44
34
265
168
116
71
82
78
71
11
12
13
10
8
9
9
a
Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
b
Rates are per 100 000 population.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 127
RATEb
3 699
21 453
6 652
3 549
2 970
2 904
2 870
88 634
26 034
91 101
124 262
141 157
148 936
154 694
917
1 115
CASE DETECTION RATEa
PERCENT
163
854
214
86
62
58
55
106
25
59
61
66
69
72
65
66
–
56
69
41
42
–
44
–
54
49
48
44
28
30
37
47
62
68
70
29
30
33
29
35
27
33
73
82
54
61
65
64
62
36
61
72
80
78
84
82
84
89
90
82
89
90
85
–
30
22
40
48
54
56
31
84
–
44
44
43
44
41
42
45
56
63
65
65
21
17
30
59
69
68
51
116
67
42
23
25
24
21
41
44
55
43
38
41
44
(110–268)
(709–1050)
(177–262)
(73–102)
(51–76)
(48–71)
(46–66)
(90–127)
(22–29)
(54–66)
(56–67)
(60–72)
(64–76)
(66–78)
(45–100)
(55–81)
(47–69)
(57–85)
(35–51)
(35–51)
(37–55)
(45–67)
(41–60)
(40–58)
(37–53)
(15–65)
(19–56)
(26–60)
(36–64)
(52–73)
(61–77)
(62–80)
(19–48)
(25–37)
(27–40)
(24–36)
(29–43)
(22–33)
(28–40)
(52–107)
(68–101)
(44–66)
(51–75)
(54–80)
(53–78)
(52–75)
(32–42)
(56–66)
(67–77)
(76–85)
(75–82)
(80–87)
(79–86)
(64–115)
(78–102)
(79–103)
(69–98)
(78–102)
(79–103)
(75–98)
African Region
INCIDENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
(25–37)
(18–27)
(34–50)
(40–59)
(45–65)
(47–68)
(21–51)
(71–101)
(37–54)
(37–54)
(36–53)
(37–54)
(30–58)
(35–51)
(38–55)
(47–68)
(56–71)
(60–69)
(60–70)
(15–30)
(13–22)
(25–36)
(56–62)
(67–72)
(65–72)
(49–53)
(78–191)
(55–82)
(35–52)
(19–29)
(21–31)
(20–29)
(18–26)
(27–67)
(37–54)
(45–67)
(36–53)
(31–46)
(34–50)
(36–53)
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
127
05/10/11 09:02
7$%/($,QFLGHQFHQRWLILFDWLRQDQGFDVHGHWHFWLRQUDWHVDOOIRUPV±
INCIDENCE (INCLUDING HIV)
YEAR
Mozambique
Namibia
Niger
Nigeria
Rwanda
Sao Tome and
Principe
Senegal
Seychelles
Sierra Leone
South Africa
Swaziland
Togo
Uganda
United Republic
of Tanzania
Zambia
Zimbabwe
128
POPULATION
(MILLIONS)
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
14
16
18
21
22
23
23
1
2
2
2
2
2
2
8
9
11
13
14
15
16
98
110
124
140
151
154
158
7
6
8
9
10
10
11
<1
<1
<1
<1
<1
<1
<1
7
8
10
11
12
12
12
<1
<1
<1
<1
<1
<1
<1
4
4
4
5
6
6
6
37
41
45
48
49
50
50
<1
<1
1
1
1
1
1
4
4
5
5
6
6
6
18
21
24
28
31
32
33
25
30
34
39
42
44
45
8
9
10
11
12
13
13
10
12
13
13
12
12
13
NUMBER
(THOUSANDS)
54
76
93
110
120
120
130
9.8
14
20
21
17
15
14
9.7
13
17
22
26
27
29
130
150
210
240
220
200
210
29
22
23
15
12
12
11
0.16
0.16
0.16
0.16
0.16
0.16
0.16
14
18
23
28
33
34
36
0.031
0.03
0.029
0.028
0.027
0.027
0.027
8.2
11
16
26
34
37
40
110
130
260
440
470
480
490
2.3
3.2
8.5
13
14
15
15
11
14
18
22
25
26
27
110
110
100
87
76
73
70
58
68
80
83
80
79
79
56
70
73
65
62
61
61
31
56
91
100
89
83
80
(7.2–150)
(23–160)
(40–170)
(61–170)
(77–170)
(84–170)
(87–170)
(7.4–13)
(12–17)
(18–23)
(19–24)
(16–19)
(14–16)
(13–15)
(5.9–14)
(10–15)
(14–20)
(18–26)
(21–31)
(22–33)
(24–34)
(0.48–560)
(5.3–540)
(11–710)
(27–700)
(76–430)
(120–310)
(99–360)
(12–53)
(11–37)
(15–34)
(14–16)
(11–13)
(11–13)
(10–13)
(0.096–0.23)
(0.13–0.19)
(0.13–0.19)
(0.13–0.19)
(0.13–0.19)
(0.13–0.19)
(0.13–0.19)
(8.6–21)
(15–22)
(18–27)
(23–34)
(27–39)
(28–41)
(29–43)
(0.019–0.046)
(0.024–0.036)
(0.023–0.035)
(0.023–0.034)
(0.022–0.033)
(0.022–0.032)
(0.022–0.032)
(5–12)
(8.9–13)
(13–19)
(21–32)
(28–41)
(30–44)
(33–48)
(75–150)
(110–160)
(210–310)
(360–530)
(390–570)
(400–580)
(400–590)
(1.4–3.4)
(2.6–3.9)
(7–10)
(10–15)
(11–17)
(12–18)
(13–18)
(6.9–17)
(11–17)
(15–22)
(18–27)
(21–30)
(21–32)
(22–33)
(57–180)
(61–180)
(62–160)
(62–120)
(60–95)
(59–89)
(56–85)
(49–67)
(58–78)
(70–91)
(76–89)
(75–86)
(74–85)
(75–85)
(49–63)
(64–77)
(67–78)
(59–71)
(56–68)
(55–68)
(55–67)
(16–50)
(39–77)
(71–110)
(79–120)
(69–110)
(64–110)
(61–100)
RATEb
401
478
513
524
535
539
544
696
862
1077
1028
793
682
603
125
138
152
168
178
181
185
128
139
172
175
145
130
133
405
394
286
162
123
115
106
135
124
114
105
99
98
96
195
215
237
261
277
282
288
43
40
37
33
32
31
31
207
279
377
509
608
644
682
301
317
576
925
960
971
981
267
337
803
1147
1227
1257
1287
308
339
374
413
438
446
455
624
542
427
304
244
226
209
226
226
236
213
190
183
177
710
788
713
566
500
482
462
296
483
726
799
716
668
633
(53–1091)
(144–1008)
(220–929)
(293–819)
(347–763)
(368–743)
(374–746)
(525–890)
(723–1012)
(938–1225)
(916–1145)
(729–860)
(637–727)
(563–643)
(76–186)
(112–166)
(124–183)
(136–202)
(145–214)
(148–217)
(152–221)
(<1–579)
(4.8–489)
(8.6–571)
(19–498)
(51–288)
(77–198)
(63–228)
(169–740)
(193–665)
(181–415)
(149–176)
(114–132)
(102–128)
(94–118)
(82–201)
(101–150)
(93–137)
(88–123)
(81–120)
(80–117)
(79–115)
(118–289)
(175–259)
(193–285)
(212–315)
(225–334)
(231–339)
(237–345)
(26–64)
(32–48)
(30–44)
(27–40)
(26–38)
(26–38)
(25–37)
(126–308)
(227–337)
(307–454)
(414–613)
(495–733)
(526–774)
(560–816)
(204–416)
(258–382)
(468–694)
(753–1115)
(781–1157)
(794–1165)
(806–1173)
(163–397)
(274–406)
(654–968)
(934–1381)
(998–1479)
(1028–1508)
(1058–1538)
(187–457)
(276–409)
(304–451)
(336–497)
(356–527)
(364–536)
(373–545)
(321–1025)
(291–869)
(256–642)
(218–405)
(191–303)
(181–275)
(168–254)
(192–262)
(192–262)
(206–269)
(196–229)
(178–203)
(171–195)
(166–189)
(623–803)
(718–862)
(660–768)
(518–616)
(452–551)
(433–533)
(417–510)
(156–482)
(332–662)
(570–901)
(630–988)
(554–899)
(510–846)
(486–799)
NOTIFIED NEW AND RELAPSEa
INCIDENCE HIV-POSITIVE
NUMBER
(THOUSANDS)
RATEb
6.9
24
46
62
72
81
77
1.4
5.7
12
13
10
9.1
7.6
0.16
1
2.1
2.6
2.9
3
3.1
13
38
55
62
57
54
51
13
11
10
6.4
4.3
3.9
3.6
(0.99–18)
(7.4–51)
(20–82)
(35–98)
(47–100)
(56–110)
(53–110)
(0.77–2.2)
(4.4–7.2)
(9.8–14)
(11–15)
(9.5–11)
(7.6–11)
(7.1–8.1)
(0.077–0.27)
(0.66–1.4)
(1.4–2.8)
(1.7–3.6)
(1.9–4)
(2.3–3.8)
(2.4–4)
(0.12–56)
(1.7–130)
(3.9–170)
(7.9–170)
(20–110)
(33–80)
(25–87)
(5.2–24)
(4.9–18)
(6–15)
(5.8–7)
(4–4.6)
(3.5–4.4)
(3.2–4)
51
152
251
300
321
355
330
98
345
619
615
473
405
333
2
11
19
20
20
20
20
14
34
44
45
38
35
32
183
189
124
69
43
38
34
<0.01
0.014
0.02
0.018
0.2
0.72
1.4
2.2
2.8
3
3.2
(<0.01–0.011)
(<0.01–0.028)
(<0.01–0.035)
(<0.01–0.03)
(0.071–0.39)
(0.46–1)
(0.89–2)
(1.4–3.1)
(2.2–3.5)
(2.6–3.5)
(2.6–4)
3.4
8.6
12
11
2.7
8.6
14
20
24
25
26
<0.01
<0.01
0.013
0.2
1.1
2.7
3.9
4.2
4
8.3
47
140
260
280
280
300
0.48
1.8
6.4
10
12
12
13
0.49
2.1
3.6
4.6
5.1
5.2
5.4
72
73
61
48
44
41
38
20
31
37
36
33
31
30
33
48
49
44
42
41
40
18
48
78
81
69
65
60
(<0.01–0.012)
(<0.01–<0.01)
(<0.01–0.028)
(<0.01–0.68)
(0.56–1.9)
(1.8–3.7)
(3.2–4.8)
(3.4–5.1)
(3.3–4.8)
(4.7–13)
(36–59)
(120–180)
(210–320)
(230–340)
(230–330)
(240–350)
(0.26–0.76)
(1.4–2.2)
(5.2–7.8)
(8.3–12)
(9.5–14)
(10–15)
(10–15)
(0.14–1.1)
(1.4–2.9)
(2.6–4.7)
(3.3–6.1)
(3.7–6.7)
(4.2–6.4)
(4.3–6.5)
(37–120)
(39–120)
(36–93)
(33–66)
(34–54)
(33–49)
(30–46)
(15–25)
(25–38)
(30–45)
(30–43)
(31–35)
(30–33)
(28–32)
(22–48)
(42–54)
(44–56)
(38–50)
(38–46)
(37–45)
(36–44)
(9.4–30)
(33–65)
(61–97)
(64–100)
(54–86)
(49–82)
(47–76)
6.3
1.8
<1
5.1
27
52
70
74
68
23
112
321
544
569
563
591
56
187
605
932
###
###
###
13
50
75
85
88
89
89
407
349
252
169
139
126
112
77
103
109
93
78
72
67
426
537
485
382
341
324
302
173
409
623
647
555
518
480
NUMBER
RATEb
15 899
17 882
21 158
33 231
39 261
43 221
43 558
2 671
1 540
10 799
14 920
13 440
11 980
11 281
5 200
1 980
4 701
7 873
9 209
9 904
10 130
20 122
13 423
25 821
62 598
85 674
88 589
84 121
6 387
3 054
6 093
7 220
7 472
7 251
6 703
17
117
112
116
160
176
189
186
189
93
570
717
611
534
494
67
22
43
61
64
66
65
21
12
21
45
57
57
53
90
55
75
78
75
70
63
15
97
136
66
78
121
4 977
7 561
8 508
9 765
11 040
11 139
11 061
41
8
20
14
6
15
17
632
1 955
3 760
6 737
10 786
11 524
12 859
80 400
73 917
151 239
270 178
343 855
360 183
354 786
69
89
41
48
73
69
90
90
90
94
92
89
58
11
25
17
7
17
20
16
50
91
131
192
201
219
219
179
338
565
697
724
708
2 050
5 877
8 062
8 685
10 038
10 101
1 324
1 520
1 409
2 537
2 967
2 986
2 791
14 740
25 316
30 372
41 040
42 178
41 703
42 885
22 249
39 847
54 442
61 022
60 490
61 537
61 098
16 863
35 958
49 806
49 576
43 686
44 879
44 154
9 132
30 831
50 855
50 454
36 650
42 971
44 209
213
552
730
755
859
852
36
37
29
47
51
51
46
83
122
125
144
135
129
128
87
133
160
157
143
141
136
215
403
488
433
353
353
337
87
264
407
401
294
344
352
(7.3–136)
(47–318)
(108–453)
(168–470)
(210–455)
(244–486)
(228–449)
(54–153)
(264–436)
(516–732)
(525–713)
(433–515)
(338–478)
(311–356)
(<1–3.4)
(7.2–15)
(13–26)
(13–27)
(13–28)
(15–25)
(15–26)
(<1–57)
(1.5–115)
(3.2–138)
(5.6–123)
(13–76)
(22–52)
(16–55)
(73–343)
(88–327)
(74–187)
(63–76)
(40–46)
(34–43)
(30–38)
(<1–7.5)
(2.9–17)
(5.7–21)
(5.7–18)
(<1–5.3)
(5.5–12)
(9.4–21)
(13–29)
(18–30)
(21–29)
(21–32)
(1.2–14)
(<1–8)
(<1–<1)
(<1–18)
(13–46)
(35–73)
(57–85)
(60–89)
(56–82)
(13–35)
(86–142)
(257–391)
(438–661)
(458–693)
(463–673)
(488–704)
(30–88)
(145–233)
(486–737)
(755–1127)
(828–1221)
(852–1245)
(873–1256)
(3.8–29)
(34–71)
(54–98)
(62–112)
(64–116)
(71–108)
(72–108)
(209–669)
(187–561)
(148–384)
(117–231)
(108–173)
(102–152)
(91–136)
(60–97)
(82–126)
(88–132)
(78–110)
(73–83)
(68–77)
(62–71)
(274–610)
(469–609)
(428–546)
(333–434)
(309–375)
(291–357)
(273–332)
(89–282)
(282–559)
(487–775)
(506–806)
(435–689)
(397–655)
(371–603)
a
Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
b
Rates are per 100 000 population.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 128
CASE DETECTION RATEa
PERCENT
29
23
23
31
33
35
34
27
11
53
70
77
78
82
53
16
28
36
36
37
35
16
9
12
26
39
44
40
22
14
26
48
61
61
60
11
–
60
85
42
49
76
35
42
38
34
34
33
31
133
27
70
50
22
56
64
8
18
24
26
32
31
32
73
56
59
61
73
75
72
–
63
69
64
62
68
66
12
11
8
11
12
11
10
13
22
29
47
55
57
61
39
59
68
74
75
77
77
30
51
68
76
71
73
73
29
55
56
50
41
52
56
(11–222)
(11–78)
(13–53)
(20–55)
(23–51)
(25–51)
(25–50)
(21–36)
(9–13)
(46–61)
(63–78)
(71–84)
(73–84)
(77–88)
(36–88)
(13–19)
(23–35)
(30–44)
(30–44)
(30–45)
(30–43)
(4–4184)
(2–254)
(4–242)
(9–232)
(20–112)
(29–75)
(23–85)
(12–53)
(8–28)
(18–42)
(45–53)
(57–65)
(55–69)
(54–67)
(7–18)
(50–74)
(72–102)
(34–51)
(41–60)
(64–93)
(24–58)
(35–52)
(31–46)
(29–42)
(28–42)
(27–40)
(26–38)
(90–219)
(22–33)
(58–86)
(42–62)
(18–27)
(46–68)
(53–78)
(5–13)
(15–22)
(20–30)
(21–32)
(26–39)
(26–38)
(27–39)
(53–107)
(47–69)
(49–72)
(51–75)
(60–89)
(62–91)
(60–88)
(52–78)
(57–85)
(53–78)
(51–76)
(57–84)
(55–80)
(8–19)
(9–13)
(7–10)
(9–14)
(10–14)
(9–14)
(8–12)
(8–26)
(14–42)
(20–49)
(36–66)
(44–70)
(47–71)
(51–76)
(33–45)
(51–69)
(60–78)
(69–80)
(71–81)
(73–83)
(72–82)
(27–34)
(47–56)
(64–74)
(70–84)
(64–78)
(66–81)
(66–81)
(18–56)
(40–80)
(45–71)
(41–64)
(33–53)
(41–67)
(44–72)
Data can be downloaded from www.who.int/tb/data
05/10/11 09:02
7$%/($&DVHQRWLILFDWLRQV±
YEAR
Algeria
• 46
63 •
Angola
• 99
234 •
Benin
• 43
42 •
Botswana
• 213
349 •
Burkina Faso
• 16
29 •
Burundi
• 82
91 •
Cameroon
• 48
123 •
Cape Verde
• 63
72 •
Central African
Republic
• 72
151 •
Chad
• 43
84 •
Comoros
• 32
17 •
Congo
• 25
251 •
Côte d'Ivoire
• 63
115 •
Democratic
Republic
of the Congo
• 58
173 •
Equatorial
Guinea
• 70
a
117 •
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
NEW AND
RELAPSEa
11 607
13 507
18 572
21 336
20 588
21 701
22 336
10 271
5 143
16 062
37 175
44 576
41 221
44 655
2 074
2 400
2 697
3 270
3 872
3 878
3 756
2 938
5 665
9 292
10 058
8 891
8 362
7 013
1 497
2 572
2 331
3 478
4 238
4 716
4 800
4 575
3 326
6 421
6 585
6 808
7 277
7 611
5 892
3 292
5 251
21 499
24 622
24 662
24 073
221
303
292
334
332
356
2 124
3 339
SMEAR- SMEAR-NEGATIVE/
POSITIVE
UNKNOWN
EXTRAPULMONARY
5 735
8 328
8 654
8 643
8 402
8 299
2 256
2 019
1 651
1 528
1 691
1 770
5 065
7 758
10 216
9 908
10 888
11 770
3 804
9 053
20 410
22 562
22 488
21 146
1 410
1 839
2 277
2 739
2 966
2 960
2 973
1 631
5 367
12 467
16 490
13 755
17 285
310
281
130
96
375
338
296
266
1 102
2 569
3 287
2 580
3 780
182
212
199
285
400
418
367
1 903
3 091
3 170
3 217
3 144
3 295
2 885
4 789
5 166
3 654
3 393
2 055
1 028
1 545
2 290
2 757
3 061
3 041
OTHER RELAPSE
267
0
230
0
451
467
548
509
490
497
0
0
0
134
540
1 729
2 237
2 398
2 444
172
68
91
150
131
162
120
720
1 231
1 220
1 679
1 429
1 210
195
196
367
625
679
736
1 121
3 159
3 262
3 610
3 974
4 590
RE-TREAT EXCL. TOTAL
HISTORY
RELAPSE
RETREAT UNKNOWN
80
165
142
122
194
451
547
713
651
612
691
0
0
189
187
105
109
85
134
540
2 871
3 584
3 863
7 776
221
68
280
337
236
271
205
0
0
0
147
181
502
341
396
453
1 058
46
754
726
619
147
1 239
548
1 095
1 122
1 072
0
0
0
195
502
571
599
671
729
90
68
92
77
45
88
160
189
213
217
90
167
311
395
335
45
178
327
500
608
552
0
0
0
0
0
908
1 489
1 160
862
1 207
963
1 116
1 568
2 089
2 188
1 880
1 826
0
0
0
24
8
181
205
74
148
192
224
20
42
57
46
108
181
225
116
205
238
332
0
0
0
0
0
2 896
3 960
13 001
14 232
14 635
14 464
142
625
5 021
6 282
5 780
5 437
18
415
2 461
3 191
3 190
3 157
236
251
1 016
917
1 057
1 015
574
503
512
479
236
251
1 590
1 420
1 569
1 494
0
0
0
0
111
150
12
135
197
172
186
93
82
94
98
43
39
53
54
0
0
0
0
0
1 142
1 347
1 465
5 332
49
30
0
0
0
21
16
13
18
0
0
0
0
0
30
13
15
20
9
0
0
0
1 794
964
393
3 210
6 803
8 743
6 643
2 591
3 186
2 153
4 232
5 132
3 638
608
1 387
1 841
1 598
286
943
1 394
1 079
2 002
518
463
6 311
6 912
8 411
9 452
140
123
120
111
132
120
123
591
3 615
9 239
9 853
8 886
9 765
10 150
7 841
11 988
15 094
19 681
23 688
22 571
22 708
21 131
42 819
61 024
97 075
104 861
111 709
114 170
260
306
2 516
3 309
3 820
3 833
2 419
2 331
2 949
3 746
1 055
924
1 206
1 217
0
0
193
321
348
436
463
194
283
240
245
515
631
676
708
0
0
0
103
87
79
77
76
10
14
14
20
15
7
15
16
27
24
0
5
0
7
4
2
3
5
1
1
3
1
7
5
3
6
6
0
2
8
2 013
4 218
3 640
3 371
3 433
3 568
849
2 016
3 249
2 868
3 398
3 545
675
2 810
2 665
2 345
2 653
2 692
78
169
299
302
281
345
650
108
171
170
171
78
819
407
473
451
516
8 254
10 276
12 496
15 294
14 300
14 131
1 508
1 616
2 315
2 733
2 321
2 381
1 577
2 756
4 235
4 592
4 952
5 179
0
0
0
0
0
649
446
635
1 069
998
1 017
447
345
360
438
502
649
893
980
1 429
1 436
1 519
0
0
0
0
0
20 914
36 513
65 040
69 720
73 078
73 653
7 953
8 089
9 959
11 490
12 968
14 039
9 112
13 785
18 494
19 654
21 313
22 340
0
2 891
2 637
3 582
3 997
4 350
4 138
2 483
3 741
4 316
4 466
2 891
2 637
6 065
7 738
8 666
8 604
0
219
45
41
541
490
579
92
109
98
58
77
109
718
707
820
188
34
31
33
27
0
0
24
163
241
376
304
188
128
132
253
117
203
0
291
373
629
421
27
31
34
0
203
1
0
0
0
0
0
0
1
23
13
33
50
44
67
0
0
0
% SMEARPOS AMONG
NEW PULM
–
72
80
84
85
83
82
–
70
63
62
58
62
55
82
87
95
97
89
90
91
–
40
39
38
47
48
62
–
84
89
86
82
82
81
–
55
68
74
81
77
83
–
95
86
72
69
72
73
–
43
–
59
71
65
65
–
65
–
78
75
74
69
–
79
–
51
59
56
51
–
91
86
85
79
84
–
–
70
68
53
54
50
50
–
85
86
84
85
86
86
–
72
82
87
86
85
84
–
83
–
–
85
82
86
African Region
NEW CASES
NEW AND RELAPSE
NOTIFICATION RATEa
1990–2010
Rates are per 100 000 population. Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 129
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
129
05/10/11 09:02
7$%/($&DVHQRWLILFDWLRQV±
NEW CASES
NEW AND RELAPSE
NOTIFICATION RATEa
1990–2010
YEAR
Eritrea
• 117
55 •
Ethiopia
• 183
186 •
Gabon
• 99
231 •
Gambia
–
120 •
Ghana
• 43
60 •
Guinea
• 35
111 •
Guinea-Bissau
• 114
144 •
Kenya
• 50
245 •
Lesotho
• 154
538 •
Liberia
–
165 •
Madagascar
• 56
118 •
Malawi
• 132
142 •
Mali
• 34
34 •
Mauritania
• 265
71 •
Mauritius
• 11
a
130
9•
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
NEW AND
RELAPSEa
3 699
21 453
6 652
3 549
2 970
2 904
2 870
88 634
26 034
91 101
124 262
141 157
148 936
154 694
917
1 115
2 512
4 540
3 073
3 473
SMEAR- SMEAR-NEGATIVE/
POSITIVE
UNKNOWN
EXTRAPULMONARY
OTHER RELAPSE
590
687
839
802
832
18 205
5 332
1 764
1 063
1 123
1 115
3 248
683
1 001
880
890
836
9 040
30 510
38 525
40 794
44 396
46 634
8 888
30 565
39 816
49 372
52 053
54 979
7 763
28 907
43 675
48 794
50 228
50 417
486
517
68
44
1 042
1 502
1 244
1 560
1 071
2 306
1 414
1 366
241
419
246
379
RE-TREAT EXCL. TOTAL
HISTORY
RELAPSE
RETREAT UNKNOWN
79
0
0
47
97
109
89
87
20
27
36
118
121
67
124
145
207
208
0
343
1 119
2 246
2 197
2 259
2 664
1 658
873
752
1 285
2 234
343
2 777
3 119
2 949
3 544
4 898
155
0
0
158
158
169
168
99
138
486
390
257
296
655
558
0
0
0
81
77
81
66
40
89
62
41
41
166
143
107
81
0
0
0
0
159
502
532
446
466
483
318
394
538
159
502
532
764
860
1 021
0
0
0
294
227
320
241
286
55
446
458
671
589
648
0
16
0
36
0
0
44
6
0
317
1 023
778
171
68
2 031
2 107
2 145
2 070
6 407
8 636
10 933
12 124
14 149
14 892
14 607
1 988
3 523
5 440
6 863
10 025
8 357
11 038
1 163
1 613
1 273
1 774
2 117
2 171
2 183
11 788
28 142
64 159
102 680
99 941
102 997
99 272
2 525
5 181
9 746
10 802
12 019
12 213
11 674
1 127
1 300
1 316
1 344
749
610
622
462
78
116
141
143
2 638
7 316
7 505
7 904
8 255
7 656
1 225
2 500
3 068
4 416
4 734
5 068
109
615
1 019
1 383
1 437
1 400
2 263
3 920
5 479
6 561
5 377
7 041
527
430
524
1 288
1 021
1 472
620
938
629
1 825
1 611
2 077
0
0
86
55
152
231
351
348
362
956
526
1 132
1 223
1 310
1 409
6 800
13 934
28 773
40 389
36 811
37 402
36 260
714
600
522
797
786
636
19
57
24
28
16
22
0
0
0
0
59
90
96
69
59
116
42
13
17
76
59
90
138
82
76
192
0
0
0
0
9 676
24 143
43 772
46 115
44 514
41 962
3 468
9 118
15 265
16 881
17 438
17 382
1 064
1 773
3 254
134
3 643
3 668
704
5 721
10 310
7 068
6 811
1 064
2 477
8 975
10 444
10 711
10 479
0
1 361
3 041
4 280
3 862
3 976
3 600
2 685
2 838
4 063
4 879
5 083
5 331
653
2 520
2 020
2 692
2 486
2 222
147
385
439
586
668
521
1 096
602
1 200
1 302
1 464
147
1 481
1 041
1 786
1 970
1 985
1 393
1 500
3 432
4 970
5 918
6 597
6 261
21 616
1 154
1 021
2 167
3 038
3 796
3 750
119
285
575
941
1 022
1 385
120
187
657
912
1 023
1 363
7
33
79
77
99
25
24
53
46
71
32
57
132
123
170
8 026
987
2 219
18 993
22 034
22 758
24 432
12 395
19 155
23 604
25 491
23 929
22 674
21 092
2 933
3 087
4 216
4 704
5 989
6 611
5 291
5 284
3 849
3 067
2 162
2 698
2 640
2 461
119
131
160
125
107
115
122
13 056
15 391
15 729
16 795
4 301
6 285
8 260
8 443
7 627
7 623
7 240
1 287
1 311
1 639
1 657
5 827
7 054
8 846
10 132
10 155
9 297
8 245
3 634
4 111
3 990
4 545
1 885
5 257
5 734
5 823
5 369
4 966
4 857
482
741
689
674
1 866
2 527
3 530
4 734
5 163
3 686
609
797
482
403
429
481
459
653
492
660
818
926
2 074
1 583
1 155
1 605
1 555
1 422
800
687
454
415
444
390
455
580
403
512
483
524
113
115
110
85
98
105
8
14
4
14
7
5
12
23
8
5
6
6
0
0
0
0
0
6
596
0
0
0
0
0
0
0
0
596
0
0
1 016
1 221
1 400
1 435
382
551
764
1 093
778
788
750
0
2 119
1 755
1 682
1 444
1 498
1 962
2 089
2 109
382
551
764
3 212
2 533
2 470
2 194
0
0
0
153
239
200
192
201
198
180
219
224
157
153
239
380
411
425
355
0
0
520
580
150
166
158
125
358
56
28
24
28
520
938
206
194
182
153
0
0
0
2
8
3
3
4
6
4
2
1
1
1
2
12
5
4
5
7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
% SMEARPOS AMONG
NEW PULM
–
–
10
28
44
42
43
–
50
50
49
45
46
46
–
48
–
49
39
47
53
–
82
–
60
68
68
74
–
68
75
71
64
64
60
–
81
90
91
84
84
83
–
57
47
68
61
63
69
–
59
54
48
44
46
46
–
34
52
51
44
44
40
–
91
78
79
76
79
73
–
89
–
91
92
91
91
42
47
48
45
43
45
47
–
75
76
88
92
92
88
–
72
70
72
79
78
78
–
93
89
96
86
93
95
Rates are per 100 000 population. Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 130
Data can be downloaded from www.who.int/tb/data
05/10/11 09:02
7$%/($&DVHQRWLILFDWLRQV±
YEAR
Mozambique
• 117
186 •
Namibia
• 189
494 •
Niger
• 67
65 •
Nigeria
• 21
53 •
Rwanda
• 90
63 •
Sao Tome and
Principe
• 15
73 •
Senegal
• 69
89 •
Seychelles
• 58
20 •
Sierra Leone
• 16
219 •
South Africa
• 219
708 •
Swaziland
–
852 •
Togo
• 36
46 •
Uganda
• 83
128 •
United Republic
of Tanzania
• 87
136 •
Zambia
• 215
337 •
Zimbabwe
• 87
a
352 •
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
NEW AND
RELAPSEa
15 899
17 882
21 158
33 231
39 261
43 221
43 558
2 671
1 540
10 799
14 920
13 440
11 980
11 281
5 200
1 980
4 701
7 873
9 209
9 904
10 130
20 122
13 423
25 821
62 598
85 674
88 589
84 121
6 387
3 054
6 093
7 220
7 472
7 251
6 703
17
97
136
66
78
121
4 977
7 561
8 508
9 765
11 040
11 139
11 061
41
8
20
14
6
15
17
632
1 955
3 760
6 737
10 786
11 524
12 859
80 400
73 917
151 239
270 178
343 855
360 183
354 786
2 050
5 877
8 062
8 685
10 038
10 101
1 324
1 520
1 409
2 537
2 967
2 986
2 791
14 740
25 316
30 372
41 040
42 178
41 703
42 885
22 249
39 847
54 442
61 022
60 490
61 537
61 098
16 863
35 958
49 806
49 576
43 686
44 879
44 154
9 132
30 831
50 855
50 454
36 650
42 971
44 209
SMEAR- SMEAR-NEGATIVE/
POSITIVE
UNKNOWN
EXTRAPULMONARY
10 566
13 257
17 877
18 824
19 579
20 097
5 054
4 037
9 184
14 117
17 019
16 408
1 363
2 262
4 771
5 012
5 301
5 621
697
4 012
5 222
4 928
4 608
4 464
507
4 724
4 455
3 714
3 628
3 309
248
1 459
1 907
2 582
2 538
2 330
1 492
3 045
5 050
5 853
6 347
6 283
116
699
1 193
1 593
1 689
1 730
372
702
1 227
1 227
1 385
1 492
9 476
17 423
35 048
46 026
44 863
45 416
3 364
6 613
22 705
34 211
37 540
32 616
280
1 069
2 836
3 026
3 560
3 422
1 840
3 681
4 166
4 173
4 184
3 785
676
845
859
1 311
1 239
1 072
338
1 289
1 727
1 743
1 582
1 577
30
49
52
52
47
56
75
11
20
63
7
1
0
4
10
5 421
5 823
6 722
7 584
7 883
7 688
1 073
1 370
1 557
1 580
1 504
1 470
504
800
921
1 283
1 233
1 404
6
11
8
4
11
9
2
7
3
0
2
8
1
2
1
2
2
0
1 454
2 472
4 370
5 826
6 092
6 898
339
821
1 679
3 952
4 491
4 919
121
400
551
854
776
831
23 112
75 967
125 460
138 803
139 468
132 107
74 399
16 392
76 680
132 972
147 187
151 772
10 636
17 486
39 739
48 251
53 411
52 095
660
1 823
2 187
3 105
3 498
3 011
687
3 198
4 106
3 379
4 157
5 064
219
583
1 458
1 762
1 903
1 631
887
984
1 798
2 234
2 267
2 096
304
91
170
231
235
164
236
287
484
408
377
397
13 631
17 246
20 559
22 766
23 113
23 456
11 553
19 955
24 049
25 264
24 171
24 895
24 769
5 912
9 003
15 040
13 190
12 315
13 567
2 070
2 618
3 780
4 710
4 893
4 571
12 362
17 624
20 810
21 935
21 750
21 184
10 038
12 927
14 857
13 211
12 995
12 639
8 965
14 392
13 155
9 830
10 195
11 654
OTHER RELAPSE
RE-TREAT EXCL. TOTAL
HISTORY
RELAPSE
RETREAT UNKNOWN
899
917
1 399
1 308
1 322
1 432
546
487
474
2 308
2 616
899
1 463
1 886
1 782
3 630
4 048
88
604
849
1 142
1 206
1 178
930
974
297
1 352
1 344
88
1 534
1 823
1 439
2 558
2 522
103
0
173
255
403
433
483
452
351
184
207
215
255
754
617
690
667
117
0
0
0
0
0
303
716
2 009
2 411
2 626
2 667
1 640
2 858
4 637
5 525
6 326
303
2 356
4 867
7 048
8 151
8 993
1 392
0
0
0
200
278
371
245
246
269
96
460
152
229
362
200
374
831
397
475
631
4
11
3
2
1
16
3
1
1
4
27
6
3
2
2
0
0
0
0
0
563
515
565
593
519
499
541
355
551
593
530
563
1 056
920
1 144
1 112
1 029
0
0
0
0
0
0
0
0
0
2
0
0
0
0
0
0
0
0
0
2
0
0
0
0
0
0
41
67
137
154
165
211
374
193
235
302
336
41
441
330
389
467
547
28 299
23 829
20 117
18 812
56 202
32 289
40 641
45 799
41 768
179
56 202
60 588
64 470
65 916
60 580
489
273
311
439
480
395
976
159
880
994
1 045
489
1 249
470
1 319
1 474
1 440
0
0
0
93
47
85
94
107
134
86
94
102
107
106
93
133
179
196
214
240
4
0
0
0
0
0
0
0
955
1 505
1 661
1 512
1 382
1 291
0
769
1 665
2 632
2 661
955
1 505
2 430
3 177
4 014
3 952
0
6 195
10 997
13 094
12 784
13 405
13 715
1 335
1 772
1 854
1 600
1 487
1 430
3 178
2 874
2 730
2 355
1 335
1 772
5 032
4 474
4 217
3 785
3 268
25 222
24 327
19 344
20 825
20 412
656
10 202
8 587
9 580
9 246
9 255
0
0
0
243
1 455
1 805
1 551
1 813
1 848
3 691
3 685
672
4 462
243
1 455
5 496
5 236
2 485
6 310
10 934
27 626
29 074
19 956
24 890
25 157
5 040
8 837
6 721
5 931
6 683
6 061
0
0
0
0
1 504
933
1 203
1 337
4 437
2 698
3 482
3 348
5 941
3 631
4 685
4 685
0
0
0
2 487
1 074
0
97
0
0
0
0
0
0
0
0
179
0
0
0
0
0
0
737
0
0
0
0
0
0
217
164
0
0
4 386
0
0
643
0
0
0
0
0
0
737
0
0
% SMEARPOS AMONG
NEW PULM
–
68
77
66
57
53
55
–
58
46
54
57
56
57
–
93
81
81
79
79
78
–
74
72
61
57
54
58
–
73
81
83
76
77
78
–
–
35
40
83
72
43
–
83
81
81
83
84
84
–
75
61
73
100
85
53
–
81
75
72
60
58
58
–
24
82
62
51
49
47
–
49
36
35
48
46
37
–
74
92
91
91
91
93
–
70
66
58
63
65
63
–
62
58
55
52
53
54
–
75
34
38
41
38
38
–
45
34
31
33
29
32
African Region
NEW CASES
NEW AND RELAPSE
NOTIFICATION RATEa
1990–2010
Rates are per 100 000 population. Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 131
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
131
05/10/11 09:03
7$%/($7UHDWPHQWRXWFRPHVQHZVPHDUSRVLWLYHFDVHV±
% OF COHORT
TREATMENT SUCCESS (%)a
1995–2009
YEAR
Algeria
–
91 •
Angola
–
72 •
• 71
90 •
• 67
79 •
• 25
76 •
• 45
90 •
• 53
78 •
Benin
Botswana
Burkina Faso
Burundi
Cameroon
Cape Verde
–
–
Central African
Republic
• 37
53 •
Chad
• 47
76 •
• 90
–
Comoros
Congo
–
78 •
• 68
79 •
• 74
88 •
• 89
66 •
Côte d'Ivoire
Democratic
Republic
of the Congo
Equatorial
Guinea
Eritrea
–
85 •
• 61
84 •
Ethiopia
a
132
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
NUMBER
NOTIFIED
5 735
8 328
8 654
8 439
8 643
8 402
3 804
9 053
20 410
21 422
22 562
22 488
1 839
2 277
2 739
2 770
2 966
2 960
1 903
3 091
3 170
3 122
3 217
3 144
1 028
1 545
2 290
2 605
2 757
3 061
1 121
3 159
3 262
3 595
3 610
3 974
2 896
3 960
13 001
13 220
14 232
14 635
111
135
158
197
172
1 794
2 153
4 232
5 132
2 002
2 516
2 513
3 309
3 820
103
87
79
SIZE OF
COHORT
8 328
8 379
8 510
8 190
8 438
6 392
20 113
21 422
22 562
21 627
1 839
2 277
2 766
2 771
2 979
2 963
2 060
3 991
3 335
3 335
3 289
3 492
1 200
1 574
2 290
2 605
2 757
3 061
1 798
3 465
3 424
3 169
3 635
3 974
2 740
3 164
13 169
13 025
14 091
14 428
14
135
197
692
1 366
3 217
4 130
3 571
5 132
529
3 820
113
85
70
56
77
77
76
2 013
4 218
3 640
3 552
3 371
3 433
8 254
10 276
12 496
14 071
15 294
14 300
20 914
36 513
65 040
66 099
69 720
73 078
219
3 263
3 634
7 221
10 631
12 496
14 071
15 294
14 300
16 247
36 123
65 066
65 975
65 962
72 367
219
541
490
436
541
490
590
687
694
839
802
9 040
30 510
38 525
38 040
40 794
44 396
765
688
795
839
804
5 087
29 662
39 430
38 078
40 794
44 807
3 114
4 121
COHORT AS
% NOTIFIED
–
100
97
101
95
100
–
71
99
100
100
96
100
100
101
100
100
100
108
129
105
107
102
111
117
102
100
100
100
100
160
110
105
88
101
100
95
80
101
99
99
99
–
–
100
–
100
–
39
–
149
–
84
100
26
–
–
–
–
100
110
98
89
–
100
–
–
74
113
–
97
106
87
103
100
100
100
100
78
99
100
100
95
99
100
–
–
–
100
100
–
130
100
115
100
100
56
97
102
100
100
101
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
80
74
79
80
81
7
13
11
10
10
1
2
2
2
2
2
0
1
0
1
5
3
4
3
3
5
8
4
4
3
68
45
48
45
47
50
57
74
79
81
82
13
22
37
50
46
57
22
53
66
67
73
72
25
42
52
74
76
83
45
67
66
61
62
65
28
26
24
25
21
20
13
8
8
9
54
55
33
23
18
22
2
7
5
5
3
4
20
39
27
12
14
7
8
10
7
15
15
13
3
3
3
4
4
6
6
7
6
6
5
5
6
7
5
5
5
5
13
14
14
11
10
3
4
4
5
4
3
7
7
6
7
6
6
2
3
2
2
2
1
2
2
3
2
2
1
0
1
2
2
3
1
2
7
7
8
9
0
0
0
1
0
1
1
2
1
1
1
1
26
19
18
18
18
17
11
3
3
2
1
12
7
8
6
4
4
3
16
6
6
4
4
14
13
17
8
6
5
35
13
14
11
10
10
2
3
3
6
5
5
3
1
1
1
0
15
10
15
15
24
9
67
9
1
1
1
2
38
1
1
0
0
0
4
1
5
6
5
5
64
56
0
8
7
3
0
2
0
19
29
12
57
17
4
2
11
11
16
36
38
47
43
33
17
21
21
28
20
29
20
30
7
0
6
8
7
3
6
0
3
2
2
2
1
1
53
34
8
12
12
13
43
3
5
19
11
9
30
3
55
90
91
91
91
90
22
0
2
0
2
0
4
4
4
3
2
4
2
0
4
4
4
0
15
6
0
0
2
4
3
0
0
1
0
3
57
24
12
4
4
0
0
1
22
13
5
58
63
66
63
47
63
62
67
69
55
69
80
83
83
85
89
13
12
6
10
11
11
9
10
20
8
5
4
4
3
0
1
1
4
5
8
7
9
8
5
6
6
4
4
4
3
0
0
1
2
2
1
2
3
1
1
1
1
1
1
0
21
13
17
16
10
13
9
7
10
8
4
4
3
3
8
1
7
9
20
6
5
4
4
9
7
4
4
4
4
0
60
42
47
0
14
19
7
4
3
1
1
1
26
31
16
6
7
14
64
83
83
72
83
56
63
64
67
67
65
12
5
5
3
2
5
17
14
17
17
19
8
7
5
4
5
5
6
5
4
3
3
1
1
2
1
3
2
1
1
1
1
1
9
2
2
1
2
13
9
4
3
3
3
6
1
3
18
5
19
4
12
8
10
10
TREATMENT SUCCESS = percent cured + percent completed then rounded to the nearest digit.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 132
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($7UHDWPHQWRXWFRPHVQHZVPHDUSRVLWLYHFDVHV±
% OF COHORT
Gabon
• 86
55 •
Gambia
• 76
89 •
• 54
87 •
• 78
79 •
Ghana
Guinea
Guinea-Bissau
• 65
67 •
• 75
86 •
Kenya
Lesotho
• 47
70 •
Liberia
• 79
83 •
Madagascar
• 55
82 •
• 71
88 •
Malawi
Mali
• 59
78 •
Mauritania
–
63 •
Mauritius
–
88 •
• 39
85 •
Mozambique
Namibia
–
85 •
Niger
–
79 •
• 49
83 •
Nigeria
a
YEAR
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
NUMBER
NOTIFIED
SIZE OF
COHORT
COHORT AS
% NOTIFIED
51
–
112
102
100
93
88
–
100
97
101
98
14
100
101
100
100
100
100
100
106
100
76
104
100
–
103
–
102
114
46
99
100
100
100
100
131
–
129
100
100
102
138
90
100
–
100
100
113
–
117
99
100
100
100
100
100
106
100
100
69
–
100
100
100
86
–
–
152
100
100
101
–
139
100
100
100
100
100
100
100
100
100
100
–
100
100
100
100
102
–
105
100
99
100
99
100
94
100
100
100
100
486
249
1 042
1 462
1 502
1 244
778
1 165
1 484
1 502
1 163
686
1 127
1 238
1 300
1 316
2 638
7 316
7 505
7 429
7 904
8 255
2 263
3 920
5 479
6 199
6 561
5 377
956
526
1 132
1 127
1 199
1 318
1 296
361
7 316
7 584
7 429
7 904
8 255
2 263
3 920
5 811
6 199
4 984
5 597
959
1 223
1 310
13 934
28 773
40 389
38 360
36 811
37 402
1 361
3 041
4 280
3 723
3 862
3 976
1 154
1 021
2 167
3 038
3 796
8 026
13 056
15 344
15 391
15 729
6 285
8 260
8 443
7 608
7 627
7 623
1 866
2 527
3 530
3 894
4 734
5 163
2 074
1 583
1 155
1 714
1 605
1 555
113
115
110
86
85
98
10 566
13 257
17 877
18 214
18 824
19 579
697
4 012
5 222
5 114
4 928
4 608
1 492
3 045
5 050
5 773
5 853
6 347
9 476
17 423
35 048
44 016
46 026
44 863
1 167
1 237
1 242
1 498
6 470
28 376
40 436
38 360
36 811
37 402
1 788
5 542
3 728
3 858
4 070
1 595
924
2 167
2 309
3 042
3 796
9 101
10 506
15 298
15 261
15 376
15 709
6 293
8 296
8 443
8 065
7 632
7 624
1 290
3 530
3 897
4 734
4 454
1 761
1 716
1 605
1 563
160
110
86
85
98
10 566
13 296
17 877
18 214
18 824
19 579
4 012
5 222
5 114
4 928
4 702
3 193
5 050
5 722
5 860
6 313
9 476
16 372
35 080
44 070
46 026
44 863
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
63
22
1
2
9
2
35
22
30
37
69
12
14
24
18
7
10
3
1
1
5
1
0
0
1
1
42
18
19
25
13
1
43
27
18
5
81
80
80
88
41
45
68
77
78
79
62
59
65
71
70
72
42
6
4
4
1
13
5
5
7
8
8
17
9
7
8
8
6
23
7
8
9
6
11
6
9
9
8
7
6
7
6
4
5
5
6
1
2
2
1
2
3
2
1
1
1
2
1
2
1
2
2
0
3
3
2
2
11
14
11
3
2
3
9
15
10
7
7
7
23
2
3
3
1
22
27
5
3
3
3
5
9
10
9
8
8
6
51
64
59
51
60
66
71
75
76
78
32
18
7
11
17
14
14
11
11
9
8
14
12
5
4
6
9
5
5
4
4
4
7
1
0
0
1
1
0
0
0
0
1
0
11
14
17
21
9
9
8
7
7
6
9
7
9
9
5
7
6
5
4
4
4
36
73
12
9
11
1
2
2
2
5
6
0
1
2
1
2
1
1
1
1
1
1
1
1
3
1
1
0
4
4
4
5
12
10
12
16
10
9
16
17
13
11
9
9
0
4
3
1
2
2
22
14
16
9
12
0
3
8
5
5
3
20
5
5
4
5
5
10
3
7
2
2
1
14
55
64
59
79
71
60
58
64
57
47
61
67
75
77
78
65
70
72
83
85
87
41
9
16
13
15
26
8
9
7
5
4
3
6
3
2
2
2
2
18
8
10
11
11
5
2
3
6
4
5
6
7
6
5
5
4
19
19
15
9
8
7
5
69
72
75
66
6
6
6
12
11
11
9
10
4
3
4
4
7
5
4
7
3
2
2
2
44
55
54
51
11
11
14
12
2
2
2
3
1
0
1
1
19
17
12
10
24
15
17
23
0
86
85
87
88
34
73
78
78
83
84
93
3
3
3
6
4
3
10
12
10
10
9
2
0
0
0
5
2
1
1
1
1
0
0
0
1
1
1
1
1
1
3
6
8
5
4
9
11
5
5
4
3
0
5
3
2
4
48
3
2
5
1
2
41
59
72
72
74
15
16
11
10
11
6
7
5
6
5
2
2
3
4
4
15
10
5
4
4
21
7
5
4
2
42
49
68
71
66
34
65
50
71
68
73
22
25
11
10
13
15
14
25
11
11
10
8
5
5
6
7
5
6
9
5
2
5
4
2
3
2
2
2
2
4
2
5
1
12
14
10
7
7
9
11
11
9
9
8
11
5
4
4
5
35
2
1
2
6
4
African Region
TREATMENT SUCCESS (%)a
1995–2009
TREATMENT SUCCESS = percent cured + percent completed then rounded to the nearest digit.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 133
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
133
05/10/11 09:03
7$%/($7UHDWPHQWRXWFRPHVQHZVPHDUSRVLWLYHFDVHV±
% OF COHORT
TREATMENT SUCCESS (%)a
1995–2009
Rwanda
–
85 •
Sao Tome and
Principe
–
98 •
• 44
85 •
• 89
64 •
• 69
79 •
• 58
73 •
Senegal
Seychelles
Sierra Leone
South Africa
Swaziland
–
69 •
Togo
• 60
81 •
• 44
67 •
• 73
88 •
• 70
90 •
• 53
78 •
Uganda
United Republic
of Tanzania
Zambia
Zimbabwe
a
134
YEAR
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
NUMBER
NOTIFIED
SIZE OF
COHORT
1 840
3 681
4 166
4 053
4 173
4 184
3 776
4 175
4 081
4 173
4 165
30
49
58
52
52
5 421
5 823
6 722
7 108
7 584
7 883
6
11
8
4
11
1 454
2 472
4 370
5 347
5 826
6 092
23 112
75 967
125 460
135 604
138 803
139 468
660
1 823
2 187
2 764
3 105
3 498
887
984
1 798
1 796
2 234
2 267
13 631
17 246
20 559
21 303
22 766
23 113
19 955
24 049
25 264
24 520
24 171
24 895
10 038
12 927
14 857
13 378
13 211
12 995
8 965
14 392
13 155
10 583
9 830
10 195
97
49
58
52
50
5 421
5 823
6 722
7 109
7 584
7 883
9
11
9
6
11
1 315
2 296
4 370
5 346
5 847
6 083
28 209
86 276
134 782
143 222
143 510
139 458
2 187
2 879
3 213
3 498
856
1 796
1 796
2 229
2 267
15 301
13 874
20 559
21 303
22 766
23 113
19 955
23 923
25 324
24 520
24 171
24 895
5 957
7 014
14 857
13 378
13 173
12 995
9 702
14 392
12 860
10 583
10 370
10 195
COHORT AS
% NOTIFIED
–
103
100
101
100
100
–
323
100
100
100
96
100
100
100
100
100
100
150
100
–
–
150
100
90
93
100
100
100
100
122
114
107
106
103
100
–
–
100
104
103
100
97
–
100
100
100
100
112
80
100
100
100
100
100
99
100
100
100
100
59
54
100
100
100
100
108
100
98
100
105
100
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
52
73
77
79
77
9
10
9
8
8
6
6
5
5
5
1
2
3
4
4
4
3
2
2
3
28
6
4
3
3
52
98
90
94
98
35
43
70
72
79
81
89
82
27
0
0
0
0
9
9
6
6
5
3
0
0
9
2
2
4
0
4
3
4
4
4
4
11
0
5
0
5
2
2
6
1
2
2
2
2
0
0
7
0
3
0
0
16
21
11
10
7
5
0
9
0
0
0
0
0
31
22
8
7
4
5
0
9
44
33
55
55
70
77
77
73
68
40
54
58
64
67
67
44
67
9
15
7
8
13
13
10
18
9
13
10
9
6
0
0
18
5
6
6
4
4
6
4
6
7
8
8
7
0
0
0
7
2
1
1
1
1
4
1
2
2
2
2
11
0
0
16
13
6
5
7
11
15
13
10
8
8
7
0
0
18
2
2
2
1
2
4
19
17
10
8
7
12
22
36
50
51
42
20
22
18
19
18
6
7
10
10
9
2
6
7
7
3
5
11
8
7
17
45
18
7
7
11
66
71
76
77
26
33
32
31
28
30
69
72
79
83
84
82
47
48
76
78
83
85
32
61
59
70
67
70
5
4
3
4
18
30
41
44
42
38
5
6
4
4
5
6
23
19
8
7
5
6
21
8
9
7
7
9
12
12
11
10
7
7
6
5
5
5
9
10
9
6
5
5
7
7
8
6
5
6
10
12
12
8
9
8
4
3
3
4
1
0
0
0
1
1
1
0
0
0
0
0
2
6
1
1
1
1
0
0
2
0
0
1
11
6
3
3
13
17
16
15
11
12
6
6
4
3
2
2
14
6
2
3
3
3
10
7
7
6
7
7
2
3
3
2
36
12
5
5
14
16
11
5
4
3
4
5
8
14
5
5
4
0
26
13
12
8
9
6
TREATMENT SUCCESS = percent cured + percent completed then rounded to the nearest digit.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 134
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($7UHDWPHQWRXWFRPHVUHWUHDWPHQWFDVHV±
% OF COHORT
YEAR
Algeria
–
84 •
Angola
–
66 •
• 67
80 •
Benin
Botswana
–
64 •
• 77
75 •
• 46
84 •
Burkina Faso
Burundi
Cameroon
–
69 •
Cape Verde
–
–
Central African
Republic
–
32 •
Chad
• 48
70 •
• 43
–
Comoros
Congo
–
81 •
Côte d'Ivoire
–
64 •
Democratic
Republic
of the Congo
• 72
77 •
• 83
50 •
Equatorial
Guinea
Eritrea
–
82 •
• 79
67 •
Ethiopia
a
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
NUMBER
NOTIFIED
451
547
713
718
651
612
134
540
2 871
3 317
3 584
3 863
68
280
337
278
236
271
147
1 239
548
719
1 095
1 122
45
178
327
463
500
608
181
225
116
225
205
238
236
251
1 590
1 465
1 420
1 569
30
34
32
31
33
188
SIZE OF
COHORT
512
713
620
553
1 613
3 317
3 584
3 044
139
282
341
278
230
270
395
219
350
1 067
1 126
26
166
272
413
427
509
265
92
219
205
238
347
1 611
1 522
1 431
1 516
34
31
291
353
291
373
629
203
1 139
629
92
515
402
631
676
7
5
3
6
6
78
819
407
349
473
451
649
893
980
1 315
1 429
1 436
2 891
2 637
6 065
6 960
7 738
8 666
1
676
7
5
5
6
6
187
477
524
418
507
980
1 315
1 429
1 436
1 202
5 448
6 412
5 399
7 193
6
50
44
27
50
44
67
124
210
145
207
343
2 777
3 119
2 934
2 949
3 544
133
145
157
193
1 556
3 116
3 014
2 949
2 942
COHORT AS
% NOTIFIED
–
94
100
–
95
90
–
–
56
100
100
79
204
101
101
100
97
100
–
32
40
49
97
100
58
93
83
89
85
84
146
41
–
97
100
100
–
138
101
104
101
97
–
–
100
–
100
–
–
–
100
–
305
100
45
–
–
–
–
100
100
100
167
–
100
–
–
23
117
–
111
93
–
57
100
100
100
100
42
–
90
92
70
83
600
–
–
–
100
100
–
–
–
63
100
76
56
56
100
103
100
83
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
61
48
16
24
5
2
4
1
5
6
10
19
72
72
11
12
4
4
2
2
6
5
6
5
23
43
39
45
48
61
60
70
65
70
24
22
18
21
19
21
21
16
12
11
5
5
4
5
9
5
10
6
13
11
17
4
4
4
4
1
3
4
7
6
26
21
18
21
19
11
6
3
3
1
4
5
18
3
1
0
1
2
0
1
21
33
32
15
22
65
57
71
71
72
70
25
50
54
28
20
30
43
12
4
4
4
5
5
21
13
8
11
10
11
13
8
13
6
9
10
9
6
15
1
5
8
3
4
12
5
10
9
9
8
2
3
11
12
10
11
8
0
15
6
6
4
5
28
17
6
11
21
30
10
4
7
4
1
1
3
18
1
69
67
81
9
9
3
8
7
6
4
1
3
10
10
4
0
5
2
50
49
49
51
51
10
7
15
16
18
9
6
9
9
9
5
3
2
2
2
26
16
15
15
13
2
19
10
8
7
41
15
0
0
24
21
32
16
6
3
29
13
33
53
16
30
1
9
4
0
39
8
8
1
41
19
29
41
12
18
3
5
5
3
2
2
6
8
40
6
53
4
49
43
100
100
67
100
21
0
0
0
0
0
4
29
0
0
0
0
3
0
0
0
33
0
15
29
0
0
0
0
8
0
0
0
0
0
49
12
13
2
3
0
3
0
28
3
4
83
49
59
22
22
3
2
4
1
21
14
0
2
45
43
46
55
50
56
10
14
21
12
14
16
8
8
8
7
13
8
9
7
4
12
11
2
21
13
16
9
9
12
7
15
4
4
3
6
71
61
70
54
83
4
14
5
23
0
10
8
9
8
0
4
3
3
2
17
6
6
5
4
0
5
8
8
8
0
19
26
36
0
10
14
15
14
14
0
4
2
63
38
16
4
8
18
66
66
70
71
60
41
47
46
47
12
2
12
8
11
15
16
29
21
9
7
7
3
10
9
6
6
5
8
7
6
5
4
2
2
2
2
2
1
2
8
8
5
3
4
3
3
17
3
5
7
28
26
13
23
African Region
TREATMENT SUCCESS (%)a
1995–2009
TREATMENT SUCCESS = percent cured + percent completed then rounded to the nearest digit.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 135
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
135
05/10/11 09:03
7$%/($7UHDWPHQWRXWFRPHVUHWUHDWPHQWFDVHV±
% OF COHORT
TREATMENT SUCCESS (%)a
1995–2009
YEAR
Gabon
–
79 •
Gambia
• 69
72 •
Ghana
• 74
76 •
• 67
–
Guinea
Guinea-Bissau
–
64 •
• 72
78 •
Kenya
Lesotho
–
62 •
Liberia
–
85 •
Madagascar
–
73 •
• 69
85 •
Malawi
Mali
–
75 •
–
62 •
Mauritania
Mauritius
–
60 •
Mozambique
–
–
Namibia
–
73 •
Niger
–
76 •
Nigeria
–
a
136
81 •
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
NUMBER
NOTIFIED
SIZE OF
COHORT
44
257
342
296
655
6
166
140
143
107
159
502
532
681
764
860
55
446
458
652
671
589
59
90
138
82
76
1 064
2 477
8 975
10 462
10 444
10 711
147
1 481
1 041
1 569
1 786
1 970
32
57
132
123
596
1 498
1 803
1 962
2 089
551
764
3 212
2 792
2 533
2 470
153
239
380
423
411
425
520
938
206
214
194
182
2
12
5
6
4
5
899
1 463
1 886
1 746
1 782
3 630
88
1 534
1 823
2 491
1 439
2 558
255
754
794
617
690
303
2 356
4 867
6 093
7 048
8 151
150
167
158
611
45
88
118
100
47
540
681
764
717
112
299
458
652
414
146
40
92
89
879
1 964
3 794
3 285
10 444
4 859
597
1 397
1 746
1 931
41
57
120
112
123
1 825
1 803
1 676
2 073
492
797
1 093
932
779
788
379
423
407
390
168
216
182
2
5
6
4
5
1 594
1 855
1 746
1 782
604
2 009
1 486
1 439
1 546
790
616
667
1 848
3 662
6 093
5 488
8 151
COHORT AS
% NOTIFIED
–
–
58
49
53
93
750
–
–
63
83
93
30
–
102
100
100
83
204
67
100
100
62
–
–
–
106
–
112
117
83
79
42
31
100
45
–
–
57
89
98
98
–
128
100
–
85
100
–
–
122
100
85
99
89
104
34
33
31
32
–
–
100
100
99
92
–
–
–
79
111
100
–
17
100
100
100
100
–
109
98
100
100
–
–
39
110
60
100
60
–
–
–
99
100
97
–
78
75
100
78
100
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
18
19
10
12
69
12
23
21
67
0
5
1
18
2
11
3
0
2
1
2
60
26
11
17
11
3
31
39
1
7
72
68
67
68
3
6
5
6
14
15
17
6
0
3
2
9
7
3
7
9
5
6
2
2
40
41
40
50
44
63
45
33
60
8
17
27
26
23
8
16
8
11
6
9
8
10
3
5
10
4
7
3
2
2
2
9
3
7
1
4
11
1
2
3
13
8
13
6
10
32
30
21
10
8
13
11
49
8
44
70
53
30
61
65
68
73
25
70
34
18
13
34
11
11
9
8
47
8
8
5
9
2
9
2
10
7
7
8
0
0
0
0
1
8
1
1
0
4
8
0
13
29
10
10
7
7
7
7
7
8
12
4
8
4
5
4
14
4
20
23
20
71
34
39
42
11
19
18
17
2
2
2
2
2
5
3
4
14
19
14
15
39
75
60
72
70
22
9
21
15
15
12
2
6
8
8
7
8
2
4
20
9
4
3
2
0
5
2
0
0
65
67
74
62
65
61
74
82
80
83
7
9
3
11
4
5
1
2
4
2
7
8
6
7
22
23
19
10
10
9
2
1
1
2
2
1
1
2
1
2
12
10
10
8
1
6
3
2
1
2
6
6
7
10
6
3
3
2
4
1
67
69
69
67
6
7
5
8
10
11
12
9
5
6
7
6
10
5
5
7
3
2
2
3
46
44
48
8
13
13
5
3
3
5
1
1
22
22
20
13
15
14
0
60
50
50
60
0
20
0
0
0
50
50
17
25
20
0
0
0
0
20
33
25
20
0
0
0
0
0
69
69
68
63
3
1
2
2
11
15
12
10
4
2
3
6
11
10
8
5
2
3
7
14
41
24
53
58
58
14
29
12
15
15
8
11
10
9
9
6
3
11
10
9
13
13
10
5
6
17
22
4
2
3
54
67
64
20
12
12
7
8
9
7
5
4
8
6
5
3
3
6
58
48
54
61
48
13
18
13
15
33
7
2
6
3
6
7
11
3
7
2
11
20
7
8
7
4
1
17
6
4
TREATMENT SUCCESS = percent cured + percent completed then rounded to the nearest digit.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 136
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($7UHDWPHQWRXWFRPHVUHWUHDWPHQWFDVHV±
% OF COHORT
YEAR
Rwanda
–
72 •
Sao Tome and
Principe
–
67 •
• 56
71 •
Senegal
Seychelles
–
–
Sierra Leone
• 87
69 •
South Africa
–
60 •
Swaziland
–
55 •
Togo
• 33
71 •
Uganda
–
70 •
• 76
83 •
United Republic
of Tanzania
Zambia
–
86 •
Zimbabwe
–
a
80 •
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
NUMBER
NOTIFIED
200
374
831
478
397
475
4
27
5
6
3
563
1 056
920
843
1 144
1 112
0
0
2
0
0
41
441
330
373
389
467
179
56 202
60 588
66 646
64 470
65 916
489
1 249
470
1 083
1 319
1 474
93
133
179
130
196
214
955
1 505
2 430
2 136
3 177
4 014
1 335
1 772
5 032
4 525
4 474
4 217
243
1 455
5 496
5 833
5 236
2 485
737
5 941
2 486
3 631
4 685
SIZE OF
COHORT
296
506
448
397
448
0
5
3
3
634
931
920
843
972
889
0
0
0
69
328
168
153
466
24 847
64 923
60 084
38 754
34 122
1 113
663
1 418
1 474
93
128
133
194
237
1 209
1 433
2 491
2 856
1 455
3 356
5 067
4 525
4 474
4 217
894
5 496
5 833
2 958
5 444
1 063
4 667
2 486
1 109
1 203
COHORT AS
% NOTIFIED
–
79
61
94
100
94
–
–
0
100
50
100
113
88
100
100
85
80
–
–
–
–
–
–
168
–
99
45
39
100
–
44
107
90
60
52
–
–
237
61
108
100
100
–
72
102
99
111
–
80
–
67
78
71
109
189
101
100
100
100
–
61
100
100
56
219
–
–
79
100
31
26
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
49
56
62
64
62
5
9
8
9
10
14
15
7
7
11
1
3
14
7
7
5
4
3
5
4
25
13
6
8
6
–
60
67
33
45
40
58
62
70
67
–
0
0
33
11
8
5
5
5
4
–
0
0
0
5
4
8
8
7
7
–
20
33
33
10
3
5
4
4
5
–
20
0
0
25
23
13
13
10
10
–
0
0
0
4
23
11
8
5
8
–
–
–
72
–
–
–
14
–
–
–
3
–
–
–
4
–
–
–
4
–
–
–
1
68
80
78
56
7
10
7
13
6
8
5
10
3
0
1
3
15
2
6
15
1
0
3
4
43
29
54
53
53
8
29
10
11
8
8
11
5
11
10
3
2
6
3
3
19
16
13
13
12
19
13
13
9
15
7
20
14
14
16
21
17
34
41
17
11
12
15
17
5
3
11
11
9
4
5
12
9
10
19
54
27
17
8
38
73
59
73
68
2
4
2
3
14
23
14
18
4
2
4
3
7
11
7
4
0
2
0
5
34
30
13
0
13
10
32
31
31
66
49
37
39
34
34
49
48
39
10
24
39
43
47
49
8
8
7
11
14
13
10
10
8
1
1
1
1
1
1
0
1
1
6
12
15
8
6
4
3
3
3
4
0
7
4
6
6
5
4
5
52
24
24
0
33
15
60
58
80
53
11
9
9
9
9
4
1
0
0
1
5
3
3
4
4
12
4
6
6
0
51
13
35
63
72
14
46
15
10
8
17
16
19
12
11
1
0
1
1
0
8
13
14
7
5
9
11
16
7
4
African Region
TREATMENT SUCCESS (%)a
1995–2009
TREATMENT SUCCESS = percent cured + percent completed then rounded to the nearest digit.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 137
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
137
05/10/11 09:03
7$%/($+,9WHVWLQJDQGSURYLVLRQRI&37$57DQG,37 –
% OF TB PATIENTS WITH
KNOWN HIV STATUS
2005–2010
YEAR
Algeria
–
–
–
5•
Angola
Benin
• 15
98 •
Botswana
• 23
80 •
• 33
83 •
Burkina Faso
Burundi
–
71 •
Cameroon
–
78 •
Cape Verde
• 98
–
Central African
Republic
–
39 •
–
39 •
Chad
Comoros
• 100
–
Congo
–
94 •
• 20
73 •
•2
24 •
–
55 •
–
–
Côte d'Ivoire
Democratic
Republic
of the Congo
Equatorial
Guinea
Eritrea
Ethiopia
•3
43 •
•7
–
Gabon
Gambia
–
93 •
Ghana
•7
69 •
–
51 •
Guinea
Guinea-Bissau
• 11
46 •
• 14
91 •
•1
84 •
•3
53 •
Kenya
Lesotho
Liberia
138
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
% OF TB
NUMBER OF TB
PATIENTS WITH PATIENTS WITH
KNOWN HIV
KNOWN HIV
STATUS
STATUS
–
–
–
–
–
–
5
5
15
96
96
98
23
63
75
80
33
95
90
83
–
8
50
71
–
71
72
78
98
–
80
–
–
–
42
39
–
–
–
39
100
80
91
–
–
2
24
94
20
72
75
73
2
20
27
24
–
100
46
55
–
–
–
–
3
23
37
43
7
21
32
–
–
73
94
93
7
51
65
69
–
10
63
51
11
25
30
46
14
83
88
91
1
68
78
84
3
80
100
53
3 801
112
110
117
21 501
20 730
21 823
22 530
38 317
45 923
42 686
49 987
3 457
3 977
3 987
3 841
10 104
9 645
9 088
7 632
3 645
4 549
5 111
5 135
6 627
6 865
7 323
7 719
22 073
25 125
25 174
24 552
305
349
352
365
3 338
6 935
8 996
6 760
6 505
7 195
8 651
9 697
112
137
129
180
2 357
9 714
4 079
17 201
17 253
16 992
1 885
21 856
31 312
28 997
9 961
9 057
9 935
10 321
20 026
24 048
23 009
23 210
99 558
108 602
116 025
118 636
2 023
2 434
503
3 802
3 845
3 774
2 291
6 120
6 795
6 098
1 213
4 308
4 602
4 282
526
3 625
5 512
17 885
18 218
19 117
298
282
3 749
2 638
741
331
470
3 211
33 021
56 040
66 955
185
966
1 130
1 578
2 045
1 962
844
7 373
9 870
10 442
1 020
5 444
5 785
200
543
664
1 046
15 658
91 463
96 676
96 930
156
9 008
10 563
11 005
114
4 002
5 964
3 533
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 138
PATIENTS
NOTIFIED
(NEW AND
RETREAT)
741
720
853
3 612
3 006
3 022
2 991
125 135
141 909
150 221
156 928
2 611
4 678
3 559
4 180
2 120
2 169
2 186
2 111
12 124
14 467
15 286
15 145
7 090
10 345
8 614
11 324
1 816
2 130
2 188
2 259
108 401
110 251
110 065
106 083
11 404
13 219
13 515
13 138
3 456
5 023
5 964
6 668
NUMBER OF HIV- % OF TESTED
POSITIVE TB
TB PATIENTS
PATIENTS
HIV-POSITIVE
306
672
57
653
633
585
1 829
4 149
4 415
3 990
559
948
903
760
243
1 305
1 260
7 211
7 383
7 628
14
57
1 230
862
663
2
0
0
36
99
757
1 551
5 073
5 207
4 112
386
3 932
6 126
5 273
41
121
225
1 321
7 891
11 098
9 809
185
613
667
294
326
224
340
1 630
2 218
2 451
197
1 288
1 539
110
250
268
396
8 954
41 174
42 294
40 069
127
6 830
8 084
8 459
14
64
72
283
–
–
–
–
–
–
15
28
11
17
16
16
80
68
65
65
46
22
20
18
–
46
36
23
–
40
41
40
5
–
20
–
–
–
33
33
–
–
–
17
2
0
0
–
–
20
4
8
38
29
30
24
20
18
20
18
–
6
37
48
–
–
–
–
41
24
20
15
100
63
59
–
–
19
16
11
40
22
22
23
–
19
24
27
55
46
40
38
57
45
44
41
81
76
77
77
12
2
1
8
% OF HIV% OF HIVNUMBER OF HIVPOSITIVE
POSITIVE TB POSITIVE TB
PEOPLE
PATIENTS ON PATIENTS ON
PROVIDED IPT
CPT
ART
–
–
–
–
–
–
14
18
–
97
98
–
–
32
31
79
68
98
97
96
–
25
47
95
–
59
86
–
–
–
–
–
–
–
66
–
–
–
–
–
100
–
–
–
–
100
2
3
38
60
71
80
74
42
45
24
–
–
14
85
–
–
–
–
88
67
68
69
100
49
52
–
–
–
–
93
100
87
72
86
–
97
40
83
100
83
–
–
44
92
92
100
79
82
94
96
–
50
42
–
–
–
–
–
–
–
9
12
–
40
44
–
–
32
36
45
32
52
53
41
–
14
32
40
–
36
50
–
100
–
–
–
–
–
35
62
–
–
–
–
100
–
–
–
–
100
2
3
14
22
31
26
1
18
21
9
–
–
55
20
–
–
–
–
29
44
41
39
–
49
52
–
–
18
11
46
37
24
24
20
–
24
7
45
30
–
–
–
17
30
34
48
–
27
28
27
–
39
49
–
18 762
12 802
11 732
738
0
0
617
0
0
674
0
0
0
0
0
0
0
0
0
1 983
1 493
2 403
6 636
0
0
0
0
0
0
0
0
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($+,9WHVWLQJDQGSURYLVLRQRI&37$57DQG,37 –
Madagascar
•9
17 •
• 44
88 •
–
43 •
•0
24 •
• 91
95 •
–
88 •
• 16
76 •
–
46 •
• 10
79 •
• 65
98 •
• 100
92 •
–
69 •
–
100 •
–
74 •
Malawi
Mali
Mauritania
Mauritius
Mozambique
Namibia
Niger
Nigeria
Rwanda
Sao Tome and
Principe
Senegal
Seychelles
Sierra Leone
South Africa
• 22
54 •
–
86 •
Swaziland
Togo
–
78 •
• 25
81 •
•3
90 •
•2
83 •
–
80 •
Uganda
United Republic
of Tanzania
Zambia
Zimbabwe
YEAR
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
% OF TB
NUMBER OF TB
PATIENTS WITH PATIENTS WITH
KNOWN HIV
KNOWN HIV
STATUS
STATUS
9
28
9
17
44
84
86
88
–
49
55
43
0
2
11
24
91
94
95
95
–
81
84
88
16
67
74
76
–
24
24
46
10
62
75
79
65
96
97
98
100
97
100
92
–
51
59
69
–
100
100
100
–
72
73
74
22
39
49
54
–
101
97
86
–
17
56
78
25
63
71
81
3
77
88
90
2
65
77
83
–
56
62
80
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 139
1 759
6 471
2 176
4 149
12 243
21 557
21 041
19 855
3 041
3 760
2 353
10
52
281
608
115
101
110
117
32 182
38 087
40 554
2 547
9 188
9 849
9 535
2 243
2 424
4 711
6 897
56 053
70 693
71 844
5 003
7 510
7 448
6 914
152
69
79
112
5 963
6 906
8 018
6
15
17
7 949
8 625
9 718
67 988
150 542
197 448
213 006
9 635
10 730
9 536
512
1 734
2 256
10 555
27 695
31 695
36 724
1 613
48 846
56 388
56 849
1 082
30 654
34 992
40 543
22 062
28 952
38 012
PATIENTS
NOTIFIED
(NEW AND
RETREAT)
19 475
22 775
23 447
25 106
27 610
25 684
24 356
22 536
4 884
6 208
6 835
5 448
2 218
2 726
2 664
2 489
127
108
116
123
33 718
39 735
45 529
46 174
15 894
13 737
13 332
12 625
8 224
9 393
10 228
10 345
66 848
90 311
94 114
90 447
7 680
7 841
7 644
7 065
152
71
79
122
10 120
11 591
11 732
11 591
14
6
15
17
6 930
11 021
11 826
13 195
302 467
388 882
405 982
396 554
8 864
9 565
11 032
11 146
2 635
3 069
3 093
2 897
41 809
43 843
44 335
45 546
64 200
63 364
64 267
63 453
53 267
47 371
45 551
48 616
54 891
39 348
46 453
47 557
NUMBER OF HIV- % OF TESTED
POSITIVE TB
TB PATIENTS
PATIENTS
HIV-POSITIVE
16
9
7
14
8 447
13 687
13 558
12 476
452
585
416
0
52
27
35
2
10
7
8
19 330
25 056
24 574
1 465
5 718
5 676
5 227
152
320
403
402
1 241
15 301
18 087
17 736
2 276
2 560
2 529
2 199
5
6
10
13
601
455
776
2
0
3
1
920
987
976
35 299
89 950
114 523
128 457
8 081
8 889
7 788
162
342
444
7 523
16 432
17 131
19 836
841
19 940
21 541
21 662
614
20 839
23 584
26 418
16 619
22 745
28 662
1
0
0
0
69
63
64
63
–
15
16
18
0
100
10
6
2
10
6
7
–
60
66
61
58
62
58
55
–
14
17
9
18
27
26
25
45
34
34
32
3
9
13
12
–
10
7
10
–
0
20
6
–
12
11
10
52
60
58
60
–
84
83
82
–
32
20
20
71
59
54
54
52
41
38
38
57
68
67
65
–
75
79
75
% OF HIV% OF HIVNUMBER OF HIVPOSITIVE
POSITIVE TB POSITIVE TB
PEOPLE
PATIENTS ON PATIENTS ON
PROVIDED IPT
CPT
ART
–
–
–
–
92
96
94
94
–
9
100
75
–
100
–
–
100
50
100
100
–
92
89
97
–
92
78
92
43
45
24
–
–
26
48
59
15
87
92
97
–
100
100
92
–
71
85
85
100
–
100
100
–
–
7
6
100
72
71
74
–
94
94
93
–
34
74
–
25
78
86
90
61
82
89
92
–
46
64
77
–
75
92
18
–
–
71
100
49
38
45
46
–
4
10
52
–
100
–
–
50
50
71
75
–
30
22
25
–
35
35
42
34
–
–
–
–
45
39
33
13
60
63
–
–
50
30
54
–
34
27
37
100
–
100
100
–
–
13
19
33
25
42
54
–
24
26
35
–
30
36
–
10
22
22
24
22
30
31
35
68
41
42
47
–
28
38
30
0
0
0
0
0
0
0
0
724
2 429
8 904
17 737
13 989
2 099
1 853
1 750
0
0
2
0
African Region
% OF TB PATIENTS WITH
KNOWN HIV STATUS
2005–2010
0
0
0
0
0
1 466
7 359
23 583
124 049
0
2 107
0
0
0
153
850
226
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
139
05/10/11 09:03
7$%/($7HVWLQJIRU0'57%DQGQXPEHURIFRQILUPHGFDVHVRI0'57%±
YEAR
Algeria
Angola
Benin
Botswana
Burkina Faso
Burundi
Cameroon
Cape Verde
Central African
Republic
Chad
Comoros
Congo
Côte d'Ivoire
Democratic
Republic
of the Congo
Equatorial
Guinea
Eritrea
Ethiopia
Gabon
Gambia
Ghana
Guinea
Guinea-Bissau
Kenya
Lesotho
Liberia
a
140
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
TOTAL
CONFIRMED
CASES OF
MDR-TBa
74
56
3
28
4
14
15
126
101
106
3
16
19
31
17
0
24
26
35
0
0
0
12
7
9
3
2
0
47
24
43
50
128
91
87
5
0
130
233
140
0
0
0
0
1
2
4
20
72
69
31
44
102
150
112
527
0
NEW CASES
NOTIFIED
20 788
20 079
21 211
21 839
35 446
42 339
38 823
42 211
3 120
3 741
3 716
3 636
9 556
8 550
7 966
6 560
3 318
4 049
4 503
4 583
6 511
6 660
7 085
7 387
20 483
23 705
23 605
23 058
271
318
319
338
3 047
6 562
8 367
6 339
5 990
6 564
7 975
8 989
109
129
115
9 554
8 584
9 484
9 805
19 046
22 619
21 573
21 691
93 493
100 864
107 359
110 032
691
676
786
3 452
2 861
2 815
2 783
122 016
138 960
146 677
152 030
2 354
4 382
2 904
3 305
1 954
2 026
2 079
2 030
11 592
13 703
14 426
14 124
6 632
9 674
8 009
10 676
1 678
2 048
2 112
2 067
99 426
99 807
99 354
95 604
10 363
11 433
11 545
11 153
3 399
4 891
5 841
6 498
PREVIOUSLY TREATED CASES
NUMBER OF
% OF NOTIFIED
NUMBER OF
NOTIFIED TESTED TESTED FOR CONFIRMED CASES
FOR MDR-TB
MDR-TB
OF MDR-TB
809
31
0
103
530
268
488
1
3
1
0
0
22
0
0
0
0
233
225
9
0
0
0
0
0
0
0
40
1
0
16
42
0
0
50
0
215
0
6
5
0
0
0
0
4
–
–
–
–
–
–
–
1
0
–
3
–
6
3
7
–
0
0
0
–
0
0
0
–
–
0
0
–
0
0
–
–
4
3
0
–
–
–
0
–
0
0
–
–
–
–
–
0
0
0
0
–
0
–
–
–
0
–
0
–
–
–
–
–
–
0
0
–
–
–
–
–
0
0
–
0
0
–
–
3
0
0
0
–
–
–
–
0
0
0
–
–
–
–
–
–
–
–
0
14
3
0
15
51
30
45
1
0
1
0
0
22
0
0
0
0
1
1
9
0
0
0
0
0
0
3
1
0
12
19
0
0
0
0
5
0
6
5
0
0
0
0
NOTIFIED
713
651
612
691
2 871
3 584
3 863
7 776
337
236
271
205
548
1 095
1 122
1 072
327
500
608
552
116
205
238
332
1 590
1 420
1 569
1 494
34
31
33
27
291
373
629
421
515
631
676
708
3
6
6
407
473
451
516
980
1 429
1 436
1 519
6 065
7 738
8 666
8 604
50
44
67
124
145
207
208
3 119
2 949
3 544
4 898
257
296
655
558
166
143
107
81
532
764
860
1 021
458
671
589
648
138
82
76
192
8 975
10 444
10 711
10 479
1 041
1 786
1 970
1 985
57
132
123
170
NUMBER OF NOTIFIED
TESTED FOR MDR-TB
% OF NOTIFIED
NUMBER OF
TESTED FOR CONFIRMED CASES
MDR-TB
OF MDR-TB
164
107
141
94
6
299
251
286
126
0
52
117
0
0
2
216
35
1
0
21
21
0
0
0
0
0
53
309
72
190
111
100
0
0
298
510
143
0
2
100
21
34
0
63
26
1 829
5 043
1 971
706
0
23
–
–
–
–
–
–
–
32
60
35
3
–
27
22
27
39
0
9
21
–
0
0
1
–
–
14
2
–
3
0
–
–
6
3
0
–
–
–
0
–
0
0
–
–
–
–
–
0
4
22
5
–
2
1
1
–
0
–
0
–
–
–
–
–
–
8
10
–
–
–
–
–
100
0
–
0
13
–
2
7
0
11
4
–
–
–
–
20
48
18
7
–
–
–
–
–
–
–
0
60
25
4
14
0
75
54
51
3
0
19
30
0
0
2
26
35
0
0
11
6
0
0
0
0
24
43
50
125
91
87
0
0
180
121
0
0
1
2
4
15
0
63
26
44
102
130
103
0
TOTAL CONFIRMED CASES OF MDR-TB includes cases with unknown previous treatment history (i.e. not included under NEW CASES or PREVIOUSLY TREATED CASES).
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 140
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($7HVWLQJIRU0'57%DQGQXPEHURIFRQILUPHGFDVHVRI0'57%±
Madagascar
Malawi
Mali
Mauritania
Mauritius
Mozambique
Namibia
Niger
Nigeria
Rwanda
Sao Tome and
Principe
Senegal
Seychelles
Sierra Leone
South Africa
Swaziland
Togo
Uganda
United Republic
of Tanzania
Zambia
Zimbabwe
a
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
6
3
3
9
16
6
40
2
7
22
12
11
6
35
0
1
1
2
115
181
140
165
221
301
214
52
24
39
23
28
21
35
79
78
90
0
7
11
38
0
0
2 000
8 026
9 070
7 386
170
190
326
2
4
2
46
26
57
93
10
24
24
34
56
29
17
NEW CASES
NOTIFIED
17 977
20 813
21 358
22 997
24 398
23 151
21 886
20 342
4 504
5 797
6 410
5 093
2 012
2 532
2 482
2 336
122
104
111
116
31 832
37 953
41 899
42 126
14 071
12 298
10 774
10 103
7 470
8 776
9 421
9 678
60 589
83 263
85 963
81 454
6 849
7 227
7 005
6 434
125
63
76
120
9 200
10 447
10 620
10 562
12
6
15
17
6 600
10 632
11 359
12 648
241 879
320 026
340 066
335 974
7 751
8 246
9 558
9 706
2 452
2 873
2 879
2 657
39 379
40 666
40 321
41 594
59 168
58 890
60 050
59 668
47 771
42 135
43 066
42 306
48 950
35 717
41 768
42 872
PREVIOUSLY TREATED CASES
NUMBER OF
% OF NOTIFIED
NUMBER OF
NOTIFIED TESTED TESTED FOR CONFIRMED CASES
FOR MDR-TB
MDR-TB
OF MDR-TB
44
60
0
0
871
0
0
14
0
161
114
85
98
105
113
75
73
80
0
0
168
17
27
57
41
77
171
168
57
41
298
2 200
148
0
0
476
369
358
276
450
348
201
0
63
–
–
0
0
–
0
0
4
0
0
0
0
8
–
–
–
93
82
88
91
0
0
0
0
–
–
–
–
–
–
0
0
–
0
0
0
1
1
1
3
–
–
–
–
–
2
1
0
–
–
–
–
–
–
–
–
–
–
–
–
–
4
23
2
–
0
0
–
–
1
1
1
0
1
1
0
–
0
0
–
–
–
–
–
0
0
0
0
1
0
0
11
0
4
6
0
0
1
1
18
30
45
18
13
25
19
0
0
9
12
8
35
31
8
8
3
3
2
197
17
190
51
0
0
5
6
15
1
6
9
9
0
13
NOTIFIED
1 498
1 962
2 089
2 109
3 212
2 533
2 470
2 194
380
411
425
355
206
194
182
153
5
4
5
7
1 886
1 782
3 630
4 048
1 823
1 439
2 558
2 522
754
617
690
667
4 867
7 048
8 151
8 993
831
397
475
631
27
6
3
2
920
1 144
1 112
1 029
2
0
0
0
330
389
467
547
60 588
64 470
65 916
60 580
470
1 319
1 474
1 440
179
196
214
240
2 430
3 177
4 014
3 952
5 032
4 474
4 217
3 785
5 496
5 236
2 485
6 310
5 941
3 631
4 685
4 685
NUMBER OF NOTIFIED
TESTED FOR MDR-TB
% OF NOTIFIED
NUMBER OF
TESTED FOR CONFIRMED CASES
MDR-TB
OF MDR-TB
144
22
24
917
867
34
449
0
16
14
12
30
6
3
4
5
7
305
277
213
251
33
47
19
25
19
0
76
138
431
31
31
66
980
505
39
4
407
228
356
405
191
177
246
566
30
–
7
1
1
29
34
1
20
0
4
3
3
15
3
–
–
60
100
100
100
16
16
6
6
–
–
–
–
–
–
5
7
–
0
0
0
0
19
29
68
–
–
–
–
–
3
3
6
–
–
–
–
–
–
–
–
–
–
–
–
–
74
–
35
–
20
2
–
–
13
6
9
8
4
4
6
–
11
1
–
–
–
–
–
6
3
3
9
16
39
0
7
11
12
7
0
1
0
1
97
109
95
130
208
267
193
24
39
14
11
11
0
48
70
82
African Region
YEAR
TOTAL
CONFIRMED
CASES OF
MDR-TBa
4
8
35
1 803
105
246
2
4
21
41
37
9
17
15
22
56
16
TOTAL CONFIRMED CASES OF MDR-TB includes cases with unknown previous treatment history (i.e. not included under NEW CASES or PREVIOUSLY TREATED CASES).
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 141
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
141
05/10/11 09:03
7$%/($1HZVPHDUSRVLWLYHFDVHQRWLILFDWLRQE\DJHDQGVH[±
MALE
YEAR
Algeria
Angola
Benin
Botswana
Burkina Faso
Burundi
Cameroon
Cape Verde
Central African
Republic
Chad
Comoros
Congo
Côte d'Ivoire
Democratic
Republic
of the Congo
Equatorial
Guinea
Eritrea
Ethiopia
Gabon
Gambia
Ghana
Guinea
Guinea-Bissau
Kenya
Lesotho
Liberia
Madagascar
142
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
FEMALE
0–14
15–24
25–34
35–44
45–54
55–64
65+
59
53
52
386
186
520
448
14
19
21
18
927
1 309
1 203
724
999
2 549
2 900
186
277
306
314
1 516
1 841
1 669
562
1 003
2 797
3 584
352
428
595
631
610
919
825
346
912
1 918
2 415
306
327
396
443
491
473
513
224
482
1 255
1 424
176
213
270
267
234
314
392
155
312
665
691
101
103
135
164
299
426
397
14
194
461
355
92
74
87
85
25
27
45
4
12
18
20
5
185
260
256
67
91
181
231
128
605
563
590
133
274
430
620
238
488
506
477
124
252
370
493
224
267
272
239
62
133
273
328
73
135
135
137
48
68
144
224
32
96
97
107
29
65
113
173
19
34
56
20
41
134
106
352
481
208
518
1 472
1 497
591
773
569
842
2 482
2 750
525
651
323
584
1 766
1 996
372
570
287
284
1 035
1 314
111
270
204
130
463
559
55
157
164
75
289
329
0
0
0
0
0–14
15–24
25–34
35–44
45–54
55–64
65+
36
102
79
371
247
704
558
26
36
25
29
1 005
1 044
1 086
707
1 142
2 926
2 763
148
239
249
265
1 293
820
826
443
1 091
2 682
2 594
197
275
331
382
746
389
417
264
844
1 797
1 688
118
149
145
200
314
270
251
248
417
1 138
958
69
76
89
98
208
229
222
130
200
581
482
32
45
51
42
312
465
367
18
120
417
286
22
25
39
35
37
45
68
7
7
15
33
19
335
321
338
76
59
125
158
109
469
491
509
53
128
248
259
124
262
253
301
39
101
174
198
89
98
97
119
26
45
109
124
33
57
55
56
11
38
54
97
12
36
48
53
10
14
40
83
4
46
78
9
63
226
172
298
390
185
368
1 467
1 474
399
421
313
530
1 788
2 031
288
332
223
293
1 028
1 121
122
225
153
139
503
642
36
99
106
60
205
290
33
87
93
33
143
183
0
22
23
26
9
2
8
2
9
16
4
5
3
6
38
162
356
206
120
40
18
39
233
350
145
57
21
9
29
78
40
379
1 136
633
160
468
26
251
35
135
15
63
30
88
32
367
420
576
145
319
30
155
40
73
15
44
25
76
0
0
0
194
382
18
18
12
535
850
13
7
9
409
666
9
14
6
229
379
7
9
4
123
173
8
3
2
82
99
4
4
4
28
59
1
1
2
148
274
13
9
10
298
413
9
6
7
211
263
8
12
4
148
158
6
1
8
59
79
5
2
3
27
44
2
1
8
16
265
409
221
73
44
15
17
296
353
167
61
38
11
41
41
435
989
672
2 092
424
1 344
203
759
77
283
55
130
49
99
409
810
510
813
296
497
152
273
70
105
56
19
128
159
373
485
1 321
1 707
8
1 346
1 751
1 572
4 048
6 675
6 859
15
2 449
2 858
2 382
5 833
9 808
10 412
45
1 606
1 882
1 890
4 151
7 577
9 134
37
888
1 010
1 184
2 549
5 022
6 464
15
422
505
634
1 295
2 637
3 641
11
385
375
289
602
1 499
1 907
7
193
246
331
718
1 695
1 987
2
1 280
1 431
1 223
4 422
7 570
7 199
18
1 756
1 819
1 532
5 146
8 501
9 120
28
989
1 051
1 232
3 309
5 832
6 721
20
528
531
863
1 724
3 898
4 579
4
232
304
427
855
2 054
2 612
7
201
209
137
351
951
1 311
1
10
71
80
59
35
16
10
9
9
10
247
915
1 109
1 582
3
70
68
93
1 221
5 095
6 726
7 400
45
75
73
109
1 017
5 187
6 181
7 785
74
57
50
81
541
3 082
3 454
4 451
80
32
45
51
276
1 495
1 985
2 746
54
25
51
37
142
610
1 027
1 473
30
20
39
60
51
397
475
822
15
13
15
3
123
145
68
199
223
181
140
208
88
70
130
72
38
89
29
25
91
24
13
9
42
73
49
63
18
39
51
61
133
194
223
550
592
570
244
551
749
679
292
314
397
1 266
1 201
1 146
538
860
1 165
877
206
184
398
1 115
1 311
1 301
357
570
778
982
62
141
302
811
944
1 030
189
282
463
876
53
68
190
495
462
540
98
203
195
565
44
39
112
426
414
447
61
103
130
289
2
14
18
154
264
359
357
9
8
32
16
52
116
164
2 072
3 739
4 790
4 698
108
165
395
222
92
167
219
3 073
6 653
8 832
7 945
214
458
695
607
80
153
183
1 675
3 548
5 069
5 077
256
517
397
497
64
130
141
920
1 630
2 521
2 509
189
395
148
364
39
72
80
485
630
1 031
994
96
198
82
244
19
42
43
296
414
590
658
88
76
37
133
12
26
90
79
133
240
338
791
196
352
621
1 289
127
333
510
1 173
52
155
295
630
17
74
114
423
26
65
21
242
98
204
1 159
1 721
1 867
1 621
1 732
2 525
1 349
1 782
582
960
333
485
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 142
UNKNOWN
1
0
0
0
0
0
0
0
0
13
80
57
45
26
9
6
10
8
3
283
1 037
1 326
1 608
9
100
67
88
908
4 699
5 885
5 708
47
87
127
111
781
4 424
5 663
6 480
54
71
72
79
382
2 105
2 730
3 439
28
21
39
43
152
976
1 296
1 950
25
12
21
31
64
366
513
855
19
8
18
36
15
122
155
335
3
19
13
4
128
110
39
123
164
61
88
122
44
29
100
25
29
86
12
18
64
8
2
6
40
74
68
64
28
66
65
51
84
104
199
456
450
446
202
314
594
549
87
121
272
791
693
667
255
446
583
739
64
71
205
566
527
560
153
245
354
751
38
35
122
338
366
369
64
114
203
405
22
40
88
179
207
204
37
82
94
145
27
18
48
176
221
249
19
45
55
72
4
13
30
187
416
577
549
14
11
19
27
30
78
100
1 802
3 916
5 144
4 044
106
222
226
283
46
110
161
1 759
4 363
6 521
5 112
125
336
721
597
47
92
133
741
1 874
2 781
2 372
71
195
616
329
24
82
80
411
831
1 266
1 056
49
83
494
169
15
44
38
242
347
593
544
17
36
297
64
12
19
19
117
148
315
345
19
29
121
48
21
37
254
100
140
232
339
799
149
297
488
1 108
88
171
259
744
28
108
171
340
16
52
151
230
16
25
99
78
150
323
1 012
1 621
1 451
1 943
1 047
1 376
614
946
248
397
129
192
UNKNOWN
0
0
0
0
8
0
0
0
0
0
0
0
0
MALE/FEMALE
RATIO
–
1.1
1.6
1.6
1.1
1.0
1.0
1.3
2.0
1.7
1.9
1.8
–
1.4
1.4
1.3
2.1
2.3
2.0
2.2
1.8
–
1.7
1.8
1.6
1.7
1.4
1.4
–
–
2.0
–
1.1
–
2.0
1.2
–
–
1.7
2.0
1.3
1.7
0.9
–
1.1
–
–
1.2
2.2
–
1.4
1.5
1.4
1.1
1.1
1.2
1.7
–
–
1.2
–
0.9
1.0
1.1
1.4
1.2
1.2
1.3
1.6
–
1.4
1.4
2.4
–
2.5
2.4
1.7
1.8
2.0
2.0
2.0
2.0
1.8
1.6
–
2.0
1.6
1.5
1.6
1.4
1.3
1.6
2.4
2.0
0.7
1.4
–
1.2
1.4
1.1
1.4
–
1.5
1.4
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($1HZVPHDUSRVLWLYHFDVHQRWLILFDWLRQE\DJHDQGVH[±
Malawi
Mali
Mauritania
Mauritius
Mozambique
Namibia
Niger
Nigeria
Rwanda
Sao Tome and
Principe
Senegal
Seychelles
Sierra Leone
South Africa
Swaziland
Togo
Uganda
United Republic
of Tanzania
Zambia
Zimbabwe
FEMALE
0–14
15–24
25–34
35–44
45–54
55–64
65+
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
25
50
58
50
27
23
26
94
493
653
622
565
72
206
350
381
1 195
1 476
1 653
1 509
357
430
628
707
833
1 113
1 031
985
294
396
539
526
519
585
549
485
181
297
365
354
215
245
279
275
138
235
263
227
89
114
157
187
102
144
193
207
17
2
2
0
187
192
17
6
10
9
1 136
295
13
9
15
9
1 475
206
22
18
21
13
1 338
137
27
19
20
23
1 022
99
13
14
10
15
664
76
8
8
6
7
320
0
18
98
36
68
269
355
359
235
874
1 027
852
113
665
874
680
55
300
365
287
21
147
146
146
29
35
44
450
157
325
521
270
557
669
845
2 173
3 824
4 457
174
1 204
1 587
921
3 164
6 758
9 186
441
819
988
937
1 836
4 544
6 218
252
497
615
557
1 091
2 863
3 804
155
45
48
466
494
430
974
713
741
824
592
526
1
2
0
94
60
71
81
0
5
5
10
717
772
1 050
1 351
2
0
0
10
18
45
64
2
0
184
287
490
718
11
7
14
1 219
1 297
1 561
1 793
0
2
1
0
305
486
792
1 176
116
2 035
1 496
4
11
9
30
7
4
11
21
370
283
257
268
183
200
190
232
91
349
135
723
10 422
9 925
59
130
162
207
95
101
177
150
1 193
1 511
1 598
2 055
2 108
2 357
2 062
1 975
659
2 175
1 240
210
150
837
710
0–14
15–24
25–34
35–44
45–54
55–64
65+
65
66
84
103
31
14
33
31
802
1 038
913
610
132
174
208
265
1 028
1 481
1 598
1 196
184
232
348
337
573
831
859
661
128
152
245
247
294
401
386
314
107
106
152
144
108
148
180
198
61
75
101
96
45
64
74
102
52
43
72
70
14
2
1
0
226
90
4
5
4
7
994
104
12
8
5
9
1 314
82
10
8
5
4
1 016
52
8
6
11
4
551
29
4
7
2
3
234
29
4
4
1
2
89
6
81
120
126
5
16
105
67
49
352
399
429
78
654
809
685
50
348
525
382
16
161
213
206
1
76
95
122
0
52
91
87
151
350
415
611
566
1 464
1 974
78
198
342
515
463
950
1 363
31
34
39
404
239
482
595
123
214
272
842
2 934
3 996
4 182
206
388
418
795
2 434
4 884
6 117
168
330
347
770
1 110
2 448
3 431
151
223
238
724
676
1 350
1 846
63
131
174
654
344
745
1 040
9
70
135
451
231
415
682
393
408
325
129
142
202
56
71
126
105
73
48
396
483
399
473
442
448
309
262
261
109
157
128
52
60
65
14
29
38
4
6
7
813
857
904
972
1
4
2
6
201
361
651
1 076
7
4
1
408
470
533
590
1
1
1
0
99
190
397
663
3
5
0
300
279
274
329
2
1
0
0
47
113
226
320
10
2
1
213
189
236
221
1
3
1
0
84
77
83
81
0
7
4
5
428
521
709
835
0
0
2
165
249
393
648
5
3
3
283
376
351
332
0
0
1
0
110
225
312
556
7
2
2
203
217
185
217
0
1
0
0
65
92
207
293
4
3
0
126
107
116
136
0
1
0
0
24
49
114
180
15
0
0
72
61
81
105
1
0
0
18
27
54
77
15
5
4
461
540
568
643
1
1
1
0
193
298
518
742
0
0
11
30
47
131
1 999
20 576
20 855
117
352
406
537
151
168
320
350
2 491
3 497
4 075
4 735
4 091
4 836
4 939
4 493
1 668
2 610
3 166
2 135
19 465
19 842
130
249
285
369
123
144
283
358
1 797
2 479
3 209
4 133
2 916
3 430
4 025
4 141
1 124
3 045
2 160
1 146
11 143
12 386
98
138
139
192
82
109
125
217
1 115
1 279
1 576
2 214
1 754
2 022
2 310
2 427
487
435
917
435
4 124
5 155
40
37
57
109
64
48
79
116
602
607
725
905
1 007
1 202
1 279
1 309
231
261
358
212
1 705
2 211
16
17
27
50
49
39
69
80
323
395
539
613
640
834
1 054
1 161
130
174
321
122
2 561
1 933
5
10
14
51
9
13
23
39
402
400
371
401
201
257
271
248
129
150
168
1 283
13 632
13 023
52
198
318
354
80
107
157
163
1 376
1 649
1 811
1 964
1 904
2 106
1 852
1 689
1 125
932
1 507
1 716
19 343
20 205
57
298
453
662
96
124
236
285
1 845
2 782
3 099
2 923
2 532
3 426
3 521
2 988
1 779
1 118
2 463
933
11 338
12 910
39
62
207
276
45
50
146
148
1 104
1 510
1 800
1 691
1 324
1 738
1 892
2 013
717
1 305
1 433
423
5 416
6 873
29
62
73
104
38
36
67
78
635
671
818
924
735
868
968
1 044
257
186
569
167
2 352
3 165
8
24
21
54
23
24
41
62
312
316
389
365
380
494
547
578
117
112
235
80
1 348
2 128
6
5
8
16
15
15
32
29
113
163
257
248
179
269
354
471
63
75
185
2 264
2 208
1 855
1 682
762
761
295
350
656
252
269
173
1 136
974
2 242
2 185
1 255
1 283
578
490
193
265
603
171
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 143
UNKNOWN
0
1
22
47
124
254
0
0
0
0
0
0
0
0
16
0
0
UNKNOWN
0
0
0
0
0
0
0
0
1
0
0
MALE/FEMALE
RATIO
1.2
1.1
1.1
1.3
1.7
2.2
2.0
2.1
–
–
–
2.6
2.3
1.9
2.9
2.6
1.4
–
–
–
2.5
1.4
1.3
1.3
–
1.9
2.6
2.9
1.0
1.2
1.4
1.5
–
2.1
1.6
1.7
–
0.7
1.7
2.4
2.3
2.1
2.2
2.3
3.5
2.7
3.0
3.5
1.5
1.5
1.7
1.6
–
1.4
1.2
1.2
2.4
1.4
1.0
1.0
1.9
1.7
1.5
1.6
1.4
1.3
1.4
1.8
1.8
1.6
1.7
1.7
1.0
2.3
1.3
–
–
–
1.1
1.1
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
African Region
MALE
YEAR
143
05/10/11 09:03
144
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 144
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
5.6
0.3
0.6
2.5
0.3
0.6
0.8
0
1.1
0
0
0.3
<0.1
0
1.0
0.1
3.3
2.9
0.6
0.5
3.3
0.7
2.3
1.3
0.2
1.3
1.0
1.4
0.4
2.2
0.3
0.2
0.9
0
1.2
0
1.5
4.2
0.8
1.2
0.4
0.8
0.9
0.8
0.7
2.8
0.7
2.0
1.1
3.2
1.7
0.5
0.6
0.6
2.2
3.3
1.5
2.3
1.0
1.7
1.0
0.6
2.6
3.3
0.8
3.6
1.2
1.4
0.5
1.7
1.9
1.4
1.1
0.6
1.8
1.2
0.7
2.5
0.5
1.3
1.8
2.9
1.6
0.9
0.8
0
1.5
4.2
0.8
0.6
0.2
0.4
2.2
0.3
0.1
0.5
0
1.2
0
1.0
0.1
3.3
2.9
0.6
0.5
0
0.5
2.3
0
0.2
0.3
1.0
<0.1
0
0.3
0.4
0.3
0.6
2.5
0
0.6
0.5
0
1.1
0
DST LABS
PER 5M
POPULATION
LABORATORIES
CULTURE LABS
PER 5M
POPULATION
No
No
In country
No
No
No
No
No
Out of country
Out of country
No
In country
Out of country
No
No
Out of country
Out of country
Out of country
Out of country
Out of country
No
No
In country
Out of country
No
In country
Out of country
No
In country
In and out of cty
No
No
No
No
No
In country
No
In country
Out of country
Out of country
Out of country
In and out of cty
Out of country
No
No
SECOND-LINE
DST
AVAILABLE
No
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
NRLa
Yes, all suspects
If TB is confirmed
Yes, all suspects
No
Yes, all suspects
Yes, all suspects
If TB is confirmed
Yes, all suspects
Yes, all suspects
If TB is confirmed
If TB is confirmed
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
If TB is confirmed
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
If TB is confirmed
Yes, all suspects
Yes, all suspects
Yes, all suspects
If TB is confirmed
For smear-positive TB
If TB is confirmed
Yes, all suspects
Yes, all suspects
Yes, all suspects
If TB is confirmed
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
If TB is confirmed
Yes, all suspects
Yes, all suspects
Yes, all suspects
No
Yes, all suspects
Yes, all suspects
Yes, all suspects
TB DIAGNOSIS
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
FIRST-LINE DRUGS
FREE THROUGH NTP
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
RIFAMPICIN USED
THROUGHOUT
TREATMENT
100
100
100
100
100
100
100
100
100
100
100
99
100
100
100
100
90
95
98
100
100
100
0
100
100
100
100
100
100
100
100
100
100
100
98
100
100
100
100
100
100
100
100
0
% OF PATIENTS
TREATED WITH FDCb
DRUG MANAGEMENT
a NRL = national reference laboratory
b FDC = fixed-dose combination
c NURSES (Registered Nurses, Registered Midwives, Enrolled Nurses, Enrolled Midwives); HEALTH ASSISTANTS (Medical Assistants, Clinical Officers); LABORATORY TECHNICIANS (Microscopists)
Algeria
Angola
Benin
Botswana
Burkina Faso
Burundi
Cameroon
Cape Verde
Central African Republic
Chad
Comoros
Congo
Côte d'Ivoire
Democratic Republic
of the Congo
Equatorial Guinea
Eritrea
Ethiopia
Gabon
Gambia
Ghana
Guinea
Guinea-Bissau
Kenya
Lesotho
Liberia
Madagascar
Malawi
Mali
Mauritania
Mauritius
Mozambique
Namibia
Niger
Nigeria
Rwanda
Sao Tome and Principe
Senegal
Seychelles
Sierra Leone
South Africa
Swaziland
Togo
Uganda
United Republic of Tanzania
Zambia
Zimbabwe
SMEAR LABS
PER 100K
POPULATION
7$%/($/DERUDWRULHV173VHUYLFHVGUXJPDQDJHPHQWKXPDQUHVRXUFHVDQGLQIHFWLRQFRQWURO
Yes
Yes
Yes
No
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
No
Yes
No
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
PAEDIATRIC
FORMULATIONS
PROCURED
15
37
25
23
100
63
5
20
0
0
1
0
0
75
1
0
0
6
7
60
100
60
3
0
35
5
0
28
41
100
100
0
50
28
29
100
0
0
0
0
NURSES
0
50
53
0
100
0
0
0
20
MEDICAL
OFFICERS
29
0
0
0
20
10
0
0
0
70
3
0
0
50
13
100
0
0
0
0
HEALTH
ASSISTANTS
20
50
64
20
100
22
0
23
0
0
0
65
12
0
4
50
58
30
100
0
0
0
30
LABORATORY
TECHNICIANS
% OF STAFF TRAINED BY THE NTP (IN 2010)c
408
198
0
55
60
100
0
31
0
0
1176
49
0
1587
64
TB NOTIFICATION
RATE PER 100 000
HEALTH-CARE
WORKERS
Region of the Americas
Table A3.1 Estimates of the burden of disease caused by TB, 1990–2010
147
Table A3.2 Incidence, notification and case detection rates, all forms, 1990–2010
150
Table A3.3 Case notifications, 1990–2010
153
Table A3.4 Treatment outcomes, new smear-positive cases, 1995–2009
156
Table A3.5 Treatment outcomes, retreatment cases, 1995–2009
159
Table A3.6 HIV testing and provision of CPT, ART and IPT, 2005–2010
162
Table A3.7 Testing for MDR-TB and number of confirmed cases of MDR-TB, 2005–2010
164
Table A3.8 New smear-positive case notification by age and sex, 1995–2010
166
Table A3.9 Laboratories, NTP services, drug management, human resources and infection
control, 2010
168
1109_0319_P_111_246 145
05/10/11 09:03
Estimates of mortality, prevalence and incidence
Estimated values are shown as best estimates followed by lower and upper bounds. The lower and upper bounds are
defi ned as the 2.5th and 97.5th centiles of outcome distributions produced in simulations. See ANNEX 1 for further
details.
Estimated numbers are shown rounded to two significant figures. Estimated rates are shown rounded to three
significant figures unless the value is under 100, in which case rates are shown rounded to two significant figures.
Estimates for all years are recalculated as new information becomes available and techniques are refi ned, so they
may differ from those published in previous reports in this series. Estimates published in previous global TB control
reports should no longer be used.
Data source
Data shown in this annex are taken from the WHO global TB database on 2 September 2011. Data shown in the main
part of the report were taken from the database on 21 June 2011. As a result, data in this annex may differ slightly from
those in the main part of the report.
Data can be downloaded from www.who.int/tb/data.
Country notes
Caribbean Islands
Data from the territories of Anguilla; Bermuda; Bonaire, Saint Eustatius and Saba; British Virgin Islands; Cayman
Islands; Curaçao; Montserrat; Sint Maarten (Dutch part); Turks and Caicos Islands; and US Virgin Islands have been
re-introduced with support from the Caribbean Epidemiology Centre (CAREC/PAHO/WHO).
USA
In addition to the 51 reporting areas, the USA includes territories that report separately to WHO. The data for these
territories are not included in the data reported by the USA.
Defi nitions of case types and outcomes do not exactly match those used by WHO.
146
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 146
05/10/11 09:03
7$%/($(VWLPDWHVRIWKHEXUGHQRIGLVHDVHFDXVHGE\7%±
Anguilla
Antigua and
Barbuda
Argentina
Aruba
Bahamas
Barbados
Belize
Bermuda
Bolivia
(Plurinational
State of)
Bonaire, Saint
Eustatius and
Saba
Brazil
British Virgin
Islands
Canada
Cayman Islands
Chile
Colombia
a
PREVALENCE (INCLUDING HIV)
POPULATION
(MILLIONS)
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
33
35
37
39
40
40
40
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
7
7
8
9
10
10
10
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
1.6
0.99
0.85
0.74
0.62
0.76
0.77
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.011
0.012
0.011
<0.01
0.018
0.019
0.015
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
2.4
2.1
2.1
2
2
2
1.9
2010
<1
<0.01 (<0.01–<0.01)
<1 (<1–<1)
<0.01 (<0.01–<0.01)
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
150
162
174
186
192
193
195
<1
<1
<1
<1
<1
<1
<1
28
29
31
32
33
34
34
<1
<1
<1
<1
<1
<1
<1
13
14
15
16
17
17
17
33
36
40
43
45
46
46
13
10
8.2
6.6
6.6
5.4
5
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.12
0.11
0.082
0.086
0.081
0.078
0.078
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.84
0.51
0.31
0.25
0.29
0.28
0.28
1.6
1.9
1.5
1.3
1.5
1.4
1.3
8.9
6.3
4.7
3.6
3.4
2.8
2.6
1.5
1.1
1.1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
6.4
3.5
2
1.6
1.7
1.7
1.6
4.8
5.3
3.7
3
3.3
3.1
2.8
170
150
140
110
100
96
92
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
2.9
2.8
2.4
2.1
2
1.8
1.9
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
12
7.9
5.5
4.6
4.5
4.4
4.4
27
29
25
25
24
24
22
NUMBER
(THOUSANDS)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.013)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.68–3)
(0.58–1.6)
(0.85–0.86)
(0.74–0.74)
(0.62–0.62)
(0.48–1.1)
(0.5–1.1)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.026)
(<0.01–0.021)
(0.01–0.011)
(<0.01–<0.01)
(0.017–0.018)
(0.011–0.035)
(0.01–0.029)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(1–4.7)
(1.5–2.9)
(1.4–3.1)
(1.3–3)
(1.3–2.9)
(1.3–2.9)
(1.3–2.8)
(5.4–27)
(6–17)
(8.2–8.2)
(6.6–6.6)
(6.6–6.6)
(3.3–9)
(3.1–8.3)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.1–0.14)
(0.097–0.14)
(0.082–0.082)
(0.073–0.1)
(0.07–0.098)
(0.069–0.094)
(0.067–0.094)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.52–1.3)
(0.31–0.81)
(0.3–0.31)
(0.25–0.25)
(0.17–0.46)
(0.17–0.45)
(0.16–0.45)
(0.71–3.1)
(1.3–2.7)
(1.5–1.5)
(1.3–1.3)
(0.96–2.1)
(0.9–2.1)
(0.8–1.9)
RATEa
2.4
2.1
2.3
2.2
2.1
2
2
5.3
8.9
4.9
5.9
1.9
2.1
<1
4.8
2.8
2.3
1.9
1.6
1.9
1.9
<1
<1
<1
<1
<1
<1
<1
1.9
2
2.5
1.5
1.6
1.6
<1
<1
<1
<1
<1
<1
<1
<1
6
5.3
4.3
2.5
5.9
6.2
4.9
<1
<1
<1
<1
<1
<1
<1
36
28
26
22
21
20
20
(1.4–3.7)
(1.6–2.5)
(1.7–2.9)
(1.6–2.8)
(1.6–2.8)
(1.5–2.5)
(1.5–2.5)
(4.3–6.5)
(7.2–11)
(3.1–7.3)
(1.4–15)
(1.5–2.5)
(1.6–3.7)
(<1–1.5)
(2.1–9.2)
(1.7–4.7)
(2.3–2.3)
(1.9–1.9)
(1.6–1.6)
(1.2–2.9)
(1.2–2.8)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(1.3–2.7)
(1.5–2.5)
(2.4–2.6)
(1.5–1.6)
(1.1–2.3)
(1.2–2.3)
(<1–1.2)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(3.8–14)
(3.6–9.5)
(4.1–4.4)
(2.4–2.6)
(5.7–6.1)
(3.6–11)
(3.2–9.2)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(16–71)
(20–39)
(17–38)
(14–33)
(14–30)
(13–29)
(13–28)
(3.6–18)
(3.7–10)
(4.7–4.7)
(3.6–3.6)
(3.4–3.4)
(1.7–4.7)
(1.6–4.3)
(1.1–2.4)
(1.1–1.2)
(<1–1.4)
(<1–1.2)
(<1–1.2)
(<1–1.1)
(<1–1.1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(3.9–9.7)
(2.1–5.6)
(2–2)
(1.5–1.6)
(1–2.7)
(<1–2.7)
(<1–2.6)
(2.1–9.5)
(3.7–7.3)
(3.7–3.8)
(3–3.1)
(2.1–4.7)
(2–4.5)
(1.7–4.2)
NUMBER
(THOUSANDS)
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
31
23
20
17
16
16
16
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.048
0.056
0.091
0.049
0.054
0.055
0.032
<0.01
<0.01
<0.01
0.012
0.014
<0.01
<0.01
0.088
0.096
0.12
0.13
0.16
0.14
0.13
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
26
24
23
22
22
21
21
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.01)
(<0.01–0.012)
(<0.01–0.013)
(<0.01–0.011)
(<0.01–0.011)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.016)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(11–61)
(8.5–40)
(7.5–35)
(6.7–30)
(6.3–27)
(6.8–27)
(6.9–27)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.011)
(<0.01–0.012)
(<0.01–0.012)
(<0.01–0.012)
(0.016–0.089)
(0.017–0.099)
(0.035–0.16)
(0.015–0.089)
(0.02–0.098)
(0.021–0.098)
(<0.01–0.057)
(<0.01–0.014)
(<0.01–0.011)
(<0.01–0.015)
(<0.01–0.022)
(<0.01–0.027)
(<0.01–0.013)
(<0.01–0.013)
(0.021–0.17)
(0.027–0.17)
(0.032–0.2)
(0.051–0.22)
(0.069–0.27)
(0.047–0.24)
(0.04–0.23)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(9–51)
(10–39)
(9.9–39)
(9.5–37)
(9.3–36)
(9.2–36)
(9–35)
(62–350)
(60–250)
(56–230)
(37–180)
(39–170)
(35–160)
(34–160)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(1.1–4.9)
(0.98–4.7)
(0.84–4.1)
(0.76–3.6)
(0.68–3.3)
(0.57–3.2)
(0.64–3.2)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.012)
(5–21)
(3.1–14)
(2–9.6)
(1.7–8)
(1.8–7.8)
(1.7–7.6)
(1.7–7.5)
(9.1–52)
(13–48)
(11–42)
(11–41)
(11–40)
(10–39)
(9.1–37)
RATE
60
44
56
55
54
44
44
5.3
8.9
6.6
8.1
3.2
4.3
3.1
94
66
55
45
41
41
40
6.2
6.2
6.1
6.1
6.2
6.1
6.2
19
20
31
15
16
16
9.2
3.2
2.6
3.5
4.6
5
2.2
1.9
46
43
46
46
53
45
41
2.7
9
<1
9.2
5.5
3.7
2
390
319
281
243
225
217
209
(22–114)
(21–71)
(24–94)
(23–91)
(22–90)
(21–73)
(20–72)
(2.5–8.4)
(4.2–14)
(2.6–11)
(2.4–19)
(1–6.3)
(<1–8.5)
(<1–6.8)
(33–187)
(24–116)
(20–94)
(17–78)
(16–69)
(17–69)
(17–67)
(1.4–11)
(1.4–11)
(1.4–11)
(1.4–11)
(1.4–11)
(1.4–11)
(1.4–11)
(6.1–35)
(6.1–35)
(12–54)
(4.7–28)
(6–29)
(6.2–29)
(2.8–17)
(1.2–5.2)
(1.1–4.1)
(1.6–5.6)
(1.5–8.2)
(1.9–10)
(<1–4.9)
(<1–4.6)
(11–87)
(12–76)
(13–80)
(18–78)
(23–90)
(15–79)
(13–73)
(<1–4.9)
(3.7–15)
(<1–<1)
(2.7–16)
(2.3–9)
(1.4–6.1)
(<1–4.3)
(135–772)
(134–523)
(119–473)
(104–405)
(97–376)
(94–364)
(91–349)
INCIDENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
RATE
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
19
17
15
13
12
11
11
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(12–28)
(14–21)
(12–18)
(10–16)
(9.6–14)
(9.3–14)
(9.1–13)
24
23
23
22
22
21
21
2.6
4.4
4.6
6.5
2.6
3.8
4.9
60
49
40
33
30
28
27
(15–36)
(20–27)
(18–27)
(18–26)
(17–26)
(18–26)
(17–25)
(2.2–3)
(3.7–5)
(3.8–5.4)
(5.5–7.6)
(2.4–2.7)
(3.2–4.5)
(4.3–5.5)
(38–86)
(40–59)
(33–49)
(27–40)
(24–36)
(23–34)
(22–33)
0.054
0.077
0.083
0.058
0.054
0.048
0.039
<0.01
<0.01
<0.01
0.013
<0.01
<0.01
<0.01
0.076
0.088
0.1
0.11
0.12
0.12
0.12
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
17
16
15
14
14
14
13
(0.048–0.061)
(0.069–0.085)
(0.071–0.095)
(0.051–0.065)
(0.047–0.062)
(0.042–0.055)
(0.035–0.044)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.011–0.014)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.052–0.1)
(0.072–0.11)
(0.081–0.12)
(0.097–0.13)
(0.097–0.14)
(0.099–0.15)
(0.1–0.15)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(11–24)
(14–19)
(12–18)
(12–17)
(11–17)
(11–16)
(11–16)
21
27
28
18
16
14
11
2.4
1.7
2.4
4.7
3.1
2.4
1.7
40
40
40
40
40
40
40
1.6
6
<1
7.5
3.8
2.6
1.6
251
215
184
158
144
140
135
(19–24)
(25–31)
(24–32)
(16–20)
(14–18)
(12–16)
(10–13)
(2.1–2.7)
(1.5–1.9)
(2.2–2.6)
(4.1–5.4)
(2.9–3.3)
(2.3–2.5)
(1.4–2)
(27–55)
(33–48)
(33–48)
(34–46)
(33–48)
(32–48)
(33–48)
(<1–3.1)
(5.1–7)
(<1–<1)
(6.5–8.6)
(3.3–4.2)
(2.3–3)
(1.4–1.9)
(164–357)
(184–249)
(150–222)
(129–190)
(117–173)
(114–168)
(111–162)
130
110
110
95
89
87
85
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
2.3
2.3
2
1.7
1.7
1.6
1.6
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
8.2
5.5
4
3.3
3.2
3.2
3.2
18
18
17
17
16
16
16
(78–180)
(94–140)
(86–130)
(79–110)
(73–110)
(72–100)
(70–100)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(2–2.6)
(2–2.5)
(1.7–2.2)
(1.5–2)
(1.4–1.9)
(1.4–1.9)
(1.4–1.8)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(6.6–10)
(4.5–6.7)
(3.2–4.9)
(2.7–4.1)
(2.6–3.9)
(2.6–3.9)
(2.6–3.8)
(12–25)
(14–21)
(14–21)
(13–20)
(13–20)
(13–19)
(13–19)
84
71
60
51
46
45
43
19
15
12
10
10
9.9
9.7
8.4
7.7
6.4
5.4
5
4.8
4.7
10
4.6
8.4
<1
3.9
6
8.2
62
38
26
20
19
19
19
54
48
43
38
36
35
34
(52–122)
(58–86)
(49–73)
(43–61)
(38–55)
(37–53)
(36–51)
(12–29)
(12–18)
(9.7–14)
(8.5–13)
(8.2–12)
(8.1–12)
(8–12)
(7.4–9.5)
(6.8–8.7)
(5.6–7.2)
(4.7–6)
(4.3–5.6)
(4.2–5.5)
(4.1–5.3)
(9–11)
(3.8–5.6)
(6.7–10)
(<1–<1)
(3.4–4.5)
(5.3–6.8)
(7.2–9.2)
(50–76)
(31–47)
(21–32)
(17–25)
(16–23)
(15–23)
(15–22)
(36–75)
(39–58)
(35–52)
(31–46)
(29–43)
(29–42)
(28–41)
<1 (<1–<1)
116
92
78
57
53
50
47
26
17
23
22
21
19
18
11
9.5
7.9
6.6
5.9
5.5
5.6
12
5.7
12
<1
5.6
8.3
12
94
55
36
28
27
26
25
80
79
63
57
54
52
48
(41–234)
(37–157)
(32–133)
(20–98)
(20–91)
(18–84)
(17–80)
(7.2–54)
(3.8–30)
(11–38)
(10–36)
(9.7–35)
(8.6–31)
(8.4–30)
(3.9–18)
(3.3–16)
(2.8–13)
(2.4–11)
(2–10)
(1.7–9.4)
(1.9–9.4)
(3.5–21)
(1.7–10)
(4.1–21)
(<1–1.7)
(2.2–9.2)
(3.2–14)
(5.1–20)
(38–159)
(21–95)
(13–62)
(11–49)
(11–46)
(10–45)
(9.8–44)
(28–158)
(36–131)
(27–106)
(25–96)
(24–90)
(22–86)
(20–81)
Region of the Americas
MORTALITY (EXCLUDING HIV)
YEAR
Rates are per 100 000 population.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 147
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
147
05/10/11 09:03
7$%/($(VWLPDWHVRIWKHEXUGHQRIGLVHDVHFDXVHGE\7%±
MORTALITY (EXCLUDING HIV)
YEAR
Costa Rica
Cuba
Curaçao
Dominica
Dominican
Republic
Ecuador
El Salvador
Grenada
Guatemala
Guyana
Haiti
Honduras
Jamaica
Mexico
Montserrat
Netherlands
Antilles
a
148
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
POPULATION
(MILLIONS)
3
3
4
4
5
5
5
11
11
11
11
11
11
11
<1
<1
<1
<1
<1
<1
<1
<1
7
8
9
9
10
10
10
10
11
12
13
14
14
14
5
6
6
6
6
6
6
<1
<1
<1
<1
<1
<1
<1
9
10
11
13
14
14
14
<1
<1
<1
<1
<1
<1
<1
7
8
9
9
10
10
10
5
6
6
7
7
7
8
2
2
3
3
3
3
3
84
92
100
106
111
112
113
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
NUMBER
(THOUSANDS)
0.021
0.064
0.072
0.066
0.055
0.046
0.052
0.19
0.065
0.044
0.035
0.035
0.031
0.032
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
2.6
1.5
1.1
0.96
0.92
0.92
0.81
2.2
1.5
1.6
1.2
0.99
0.84
0.97
0.25
0.079
0.16
0.12
0.1
0.065
0.057
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.4
0.45
0.56
0.42
0.38
0.51
0.56
0.16
0.14
0.16
0.14
0.13
0.11
0.097
2.6
3.2
3.5
3.3
2.9
2.9
2.9
0.79
0.91
0.8
0.95
0.69
0.54
0.39
0.012
0.015
0.015
0.023
0.017
0.02
0.016
11
7.5
3.6
2.7
2.4
1.1
0.96
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
(0.011–0.038)
(0.036–0.11)
(0.071–0.073)
(0.065–0.066)
(0.054–0.055)
(0.046–0.046)
(0.029–0.087)
(0.11–0.3)
(0.038–0.11)
(0.044–0.044)
(0.035–0.035)
(0.035–0.035)
(0.019–0.048)
(0.018–0.053)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(1.5–4.1)
(1–2.1)
(0.69–1.6)
(0.62–1.4)
(0.6–1.3)
(0.62–1.3)
(0.55–1.1)
(1.1–3.8)
(0.97–2.1)
(1.6–1.6)
(1.2–1.2)
(0.98–0.99)
(0.84–0.85)
(0.7–1.3)
(0.11–0.49)
(0.063–0.096)
(0.16–0.16)
(0.11–0.12)
(0.1–0.1)
(0.044–0.11)
(0.04–0.093)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.19–0.71)
(0.33–0.59)
(0.55–0.56)
(0.42–0.42)
(0.38–0.38)
(0.39–0.66)
(0.42–0.71)
(0.081–0.28)
(0.084–0.21)
(0.095–0.25)
(0.13–0.14)
(0.071–0.21)
(0.065–0.19)
(0.058–0.17)
(1.1–5.1)
(2.3–4.2)
(2.5–4.8)
(2.2–4.7)
(1.9–4.3)
(1.9–4.2)
(1.9–4)
(0.33–1.6)
(0.58–1.3)
(0.52–1.2)
(0.66–1.3)
(0.47–0.97)
(0.35–0.78)
(0.24–0.62)
(<0.01–0.025)
(<0.01–0.025)
(<0.01–0.026)
(0.015–0.033)
(<0.01–0.029)
(0.012–0.031)
(<0.01–0.027)
(5.9–17)
(5.6–9.8)
(3.6–3.6)
(2.7–2.7)
(2.4–2.4)
(0.8–1.7)
(0.77–1.2)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
<0.01 (<0.01–<0.01)
<0.01 (<0.01–<0.01)
<0.01 (<0.01–<0.01)
RATEa
<1
1.8
1.8
1.5
1.2
1
1.1
1.8
<1
<1
<1
<1
<1
<1
<1
1.8
1.6
4.9
1.8
3
1.4
3.4
36
19
13
10
9.5
9.4
8.2
21
13
13
9.1
7
5.9
6.7
4.6
1.4
2.6
1.9
1.6
1.1
<1
2.4
1.5
1.3
2.6
<1
<1
<1
4.4
4.5
5
3.3
2.8
3.6
3.9
23
19
22
18
17
15
13
37
40
41
35
30
30
29
16
16
13
14
9.5
7.2
5.2
<1
<1
<1
<1
<1
<1
<1
13
8.2
3.6
2.5
2.2
<1
<1
<1
<1
<1
<1
<1
<1
<1
(<1–1.2)
(1–3.1)
(1.8–1.9)
(1.5–1.5)
(1.2–1.2)
(1–1)
(<1–1.9)
(1–2.8)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(1.2–4.9)
(1.2–3)
(4.9–5.1)
(1.5–2.2)
(1.8–4.8)
(<1–4.7)
(2.2–5)
(20–57)
(13–26)
(8.1–18)
(6.7–15)
(6.2–14)
(6.4–13)
(5.5–12)
(10–37)
(8.6–18)
(13–13)
(9.1–9.2)
(7–7.1)
(5.9–5.9)
(4.8–9)
(2–9.2)
(1.1–1.7)
(2.6–2.7)
(1.9–1.9)
(1.6–1.6)
(<1–1.7)
(<1–1.5)
(1.4–3.7)
(1.1–1.9)
(<1–1.9)
(2.5–2.8)
(<1–<1)
(<1–<1)
(<1–<1)
(2.1–7.9)
(3.3–5.9)
(4.9–5)
(3.3–3.3)
(2.8–2.8)
(2.8–4.7)
(2.9–4.9)
(11–38)
(11–29)
(13–34)
(18–19)
(9.5–28)
(8.7–26)
(7.7–22)
(15–72)
(29–53)
(29–55)
(23–50)
(19–44)
(19–43)
(19–40)
(6.7–33)
(10–24)
(8.4–19)
(9.5–19)
(6.5–13)
(4.7–11)
(3.1–8.2)
(<1–1)
(<1–1)
(<1–1)
(<1–1.2)
(<1–1.1)
(<1–1.1)
(<1–1)
(7–21)
(6.1–11)
(3.6–3.6)
(2.5–2.5)
(2.2–2.2)
(<1–1.5)
(<1–1)
(<1–<1)
(<1–1)
(<1–<1)
(<1–1.1)
(<1–<1)
(<1–<1)
(<1–<1)
<1 (<1–<1)
<1 (<1–<1)
<1 (<1–<1)
PREVALENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
0.36
0.99
1.3
1
0.88
0.86
0.84
5.8
2.9
2.1
1.5
1.5
1.4
1.4
<0.01
0.012
0.012
0.02
0.013
0.013
<0.01
0.014
22
15
12
10
9.8
9.8
8.9
31
23
21
18
16
15
15
5.1
2.9
3.1
3.3
2.3
2
1.9
0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
12
13
14
14
14
15
16
0.8
0.78
0.96
0.97
0.96
0.93
0.87
27
29
34
34
32
32
31
8.8
9.9
9.6
9.6
7.2
6.1
5
0.17
0.19
0.19
0.24
0.21
0.23
0.21
100
76
50
35
25
22
21
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.012
<0.01
<0.01
(0.12–0.64)
(0.37–1.8)
(0.49–2.1)
(0.42–1.7)
(0.34–1.5)
(0.35–1.5)
(0.33–1.5)
(2.3–11)
(1.1–5)
(0.76–3.6)
(0.55–2.6)
(0.61–2.5)
(0.54–2.4)
(0.54–2.5)
(<0.01–0.013)
(<0.01–0.024)
(<0.01–0.02)
(<0.01–0.032)
(<0.01–0.023)
(<0.01–0.023)
(<0.01–0.021)
(<0.01–0.023)
(8.7–42)
(6.8–24)
(5.3–20)
(4.7–17)
(4.5–16)
(4.5–16)
(4.1–15)
(12–61)
(11–39)
(9.8–35)
(8.5–30)
(7.6–27)
(7–24)
(7–24)
(1.8–10)
(0.69–5.1)
(1.3–5.3)
(1.4–5.6)
(0.82–3.9)
(0.64–3.5)
(0.53–3.3)
(<0.01–0.02)
(<0.01–0.013)
(<0.01–0.013)
(<0.01–0.014)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(4.7–23)
(6–21)
(6.6–23)
(6.6–23)
(6.9–24)
(7–24)
(7.5–26)
(0.32–1.6)
(0.36–1.3)
(0.44–1.7)
(0.36–1.7)
(0.38–1.7)
(0.36–1.6)
(0.32–1.5)
(9.8–54)
(14–47)
(16–55)
(16–57)
(15–53)
(15–53)
(14–51)
(3.1–18)
(4.4–17)
(4.1–16)
(4.4–16)
(3.3–12)
(2.7–10)
(2–8.4)
(0.06–0.31)
(0.079–0.32)
(0.08–0.33)
(0.11–0.4)
(0.082–0.37)
(0.1–0.39)
(0.084–0.36)
(42–200)
(36–120)
(22–83)
(15–60)
(7.8–42)
(5.5–37)
(5–36)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.012)
(<0.01–0.021)
(<0.01–<0.01)
(<0.01–<0.01)
INCIDENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
RATE
12
29
32
24
19
19
18
55
27
18
13
13
12
13
5.1
17
16
28
19
19
13
20
302
186
137
113
102
100
90
307
204
170
136
116
104
103
96
50
53
55
38
33
31
11
8
7.4
8.5
4.6
4.4
4.1
134
130
124
110
106
105
111
110
107
131
129
128
123
115
376
364
388
368
326
323
314
180
178
155
140
99
81
65
7.1
7.6
7.4
8.9
7.6
8.4
7.6
123
82
51
33
22
19
18
10
21
13
15
13
<1
<1
<1
2.9
3.7
6.5
<1
<1
(3.9–21)
(11–51)
(13–54)
(9.7–40)
(7.4–33)
(7.6–32)
(7–32)
(22–106)
(9.9–46)
(6.8–33)
(4.9–23)
(5.4–22)
(4.8–21)
(4.8–22)
(1.7–8.8)
(3.7–34)
(3.6–28)
(13–46)
(4.3–34)
(7.5–34)
(3.1–32)
(8.5–34)
(121–580)
(86–309)
(62–230)
(51–189)
(46–168)
(46–165)
(41–147)
(122–595)
(94–339)
(79–280)
(64–225)
(54–191)
(49–168)
(48–167)
(33–189)
(12–88)
(22–89)
(23–92)
(13–64)
(10–56)
(8.6–53)
(4.2–21)
(3.7–13)
(3.3–12)
(3.9–14)
(1–8.2)
(1.1–9)
(<1–8.7)
(52–262)
(60–213)
(58–203)
(52–180)
(50–172)
(50–170)
(52–179)
(44–218)
(49–184)
(60–226)
(48–225)
(50–220)
(48–208)
(43–195)
(138–756)
(173–599)
(185–639)
(170–611)
(149–541)
(148–532)
(145–512)
(63–361)
(79–297)
(66–257)
(64–231)
(45–162)
(36–135)
(26–111)
(2.5–13)
(3.2–13)
(3.1–13)
(4.2–15)
(3–13)
(3.8–14)
(3.1–13)
(50–237)
(39–135)
(22–83)
(14–56)
(7.1–38)
(4.9–33)
(4.4–32)
(2.3–18)
(9–33)
(2.9–23)
(6–28)
(2.8–22)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–5.2)
(<1–6.5)
(2.2–11)
(<1–<1)
(<1–<1)
0.26
0.69
0.9
0.75
0.66
0.64
0.63
2.6
2
1.4
1
1
1
1
<0.01
0.01
0.01
<0.01
<0.01
<0.01
<0.01
<0.01
11
9.6
8.6
7.6
7
6.9
6.7
18
16
13
11
10
9.7
9.4
3.4
2.6
2.2
2.4
2
1.8
1.8
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
6.6
7.1
7.6
8.2
8.6
8.7
8.9
0.65
0.65
0.76
0.86
0.85
0.84
0.84
18
19
23
25
24
24
23
6.1
7
7.2
6.1
4.7
4.3
3.9
0.15
0.16
0.17
0.18
0.18
0.18
0.18
52
41
32
24
21
20
18
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.11
0.054
(0.2–0.33)
(0.54–0.86)
(0.75–1.1)
(0.61–0.9)
(0.53–0.8)
(0.52–0.76)
(0.5–0.77)
(1.6–3.9)
(1.6–2.5)
(1.1–1.8)
(0.84–1.3)
(0.81–1.3)
(0.84–1.2)
(0.83–1.3)
(<0.01–<0.01)
(<0.01–0.015)
(<0.01–0.012)
(<0.01–0.012)
(<0.01–0.011)
(<0.01–0.011)
(<0.01–0.011)
(<0.01–0.011)
(6.5–16)
(7.8–12)
(7–10)
(6.2–9.2)
(5.7–8.5)
(5.6–8.2)
(5.5–8)
(11–27)
(13–19)
(11–16)
(9.1–13)
(8.2–12)
(8–12)
(7.7–11)
(2.3–4.7)
(2.2–2.9)
(1.8–2.6)
(1.9–2.9)
(1.7–2.3)
(1.6–2.1)
(1.5–2)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(4.1–9.8)
(5.8–8.6)
(6.2–9.2)
(6.7–9.9)
(7–10)
(7.2–10)
(7.3–11)
(0.39–0.96)
(0.53–0.78)
(0.62–0.92)
(0.7–1)
(0.69–1)
(0.69–1)
(0.69–1)
(11–26)
(16–23)
(19–28)
(21–31)
(20–29)
(19–28)
(19–28)
(3.8–9)
(5.7–8.4)
(6.1–8.4)
(5–7.4)
(3.8–5.7)
(3.5–5.1)
(3.2–4.6)
(0.11–0.21)
(0.13–0.19)
(0.14–0.2)
(0.14–0.21)
(0.14–0.21)
(0.15–0.21)
(0.15–0.21)
(31–77)
(33–49)
(26–38)
(20–29)
(18–24)
(17–22)
(16–21)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.01)
(0.086–0.13)
(0.044–0.065)
RATE
8.5
20
23
17
15
14
13
25
19
13
9.2
9.1
9.1
9.3
4
15
14
14
13
13
13
13
148
121
100
82
73
70
67
174
136
107
83
72
68
65
63
45
37
39
32
30
28
4.6
4.5
4.4
4.2
4.2
4.1
4.1
74
71
68
65
63
62
62
89
89
104
115
113
112
111
247
247
271
272
246
238
230
125
125
116
89
64
58
51
6.5
6.5
6.5
6.5
6.6
6.6
6.6
61
44
32
23
19
17
16
7.9
8.4
8.9
9.4
9.7
9.8
9.9
<1
2.6
3.2
5
54
27
(6.6–11)
(16–25)
(19–27)
(14–21)
(12–18)
(11–17)
(11–16)
(15–37)
(15–23)
(10–16)
(7.5–11)
(7.2–11)
(7.5–11)
(7.4–11)
(3.5–4.5)
(9.2–22)
(12–17)
(11–17)
(11–16)
(11–16)
(11–16)
(11–16)
(90–220)
(99–146)
(81–120)
(67–99)
(59–88)
(57–84)
(55–80)
(106–259)
(111–164)
(87–128)
(68–100)
(58–87)
(56–82)
(53–78)
(42–89)
(39–50)
(30–44)
(32–47)
(27–37)
(25–35)
(24–33)
(2.8–6.9)
(3.8–5.2)
(3.6–5.3)
(3.4–5.1)
(3.4–5)
(3.4–5)
(3.4–4.9)
(46–110)
(58–86)
(55–82)
(53–78)
(51–76)
(51–75)
(51–74)
(54–133)
(73–108)
(85–125)
(94–139)
(92–136)
(91–134)
(91–133)
(151–368)
(201–298)
(220–327)
(221–327)
(200–297)
(195–286)
(189–276)
(78–183)
(102–151)
(99–135)
(72–107)
(52–78)
(47–69)
(42–61)
(4.6–8.8)
(5.3–7.9)
(5.3–7.9)
(5.3–7.9)
(5.3–7.9)
(5.4–7.9)
(5.4–7.8)
(37–91)
(36–53)
(26–38)
(19–27)
(16–21)
(15–20)
(14–19)
(6.6–9.3)
(7.9–8.9)
(<1–18)
(7–12)
(<1–19)
(<1–20)
(<1–20)
(<1–<1)
(2.3–3)
(2.8–3.6)
(4.3–5.6)
(44–65)
(22–33)
Rates are per 100 000 population.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 148
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($(VWLPDWHVRIWKHEXUGHQRIGLVHDVHFDXVHGE\7%±
Nicaragua
Panama
Paraguay
Peru
Puerto Rico
Saint Kitts and
Nevis
Saint Lucia
Saint Vincent and
the Grenadines
Sint Maarten
(Dutch part)
Suriname
Trinidad and
Tobago
Turks and Caicos
Islands
United States
of America
Uruguay
US Virgin Islands
Venezuela
(Bolivarian
Republic of)
a
PREVALENCE (INCLUDING HIV)
POPULATION
(MILLIONS)
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
4
5
5
5
6
6
6
2
3
3
3
3
3
4
4
5
5
6
6
6
6
22
24
26
28
28
29
29
4
4
4
4
4
4
4
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
0.67
0.5
0.44
0.38
0.22
0.18
0.15
0.37
0.22
0.2
0.22
0.22
0.29
0.3
0.25
0.24
0.24
0.3
0.24
0.28
0.27
11
6.3
4.9
3.4
2.3
2
1.8
0.016
0.023
0.015
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
2010
<1
<0.01 (<0.01–<0.01)
<1 (<1–<1)
<0.01 (<0.01–<0.01)
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
<1
<1
<1
<1
<1
<1
<1
1
1
1
1
1
1
1
<1
<1
<1
<1
<1
<1
<1
253
266
282
297
305
308
310
3
3
3
3
3
3
3
<1
<1
<1
<1
<1
<1
<1
20
22
24
27
28
29
29
<0.01
<0.01
<0.01
0.011
0.013
0.014
0.015
0.024
0.031
0.029
0.022
0.039
0.04
0.037
<0.01
(<0.01–0.011)
(<0.01–<0.01)
(<0.01–<0.01)
(0.011–0.011)
(<0.01–0.016)
(0.01–0.018)
(0.011–0.019)
(0.021–0.029)
(0.025–0.038)
(0.029–0.029)
(0.021–0.022)
(0.033–0.047)
(0.033–0.049)
(0.032–0.045)
(<0.01–<0.01)
1.7
1.1
1.4
2.2
2.5
2.6
2.8
2
2.4
2.2
1.6
2.9
3
2.8
<1
(<1–2.7)
(<1–1.4)
(1.4–1.4)
(2.2–2.3)
(1.8–3.2)
(2–3.4)
(2.1–3.7)
(1.7–2.4)
(2–3)
(2.2–2.3)
(1.6–1.7)
(2.5–3.6)
(2.4–3.7)
(2.4–3.4)
(<1–<1)
<0.01
<0.01
<0.01
<0.01
<0.01
1.3
1.1
0.79
0.66
0.63
0.59
0.55
0.055
0.081
0.07
0.058
0.046
0.04
0.036
<0.01
<0.01
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(1.1–1.6)
(0.96–1.4)
(0.79–0.79)
(0.66–0.66)
(0.54–0.76)
(0.51–0.7)
(0.48–0.66)
(0.035–0.15)
(0.047–0.13)
(0.069–0.07)
(0.034–0.098)
(0.031–0.072)
(0.028–0.063)
(0.026–0.061)
(<0.01–<0.01)
(<0.01–<0.01)
5.1
2
1.8
1.7
1.3
<1
<1
<1
<1
<1
<1
<1
1.8
2.5
2.1
1.7
1.4
1.2
1.1
<1
<1
(4.3–6.1)
(1.7–2.4)
(1.5–2.1)
(1.5–2)
(<1–2.2)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(1.1–4.7)
(1.5–4.2)
(2.1–2.1)
(1–3)
(<1–2.1)
(<1–1.9)
(<1–1.8)
(<1–<1)
(<1–<1)
(0.26–1.1)
(0.42–1)
(0.64–0.64)
(0.63–0.63)
(0.47–1.1)
(0.51–1.2)
(0.54–1.2)
2.8
3.1
2.6
2.4
2.7
2.8
2.8
(1.3–5.4)
(1.9–4.7)
(2.6–2.6)
(2.4–2.4)
(1.7–4)
(1.8–4.1)
(1.9–4.1)
0.57
0.4
0.62
0.82
1.1
1.1
1.2
0.17
0.23
0.23
0.27
0.29
0.33
0.29
<0.01
<0.01
0.017
0.01
0.011
0.01
<0.01
36
31
22
19
18
16
15
0.99
1.1
1
0.89
0.81
0.78
0.75
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
10
12
12
13
13
14
14
NUMBER
(THOUSANDS)
0.54
0.67
0.64
0.63
0.75
0.79
0.82
(0.3–1.3)
(0.31–0.77)
(0.27–0.66)
(0.24–0.57)
(0.14–0.36)
(0.12–0.3)
(0.11–0.25)
(0.17–0.73)
(0.13–0.43)
(0.2–0.21)
(0.18–0.27)
(0.22–0.22)
(0.2–0.44)
(0.2–0.46)
(0.2–0.32)
(0.19–0.29)
(0.19–0.29)
(0.3–0.3)
(0.24–0.25)
(0.22–0.35)
(0.21–0.33)
(4.8–22)
(3.7–10)
(2.8–8.1)
(2.1–5.6)
(1.6–3.5)
(1.5–3.2)
(1.4–2.2)
(0.014–0.018)
(0.02–0.028)
(0.013–0.018)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
RATEa
16
11
8.6
7
4
3.2
2.6
15
8.3
6.9
6.9
6.5
8.3
8.6
5.9
5
4.4
5.1
3.9
4.4
4.2
53
26
19
12
8.1
7
6.1
<1
<1
<1
<1
<1
<1
<1
<1
11
2.2
<1
2.5
2.2
4.7
4
1.6
<1
4
2.5
<1
1.8
4.8
4
3.1
1
1
<1
2
(7.2–32)
(6.7–17)
(5.3–13)
(4.4–10)
(2.5–6.4)
(2.2–5.3)
(1.9–4.2)
(7.1–30)
(4.8–16)
(6.8–6.9)
(5.6–8.4)
(6.4–6.5)
(5.7–13)
(5.8–13)
(4.6–7.5)
(4–6.1)
(3.5–5.5)
(5.1–5.2)
(3.9–4)
(3.4–5.5)
(3.3–5.2)
(22–102)
(15–43)
(11–31)
(7.7–20)
(5.7–12)
(5.2–11)
(5–7.4)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(8.2–14)
(2.2–2.3)
(<1–<1)
(2–3)
(1.7–3.7)
(3.8–5.7)
(3.3–4.8)
(1.3–2.2)
(<1–<1)
(3.9–4.1)
(1.1–4.8)
(<1–<1)
(1.4–2.2)
(2.9–7.2)
(3.1–5)
(3–3.2)
(<1–1.1)
(<1–1.1)
(<1–2.5)
(<1–3.7)
NUMBER
(THOUSANDS)
7.1
5.8
5
4.3
3.2
3
2.7
1.6
1.4
1.4
1.7
1.7
1.8
1.8
3.9
3.6
3.6
4
4.2
4.2
4.1
120
79
63
48
39
36
34
0.24
0.39
0.24
0.13
0.13
0.08
0.11
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.038
0.026
0.034
0.024
0.031
0.012
0.021
0.071
0.063
0.053
0.048
0.033
0.019
0.036
(2.5–14)
(2.3–9.9)
(2–8.5)
(1.8–7.3)
(1.1–5.6)
(0.87–5.1)
(0.69–4.7)
(0.55–3.1)
(0.44–2.4)
(0.39–2.4)
(0.46–2.9)
(0.51–2.8)
(0.59–3)
(0.62–3.1)
(1.6–6.3)
(1.5–5.7)
(1.5–5.9)
(1.7–6.4)
(1.7–6.7)
(1.8–6.7)
(1.7–6.6)
(41–230)
(29–140)
(22–110)
(16–84)
(10–67)
(9.1–63)
(7.9–61)
(0.065–0.42)
(0.14–0.66)
(0.081–0.42)
(0.047–0.23)
(0.051–0.22)
(0.022–0.14)
(0.045–0.19)
(<0.01–<0.01)
(<0.01–0.015)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.017–0.061)
(<0.01–0.046)
(0.015–0.053)
(<0.01–0.039)
(0.012–0.058)
(<0.01–0.023)
(<0.01–0.034)
(0.027–0.14)
(0.029–0.1)
(0.025–0.088)
(0.02–0.09)
(0.013–0.066)
(<0.01–0.049)
(0.014–0.073)
(0.23–1.1)
(0.18–0.67)
(0.29–1)
(0.38–1.4)
(0.49–1.7)
(0.53–1.9)
(0.58–2.1)
(0.055–0.29)
(0.086–0.4)
(0.081–0.39)
(0.12–0.44)
(0.1–0.5)
(0.14–0.54)
(0.1–0.48)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.028)
(<0.01–0.017)
(<0.01–0.018)
(<0.01–0.018)
(<0.01–0.019)
(12–60)
(11–53)
(7.8–38)
(6.8–32)
(6.3–30)
(5.8–27)
(5–25)
(0.23–2)
(0.41–2)
(0.37–1.8)
(0.32–1.5)
(0.27–1.4)
(0.24–1.3)
(0.22–1.3)
(<0.01–0.01)
(<0.01–0.014)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(3.2–19)
(4.7–20)
(4.4–21)
(4.9–23)
(5.6–22)
(6–23)
(6.1–23)
RATE
172
125
99
79
57
52
47
68
51
47
53
49
52
52
92
75
68
68
67
66
64
532
330
244
176
136
126
118
6.9
11
6.4
3.5
3.4
2.1
3
1.3
22
4
2.2
9.3
8.1
11
28
18
22
14
18
6.8
12
66
58
49
44
30
17
33
(61–339)
(50–213)
(39–168)
(33–134)
(19–99)
(15–90)
(12–81)
(23–130)
(17–90)
(13–83)
(14–91)
(15–83)
(17–87)
(18–88)
(37–149)
(32–119)
(28–110)
(28–109)
(28–107)
(28–106)
(26–103)
(191–1078)
(122–570)
(86–425)
(58–305)
(37–235)
(31–218)
(27–210)
(1.8–12)
(3.7–18)
(2.1–11)
(1.2–6)
(1.4–5.7)
(<1–3.8)
(1.2–5.1)
(<1–2.4)
(9.9–35)
(<1–7.1)
(<1–4)
(2.1–17)
(1.8–16)
(4.6–19)
(12–44)
(4.3–32)
(9.8–33)
(5.2–24)
(6.8–34)
(1.9–13)
(5.4–19)
(25–126)
(27–96)
(23–81)
(18–83)
(12–60)
(4.5–45)
(13–67)
12 (3.7–22)
140
92
133
164
205
221
238
14
19
18
20
22
25
21
<1
<1
90
33
29
28
23
14
12
8
6.4
5.8
5.3
4.8
32
35
31
27
24
23
22
5.7
7.5
<1
<1
<1
<1
<1
51
53
49
49
47
48
48
(56–267)
(42–154)
(62–221)
(76–272)
(95–340)
(102–368)
(110–396)
(4.5–24)
(6.8–31)
(6.3–30)
(8.8–33)
(7.6–37)
(10–41)
(7.6–36)
(<1–<1)
(<1–<1)
(36–149)
(11–56)
(9.8–50)
(9.4–48)
(5.7–50)
(4.9–24)
(4.1–20)
(2.7–13)
(2.3–11)
(2.1–9.7)
(1.9–8.9)
(1.6–8.2)
(7.4–64)
(13–60)
(11–54)
(9.5–47)
(8–41)
(7.2–39)
(6.4–38)
(1.9–9.8)
(1.7–13)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(16–97)
(21–91)
(18–85)
(18–85)
(20–79)
(21–80)
(21–80)
INCIDENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
4.4
4
3.4
2.9
2.6
2.5
2.4
1.1
1.3
1.4
1.5
1.6
1.6
1.7
2.8
2.5
2.6
2.9
3
3
3
69
58
48
39
34
32
31
0.21
0.3
0.19
0.13
0.1
0.091
0.083
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.026
0.024
0.021
0.018
0.015
0.015
0.014
0.029
0.029
0.028
0.027
0.027
0.027
0.027
(2.9–6.3)
(3.2–4.8)
(2.8–4.1)
(2.4–3.5)
(2.2–3)
(2.2–2.9)
(2.1–2.8)
(0.78–1.6)
(1–1.5)
(1.2–1.7)
(1.3–1.9)
(1.4–1.8)
(1.4–1.9)
(1.5–1.9)
(2.6–3)
(2.3–2.7)
(2.4–2.8)
(2.7–3.1)
(2.7–3.2)
(2.7–3.2)
(2.7–3.2)
(42–100)
(47–69)
(39–57)
(32–45)
(30–38)
(28–37)
(27–35)
(0.19–0.23)
(0.26–0.34)
(0.17–0.22)
(0.11–0.15)
(0.089–0.12)
(0.082–0.1)
(0.072–0.095)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.024–0.028)
(0.022–0.025)
(0.02–0.022)
(0.016–0.02)
(0.012–0.019)
(0.013–0.016)
(0.013–0.015)
(0.018–0.044)
(0.023–0.035)
(0.023–0.034)
(0.022–0.033)
(0.022–0.032)
(0.022–0.032)
(0.022–0.032)
RATE
108
85
68
53
46
44
42
47
47
47
47
47
48
48
66
52
49
49
48
47
46
317
242
184
140
119
113
106
5.9
8
5
3.4
2.7
2.4
2.2
2.7
13
7.9
4.2
6.6
7.2
7.6
19
16
13
11
9
8.5
7.9
27
27
26
25
25
24
24
(70–153)
(69–103)
(55–81)
(44–64)
(40–54)
(38–51)
(36–49)
(32–65)
(39–57)
(39–56)
(39–57)
(42–53)
(42–53)
(42–54)
(61–72)
(48–56)
(45–53)
(45–53)
(44–52)
(43–51)
(42–50)
(193–472)
(197–291)
(150–221)
(118–165)
(104–135)
(98–128)
(93–121)
(5.3–6.6)
(7–9.1)
(4.3–5.7)
(3–3.9)
(2.4–3.1)
(2.2–2.7)
(1.9–2.5)
(<1–5.5)
(11–15)
(<1–16)
(<1–8.4)
(5.3–8.1)
(6.1–8.4)
(7.1–8.2)
(17–20)
(15–17)
(13–14)
(9.4–12)
(7.3–11)
(7.6–9.3)
(7.2–8.7)
(17–41)
(22–32)
(21–31)
(20–30)
(20–30)
(20–29)
(20–29)
<0.01 (<0.01–<0.01)
9.1 (7.9–10)
0.27
0.22
0.37
0.5
0.65
0.7
0.76
0.14
0.19
0.23
0.19
0.32
0.31
0.25
<0.01
<0.01
0.012
<0.01
<0.01
<0.01
<0.01
30
26
19
16
15
14
13
0.86
0.84
0.81
0.76
0.74
0.73
0.72
<0.01
<0.01
66
51
80
100
125
135
145
11
15
18
15
24
23
19
<1
37
64
25
23
22
21
12
9.8
6.7
5.5
4.8
4.4
4.1
28
26
24
23
22
22
21
4.5
4.3
7
7.7
8.3
9
9.4
9.5
9.7
(0.16–0.4)
(0.18–0.27)
(0.3–0.45)
(0.4–0.6)
(0.53–0.78)
(0.57–0.84)
(0.62–0.91)
(0.12–0.16)
(0.17–0.22)
(0.2–0.26)
(0.17–0.22)
(0.28–0.36)
(0.27–0.35)
(0.22–0.29)
(<0.01–<0.01)
(<0.01–<0.01)
(0.011–0.014)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(26–34)
(23–30)
(17–21)
(14–18)
(13–17)
(12–15)
(11–14)
(0.52–1.3)
(0.68–1)
(0.66–0.98)
(0.62–0.91)
(0.64–0.84)
(0.63–0.83)
(0.62–0.84)
(<0.01–<0.01)
(<0.01–<0.01)
(4.9–9.4)
(6.2–9.2)
(6.8–10)
(7.3–11)
(7.6–11)
(7.8–11)
(7.9–12)
35
35
34
34
33
33
33
(40–98)
(42–62)
(65–96)
(81–120)
(102–151)
(110–162)
(118–173)
(9.9–13)
(13–17)
(15–20)
(13–16)
(21–27)
(21–26)
(16–21)
(<1–<1)
(32–42)
(56–72)
(22–29)
(20–26)
(19–25)
(18–24)
(10–13)
(8.6–11)
(5.9–7.6)
(4.8–6.2)
(4.2–5.4)
(3.9–5)
(3.6–4.7)
(17–41)
(21–31)
(20–29)
(19–27)
(19–25)
(19–25)
(18–25)
(3.9–5)
(3.7–4.9)
Region of the Americas
MORTALITY (EXCLUDING HIV)
YEAR
(25–48)
(28–42)
(28–41)
(27–41)
(27–40)
(27–40)
(27–40)
Rates are per 100 000 population.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 149
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
149
05/10/11 09:03
7$%/($,QFLGHQFHQRWLILFDWLRQDQGFDVHGHWHFWLRQUDWHVDOOIRUPV±
INCIDENCE (INCLUDING HIV)
YEAR
Anguilla
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
33
35
37
39
40
40
40
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
7
7
8
9
10
10
10
Bonaire, Saint
2010
Eustatius and Saba
Brazil
1990
1995
2000
2005
2008
2009
2010
British Virgin
1990
Islands
1995
2000
2005
2008
2009
2010
Canada
1990
1995
2000
2005
2008
2009
2010
Cayman Islands
1990
1995
2000
2005
2008
2009
2010
Chile
1990
1995
2000
2005
2008
2009
2010
Colombia
1990
1995
2000
2005
2008
2009
2010
150
162
174
186
192
193
195
<1
<1
<1
<1
<1
<1
<1
28
29
31
32
33
34
34
<1
<1
<1
<1
<1
<1
<1
13
14
15
16
17
17
17
33
36
40
43
45
46
46
Antigua and
Barbuda
Argentina
Aruba
Bahamas
Barbados
Belize
Bermuda
Bolivia
(Plurinational
State of)
150
POPULATION
(MILLIONS)
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
NUMBER
(THOUSANDS)
RATEb
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
19
17
15
13
12
11
11
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(12–28)
(14–21)
(12–18)
(10–16)
(9.6–14)
(9.3–14)
(9.1–13)
24
23
23
22
22
21
21
2.6
4.4
4.6
6.5
2.6
3.8
4.9
60
49
40
33
30
28
27
(15–36)
(20–27)
(18–27)
(18–26)
(17–26)
(18–26)
(17–25)
(2.2–3)
(3.7–5)
(3.8–5.4)
(5.5–7.6)
(2.4–2.7)
(3.2–4.5)
(4.3–5.5)
(38–86)
(40–59)
(33–49)
(27–40)
(24–36)
(23–34)
(22–33)
0.054
0.077
0.083
0.058
0.054
0.048
0.039
<0.01
<0.01
<0.01
0.013
<0.01
<0.01
<0.01
0.076
0.088
0.1
0.11
0.12
0.12
0.12
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
17
16
15
14
14
14
13
(0.048–0.061)
(0.069–0.085)
(0.071–0.095)
(0.051–0.065)
(0.047–0.062)
(0.042–0.055)
(0.035–0.044)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.011–0.014)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.052–0.1)
(0.072–0.11)
(0.081–0.12)
(0.097–0.13)
(0.097–0.14)
(0.099–0.15)
(0.1–0.15)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(11–24)
(14–19)
(12–18)
(12–17)
(11–17)
(11–16)
(11–16)
21
27
28
18
16
14
11
2.4
1.7
2.4
4.7
3.1
2.4
1.7
40
40
40
40
40
40
40
1.6
6
<1
7.5
3.8
2.6
1.6
251
215
184
158
144
140
135
(19–24)
(25–31)
(24–32)
(16–20)
(14–18)
(12–16)
(10–13)
(2.1–2.7)
(1.5–1.9)
(2.2–2.6)
(4.1–5.4)
(2.9–3.3)
(2.3–2.5)
(1.4–2)
(27–55)
(33–48)
(33–48)
(34–46)
(33–48)
(32–48)
(33–48)
(<1–3.1)
(5.1–7)
(<1–<1)
(6.5–8.6)
(3.3–4.2)
(2.3–3)
(1.4–1.9)
(164–357)
(184–249)
(150–222)
(129–190)
(117–173)
(114–168)
(111–162)
130
110
110
95
89
87
85
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
2.3
2.3
2
1.7
1.7
1.6
1.6
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
8.2
5.5
4
3.3
3.2
3.2
3.2
18
18
17
17
16
16
16
(78–180)
(94–140)
(86–130)
(79–110)
(73–110)
(72–100)
(70–100)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(2–2.6)
(2–2.5)
(1.7–2.2)
(1.5–2)
(1.4–1.9)
(1.4–1.9)
(1.4–1.8)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(6.6–10)
(4.5–6.7)
(3.2–4.9)
(2.7–4.1)
(2.6–3.9)
(2.6–3.9)
(2.6–3.8)
(12–25)
(14–21)
(14–21)
(13–20)
(13–20)
(13–19)
(13–19)
84
71
60
51
46
45
43
19
15
12
10
10
9.9
9.7
8.4
7.7
6.4
5.4
5
4.8
4.7
10
4.6
8.4
<1
3.9
6
8.2
62
38
26
20
19
19
19
54
48
43
38
36
35
34
(52–122)
(58–86)
(49–73)
(43–61)
(38–55)
(37–53)
(36–51)
(12–29)
(12–18)
(9.7–14)
(8.5–13)
(8.2–12)
(8.1–12)
(8–12)
(7.4–9.5)
(6.8–8.7)
(5.6–7.2)
(4.7–6)
(4.3–5.6)
(4.2–5.5)
(4.1–5.3)
(9–11)
(3.8–5.6)
(6.7–10)
(<1–<1)
(3.4–4.5)
(5.3–6.8)
(7.2–9.2)
(50–76)
(31–47)
(21–32)
(17–25)
(16–23)
(15–23)
(15–22)
(36–75)
(39–58)
(35–52)
(31–46)
(29–43)
(29–42)
(28–41)
INCIDENCE HIV-POSITIVE
NUMBER
(THOUSANDS)
RATEb
<0.01 (<0.01–<0.01)
4.1 (1.2–7.2)
<0.01
0.71
0.74
0.79
0.81
0.8
0.78
0.76
(<0.01–<0.01)
(0.36–1.2)
(0.44–1.1)
(0.49–1.2)
(0.51–1.2)
(0.49–1.2)
(0.49–1.1)
(0.48–1.1)
3.9
2.2
2.1
2.1
2.1
2
1.9
1.9
(1.9–5)
(1.1–3.6)
(1.3–3.2)
(1.3–3.1)
(1.3–3)
(1.2–3)
(1.2–2.8)
(1.2–2.7)
0.024
0.033
0.031
0.023
0.019
0.018
0.017
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.01
0.016
0.027
0.024
0.023
0.025
(0.016–0.034)
(0.024–0.043)
(0.02–0.044)
(0.016–0.032)
(0.012–0.029)
(0.011–0.026)
(0.011–0.024)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.014)
(0.011–0.021)
(0.018–0.037)
(0.015–0.037)
(0.014–0.036)
(0.017–0.036)
9.4
12
10
7.2
5.8
5.3
4.8
<1
<1
<1
1.4
1.2
1
<1
1.4
4.6
6.3
9.5
8.2
7.6
8.1
(6.3–13)
(8.6–15)
(6.8–15)
(4.9–10)
(3.6–8.6)
(3.4–7.7)
(3.1–6.9)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–2.2)
(<1–1.8)
(<1–1.8)
(<1–1.9)
(<1–2.2)
(3–6.5)
(4.4–8.4)
(6.3–13)
(4.9–12)
(4.4–12)
(5.3–11)
0.33
0.45
0.59
0.52
0.47
0.46
0.45
NOTIFIED NEW AND RELAPSEa
NUMBER
7
2
0
5
7
1
3
7
38
39
32
25
23
19
18
6
46
57
82
48
48
45
31
5
3
3
6
18
20
28
15
14
13
9
2
1
1
3
2
6
57
95
106
102
88
88
145
0
4
0
1
<1
2
30
43
42
36
29
29
47
0
7
0
2
168
193
122
107
94
91
84
0
88
–
–
–
–
31
63
0
113
110
45
89
137
63
79
79
76
78
68
66
–
–
–
–
–
–
–
85
74
99
83
88
94
79
81
67
47
–
36
31
130
75
108
106
91
74
72
116
0
108
–
–
–
–
94
67
90
66
67
66
65
62
(1.8–9.5)
(3.5–9.2)
(4.2–11)
(3.4–8.5)
(2.9–7.5)
(2.7–7.2)
(2.6–6.9)
1
11 166
14 422
10 127
9 748
9 070
8 847
8 345
0
0
–
(11–34)
(12–28)
(11–25)
(14–20)
(15–21)
(15–21)
(15–22)
14
12
10
9.2
9.2
9.3
9.3
(7.1–23)
(7.2–17)
(6.2–15)
(7.8–11)
(7.6–11)
(7.7–11)
(7.7–11)
74 570
91 013
77 899
80 209
73 395
75 040
74 395
50
56
45
43
38
39
38
1
0
5
0
1
1 968
1 921
1 667
1 484
1 452
1 505
1 322
2
2
5
4
7
7
5
5
4
4
4
8
6
12
4
6 151
4 150
3 021
2 505
2 427
2 398
2 376
12 447
9 912
11 630
10 360
11 344
11 324
11 420
7
47
29
20
15
14
14
14
37
27
29
24
25
25
25
60
79
74
84
82
86
88
–
–
41
0
–
–
44
85
85
85
86
88
93
83
76
132
147
–
–
–
87
75
75
75
75
75
75
75
70
57
68
63
70
70
72
0.14
0.14
0.14
0.14
0.14
0.14
0.14
(0.093–0.2)
(0.092–0.21)
(0.093–0.2)
(0.093–0.2)
(0.11–0.18)
(0.12–0.16)
(0.092–0.2)
<1
<1
<1
<1
<1
<1
<1
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
0.048
0.097
0.15
0.18
0.19
0.19
0.19
0.44
1.1
1.4
1.1
1.1
1.1
1.1
(0.014–0.1)
(0.043–0.17)
(0.089–0.23)
(0.11–0.26)
(0.12–0.28)
(0.12–0.28)
(0.12–0.28)
(0.23–0.71)
(0.67–1.7)
(0.89–2)
(0.92–1.4)
(0.76–1.4)
(0.56–1.8)
(0.75–1.5)
<1
<1
<1
1.1
1.1
1.1
1.1
1.3
3
3.5
2.6
2.4
2.4
2.4
(<1–<1)
(<1–1.2)
(<1–1.5)
(<1–1.6)
(<1–1.7)
(<1–1.7)
(<1–1.7)
(<1–2.1)
(1.8–4.5)
(2.2–5.1)
(2.1–3.2)
(1.7–3.2)
(1.2–3.9)
(1.6–3.3)
a
Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
Rates are per 100 000 population.
1109_0319_P_111_246 150
1
1
0
4
6
1
3
6
12 309
13 450
11 767
9 770
9 196
7 701
7 287
PERCENT
4.9
6
7.1
5.7
4.9
4.7
4.5
b
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
0
20
(0.12–0.63)
(0.26–0.69)
(0.35–0.89)
(0.31–0.78)
(0.28–0.72)
(0.27–0.71)
(0.26–0.68)
<1
21
19
17
17
18
18
18
RATEb
0
2
CASE DETECTION RATEa
(75–104)
(26–37)
(54–74)
(96–134)
(94–130)
(42–48)
(75–107)
(122–156)
(44–99)
(65–97)
(65–97)
(63–93)
(65–96)
(56–82)
(55–80)
(75–96)
(67–83)
(86–115)
(74–95)
(78–101)
(82–108)
(71–89)
(72–92)
(61–74)
(43–50)
(34–38)
(30–32)
(108–159)
(55–109)
(89–133)
(88–130)
(79–106)
(61–90)
(60–89)
(97–143)
(93–127)
(83–109)
(47–102)
(78–105)
(55–81)
(56–83)
(54–81)
(54–79)
(52–76)
(41–95)
(66–97)
(61–91)
(71–101)
(69–100)
(73–104)
(74–106)
(34–50)
(37–54)
(75–96)
(75–97)
(75–97)
(76–98)
(77–100)
(81–107)
(74–94)
(68–86)
(110–162)
(120–185)
(77–99)
(62–93)
(62–93)
(62–93)
(62–93)
(62–93)
(62–93)
(62–93)
(50–105)
(47–70)
(56–84)
(52–77)
(58–86)
(59–86)
(60–87)
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($,QFLGHQFHQRWLILFDWLRQDQGFDVHGHWHFWLRQUDWHVDOOIRUPV±
YEAR
Costa Rica
Cuba
Curaçao
Dominica
Dominican
Republic
Ecuador
El Salvador
Grenada
Guatemala
Guyana
Haiti
Honduras
Jamaica
Mexico
Montserrat
Netherlands
Antilles
POPULATION
(MILLIONS)
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
3
3
4
4
5
5
5
11
11
11
11
11
11
11
<1
<1
<1
<1
<1
<1
<1
<1
7
8
9
9
10
10
10
10
11
12
13
14
14
14
5
6
6
6
6
6
6
<1
<1
<1
<1
<1
<1
<1
9
10
11
13
14
14
14
<1
<1
<1
<1
<1
<1
<1
7
8
9
9
10
10
10
5
6
6
7
7
7
8
2
2
3
3
3
3
3
84
92
100
106
111
112
113
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
0.26
0.69
0.9
0.75
0.66
0.64
0.63
2.6
2
1.4
1
1
1
1
<0.01
0.01
0.01
<0.01
<0.01
<0.01
<0.01
<0.01
11
9.6
8.6
7.6
7
6.9
6.7
18
16
13
11
10
9.7
9.4
3.4
2.6
2.2
2.4
2
1.8
1.8
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
6.6
7.1
7.6
8.2
8.6
8.7
8.9
0.65
0.65
0.76
0.86
0.85
0.84
0.84
18
19
23
25
24
24
23
6.1
7
7.2
6.1
4.7
4.3
3.9
0.15
0.16
0.17
0.18
0.18
0.18
0.18
52
41
32
24
21
20
18
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.11
0.054
(0.2–0.33)
(0.54–0.86)
(0.75–1.1)
(0.61–0.9)
(0.53–0.8)
(0.52–0.76)
(0.5–0.77)
(1.6–3.9)
(1.6–2.5)
(1.1–1.8)
(0.84–1.3)
(0.81–1.3)
(0.84–1.2)
(0.83–1.3)
(<0.01–<0.01)
(<0.01–0.015)
(<0.01–0.012)
(<0.01–0.012)
(<0.01–0.011)
(<0.01–0.011)
(<0.01–0.011)
(<0.01–0.011)
(6.5–16)
(7.8–12)
(7–10)
(6.2–9.2)
(5.7–8.5)
(5.6–8.2)
(5.5–8)
(11–27)
(13–19)
(11–16)
(9.1–13)
(8.2–12)
(8–12)
(7.7–11)
(2.3–4.7)
(2.2–2.9)
(1.8–2.6)
(1.9–2.9)
(1.7–2.3)
(1.6–2.1)
(1.5–2)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(4.1–9.8)
(5.8–8.6)
(6.2–9.2)
(6.7–9.9)
(7–10)
(7.2–10)
(7.3–11)
(0.39–0.96)
(0.53–0.78)
(0.62–0.92)
(0.7–1)
(0.69–1)
(0.69–1)
(0.69–1)
(11–26)
(16–23)
(19–28)
(21–31)
(20–29)
(19–28)
(19–28)
(3.8–9)
(5.7–8.4)
(6.1–8.4)
(5–7.4)
(3.8–5.7)
(3.5–5.1)
(3.2–4.6)
(0.11–0.21)
(0.13–0.19)
(0.14–0.2)
(0.14–0.21)
(0.14–0.21)
(0.15–0.21)
(0.15–0.21)
(31–77)
(33–49)
(26–38)
(20–29)
(18–24)
(17–22)
(16–21)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.01)
(0.086–0.13)
(0.044–0.065)
RATEb
8.5
20
23
17
15
14
13
25
19
13
9.2
9.1
9.1
9.3
4
15
14
14
13
13
13
13
148
121
100
82
73
70
67
174
136
107
83
72
68
65
63
45
37
39
32
30
28
4.6
4.5
4.4
4.2
4.2
4.1
4.1
74
71
68
65
63
62
62
89
89
104
115
113
112
111
247
247
271
272
246
238
230
125
125
116
89
64
58
51
6.5
6.5
6.5
6.5
6.6
6.6
6.6
61
44
32
23
19
17
16
7.9
8.4
8.9
9.4
9.7
9.8
9.9
<1
2.6
3.2
5
54
27
(6.6–11)
(16–25)
(19–27)
(14–21)
(12–18)
(11–17)
(11–16)
(15–37)
(15–23)
(10–16)
(7.5–11)
(7.2–11)
(7.5–11)
(7.4–11)
(3.5–4.5)
(9.2–22)
(12–17)
(11–17)
(11–16)
(11–16)
(11–16)
(11–16)
(90–220)
(99–146)
(81–120)
(67–99)
(59–88)
(57–84)
(55–80)
(106–259)
(111–164)
(87–128)
(68–100)
(58–87)
(56–82)
(53–78)
(42–89)
(39–50)
(30–44)
(32–47)
(27–37)
(25–35)
(24–33)
(2.8–6.9)
(3.8–5.2)
(3.6–5.3)
(3.4–5.1)
(3.4–5)
(3.4–5)
(3.4–4.9)
(46–110)
(58–86)
(55–82)
(53–78)
(51–76)
(51–75)
(51–74)
(54–133)
(73–108)
(85–125)
(94–139)
(92–136)
(91–134)
(91–133)
(151–368)
(201–298)
(220–327)
(221–327)
(200–297)
(195–286)
(189–276)
(78–183)
(102–151)
(99–135)
(72–107)
(52–78)
(47–69)
(42–61)
(4.6–8.8)
(5.3–7.9)
(5.3–7.9)
(5.3–7.9)
(5.3–7.9)
(5.4–7.9)
(5.4–7.8)
(37–91)
(36–53)
(26–38)
(19–27)
(16–21)
(15–20)
(14–19)
(6.6–9.3)
(7.9–8.9)
(<1–18)
(7–12)
(<1–19)
(<1–20)
(<1–20)
(<1–<1)
(2.3–3)
(2.8–3.6)
(4.3–5.6)
(44–65)
(22–33)
INCIDENCE HIV-POSITIVE
NUMBER
(THOUSANDS)
<0.01
<0.01
0.036
0.095
0.06
0.062
0.07
<0.01
0.01
0.02
0.018
0.068
0.074
0.074
(<0.01–<0.01)
(<0.01–0.02)
(0.02–0.057)
(0.067–0.13)
(0.041–0.082)
(0.037–0.092)
(0.043–0.1)
(<0.01–0.012)
(<0.01–0.021)
(<0.01–0.034)
(0.01–0.029)
(0.039–0.1)
(0.054–0.096)
(0.054–0.098)
RATEb
<1
<1
<1
2.2
1.3
1.3
1.5
<1
<1
<1
<1
<1
<1
<1
(<1–<1)
(<1–<1)
(<1–1.4)
(1.6–3)
(<1–1.8)
(<1–2)
(<1–2.2)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
<0.01 (<0.01–<0.01)
3.3 (<1–9.7)
0.83
1.7
1.7
1.4
1.3
1.1
1.5
1.6
2.3
2
1.6
1.4
1.8
1.2
0.062
0.13
0.19
0.22
0.23
0.23
0.23
12
21
20
16
14
11
15
16
21
16
12
9.7
13
8.2
1.2
2.2
3.1
3.6
3.7
3.7
3.7
<0.01
<0.01
0.1
0.36
0.73
1.1
1.5
1.5
1
0.29
0.27
0.24
0.22
0.21
0.2
0.2
2.3
5.9
6.5
6.2
5.8
5.3
4.6
0.69
0.99
0.93
0.64
0.55
0.52
0.49
0.047
0.05
0.052
0.051
0.047
0.046
0.045
2.5
1.9
1.5
1.1
1
0.98
0.92
(0.13–2.1)
(0.97–2.5)
(1.1–2.4)
(0.98–2)
(0.9–1.9)
(0.88–1.3)
(1.2–1.8)
(0.63–3.1)
(1.4–3.5)
(1.2–2.9)
(0.95–2.4)
(0.82–2.1)
(1.5–2.2)
(0.96–1.4)
(0.022–0.12)
(0.076–0.2)
(0.11–0.27)
(0.16–0.29)
(0.19–0.28)
(0.19–0.28)
(0.2–0.27)
(<0.01–<0.01)
(<0.01–<0.01)
(0.028–0.23)
(0.17–0.6)
(0.44–1.1)
(0.65–1.5)
(1.2–1.8)
(1.2–1.8)
(0.82–1.3)
(0.16–0.46)
(0.18–0.37)
(0.15–0.36)
(0.18–0.26)
(0.16–0.26)
(0.15–0.26)
(0.15–0.25)
(0.96–4.3)
(4.2–7.8)
(4.7–8.6)
(4.5–8.3)
(4.3–7.6)
(3.7–7.1)
(3.8–5.5)
(0.37–1.1)
(0.64–1.4)
(0.59–1.3)
(0.4–0.95)
(0.42–0.7)
(0.41–0.65)
(0.39–0.61)
(0.029–0.069)
(0.034–0.07)
(0.036–0.072)
(0.031–0.075)
(0.032–0.065)
(0.029–0.067)
(0.031–0.061)
(1.3–4.1)
(1.2–2.8)
(0.91–2.1)
(0.71–1.7)
(0.66–1.5)
(0.73–1.3)
(0.68–1.2)
NOTIFIED NEW AND RELAPSEa
<1
1
1.2
3.6
6.5
8.3
11
11
7.2
40
36
33
30
28
27
26
33
75
75
67
60
54
46
14
18
15
9.4
7.6
7
6.5
2
2
2
1.9
1.7
1.7
1.6
3
2.1
1.5
1.1
<1
<1
<1
(1.9–30)
(12–32)
(13–28)
(11–22)
(9.3–19)
(9–14)
(12–18)
(6.1–30)
(13–30)
(9.7–23)
(7.1–18)
(5.8–15)
(10–15)
(6.6–10)
(<1–2.3)
(1.3–3.4)
(1.9–4.6)
(2.6–4.8)
(3–4.5)
(3–4.5)
(3.1–4.4)
(<1–2.7)
(<1–3)
(<1–2.6)
(1.7–6)
(3.9–9.6)
(5.1–12)
(8.7–13)
(8.5–13)
(5.7–8.8)
(22–64)
(25–50)
(20–49)
(24–35)
(21–34)
(21–34)
(20–33)
(14–61)
(54–99)
(54–100)
(48–89)
(44–78)
(38–72)
(38–55)
(7.5–23)
(11–25)
(9.5–22)
(5.8–14)
(5.8–9.6)
(5.6–8.7)
(5.1–8)
(1.2–2.9)
(1.4–2.8)
(1.4–2.8)
(1.2–2.8)
(1.2–2.4)
(1–2.5)
(1.1–2.2)
(1.5–4.9)
(1.3–3)
(<1–2.1)
(<1–1.6)
(<1–1.3)
(<1–1.1)
(<1–1.1)
a
Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
b
Rates are per 100 000 population.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 151
NUMBER
RATEb
230
586
585
534
501
443
490
546
1 553
1 183
770
817
712
827
5
6
8
7
17
15
12
11
10
11
5
14
11
7
7
6
7
3
8
11
13
4
8
2 597
4 053
5 291
5 003
4 280
4 256
3 964
8 243
7 893
6 908
4 416
4 845
4 703
4 832
2 367
2 422
1 485
1 794
1 718
1 686
1 700
0
4
0
19
6
12
36
51
62
54
44
43
40
80
69
56
33
34
33
33
44
42
25
30
28
27
27
0
4
0
5
5
4
3 813
3 119
2 913
3 365
3 246
2 902
3 322
168
296
422
639
653
763
712
5
5
4
43
31
26
26
24
21
23
23
41
58
86
87
101
94
6 212
10 420
14 311
14 602
79
121
153
150
14 222
3 647
4 984
6 406
3 333
2 829
2 924
2 876
123
109
127
90
105
139
130
14 437
11 329
18 434
18 524
18 810
18 846
19 570
1
142
75
89
103
48
39
39
38
5
4
5
3
4
5
5
17
12
18
17
17
17
17
9
0
1
0
18
0
0
5
3
CASE DETECTION RATEa
PERCENT
88
85
65
71
76
70
78
21
76
83
74
80
69
79
87
57
78
–
–
144
45
90
24
42
62
66
61
62
59
46
51
53
39
48
48
51
70
95
68
76
88
92
96
0
89
0
–
116
116
93
57
44
38
41
38
33
37
26
45
55
74
77
91
85
–
32
44
56
61
–
62
60
71
89
55
60
68
74
79
68
75
51
59
78
72
28
28
58
76
91
96
106
118
–
0
190
–
–
0
–
–
87
–
–
–
(70–114)
(68–109)
(55–78)
(59–87)
(62–94)
(58–85)
(64–98)
(14–35)
(63–95)
(67–105)
(61–91)
(65–101)
(58–84)
(65–100)
(77–100)
(39–92)
(65–96)
(119–177)
(37–55)
(75–110)
(16–40)
(35–52)
(51–76)
(55–81)
(50–75)
(52–76)
(50–72)
(31–76)
(42–63)
(44–65)
(33–49)
(40–59)
(40–59)
(43–63)
(50–105)
(84–108)
(56–83)
(63–93)
(76–104)
(79–108)
(83–113)
(77–104)
(96–142)
(96–142)
(77–113)
(39–93)
(36–54)
(32–47)
(34–50)
(31–46)
(28–41)
(31–46)
(17–43)
(38–56)
(46–68)
(62–91)
(64–95)
(75–111)
(71–104)
(26–39)
(37–55)
(47–69)
(50–75)
Region of the Americas
INCIDENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
(52–75)
(41–95)
(59–88)
(77–104)
(45–67)
(50–74)
(57–83)
(62–90)
(59–113)
(56–83)
(62–92)
(43–63)
(49–72)
(65–95)
(61–88)
(19–46)
(23–34)
(48–72)
(63–94)
(80–104)
(84–112)
(91–124)
(100–142)
(146–256)
(77–100)
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
151
05/10/11 09:03
7$%/($,QFLGHQFHQRWLILFDWLRQDQGFDVHGHWHFWLRQUDWHVDOOIRUPV±
INCIDENCE (INCLUDING HIV)
YEAR
Nicaragua
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
4
5
5
5
6
6
6
2
3
3
3
3
3
4
4
5
5
6
6
6
6
22
24
26
28
28
29
29
4
4
4
4
4
4
4
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
4.4
4
3.4
2.9
2.6
2.5
2.4
1.1
1.3
1.4
1.5
1.6
1.6
1.7
2.8
2.5
2.6
2.9
3
3
3
69
58
48
39
34
32
31
0.21
0.3
0.19
0.13
0.1
0.091
0.083
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.026
0.024
0.021
0.018
0.015
0.015
0.014
0.029
0.029
0.028
0.027
0.027
0.027
0.027
Sint Maarten (Dutch
2010
part)
Suriname
1990
1995
2000
2005
2008
2009
2010
Trinidad and
1990
Tobago
1995
2000
2005
2008
2009
2010
Turks and Caicos
1990
Islands
1995
2000
2005
2008
2009
2010
United States
1990
of America
1995
2000
2005
2008
2009
2010
Uruguay
1990
1995
2000
2005
2008
2009
2010
US Virgin Islands
1990
1995
2000
2005
2008
2009
2010
Venezuela
1990
(Bolivarian
1995
Republic of)
2000
2005
2008
2009
2010
<1
<0.01 (<0.01–<0.01)
<1
<1
<1
<1
<1
<1
<1
1
1
1
1
1
1
1
<1
<1
<1
<1
<1
<1
<1
253
266
282
297
305
308
310
3
3
3
3
3
3
3
<1
<1
<1
<1
<1
<1
<1
20
22
24
27
28
29
29
Panama
Paraguay
Peru
Puerto Rico
Saint Kitts and
Nevis
Saint Lucia
Saint Vincent and
the Grenadines
152
POPULATION
(MILLIONS)
NUMBER
(THOUSANDS)
0.27
0.22
0.37
0.5
0.65
0.7
0.76
0.14
0.19
0.23
0.19
0.32
0.31
0.25
<0.01
<0.01
0.012
<0.01
<0.01
<0.01
<0.01
30
26
19
16
15
14
13
0.86
0.84
0.81
0.76
0.74
0.73
0.72
<0.01
<0.01
7
7.7
8.3
9
9.4
9.5
9.7
(2.9–6.3)
(3.2–4.8)
(2.8–4.1)
(2.4–3.5)
(2.2–3)
(2.2–2.9)
(2.1–2.8)
(0.78–1.6)
(1–1.5)
(1.2–1.7)
(1.3–1.9)
(1.4–1.8)
(1.4–1.9)
(1.5–1.9)
(2.6–3)
(2.3–2.7)
(2.4–2.8)
(2.7–3.1)
(2.7–3.2)
(2.7–3.2)
(2.7–3.2)
(42–100)
(47–69)
(39–57)
(32–45)
(30–38)
(28–37)
(27–35)
(0.19–0.23)
(0.26–0.34)
(0.17–0.22)
(0.11–0.15)
(0.089–0.12)
(0.082–0.1)
(0.072–0.095)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.024–0.028)
(0.022–0.025)
(0.02–0.022)
(0.016–0.02)
(0.012–0.019)
(0.013–0.016)
(0.013–0.015)
(0.018–0.044)
(0.023–0.035)
(0.023–0.034)
(0.022–0.033)
(0.022–0.032)
(0.022–0.032)
(0.022–0.032)
(0.16–0.4)
(0.18–0.27)
(0.3–0.45)
(0.4–0.6)
(0.53–0.78)
(0.57–0.84)
(0.62–0.91)
(0.12–0.16)
(0.17–0.22)
(0.2–0.26)
(0.17–0.22)
(0.28–0.36)
(0.27–0.35)
(0.22–0.29)
(<0.01–<0.01)
(<0.01–<0.01)
(0.011–0.014)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(26–34)
(23–30)
(17–21)
(14–18)
(13–17)
(12–15)
(11–14)
(0.52–1.3)
(0.68–1)
(0.66–0.98)
(0.62–0.91)
(0.64–0.84)
(0.63–0.83)
(0.62–0.84)
(<0.01–<0.01)
(<0.01–<0.01)
(4.9–9.4)
(6.2–9.2)
(6.8–10)
(7.3–11)
(7.6–11)
(7.8–11)
(7.9–12)
RATEb
108
85
68
53
46
44
42
47
47
47
47
47
48
48
66
52
49
49
48
47
46
317
242
184
140
119
113
106
5.9
8
5
3.4
2.7
2.4
2.2
2.7
13
7.9
4.2
6.6
7.2
7.6
19
16
13
11
9
8.5
7.9
27
27
26
25
25
24
24
(70–153)
(69–103)
(55–81)
(44–64)
(40–54)
(38–51)
(36–49)
(32–65)
(39–57)
(39–56)
(39–57)
(42–53)
(42–53)
(42–54)
(61–72)
(48–56)
(45–53)
(45–53)
(44–52)
(43–51)
(42–50)
(193–472)
(197–291)
(150–221)
(118–165)
(104–135)
(98–128)
(93–121)
(5.3–6.6)
(7–9.1)
(4.3–5.7)
(3–3.9)
(2.4–3.1)
(2.2–2.7)
(1.9–2.5)
(<1–5.5)
(11–15)
(<1–16)
(<1–8.4)
(5.3–8.1)
(6.1–8.4)
(7.1–8.2)
(17–20)
(15–17)
(13–14)
(9.4–12)
(7.3–11)
(7.6–9.3)
(7.2–8.7)
(17–41)
(22–32)
(21–31)
(20–30)
(20–30)
(20–29)
(20–29)
INCIDENCE HIV-POSITIVE
NUMBER
(THOUSANDS)
NOTIFIED NEW AND RELAPSEa
RATEb
0.023
0.057
0.081
0.094
0.098
0.1
0.1
0.046
0.28
0.3
0.2
0.29
0.26
0.27
<0.01
0.03
0.043
0.051
0.056
0.057
0.058
1.7
2.1
1.8
1.4
1.2
0.98
0.7
(<0.01–0.046)
(0.03–0.093)
(0.046–0.12)
(0.055–0.14)
(0.059–0.15)
(0.06–0.15)
(0.074–0.13)
(<0.01–0.12)
(0.16–0.43)
(0.16–0.49)
(0.15–0.24)
(0.24–0.34)
(0.21–0.3)
(0.22–0.31)
(<0.01–<0.01)
(0.015–0.051)
(0.027–0.062)
(0.033–0.073)
(0.036–0.08)
(0.036–0.084)
(0.045–0.074)
(0.82–2.9)
(1.3–3.1)
(1.2–2.6)
(0.92–2)
(0.8–1.7)
(0.59–1.5)
(0.42–1)
<1
1.2
1.6
1.7
1.7
1.8
1.8
1.9
10
10
6
8.5
7.4
7.6
<1
<1
<1
<1
<1
<1
<1
7.8
8.9
7
5.2
4.3
3.4
2.4
(<1–1.1)
(<1–2)
(<1–2.5)
(1–2.6)
(1–2.6)
(1–2.6)
(1.3–2.3)
(<1–5)
(6–16)
(5.4–16)
(4.7–7.5)
(7.2–9.9)
(6.2–8.7)
(6.3–8.9)
(<1–<1)
(<1–1.1)
(<1–1.2)
(<1–1.2)
(<1–1.3)
(<1–1.3)
(<1–1.1)
(3.8–13)
(5.6–13)
(4.5–10)
(3.3–7.4)
(2.8–6)
(2.1–5.1)
(1.5–3.6)
0.039
0.028
0.011
0.017
(0.027–0.053)
(0.018–0.039)
(<0.01–0.019)
(<0.01–0.026)
1
<1
<1
<1
(<1–1.4)
(<1–1)
(<1–<1)
(<1–<1)
<0.01 (<0.01–0.011)
<0.01 (<0.01–<0.01)
3.1 (<1–6.4)
2.4 (<1–4.5)
<0.01
0.011
0.019
<0.01
(<0.01–0.015)
(<0.01–0.018)
(<0.01–0.028)
(<0.01–0.017)
3.6
9.8
18
7.3
(<1–13)
(4–17)
(8.1–26)
(1.6–15)
<0.01
0.041
0.094
0.13
0.17
0.18
0.19
0.012
0.027
0.043
0.059
0.069
0.072
0.076
(<0.01–0.017)
(0.021–0.068)
(0.06–0.14)
(0.083–0.19)
(0.11–0.25)
(0.12–0.27)
(0.12–0.28)
(<0.01–0.018)
(0.016–0.041)
(0.027–0.062)
(0.043–0.078)
(0.053–0.087)
(0.054–0.094)
(0.062–0.091)
1.8
9.4
20
26
34
35
37
1
2.2
3.3
4.5
5.2
5.4
5.6
(<1–4.2)
(4.7–16)
(13–29)
(17–38)
(22–48)
(22–51)
(23–53)
(<1–1.5)
(1.3–3.3)
(2.1–4.8)
(3.2–5.9)
(4–6.6)
(4–7)
(4.6–6.8)
<0.01
2.8
2.5
1.9
2.1
1.5
1.3
1.1
0.031
0.046
0.082
0.11
0.11
0.12
0.12
(<0.01–<0.01)
(1.8–4.1)
(1.6–3.6)
(1.2–2.8)
(1.8–2.4)
(1.3–1.7)
(1.1–1.5)
(0.96–1.3)
(<0.01–0.068)
(0.021–0.082)
(0.051–0.12)
(0.083–0.14)
(0.092–0.14)
(0.093–0.14)
(0.094–0.15)
4.2
1.1
<1
<1
<1
<1
<1
<1
1
1.4
2.5
3.3
3.4
3.5
3.5
(<1–14)
(<1–1.6)
(<1–1.3)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–2.2)
(<1–2.5)
(1.5–3.7)
(2.5–4.2)
(2.8–4.2)
(2.8–4.3)
(2.8–4.4)
9.1 (7.9–10)
66
51
80
100
125
135
145
11
15
18
15
24
23
19
<1
37
64
25
23
22
21
12
9.8
6.7
5.5
4.8
4.4
4.1
28
26
24
23
22
22
21
4.5
4.3
35
35
34
34
33
33
33
(40–98)
(42–62)
(65–96)
(81–120)
(102–151)
(110–162)
(118–173)
(9.9–13)
(13–17)
(15–20)
(13–16)
(21–27)
(21–26)
(16–21)
(<1–<1)
(32–42)
(56–72)
(22–29)
(20–26)
(19–25)
(18–24)
(10–13)
(8.6–11)
(5.9–7.6)
(4.8–6.2)
(4.2–5.4)
(3.9–5)
(3.6–4.7)
(17–41)
(21–31)
(20–29)
(19–27)
(19–25)
(19–25)
(18–25)
(3.9–5)
(3.7–4.9)
(25–48)
(28–42)
(28–41)
(27–41)
(27–40)
(27–40)
(27–40)
1.1 (0.85–1.3)
0.96 (0.77–1.2)
0.89 (0.71–1.1)
3.8 (3–4.7)
3.4 (2.7–4.1)
3.1 (2.5–3.7)
a
Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
b
Rates are per 100 000 population.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 152
NUMBER
RATEb
2 944
2 842
2 402
1 907
2 336
2 283
2 448
846
1 300
1 169
1 637
1 532
1 539
1 496
2 167
1 745
1 950
2 075
2 222
2 346
2 277
37 905
45 310
38 661
33 421
32 193
31 844
31 073
159
262
174
113
95
63
80
0
5
0
0
5
4
2
13
11
9
14
21
10
9
2
13
16
7
12
9
15
71
61
47
35
41
40
42
35
49
40
51
45
44
43
51
36
36
35
36
37
35
175
190
149
121
113
111
107
5
7
5
3
3
2
2
0
12
0
0
10
8
4
9
7
6
8
12
6
5
2
12
15
6
11
8
14
3
8
82
20
89
117
108
177
179
120
166
198
166
279
272
219
0
19
23
21
34
34
10
13
15
13
21
20
16
0
6
25 701
22 728
16 310
14 080
12 904
11 545
11 181
886
625
645
622
686
704
699
4
4
16
10
9
6
5
4
4
4
28
19
19
19
21
21
21
4
4
5 457
5 578
6 466
6 847
6 408
6 474
6 335
28
25
27
26
23
23
22
CASE DETECTION RATEa
PERCENT
66
72
70
66
89
90
100
74
102
83
107
95
94
89
77
70
74
72
75
79
77
55
79
81
86
95
98
100
76
88
91
87
93
69
96
0
89
0
0
148
107
50
50
47
43
80
136
68
65
7
45
57
26
45
34
56
(47–102)
(60–88)
(58–86)
(55–81)
(77–105)
(78–106)
(87–117)
(54–108)
(85–126)
(70–101)
(88–131)
(84–108)
(83–106)
(79–102)
(71–84)
(65–75)
(69–81)
(66–78)
(69–81)
(72–86)
(71–83)
(37–91)
(65–97)
(68–99)
(73–103)
(84–108)
(87–113)
(89–115)
(68–85)
(78–101)
(80–105)
(77–100)
(82–107)
(63–77)
(84–111)
(78–102)
(120–186)
(92–126)
(46–54)
(47–54)
(44–50)
(40–46)
(71–90)
(113–169)
(62–76)
(59–72)
(5–11)
(38–56)
(48–71)
(21–32)
(37–55)
(28–41)
(47–69)
87 (77–100)
30
–
24
23
17
25
24
87
87
87
87
87
87
87
–
–
–
–
–
–
75
86
87
86
87
89
85
88
103
75
80
82
93
96
97
87
87
–
–
–
–
–
79
73
77
76
68
68
66
(21–50)
(20–29)
(19–29)
(14–21)
(21–31)
(20–29)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(66–85)
(76–99)
(77–99)
(76–98)
(77–99)
(78–101)
(75–97)
(77–100)
(69–169)
(62–92)
(66–98)
(68–100)
(82–107)
(84–111)
(84–113)
(77–100)
(77–100)
(58–112)
(60–89)
(64–95)
(63–93)
(57–84)
(57–83)
(55–80)
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($&DVHQRWLILFDWLRQV±
YEAR
Anguilla
•0
7•
Antigua and
Barbuda
•2
7•
Argentina
• 38
18 •
Aruba
–
6•
Bahamas
• 18
9•
Barbados
•2
2•
Belize
• 30
47 •
Bermuda
•0
2•
Bolivia
(Plurinational
State of)
• 168
Bonaire, Saint Eustatius and Saba
Brazil
• 50
84 •
38 •
British Virgin
Islands
–
4•
Canada
•7
4•
Cayman Islands
•8
7•
Chile
• 47
14 •
Colombia
• 37
a
25 •
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
NEW AND
RELAPSEa
0
2
1
1
0
4
6
1
3
6
12 309
13 450
11 767
9 770
9 196
7 701
7 287
6
46
57
82
48
48
45
31
5
3
3
3
2
6
57
95
106
102
88
88
145
0
4
0
SMEAR- SMEAR-NEGATIVE/
POSITIVE
UNKNOWN
EXTRAPULMONARY
OTHER RELAPSE
0
2
0
0
0
1
0
0
0
0
0
0
3
6
1
1
6
1
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
1
0
0
0
0
2
0
0
0
0
1
5 698
4 749
4 709
4 758
4 044
3 973
4 668
4 110
3 357
2 783
2 165
2 011
3 067
1 773
1 561
1 493
937
854
0
24
217
159
104
143
138
338
290
1 724
666
1 254
489
426
1 828
809
1 392
827
716
1
0
0
1
1
0
2
2
4
1
0
2
2
1
1
1
0
4
4
5
2
0
0
0
0
0
0
0
0
0
0
0
0
4
2
38
56
30
31
26
19
11
23
8
10
10
3
8
4
7
5
5
7
3
3
0
0
1
2
6
2
0
0
0
0
0
0
0
0
36
44
59
83
82
97
34
55
29
1
1
3
0
0
47
0
0
0
2
0
2
0
0
1
11 166
14 422
10 127
9 748
9 070
8 847
8 345
0
74 570
91 013
77 899
80 209
73 395
75 040
74 395
1
0
0
7 010
6 458
6 278
6 048
5 937
5 613
0
1 408
1 565
1 250
893
699
630
0
1 133
1 288
1 673
1 693
1 742
1 694
0
0
0
45 650
41 186
42 093
37 697
39 267
37 932
29 291
23 622
23 990
22 665
22 144
23 030
13 814
10 457
11 037
10 122
10 275
10 017
1
0
1
0
0
1
1 968
1 921
1 667
1 484
1 452
1 505
1 322
2
2
5
1
549
436
492
433
488
462
358
0
5
4
6 151
4 150
3 021
2 505
2 427
2 398
2 376
12 447
9 912
11 630
10 360
11 344
11 324
11 420
RE-TREAT EXCL. TOTAL
HISTORY
RELAPSE
RETREAT UNKNOWN
0
4
6
11
5
6
1
0
6
0
4
6
15
5
12
1
0
0
0
0
0
4
806
49
0
1
0
0
0
0
0
0
0
0
0
0
0
63
451
547
436
469
408
1 630
225
154
263
257
63
2 081
772
590
732
665
18
18
10
14
18
2 634
3 089
2 901
3 340
3 398
8 700
6 548
8 263
6 478
7 551
11 334
9 637
11 164
9 818
10 949
466
0
3 641
0
0
0
0
0
0
0
0
516
656
528
446
466
519
472
0
723
634
482
562
416
466
444
0
0
0
20
4
0
0
0
0
180
195
145
39
82
58
48
0
64
40
36
24
0
180
195
145
103
122
94
72
0
29
44
56
68
109
58
39
2
0
1
0
0
0
0
0
0
2
2
0
0
0
0
0
0
1 561
1 290
1 186
1 114
1 152
1 154
1 284
879
502
525
509
502
1 017
694
631
636
549
553
0
0
225
158
186
152
188
167
128
67
118
96
225
158
314
219
306
263
0
0
7 530
8 358
6 870
7 196
7 319
7 028
1 380
1 446
1 429
1 709
1 611
1 696
1 002
1 487
1 618
2 026
2 117
1 985
0
0
311
339
443
413
277
400
0
339
469
339
443
413
616
869
0
0
0
% SMEARPOS AMONG
NEW PULM
–
0
–
–
–
–
0
–
–
75
100
100
50
100
–
55
54
58
63
65
66
–
–
–
–
–
–
67
–
78
71
79
76
72
86
–
–
100
–
33
100
100
–
51
44
67
–
100
67
–
50
–
–
–
–
100
–
83
80
83
87
89
90
–
–
61
64
64
62
64
62
–
–
–
–
–
–
100
52
40
48
49
51
47
43
–
0
100
–
–
–
50
–
55
59
70
68
69
70
–
85
85
83
81
82
81
Region of the Americas
NEW CASES
NEW AND RELAPSE
NOTIFICATION RATEa
1990–2010
Rates are per 100 000 population. Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 153
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
153
05/10/11 09:03
7$%/($&DVHQRWLILFDWLRQV±
NEW CASES
NEW AND RELAPSE
NOTIFICATION RATEa
1990–2010
YEAR
Costa Rica
•7
11 •
Cuba
•5
7•
Curaçao
Dominica
•8
12 •
Dominican
Republic
• 36
40 •
Ecuador
• 80
33 •
El Salvador
• 44
27 •
Grenada
•0
4•
Guatemala
• 43
23 •
Guyana
• 23
94 •
Haiti
–
142 •
Honduras
• 75
38 •
Jamaica
•5
5•
Mexico
• 17
17 •
Montserrat
•9
0•
Netherlands
Antilles
–
a
154
–
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
NEW AND
RELAPSEa
230
586
585
534
501
443
490
546
1 553
1 183
770
817
712
827
5
6
8
13
4
8
2 597
4 053
5 291
5 003
4 280
4 256
3 964
8 243
7 893
6 908
4 416
4 845
4 703
4 832
2 367
2 422
1 485
1 794
1 718
1 686
1 700
0
4
0
SMEAR- SMEAR-NEGATIVE/
POSITIVE
UNKNOWN
EXTRAPULMONARY
245
349
330
287
271
267
71
184
81
14
66
89
31
98
104
107
89
108
834
675
467
498
418
462
5
520
257
160
167
150
212
0
199
201
103
106
91
98
0
OTHER RELAPSE
79
1
7
10
0
5
0
35
19
14
17
25
54
50
40
46
46
45
RE-TREAT EXCL. TOTAL
HISTORY
RELAPSE
RETREAT UNKNOWN
26
10
14
7
0
35
45
24
31
32
122
9
14
5
11
54
172
49
60
51
56
3
3
4
8
9
0
0
0
0
0
2 787
2 907
2 949
2 458
2 441
2 159
1 418
1 234
1 032
933
822
803
244
540
602
580
615
578
5 890
5 064
3 048
3 380
3 317
3 373
2 237
1 338
635
435
369
404
420
400
330
609
584
655
1 008
1 059
985
930
972
2 241
278
402
362
363
338
181
108
255
313
329
328
2
0
0
0
5
4
4
0
1
0
0
0
0
2 368
2 052
2 420
2 070
1 609
2 121
546
518
588
326
170
265
85
119
240
320
328
325
2
2
0
0
3
0
0
0
1
0
0
3
1
0
4
1
0
0
0
0
0
112
100
204
610
420
309
266
324
309
188
186
196
204
610
729
497
452
520
0
0
0
0
106
403
421
433
400
280
392
357
323
263
386
795
778
756
663
0
0
1
0
91
78
58
63
62
180
36
28
50
30
271
114
86
113
92
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
1
0
0
0
0
0
205
202
256
346
207
348
372
828
436
249
141
101
132
88
152
58
70
40
29
249
141
159
202
128
181
438
0
0
0
187
231
352
242
301
274
22
34
33
61
78
75
6
0
0
0
2
38
8
30
56
38
46
17
87
149
124
2
84
25
117
205
162
0
0
0
0
5 887
7 340
8 171
2 930
5 292
4 655
1 367
1 484
1 463
0
236
195
313
110
33
60
346
228
373
0
8 242
4 335
1 307
0
338
43
381
0
2 306
3 404
2 069
1 897
1 881
1 842
2 214
2 396
721
451
520
482
232
370
362
330
331
382
0
0
0
100
236
181
151
192
170
33
33
25
100
236
181
184
225
195
0
0
0
93
90
53
78
77
76
14
20
31
22
48
46
2
4
6
2
5
6
0
0
0
0
2
13
0
3
9
2
5
0
11
17
2
13
5
3
20
19
0
0
0
0
9 220
11 676
11 997
11 903
11 862
12 572
1 807
1 675
421
1 062
958
2 812
302
2 081
2 657
3 175
3 193
3 464
2 831
1 896
2 114
0
421
618
774
719
722
914
1 408
596
816
544
1 335
2 026
1 370
1 535
1 266
0
111
585
0
1
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
2
3
0
0
0
0
0
5
5
4
3 813
3 119
2 913
3 365
3 246
2 902
3 322
168
296
422
639
653
763
712
6 212
10 420
14 311
14 602
14 222
3 647
4 984
6 406
3 333
2 829
2 924
2 876
123
109
127
90
105
139
130
14 437
11 329
18 434
18 524
18 810
18 846
19 570
1
0
% SMEARPOS AMONG
NEW PULM
–
78
65
80
95
80
75
–
62
72
74
75
74
69
100
–
–
–
–
25
100
100
–
66
70
74
72
75
73
–
72
79
83
89
90
89
–
–
78
72
73
72
74
–
–
–
–
100
80
100
–
81
80
80
86
90
89
–
31
34
41
57
52
54
–
–
67
58
64
–
66
–
51
59
74
81
78
79
–
87
82
63
78
62
62
–
84
87
97
92
93
82
–
–
–
100
–
–
–
–
–
40
–
–
–
Rates are per 100 000 population. Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 154
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($&DVHQRWLILFDWLRQV±
YEAR
Nicaragua
• 71
42 •
Panama
• 35
43 •
Paraguay
• 51
35 •
Peru
• 175
107 •
Puerto Rico
•5
2•
Saint Kitts and
Nevis
•0
4•
Saint Lucia
•9
5•
Saint Vincent and
the Grenadines
•2
Sint Maarten (Dutch part)
Suriname
• 20
14 •
34 •
Trinidad and
Tobago
• 10
16 •
•0
16 •
Turks and Caicos
Islands
United States
of America
• 10
4•
Uruguay
• 28
21 •
US Virgin Islands
•4
–
Venezuela
(Bolivarian
Republic of)
• 28
a
22 •
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
NEW AND
RELAPSEa
2 944
2 842
2 402
1 907
2 336
2 283
2 448
846
1 300
1 169
1 637
1 532
1 539
1 496
2 167
1 745
1 950
2 075
2 222
2 346
2 277
37 905
45 310
38 661
33 421
32 193
31 844
31 073
159
262
174
113
95
63
80
0
5
0
0
5
4
2
13
11
9
14
21
10
9
2
13
16
7
12
9
15
3
82
89
117
108
177
179
120
166
198
166
279
272
219
0
6
25 701
22 728
16 310
14 080
12 904
11 545
11 181
886
625
645
622
686
704
699
4
4
5 457
5 578
6 466
6 847
6 408
6 474
6 335
SMEAR- SMEAR-NEGATIVE/
POSITIVE
UNKNOWN
EXTRAPULMONARY
OTHER RELAPSE
1 568
1 471
1 253
1 394
1 329
1 440
854
541
395
530
541
575
253
231
160
245
261
274
1 066
460
860
829
755
707
993
748
900
1 260
1 345
1 498
1 318
114
589
505
402
452
425
28
74
216
251
287
287
870
791
665
554
428
499
127
170
150
240
283
269
7
41
86
32 096
22 580
18 490
17 989
17 391
17 264
7 803
6 018
5 592
5 176
5 203
5 201
5 411
5 682
5 335
5 137
5 380
5 185
128
81
60
52
30
37
111
69
37
30
25
35
4
0
0
5
4
2
RE-TREAT EXCL. TOTAL
HISTORY
RELAPSE
RETREAT UNKNOWN
167
159
99
167
152
159
169
0
130
127
167
159
268
167
282
286
108
41
56
50
45
77
93
191
141
190
134
108
134
247
191
235
211
76
96
105
516
273
78
81
109
28
530
273
154
177
214
809
831
871
647
4 381
3 195
3 060
2 999
2 776
1 794
1 474
1 325
1 404
4 381
4 989
4 534
4 324
4 180
326
0
0
23
24
16
13
8
4
0
0
0
0
0
0
0
4
0
0
0
0
0
0
0
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
0
0
0
0
2
0
0
0
0
0
0
11
7
11
18
7
9
1
1
1
0
0
0
0
1
1
0
0
0
0
0
1
2
1
2
0
2
0
0
1
0
3
2
1
3
0
0
0
0
5
9
6
11
3
8
3
7
4
1
0
6
7
0
0
0
0
0
0
0
0
0
0
0
0
0
4
3
0
1
0
0
0
0
0
3
2
2
0
4
3
0
4
2
2
0
37
49
68
149
40
54
24
14
12
6
13
9
2
1
0
0
6
2
5
1
2
5
10
1
8
7
15
0
0
1
7
115
95
169
154
136
68
61
50
97
91
58
12
17
12
9
19
20
0
0
0
0
22
5
9
4
8
5
26
13
43
52
39
22
31
22
47
60
44
0
0
0
1
1
2
0
4
25
0
20
39
19
56
37
41
0
103
197
167
194
272
377
350
432
428
442
0
0
116
0
0
0
5
0
0
0
28
14
3
1
1
0
8 093
5 883
5 111
4 742
4 014
3 695
10 795
7 204
6 030
5 515
4 990
4 990
3 835
3 211
2 939
2 638
2 383
2 134
5
12
0
9
158
362
349
348
355
424
409
368
178
165
147
159
192
218
78
77
73
72
66
72
32
0
0
0
20
39
15
31
37
41
2
2
0
3 056
3 525
3 653
3 344
3 436
3 252
1 517
1 616
1 853
1 599
1 665
1 758
709
948
1 094
1 116
1 112
1 077
114
0
0
272
377
247
235
261
248
0
0
0
0
52
0
70
0
75
0
0
0
0
0
% SMEARPOS AMONG
NEW PULM
–
65
73
76
72
71
71
–
90
44
63
67
63
62
–
46
53
65
71
78
73
–
80
79
77
78
77
77
–
54
54
62
63
55
51
–
–
–
–
100
100
100
–
–
88
92
95
100
100
–
42
69
86
100
33
53
100
–
–
48
48
74
91
–
–
9
65
66
64
63
70
–
–
–
–
–
–
75
–
43
45
46
46
45
43
–
66
68
71
73
68
63
–
50
–
–
–
–
–
–
67
69
66
68
67
65
Region of the Americas
NEW CASES
NEW AND RELAPSE
NOTIFICATION RATEa
1990–2010
Rates are per 100 000 population. Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 155
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
155
05/10/11 09:03
7$%/($7UHDWPHQWRXWFRPHVQHZVPHDUSRVLWLYHFDVHV±
% OF COHORT
TREATMENT SUCCESS (%)a
1995–2009
YEAR
Anguilla
–
–
Antigua and
Barbuda
–
67 •
• 12
46 •
Argentina
Aruba
–
–
Bahamas
–
81 •
Barbados
–
100 •
Belize
• 52
–
–
–
Bermuda
Bolivia
(Plurinational
State of)
• 62
Bonaire, Saint Eustatius and Saba
Brazil
• 17
86 •
72 •
British Virgin
Islands
–
100 •
Canada
–
75 •
Cayman Islands
–
50 •
Chile
• 79
72 •
Colombia
–
77 •
Costa Rica
–
54 •
• 90
90 •
Cuba
Curaçao
a
156
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
2009
NUMBER
NOTIFIED
SIZE OF
COHORT
0
0
0
3
6
2
1
1
5 698
4 749
4 709
4 985
4 758
4 044
4
6
2
1
3
5 707
5 177
4 709
5 036
2 577
5 062
6
38
56
30
32
31
26
3
3
30
32
31
26
11
8
3
2
29
45
59
63
82
8
1
2
36
44
59
54
83
82
2
0
7 010
6 458
6 278
5 686
6 048
5 937
45 650
41 186
42 093
38 444
37 697
39 267
1
7 010
6 212
6 278
5 686
6 048
5 897
0
45 650
34 007
42 093
38 133
40 714
40 818
1
0
0
1
1
436
492
433
463
488
462
0
5
492
459
813
919
850
5
1
1
1 561
1 290
1 186
1 166
1 114
1 152
7 530
8 358
6 870
7 188
7 196
7 319
245
349
330
322
287
271
834
675
467
432
498
418
2
1 111
1 360
1 147
1 143
1 259
1 365
1 634
7 778
7 027
7 288
6 899
349
306
296
280
166
834
673
466
430
496
415
5
COHORT AS
% NOTIFIED
–
–
–
–
–
–
–
133
100
100
100
300
100
109
100
101
54
125
–
–
–
–
–
–
–
–
100
100
100
100
–
–
–
100
300
100
81
102
100
117
99
–
–
–
–
–
–
–
100
96
100
100
100
99
–
100
83
100
99
108
104
–
100
–
–
–
–
–
100
106
176
188
184
–
100
–
–
–
–
71
105
97
98
113
118
–
20
113
98
101
94
–
100
93
92
98
61
100
100
100
100
100
99
–
CURED
COMPLETED
0
DIED
FAILED
DEFAULTED
NOT
EVALUATED
100
50
0
100
67
5
26
19
26
24
19
0
33
0
0
33
1
5
5
5
4
4
0
0
50
0
0
7
20
34
36
19
26
0
0
0
0
0
0
0
0
0
50
0
0
3
6
5
11
5
7
0
17
0
0
0
84
43
37
21
47
43
17
6
32
12
40
56
42
69
17
13
6
8
7
0
3
0
20
25
10
12
0
0
6
0
45
100
100
100
52
78
56
44
83
45
0
0
0
0
0
19
2
0
9
0
0
0
10
9
12
6
17
0
0
0
3
0
2
3
0
0
0
0
28
2
12
13
0
0
0
0
0
7
11
0
32
0
0
53
73
76
82
82
84
–
17
49
31
33
33
31
0
9
6
2
2
2
1
–
0
22
44
39
38
41
0
4
4
3
4
4
4
–
1
4
5
5
5
5
0
1
1
1
1
1
1
–
1
0
1
1
1
1
0
9
9
5
5
5
5
–
3
9
9
10
9
10
100
24
7
12
5
7
4
–
79
16
9
12
14
11
100
0
0
100
0
0
0
0
22
8
5
12
10
13
59
59
65
65
5
9
10
9
7
0
0
0
0
1
1
2
1
0
59
22
24
13
17
0
0
40
0
0
0
0
0
0
100
60
0
50
79
82
83
78
72
61
0
11
0
7
9
9
9
9
9
0
0
0
0
0
0
0
0
8
6
6
6
7
7
50
5
3
2
0
12
12
70
63
66
67
68
10
9
11
9
9
5
6
7
6
6
1
1
1
2
2
8
7
9
8
9
6
14
6
8
6
43
85
83
86
49
90
91
90
89
88
87
14
4
5
3
4
0
2
2
3
0
3
10
5
3
5
5
4
4
6
6
8
7
1
2
2
1
1
3
1
1
0
1
2
12
3
4
2
1
2
1
1
1
2
1
19
1
3
3
39
2
1
1
1
0
0
0
7
TREATMENT SUCCESS = percent cured + percent completed then rounded to the nearest digit.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 156
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($7UHDWPHQWRXWFRPHVQHZVPHDUSRVLWLYHFDVHV±
% OF COHORT
YEAR
Dominica
–
100 •
Dominican
Republic
• 64
85 •
Ecuador
• 39
75 •
El Salvador
–
89 •
Grenada
–
50 •
Guatemala
• 61
83 •
• 44
70 •
Guyana
Haiti
• 70
79 •
Honduras
• 64
86 •
• 67
70 •
• 75
86 •
Jamaica
Mexico
Montserrat
–
–
Netherlands
Antilles
–
–
Nicaragua
• 80
85 •
• 69
80 •
• 51
80 •
• 83
81 •
Panama
Paraguay
Peru
a
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
NUMBER
NOTIFIED
SIZE OF
COHORT
5
3
3
4
2 787
2 907
2 949
2 373
2 458
2 441
5 890
5 064
3 048
3 448
3 380
3 317
3
3
4
2 007
2 760
2 697
2 373
2 458
2 441
5 236
1 008
1 059
942
985
930
2
0
1 008
1 059
942
985
930
3
5
4
2 368
2 052
2 420
2 348
2 070
1 609
85
119
240
233
320
328
5 887
7 340
7 915
8 171
2 306
3 404
2 069
1 974
1 897
1 881
93
90
53
78
78
77
9 220
11 676
11 997
11 531
11 903
11 862
2 150
3 448
3 380
3 330
6
3
6
4
2 368
1 908
1 920
2 070
2 121
296
119
257
309
340
328
3 081
5 887
7 340
7 915
8 435
2 226
2 362
1 905
1 830
1 888
1 881
93
99
53
78
78
76
9 220
11 538
12 172
11 432
11 840
11 821
0
1
1
0
2
5
1 568
1 471
1 253
1 453
1 394
1 329
1 066
460
860
833
829
755
748
900
1 260
1 276
1 345
1 498
32 096
22 580
18 490
17 796
17 989
17 391
1 536
1 437
1 496
1 708
1 481
1 552
1 388
460
873
858
883
768
748
900
1 452
1 279
1 350
1 467
28 185
22 230
14 793
14 056
14 805
14 212
COHORT AS
% NOTIFIED
–
–
–
100
100
100
72
95
91
100
100
100
89
–
71
100
100
100
–
100
100
100
100
100
–
–
–
100
120
100
100
93
–
82
100
132
348
100
107
133
106
100
–
100
100
100
–
–
97
69
92
93
100
100
100
110
100
100
100
99
100
99
101
99
99
100
–
–
–
–
–
–
–
250
–
–
–
98
98
119
118
106
117
130
100
102
103
107
102
100
100
115
100
100
98
88
98
80
79
82
82
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
67
100
100
43
37
80
72
71
79
0
0
0
21
34
5
5
4
6
39
0
0
0
5
5
4
3
3
4
2
0
0
0
2
2
2
1
1
2
8
33
0
0
13
19
7
8
8
7
14
0
0
0
16
4
3
10
12
2
37
81
72
74
71
3
3
4
4
3
3
4
4
3
3
4
3
6
6
8
8
5
12
7
11
78
91
90
91
88
1
0
1
1
1
7
4
6
5
5
1
1
1
1
4
5
2
3
3
2
8
1
0
0
0
1
1
4
7
0
0
0
0
31
1
2
1
1
1
5
2
2
1
6
3
9
6
8
2
3
10
6
5
7
25
3
3
4
3
2
5
20
4
21
15
5
6
8
11
3
3
2
67
33
100
33
50
56
75
5
11
67
50
3
5
57
72
71
7
4
6
34
13
57
61
55
57
70
14
8
11
5
5
6
11
12
7
7
5
8
4
5
6
5
2
2
1
1
1
1
1
8
9
9
38
24
26
14
16
19
21
13
7
7
67
39
81
81
80
80
79
2
5
4
14
13
55
69
64
71
78
81
82
12
25
5
7
5
6
6
65
40
53
42
51
14
6
12
6
5
4
4
5
7
6
5
6
5
6
10
23
13
15
10
14
4
6
5
6
6
6
1
0
1
0
0
1
1
1
0
0
0
0
0
3
1
1
1
1
1
8
4
5
4
5
6
6
17
11
26
8
10
11
12
9
6
6
5
5
–
–
–
–
–
78
79
77
10
43
2
10
14
13
20
66
70
73
72
73
69
10
27
68
61
67
65
8
21
46
64
68
75
75
90
91
87
78
70
14
13
13
14
16
16
60
33
12
18
13
16
43
45
33
19
12
5
9
0
5
4
11
4
5
5
3
3
4
14
7
8
6
7
7
3
5
5
5
5
7
3
2
2
2
3
3
Region of the Americas
TREATMENT SUCCESS (%)a
1995–2009
–
80
2
1
2
1
1
1
1
2
0
0
0
1
0
0
0
0
0
2
2
2
2
1
1
10
9
6
6
7
7
13
22
10
14
13
12
17
22
8
7
6
5
6
3
4
4
6
6
4
2
3
3
0
3
3
10
1
1
0
0
29
7
7
5
8
7
6
4
1
1
8
9
TREATMENT SUCCESS = percent cured + percent completed then rounded to the nearest digit.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 157
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
157
05/10/11 09:03
7$%/($7UHDWPHQWRXWFRPHVQHZVPHDUSRVLWLYHFDVHV±
% OF COHORT
TREATMENT SUCCESS (%)a
1995–2009
YEAR
Puerto Rico
• 68
81 •
• 60
80 •
Saint Kitts and
Nevis
Saint Lucia
–
57 •
Saint Vincent and
the Grenadines
–
Sint Maarten (Dutch part)
Suriname
• 14
–
–
Trinidad and
Tobago
• 69
69 •
Turks and Caicos
Islands
–
–
United States
of America
• 76
60 •
Uruguay
• 68
80 •
• 50
–
US Virgin Islands
Venezuela
(Bolivarian
Republic of)
• 74
a
158
84 •
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
NUMBER
NOTIFIED
128
81
60
56
52
30
4
0
0
4
5
4
11
7
11
18
18
7
5
9
6
4
11
3
SIZE OF
COHORT
128
81
60
56
43
37
5
4
5
5
8
13
19
18
7
13
4
1
51
37
37
49
68
149
7
115
95
130
169
154
71
78
194
106
144
169
154
2
3
8 093
5 883
5 111
4 864
4 742
4 014
349
348
355
380
424
409
2
8 116
5 901
5 136
4 881
3 709
7 460
370
344
345
373
422
406
2
3 056
3 525
3 653
3 392
3 344
3 436
3 056
3 390
3 581
3 336
3 301
3 433
COHORT AS
% NOTIFIED
100
100
100
100
83
123
125
–
–
100
100
125
–
114
118
106
100
100
–
144
–
–
36
33
–
–
100
–
–
104
–
1 114
169
112
111
100
100
–
–
–
–
–
–
100
100
100
100
78
186
106
99
97
98
100
99
100
–
–
–
–
–
100
96
98
98
99
100
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
68
64
0
0
63
0
40
23
31
22
9
33
16
20
0
0
0
0
0
8
5
3
2
5
0
20
2
0
0
4
0
3
0
25
80
0
50
0
0
0
0
0
0
0
0
25
20
20
88
15
11
28
13
54
74
67
57
0
31
11
6
29
0
0
0
0
0
0
0
5
0
14
0
0
0
0
0
100
0
0
0
0
0
0
100
0
0
0
0
0
0
0
0
100
10
49
4
19
12
16
0
8
14
67
3
38
21
13
0
24
4
49
22
68
61
65
61
21
46
4
4
2
8
19
11
12
15
15
14
1
2
2
4
1
10
6
16
18
14
14
0
13
0
0
0
1
0
33
0
33
0
0
0
0
100
0
0
33
76
83
84
85
85
60
27
0
4
2
7
7
15
11
8
8
9
6
10
13
11
11
9
12
0
4
3
6
0
4
4
5
5
4
4
75
86
0
81
20
0
80
41
85
80
82
77
73
50
68
76
83
82
83
84
0
0
0
1
1
0
0
1
0
0
2
1
4
1
4
6
5
6
0
6
3
6
5
5
32
17
0
1
0
2
2
50
1
0
0
0
0
0
8
13
10
11
11
11
13
6
2
2
1
1
2
3
TREATMENT SUCCESS = percent cured + percent completed then rounded to the nearest digit.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 158
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($7UHDWPHQWRXWFRPHVUHWUHDWPHQWFDVHV±
% OF COHORT
YEAR
Anguilla
–
–
Antigua and
Barbuda
–
100 •
Argentina
–
30 •
–
–
Aruba
Bahamas
–
80 •
Barbados
–
–
Belize
• 23
–
Bermuda
–
–
Bolivia
(Plurinational
State of)
• 66
Bonaire, Saint Eustatius and Saba
Brazil
–
78 •
42 •
British Virgin
Islands
–
–
Canada
–
64 •
Cayman Islands
–
–
Chile
–
24 •
Colombia
–
–
Costa Rica
–
0•
Cuba
• 82
Curaçao
a
74 •
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
2009
NUMBER
NOTIFIED
SIZE OF
COHORT
0
0
0
0
0
0
0
2
0
1
1 828
809
618
1 392
827
1 615
1 083
374
893
1
0
4
3
4
5
4
1
3
5
0
0
0
0
4
6
15
7
5
12
0
0
0
13
14
0
0
63
2 081
772
652
590
732
0
462
804
772
652
590
598
0
11 334
9 637
8 634
11 164
9 818
7 859
9 479
9 519
9 494
10 664
0
0
0
195
145
103
109
122
94
0
0
145
106
110
126
95
0
2
0
225
158
314
226
219
306
339
443
423
413
616
0
35
45
42
24
31
54
172
49
59
60
51
150
140
212
231
219
0
69
49
34
32
2
55
58
48
58
56
61
COHORT AS
% NOTIFIED
–
–
–
–
–
–
–
–
–
–
–
50
–
–
200
175
27
108
–
–
–
–
–
–
–
–
100
33
75
100
–
–
–
–
–
–
325
–
93
–
0
–
–
–
–
–
–
–
733
39
100
100
100
82
–
–
69
98
110
85
109
–
–
–
–
–
–
–
100
103
101
103
101
–
–
–
–
–
–
–
95
45
94
105
72
–
–
0
–
–
–
–
197
109
81
133
6
102
34
98
98
93
120
–
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
–
100
–
0
–
0
–
0
–
0
–
0
7
14
10
10
26
29
16
20
5
6
6
4
0
1
1
1
9
16
9
13
53
34
59
52
25
0
0
20
50
100
33
60
0
0
33
20
0
0
0
0
25
0
0
0
0
0
33
0
–
–
–
23
–
–
–
0
–
–
–
23
–
–
–
8
–
–
–
38
–
–
–
8
57
29
14
0
0
0
–
–
–
–
–
–
–
57
49
63
73
72
73
–
–
9
11
3
3
4
5
–
–
7
12
5
4
8
7
–
–
5
2
3
2
2
2
–
–
15
8
7
10
7
7
–
–
7
16
19
9
7
7
–
30
26
18
18
15
10
22
33
32
28
4
7
8
8
8
0
2
1
2
2
14
19
23
25
23
41
25
17
15
24
–
–
–
–
–
–
16
8
4
7
4
16
59
59
71
60
6
7
6
10
7
1
0
2
0
0
2
3
3
0
1
60
23
26
11
27
–
–
–
–
–
–
–
–
–
–
–
–
32
69
29
22
15
26
3
9
8
14
3
8
7
1
1
0
1
2
18
9
9
10
7
15
3
58
59
60
–
–
–
–
–
–
23
55
59
56
0
82
78
67
83
64
69
9
12
9
28
0
0
7
10
4
9
3
50
7
10
6
14
18
15
3
2
3
25
24
21
6
0
5
2
2
3
2
7
30
2
0
6
50
0
0
21
0
0
0
16
5
0
5
3
4
0
5
Region of the Americas
TREATMENT SUCCESS (%)a
1995–2009
TREATMENT SUCCESS = percent cured + percent completed then rounded to the nearest digit.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 159
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
159
05/10/11 09:03
7$%/($7UHDWPHQWRXWFRPHVUHWUHDWPHQWFDVHV±
% OF COHORT
TREATMENT SUCCESS (%)a
1995–2009
YEAR
Dominica
–
–
Dominican
Republic
–
53 •
Ecuador
–
55 •
El Salvador
–
88 •
Grenada
–
–
Guatemala
• 73
64 •
Guyana
–
51 •
Haiti
–
69 •
Honduras
–
57 •
Jamaica
• 67
74 •
Mexico
–
61 •
Montserrat
–
–
Netherlands
Antilles
–
–
Nicaragua
• 78
76 •
Panama
–
48 •
Paraguay
–
56 •
Peru
–
a
160
70 •
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
NUMBER
NOTIFIED
SIZE OF
COHORT
3
0
4
1
204
610
729
565
497
452
1
0
0
498
530
565
497
434
386
795
831
778
756
554
831
778
756
271
114
86
86
113
181
114
86
86
113
0
0
1
0
249
141
159
197
202
128
2
84
25
78
117
205
346
228
374
373
0
0
254
164
199
202
181
38
23
95
146
205
55
228
367
381
100
236
181
189
184
225
2
13
5
2
3
20
1 335
2 026
1 656
1 370
1 535
180
169
189
145
192
6
5
0
3
19
138
1 456
1 806
1 829
1 229
0
0
0
0
0
167
159
268
296
167
282
108
134
247
228
191
235
28
530
273
163
154
177
289
230
181
228
150
178
4 381
4 989
5 141
4 534
4 324
4 521
2 299
2 201
42
237
233
238
203
144
164
160
164
188
2 163
COHORT AS
% NOTIFIED
–
–
–
–
0
0
–
82
73
100
100
96
–
–
70
100
100
100
–
67
100
100
100
100
–
–
–
–
0
–
102
116
–
101
100
141
–
45
92
122
125
100
–
16
100
98
–
–
–
76
93
100
79
85
300
–
100
0
100
95
–
10
72
109
134
80
–
–
–
–
–
–
–
–
–
–
–
173
145
68
77
90
63
–
31
96
102
125
86
–
27
60
98
106
106
–
103
46
43
–
50
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
0
–
–
0
–
–
0
–
–
0
–
–
100
–
–
0
–
–
29
56
34
0
47
26
5
4
0
6
3
7
4
0
13
4
8
5
0
5
27
19
16
0
29
11
6
37
100
0
56
39
61
46
8
8
8
9
5
5
7
6
10
7
8
8
12
10
15
16
9
31
0
16
63
68
81
84
85
3
0
1
0
3
9
6
3
8
3
3
4
0
0
1
18
13
14
5
8
3
8
0
3
1
59
63
15
16
4
4
2
4
4
10
17
2
65
55
55
8
10
8
5
8
5
7
6
7
11
16
20
5
5
4
24
22
3
4
0
29
35
51
22
51
13
9
12
10
14
5
9
4
2
0
26
13
26
24
18
3
13
4
38
17
42
63
59
15
7
10
5
3
10
7
0
3
22
13
10
9
14
8
49
20
7
3
10
11
44
59
0
65
50
0
10
9
100
6
7
67
8
6
0
10
10
17
2
2
0
3
1
0
6
17
0
14
10
17
29
7
0
3
22
0
–
0
16
20
–
67
58
–
0
5
–
0
0
80
–
33
21
0
–
0
0
33
48
58
55
56
4
7
8
7
5
8
7
5
11
9
7
4
9
4
6
12
14
13
11
10
36
20
7
11
14
–
–
–
–
–
–
69
65
71
72
97
70
10
10
12
6
0
6
4
6
7
5
0
3
3
2
2
3
0
6
11
15
7
9
3
11
3
2
2
5
0
3
19
23
19
16
18
24
35
30
30
30
2
9
11
9
10
0
4
2
2
0
48
22
36
42
37
7
7
2
1
4
19
44
49
46
47
40
26
21
14
9
6
4
4
9
9
1
1
1
4
25
10
14
10
11
9
16
11
21
20
78
78
74
0
7
4
5
3
7
5
3
6
11
11
4
1
1
49
21
4
2
12
12
TREATMENT SUCCESS = percent cured + percent completed then rounded to the nearest digit.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 160
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($7UHDWPHQWRXWFRPHVUHWUHDWPHQWFDVHV±
% OF COHORT
YEAR
Puerto Rico
–
–
Saint Kitts and
Nevis
–
–
Saint Lucia
–
33 •
Saint Vincent and
the Grenadines
–
Sint Maarten (Dutch part)
Suriname
–
0•
–
Trinidad and
Tobago
–
68 •
Turks and Caicos
Islands
–
–
–
–
United States
of America
Uruguay
• 76
56 •
US Virgin Islands
–
–
Venezuela
(Bolivarian
Republic of)
–
a
80 •
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
NUMBER
NOTIFIED
SIZE OF
COHORT
0
0
0
0
113
0
0
0
0
2
0
0
0
2
0
0
0
3
2
1
1
3
4
3
0
6
4
2
1
1
1
3
3
4
1
1
8
7
15
22
31
22
52
47
60
3
22
21
51
47
60
3
0
20
39
19
47
56
37
272
377
350
351
432
428
25
30
45
57
41
247
248
227
261
COHORT AS
% NOTIFIED
–
–
–
–
–
–
–
–
100
–
–
–
–
33
–
100
100
100
–
100
–
–
100
50
–
–
–
–
–
43
–
–
71
95
98
100
100
–
–
–
–
–
–
–
–
–
–
–
–
125
–
158
96
102
111
–
–
–
–
–
–
–
–
71
71
53
61
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
–
–
–
73
–
–
–
23
–
–
–
0
–
–
–
4
–
–
–
1
–
–
–
–
–
–
50
–
–
–
–
–
–
–
–
–
–
–
–
50
–
–
–
100
0
0
0
0
0
100
0
0
0
33
0
0
67
0
100
0
0
0
0
0
0
0
100
0
0
0
0
0
0
0
0
0
0
0
0
0
100
100
0
0
0
33
0
0
33
33
23
19
27
32
48
45
38
2
4
20
14
29
37
11
15
9
0
6
0
9
14
31
47
17
0
0
2
0
0
33
33
33
0
0
0
56
20
16
0
8
0
57
69
60
46
17
4
12
10
13
20
14
34
3
0
0
0
7
4
14
7
3
2
0
2
80
79
84
80
0
0
0
4
6
5
4
2
2
1
2
12
12
10
13
2
1
0
2
Region of the Americas
TREATMENT SUCCESS (%)a
1995–2009
TREATMENT SUCCESS = percent cured + percent completed then rounded to the nearest digit.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 161
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
161
05/10/11 09:03
7$%/($+,9WHVWLQJDQGSURYLVLRQRI&37$57DQG,37 –
% OF TB PATIENTS WITH
KNOWN HIV STATUS
2005–2010
YEAR
Anguilla
–
0•
Antigua and
Barbuda
• 100
86 •
–
13 •
–
–
Argentina
Aruba
Bahamas
–
100 •
–
100 •
Barbados
Belize
• 100
99 •
Bermuda
–
100 •
Bolivia
(Plurinational
State of)
•0
Bonaire, Saint Eustatius and Saba
Brazil
• 59
23 •
45 •
British Virgin
Islands
–
0•
Canada
• 26
28 •
Cayman Islands
–
100 •
–
–
Chile
Colombia
• 53
43 •
• 67
–
Costa Rica
Cuba
• 93
103 •
Curaçao
Dominica
–
38 •
Dominican
Republic
•1
60 •
•0
66 •
• 84
96 •
Ecuador
El Salvador
Grenada
–
100 •
Guatemala
• 16
63 •
• 70
88 •
• 35
67 •
Guyana
Haiti
162
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
% OF TB
NUMBER OF TB
PATIENTS WITH PATIENTS WITH
KNOWN HIV
KNOWN HIV
STATUS
STATUS
–
–
–
0
100
100
100
86
–
7
13
13
–
–
–
–
–
88
100
100
–
100
100
100
100
100
95
99
–
–
–
100
0
5
17
23
–
59
51
52
45
–
–
–
0
26
36
40
28
–
–
–
100
–
–
–
–
53
40
43
43
67
96
104
–
93
84
99
103
0
–
19
80
38
1
45
57
60
0
18
47
66
84
95
95
96
–
33
100
100
16
56
65
63
70
70
79
88
35
65
–
67
0
6
1
4
6
715
1 093
1 008
45
46
32
8
3
2
6
106
88
89
143
1
1
0
485
1 509
2 003
0
51 552
41 796
44 038
37 210
0
1
0
414
574
645
382
1
2
4
1
6
1
4
7
11 242
10 450
8 190
7 762
6
50
51
46
32
NUMBER OF HIV- % OF TESTED
POSITIVE TB
TB PATIENTS
PATIENTS
HIV-POSITIVE
0
3
0
0
5
375
530
566
17
15
15
2
2
3
2
6
106
88
94
145
2
25
18
17
29
1
9 973
9 224
9 128
8 620
0
87 223
81 658
85 159
81 946
0
0
0
19
38
140
0
8 249
8 331
8 828
8 558
0
1
1 616
1 601
1 599
1 385
1
0
63
94
64
23
729
698
710
862
0
4
2 633
2 494
2 516
2 472
10 360
11 344
11 663
11 889
560
511
457
499
781
831
717
838
5
3
4
3
78
2 011
2 516
2 489
10
959
2 385
3 379
1 544
1 655
1 650
1 667
16
5
8
5 312
4 468
4 442
4 160
4 808
5 202
5 026
5 095
1 830
1 746
1 736
1 730
2
1
1
3
399
403
547
3
402
443
427
188
194
204
180
2
5
4
600
1 871
1 920
2 103
456
516
717
734
5 062
9 476
9 886
9 518
6
5
4
3 861
3 316
2 942
3 351
656
740
912
836
14 344
14 662
2
1
1
478
326
260
325
80
123
195
209
1 797
2 068
2 236
1 892
5 537
4 540
5 031
5 079
374
491
476
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 162
PATIENTS
NOTIFIED
(NEW AND
RETREAT)
14 265
0
353
956
1 133
1 231
50
44
41
71
46
53
0
–
–
–
–
50
0
0
83
–
52
48
56
–
–
–
–
–
38
33
47
25
67
–
33
24
20
19
20
–
–
–
0
–
4
3
7
–
16
20
20
23
–
–
100
–
15
16
10
6
–
–
–
0
–
–
–
–
6
21
23
24
13
9
9
–
–
10
6
6
–
–
67
25
33
4
20
16
22
30
42
19
13
12
12
12
11
–
100
20
25
80
17
14
15
18
24
27
28
35
22
23
20
% OF HIV% OF HIVNUMBER OF HIVPOSITIVE
POSITIVE TB POSITIVE TB
PEOPLE
PATIENTS ON PATIENTS ON
PROVIDED IPT
CPT
ART
–
–
–
–
100
–
–
20
–
84
–
–
–
–
–
–
–
59
40
27
–
100
–
–
68
100
100
100
–
–
–
–
–
84
21
0
–
–
–
–
–
–
–
100
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
0
0
–
–
100
0
100
–
–
–
8
0
–
–
–
20
53
28
82
–
100
100
0
–
100
100
100
–
97
82
77
–
9
5
13
–
–
–
–
100
–
–
100
–
84
–
–
–
–
–
–
–
65
67
67
–
100
–
100
68
100
100
100
–
–
–
–
–
16
76
81
–
85
91
88
93
–
–
100
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
21
35
84
–
–
–
–
17
80
66
–
–
50
100
100
–
–
–
4
–
100
100
100
38
47
35
63
–
100
100
0
243
100
100
100
–
59
55
59
–
10
8
10
0
0
0
2
0
0
409
50
674
27
0
1 561
1 366
0
2
953
443
822
5 041
3
97
455
0
0
0
20
250
132
162
144
7 250
4 112
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($+,9WHVWLQJDQGSURYLVLRQRI&37$57DQG,37 –
YEAR
Honduras
• 44
54 •
• 83
87 •
•7
43 •
Jamaica
Mexico
Montserrat
• 100
–
–
–
Netherlands
Antilles
Nicaragua
• 27
56 •
• 86
82 •
–
32 •
Panama
Paraguay
Peru
•2
29 •
• 82
95 •
Puerto Rico
Saint Kitts and
Nevis
–
100 •
•7
100 •
Saint Lucia
Saint Vincent and
the Grenadines
• 100
Sint Maarten (Dutch part)
Suriname
• 73
59 •
–
Trinidad and
Tobago
• 69
98 •
–
71 •
• 59
64 •
• 92
89 •
Turks and Caicos
Islands
United States
of America
Uruguay
US Virgin Islands
–
–
Venezuela
(Bolivarian
Republic of)
• 39
78 •
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
% OF TB
NUMBER OF TB
PATIENTS WITH PATIENTS WITH
KNOWN HIV
KNOWN HIV
STATUS
STATUS
44
56
55
54
83
82
64
87
7
35
30
43
100
–
–
–
–
–
–
27
45
45
56
86
89
79
82
–
4
11
32
2
32
35
29
82
96
97
95
–
–
100
100
7
86
100
100
100
100
64
59
100
73
89
82
–
69
100
94
98
–
–
–
71
59
63
62
64
92
96
94
89
–
–
–
–
39
64
73
78
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 163
PATIENTS
NOTIFIED
(NEW AND
RETREAT)
NUMBER OF HIV- % OF TESTED
POSITIVE TB
TB PATIENTS
PATIENTS
HIV-POSITIVE
1 455
1 595
1 619
1 557
79
86
96
128
1 382
6 878
5 879
8 842
1
3 333
2 862
2 957
2 901
95
105
150
147
19 932
19 406
19 773
20 699
1
200
205
192
201
28
16
29
29
217
581
945
1 189
0
0
2
0
0
2
556
1 062
1 081
1 445
1 569
1 540
1 364
1 337
2 076
2 336
2 413
2 575
1 828
1 725
1 729
1 630
2 348
2 370
2 427
2 461
35 541
33 667
33 169
32 477
113
95
63
80
2
5
4
2
14
21
11
9
7
15
11
17
3
119
113
188
30
28
32
60
200
275
213
213
103
271
777
668
10 636
11 710
9 539
93
91
61
76
4
2
1
18
11
9
7
15
7
10
3
87
101
154
124
322
306
254
5
179
322
324
258
88
140
138
668
775
678
853
28
23
9
14
0
0
0
4
4
0
1
6
5
3
0
20
28
49
42
73
95
58
1
3
5
8 273
8 177
7 197
7 107
574
686
662
620
7
14 080
12 904
11 545
11 181
626
711
704
699
1
1
1 035
826
711
612
74
100
102
103
2 678
4 248
4 856
5 213
6 950
6 605
6 641
6 645
392
482
487
479
14
13
12
13
35
19
30
23
16
8
16
13
0
–
–
–
100
–
–
5
3
3
4
13
18
16
16
–
85
52
18
100
7
6
9
30
25
15
18
–
–
0
0
0
22
36
0
14
40
71
30
0
23
28
32
–
34
23
31
23
20
–
33
20
13
10
10
9
13
15
15
17
–
–
–
–
15
11
10
9
% OF HIV% OF HIVNUMBER OF HIVPOSITIVE
POSITIVE TB POSITIVE TB
PEOPLE
PATIENTS ON PATIENTS ON
PROVIDED IPT
CPT
ART
–
–
100
90
43
63
–
–
–
100
100
100
–
–
–
–
–
–
–
–
100
94
67
–
–
42
64
–
0
0
0
–
0
–
–
–
17
33
43
–
–
–
–
–
0
0
–
0
–
–
–
–
–
7
12
–
29
14
14
19
–
–
–
0
–
–
–
–
0
0
0
0
–
–
–
–
–
0
0
–
–
100
89
90
54
100
100
100
–
38
23
36
–
–
–
–
–
–
–
–
100
94
67
10
13
28
66
–
66
51
70
–
17
18
10
–
9
56
50
–
–
–
–
–
25
25
–
0
33
20
100
–
10
32
51
–
36
49
6
12
–
–
–
100
–
–
–
–
–
19
19
31
–
–
–
–
39
17
21
33
0
153
96
27
0
1 490
676
60
465
400
16
196
0
0
1 214
2 137
1 361
1 183
0
0
0
1
0
6
4
11
Region of the Americas
% OF TB PATIENTS WITH
KNOWN HIV STATUS
2005–2010
76
102
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
163
05/10/11 09:03
7$%/($7HVWLQJIRU0'57%DQGQXPEHURIFRQILUPHGFDVHVRI0'57%±
YEAR
Anguilla
Antigua and
Barbuda
Argentina
Aruba
Bahamas
Barbados
Belize
Bermuda
Bolivia
(Plurinational
State of)
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
Bonaire, Saint
2010
Eustatius and Saba
Brazil
British Virgin
Islands
Canada
Cayman Islands
Chile
Colombia
Costa Rica
Cuba
Curaçao
Dominica
Dominican
Republic
Ecuador
El Salvador
Grenada
Guatemala
Guyana
a
164
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
TOTAL
CONFIRMED
CASES OF
MDR-TBa
NEW CASES
NOTIFIED
NUMBER OF
% OF NOTIFIED
NUMBER OF
NOTIFIED TESTED TESTED FOR CONFIRMED CASES
FOR MDR-TB
MDR-TB
OF MDR-TB
0
0
276
142
89
109
1
6
1
2
6
9 627
9 058
7 363
6 997
1
0
0
6
46
46
41
30
0
0
0
1
1
0
3
2
6
91
83
82
144
0
63
34
60
106
1
9 201
8 634
8 378
7 937
0
–
–
–
0
–
–
0
0
25
–
–
–
–
–
–
–
–
96
93
70
–
–
0
0
0
–
1
–
–
–
–
100
–
–
–
0
0
0
0
–
373
339
449
573
77 120
70 494
71 700
70 997
0
0
22
14
18
15
1
1 445
1 370
1 447
1 274
0
1 130
1 098
1 321
987
0
6
7
23
10
4
2 319
2 275
2 210
2 209
9 917
10 931
11 047
11 020
515
487
426
465
730
771
666
782
5
1
49
1
56
65
0
91
110
131
3
0
3
1
10
3
7
0
0
12
0
108
253
155
156
176
14
6
2
2
0
40
27
230
18
0
0
5
12
4
8
4 583
3 971
3 990
3 640
4 013
4 424
4 270
4 432
1 716
1 660
1 623
1 638
5
5
4
3 264
3 114
2 814
3 170
631
623
707
674
PREVIOUSLY TREATED CASES
0
0
0
2 369
44
38
21
0
0
0
1
1
22
696
455
1 240
2
0
203
169
202
172
174
5
1
0
32
117
183
363
12
11
65
0
20
73
134
34
0
0
–
–
–
0
–
–
–
0
78
80
91
77
–
–
–
25
2
0
3
3
–
6
4
11
0
0
–
44
23
26
26
22
100
–
–
–
13
–
–
0
1
3
4
–
8
1
1
4
0
–
–
–
–
1
2
5
–
–
5
0
0
0
0
0
66
12
0
0
0
0
0
0
1
1
0
0
NOTIFIED
0
0
0
2
0
809
1 392
827
716
4
4
5
2
0
0
0
15
5
12
1
0
772
590
732
665
0
35
397
21
9 637
11 164
9 818
10 949
0
0
8
9
13
15
0
103
122
94
72
0
0
1
3
2
0
314
219
306
263
443
413
616
869
45
24
31
32
49
60
51
56
23
6
48
2
0
3
0
1
1
2
0
0
0
25
12
15
10
28
7
0
1
0
20
10
48
0
0
0
4
1
0
729
497
452
520
795
778
756
663
114
86
113
92
1
0
0
159
202
128
181
25
117
205
162
NUMBER OF NOTIFIED
TESTED FOR MDR-TB
% OF NOTIFIED
NUMBER OF
TESTED FOR CONFIRMED CASES
MDR-TB
OF MDR-TB
0
1
0
1 290
3
4
2
0
0
3
0
0
251
670
664
–
–
–
–
–
–
50
–
159
–
–
–
–
–
–
–
–
75
80
100
–
–
–
–
20
–
0
–
–
–
–
–
–
43
92
100
0
0
0
210
54
1
0
0
0
0
0
0
0
34
60
106
0
–
0
5 917
61
–
–
6
–
–
–
–
–
75
–
71
–
–
–
–
72
91
72
105
–
133
79
57
2
117
–
–
39
55
37
55
–
–
–
–
–
–
–
0
20
63
70
–
88
12
95
75
2
–
–
–
–
25
18
142
10
–
9
–
0
373
37
52
552
643
0
91
51
0
226
199
221
276
551
487
495
1
28
19
33
19
31
1
0
106
502
548
584
14
82
85
2
40
37
182
18
11
0
0
4
2
0
0
6
6
20
8
68
102
78
1
0
1
9
2
5
0
0
83
241
138
133
148
7
6
1
2
20
17
182
18
0
0
TOTAL CONFIRMED CASES OF MDR-TB includes cases with unknown previous treatment history (i.e. not included under NEW CASES or PREVIOUSLY TREATED CASES).
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 164
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($7HVWLQJIRU0'57%DQGQXPEHURIFRQILUPHGFDVHVRI0'57%±
Haiti
Honduras
Jamaica
Mexico
Montserrat
Netherlands
Antilles
Nicaragua
Panama
Paraguay
Peru
Puerto Rico
Saint Kitts and
Nevis
Saint Lucia
Saint Vincent and
the Grenadines
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
Sint Maarten (Dutch
2010
part)
Suriname
2005
2008
2009
2010
Trinidad and
2005
Tobago
2008
2009
2010
Turks and Caicos
2005
Islands
2008
2009
2010
United States
2005
of America
2008
2009
2010
Uruguay
2005
2008
2009
2010
US Virgin Islands
2005
2008
2009
2010
Venezuela
2005
(Bolivarian
2008
Republic of)
2009
2010
a
NOTIFIED
43
14 116
14 289
53
0
41
3
10
4
9
0
0
0
1
394
121
11
140
1
13 884
3 152
2 678
2 732
2 706
90
102
130
128
17 906
18 036
18 127
18 848
1
2
3
0
27
57
11
78
67
40
314
0
1
21
0
0
0
0
50
16
8
4
0
1 808
2 169
2 131
2 289
1 581
1 482
1 494
1 419
2 075
2 146
2 250
2 172
30 226
29 133
28 845
28 297
113
95
63
76
0
5
4
2
12
20
8
9
7
11
9
15
0
3
1
1
1
111
106
172
49
44
1
3
0
0
0
157
275
264
214
0
6
0
1
124
103
114
92
1
5
14 080
12 904
11 545
11 181
607
655
667
658
28
8
21
21
6 600
6 173
6 213
6 087
18
5
5
8
10
13
6
6
1
2 748
1 074
1 578
1 048
0
1
0
0
0
0
0
6
0
PREVIOUSLY TREATED CASES
NUMBER OF
% OF NOTIFIED
NUMBER OF
NOTIFIED TESTED TESTED FOR CONFIRMED CASES
FOR MDR-TB
MDR-TB
OF MDR-TB
50
29
33
58
271
64
115
243
966
89
54
69
0
0
0
6
2
0
0
–
0
0
0
1
2
12
76
52
31
2
0
0
0
0
–
–
–
–
–
–
0
0
–
2
2
2
–
4
–
13
3
5
–
1
3
–
–
94
86
91
–
–
–
0
–
–
0
0
86
–
–
13
8 869
8 071
6 514
468
160
163
13
20
26
NUMBER OF NOTIFIED
TESTED FOR MDR-TB
0
228
373
2
3
0
1
0
0
0
0
0
63
0
1
4
0
381
181
184
225
195
5
3
20
19
2 026
1 370
1 535
1 266
0
5
74
389
11
505
0
0
0
0
8
0
8
103
0
268
167
282
286
247
191
235
211
273
154
177
214
4 989
4 534
4 324
4 180
0
0
0
4
2
0
0
0
2
1
3
0
0
4
2
2
1
1
1
8
7
15
0
3
0
0
0
0
22
47
60
44
3
3
0
2
3
1
0
1
0
155
413
1
0
0
0
0
0
6
–
44
42
1
–
0
2
0
–
–
–
–
–
–
69
70
58
–
71
–
24
–
–
–
–
2
0
0
0
NOTIFIED
% OF NOTIFIED
NUMBER OF
TESTED FOR CONFIRMED CASES
MDR-TB
OF MDR-TB
43
39
0
112
43
62
2
0
150
48
4
17
48
46
52
2 336
1 178
803
1
1
4
0
0
0
0
0
408
323
293
1
19
56
37
41
13
1
1
0
350
432
428
442
0
43
36
0
10
3
9
0
0
1
63
121
10
119
0
0
8
16
16
2
4
6
5
1
2 102
919
524
0
0
0
0
0
0
0
–
2
86
94
73
–
12
–
10
0
61
19
32
40
0
–
26
4
28
1
40
–
–
–
–
–
–
–
3
62
–
52
19
2
–
8
–
31
26
24
47
26
19
–
–
–
–
100
–
–
–
–
–
–
0
–
–
–
–
–
43
22
15
117
160
160
0
43
0
–
14
6
0
–
–
–
–
–
–
–
–
–
–
77
–
54
–
–
–
–
4
27
37
36
0
0
0
3
0
0
Region of the Americas
YEAR
NEW CASES
TOTAL
CONFIRMED
CASES OF
MDR-TBa
17
19
13
0
0
15
7
20
21
TOTAL CONFIRMED CASES OF MDR-TB includes cases with unknown previous treatment history (i.e. not included under NEW CASES or PREVIOUSLY TREATED CASES).
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 165
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
165
05/10/11 09:03
7$%/($1HZVPHDUSRVLWLYHFDVHQRWLILFDWLRQE\DJHDQGVH[±
MALE
YEAR
Anguilla
Antigua and
Barbuda
Argentina
Aruba
Bahamas
Barbados
Belize
Bermuda
Bolivia
(Plurinational
State of)
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
Bonaire, Saint
2010
Eustatius and Saba
Brazil
1995
2000
2005
2010
British Virgin
1995
Islands
2000
2005
2010
Canada
1995
2000
2005
2010
Cayman Islands
1995
2000
2005
2010
Chile
1995
2000
2005
2010
Colombia
1995
2000
2005
2010
Costa Rica
1995
2000
2005
2010
Cuba
1995
2000
2005
2010
Curaçao
2010
Dominica
1995
2000
2005
2010
Dominican
1995
Republic
2000
2005
2010
Ecuador
1995
2000
2005
2010
El Salvador
1995
2000
2005
2010
Grenada
1995
2000
2005
2010
Guatemala
1995
2000
2005
2010
Guyana
1995
2000
2005
2010
Haiti
1995
2000
2005
2010
166
0–14
15–24
25–34
35–44
FEMALE
45–54
55–64
65+
0–14
15–24
25–34
35–44
45–54
55–64
65+
UNKNOWN
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
1
1
0
0
0
2
1
0
1
2
1
0
0
0
1
2
0
0
0
1
0
0
0
0
0
0
97
64
56
278
621
536
594
530
491
402
358
309
419
384
302
368
340
340
330
348
282
1
3
1
3
2
5
7
7
9
4
4
2
3
2
2
0
2
3
5
0
2
0
0
0
0
2
0
0
0
0
1
2
0
2
0
1
5
8
9
0
2
7
8
16
1
4
2
6
22
2
0
6
8
24
0
1
3
5
11
0
1
5
3
18
0
0
0
0
0
1
2
0
2
121
90
59
544
530
421
479
474
426
262
290
233
230
198
184
179
169
153
216
240
176
0
2
1
5
7
7
2
8
0
2
0
3
1
1
0
5
1
1
0
0
0
0
0
1
0
0
0
0
0
0
0
0
4
1
6
2
4
5
0
2
1
4
7
0
0
2
4
7
2
1
4
3
9
0
1
1
2
4
0
2
4
4
5
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
166
157
95
1 182
1 320
1 150
797
725
622
518
439
415
466
391
395
340
346
338
366
415
409
191
160
119
831
846
744
588
533
471
334
276
238
254
226
191
192
182
162
233
262
264
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1 894
317
298
7 268
5 074
4 405
11 568
6 119
6 381
11 906
6 128
5 293
8 623
5 259
4 762
5 085
2 803
2 875
4 494
2 140
1 947
43
1 859
355
280
6 719
3 496
2 677
7 215
3 663
3 008
5 395
2 626
2 211
3 582
1 897
1 720
2 384
1 112
1 038
2 496
1 104
979
0
7
4
6
1
0
33
33
28
28
0
28
40
40
24
0
22
30
27
16
0
12
25
24
10
0
18
12
13
19
0
51
66
37
44
0
24
10
4
6
0
100
66
55
56
0
120
96
78
76
0
108
70
60
59
1
75
54
56
56
0
73
58
36
40
0
107
83
93
72
194
179
146
2
13
1
0
1
2
2
1
0
587
581
560
17
21
21
18
17
9
14
15
1
758
533
576
15
33
31
20
52
22
17
15
1
523
457
428
11
24
18
12
29
26
26
14
0
381
389
374
7
20
16
14
39
22
13
16
0
304
292
284
9
23
6
15
48
23
22
17
0
510
395
471
14
24
14
8
80
39
29
26
0
0
0
1
5
3
3
0
28
34
37
30
0
31
45
45
28
0
60
46
44
36
0
34
41
40
32
1
41
32
20
25
0
70
79
68
62
0
0
3
1
0
1
0
0
24
6
3
2
0
148
81
74
90
0
182
160
128
115
1
204
198
179
144
0
155
150
162
159
0
141
132
115
122
0
163
126
133
157
246
178
148
1
14
1
2
2
0
2
3
0
763
623
602
17
31
43
18
59
71
20
17
0
1 030
685
765
38
53
38
48
118
167
73
61
0
963
666
540
24
62
53
33
83
90
90
89
2
743
687
710
19
39
34
27
75
74
50
78
1
610
510
610
23
28
20
22
75
55
58
53
0
746
695
814
22
49
34
28
156
75
51
57
0
0
0
0
0
0
3
1
73
43
29
410
399
276
481
483
346
344
386
292
173
228
170
125
123
112
113
105
85
48
32
446
499
468
529
308
314
237
309
150
227
159
246
13
5
5
99
97
101
124
140
170
114
128
96
92
104
77
62
74
62
107
117
101
51
36
39
60
7
4
12
2
235
220
251
187
8
20
48
32
280
236
258
245
5
19
130
38
1
236
216
185
207
6
14
116
65
1
165
177
187
172
9
7
81
49
1
142
112
127
143
6
6
41
22
139
140
115
165
7
9
20
13
67
69
98
836
1 045
1 225
898
1 035
1 357
613
701
718
350
451
469
147
222
259
118
156
160
0
0
0
0
0
1
0
0
MALE/FEMALE
RATIO
–
–
–
–
–
0.3
0.5
5.0
–
1.2
1.3
1.4
–
–
–
–
2.4
1.0
–
1.7
–
2.0
–
1.0
0.8
2.1
1.8
2.5
–
–
–
–
–
1.5
1.5
1.6
–
15
1
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 166
UNKNOWN
0
0
0
0
0
1
0
0
0
0
0
0
1
2
1
0
0
0
65
57
43
317
339
239
325
332
207
212
209
142
115
119
102
79
72
54
75
54
62
0
48
52
329
298
305
308
199
178
139
158
85
113
127
110
0
28
6
6
81
85
63
76
82
65
63
59
49
63
50
58
39
42
51
47
70
68
0
0
51
41
38
29
3
1
14
2
224
199
339
194
5
11
41
22
1
255
167
245
190
7
8
62
25
221
175
277
179
6
7
41
19
146
135
176
139
5
5
30
20
129
87
88
108
2
5
11
10
94
111
95
103
4
3
9
6
0
0
96
116
158
914
1 097
1 268
857
1 099
1 223
513
633
608
275
414
358
132
170
207
71
132
134
0
–
1.7
2.0
2.2
–
–
–
–
1.5
1.3
1.5
1.5
–
–
–
1.0
1.7
2.0
2.1
2.2
–
1.6
1.4
1.5
1.9
1.7
2.1
2.0
2.1
3.7
2.8
3.4
1.5
–
–
–
1.0
–
1.4
1.5
1.5
–
–
1.5
1.8
–
1.5
1.7
1.7
–
–
–
3.0
1.1
1.2
0.9
1.3
1.5
2.0
2.2
2.1
–
1.1
1.0
1.1
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($1HZVPHDUSRVLWLYHFDVHQRWLILFDWLRQE\DJHDQGVH[±
Honduras
Jamaica
Mexico
Montserrat
Netherlands
Antilles
Nicaragua
Panama
Paraguay
Peru
Puerto Rico
Saint Kitts and
Nevis
Saint Lucia
Saint Vincent and
the Grenadines
FEMALE
0–14
15–24
25–34
35–44
45–54
55–64
65+
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
42
30
13
15
2
0
0
1
280
123
238
177
9
6
4
7
540
371
280
246
14
13
6
15
204
246
215
207
9
13
6
15
130
277
152
165
11
15
10
8
236
214
134
113
8
6
6
6
58
43
152
157
9
5
7
7
214
100
125
1 079
1 095
1 081
1 387
1 376
1 375
1 162
1 314
1 380
1 235
1 238
1 392
972
1 042
1 119
1 126
1 288
1 303
0
0
0
0
1
0
0
0
Sint Maarten (Dutch
2010
part)
Suriname
1995
2000
2005
2010
Trinidad and
1995
Tobago
2000
2005
2010
Turks and Caicos
1995
Islands
2000
2005
2010
United States
1995
of America
2000
2005
2010
Uruguay
1995
2000
2005
2010
US Virgin Islands
1995
2000
2005
2010
Venezuela
1995
(Bolivarian
2000
Republic of)
2005
2010
UNKNOWN
0–14
15–24
25–34
35–44
45–54
55–64
65+
0
54
25
27
28
2
1
0
0
208
21
219
186
7
8
1
5
292
269
222
163
6
8
5
4
134
258
125
106
5
7
4
5
76
270
107
103
5
2
0
1
136
160
81
69
2
5
1
0
48
38
104
107
2
1
3
2
0
176
125
112
663
771
791
828
733
763
698
710
730
832
784
852
595
637
713
709
784
836
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
2
0
0
0
0
0
1
0
0
1
0
23
18
17
22
86
3
5
6
18
16
23
18
147
552
371
178
194
163
157
155
44
76
69
64
112
168
163
1 311
5 290
3 802
172
174
159
189
193
78
129
127
71
103
185
244
849
2 875
2 670
175
147
116
141
112
61
129
80
96
105
136
129
454
1 546
1 513
126
108
106
115
126
37
84
62
74
86
117
143
322
1 041
1 075
96
64
61
82
42
27
57
61
57
80
87
103
200
801
641
92
90
79
108
83
26
49
49
61
71
99
99
216
796
708
24
34
23
27
72
6
11
7
13
12
31
18
149
633
375
176
188
135
154
120
43
73
51
65
69
89
106
1 005
3 686
2 674
215
173
122
149
111
34
81
52
49
86
98
99
660
2 472
2 111
98
98
103
92
75
35
62
46
46
41
69
39
373
1 156
1 046
83
76
61
75
57
19
33
45
35
41
52
50
259
609
699
64
46
54
50
16
12
30
23
34
30
29
46
162
499
333
46
61
47
79
40
16
41
29
53
46
71
45
152
624
472
4
0
0
0
3
1
4
0
12
4
4
3
20
19
7
2
15
9
9
4
9
10
7
5
19
14
7
8
0
1
1
0
0
2
4
3
1
6
5
2
0
5
3
5
2
7
7
4
6
4
1
1
2
9
3
7
4
0
0
0
0
0
1
0
0
0
0
0
0
1
0
1
1
0
0
0
0
1
1
1
0
1
0
1
0
1
0
2
1
0
0
1
0
0
0
0
0
0
1
1
0
0
0
0
1
0
0
0
1
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
1
1
0
2
0
2
0
1
1
1
2
2
2
0
0
0
1
0
0
0
0
1
4
2
0
2
1
3
0
0
0
1
2
2
0
0
11
1
0
0
5
2
6
7
6
8
3
12
2
6
0
3
4
4
2
0
3
3
6
2
3
1
0
2
1
1
1
2
2
0
0
0
6
7
10
11
15
18
11
21
10
27
13
17
12
17
21
32
7
7
10
20
4
7
3
8
0
0
0
0
6
5
4
4
4
7
9
7
2
9
3
7
5
5
5
5
3
2
4
2
0
4
3
2
0
19
6
14
5
4
0
1
1
0
0
355
365
383
246
28
36
42
46
0
0
876
602
535
360
40
48
48
70
0
1
1 417
906
666
371
35
45
39
35
1
0
1 121
904
767
505
49
41
45
46
1
0
742
577
499
403
38
30
34
33
0
0
1 099
738
624
466
50
34
36
31
0
0
26
14
11
9
2
2
1
3
0
280
246
241
195
21
28
33
24
0
579
376
348
265
26
22
30
36
1
499
349
276
183
18
21
17
12
1
285
253
242
165
12
13
9
10
0
202
152
161
130
9
12
8
5
0
591
396
322
223
17
16
12
16
35
22
312
320
395
376
413
333
402
391
265
253
332
288
37
26
351
269
299
306
267
188
183
145
146
147
216
188
0
0
2
0
MALE/FEMALE
RATIO
1.6
1.3
1.3
1.4
2.1
1.8
2.8
3.5
–
1.6
1.6
1.6
–
–
–
–
–
1.5
–
1.2
1.2
1.3
1.3
1.6
1.7
1.6
1.8
1.5
1.8
1.9
2.2
1.3
1.3
1.4
–
2.4
2.4
1.7
1.5
–
–
–
1.0
–
1.3
0.8
2.0
–
8.0
2.5
3.0
0.5
1
0
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 167
UNKNOWN
0
0
0
0
–
1.4
3.6
–
2.8
2.6
2.4
4.0
–
–
–
0.5
2.3
2.3
2.2
2.0
2.3
2.1
2.2
2.5
–
–
–
–
–
–
1.4
1.6
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
Region of the Americas
MALE
YEAR
167
05/10/11 09:03
168
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 168
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
19
136
4.0
5.9
8.1
3.8
6.6
0.5
3.3
1.8
2.8
2.6
11
3.9
11
1.5
7.9
2.3
2.2
3.2
1.9
2.7
2.3
2.0
0.1
1.1
3.2
1.7
1.6
4.9
3.6
6.5
2.0
2.0
21
5.0
1.5
0
1.3
<0.1
14
1.7
0.2
1.5
0.9
1.4
0.8
1.0
0.3
6.6
0.5
0.7
0
0.7
0.5
0.3
0.8
0.3
0.8
1.0
0.5
0
2.1
DST LABS
PER 5M
POPULATION
LABORATORIES
CULTURE LABS
PER 5M
POPULATION
Yes
No
Yes
Yes
Yes
No
Out of country
Out of country
Out of country
Out of country
In country
Out of country
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
No
Yes
In country
Out of country
Out of country
In and out of cty
In country
No
Out of country
Out of country
In and out of cty
Out of country
Out of country
Out of country
In and out of cty
Out of country
Out of country
No
In and out of cty
In country
Out of country
No
Out of country
In country
Yes
Yes
Yes
Yes
Yes
Yes
Yes
In and out of cty
Out of country
In and out of cty
Out of country
In country
In and out of cty
Yes
Yes
Yes
No
Yes
Out of country
country
country
country
country
No
Yes
Yes
NRLa
Out of country
Out of
Out of
Out of
Out of
No
Out of country
In and out of cty
SECOND-LINE
DST
AVAILABLE
Yes, all suspects
Yes, all suspects
If TB is confirmed
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
For smear-positive TB
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
If TB is confirmed
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
For certain income groups
Yes, all suspects
Yes, all suspects
Yes, all suspects
No
Yes, all suspects
Yes, all suspects
TB DIAGNOSIS
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
FIRST-LINE DRUGS
FREE THROUGH NTP
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
RIFAMPICIN USED
THROUGHOUT
TREATMENT
80
95
0
100
100
100
100
0
0
100
100
100
0
0
100
90
0
100
0
0
89
100
100
0
90
100
100
0
100
0
100
0
100
0
0
80
50
0
90
% OF PATIENTS
TREATED WITH FDCb
DRUG MANAGEMENT
a NRL = national reference laboratory
b FDC = fixed-dose combination
c NURSES (Registered Nurses, Registered Midwives, Enrolled Nurses, Enrolled Midwives); HEALTH ASSISTANTS (Medical Assistants, Clinical Officers); LABORATORY TECHNICIANS (Microscopists)
Anguilla
Antigua and Barbuda
Argentina
Aruba
Bahamas
Barbados
Belize
Bermuda
Bolivia
(Plurinational State of)
Bonaire, Saint Eustatius
and Saba
Brazil
British Virgin Islands
Canada
Cayman Islands
Chile
Colombia
Costa Rica
Cuba
Curaçao
Dominica
Dominican Republic
Ecuador
El Salvador
Grenada
Guatemala
Guyana
Haiti
Honduras
Jamaica
Mexico
Montserrat
Nicaragua
Panama
Paraguay
Peru
Puerto Rico
Saint Kitts and Nevis
Saint Lucia
Saint Vincent and
the Grenadines
Sint Maarten (Dutch part)
Suriname
Trinidad and Tobago
Turks and Caicos Islands
United States of America
Uruguay
US Virgin Islands
Venezuela
(Bolivarian Republic of)
SMEAR LABS
PER 100K
POPULATION
7$%/($/DERUDWRULHV173VHUYLFHVGUXJPDQDJHPHQWKXPDQUHVRXUFHVDQGLQIHFWLRQFRQWURO
Yes
Yes
No
Yes
Yes
No
No
No
No
No
No
No
Yes
No
Yes
Yes
Yes
Yes
No
No
No
No
No
Yes
Yes
Yes
No
No
No
No
Yes
Yes
Yes
Yes
No
Yes
No
No
No
No
No
No
Yes
PAEDIATRIC
FORMULATIONS
PROCURED
86
100
83
90
85
0
5
10
25
5
71
85
0
6
75
70
60
50
50
40
10
100
5
66
0
NURSES
100
29
0
MEDICAL
OFFICERS
78
0
0
16
0
2
50
65
70
100
5
3
0
HEALTH
ASSISTANTS
48
100
85
0
3
5
2
80
75
35
20
100
100
2
0
LABORATORY
TECHNICIANS
% OF STAFF TRAINED BY THE NTP (IN 2010)c
28
619
22
5
7
0
14
271
31
TB NOTIFICATION
RATE PER 100 000
HEALTH-CARE
WORKERS
Eastern Mediterranean Region
Table A3.1 Estimates of the burden of disease caused by TB, 1990–2010
171
Table A3.2 Incidence, notification and case detection rates, all forms, 1990–2010
173
Table A3.3 Case notifications, 1990–2010
175
Table A3.4 Treatment outcomes, new smear-positive cases, 1995–2009
177
Table A3.5 Treatment outcomes, retreatment cases, 1995–2009
179
Table A3.6 HIV testing and provision of CPT, ART and IPT, 2005–2010
181
Table A3.7 Testing for MDR-TB and number of confirmed cases of MDR-TB, 2005–2010
182
Table A3.8 New smear-positive case notification by age and sex, 1995–2010
183
Table A3.9 Laboratories, NTP services, drug management, human resources and infection
control, 2010
184
1109_0319_P_111_246 169
05/10/11 09:03
Estimates of mortality, prevalence and incidence
Estimated values are shown as best estimates followed by lower and upper bounds. The lower and upper bounds are
defi ned as the 2.5th and 97.5th centiles of outcome distributions produced in simulations. See ANNEX 1 for further
details.
Estimated numbers are shown rounded to two significant figures. Estimated rates are shown rounded to three
significant figures unless the value is under 100, in which case rates are shown rounded to two significant figures.
Estimates for all years are recalculated as new information becomes available and techniques are refi ned, so they
may differ from those published in previous reports in this series. Estimates published in previous global TB control
reports should no longer be used.
Data source
Data shown in this annex are taken from the WHO global TB database on 2 September 2011. Data shown in the main
part of the report were taken from the database on 21 June 2011. As a result, data in this annex may differ slightly from
those in the main part of the report.
Data can be downloaded from www.who.int/tb/data.
170
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 170
05/10/11 09:03
7$%/($(VWLPDWHVRIWKHEXUGHQRIGLVHDVHFDXVHGE\7%±
Afghanistan
Bahrain
Djibouti
Egypt
Iran (Islamic
Republic of)
Iraq
Jordan
Kuwait
Lebanon
Libyan Arab
Jamahiriya
Morocco
Oman
Pakistan
Qatar
Saudi Arabia
a
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
POPULATION
(MILLIONS)
13
20
23
28
30
31
31
<1
<1
<1
<1
1
1
1
<1
<1
<1
<1
<1
<1
<1
57
62
68
74
78
80
81
55
60
65
70
72
73
74
17
20
24
27
30
31
32
3
4
5
5
6
6
6
2
2
2
2
3
3
3
3
3
4
4
4
4
4
4
5
5
6
6
6
6
25
27
29
30
31
32
32
2
2
2
2
3
3
3
112
127
145
159
167
170
174
<1
<1
<1
<1
1
2
2
16
18
20
24
26
27
27
NUMBER
(THOUSANDS)
7.4
11
12
11
11
11
12
<0.01
<0.01
0.018
0.011
<0.01
<0.01
0.011
0.45
0.34
0.33
0.71
0.69
0.61
0.63
2.3
1.7
1.1
1
0.94
0.78
0.66
3.2
3
3.4
2.8
2
1.6
1.3
1.6
1.8
2.1
3.1
3.8
3.8
3.9
0.065
0.052
0.04
0.023
0.022
0.038
0.044
0.01
0.012
0.015
0.023
0.021
0.034
0.034
0.076
0.099
0.041
0.032
0.047
0.063
0.09
0.46
0.25
0.27
0.23
0.24
0.25
0.25
4.5
5
2.4
2.4
2.3
2.1
2
0.043
0.025
0.025
0.025
0.029
0.029
0.028
79
89
100
81
59
58
58
0.012
0.021
0.019
0.022
0.038
0.041
0.037
0.22
0.25
0.31
0.31
0.36
0.36
0.39
(3.7–11)
(7.3–15)
(9.4–15)
(7.9–14)
(7.6–15)
(8.1–15)
(8.6–16)
(<0.01–<0.01)
(<0.01–<0.01)
(0.017–0.018)
(0.011–0.011)
(<0.01–<0.01)
(<0.01–<0.01)
(0.01–0.012)
(0.19–0.93)
(0.2–0.59)
(0.21–0.54)
(0.48–1)
(0.45–1)
(0.38–0.94)
(0.4–0.94)
(1.9–2.8)
(1.3–2.1)
(0.8–1.6)
(1–1)
(0.94–0.94)
(0.78–0.79)
(0.66–0.67)
(1.3–6.4)
(2–4.5)
(2.3–4.7)
(1.9–3.9)
(1.3–2.9)
(1–2.5)
(0.79–2.2)
(0.78–2.3)
(1.1–2.5)
(1.5–2.8)
(2.1–4.3)
(2.7–5)
(2.7–5.1)
(2.8–5.2)
(0.031–0.13)
(0.03–0.089)
(0.025–0.062)
(0.017–0.039)
(0.017–0.036)
(0.025–0.056)
(0.031–0.06)
(<0.01–0.012)
(<0.01–0.014)
(0.015–0.015)
(0.023–0.023)
(0.021–0.021)
(0.034–0.034)
(0.029–0.041)
(0.043–0.2)
(0.062–0.16)
(0.028–0.068)
(0.021–0.051)
(0.03–0.076)
(0.041–0.093)
(0.064–0.12)
(0.36–0.58)
(0.16–0.39)
(0.17–0.42)
(0.14–0.37)
(0.14–0.41)
(0.15–0.43)
(0.15–0.43)
(2.1–8.7)
(3–7.8)
(1.6–3.8)
(1.6–3.8)
(1.5–3.6)
(1.4–3.2)
(1.4–3.1)
(0.037–0.051)
(0.022–0.029)
(0.022–0.031)
(0.022–0.03)
(0.025–0.035)
(0.025–0.035)
(0.024–0.033)
(49–120)
(72–110)
(82–120)
(61–100)
(39–84)
(38–84)
(39–84)
(0.011–0.015)
(0.019–0.022)
(0.016–0.022)
(0.019–0.026)
(0.033–0.046)
(0.035–0.05)
(0.034–0.044)
(0.18–0.26)
(0.21–0.3)
(0.26–0.37)
(0.27–0.38)
(0.31–0.43)
(0.31–0.44)
(0.33–0.46)
RATEa
57
57
52
39
36
37
38
1.1
<1
2.8
1.5
<1
<1
<1
80
54
45
88
81
70
71
4.1
2.7
1.7
1.4
1.2
<1
<1
5.8
5.1
5.2
4
2.7
2.3
1.8
9
9
9
11
13
12
12
1.9
1.2
<1
<1
<1
<1
<1
<1
<1
<1
1
<1
1.3
1.2
2.6
2.9
1.1
<1
1.1
1.5
2.1
11
5.3
5.2
4
3.9
4
4
18
19
8.5
7.8
7.3
6.5
6.2
2.3
1.1
1.1
1
1.1
1.1
<1
71
70
70
51
35
34
34
2.6
4.1
3.1
2.7
2.7
2.6
2.1
1.3
1.3
1.5
1.3
1.4
1.4
1.4
(29–86)
(37–77)
(41–65)
(29–52)
(26–49)
(27–50)
(27–50)
(1–1.3)
(<1–<1)
(2.7–2.9)
(1.5–1.5)
(<1–<1)
(<1–<1)
(<1–<1)
(33–165)
(31–94)
(29–74)
(59–125)
(52–118)
(43–108)
(45–106)
(3.4–4.9)
(2–3.4)
(1.2–2.3)
(1.4–1.4)
(1.2–1.2)
(<1–<1)
(<1–<1)
(2.4–12)
(3.3–7.5)
(3.5–7.2)
(2.7–5.5)
(1.8–4)
(1.4–3.4)
(1.1–2.9)
(4.5–13)
(5.4–13)
(6.3–12)
(7.8–16)
(9–17)
(8.8–16)
(8.9–16)
(<1–3.7)
(<1–2)
(<1–1.3)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(1–1)
(<1–<1)
(1.3–1.3)
(1.1–1.5)
(1.4–6.7)
(1.8–4.5)
(<1–1.8)
(<1–1.3)
(<1–1.8)
(<1–2.2)
(1.5–2.9)
(8.3–13)
(3.3–8.1)
(3.2–8.1)
(2.5–6.3)
(2.3–6.7)
(2.3–6.9)
(2.3–6.8)
(8.4–35)
(11–29)
(5.7–13)
(5.1–12)
(4.9–11)
(4.5–10)
(4.4–9.7)
(2–2.8)
(<1–1.3)
(<1–1.4)
(<1–1.2)
(<1–1.3)
(<1–1.3)
(<1–1.2)
(44–104)
(57–85)
(57–85)
(38–66)
(23–50)
(22–49)
(22–49)
(2.2–3.1)
(3.9–4.4)
(2.7–3.8)
(2.3–3.2)
(2.3–3.3)
(2.2–3.1)
(1.9–2.5)
(1.1–1.6)
(1.1–1.6)
(1.3–1.8)
(1.1–1.6)
(1.2–1.6)
(1.2–1.6)
(1.2–1.7)
PREVALENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
60
91
99
100
100
110
110
0.17
0.079
0.3
0.41
0.43
0.51
0.32
5.1
4.8
5.2
7.5
7.7
7.3
7.5
45
36
28
24
24
24
23
33
33
34
28
22
19
17
17
20
24
31
35
36
37
0.78
0.71
0.53
0.41
0.4
0.48
0.5
0.4
0.48
0.76
0.69
1.4
1.4
1.4
1.2
1.4
0.7
0.49
0.69
0.82
1
3.9
2.9
3.1
3.1
3.2
3.3
3.4
53
59
38
35
35
34
34
0.74
0.4
0.42
0.41
0.49
0.48
0.46
630
710
810
720
620
620
630
0.27
0.49
0.42
0.51
0.89
0.95
0.78
3.7
4.3
5.1
5.2
5.9
6
6.6
(26–99)
(39–150)
(44–160)
(46–170)
(47–170)
(49–180)
(51–180)
(0.048–0.29)
(0.031–0.13)
(0.11–0.5)
(0.14–0.7)
(0.14–0.74)
(0.2–0.84)
(0.076–0.57)
(1.6–10)
(1.6–8.4)
(1.7–8.9)
(3.4–12)
(3.4–13)
(3–12)
(3.1–13)
(20–73)
(17–58)
(12–46)
(10–39)
(10–39)
(10–39)
(10–37)
(11–66)
(14–56)
(15–57)
(13–46)
(9.2–36)
(7.7–33)
(6.1–30)
(7.1–29)
(8.2–34)
(9.7–40)
(14–51)
(16–58)
(16–59)
(17–61)
(0.25–1.5)
(0.23–1.3)
(0.18–0.91)
(0.093–0.71)
(0.092–0.7)
(0.18–0.8)
(0.21–0.82)
(0.12–0.69)
(0.16–0.82)
(0.26–1.3)
(0.18–1.2)
(0.5–2.3)
(0.48–2.4)
(0.46–2.4)
(0.27–2.3)
(0.47–2.3)
(0.2–1.2)
(0.16–0.85)
(0.23–1.2)
(0.32–1.4)
(0.45–1.7)
(1.8–6.4)
(1.1–4.9)
(1.2–5.3)
(1.1–5.3)
(1–5.7)
(1.1–5.9)
(1.1–5.9)
(17–100)
(23–100)
(11–66)
(11–61)
(10–60)
(9.3–59)
(8.9–58)
(0.28–1.2)
(0.13–0.69)
(0.14–0.73)
(0.14–0.7)
(0.17–0.84)
(0.16–0.82)
(0.15–0.78)
(240–1200)
(310–1200)
(350–1300)
(340–1200)
(270–1000)
(270–1000)
(270–1100)
(0.085–0.46)
(0.19–0.8)
(0.14–0.71)
(0.19–0.85)
(0.34–1.5)
(0.34–1.6)
(0.21–1.4)
(1.3–6.2)
(1.6–7.2)
(1.7–8.7)
(1.7–8.9)
(2–10)
(1.9–10)
(2.4–11)
RATE
457
457
431
362
344
348
352
34
14
46
57
41
44
25
905
763
708
927
895
834
839
79
59
41
32
31
30
28
60
56
52
40
30
26
23
99
99
99
112
118
117
117
23
16
11
7.6
6.8
7.9
8
19
29
39
30
53
53
51
39
40
19
12
17
20
24
89
60
59
53
53
53
53
213
219
132
117
112
107
105
40
18
19
17
19
18
16
565
559
562
456
371
366
364
56
97
71
62
64
59
45
23
23
26
22
23
22
24
(198–760)
(198–760)
(193–714)
(167–598)
(157–568)
(159–572)
(161–578)
(9.8–58)
(5.6–23)
(17–78)
(20–97)
(13–70)
(17–72)
(6–45)
(293–1827)
(255–1342)
(231–1217)
(416–1531)
(394–1485)
(343–1413)
(348–1411)
(36–128)
(27–94)
(18–68)
(13–53)
(13–50)
(13–49)
(12–46)
(21–121)
(23–94)
(23–87)
(18–66)
(13–50)
(10–45)
(8.2–40)
(41–168)
(41–168)
(41–168)
(50–186)
(54–195)
(53–192)
(54–193)
(7.5–43)
(5.1–29)
(3.8–19)
(1.7–13)
(1.6–12)
(3–13)
(3.4–13)
(5.5–33)
(9.9–51)
(13–67)
(7.8–53)
(20–89)
(18–89)
(17–87)
(9.2–79)
(14–68)
(5.5–32)
(3.9–21)
(5.6–28)
(7.6–32)
(11–39)
(41–147)
(24–103)
(24–102)
(18–91)
(17–93)
(17–94)
(17–93)
(70–409)
(84–376)
(39–228)
(36–202)
(33–193)
(29–186)
(28–182)
(15–66)
(5.7–31)
(6.4–32)
(5.7–29)
(6.3–32)
(5.8–30)
(5.3–28)
(216–1070)
(243–929)
(243–929)
(212–744)
(159–620)
(156–614)
(154–611)
(18–96)
(38–160)
(24–120)
(23–103)
(24–107)
(21–100)
(12–78)
(8.4–39)
(8.5–39)
(8.6–44)
(7.1–37)
(7.5–39)
(7.2–38)
(8.7–41)
INCIDENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
25
37
43
52
56
58
59
0.14
0.057
0.22
0.31
0.36
0.36
0.29
3.5
3.9
4.5
5
5.3
5.4
5.5
20
20
17
16
15
15
15
20
21
21
17
14
14
13
11
13
15
17
19
20
20
0.54
0.55
0.4
0.36
0.35
0.34
0.33
0.33
0.37
0.59
0.63
0.96
1.1
1.1
0.95
1.1
0.63
0.43
0.57
0.63
0.72
1.7
1.9
2.1
2.3
2.5
2.5
2.5
36
41
32
29
29
29
29
0.55
0.33
0.33
0.34
0.39
0.38
0.36
260
290
330
370
390
390
400
0.21
0.35
0.32
0.37
0.65
0.71
0.67
2.8
3.1
4
4.1
4.6
4.7
5
(15–37)
(30–45)
(35–52)
(42–63)
(46–68)
(47–69)
(49–71)
(0.12–0.16)
(0.051–0.063)
(0.19–0.25)
(0.27–0.36)
(0.31–0.4)
(0.31–0.41)
(0.26–0.33)
(2.2–5.1)
(3.2–4.7)
(3.8–5.3)
(4.1–6)
(4.3–6.4)
(4.4–6.5)
(4.5–6.6)
(16–23)
(17–23)
(15–20)
(13–18)
(13–18)
(13–17)
(12–17)
(12–29)
(17–26)
(17–25)
(14–20)
(12–17)
(11–16)
(10–15)
(6.7–16)
(11–16)
(12–18)
(14–21)
(15–23)
(16–24)
(17–24)
(0.39–0.71)
(0.45–0.66)
(0.35–0.46)
(0.3–0.42)
(0.3–0.4)
(0.3–0.39)
(0.29–0.38)
(0.29–0.37)
(0.32–0.42)
(0.51–0.67)
(0.56–0.71)
(0.83–1.1)
(0.93–1.2)
(0.98–1.3)
(0.58–1.4)
(0.93–1.2)
(0.54–0.72)
(0.37–0.49)
(0.49–0.65)
(0.55–0.73)
(0.63–0.83)
(1.4–2.1)
(1.6–2.3)
(1.7–2.5)
(2–2.7)
(2–3)
(2–3)
(2.1–3)
(25–50)
(33–49)
(27–36)
(25–33)
(25–33)
(25–33)
(25–33)
(0.49–0.63)
(0.29–0.37)
(0.29–0.38)
(0.3–0.38)
(0.34–0.44)
(0.33–0.43)
(0.32–0.41)
(160–380)
(240–360)
(270–400)
(300–440)
(320–470)
(320–470)
(330–480)
(0.19–0.24)
(0.31–0.4)
(0.28–0.36)
(0.33–0.42)
(0.57–0.74)
(0.62–0.81)
(0.58–0.75)
(2.4–3.1)
(2.8–3.6)
(3.5–4.5)
(3.6–4.6)
(4–5.2)
(4.2–5.3)
(4.4–5.7)
RATE
189
189
189
189
189
189
189
28
10
34
43
34
30
23
619
619
619
619
619
620
620
34
32
26
21
19
19
18
36
36
32
24
20
19
17
64
64
64
64
64
64
64
16
13
8.4
6.7
6
5.7
5.4
16
23
30
28
38
40
41
32
31
17
11
14
15
17
40
40
40
40
40
40
40
147
152
109
95
93
92
91
30
15
15
14
15
14
13
231
231
231
231
231
231
231
45
70
54
46
47
45
38
17
17
20
17
18
18
18
(115–281)
(154–228)
(154–228)
(154–228)
(154–228)
(155–227)
(155–226)
(25–32)
(9.1–11)
(30–39)
(38–49)
(30–38)
(27–35)
(20–26)
(390–901)
(504–746)
(526–721)
(504–746)
(504–746)
(507–743)
(510–741)
(29–40)
(27–37)
(22–30)
(18–25)
(16–22)
(16–22)
(15–21)
(22–53)
(29–43)
(26–38)
(20–29)
(16–24)
(15–22)
(14–21)
(39–95)
(52–77)
(52–77)
(52–77)
(52–77)
(52–77)
(52–77)
(11–21)
(10–15)
(7.2–9.6)
(5.6–7.9)
(5.2–6.9)
(4.9–6.6)
(4.7–6.2)
(14–18)
(20–26)
(27–34)
(25–31)
(33–43)
(35–46)
(36–46)
(20–48)
(27–36)
(14–19)
(9.1–12)
(12–16)
(13–17)
(15–20)
(32–48)
(32–48)
(32–48)
(34–46)
(32–48)
(33–48)
(33–48)
(102–201)
(123–183)
(95–125)
(82–109)
(80–106)
(80–105)
(80–104)
(26–34)
(13–17)
(13–17)
(12–15)
(13–17)
(12–16)
(12–15)
(141–344)
(188–279)
(188–279)
(188–279)
(188–279)
(189–278)
(189–277)
(39–51)
(61–79)
(48–61)
(40–52)
(41–53)
(39–50)
(33–43)
(15–19)
(15–19)
(17–22)
(15–19)
(15–20)
(15–20)
(16–21)
Eastern Mediterranean Region
MORTALITY (EXCLUDING HIV)
YEAR
Rates are per 100 000 population.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 171
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
171
05/10/11 09:03
7$%/($(VWLPDWHVRIWKHEXUGHQRIGLVHDVHFDXVHGE\7%±
MORTALITY (EXCLUDING HIV)
Somalia
Sudan
Syrian Arab
Republic
Tunisia
United Arab
Emirates
West Bank
and Gaza Strip
Yemen
a
172
YEAR
POPULATION
(MILLIONS)
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
7
7
7
8
9
9
9
26
30
34
38
41
42
44
12
14
16
18
20
20
20
8
9
9
10
10
10
10
2
2
3
4
6
7
8
2
3
3
4
4
4
4
12
15
18
21
23
23
24
NUMBER
(THOUSANDS)
5.4
5.1
5.1
4.2
4.7
5
5.2
7.8
6.2
6.1
6.7
7.7
8.3
8.3
0.88
0.79
0.42
0.43
0.37
0.35
0.28
0.22
0.2
0.19
0.17
0.2
0.21
0.23
0.019
0.034
0.015
0.017
0.019
0.02
0.022
0.038
0.061
0.079
0.075
0.062
0.058
0.055
3.7
3.1
3.1
2.9
2.1
1.8
1.4
(3.3–8.2)
(4–6.3)
(3.9–6.4)
(3–5.7)
(3.4–6.3)
(3.6–6.5)
(3.9–6.7)
(4.3–12)
(4.3–8.5)
(4–8.7)
(4.5–9.6)
(5.4–11)
(5.9–11)
(5.9–11)
(0.41–1.7)
(0.47–1.3)
(0.28–0.68)
(0.27–0.72)
(0.23–0.64)
(0.22–0.6)
(0.19–0.49)
(0.12–0.43)
(0.14–0.31)
(0.12–0.3)
(0.12–0.27)
(0.13–0.31)
(0.14–0.32)
(0.15–0.35)
(0.017–0.02)
(0.032–0.037)
(<0.01–0.023)
(0.012–0.024)
(0.014–0.026)
(0.014–0.028)
(0.016–0.031)
(0.033–0.044)
(0.051–0.071)
(0.066–0.094)
(0.066–0.086)
(0.054–0.071)
(0.05–0.068)
(0.046–0.064)
(1.9–6.4)
(2–4.6)
(2–4.5)
(2–4)
(1.4–3.1)
(1.1–2.7)
(0.86–2.2)
RATEa
82
78
68
50
53
54
56
29
21
18
18
19
19
19
7.1
5.6
2.6
2.3
1.9
1.7
1.4
2.7
2.2
2
1.7
2
2
2.2
1
1.5
<1
<1
<1
<1
<1
1.8
2.3
2.5
2.1
1.6
1.5
1.4
31
20
17
14
9.5
7.7
5.9
(49–124)
(62–96)
(53–86)
(36–68)
(39–70)
(40–71)
(42–72)
(16–47)
(14–28)
(12–25)
(12–25)
(13–26)
(14–26)
(14–26)
(3.4–14)
(3.3–8.9)
(1.8–4.3)
(1.4–3.9)
(1.1–3.2)
(1.1–3)
(<1–2.4)
(1.5–5.2)
(1.5–3.5)
(1.3–3.2)
(1.2–2.7)
(1.3–3)
(1.4–3.1)
(1.5–3.3)
(<1–1.1)
(1.4–1.6)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(1.6–2.1)
(2–2.7)
(2.1–2.9)
(1.8–2.4)
(1.4–1.9)
(1.3–1.7)
(1.1–1.6)
(16–53)
(13–30)
(11–25)
(9.6–20)
(6.2–14)
(4.9–11)
(3.6–9.3)
PREVALENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
44
42
44
41
45
46
48
66
61
64
70
78
81
82
11
9.4
6.6
6.2
5.4
5.2
4.7
3.1
3.1
2.8
2.7
3
3.1
3.3
0.28
0.51
0.3
0.36
0.41
0.41
0.47
0.35
0.52
0.66
0.61
0.51
0.48
0.45
33
33
33
29
22
20
17
(17–83)
(19–69)
(20–71)
(19–67)
(21–73)
(21–75)
(23–78)
(27–130)
(28–100)
(28–110)
(31–120)
(35–130)
(38–130)
(38–130)
(3.4–20)
(3.6–16)
(1.8–12)
(1.9–11)
(1.6–9.6)
(1.5–9.2)
(1.1–8.3)
(0.89–5.7)
(0.9–5.4)
(0.85–4.9)
(0.78–4.6)
(0.92–5.2)
(0.98–5.4)
(1.1–5.6)
(0.062–0.5)
(0.11–0.91)
(0.11–0.59)
(0.15–0.64)
(0.18–0.71)
(0.18–0.74)
(0.2–0.83)
(0.17–0.54)
(0.25–0.81)
(0.31–1.1)
(0.28–0.97)
(0.24–0.81)
(0.22–0.77)
(0.21–0.72)
(13–65)
(14–56)
(14–55)
(13–48)
(9.6–37)
(8.2–33)
(6.5–29)
INCIDENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
RATE
667
641
589
489
501
506
513
251
204
187
183
188
191
188
86
66
42
33
28
26
23
37
35
30
27
29
30
31
15
22
9.9
8.7
6.6
5.9
6.2
17
20
21
17
13
12
11
277
219
184
139
99
85
71
(263–1261)
(289–1055)
(274–963)
(222–805)
(233–819)
(235–826)
(242–834)
(101–482)
(91–337)
(82–311)
(81–305)
(86–309)
(89–313)
(88–307)
(28–166)
(25–115)
(12–73)
(10–58)
(8–49)
(7.4–46)
(5.6–41)
(11–69)
(10–60)
(9–52)
(7.9–47)
(9–51)
(9.5–52)
(10–53)
(3.4–27)
(4.9–39)
(3.8–20)
(3.7–16)
(2.9–11)
(2.5–11)
(2.7–11)
(8–26)
(9.5–31)
(9.6–33)
(7.8–27)
(6.2–21)
(5.6–20)
(5.1–18)
(109–540)
(92–371)
(78–312)
(62–231)
(42–166)
(35–143)
(27–122)
19
19
21
24
25
26
27
31
36
41
46
49
50
52
7.5
6.5
5.6
4.9
4.4
4.2
4.1
2.4
2.6
2.3
2.2
2.5
2.5
2.6
0.082
0.11
0.17
0.2
0.22
0.23
0.23
0.18
0.25
0.3
0.26
0.23
0.21
0.2
16
21
20
17
14
13
12
(11–28)
(15–22)
(17–25)
(19–29)
(21–31)
(21–31)
(22–32)
(19–47)
(29–43)
(33–49)
(37–55)
(40–59)
(41–61)
(43–62)
(5.2–10)
(5.3–7.8)
(4.7–6.4)
(4.1–5.7)
(3.6–5.3)
(3.5–5.1)
(3.3–4.8)
(1.7–3.1)
(2.2–2.9)
(2–2.6)
(1.9–2.5)
(2.2–2.8)
(2.2–2.9)
(2.3–2.9)
(0.06–0.11)
(0.078–0.14)
(0.11–0.24)
(0.14–0.26)
(0.17–0.28)
(0.17–0.3)
(0.16–0.31)
(0.17–0.2)
(0.22–0.27)
(0.26–0.34)
(0.23–0.29)
(0.2–0.25)
(0.19–0.24)
(0.17–0.23)
(10–24)
(17–25)
(17–25)
(14–20)
(11–16)
(10–15)
(9.6–14)
RATE
285
285
285
285
285
285
286
119
119
119
119
119
119
119
61
46
35
26
22
21
20
29
29
24
23
24
24
25
4.5
4.6
5.5
4.8
3.6
3.3
3.1
8.7
9.5
9.4
7.4
5.9
5.4
4.9
137
137
116
81
60
54
49
(174–424)
(232–344)
(232–344)
(232–344)
(232–344)
(233–343)
(235–342)
(72–177)
(97–143)
(97–143)
(97–143)
(97–143)
(97–143)
(98–142)
(42–82)
(37–55)
(30–40)
(22–31)
(18–27)
(17–25)
(16–24)
(21–38)
(25–33)
(21–28)
(20–26)
(21–27)
(21–28)
(22–28)
(3.3–6)
(3.3–6)
(3.5–8)
(3.4–6.4)
(2.7–4.5)
(2.4–4.3)
(2.1–4.2)
(8–9.5)
(8.4–11)
(8.1–11)
(6.6–8.2)
(5.2–6.6)
(4.7–6.1)
(4.3–5.6)
(83–204)
(112–165)
(94–139)
(66–97)
(49–73)
(44–65)
(40–58)
Rates are per 100 000 population.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 172
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($,QFLGHQFHQRWLILFDWLRQDQGFDVHGHWHFWLRQUDWHVDOOIRUPV±
YEAR
Afghanistan
Bahrain
Djibouti
Egypt
Iran (Islamic
Republic of)
Iraq
Jordan
Kuwait
Lebanon
Libyan Arab
Jamahiriya
Morocco
Oman
Pakistan
Qatar
POPULATION
(MILLIONS)
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
13
20
23
28
30
31
31
<1
<1
<1
<1
1
1
1
<1
<1
<1
<1
<1
<1
<1
57
62
68
74
78
80
81
55
60
65
70
72
73
74
17
20
24
27
30
31
32
3
4
5
5
6
6
6
2
2
2
2
3
3
3
3
3
4
4
4
4
4
4
5
5
6
6
6
6
25
27
29
30
31
32
32
2
2
2
2
3
3
3
112
127
145
159
167
170
174
<1
<1
<1
<1
1
2
2
25
37
43
52
56
58
59
0.14
0.057
0.22
0.31
0.36
0.36
0.29
3.5
3.9
4.5
5
5.3
5.4
5.5
20
20
17
16
15
15
15
20
21
21
17
14
14
13
11
13
15
17
19
20
20
0.54
0.55
0.4
0.36
0.35
0.34
0.33
0.33
0.37
0.59
0.63
0.96
1.1
1.1
0.95
1.1
0.63
0.43
0.57
0.63
0.72
1.7
1.9
2.1
2.3
2.5
2.5
2.5
36
41
32
29
29
29
29
0.55
0.33
0.33
0.34
0.39
0.38
0.36
260
290
330
370
390
390
400
0.21
0.35
0.32
0.37
0.65
0.71
0.67
(15–37)
(30–45)
(35–52)
(42–63)
(46–68)
(47–69)
(49–71)
(0.12–0.16)
(0.051–0.063)
(0.19–0.25)
(0.27–0.36)
(0.31–0.4)
(0.31–0.41)
(0.26–0.33)
(2.2–5.1)
(3.2–4.7)
(3.8–5.3)
(4.1–6)
(4.3–6.4)
(4.4–6.5)
(4.5–6.6)
(16–23)
(17–23)
(15–20)
(13–18)
(13–18)
(13–17)
(12–17)
(12–29)
(17–26)
(17–25)
(14–20)
(12–17)
(11–16)
(10–15)
(6.7–16)
(11–16)
(12–18)
(14–21)
(15–23)
(16–24)
(17–24)
(0.39–0.71)
(0.45–0.66)
(0.35–0.46)
(0.3–0.42)
(0.3–0.4)
(0.3–0.39)
(0.29–0.38)
(0.29–0.37)
(0.32–0.42)
(0.51–0.67)
(0.56–0.71)
(0.83–1.1)
(0.93–1.2)
(0.98–1.3)
(0.58–1.4)
(0.93–1.2)
(0.54–0.72)
(0.37–0.49)
(0.49–0.65)
(0.55–0.73)
(0.63–0.83)
(1.4–2.1)
(1.6–2.3)
(1.7–2.5)
(2–2.7)
(2–3)
(2–3)
(2.1–3)
(25–50)
(33–49)
(27–36)
(25–33)
(25–33)
(25–33)
(25–33)
(0.49–0.63)
(0.29–0.37)
(0.29–0.38)
(0.3–0.38)
(0.34–0.44)
(0.33–0.43)
(0.32–0.41)
(160–380)
(240–360)
(270–400)
(300–440)
(320–470)
(320–470)
(330–480)
(0.19–0.24)
(0.31–0.4)
(0.28–0.36)
(0.33–0.42)
(0.57–0.74)
(0.62–0.81)
(0.58–0.75)
RATEb
189
189
189
189
189
189
189
28
10
34
43
34
30
23
619
619
619
619
619
620
620
34
32
26
21
19
19
18
36
36
32
24
20
19
17
64
64
64
64
64
64
64
16
13
8.4
6.7
6
5.7
5.4
16
23
30
28
38
40
41
32
31
17
11
14
15
17
40
40
40
40
40
40
40
147
152
109
95
93
92
91
30
15
15
14
15
14
13
231
231
231
231
231
231
231
45
70
54
46
47
45
38
(115–281)
(154–228)
(154–228)
(154–228)
(154–228)
(155–227)
(155–226)
(25–32)
(9.1–11)
(30–39)
(38–49)
(30–38)
(27–35)
(20–26)
(390–901)
(504–746)
(526–721)
(504–746)
(504–746)
(507–743)
(510–741)
(29–40)
(27–37)
(22–30)
(18–25)
(16–22)
(16–22)
(15–21)
(22–53)
(29–43)
(26–38)
(20–29)
(16–24)
(15–22)
(14–21)
(39–95)
(52–77)
(52–77)
(52–77)
(52–77)
(52–77)
(52–77)
(11–21)
(10–15)
(7.2–9.6)
(5.6–7.9)
(5.2–6.9)
(4.9–6.6)
(4.7–6.2)
(14–18)
(20–26)
(27–34)
(25–31)
(33–43)
(35–46)
(36–46)
(20–48)
(27–36)
(14–19)
(9.1–12)
(12–16)
(13–17)
(15–20)
(32–48)
(32–48)
(32–48)
(34–46)
(32–48)
(33–48)
(33–48)
(102–201)
(123–183)
(95–125)
(82–109)
(80–106)
(80–105)
(80–104)
(26–34)
(13–17)
(13–17)
(12–15)
(13–17)
(12–16)
(12–15)
(141–344)
(188–279)
(188–279)
(188–279)
(188–279)
(189–278)
(189–277)
(39–51)
(61–79)
(48–61)
(40–52)
(41–53)
(39–50)
(33–43)
INCIDENCE HIV-POSITIVE
NUMBER
(THOUSANDS)
0.011
0.012
0.011
0.15
0.35
0.52
0.59
0.61
0.62
0.62
<0.01
0.011
0.02
0.035
0.046
0.05
0.055
0.12
0.19
0.41
0.58
0.49
0.47
0.44
(<0.01–0.022)
(<0.01–0.022)
(<0.01–0.021)
(0.015–0.42)
(0.16–0.62)
(0.35–0.72)
(0.42–0.79)
(0.41–0.85)
(0.5–0.74)
(0.49–0.77)
(<0.01–0.01)
(<0.01–0.023)
(<0.01–0.035)
(0.018–0.058)
(0.023–0.076)
(0.025–0.083)
(0.028–0.09)
(0.053–0.21)
(0.1–0.3)
(0.24–0.62)
(0.35–0.88)
(0.3–0.73)
(0.28–0.71)
(0.26–0.66)
RATEb
1.1
1
<1
26
56
71
73
72
71
70
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
NUMBER
RATEb
4 332
33
7 107
21 844
28 301
25 417
28 029
117
43
207
280
304
326
246
2 100
31
79
95
83
89
24
8
32
39
29
28
19
373
3 971
3 109
3 682
3 783
4 172
2 142
11 145
10 762
11 446
9 452
9 685
9 260
9 255
15 936
11 850
9 192
9 453
10 097
10 362
14 735
9 697
9 697
9 454
9 099
9 385
9 707
439
498
306
367
338
367
338
277
336
513
517
867
933
957
543
385
430
434
469
4
18
16
15
12
12
11
17
27
18
13
13
14
14
85
48
41
35
31
31
31
13
11
6
7
6
6
5
13
21
26
23
34
35
35
983
571
391
523
499
513
442
1 440
1 341
2 098
2 010
2 096
2 127
27 658
29 829
28 852
26 269
26 838
27 348
28 359
482
276
321
261
350
332
308
156 759
13 142
11 050
142 017
245 635
264 248
261 199
184
304
279
325
567
619
580
28
15
10
13
12
12
10
30
26
36
33
33
33
112
111
100
86
86
86
89
26
12
14
11
13
12
11
140
10
8
90
147
155
150
39
61
47
40
41
39
33
(<1–2.1)
(<1–1.9)
(<1–1.7)
(2.7–76)
(25–99)
(48–98)
(52–98)
(48–100)
(58–85)
(56–86)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–1.3)
(<1–1)
(<1–<1)
(<1–<1)
<0.01 (<0.01–0.016)
<0.01 (<0.01–0.015)
<1 (<1–<1)
<1 (<1–<1)
<0.01 (<0.01–<0.01)
<1 (<1–<1)
<0.01
<0.01
<0.01
<0.01
<0.01
0.01
0.055
0.059
0.039
0.049
0.054
0.059
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.022)
(0.029–0.089)
(0.035–0.09)
(0.023–0.061)
(0.029–0.075)
(0.034–0.077)
(0.034–0.089)
<1
<1
<1
<1
<1
<1
1.6
1.6
<1
1.2
1.3
1.4
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–2.6)
(<1–2.4)
(<1–1.5)
(<1–1.8)
(<1–1.8)
(<1–2.1)
0.091
0.18
0.25
0.27
0.35
0.42
0.5
<0.01
<0.01
<0.01
0.013
<0.01
<0.01
<0.01
0.034
0.12
0.41
0.92
1.1
1.1
1.2
<0.01
<0.01
<0.01
(0.036–0.17)
(0.093–0.3)
(0.14–0.38)
(0.15–0.42)
(0.2–0.53)
(0.23–0.67)
(0.31–0.75)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.014)
(<0.01–0.021)
(<0.01–0.017)
(<0.01–0.012)
(<0.01–0.01)
(<0.01–0.1)
(0.046–0.24)
(0.23–0.65)
(0.53–1.4)
(0.62–1.7)
(0.67–1.8)
(0.66–1.9)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
<1
<1
<1
<1
1.1
1.3
1.6
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
(<1–<1)
(<1–1.1)
(<1–1.3)
(<1–1.4)
(<1–1.7)
(<1–2.1)
(<1–2.3)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–1)
(<1–1)
(<1–1.1)
(<1–<1)
(<1–<1)
(<1–<1)
<0.01 (<0.01–<0.01)
NOTIFIED NEW AND RELAPSEa
<1 (<1–<1)
a
Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
b
Rates are per 100 000 population.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 173
CASE DETECTION RATEa
PERCENT
18
–
16
42
50
44
47
85
76
94
90
85
91
84
60
–
88
62
69
70
76
11
57
62
73
63
65
64
47
74
58
54
66
75
81
133
75
64
54
48
48
48
82
91
76
103
96
107
101
83
90
87
82
91
88
86
–
91
91
92
92
79
71
26
76
64
91
82
84
84
76
73
92
91
92
94
97
87
84
96
78
90
87
85
61
4
3
39
63
67
65
87
87
87
87
87
87
87
(12–29)
(14–20)
(35–51)
(42–62)
(37–54)
(39–57)
(75–96)
(68–85)
(83–109)
(79–103)
(75–97)
(80–105)
(75–95)
(41–96)
(75–103)
(52–76)
(58–85)
(58–86)
(63–92)
(9–13)
(48–68)
(53–74)
(62–86)
(54–75)
(56–77)
(55–75)
(32–77)
(62–91)
(48–71)
(45–67)
(55–81)
(62–91)
(68–99)
(89–218)
(62–92)
(53–78)
(45–67)
(40–59)
(40–59)
(40–59)
(62–114)
(75–111)
(66–88)
(87–122)
(84–112)
(93–124)
(89–117)
(74–94)
(79–104)
(77–100)
(73–93)
(80–104)
(77–100)
(76–98)
(79–106)
(79–106)
(80–106)
(80–106)
(69–91)
(62–82)
(21–31)
(63–93)
(53–79)
(79–107)
(68–101)
(70–103)
(70–102)
(55–110)
(61–90)
(80–106)
(79–106)
(81–107)
(82–108)
(85–112)
(77–99)
(75–96)
(84–111)
(70–87)
(79–103)
(77–99)
(75–96)
(41–100)
(4–5)
(3–4)
(32–48)
(53–78)
(56–82)
(54–79)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
Eastern Mediterranean Region
INCIDENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
173
05/10/11 09:03
7$%/($,QFLGHQFHQRWLILFDWLRQDQGFDVHGHWHFWLRQUDWHVDOOIRUPV±
INCIDENCE (INCLUDING HIV)
YEAR
Saudi Arabia
Somalia
Sudan
Syrian Arab
Republic
Tunisia
United Arab
Emirates
West Bank
and Gaza Strip
Yemen
174
POPULATION
(MILLIONS)
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
16
18
20
24
26
27
27
7
7
7
8
9
9
9
26
30
34
38
41
42
44
12
14
16
18
20
20
20
8
9
9
10
10
10
10
2
2
3
4
6
7
8
2
3
3
4
4
4
4
12
15
18
21
23
23
24
NUMBER
(THOUSANDS)
2.8
3.1
4
4.1
4.6
4.7
5
19
19
21
24
25
26
27
31
36
41
46
49
50
52
7.5
6.5
5.6
4.9
4.4
4.2
4.1
2.4
2.6
2.3
2.2
2.5
2.5
2.6
0.082
0.11
0.17
0.2
0.22
0.23
0.23
0.18
0.25
0.3
0.26
0.23
0.21
0.2
16
21
20
17
14
13
12
(2.4–3.1)
(2.8–3.6)
(3.5–4.5)
(3.6–4.6)
(4–5.2)
(4.2–5.3)
(4.4–5.7)
(11–28)
(15–22)
(17–25)
(19–29)
(21–31)
(21–31)
(22–32)
(19–47)
(29–43)
(33–49)
(37–55)
(40–59)
(41–61)
(43–62)
(5.2–10)
(5.3–7.8)
(4.7–6.4)
(4.1–5.7)
(3.6–5.3)
(3.5–5.1)
(3.3–4.8)
(1.7–3.1)
(2.2–2.9)
(2–2.6)
(1.9–2.5)
(2.2–2.8)
(2.2–2.9)
(2.3–2.9)
(0.06–0.11)
(0.078–0.14)
(0.11–0.24)
(0.14–0.26)
(0.17–0.28)
(0.17–0.3)
(0.16–0.31)
(0.17–0.2)
(0.22–0.27)
(0.26–0.34)
(0.23–0.29)
(0.2–0.25)
(0.19–0.24)
(0.17–0.23)
(10–24)
(17–25)
(17–25)
(14–20)
(11–16)
(10–15)
(9.6–14)
RATEb
17
17
20
17
18
18
18
285
285
285
285
285
285
286
119
119
119
119
119
119
119
61
46
35
26
22
21
20
29
29
24
23
24
24
25
4.5
4.6
5.5
4.8
3.6
3.3
3.1
8.7
9.5
9.4
7.4
5.9
5.4
4.9
137
137
116
81
60
54
49
(15–19)
(15–19)
(17–22)
(15–19)
(15–20)
(15–20)
(16–21)
(174–424)
(232–344)
(232–344)
(232–344)
(232–344)
(233–343)
(235–342)
(72–177)
(97–143)
(97–143)
(97–143)
(97–143)
(97–143)
(98–142)
(42–82)
(37–55)
(30–40)
(22–31)
(18–27)
(17–25)
(16–24)
(21–38)
(25–33)
(21–28)
(20–26)
(21–27)
(21–28)
(22–28)
(3.3–6)
(3.3–6)
(3.5–8)
(3.4–6.4)
(2.7–4.5)
(2.4–4.3)
(2.1–4.2)
(8–9.5)
(8.4–11)
(8.1–11)
(6.6–8.2)
(5.2–6.6)
(4.7–6.1)
(4.3–5.6)
(83–204)
(112–165)
(94–139)
(66–97)
(49–73)
(44–65)
(40–58)
INCIDENCE HIV-POSITIVE
NUMBER
(THOUSANDS)
RATEb
0.12
0.15
0.31
0.6
1.1
1.7
1.9
2.1
0.4
0.86
1.8
3.7
5.5
6.3
7.1
(0.091–0.15)
(<0.01–0.51)
(0.088–0.66)
(0.25–1.1)
(0.68–1.7)
(1.1–2.5)
(1.1–2.8)
(1.6–2.7)
(0.017–1.4)
(0.19–2)
(0.91–3)
(2.4–5.3)
(3.6–7.8)
(4.1–8.9)
(4.8–9.9)
<1
2.3
4.7
8.1
14
19
21
23
1.5
2.9
5.3
9.7
13
15
16
(<1–<1)
(<1–7.7)
(1.3–10)
(3.4–15)
(8.1–21)
(12–28)
(13–31)
(18–29)
(<1–5.1)
(<1–6.7)
(2.7–8.8)
(6.3–14)
(8.8–19)
(9.8–21)
(11–23)
<0.01
<0.01
<0.01
0.011
0.017
0.019
0.022
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.018)
(<0.01–0.027)
(0.01–0.031)
(0.012–0.035)
<1
<1
<1
<1
<1
<1
<1
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
<0.01 (<0.01–0.013)
NOTIFIED NEW AND RELAPSEa
<1 (<1–<1)
a
Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
b
Rates are per 100 000 population.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 174
NUMBER
RATEb
2 415
15
3 452
3 539
4 025
4 043
4 422
17
15
15
15
16
2 504
5 686
12 904
12 481
11 075
10 139
212
14 320
24 807
27 562
24 281
26 001
26 131
6 018
4 404
5 090
4 310
3 724
4 050
3 666
2 054
2 383
2 038
2 079
2 280
2 155
2 368
285
38
77
154
140
121
109
<1
48
73
72
59
61
60
49
31
32
23
19
20
18
25
27
22
21
22
21
23
16
115
103
93
116
131
64
77
82
28
40
35
31
4 650
14 428
13 651
9 063
8 290
8 562
8 916
4
3
1
2
2
3
3
3
<1
1
<1
<1
39
95
77
44
37
37
37
CASE DETECTION RATEa
PERCENT
87
–
87
87
87
86
88
–
13
27
54
49
43
38
1
40
61
60
49
51
50
81
68
92
89
85
96
90
87
92
90
93
92
85
91
348
–
68
53
42
51
57
35
31
27
11
18
16
16
28
69
67
54
61
67
76
(77–100)
(77–99)
(77–99)
(77–100)
(76–97)
(77–100)
(11–17)
(22–33)
(45–66)
(41–60)
(35–52)
(32–46)
(0–1)
(33–49)
(51–75)
(50–74)
(41–61)
(43–63)
(42–61)
(60–115)
(56–83)
(79–107)
(75–106)
(70–104)
(80–117)
(76–110)
(67–118)
(81–106)
(78–104)
(82–107)
(82–105)
(76–97)
(81–104)
(264–479)
(47–107)
(40–74)
(33–54)
(38–70)
(42–83)
(32–38)
(28–35)
(24–32)
(10–12)
(16–20)
(15–19)
(14–18)
(19–47)
(58–85)
(55–82)
(45–67)
(50–75)
(56–83)
(63–92)
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($&DVHQRWLILFDWLRQV±
YEAR
Afghanistan
• 33
89 •
Bahrain
• 24
19 •
Djibouti
• 373
469 •
Egypt
•4
11 •
Iran (Islamic
Republic of)
• 17
14 •
Iraq
• 85
31 •
Jordan
• 13
5•
Kuwait
• 13
35 •
Lebanon
–
12 •
Libyan Arab
Jamahiriya
• 10
33 •
Morocco
• 112
89 •
Oman
• 26
11 •
Pakistan
• 140
150 •
Qatar
• 39
a
33 •
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
NEW AND
RELAPSEa
4 332
SMEAR- SMEAR-NEGATIVE/
POSITIVE
UNKNOWN
EXTRAPULMONARY
OTHER RELAPSE
7 107
21 844
28 301
25 417
28 029
117
43
207
280
304
326
246
2 100
2 892
9 949
13 136
12 497
12 947
2 358
6 085
7 903
6 108
7 085
1 620
4 954
6 127
5 730
6 248
633
237
856
1 135
1 082
1 116
17
23
101
141
131
90
14
16
72
59
74
58
85
8
107
104
121
98
0
0
0
0
3 971
3 109
3 682
3 783
4 172
2 142
11 145
10 762
11 446
9 452
9 685
9 260
9 255
15 936
11 850
9 192
9 453
10 097
10 362
14 735
9 697
9 697
9 454
9 099
9 385
9 707
439
498
306
367
338
367
338
277
336
513
517
867
933
957
1 391
1 120
1 375
1 377
1 181
518
739
477
507
538
1 875
1 058
1 669
1 710
2 253
4 229
4 606
5 217
5 102
5 201
4 679
9 204
2 693
2 617
1 190
1 238
1 158
4 684
2 843
3 163
2 676
2 850
3 048
5 347
5 361
4 581
4 722
5 152
5 188
1 587
3 194
3 194
3 096
3 150
3 347
3 618
6 432
2 642
1 807
1 865
1 926
1 985
12 394
13 962
3 188
2 887
2 727
2 666
2 693
3 779
3 442
2 530
2 569
2 685
2 869
754
1 367
2 753
2 703
2 718
2 904
3 009
187
89
86
104
109
117
210
69
76
68
64
69
175
180
187
345
386
385
983
571
391
523
499
513
442
1 440
1 341
2 098
2 010
2 096
2 127
27 658
29 829
28 852
26 269
26 838
27 348
28 359
482
276
321
261
350
332
308
156 759
13 142
11 050
142 017
245 635
264 248
261 199
184
304
279
325
567
619
580
RE-TREAT EXCL. TOTAL
HISTORY
RELAPSE
RETREAT UNKNOWN
0
208
209
237
856
1 135
1 290
1 325
0
0
0
0
0
0
0
0
0
0
0
0
0
0
184
192
161
189
200
61
35
21
19
184
253
196
210
219
0
0
0
0
0
0
753
620
449
484
396
375
289
308
352
328
753
620
738
792
748
703
0
0
0
0
0
0
0
477
405
274
297
334
320
154
126
439
440
477
405
428
423
773
760
20
0
0
0
0
0
0
68
562
768
504
468
387
181
283
390
68
562
768
685
751
777
0
0
0
101
145
187
165
190
150
12
0
0
0
6
3
6
1
4
2
4
0
16
16
6
3
10
1
20
18
0
18
4
0
42
89
95
158
155
163
115
244
234
363
391
407
0
0
0
0
0
0
4
0
1
1
1
2
0
0
0
0
0
0
4
0
1
1
1
2
0
0
0
0
0
0
197
202
131
158
179
194
528
149
75
123
94
99
255
214
181
231
218
210
0
0
0
0
3
6
4
11
8
10
0
0
2
2
3
6
4
11
10
12
0
0
0
0
607
860
871
936
626
82
474
390
455
814
652
762
749
696
2
269
271
0
0
9
14
23
0
14 171
12 872
12 757
11 825
11 907
12 239
4 095
2 934
2 142
2 002
2 021
2 174
11 563
13 046
11 370
11 646
12 131
12 730
0
0
0
0
1 365
1 289
1 216
281
316
429
1 646
1 605
1 645
0
0
0
135
164
131
171
164
152
60
37
37
48
36
28
81
112
89
129
127
124
0
0
0
0
8
4
2
5
4
2
2
5
0
8
4
4
7
9
0
0
0
2 578
3 285
48 220
100 102
101 887
104 263
3 806
5 578
68 337
106 207
112 948
105 623
3 037
1 846
22 789
34 386
43 416
45 443
0
184
341
2 671
4 940
5 997
5 870
2 754
3 043
3 203
5 055
184
341
5 425
7 983
9 200
10 925
3 036
60
53
96
201
220
223
135
98
73
112
102
101
109
128
156
254
297
256
0
0
0
1
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
733
0
0
0
0
0
0
% SMEARPOS AMONG
NEW PULM
–
–
55
62
62
67
65
–
55
59
58
71
64
61
–
–
73
60
74
73
69
–
31
63
67
81
81
80
–
45
67
72
72
73
72
11
19
50
52
54
56
57
–
47
56
53
60
63
63
–
81
67
66
69
71
70
–
27
58
64
56
66
66
–
–
88
64
69
67
–
–
78
81
86
86
85
85
–
69
82
78
78
82
84
–
40
37
41
49
47
50
–
31
35
57
64
68
69
Eastern Mediterranean Region
NEW CASES
NEW AND RELAPSE
NOTIFICATION RATEa
1990–2010
Rates are per 100 000 population. Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 175
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
175
05/10/11 09:03
7$%/($&DVHQRWLILFDWLRQV±
NEW CASES
NEW AND RELAPSE
NOTIFICATION RATEa
1990–2010
YEAR
Saudi Arabia
• 15
16 •
Somalia
–
109 •
Sudan
•1
60 •
Syrian Arab
Republic
• 49
18 •
Tunisia
• 25
23 •
United Arab
Emirates
• 16
2•
West Bank
and Gaza Strip
•3
1•
Yemen
• 39
a
176
37 •
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
NEW AND
RELAPSEa
2 415
SMEAR- SMEAR-NEGATIVE/
POSITIVE
UNKNOWN
EXTRAPULMONARY
3 452
3 539
4 025
4 043
4 422
1 595
1 722
2 108
2 201
2 302
722
545
545
578
687
1 023
1 067
1 266
1 170
1 311
2 504
5 686
12 904
12 481
11 075
10 139
212
14 320
24 807
27 562
24 281
26 001
26 131
6 018
4 404
5 090
4 310
3 724
4 050
3 666
2 054
2 383
2 038
2 079
2 280
2 155
2 368
285
1 572
3 776
7 068
6 520
6 047
5 225
692
837
3 168
2 983
2 604
2 654
318
722
2 258
2 357
1 965
1 885
8 761
12 311
12 730
10 800
10 541
9 958
2 655
6 512
9 212
7 849
8 897
9 144
1 675
3 843
5 434
4 715
5 530
6 217
1 295
1 584
1 350
1 116
1 143
1 122
1 507
1 409
796
667
796
544
1 574
2 000
2 103
1 888
2 036
1 948
1 243
1 099
915
1 005
931
1 091
407
179
239
355
232
151
733
727
874
882
950
1 090
73
62
50
71
56
3
12
17
15
28
41
25
25
30
47
9
37
7
16
10
13
0
3 681
5 565
3 379
3 540
3 576
3 584
58
10
6
3
9
6
15
21
15
12
7 390
4 176
2 780
2 032
2 108
2 313
3 082
3 470
2 553
2 307
2 564
2 715
115
103
93
116
131
64
77
82
28
40
35
31
4 650
14 428
13 651
9 063
8 290
8 562
8 916
OTHER RELAPSE
RE-TREAT EXCL. TOTAL
HISTORY
RELAPSE
RETREAT UNKNOWN
0
112
205
106
94
122
0
0
0
0
134
351
410
621
459
375
102
0
196
330
134
351
512
621
655
705
474
2 141
186
917
957
812
1 616
1 163
1 036
1 110
474
2 141
1 802
2 080
1 993
1 922
28
97
61
53
75
52
83
214
101
54
28
97
144
267
176
106
0
0
0
76
0
0
0
0
39
50
84
112
205
145
144
206
43
0
0
0
0
61
51
38
42
36
0
0
0
107
61
51
38
42
36
0
0
0
0
0
4
1
0
0
2
0
0
1
0
6
1
0
1
0
0
0
0
0
0
0
0
1
0
1
1
0
1
2
0
0
0
0
0
0
0
275
440
351
411
314
304
0
134
275
440
351
411
314
438
0
0
% SMEARPOS AMONG
NEW PULM
–
–
69
76
79
79
77
–
69
82
69
69
70
66
–
77
65
58
58
54
52
–
46
53
63
63
59
67
–
75
86
79
74
80
88
–
–
96
84
75
83
67
–
13
–
54
84
53
68
–
33
57
55
64
63
61
Rates are per 100 000 population. Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 176
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($7UHDWPHQWRXWFRPHVQHZVPHDUSRVLWLYHFDVHV±
% OF COHORT
YEAR
Afghanistan
–
86 •
Bahrain
–
98 •
Djibouti
• 75
79 •
• 62
88 •
Egypt
Iran (Islamic
Republic of)
–
83 •
• 80
90 •
• 92
75 •
• 71
85 •
• 91
82 •
Iraq
Jordan
Kuwait
Lebanon
Libyan Arab
Jamahiriya
• 65
–
Morocco
• 90
84 •
• 84
98 •
• 70
91 •
• 81
80 •
Oman
Pakistan
Qatar
Saudi Arabia
–
65 •
• 86
85 •
• 79
80 •
Somalia
Sudan
a
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
NUMBER
NOTIFIED
SIZE OF
COHORT
2 892
9 949
13 213
13 136
12 497
17
23
101
109
141
131
3 136
10 013
13 213
13 136
12 497
1 391
1 120
1 208
1 375
1 377
4 229
4 606
5 217
4 887
5 102
5 201
5 347
5 361
4 581
4 701
4 722
5 152
3 194
3 194
3 096
2 726
3 150
3 347
187
89
86
109
104
109
175
180
187
274
345
386
197
202
131
143
158
179
22
15
160
142
192
1 751
1 391
1 120
1 205
1 375
1 277
2 118
4 611
5 154
4 887
5 101
5 201
5 866
4 581
4 707
4 824
5 201
11 553
3 194
3 096
2 726
3 150
3 347
193
89
86
109
104
109
175
180
187
274
345
386
200
190
131
143
158
179
626
607
860
772
871
936
14 171
12 872
12 757
11 937
11 825
11 907
135
164
131
187
171
164
2 578
3 285
48 220
88 747
100 102
101 887
60
53
96
116
201
220
14 171
12 872
12 683
11 937
11 956
11 935
93
112
104
187
171
334
802
4 074
48 205
88 502
100 103
101 809
43
53
96
116
201
5
1 595
1 722
1 984
2 108
2 201
1 572
3 776
7 068
6 130
6 520
6 047
8 761
12 311
12 730
12 627
10 800
10 541
1 285
1 722
1 920
2 104
2 201
1 278
3 776
7 059
6 150
6 520
6 047
8 326
14 599
12 730
12 958
10 766
10 883
860
772
872
COHORT AS
% NOTIFIED
–
108
101
100
100
100
–
96
15
147
101
147
–
100
100
100
100
93
50
100
99
100
100
100
–
109
100
100
102
101
362
100
100
100
100
100
103
100
100
100
100
100
100
100
100
100
100
100
102
94
100
100
100
100
–
–
100
100
100
–
100
100
99
100
101
100
69
68
79
100
100
204
31
124
100
100
100
100
72
100
100
100
100
2
–
81
100
97
100
100
81
100
100
100
100
100
95
119
100
103
100
103
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
76
83
82
83
83
9
7
5
5
4
3
2
2
2
2
3
1
1
1
1
6
2
2
2
2
2
5
8
7
9
73
93
14
8
98
60
48
71
72
78
72
38
75
66
72
69
72
0
0
0
0
0
16
14
9
9
6
7
24
12
13
16
20
16
27
7
4
1
2
3
2
1
1
1
1
2
3
3
3
3
3
0
0
0
0
0
1
1
1
1
0
1
3
2
2
2
3
2
0
0
0
0
0
20
21
16
14
13
17
19
5
3
3
3
4
0
0
82
90
0
1
14
2
2
2
3
14
3
13
3
3
3
81
78
76
78
77
60
86
76
78
79
80
91
89
71
66
73
54
40
54
53
41
43
41
35
89
81
78
63
65
65
4
5
6
6
6
20
5
10
8
9
10
1
1
12
11
11
21
31
15
10
38
37
44
56
3
11
12
13
17
0
6
7
8
8
7
0
3
3
2
3
2
3
2
5
5
3
6
3
1
1
0
0
0
0
4
2
1
3
6
1
2
3
2
3
3
5
2
2
2
2
1
1
1
7
0
1
7
0
0
0
0
0
0
0
1
1
1
1
1
1
3
3
3
2
2
10
3
7
8
6
6
2
4
6
9
4
11
1
9
7
7
7
4
10
3
6
4
2
2
33
3
4
5
3
5
5
1
3
2
1
1
3
2
0
9
9
0
25
21
29
14
12
11
0
1
0
4
18
10
0
40
43
52
29
24
17
2
2
3
0
0
1
27
27
24
2
4
4
75
82
76
78
79
77
84
93
90
91
96
49
51
58
71
77
74
74
81
66
74
60
60
80
14
7
5
8
7
8
0
0
1
1
1
1
1
2
1
3
7
7
9
10
10
9
1
0
0
2
49
20
16
13
14
16
17
0
0
9
7
13
0
2
3
2
2
2
2
9
4
10
9
2
2
4
4
3
2
2
2
5
8
1
0
1
0
0
0
0
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
20
17
9
4
5
4
0
0
0
1
0
20
1
1
7
1
1
2
5
0
0
0
0
0
4
4
4
2
3
2
14
26
16
32
26
0
62
60
59
54
54
82
81
85
82
78
83
44
50
64
60
62
62
11
5
8
6
11
4
2
4
4
3
2
35
25
18
18
20
19
7
7
6
6
6
4
4
4
4
3
4
2
4
3
3
3
3
0
1
1
2
1
5
2
1
2
2
2
7
2
1
1
1
1
13
10
13
8
10
5
3
4
3
3
3
11
9
9
7
10
10
6
17
12
24
18
0
9
2
5
11
7
1
11
5
11
5
6
Eastern Mediterranean Region
TREATMENT SUCCESS (%)a
1995–2009
TREATMENT SUCCESS = percent cured + percent completed then rounded to the nearest digit.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 177
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
177
05/10/11 09:03
7$%/($7UHDWPHQWRXWFRPHVQHZVPHDUSRVLWLYHFDVHV±
% OF COHORT
TREATMENT SUCCESS (%)a
1995–2009
Syrian Arab
Republic
• 61
88 •
Tunisia
–
83 •
United Arab
Emirates
–
73 •
West Bank
and Gaza Strip
• 100
82 •
• 52
88 •
Yemen
a
178
YEAR
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
NUMBER
NOTIFIED
SIZE OF
COHORT
COHORT AS
% NOTIFIED
1 295
1 584
1 350
1 155
1 116
1 143
1 243
1 099
915
941
1 005
931
1 295
1 562
1 350
1 155
1 115
1 144
73
62
56
50
71
9
37
7
13
16
10
3 681
5 565
3 379
3 537
3 540
3 576
73
62
59
53
71
13
100
99
100
100
100
100
–
100
99
100
96
100
–
100
100
105
106
100
144
–
171
108
100
110
100
100
106
100
100
99
1 099
910
941
967
931
12
14
16
11
3 681
5 565
3 566
3 523
3 540
3 557
CURED
45
69
76
76
86
76
87
83
74
76
72
COMPLETED
16
10
13
13
DIED
FAILED
DEFAULTED
NOT
EVALUATED
12
2
4
3
3
3
4
9
3
2
1
2
1
24
11
6
6
6
4
5
4
1
2
2
3
4
7
15
10
11
3
2
3
3
3
2
1
1
1
2
2
2
2
2
3
2
4
4
8
9
56
42
20
25
21
100
18
31
44
43
52
7
6
12
9
11
4
0
3
0
1
5
15
20
23
14
10
6
0
0
0
0
58
50
38
18
43
59
69
75
75
79
42
43
56
64
9
13
11
9
9
9
0
0
0
9
1
3
3
3
3
3
0
7
0
0
1
1
1
1
1
1
0
0
6
9
35
14
6
5
5
4
0
0
0
0
11
10
10
6
7
4
TREATMENT SUCCESS = percent cured + percent completed then rounded to the nearest digit.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 178
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($7UHDWPHQWRXWFRPHVUHWUHDWPHQWFDVHV±
% OF COHORT
YEAR
Afghanistan
–
–
Bahrain
–
–
Djibouti
–
75 •
Egypt
–
78 •
Iran (Islamic
Republic of)
–
73 •
Iraq
–
84 •
Jordan
–
79 •
Kuwait
–
100 •
Lebanon
–
80 •
Libyan Arab
Jamahiriya
–
–
Morocco
• 76
69 •
Oman
–
100 •
Pakistan
• 70
82 •
• 67
–
Qatar
Saudi Arabia
–
60 •
Somalia
–
60 •
Sudan
–
a
70 •
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
NUMBER
NOTIFIED
SIZE OF
COHORT
237
856
1 078
1 135
1 290
0
304
856
1 078
0
2
0
0
184
253
228
196
210
753
620
738
585
792
748
477
405
428
444
423
773
68
562
768
554
685
751
6
3
10
11
1
20
4
0
1
1
1
1
3
6
4
3
11
10
271
0
0
0
0
268
253
192
196
194
956
738
585
779
748
606
448
447
692
708
953
797
685
751
6
3
12
24
1
1
1
1
5
4
3
11
10
0
32
23
1 469
1 646
1 605
0
8
4
6
4
7
184
341
5 425
7 738
7 983
9 200
1
0
0
0
0
0
112
205
150
145
144
134
351
512
497
621
655
474
2 141
1 802
2 095
2 080
1 993
1 650
1 421
1 535
1 668
7
6
4
7
374
907
5 009
7 184
7 685
8 801
3
0
0
0
139
96
133
141
151
351
524
0
621
655
1 828
1 914
1 953
2 147
COHORT AS
% NOTIFIED
–
128
100
100
–
–
–
–
–
0
–
–
–
146
100
84
100
92
–
154
100
100
98
100
–
150
105
101
164
92
–
–
124
144
100
100
–
200
–
27
1 200
120
–
–
100
100
100
100
–
83
100
100
100
100
–
–
–
–
–
–
–
–
–
–
93
104
–
88
–
100
100
100
203
266
92
93
96
96
300
–
–
–
–
–
–
124
47
89
97
105
–
100
102
0
100
100
–
–
101
91
94
108
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
73
87
80
5
2
3
4
3
4
4
1
2
11
2
2
3
5
9
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
27
58
56
66
67
9
10
11
9
8
0
3
2
3
3
3
2
3
2
2
22
24
23
14
18
37
2
5
6
3
52
41
49
39
39
11
17
16
32
39
7
10
8
8
6
12
12
10
8
5
13
8
8
9
7
5
12
9
4
4
63
68
68
57
48
13
8
9
15
25
6
9
8
8
8
5
3
3
4
3
6
4
5
5
5
7
8
8
11
11
60
58
62
57
12
14
18
27
4
4
2
3
8
4
4
3
12
17
11
9
4
2
2
1
83
17
0
0
0
0
0
8
17
67
67
63
33
0
4
0
8
0
0
17
17
0
0
0
0
0
0
0
100
100
100
100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
80
75
67
55
60
25
33
9
20
0
0
27
0
0
0
0
0
0
0
0
0
20
0
0
9
20
–
6
–
31
–
0
–
0
–
63
–
0
65
12
4
4
10
7
55
65
65
60
17
8
8
9
4
4
4
4
5
3
5
3
14
14
18
16
5
6
1
8
86
0
0
14
0
0
100
50
57
48
37
61
61
62
63
67
0
50
43
22
17
15
18
17
18
0
0
0
0
2
6
5
4
5
4
0
0
0
0
5
3
3
3
3
3
0
0
0
0
24
29
11
11
10
8
0
0
0
0
0
8
5
3
4
3
33
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
43
40
46
34
45
15
9
16
10
15
7
9
6
5
8
3
5
3
4
1
13
18
27
16
17
19
19
2
31
14
53
76
–
48
50
1
5
–
4
10
5
6
–
5
6
5
2
–
2
4
3
5
–
3
3
34
6
–
38
27
53
50
39
33
29
30
35
38
3
3
2
3
1
0
1
1
9
6
14
15
6
11
8
10
Eastern Mediterranean Region
TREATMENT SUCCESS (%)a
1995–2009
TREATMENT SUCCESS = percent cured + percent completed then rounded to the nearest digit.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 179
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
179
05/10/11 09:03
7$%/($7UHDWPHQWRXWFRPHVUHWUHDWPHQWFDVHV±
% OF COHORT
TREATMENT SUCCESS (%)a
1995–2009
YEAR
Syrian Arab
Republic
–
70 •
Tunisia
–
–
United Arab
Emirates
–
–
West Bank
and Gaza Strip
–
–
Yemen
• 43
a
180
77 •
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
NUMBER
NOTIFIED
28
97
144
148
267
176
SIZE OF
COHORT
189
144
279
266
176
61
51
27
38
42
42
0
6
5
1
0
5
5
1
0
1
1
2
275
440
351
325
411
314
0
0
0
0
14
437
351
324
376
291
COHORT AS
% NOTIFIED
–
195
100
189
100
100
–
69
–
–
–
–
–
–
83
100
100
–
–
–
–
0
0
0
5
99
100
100
91
93
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
44
53
25
26
48
10
14
47
51
22
4
5
5
5
9
20
9
8
5
4
15
19
13
12
15
7
0
3
3
3
74
0
5
2
10
10
80
40
100
–
0
0
0
–
0
0
0
–
0
20
0
–
20
20
0
–
0
20
0
–
–
–
–
–
29
64
48
64
66
70
–
–
–
–
14
8
9
7
9
7
–
–
–
–
21
7
2
4
3
3
–
–
–
–
14
6
3
3
3
4
–
–
–
–
14
11
7
7
9
7
–
–
–
–
7
4
30
15
10
9
TREATMENT SUCCESS = percent cured + percent completed then rounded to the nearest digit.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 180
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($+,9WHVWLQJDQGSURYLVLRQRI&37$57DQG,37 –
YEAR
Afghanistan
–
18 •
• 46
65 •
Bahrain
Djibouti
•7
52 •
–
47 •
–
8•
–
66 •
Egypt
Iran (Islamic
Republic of)
Iraq
Jordan
• 23
100 •
• 100
100 •
Kuwait
Lebanon
•1
46 •
Libyan Arab
Jamahiriya
–
–
Morocco
–
0•
Oman
• 98
100 •
Pakistan
•0
2•
Qatar
• 100
100 •
Saudi Arabia
–
72 •
•3
26 •
•1
41 •
•8
2•
•6
8•
Somalia
Sudan
Syrian Arab
Republic
Tunisia
United Arab
Emirates
–
100 •
• 46
100 •
West Bank
and Gaza Strip
Yemen
–
0•
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
% OF TB
NUMBER OF TB
PATIENTS WITH PATIENTS WITH
KNOWN HIV
KNOWN HIV
STATUS
STATUS
–
0
4
18
46
72
79
65
7
44
55
52
–
5
32
47
–
7
7
8
–
49
63
66
23
29
100
100
100
100
100
100
1
28
59
46
–
48
45
–
–
5
3
0
98
100
100
100
0
3
3
2
100
100
100
100
–
–
47
72
3
–
8
26
1
14
60
41
8
5
–
2
6
4
4
8
–
–
99
100
46
98
97
100
–
–
–
0
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 181
0
1 175
5 170
128
218
256
161
224
1 638
2 091
2 163
521
3 204
4 483
670
700
864
4 513
6 121
6 711
86
104
387
354
517
867
933
957
3
144
298
238
970
950
1 254
930
96
257
352
334
313
0
8 450
8 208
6 289
325
567
619
580
1 929
3 278
375
875
2 741
180
3 680
16 168
11 123
345
203
85
129
89
80
200
115
132
13
40
35
31
0
PATIENTS
NOTIFIED
(NEW AND
RETREAT)
21 844
28 301
26 358
28 238
280
304
326
246
3 170
3 717
3 804
4 191
11 735
9 760
10 037
9 588
9 366
9 579
10 536
10 802
9 454
9 280
9 668
10 097
371
356
387
354
517
867
933
957
391
523
501
515
2 367
2 010
2 110
26 269
27 119
27 664
28 788
261
352
334
313
144 771
248 678
267 451
269 290
325
567
619
580
3 539
4 064
4 093
4 549
13 006
12 481
11 271
10 469
29 178
25 444
27 037
27 241
4 393
3 938
4 151
3 827
2 079
2 280
2 155
2 368
105
93
116
132
28
41
36
31
9 063
8 290
8 562
9 050
NUMBER OF HIV- % OF TESTED
POSITIVE TB
TB PATIENTS
PATIENTS
HIV-POSITIVE
0
5
0
6
7
8
6
135
191
207
248
9
11
7
213
223
232
1
1
1
0
0
0
0
3
2
4
3
3
10
25
19
174
144
21
99
6
10
8
3
4
0
17
31
22
1
0
0
31
63
77
21
107
231
150
471
692
691
0
0
5
2
2
2
11
2
0
0
0
0
0
–
–
0
0
5
3
3
4
60
12
10
11
–
2
0
0
–
32
32
27
–
0
0
0
0
0
0
0
1
0
0
0
100
7
8
8
–
18
15
–
–
2
11
6
4
2
1
1
–
0
0
0
–
0
0
0
–
–
3
2
6
–
12
8
83
13
4
6
0
0
–
6
2
2
3
6
–
–
–
2
0
0
0
0
–
–
–
–
% OF HIV% OF HIVNUMBER OF HIVPOSITIVE
POSITIVE TB POSITIVE TB
PEOPLE
PATIENTS ON PATIENTS ON
PROVIDED IPT
CPT
ART
–
–
100
–
0
0
0
0
15
85
–
–
–
100
100
0
–
8
13
12
–
100
100
100
–
–
–
–
100
100
100
100
–
100
100
100
–
–
–
–
–
–
23
–
100
100
100
100
–
100
23
–
–
100
–
–
–
100
–
–
38
–
88
68
10
32
43
58
–
–
–
–
100
0
0
0
–
–
–
–
–
–
–
–
–
–
–
–
–
–
100
–
0
14
13
0
15
29
23
11
–
100
100
71
–
13
21
19
–
0
0
0
–
–
–
–
100
100
100
100
–
100
100
100
–
–
–
–
–
–
45
–
100
100
100
100
–
100
39
9
–
100
–
–
–
100
–
–
–
–
7
26
10
52
54
54
–
–
–
–
100
100
100
100
–
–
–
–
–
–
–
–
–
–
–
–
0
0
0
0
1
0
443
418
161
45
0
0
0
2
0
0
0
5
19
68
144
0
0
0
0
0
2
0
12
0
0
0
0
0
51
24
24
0
0
0
Eastern Mediterranean Region
% OF TB PATIENTS WITH
KNOWN HIV STATUS
2005–2010
0
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
181
05/10/11 09:03
7$%/($7HVWLQJIRU0'57%DQGQXPEHURIFRQILUPHGFDVHVRI0'57%±
YEAR
Afghanistan
Bahrain
Djibouti
Egypt
Iran (Islamic
Republic of)
Iraq
Jordan
Kuwait
Lebanon
Libyan Arab
Jamahiriya
Morocco
Oman
Pakistan
Qatar
Saudi Arabia
Somalia
Sudan
Syrian Arab
Republic
Tunisia
United Arab
Emirates
West Bank
and Gaza Strip
Yemen
a
182
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
TOTAL
CONFIRMED
CASES OF
MDR-TBa
19
4
0
0
0
39
96
204
27
19
58
63
72
110
19
6
8
10
6
8
9
5
3
3
4
7
8
7
180
143
54
5
4
5
1
40
49
444
2
5
3
4
21
14
57
45
70
94
62
7
31
14
25
36
21
12
4
1
0
0
0
1
2
13
4
NEW CASES
NOTIFIED
20 988
27 166
24 335
26 913
280
304
326
246
2 917
3 521
3 594
3 972
10 997
8 968
9 289
8 885
8 918
9 156
9 763
10 042
8 686
8 595
8 917
9 320
361
337
363
336
516
866
932
955
387
512
491
503
2 096
2 010
2 087
26 269
25 473
26 059
27 143
257
348
327
304
139 346
240 695
258 251
255 329
325
567
619
580
3 334
3 919
3 949
4 300
12 494
11 860
10 616
9 764
27 376
23 364
25 044
25 319
4 249
3 671
3 975
3 614
2 028
2 242
2 113
2 332
99
92
116
131
28
40
34
31
8 712
7 879
8 248
8 612
PREVIOUSLY TREATED CASES
NUMBER OF
% OF NOTIFIED
NUMBER OF
NOTIFIED TESTED TESTED FOR CONFIRMED CASES
FOR MDR-TB
MDR-TB
OF MDR-TB
238
2
24
42
162
0
42
60
205
208
271
0
0
0
98
58
95
74
516
866
427
437
48
7
14
4
4
4
180
140
47
125
139
248
185
2
5
9
264
440
322
324
488
93
125
0
0
63
380
6
0
0
66
42
89
–
–
–
1
1
8
13
66
0
–
–
–
–
0
1
–
2
2
–
3
–
0
0
0
27
17
26
22
100
100
46
46
12
1
3
1
0
0
–
–
1
1
–
0
49
40
76
61
–
0
0
0
81
78
52
56
–
–
–
–
–
–
–
5
–
0
0
–
0
0
–
2
–
–
18
0
–
–
–
–
–
–
0
0
–
1
1
1
13
2
0
0
0
0
7
10
7
3
17
0
0
0
9
5
6
5
6
8
9
5
0
0
1
2
4
4
NOTIFIED
856
1 135
1 290
1 325
0
0
0
0
253
196
210
219
738
792
748
703
428
423
773
760
768
685
751
777
10
1
20
18
1
1
1
2
4
11
10
12
271
NUMBER OF NOTIFIED
TESTED FOR MDR-TB
% OF NOTIFIED
NUMBER OF
TESTED FOR CONFIRMED CASES
MDR-TB
OF MDR-TB
34
0
0
0
0
0
792
775
41
90
169
173
163
185
33
4
7
7
1
1
1
0
4
11
10
14
7
23
9
0
0
3
4
0
2
5
9
2
5
3
4
27
36
35
0
0
13
8
5
6
1
0
0
1
2
3
1 646
1 605
1 645
4
4
7
9
5 425
7 983
9 200
10 925
0
0
0
0
205
145
144
206
512
621
655
705
1 802
2 080
1 993
1 922
144
267
176
106
51
38
42
36
6
1
0
1
1
2
0
351
411
314
438
305
403
11
12
7
8
38
60
306
0
0
0
0
79
4
65
207
0
0
14
12
6
1
0
0
56
30
34
–
–
–
3
–
–
–
–
0
–
–
–
–
100
104
–
10
21
–
22
–
25
22
24
330
400
35
39
100
100
100
0
100
100
100
117
–
–
–
–
–
19
–
24
275
300
100
89
–
0
1
3
–
–
–
–
–
–
–
–
–
–
–
11
0
3
10
–
0
0
8
11
–
–
–
17
–
100
–
–
–
–
0
–
–
14
10
8
6
2
0
0
0
0
89
190
15
16
41
63
72
110
10
1
2
3
0
0
0
0
2
3
3
5
4
3
57
54
5
1
1
1
38
43
306
0
0
0
0
30
4
34
59
0
0
14
12
28
6
4
0
0
0
1
11
1
TOTAL CONFIRMED CASES OF MDR-TB includes cases with unknown previous treatment history (i.e. not included under NEW CASES or PREVIOUSLY TREATED CASES).
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 182
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($1HZVPHDUSRVLWLYHFDVHQRWLILFDWLRQE\DJHDQGVH[±
Afghanistan
Bahrain
Djibouti
Egypt
Iran (Islamic
Republic of)
Iraq
Jordan
Kuwait
Lebanon
Libyan Arab
Jamahiriya
Morocco
Oman
Pakistan
Qatar
Saudi Arabia
Somalia
Sudan
Syrian Arab
Republic
Tunisia
United Arab
Emirates
West Bank
and Gaza Strip
Yemen
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
FEMALE
0–14
15–24
25–34
35–44
45–54
55–64
65+
52
151
197
0
0
0
0
228
606
986
0
0
0
10
183
560
819
1
3
0
16
149
472
491
2
2
2
11
129
453
490
3
5
3
12
94
470
641
1
3
0
4
80
419
622
3
4
4
4
17
18
28
223
21
25
9
118
29
16
18
1 125
21
13
42
0
0
0
2
0
0
0
1
3
5
0
1
2
5
2
302
220
211
542
641
524
358
751
438
352
292
862
627
424
370
19
8
8
5
15
10
12
16
26
16
12
8
112
101
114
347
252
243
665
827
606
617
754
467
531
487
1 409
317
644
482
37
16
17
14
51
44
45
67
32
28
19
21
212
239
293
139
119
151
460
667
421
783
636
387
338
354
1 085
297
261
384
17
13
9
10
32
32
29
50
30
20
15
15
78
86
168
67
62
67
408
476
414
725
494
295
281
296
863
205
245
276
20
9
4
12
17
21
26
48
16
15
10
12
46
36
52
60
47
49
463
307
243
407
737
344
260
310
900
135
189
286
26
14
6
12
9
11
8
10
16
17
12
12
22
29
19
42
29
20
160
158
123
217
921
642
630
760
271
101
148
228
11
2
5
6
0
5
3
11
10
14
8
10
21
32
35
142
99
79
51
1
1
1
2
29
55
621
1 548
0
0
0
2 508
2 061
2 222
1 982
7
8
21
12
274
498
5 278
11 860
8
7
19
59
2 872
2 423
2 515
2 553
12
9
11
27
230
387
4 759
10 462
12
19
15
72
1 737
1 705
1 583
1 611
7
11
24
15
178
256
4 263
8 320
11
9
17
38
819
855
1 057
1 273
7
12
15
16
140
232
3 834
7 969
13
7
19
22
573
485
580
712
10
9
19
8
124
153
3 332
6 934
4
2
5
5
553
595
591
515
11
11
5
10
95
130
2 453
6 066
4
1
1
0
0
8
14
46
113
125
109
250
785
425
209
13
8
9
7
131
182
335
334
740
1 343
1 036
604
1 028
1 358
1 185
332
359
266
170
268
276
458
730
724
1 114
886
796
1 511
1 990
1 781
255
289
237
212
213
201
242
201
408
725
496
634
1 351
1 541
1 335
111
125
111
101
158
175
210
127
254
458
355
486
1 119
1 151
863
70
86
112
80
86
70
116
278
195
330
266
362
638
724
497
59
76
62
65
107
107
102
109
142
319
277
337
677
493
391
50
55
63
49
16
5
9
139
103
115
208
172
194
156
133
170
109
115
125
65
53
93
101
81
88
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0–14
15–24
25–34
35–44
45–54
55–64
65+
93
320
445
0
0
1
0
414
1 651
2 107
1
1
1
8
565
1 959
2 263
1
2
0
15
339
1 302
1 455
2
0
3
7
205
869
1 112
0
1
1
1
99
471
831
1
1
0
1
36
246
488
1
1
0
1
12
23
20
134
55
48
8
234
77
45
54
725
37
44
73
1
0
1
3
0
1
0
4
1
4
1
0
5
6
8
147
123
104
288
457
431
199
1 039
593
394
433
304
338
305
394
15
8
6
14
8
11
13
41
16
31
25
36
34
43
36
156
117
120
367
343
298
352
890
410
205
288
1 208
241
260
294
4
9
6
24
24
24
31
78
18
26
14
48
31
35
36
47
66
89
274
257
205
423
664
322
186
208
915
136
151
198
10
1
6
4
9
12
11
30
13
9
8
17
19
24
35
31
23
36
256
211
218
292
613
320
260
276
800
134
197
205
14
2
5
3
4
5
3
10
8
7
3
7
20
24
21
17
13
24
160
112
132
192
685
407
382
398
886
103
135
220
12
2
8
5
4
3
1
11
5
4
3
4
13
16
21
10
8
19
75
48
42
97
788
647
701
1 014
200
87
80
166
7
5
5
3
2
1
5
8
3
6
1
3
11
22
20
191
170
167
117
2
2
2
3
85
130
1 447
3 212
1
0
0
1 708
1 530
1 330
1 098
18
17
13
18
375
591
6 463
14 481
2
0
5
7
1 288
1 121
943
841
13
5
5
22
381
416
5 611
10 513
3
4
10
16
703
672
546
426
5
7
3
6
267
274
3 987
7 749
1
3
2
2
461
398
403
386
5
5
4
4
178
163
2 866
6 410
0
1
1
1
317
406
343
310
6
11
5
4
143
103
2 060
4 879
0
0
2
1
299
352
398
364
3
6
3
5
79
56
1 338
4 338
1
0
0
0
28
31
33
38
85
169
91
359
817
381
195
22
23
27
16
172
205
239
158
354
752
467
490
925
1 102
761
158
195
182
164
182
184
271
139
319
636
444
613
1 134
1 203
979
97
101
108
105
79
98
105
97
219
436
341
299
905
978
772
53
53
59
47
51
73
70
40
110
292
188
403
771
729
520
44
46
59
41
50
51
49
25
72
212
137
342
327
411
279
37
38
32
38
70
61
58
16
41
157
132
305
323
244
191
20
28
23
27
7
7
4
68
66
64
59
61
64
43
39
39
21
36
34
21
16
40
58
28
52
UNKNOWN
0
0
0
0
0
0
0
0
0
0
0
0
0
2
4
4
6
5
12
10
3
16
1
3
0
0
4
1
1
7
2
13
0
7
0
3
1
4
0
4
3
0
1
0
2
1
4
0
1
0
5
1
1
0
3
0
0
0
57
110
48
68
1
2
400
789
493
507
0
605
689
553
569
2
256
493
366
322
1
1
201
314
242
231
3
1
148
255
149
164
3
45
127
78
138
0
0
83
161
44
98
0
420
799
426
471
1
1
720
627
410
409
0
348
517
265
264
1
1
200
345
181
174
2
106
247
85
106
0
92
92
39
63
0
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 183
UNKNOWN
0
0
MALE/FEMALE
RATIO
–
0.5
0.5
0.5
1.7
2.8
1.5
1.7
–
2.3
2.0
1.9
1.9
2.1
1.7
2.0
0.9
0.9
1.1
0.9
1.3
1.6
1.6
1.3
2.1
2.3
1.3
1.1
2.4
2.2
1.9
1.1
2.1
1.3
1.4
0.7
3.7
3.1
3.9
–
1.9
1.8
2.1
2.5
1.1
1.2
2.7
1.5
0.7
1.0
1.0
1.0
6.5
5.6
3.8
7.3
–
1.5
1.4
1.8
3.6
2.1
1.7
1.9
1.2
1.4
1.5
1.7
2.1
2.1
1.8
1.6
–
2.9
2.6
2.7
–
1.6
–
2.3
3.5
–
2.5
2.3
0.9
1.0
1.3
1.3
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
Eastern Mediterranean Region
MALE
YEAR
183
05/10/11 09:03
184
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 184
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
0.2
7.9
0
1.1
3.2
0.6
44
1.8
3.5
2.5
18
0.4
2.8
1.8
0
1.0
5.2
1.2
0.8
1.9
1.4
1.8
0.4
0.5
0.6
2.6
0.4
3.9
0.5
8.9
0.7
<0.1
1.2
0.7
0.9
2.7
0.6
1.6
0.8
0
0.4
0.3
1.8
0.3
2.8
1.8
0
0.1
0.2
2.4
0
4.0
0
<0.1
0.1
0.2
0.8
1.8
1.2
DST LABS
PER 5M
POPULATION
LABORATORIES
CULTURE LABS
PER 5M
POPULATION
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
No
Yes
Yes
No
No
No
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
NRLa
No
In country
In country
In and out of cty
No
Out of country
Out of country
In country
Out of country
Out of country
Out of country
In country
In country
In country
No
No
Out of country
SECOND-LINE
DST
AVAILABLE
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
If TB is confirmed
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
If TB is confirmed
Yes, all suspects
If TB is confirmed
Yes, all suspects
Yes, all suspects
For smear-positive TB
TB DIAGNOSIS
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
FIRST-LINE DRUGS
FREE THROUGH NTP
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
RIFAMPICIN USED
THROUGHOUT
TREATMENT
100
98
100
100
0
100
10
75
80
0
0
100
100
0
100
80
0
100
95
65
100
% OF PATIENTS
TREATED WITH FDCb
DRUG MANAGEMENT
a NRL = national reference laboratory
b FDC = fixed-dose combination
c NURSES (Registered Nurses, Registered Midwives, Enrolled Nurses, Enrolled Midwives); HEALTH ASSISTANTS (Medical Assistants, Clinical Officers); LABORATORY TECHNICIANS (Microscopists)
Afghanistan
Bahrain
Djibouti
Egypt
Iran (Islamic Republic of)
Iraq
Jordan
Kuwait
Lebanon
Libyan Arab Jamahiriya
Morocco
Oman
Pakistan
Qatar
Saudi Arabia
Somalia
Sudan
Syrian Arab Republic
Tunisia
United Arab Emirates
West Bank and Gaza Strip
Yemen
SMEAR LABS
PER 100K
POPULATION
7$%/($/DERUDWRULHV173VHUYLFHVGUXJPDQDJHPHQWKXPDQUHVRXUFHVDQGLQIHFWLRQFRQWURO
Yes
No
Yes
Yes
No
Yes
Yes
No
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
PAEDIATRIC
FORMULATIONS
PROCURED
0
0
0
0
100
99
100
100
98
100
10
90
70
0
18
100
70
0
50
80
100
100
100
50
100
100
18
NURSES
20
MEDICAL
OFFICERS
0
0
100
98
100
50
80
100
13
90
70
0
100
HEALTH
ASSISTANTS
0
0
100
97
90
50
100
100
25
100
70
0
100
26
LABORATORY
TECHNICIANS
% OF STAFF TRAINED BY THE NTP (IN 2010)c
0
0
0
66
12
2
0
12
0
TB NOTIFICATION
RATE PER 100 000
HEALTH-CARE
WORKERS
European Region
Table A3.1 Estimates of the burden of disease caused by TB, 1990–2010
187
Table A3.2 Incidence, notification and case detection rates, all forms, 1990–2010
191
Table A3.3 Case notifications, 1990–2010
195
Table A3.4 Treatment outcomes, new smear-positive cases, 1995–2009
199
Table A3.5 Treatment outcomes, retreatment cases, 1995–2009
202
Table A3.6 HIV testing and provision of CPT, ART and IPT, 2005–2010
205
Table A3.7 Testing for MDR-TB and number of confirmed cases of MDR-TB, 2005–2010
207
Table A3.8 New smear-positive case notification by age and sex, 1995–2010
209
Table A3.9 Laboratories, NTP services, drug management, human resources and
infection control, 2010
211
1109_0319_P_111_246 185
05/10/11 09:03
Estimates of mortality, prevalence and incidence
Estimated values are shown as best estimates followed by lower and upper bounds. The lower and upper bounds are
defi ned as the 2.5th and 97.5th centiles of outcome distributions produced in simulations. See ANNEX 1 for further
details.
Estimated numbers are shown rounded to two significant figures. Estimated rates are shown rounded to three
significant figures unless the value is under 100, in which case rates are shown rounded to two significant figures.
Estimates for all years are recalculated as new information becomes available and techniques are refi ned, so they
may differ from those published in previous reports in this series. Estimates published in previous global TB control
reports should no longer be used.
Data source
Data shown in this annex are taken from the WHO global TB database on 2 September 2011. Data shown in the main
part of the report were taken from the database on 21 June 2011. As a result, data in this annex may differ slightly from
those in the main part of the report.
Data can be downloaded from www.who.int/tb/data.
Country notes
EU/EEA countries
Notification and treatment outcome data for European Union and European Economic Area countries are provisional.
Denmark
Data for Denmark exclude Greenland.
186
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 186
05/10/11 09:03
7$%/($(VWLPDWHVRIWKHEXUGHQRIGLVHDVHFDXVHGE\7%±
Albania
Andorra
Armenia
Austria
Azerbaijan
Belarus
Belgium
Bosnia and
Herzegovina
Bulgaria
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Finland
a
POPULATION
(MILLIONS)
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
3
3
3
3
3
3
3
<1
<1
<1
<1
<1
<1
<1
4
3
3
3
3
3
3
8
8
8
8
8
8
8
7
8
8
9
9
9
9
10
10
10
10
10
10
10
10
10
10
10
11
11
11
4
3
4
4
4
4
4
9
8
8
8
8
8
7
5
5
5
4
4
4
4
<1
<1
<1
1
1
1
1
10
10
10
10
10
10
10
5
5
5
5
5
6
6
2
1
1
1
1
1
1
5
5
5
5
5
5
5
NUMBER
(THOUSANDS)
0.038
0.027
0.024
0.023
0.019
0.016
0.012
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.2
0.23
0.32
0.21
0.28
0.31
0.33
0.097
0.087
0.096
0.052
0.044
0.042
0.022
1.3
1.5
1.1
1
0.99
0.96
0.94
2.3
1.8
0.85
1.1
1.1
1.1
1
0.11
0.09
0.083
0.067
0.051
0.052
0.052
0.21
0.3
0.12
0.094
0.088
0.12
0.11
0.68
0.23
0.33
0.28
0.23
0.3
0.31
0.32
0.27
0.18
0.11
0.11
0.13
0.1
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.15
0.14
0.13
0.069
0.053
0.051
0.045
0.019
0.026
0.021
0.02
0.018
0.016
0.016
0.066
0.1
0.11
0.051
0.048
0.044
0.039
0.081
0.071
0.084
0.038
0.027
0.025
0.036
(0.019–0.074)
(0.017–0.045)
(0.016–0.04)
(0.014–0.038)
(0.012–0.031)
(0.01–0.026)
(<0.01–0.021)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.083–0.38)
(0.15–0.33)
(0.21–0.47)
(0.12–0.35)
(0.17–0.43)
(0.2–0.45)
(0.22–0.47)
(0.084–0.12)
(0.075–0.11)
(0.096–0.096)
(0.052–0.053)
(0.044–0.045)
(0.042–0.042)
(0.02–0.026)
(0.66–2.1)
(1.1–1.8)
(0.74–1.5)
(0.69–1.5)
(0.64–1.4)
(0.62–1.4)
(0.61–1.4)
(1.1–3.9)
(1.2–2.5)
(0.85–0.85)
(0.65–1.7)
(0.63–1.7)
(0.63–1.7)
(0.6–1.6)
(0.092–0.13)
(0.078–0.11)
(0.071–0.1)
(0.067–0.067)
(0.045–0.06)
(0.044–0.062)
(0.045–0.063)
(0.14–0.57)
(0.19–0.46)
(0.097–0.14)
(0.076–0.11)
(0.071–0.11)
(0.079–0.19)
(0.076–0.18)
(0.28–1.3)
(0.19–0.28)
(0.33–0.34)
(0.28–0.28)
(0.23–0.23)
(0.2–0.47)
(0.21–0.47)
(0.27–0.38)
(0.23–0.32)
(0.18–0.18)
(0.11–0.11)
(0.11–0.11)
(0.12–0.13)
(0.087–0.12)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.13–0.18)
(0.12–0.17)
(0.13–0.13)
(0.069–0.069)
(0.053–0.053)
(0.051–0.051)
(0.04–0.054)
(0.017–0.023)
(0.023–0.031)
(0.021–0.021)
(0.02–0.02)
(0.015–0.021)
(0.014–0.019)
(0.014–0.019)
(0.057–0.079)
(0.087–0.12)
(0.11–0.11)
(0.051–0.051)
(0.048–0.048)
(0.044–0.044)
(0.036–0.046)
(0.07–0.097)
(0.061–0.084)
(0.084–0.085)
(0.038–0.038)
(0.027–0.027)
(0.025–0.025)
(0.033–0.039)
RATEa
1.1
<1
<1
<1
<1
<1
<1
3.8
2.5
1.5
<1
<1
<1
<1
5.6
7.1
10
6.8
9.2
10
11
1.3
1.1
1.2
<1
<1
<1
<1
17
19
13
12
11
11
10
22
17
8.5
11
11
11
11
1.1
<1
<1
<1
<1
<1
<1
5
9
3.2
2.5
2.3
3.2
3
7.7
2.8
4.2
3.6
3.1
4
4.2
7
5.7
3.9
2.6
2.4
2.8
2.3
<1
<1
<1
<1
<1
<1
<1
1.4
1.4
1.2
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
4.2
7
8.1
3.8
3.6
3.3
2.9
1.6
1.4
1.6
<1
<1
<1
<1
(<1–2.2)
(<1–1.4)
(<1–1.3)
(<1–1.2)
(<1–<1)
(<1–<1)
(<1–<1)
(3.3–4.5)
(2.2–2.9)
(1.3–1.9)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(2.4–11)
(4.7–10)
(6.9–15)
(4–12)
(5.6–14)
(6.4–15)
(7–15)
(1.1–1.5)
(<1–1.3)
(1.2–1.2)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(9.1–29)
(14–24)
(9.1–18)
(8.1–17)
(7.2–16)
(6.8–15)
(6.6–15)
(11–38)
(12–24)
(8.4–8.5)
(6.6–18)
(6.6–17)
(6.6–18)
(6.3–17)
(<1–1.3)
(<1–1.1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(3.4–13)
(5.6–14)
(2.6–3.9)
(2–3)
(1.9–2.8)
(2.1–5.2)
(2–4.9)
(3.2–15)
(2.2–3.4)
(4.2–4.2)
(3.6–3.6)
(3.1–3.1)
(2.6–6.2)
(2.8–6.2)
(6–8.4)
(4.9–6.8)
(3.9–3.9)
(2.6–2.6)
(2.4–2.4)
(2.8–2.9)
(2–2.8)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(1.2–1.7)
(1.2–1.6)
(1.2–1.2)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(3.6–5)
(6.1–8.4)
(8.1–8.2)
(3.8–3.8)
(3.6–3.6)
(3.3–3.3)
(2.7–3.4)
(1.4–2)
(1.2–1.7)
(1.6–1.6)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
PREVALENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
1.1
0.94
0.85
0.75
0.63
0.56
0.51
0.032
0.024
0.017
0.011
0.011
<0.01
<0.01
2
2.4
3.4
2.9
3.3
3.4
3.5
2.2
2
1.7
1.3
0.99
0.76
0.48
16
18
15
15
15
15
15
16
14
9.4
10
9.8
9.8
9.4
2.4
1.9
1.9
1.5
1.1
1.1
1.1
4.7
4.3
2.9
2.3
2.1
2.3
2.2
6.7
4.3
4.2
4.5
4.1
4
4
4
3.1
2.4
1.5
1.4
1.2
1.2
0.054
0.061
0.05
0.057
0.055
0.058
0.061
2.9
2.8
2.1
1.4
1.1
1
0.88
0.51
0.67
0.84
0.55
0.47
0.42
0.41
0.61
0.94
1.1
0.67
0.55
0.5
0.35
1.1
1
0.79
0.53
0.42
0.94
0.45
(0.35–2.1)
(0.27–1.7)
(0.25–1.5)
(0.25–1.3)
(0.2–1.1)
(0.16–0.99)
(0.12–0.89)
(0.01–0.056)
(<0.01–0.042)
(<0.01–0.028)
(<0.01–0.019)
(<0.01–0.017)
(<0.01–0.015)
(<0.01–0.015)
(0.71–4)
(1–4.1)
(1.5–5.8)
(0.92–5)
(1.3–5.6)
(1.4–5.7)
(1.5–5.9)
(0.77–3.8)
(0.66–3.4)
(0.6–2.8)
(0.46–2.2)
(0.33–1.7)
(0.27–1.3)
(0.14–0.83)
(6.5–31)
(8.3–30)
(6.9–25)
(6.8–26)
(6.6–26)
(6.4–26)
(6.3–26)
(6.3–31)
(6–23)
(3–16)
(3.8–17)
(3.7–17)
(3.8–17)
(3.6–16)
(0.87–4)
(0.62–3.3)
(0.69–3.1)
(0.52–2.6)
(0.33–1.9)
(0.39–1.9)
(0.39–1.9)
(0.99–9.1)
(1.7–7.3)
(0.64–5.1)
(0.51–4.1)
(0.48–3.8)
(0.69–4)
(0.64–3.9)
(2.3–14)
(0.96–7.6)
(1–7.3)
(1.4–7.7)
(1.3–7.1)
(1.4–6.9)
(1.4–6.8)
(1.5–6.6)
(1–5.4)
(0.8–4)
(0.5–2.7)
(0.49–2.4)
(0.4–2.1)
(0.39–2)
(0.019–0.09)
(0.024–0.1)
(0.015–0.085)
(0.022–0.094)
(0.016–0.095)
(0.017–0.1)
(0.019–0.1)
(0.95–5)
(0.94–4.8)
(0.73–3.6)
(0.45–2.4)
(0.4–1.9)
(0.33–1.7)
(0.27–1.5)
(0.17–0.86)
(0.22–1.2)
(0.29–1.4)
(0.2–0.94)
(0.16–0.8)
(0.14–0.72)
(0.14–0.7)
(0.2–1)
(0.31–1.6)
(0.4–1.9)
(0.23–1.1)
(0.19–0.93)
(0.18–0.84)
(0.096–0.61)
(0.39–1.9)
(0.38–1.7)
(0.28–1.3)
(0.21–0.88)
(0.095–0.74)
(0.42–1.5)
(0.1–0.8)
RATE
34
30
28
24
20
18
16
62
38
26
14
13
9.9
9.8
56
75
112
93
106
111
114
29
25
21
16
12
9
5.8
222
232
189
180
173
169
166
154
134
94
102
101
101
98
24
19
18
15
10
11
11
108
128
78
60
56
61
60
76
51
52
58
54
54
54
87
67
52
35
32
28
27
7
7.1
5.3
5.5
5.1
5.3
5.5
28
27
21
14
11
9.6
8.4
9.9
13
16
10
8.6
7.7
7.4
39
65
82
50
41
37
26
23
20
15
10
7.9
18
8.5
(11–64)
(8.7–53)
(8.1–49)
(7.8–42)
(6.3–35)
(5–31)
(3.8–28)
(19–106)
(9–66)
(8.9–44)
(3–24)
(5.5–21)
(2.8–17)
(2.2–17)
(20–114)
(32–126)
(48–187)
(30–164)
(42–182)
(46–186)
(48–189)
(10–49)
(8.3–43)
(7.5–36)
(5.6–27)
(3.9–20)
(3.2–15)
(1.7–9.9)
(90–430)
(107–380)
(85–313)
(79–301)
(74–292)
(70–284)
(69–279)
(61–301)
(59–223)
(30–162)
(39–177)
(38–175)
(40–175)
(38–170)
(8.7–40)
(6.2–33)
(6.8–31)
(5–25)
(3.2–17)
(3.6–18)
(3.7–18)
(23–211)
(52–219)
(17–139)
(14–108)
(13–100)
(18–106)
(17–104)
(26–155)
(11–91)
(13–91)
(19–99)
(17–93)
(18–91)
(19–91)
(33–146)
(22–115)
(18–89)
(11–60)
(11–54)
(9.2–48)
(8.8–46)
(2.5–12)
(2.8–12)
(1.6–9)
(2.1–9.1)
(1.5–8.8)
(1.6–9.1)
(1.7–9.4)
(9.3–48)
(9.1–46)
(7.1–35)
(4.5–23)
(3.8–19)
(3.2–16)
(2.6–14)
(3.3–17)
(4.3–22)
(5.5–27)
(3.6–17)
(3–15)
(2.5–13)
(2.5–13)
(13–67)
(22–111)
(29–138)
(17–84)
(14–70)
(14–62)
(7.1–45)
(7.7–39)
(7.5–33)
(5.3–26)
(3.9–17)
(1.8–14)
(7.9–28)
(1.9–15)
INCIDENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
0.8
0.77
0.7
0.59
0.5
0.47
0.45
0.026
0.021
0.013
<0.01
<0.01
<0.01
<0.01
1.2
1.5
2.2
2.2
2.2
2.2
2.3
1.7
1.6
1.3
1
0.79
0.61
0.42
7.9
8.5
8.9
9.4
9.8
9.9
10
8.2
8.3
7.5
7
6.9
6.9
6.8
1.8
1.6
1.5
1.2
0.93
0.93
0.93
4
2.8
2.3
2
1.9
1.9
1.9
4.1
3.9
3.7
3.5
3.2
3.1
3
2.9
2.5
1.8
1.2
1.1
0.99
0.94
0.041
0.042
0.041
0.041
0.045
0.047
0.049
2.3
2.2
1.7
1.1
0.88
0.79
0.71
0.39
0.54
0.65
0.43
0.38
0.35
0.33
0.47
0.74
0.88
0.55
0.47
0.41
0.33
0.89
0.76
0.61
0.39
0.38
0.6
0.36
(0.57–1.1)
(0.64–0.91)
(0.59–0.81)
(0.5–0.69)
(0.42–0.58)
(0.4–0.55)
(0.38–0.52)
(0.023–0.029)
(0.018–0.024)
(0.011–0.014)
(<0.01–0.011)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.71–1.7)
(1.2–1.8)
(1.8–2.6)
(1.8–2.7)
(1.8–2.7)
(1.8–2.7)
(1.9–2.7)
(1.5–1.9)
(1.3–1.8)
(1.1–1.5)
(0.91–1.2)
(0.68–0.91)
(0.55–0.68)
(0.37–0.48)
(4.8–12)
(6.9–10)
(7.2–11)
(7.7–11)
(8–12)
(8.1–12)
(8.3–12)
(5–12)
(6.7–10)
(6.4–8.6)
(5.7–8.5)
(5.6–8.4)
(5.5–8.4)
(5.5–8.2)
(1.6–2.1)
(1.4–1.8)
(1.3–1.7)
(1.1–1.4)
(0.82–1.1)
(0.81–1)
(0.82–1.1)
(2.5–6)
(2.3–3.4)
(1.9–2.8)
(1.6–2.4)
(1.6–2.2)
(1.6–2.2)
(1.6–2.2)
(2.5–6)
(3.2–4.6)
(3.2–4.2)
(3.1–4.1)
(2.8–3.7)
(2.7–3.6)
(2.6–3.5)
(2.5–3.3)
(2.2–2.8)
(1.6–2.1)
(1.1–1.4)
(0.94–1.2)
(0.88–1.1)
(0.83–1.1)
(0.037–0.046)
(0.037–0.048)
(0.036–0.046)
(0.036–0.046)
(0.039–0.052)
(0.041–0.054)
(0.042–0.055)
(2–2.6)
(1.9–2.5)
(1.5–1.9)
(0.97–1.3)
(0.76–1)
(0.7–0.89)
(0.62–0.81)
(0.34–0.45)
(0.48–0.61)
(0.57–0.74)
(0.37–0.49)
(0.33–0.43)
(0.31–0.39)
(0.29–0.38)
(0.41–0.54)
(0.65–0.83)
(0.77–1)
(0.48–0.62)
(0.41–0.53)
(0.36–0.46)
(0.29–0.37)
(0.78–1)
(0.67–0.86)
(0.53–0.69)
(0.34–0.44)
(0.33–0.43)
(0.52–0.68)
(0.31–0.41)
RATE
24
24
23
19
16
15
14
49
33
19
12
9
8.2
7.4
33
47
71
72
73
73
73
22
20
16
13
9.5
7.3
5
110
110
110
110
110
110
110
80
81
74
72
72
71
70
18
16
14
12
8.8
8.7
8.7
94
84
63
52
51
50
50
46
46
46
46
43
41
40
64
53
41
28
24
23
21
5.4
5
4.3
4
4.2
4.3
4.4
22
21
16
11
8.4
7.6
6.8
7.7
10
12
7.9
6.8
6.3
6
30
51
64
41
35
30
25
18
15
12
7.4
7.2
11
6.7
(17–33)
(20–29)
(19–26)
(16–22)
(13–18)
(12–17)
(12–16)
(43–56)
(28–38)
(17–22)
(10–14)
(8.3–9.8)
(6.9–9.7)
(6.2–8.7)
(20–49)
(38–56)
(57–85)
(58–87)
(59–87)
(60–87)
(60–87)
(20–25)
(17–22)
(14–18)
(11–14)
(8.1–11)
(6.6–8.1)
(4.4–5.7)
(67–163)
(89–132)
(89–132)
(89–132)
(89–132)
(90–132)
(90–131)
(49–119)
(66–97)
(64–85)
(58–87)
(58–87)
(57–87)
(57–85)
(16–21)
(14–18)
(13–16)
(10–13)
(7.7–10)
(7.6–9.8)
(7.6–9.8)
(57–139)
(69–102)
(51–76)
(42–63)
(43–58)
(43–58)
(42–57)
(28–68)
(38–54)
(40–53)
(40–53)
(37–49)
(36–47)
(35–46)
(56–73)
(47–60)
(36–46)
(24–31)
(21–28)
(20–25)
(19–24)
(4.9–6)
(4.4–5.6)
(3.8–4.9)
(3.5–4.5)
(3.7–4.8)
(3.7–4.9)
(3.8–5)
(20–25)
(19–24)
(14–18)
(9.5–12)
(7.3–9.6)
(6.7–8.5)
(5.9–7.7)
(6.7–8.7)
(9.1–12)
(11–14)
(6.8–9)
(6–7.7)
(5.6–7.1)
(5.3–6.8)
(26–34)
(45–58)
(56–73)
(36–46)
(30–39)
(27–35)
(22–28)
(16–20)
(13–17)
(10–13)
(6.5–8.4)
(6.3–8.1)
(9.8–13)
(5.9–7.6)
European Region
MORTALITY (EXCLUDING HIV)
YEAR
Rates are per 100 000 population.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 187
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
187
05/10/11 09:03
7$%/($(VWLPDWHVRIWKHEXUGHQRIGLVHDVHFDXVHGE\7%±
MORTALITY (EXCLUDING HIV)
France
Georgia
Germany
Greece
Hungary
Iceland
Ireland
Israel
Italy
Kazakhstan
Kyrgyzstan
Latvia
Lithuania
Luxembourg
Malta
a
188
YEAR
POPULATION
(MILLIONS)
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
57
58
59
61
62
62
63
5
5
5
4
4
4
4
79
82
82
83
82
82
82
10
11
11
11
11
11
11
10
10
10
10
10
10
10
<1
<1
<1
<1
<1
<1
<1
4
4
4
4
4
4
4
4
5
6
7
7
7
7
57
57
57
59
60
60
61
17
16
15
15
16
16
16
4
5
5
5
5
5
5
3
2
2
2
2
2
2
4
4
4
3
3
3
3
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
NUMBER
(THOUSANDS)
0.88
0.84
0.69
0.46
0.38
0.46
0.45
1.1
0.78
0.3
0.28
0.24
0.21
0.2
0.89
0.73
0.51
0.33
0.21
0.22
0.2
0.15
0.17
0.092
0.098
0.086
0.094
0.081
0.36
0.44
0.36
0.19
0.12
0.12
0.13
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.046
0.034
0.036
0.016
0.018
0.024
0.022
0.019
0.025
0.037
0.024
0.015
0.019
0.017
0.45
0.51
0.47
0.38
0.34
0.29
0.26
6.8
6
5.4
4.6
3.5
2.8
3.6
1.6
1.4
0.82
1.1
0.84
0.79
1.4
0.82
0.53
0.32
0.19
0.12
0.1
0.074
1.1
0.69
0.39
0.38
0.36
0.28
0.37
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
(0.79–0.98)
(0.76–0.94)
(0.68–0.69)
(0.46–0.46)
(0.38–0.38)
(0.41–0.51)
(0.4–0.5)
(0.6–1.7)
(0.56–1)
(0.3–0.3)
(0.19–0.43)
(0.17–0.36)
(0.16–0.32)
(0.16–0.24)
(0.76–1.1)
(0.63–0.88)
(0.51–0.51)
(0.33–0.33)
(0.19–0.25)
(0.19–0.26)
(0.18–0.24)
(0.13–0.18)
(0.14–0.2)
(0.091–0.092)
(0.098–0.098)
(0.086–0.086)
(0.094–0.094)
(0.07–0.097)
(0.31–0.44)
(0.38–0.54)
(0.36–0.36)
(0.19–0.19)
(0.12–0.12)
(0.12–0.12)
(0.12–0.16)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.04–0.055)
(0.029–0.041)
(0.036–0.036)
(0.016–0.016)
(0.018–0.018)
(0.024–0.024)
(0.019–0.026)
(0.017–0.022)
(0.021–0.029)
(0.037–0.037)
(0.024–0.024)
(0.015–0.015)
(0.016–0.023)
(0.015–0.02)
(0.38–0.54)
(0.44–0.61)
(0.47–0.47)
(0.33–0.45)
(0.34–0.34)
(0.25–0.35)
(0.23–0.32)
(3.2–12)
(4.2–8.2)
(5.4–5.4)
(4.6–4.6)
(3.5–3.5)
(2.8–2.8)
(2.2–5.8)
(0.8–2.7)
(0.99–1.9)
(0.5–1.4)
(1.1–1.1)
(0.83–0.84)
(0.78–0.79)
(0.91–2)
(0.41–1.4)
(0.36–0.76)
(0.32–0.32)
(0.19–0.19)
(0.12–0.12)
(0.1–0.1)
(0.059–0.089)
(0.51–1.8)
(0.43–1)
(0.39–0.4)
(0.38–0.38)
(0.36–0.36)
(0.28–0.28)
(0.24–0.56)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
RATEa
1.5
1.5
1.2
<1
<1
<1
<1
20
15
6.4
6.3
5.4
4.8
4.6
1.1
<1
<1
<1
<1
<1
<1
1.5
1.6
<1
<1
<1
<1
<1
3.5
4.3
3.5
1.9
1.2
1.2
1.3
<1
<1
<1
<1
<1
<1
<1
1.3
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
41
38
36
30
22
18
23
36
30
17
21
16
15
26
31
21
13
8.2
5.2
4.4
3.3
29
19
11
11
11
8.3
11
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
(1.4–1.7)
(1.3–1.6)
(1.2–1.2)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(11–32)
(11–20)
(6.3–6.4)
(4.3–9.7)
(3.9–8.1)
(3.7–7.2)
(3.7–5.6)
(<1–1.3)
(<1–1.1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(1.3–1.8)
(1.3–1.9)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(3–4.2)
(3.7–5.2)
(3.5–3.6)
(1.9–1.9)
(1.2–1.2)
(1.2–1.2)
(1.2–1.6)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(1.1–1.6)
(<1–1.1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–1.1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(19–73)
(26–52)
(36–36)
(30–30)
(22–22)
(18–18)
(14–36)
(18–62)
(22–41)
(10–28)
(21–21)
(16–16)
(15–15)
(17–38)
(16–52)
(14–31)
(13–13)
(8.2–8.2)
(5.2–5.2)
(4.4–4.5)
(2.6–4)
(14–50)
(12–29)
(11–11)
(11–11)
(11–11)
(8.3–8.3)
(7.1–17)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
PREVALENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
15
15
10
7.9
8.6
7.8
7.7
12
9.9
6.5
5.8
5.3
5.2
5.1
22
18
14
8.1
4.9
5.4
4.8
1.3
1.3
1.1
0.91
0.77
0.7
0.65
5.2
6.4
4.3
2.5
2.1
1.9
1.9
0.024
0.018
0.014
0.012
0.02
0.017
0.017
0.93
0.69
0.58
0.57
0.52
0.49
0.43
0.48
0.7
0.66
0.65
0.53
0.52
0.41
6.4
6.7
6.7
4.9
4.6
4
3.6
42
38
37
46
36
35
32
12
12
9.7
11
12
12
13
4.8
3.7
2.7
2
1.4
1.2
0.97
6.4
5.1
3.8
3.3
3.1
3.1
3.1
0.052
0.06
0.057
0.059
0.053
0.053
0.052
0.024
0.028
0.023
0.032
0.056
0.058
0.062
(6.4–24)
(6.2–23)
(4.2–16)
(3.2–13)
(3.6–14)
(3.2–13)
(3.2–12)
(5–24)
(4.5–16)
(2.1–11)
(1.8–9.9)
(1.4–9.3)
(1.2–9)
(1.2–9.1)
(8.2–37)
(5.8–30)
(5–23)
(2.7–14)
(1.4–8.5)
(1.9–9.1)
(1.5–8.3)
(0.45–2.1)
(0.45–2.3)
(0.38–1.8)
(0.31–1.5)
(0.26–1.3)
(0.24–1.2)
(0.21–1.1)
(1.7–8.9)
(2.2–11)
(1.4–7.4)
(0.74–4.3)
(0.7–3.6)
(0.59–3.2)
(0.64–3.3)
(<0.01–0.041)
(<0.01–0.031)
(<0.01–0.025)
(<0.01–0.023)
(<0.01–0.038)
(<0.01–0.029)
(<0.01–0.029)
(0.31–1.6)
(0.23–1.2)
(0.19–0.99)
(0.2–0.96)
(0.18–0.88)
(0.17–0.83)
(0.14–0.74)
(0.15–0.81)
(0.29–1.1)
(0.2–1.1)
(0.26–1.1)
(0.19–0.88)
(0.2–0.86)
(0.11–0.71)
(2.4–11)
(2.1–12)
(2.7–11)
(1.5–8.5)
(1.8–7.7)
(1.4–6.7)
(1.3–6.2)
(16–83)
(17–64)
(12–65)
(17–80)
(12–63)
(12–60)
(11–55)
(4.8–24)
(5.3–19)
(3.1–17)
(4.2–19)
(4.7–20)
(4.9–21)
(5.5–22)
(1.9–9.4)
(1.6–6.2)
(0.86–4.6)
(0.63–3.3)
(0.44–2.3)
(0.35–2)
(0.25–1.7)
(2.5–13)
(2–8.6)
(1.2–6.5)
(1.1–5.7)
(1–5.3)
(1.1–5.3)
(1.1–5.3)
(0.012–0.093)
(0.023–0.098)
(0.02–0.098)
(0.024–0.098)
(0.017–0.091)
(0.016–0.09)
(0.015–0.089)
(<0.01–0.04)
(<0.01–0.046)
(<0.01–0.04)
(0.011–0.056)
(0.018–0.099)
(0.019–0.1)
(0.022–0.11)
INCIDENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
RATE
27
25
17
13
14
13
12
227
194
137
129
122
118
118
28
22
17
9.8
5.9
6.6
5.9
12
13
9.8
8.2
6.9
6.2
5.7
50
62
43
25
21
19
19
9.3
6.6
5
4
6.3
5.4
5.2
26
19
15
14
12
11
9.7
11
13
11
9.8
7.4
7.1
5.6
11
12
12
8.4
7.7
6.6
6
255
242
250
304
232
221
198
280
252
195
223
230
234
243
182
149
113
85
60
51
43
173
139
107
97
92
93
94
14
15
13
13
11
11
10
6.4
7.2
5.9
7.9
14
14
15
(11–43)
(11–40)
(7.1–27)
(5.3–21)
(5.8–22)
(5.1–20)
(5.1–20)
(92–434)
(89–318)
(44–237)
(39–221)
(32–211)
(28–207)
(27–209)
(10–47)
(7.1–37)
(6.1–28)
(3.3–17)
(1.7–10)
(2.3–11)
(1.9–10)
(4.4–21)
(4.2–22)
(3.5–16)
(2.8–14)
(2.3–12)
(2.1–11)
(1.9–9.8)
(16–85)
(21–105)
(13–73)
(7.4–43)
(7–36)
(5.9–32)
(6.4–33)
(3.1–16)
(2.1–11)
(1.4–8.9)
(<1–7.7)
(2.3–12)
(1.9–9.2)
(1.4–9.2)
(8.8–45)
(6.4–32)
(5.1–26)
(4.7–23)
(4–20)
(3.9–19)
(3–17)
(3.3–18)
(5.4–21)
(3.3–19)
(3.9–16)
(2.7–12)
(2.7–12)
(1.5–9.6)
(4.3–19)
(3.6–20)
(4.8–19)
(2.5–14)
(2.9–13)
(2.3–11)
(2.1–10)
(98–503)
(109–399)
(80–433)
(113–527)
(79–404)
(78–378)
(68–341)
(110–547)
(115–416)
(63–341)
(83–387)
(90–393)
(94–398)
(103–407)
(73–352)
(65–249)
(36–195)
(28–145)
(19–103)
(15–88)
(11–75)
(67–339)
(56–238)
(34–186)
(33–166)
(30–158)
(33–159)
(34–159)
(3.1–24)
(5.7–24)
(4.7–22)
(5.2–21)
(3.5–19)
(3.2–18)
(2.9–18)
(1.8–11)
(2.4–12)
(2–10)
(2.7–14)
(4.4–24)
(4.6–24)
(5.2–26)
11
11
7.6
6.1
6.4
6
5.9
5.8
5.4
5.1
4.8
4.7
4.7
4.6
17
14
10
6.4
4.2
4.2
4
0.97
1.1
0.84
0.72
0.61
0.56
0.52
4.1
5
3.5
2.1
1.6
1.5
1.5
0.019
0.015
0.012
0.012
0.014
0.015
0.016
0.73
0.55
0.47
0.45
0.42
0.39
0.36
0.39
0.5
0.56
0.49
0.42
0.39
0.37
4.9
5.7
5.1
4.3
3.5
3.2
2.9
23
22
29
33
27
26
24
6.3
6.5
7.5
8
8.3
8.4
8.5
2.5
2.3
2.2
1.6
1.2
1
0.89
3.4
3.4
3
2.5
2.4
2.3
2.3
0.044
0.044
0.044
0.043
0.044
0.045
0.045
0.02
0.024
0.02
0.027
0.048
0.05
0.05
(11–12)
(10–11)
(7.1–8)
(5.7–6.4)
(6–6.8)
(5.6–6.4)
(5.5–6.2)
(3.5–8.7)
(4.4–6.5)
(4.3–5.9)
(4.2–5.4)
(4.2–5.2)
(4.1–5.2)
(4.1–5.2)
(15–19)
(12–16)
(9.1–12)
(5.6–7.2)
(3.7–4.8)
(3.7–4.8)
(3.5–4.5)
(0.85–1.1)
(0.94–1.2)
(0.74–0.94)
(0.63–0.82)
(0.54–0.69)
(0.49–0.63)
(0.46–0.6)
(3.6–4.7)
(4.4–5.6)
(3.1–4)
(1.8–2.4)
(1.4–1.9)
(1.3–1.7)
(1.3–1.7)
(0.016–0.022)
(0.014–0.017)
(0.011–0.014)
(0.011–0.014)
(0.013–0.015)
(0.013–0.017)
(0.013–0.02)
(0.64–0.82)
(0.48–0.62)
(0.41–0.53)
(0.4–0.51)
(0.37–0.47)
(0.34–0.44)
(0.32–0.41)
(0.36–0.43)
(0.45–0.56)
(0.49–0.64)
(0.43–0.54)
(0.37–0.47)
(0.34–0.45)
(0.32–0.42)
(4.3–5.5)
(4.9–6.5)
(4.6–5.6)
(3.7–4.9)
(3.1–4.1)
(2.9–3.6)
(2.6–3.3)
(14–34)
(18–27)
(25–34)
(27–39)
(23–32)
(22–30)
(20–28)
(3.8–9.3)
(5.3–7.9)
(6.2–8.9)
(6.5–9.6)
(6.7–10)
(6.9–10)
(7–10)
(1.5–3.7)
(1.9–2.8)
(1.9–2.6)
(1.4–1.8)
(1–1.3)
(0.89–1.2)
(0.78–1)
(2.1–5.1)
(2.7–4)
(2.6–3.5)
(2.2–2.9)
(2–2.8)
(2–2.7)
(2–2.7)
(0.037–0.051)
(0.039–0.049)
(0.038–0.051)
(0.038–0.049)
(0.039–0.05)
(0.039–0.051)
(0.039–0.051)
(0.018–0.022)
(0.022–0.025)
(0.018–0.022)
(0.024–0.03)
(0.041–0.055)
(0.044–0.056)
(0.044–0.056)
RATE
20
19
13
9.9
10
9.6
9.3
107
107
107
107
107
107
107
21
17
13
7.7
5.1
5.1
4.8
9.6
10
7.6
6.4
5.4
4.9
4.6
40
48
35
21
16
15
15
7.4
5.7
4.4
4.1
4.5
4.8
5
21
15
12
11
9.6
8.8
8.1
8.7
9.5
9.4
7.4
5.9
5.4
4.9
8.6
10
8.9
7.3
5.9
5.4
4.9
139
139
196
215
175
163
151
143
143
151
158
159
159
159
92
93
92
69
51
45
39
92
92
86
74
71
70
69
11
11
10
9.5
9.1
9
8.8
5.5
6.1
5
6.5
11
12
12
(19–21)
(18–20)
(12–14)
(9.3–11)
(9.7–11)
(9–10)
(8.8–9.9)
(65–158)
(87–128)
(90–125)
(94–120)
(94–119)
(95–119)
(95–119)
(19–24)
(15–19)
(11–14)
(6.8–8.7)
(4.5–5.8)
(4.5–5.8)
(4.2–5.4)
(8.3–11)
(8.8–11)
(6.7–8.6)
(5.6–7.3)
(4.7–6.1)
(4.4–5.6)
(4–5.2)
(35–45)
(42–55)
(30–39)
(18–23)
(14–19)
(13–17)
(13–17)
(6.4–8.5)
(5.1–6.4)
(3.8–5.1)
(3.6–4.6)
(4.2–4.8)
(4.3–5.3)
(4.1–6.1)
(18–23)
(13–17)
(11–14)
(9.6–12)
(8.5–11)
(7.7–9.9)
(7.1–9.2)
(8–9.5)
(8.4–11)
(8.1–11)
(6.6–8.2)
(5.2–6.6)
(4.7–6.1)
(4.3–5.6)
(7.5–9.7)
(8.6–11)
(8–9.8)
(6.4–8.3)
(5.1–6.8)
(4.8–6)
(4.3–5.5)
(84–206)
(113–167)
(167–228)
(175–259)
(146–206)
(137–192)
(127–177)
(87–212)
(116–172)
(125–179)
(129–191)
(129–192)
(130–191)
(131–191)
(56–137)
(76–112)
(79–107)
(60–79)
(45–58)
(40–51)
(34–45)
(56–137)
(75–111)
(74–99)
(64–85)
(61–82)
(60–81)
(59–80)
(9.7–13)
(9.7–12)
(8.7–12)
(8.3–11)
(7.9–10)
(7.8–10)
(7.7–10)
(5–6.1)
(5.7–6.5)
(4.4–5.6)
(5.7–7.3)
(9.8–13)
(11–13)
(11–13)
Rates are per 100 000 population.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 188
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($(VWLPDWHVRIWKHEXUGHQRIGLVHDVHFDXVHGE\7%±
Monaco
Montenegro
Netherlands
Norway
Poland
Portugal
Republic of
Moldova
Romania
Russian
Federation
San Marino
Serbia
Serbia &
Montenegro
Slovakia
Slovenia
Spain
Sweden
Switzerland
a
1990
1995
2000
2005
2008
2009
2010
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
2005
2008
2009
2010
1990
1995
2000
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
POPULATION
(MILLIONS)
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
15
15
16
16
17
17
17
4
4
4
5
5
5
5
38
38
38
38
38
38
38
10
10
10
11
11
11
11
4
4
4
4
4
4
4
23
23
22
22
22
22
21
148
149
147
144
143
143
143
<1
<1
<1
<1
<1
<1
<1
10
10
10
10
10
11
11
5
5
5
5
5
5
5
2
2
2
2
2
2
2
39
39
40
43
45
46
46
9
9
9
9
9
9
9
7
7
7
7
8
8
8
NUMBER
(THOUSANDS)
RATEa
<0.01 (<0.01–<0.01)
<0.01 (<0.01–<0.01)
<0.01 (<0.01–<0.01)
<1 (<1–<1)
<1 (<1–<1)
<1 (<1–<1)
0.011
0.011
0.012
<0.01
0.041
0.051
0.034
0.034
0.026
0.038
0.031
0.01
<0.01
0.01
0.01
<0.01
<0.01
<0.01
1.7
1.6
1.1
0.87
0.87
0.79
0.78
0.45
0.37
0.3
0.19
0.16
0.16
0.16
1
0.75
0.84
0.8
0.68
0.7
0.83
3
2
2.2
1.8
1.6
1.5
1.5
68
51
33
34
27
25
26
<0.01
<0.01
<0.01
<0.01
(<0.01–0.021)
(<0.01–0.019)
(<0.01–0.018)
(<0.01–0.014)
(0.035–0.049)
(0.044–0.061)
(0.034–0.034)
(0.034–0.035)
(0.026–0.026)
(0.038–0.039)
(0.027–0.037)
(<0.01–0.012)
(<0.01–<0.01)
(0.01–0.011)
(0.01–0.011)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.01)
(1.4–2)
(1.4–2)
(1.1–1.1)
(0.86–0.87)
(0.87–0.87)
(0.79–0.8)
(0.67–0.94)
(0.38–0.54)
(0.31–0.46)
(0.3–0.3)
(0.16–0.23)
(0.16–0.16)
(0.16–0.16)
(0.13–0.2)
(0.51–1.7)
(0.52–1)
(0.84–0.85)
(0.79–0.8)
(0.67–0.68)
(0.7–0.7)
(0.55–1.2)
(1.4–5.5)
(1.3–3.1)
(2.2–2.2)
(1.8–1.8)
(1.6–1.7)
(1.5–1.5)
(1.5–1.5)
(36–110)
(35–70)
(33–33)
(34–34)
(27–27)
(25–25)
(16–42)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
1.8
1.8
1.9
1.4
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
4.4
4.3
2.9
2.3
2.3
2.1
2
4.5
3.7
2.9
1.8
1.5
1.5
1.5
23
17
21
21
19
19
23
13
9
9.8
8.2
7.6
7.1
7
46
34
22
23
19
17
18
<1
<1
<1
<1
(1.3–3.3)
(1.2–3.1)
(1.2–2.9)
(<1–2.2)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(3.8–5.3)
(3.7–5.2)
(2.9–2.9)
(2.3–2.3)
(2.3–2.3)
(2.1–2.1)
(1.8–2.4)
(3.8–5.4)
(3.1–4.5)
(2.9–2.9)
(1.6–2.2)
(1.5–1.5)
(1.5–1.5)
(1.2–1.9)
(12–39)
(12–24)
(20–21)
(21–21)
(19–19)
(19–19)
(15–33)
(6–24)
(5.6–14)
(9.7–9.8)
(8.2–8.2)
(7.6–7.7)
(7.1–7.1)
(7–7)
(24–75)
(24–47)
(22–22)
(23–24)
(19–19)
(17–17)
(11–29)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
0.29
0.17
0.17
0.14
0.49
0.49
0.34
0.099
0.11
0.055
0.048
0.043
0.043
0.026
0.063
0.044
0.018
0.017
0.029
0.024
0.016
0.39
0.45
0.41
0.36
0.26
0.34
0.32
0.027
0.026
0.019
0.015
0.018
0.019
0.026
0.057
0.036
0.034
0.022
0.02
0.021
0.021
(0.29–0.29)
(0.17–0.17)
(0.17–0.17)
(0.094–0.22)
(0.35–0.75)
(0.38–0.63)
(0.27–0.44)
(0.087–0.12)
(0.095–0.13)
(0.055–0.055)
(0.048–0.049)
(0.043–0.043)
(0.043–0.043)
(0.023–0.03)
(0.054–0.075)
(0.038–0.053)
(0.018–0.018)
(0.017–0.018)
(0.029–0.029)
(0.024–0.024)
(0.014–0.019)
(0.34–0.45)
(0.38–0.55)
(0.41–0.41)
(0.36–0.36)
(0.26–0.27)
(0.29–0.42)
(0.27–0.39)
(0.023–0.032)
(0.023–0.032)
(0.019–0.019)
(0.015–0.016)
(0.018–0.018)
(0.019–0.019)
(0.023–0.032)
(0.048–0.068)
(0.031–0.043)
(0.034–0.034)
(0.022–0.022)
(0.017–0.024)
(0.018–0.026)
(0.018–0.026)
3
1.8
1.7
1.4
4.8
4.5
3.2
1.9
2
1
<1
<1
<1
<1
3.3
2.3
<1
<1
1.5
1.2
<1
<1
1.1
1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
(2.9–3)
(1.8–1.8)
(1.7–1.7)
(<1–2.3)
(3.4–7.4)
(3.5–5.8)
(2.5–4.1)
(1.7–2.2)
(1.8–2.5)
(1–1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(2.8–3.9)
(2–2.7)
(<1–<1)
(<1–<1)
(1.5–1.5)
(1.2–1.2)
(<1–<1)
(<1–1.2)
(<1–1.4)
(1–1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
PREVALENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.19
0.17
0.17
0.14
1.9
2.4
1.9
1.6
1.4
1.5
1.5
0.44
0.34
0.36
0.41
0.39
0.39
0.37
24
24
16
12
11
11
11
9
7.7
5.4
4.1
3.7
3.4
3.4
9.8
8.3
9.4
8.5
9.1
9.6
9.9
61
49
54
52
41
38
34
330
270
250
210
200
190
190
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
4
4.1
2.4
2.2
9
9.6
6
2.1
2.4
1.5
1.1
0.7
0.63
0.52
0.45
0.16
0.1
0.17
0.31
0.26
0.28
9.6
12
11
10
9
9.1
8.4
0.82
0.82
0.61
0.8
0.65
0.74
0.83
2
1.2
0.76
0.74
0.66
0.73
0.72
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.047–0.35)
(0.048–0.31)
(0.054–0.29)
(0.041–0.25)
(0.63–3.3)
(0.8–4.1)
(0.63–3.2)
(0.54–2.8)
(0.46–2.4)
(0.49–2.5)
(0.5–2.5)
(0.16–0.74)
(0.12–0.58)
(0.12–0.6)
(0.14–0.69)
(0.14–0.66)
(0.14–0.65)
(0.12–0.63)
(7.8–40)
(8–40)
(5.2–27)
(4–20)
(3.6–18)
(3.8–19)
(3.7–19)
(3.2–15)
(2.8–13)
(1.8–9.2)
(1.5–6.7)
(1.4–6.3)
(1.2–5.9)
(1.2–5.9)
(3.9–19)
(3.7–14)
(4.3–16)
(3–15)
(3.8–16)
(4.1–16)
(4.3–16)
(23–120)
(20–83)
(21–92)
(20–88)
(16–70)
(15–66)
(12–59)
(130–620)
(120–460)
(97–440)
(75–360)
(68–340)
(71–330)
(70–330)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(1.1–6.9)
(1.5–6.8)
(0.64–4.2)
(0.67–3.8)
(3–18)
(4.2–16)
(2.1–10)
(0.63–3.6)
(0.78–4)
(0.52–2.6)
(0.42–1.9)
(0.2–1.2)
(0.19–1.1)
(0.15–0.91)
(0.15–0.93)
(0.028–0.45)
(0.015–0.29)
(0.056–0.35)
(0.11–0.53)
(0.08–0.45)
(0.091–0.47)
(2.9–17)
(4.5–20)
(4.1–19)
(3.8–17)
(3.1–15)
(3.3–15)
(2.8–14)
(0.29–1.4)
(0.29–1.4)
(0.2–1)
(0.3–1.3)
(0.2–1.1)
(0.25–1.3)
(0.3–1.4)
(0.74–3.2)
(0.43–2)
(0.22–1.3)
(0.26–1.2)
(0.23–1.1)
(0.26–1.2)
(0.25–1.2)
RATE
7
5.9
3.2
<1
<1
<1
<1
31
27
27
23
13
16
12
9.9
8.5
8.9
9
10
7.9
7.9
8.9
8.2
8
7.5
62
61
41
31
28
29
29
91
76
52
39
35
32
32
224
191
229
226
251
267
277
261
215
242
237
191
177
159
220
185
174
144
137
136
136
6.1
15
8.9
<1
<1
<1
<1
40
41
25
22
89
89
56
39
44
28
21
13
11
9.6
23
8.3
5
8.5
16
13
14
25
31
28
23
20
20
18
9.6
9.3
6.9
8.8
7
8
8.8
29
17
11
9.9
8.7
9.5
9.4
(3.3–11)
(2.7–9.3)
(<1–5.6)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(7.5–55)
(7.7–49)
(8.6–46)
(6.5–39)
(4.2–22)
(5.2–27)
(3.9–20)
(3.3–17)
(2.8–14)
(3–15)
(3–15)
(3.7–18)
(2.8–13)
(2.8–13)
(3.1–15)
(2.9–14)
(2.8–13)
(2.5–13)
(20–105)
(21–104)
(13–71)
(10–53)
(9.3–48)
(9.9–49)
(9.8–49)
(33–154)
(28–129)
(18–89)
(14–64)
(13–59)
(11–55)
(12–55)
(90–435)
(85–317)
(104–378)
(81–391)
(104–427)
(114–448)
(121–459)
(101–517)
(86–365)
(95–413)
(93–405)
(74–326)
(68–304)
(58–275)
(89–420)
(82–306)
(66–300)
(52–250)
(48–239)
(50–232)
(49–233)
(2.1–11)
(6.9–24)
(4.2–14)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(11–70)
(15–69)
(6.5–43)
(6.8–38)
(29–176)
(39–149)
(20–97)
(12–68)
(15–75)
(9.5–48)
(7.7–34)
(3.7–22)
(3.5–20)
(2.7–17)
(7.6–48)
(1.4–23)
(<1–15)
(2.8–18)
(5.5–26)
(4–22)
(4.5–23)
(7.3–43)
(11–52)
(10–46)
(8.9–39)
(6.9–33)
(7.2–34)
(6.2–31)
(3.4–16)
(3.3–16)
(2.3–12)
(3.3–15)
(2.2–12)
(2.7–14)
(3.2–15)
(11–49)
(6.1–29)
(3.1–18)
(3.4–17)
(3–15)
(3.4–16)
(3.3–16)
INCIDENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
RATE
<0.01 (<0.01–<0.01)
<0.01 (<0.01–<0.01)
<0.01 (<0.01–<0.01)
3.7 (3.2–4.2)
3.5 (3–3.9)
<1 (<1–<1)
0.17
0.14
0.13
0.12
1.5
1.9
1.5
1.3
1.1
1.2
1.2
0.34
0.27
0.28
0.32
0.31
0.3
0.3
19
18
13
9.5
8.7
8.7
8.8
7.1
6.4
4.9
3.8
3.2
3.1
3.1
5
4.9
5.6
6.2
6.3
6.4
6.5
33
33
37
36
29
27
25
160
160
180
150
150
150
150
<0.01
<0.01
<0.01
(0.16–0.2)
(0.13–0.17)
(0.12–0.15)
(0.1–0.14)
(1.3–1.7)
(1.7–2.2)
(1.4–1.7)
(1.1–1.5)
(1–1.3)
(1–1.4)
(1.1–1.4)
(0.3–0.38)
(0.24–0.3)
(0.25–0.31)
(0.28–0.36)
(0.27–0.35)
(0.26–0.34)
(0.26–0.33)
(16–21)
(16–21)
(11–14)
(8.3–11)
(7.6–9.8)
(7.6–9.9)
(7.7–10)
(6.3–8.1)
(5.6–7.3)
(4.3–5.5)
(3.3–4.3)
(2.8–3.7)
(2.7–3.5)
(2.7–3.6)
(3–7.4)
(4–5.9)
(4.6–6.7)
(5.1–7.4)
(5.2–7.7)
(5.2–7.7)
(5.3–7.8)
(20–49)
(26–39)
(30–45)
(29–43)
(24–35)
(22–32)
(20–30)
(97–240)
(130–190)
(140–220)
(130–180)
(130–180)
(130–180)
(130–180)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
27
23
21
19
10
13
9.6
8
6.9
7.2
7.3
8
6.2
6.2
6.9
6.4
6.2
6
49
48
33
25
23
23
23
72
63
47
36
30
29
29
114
114
136
164
175
178
182
143
143
167
164
134
125
116
107
107
122
107
107
106
106
4.8
9
4.3
(25–32)
(21–27)
(18–24)
(17–22)
(9–12)
(11–14)
(8.5–11)
(7–9.1)
(6–7.8)
(6.2–8.2)
(6.4–8.2)
(7–9)
(5.4–7)
(5.5–6.9)
(6.1–7.8)
(5.7–7.2)
(5.5–7)
(5.3–6.9)
(43–55)
(42–54)
(29–37)
(22–28)
(20–26)
(20–26)
(20–26)
(63–81)
(56–72)
(41–53)
(32–41)
(27–34)
(26–33)
(26–33)
(69–169)
(92–137)
(111–164)
(136–195)
(142–211)
(146–214)
(149–218)
(87–213)
(117–173)
(136–202)
(134–198)
(109–161)
(102–150)
(95–138)
(65–160)
(87–129)
(99–147)
(88–128)
(89–126)
(89–125)
(90–124)
(4.1–5.4)
(7.8–10)
(3.7–4.8)
(3.2–4.1)
(2.7–3.5)
(1.9–2.4)
(1.6–2.1)
(4–8.4)
(4.7–7)
(3.5–5.2)
(1.5–1.9)
(1.6–2.1)
(1–1.3)
(0.7–0.91)
(0.55–0.71)
(0.47–0.6)
(0.38–0.5)
(0.73–0.94)
(0.53–0.68)
(0.37–0.48)
(0.27–0.35)
(0.21–0.27)
(0.19–0.24)
(0.19–0.24)
(7.7–9.9)
(8.8–11)
(8.1–10)
(7.3–9.5)
(6.8–8.8)
(6.7–8.7)
(6.4–8.3)
(0.55–0.71)
(0.54–0.71)
(0.43–0.55)
(0.5–0.65)
(0.47–0.61)
(0.51–0.66)
(0.56–0.72)
(1.3–1.7)
(0.84–1.1)
(0.58–0.74)
(0.52–0.67)
(0.47–0.6)
(0.51–0.65)
(0.51–0.66)
34
31
21
18
59
53
40
32
34
22
15
12
9.7
8
43
31
21
15
12
11
11
22
26
23
19
17
17
16
7.3
7.1
5.5
6.3
5.8
6.2
6.8
22
14
9.2
8
7
7.6
7.6
(33–41)
(28–36)
(19–25)
(16–21)
(39–83)
(43–64)
(32–48)
(28–36)
(30–39)
(19–25)
(13–17)
(10–13)
(8.6–11)
(7–9.1)
(38–49)
(27–35)
(19–24)
(14–17)
(10–13)
(9.3–12)
(9.3–12)
(20–25)
(22–29)
(20–26)
(17–22)
(15–20)
(15–19)
(14–18)
(6.4–8.3)
(6.2–8)
(4.9–6.2)
(5.5–7.3)
(5.1–6.6)
(5.5–7.1)
(5.9–7.7)
(19–25)
(12–15)
(8–10)
(7–9)
(6.1–7.9)
(6.6–8.6)
(6.7–8.6)
3.4
3
2.1
1.8
6
5.8
4.3
1.7
1.8
1.2
0.8
0.63
0.53
0.44
0.83
0.6
0.42
0.31
0.24
0.21
0.21
8.7
10
9.2
8.4
7.8
7.7
7.3
0.63
0.62
0.49
0.57
0.54
0.58
0.63
1.5
0.95
0.66
0.59
0.53
0.58
0.58
European Region
MORTALITY (EXCLUDING HIV)
YEAR
Rates are per 100 000 population.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 189
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
189
05/10/11 09:03
7$%/($(VWLPDWHVRIWKHEXUGHQRIGLVHDVHFDXVHGE\7%±
MORTALITY (EXCLUDING HIV)
YEAR
Tajikistan
1990
1995
2000
2005
2008
2009
2010
The Former
1990
Yugoslav Republic 1995
of Macedonia
2000
2005
2008
2009
2010
Turkey
1990
1995
2000
2005
2008
2009
2010
Turkmenistan
1990
1995
2000
2005
2008
2009
2010
Ukraine
1990
1995
2000
2005
2008
2009
2010
United Kingdom of 1990
Great Britain and 1995
Northern Ireland
2000
2005
2008
2009
2010
Uzbekistan
1990
1995
2000
2005
2008
2009
2010
a
190
POPULATION
(MILLIONS)
5
6
6
6
7
7
7
2
2
2
2
2
2
2
54
59
64
68
71
72
73
4
4
5
5
5
5
5
52
51
49
47
46
46
45
57
58
59
60
61
62
62
21
23
25
26
27
27
27
NUMBER
(THOUSANDS)
0.97
1.3
1.7
2.4
2.6
2.7
2.8
0.13
0.24
0.12
0.051
0.049
0.052
0.042
3.6
5.2
4.3
2.3
2.2
2.3
2.2
0.65
0.8
1.2
0.9
0.88
0.86
1
6.1
7
12
12
11
8.7
8.6
0.34
0.36
0.36
0.39
0.38
0.35
0.4
4.9
5.1
4.5
3.9
5
5.3
5.4
(0.46–1.7)
(0.98–1.6)
(1.3–2.1)
(1.8–3.2)
(1.8–3.6)
(2–3.6)
(2.1–3.7)
(0.11–0.16)
(0.15–0.35)
(0.12–0.12)
(0.04–0.065)
(0.035–0.079)
(0.035–0.084)
(0.03–0.069)
(1.7–7.1)
(3.5–7.5)
(2.9–6.3)
(1.4–3.8)
(1.3–3.7)
(1.3–3.7)
(1.3–3.6)
(0.48–1.2)
(0.52–1.3)
(0.89–1.8)
(0.68–1.4)
(0.71–1.1)
(0.69–1)
(0.7–1.9)
(2.9–12)
(4.1–12)
(12–12)
(12–12)
(11–11)
(8.7–8.7)
(5.2–12)
(0.31–0.38)
(0.33–0.4)
(0.32–0.4)
(0.39–0.39)
(0.38–0.39)
(0.35–0.35)
(0.36–0.45)
(2.5–8.1)
(3.8–6.6)
(4.5–4.5)
(3.9–3.9)
(3.6–6.8)
(3.9–7.1)
(3.9–7.1)
RATEa
18
22
27
38
39
40
41
6.9
12
5.9
2.5
2.4
2.5
2
6.6
8.9
6.8
3.3
3.1
3.2
3.1
18
19
27
19
18
17
20
12
14
24
26
23
19
19
<1
<1
<1
<1
<1
<1
<1
24
22
18
15
19
20
20
(8.6–33)
(17–28)
(21–34)
(27–50)
(27–53)
(29–52)
(31–53)
(5.5–8.3)
(7.8–18)
(5.8–5.9)
(2–3.2)
(1.7–3.8)
(1.7–4.1)
(1.4–3.4)
(3.2–13)
(5.9–13)
(4.5–9.9)
(2–5.5)
(1.8–5.2)
(1.9–5.2)
(1.8–5)
(13–34)
(12–31)
(20–40)
(14–29)
(14–22)
(14–21)
(14–37)
(5.7–23)
(8.1–23)
(24–24)
(26–27)
(23–23)
(19–19)
(11–27)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(12–40)
(16–29)
(18–18)
(15–15)
(13–26)
(14–26)
(14–26)
PREVALENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
9.1
11
15
23
25
25
26
1.7
1.8
1.2
0.67
0.58
0.56
0.5
27
34
29
19
18
18
18
2.7
2.7
4.7
3.7
3.8
3.7
3.9
29
35
52
58
61
61
60
8.1
8.7
8.6
11
9.4
9.5
9.6
52
56
57
52
60
62
62
(3.6–18)
(5.1–18)
(7–24)
(10–37)
(11–41)
(12–41)
(12–43)
(0.39–3.1)
(0.76–3)
(0.47–2.1)
(0.15–1.2)
(0.15–1)
(0.16–0.97)
(0.12–0.88)
(10–52)
(15–57)
(13–48)
(7.4–32)
(7–31)
(7.2–31)
(7.2–30)
(0.6–4.6)
(0.81–4.7)
(1.2–8.3)
(0.86–6.5)
(0.85–6.7)
(0.82–6.6)
(0.96–6.9)
(9.1–55)
(12–61)
(18–90)
(20–100)
(23–100)
(24–100)
(25–100)
(2.7–14)
(3–14)
(3–14)
(4.1–18)
(3.2–16)
(3.3–16)
(3.3–16)
(21–100)
(26–92)
(26–93)
(22–87)
(27–98)
(28–100)
(29–100)
INCIDENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
RATE
172
191
243
349
367
370
382
91
92
60
33
28
27
24
51
58
45
28
25
25
24
73
65
105
78
77
75
77
56
69
106
124
132
133
132
14
15
15
19
15
15
15
256
244
229
201
223
228
227
(67–340)
(88–312)
(113–394)
(162–575)
(168–610)
(171–606)
(177–619)
(20–162)
(39–155)
(23–104)
(7.3–58)
(7.2–49)
(7.8–47)
(6–42)
(18–96)
(25–97)
(20–76)
(11–47)
(9.9–43)
(10–43)
(9.9–41)
(16–126)
(19–113)
(26–184)
(18–137)
(17–137)
(17–132)
(19–137)
(18–107)
(24–120)
(37–185)
(44–215)
(50–227)
(52–225)
(54–223)
(4.8–24)
(5.2–25)
(5.1–24)
(6.8–30)
(5.2–26)
(5.4–25)
(5.4–26)
(103–496)
(112–401)
(104–376)
(85–337)
(101–367)
(105–373)
(104–371)
4.9
5.3
7.7
12
13
14
14
1.5
1.1
0.83
0.6
0.5
0.46
0.43
31
34
29
23
21
21
21
2.4
2.2
4.2
3.3
3.3
3.3
3.3
21
27
41
47
47
46
46
6.6
7
6.9
8.9
7.9
7.7
7.9
26
29
32
33
34
35
35
(3–7.3)
(4.3–6.4)
(6.4–9.2)
(9.7–15)
(11–16)
(11–17)
(12–17)
(0.94–2.3)
(0.92–1.4)
(0.68–1)
(0.54–0.67)
(0.43–0.57)
(0.4–0.53)
(0.37–0.5)
(22–43)
(28–41)
(24–35)
(19–27)
(17–26)
(17–25)
(17–25)
(1.9–2.9)
(1.9–2.5)
(3.7–4.6)
(2.9–3.7)
(2.7–4)
(2.7–4)
(2.7–4)
(15–29)
(22–32)
(33–49)
(39–56)
(38–56)
(38–55)
(38–55)
(6.2–7.1)
(6.5–7.4)
(6.5–7.4)
(8.3–9.5)
(7.4–8.4)
(7.2–8.3)
(7.4–8.4)
(16–39)
(24–35)
(26–38)
(27–40)
(28–41)
(28–42)
(29–42)
RATE
93
91
125
187
202
204
206
81
58
41
30
24
23
21
58
58
46
33
30
29
28
64
52
92
70
68
67
66
41
52
84
101
102
101
101
12
12
12
15
13
13
13
128
128
128
128
128
128
128
(56–138)
(74–110)
(103–149)
(150–227)
(165–243)
(167–245)
(169–247)
(49–120)
(47–70)
(34–50)
(27–33)
(21–28)
(19–26)
(18–24)
(40–79)
(47–70)
(38–56)
(28–40)
(25–36)
(24–35)
(23–34)
(50–80)
(45–61)
(82–103)
(61–79)
(55–82)
(54–81)
(54–80)
(28–56)
(43–62)
(68–101)
(83–120)
(83–122)
(83–121)
(84–121)
(11–12)
(11–13)
(11–13)
(14–16)
(12–14)
(12–13)
(12–14)
(78–190)
(104–154)
(104–154)
(104–154)
(104–154)
(105–153)
(105–153)
Rates are per 100 000 population.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 190
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($,QFLGHQFHQRWLILFDWLRQDQGFDVHGHWHFWLRQUDWHVDOOIRUPV±
YEAR
Albania
Andorra
Armenia
Austria
Azerbaijan
Belarus
Belgium
Bosnia and
Herzegovina
Bulgaria
Croatia
Cyprus
Czech Republic
Denmark
Estonia
POPULATION
(MILLIONS)
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
3
3
3
3
3
3
3
<1
<1
<1
<1
<1
<1
<1
4
3
3
3
3
3
3
8
8
8
8
8
8
8
7
8
8
9
9
9
9
10
10
10
10
10
10
10
10
10
10
10
11
11
11
4
3
4
4
4
4
4
9
8
8
8
8
8
7
5
5
5
4
4
4
4
<1
<1
<1
1
1
1
1
10
10
10
10
10
10
10
5
5
5
5
5
6
6
2
1
1
1
1
1
1
0.8
0.77
0.7
0.59
0.5
0.47
0.45
0.026
0.021
0.013
<0.01
<0.01
<0.01
<0.01
1.2
1.5
2.2
2.2
2.2
2.2
2.3
1.7
1.6
1.3
1
0.79
0.61
0.42
7.9
8.5
8.9
9.4
9.8
9.9
10
8.2
8.3
7.5
7
6.9
6.9
6.8
1.8
1.6
1.5
1.2
0.93
0.93
0.93
4
2.8
2.3
2
1.9
1.9
1.9
4.1
3.9
3.7
3.5
3.2
3.1
3
2.9
2.5
1.8
1.2
1.1
0.99
0.94
0.041
0.042
0.041
0.041
0.045
0.047
0.049
2.3
2.2
1.7
1.1
0.88
0.79
0.71
0.39
0.54
0.65
0.43
0.38
0.35
0.33
0.47
0.74
0.88
0.55
0.47
0.41
0.33
(0.57–1.1)
(0.64–0.91)
(0.59–0.81)
(0.5–0.69)
(0.42–0.58)
(0.4–0.55)
(0.38–0.52)
(0.023–0.029)
(0.018–0.024)
(0.011–0.014)
(<0.01–0.011)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.71–1.7)
(1.2–1.8)
(1.8–2.6)
(1.8–2.7)
(1.8–2.7)
(1.8–2.7)
(1.9–2.7)
(1.5–1.9)
(1.3–1.8)
(1.1–1.5)
(0.91–1.2)
(0.68–0.91)
(0.55–0.68)
(0.37–0.48)
(4.8–12)
(6.9–10)
(7.2–11)
(7.7–11)
(8–12)
(8.1–12)
(8.3–12)
(5–12)
(6.7–10)
(6.4–8.6)
(5.7–8.5)
(5.6–8.4)
(5.5–8.4)
(5.5–8.2)
(1.6–2.1)
(1.4–1.8)
(1.3–1.7)
(1.1–1.4)
(0.82–1.1)
(0.81–1)
(0.82–1.1)
(2.5–6)
(2.3–3.4)
(1.9–2.8)
(1.6–2.4)
(1.6–2.2)
(1.6–2.2)
(1.6–2.2)
(2.5–6)
(3.2–4.6)
(3.2–4.2)
(3.1–4.1)
(2.8–3.7)
(2.7–3.6)
(2.6–3.5)
(2.5–3.3)
(2.2–2.8)
(1.6–2.1)
(1.1–1.4)
(0.94–1.2)
(0.88–1.1)
(0.83–1.1)
(0.037–0.046)
(0.037–0.048)
(0.036–0.046)
(0.036–0.046)
(0.039–0.052)
(0.041–0.054)
(0.042–0.055)
(2–2.6)
(1.9–2.5)
(1.5–1.9)
(0.97–1.3)
(0.76–1)
(0.7–0.89)
(0.62–0.81)
(0.34–0.45)
(0.48–0.61)
(0.57–0.74)
(0.37–0.49)
(0.33–0.43)
(0.31–0.39)
(0.29–0.38)
(0.41–0.54)
(0.65–0.83)
(0.77–1)
(0.48–0.62)
(0.41–0.53)
(0.36–0.46)
(0.29–0.37)
RATEb
24
24
23
19
16
15
14
49
33
19
12
9
8.2
7.4
33
47
71
72
73
73
73
22
20
16
13
9.5
7.3
5
110
110
110
110
110
110
110
80
81
74
72
72
71
70
18
16
14
12
8.8
8.7
8.7
94
84
63
52
51
50
50
46
46
46
46
43
41
40
64
53
41
28
24
23
21
5.4
5
4.3
4
4.2
4.3
4.4
22
21
16
11
8.4
7.6
6.8
7.7
10
12
7.9
6.8
6.3
6
30
51
64
41
35
30
25
(17–33)
(20–29)
(19–26)
(16–22)
(13–18)
(12–17)
(12–16)
(43–56)
(28–38)
(17–22)
(10–14)
(8.3–9.8)
(6.9–9.7)
(6.2–8.7)
(20–49)
(38–56)
(57–85)
(58–87)
(59–87)
(60–87)
(60–87)
(20–25)
(17–22)
(14–18)
(11–14)
(8.1–11)
(6.6–8.1)
(4.4–5.7)
(67–163)
(89–132)
(89–132)
(89–132)
(89–132)
(90–132)
(90–131)
(49–119)
(66–97)
(64–85)
(58–87)
(58–87)
(57–87)
(57–85)
(16–21)
(14–18)
(13–16)
(10–13)
(7.7–10)
(7.6–9.8)
(7.6–9.8)
(57–139)
(69–102)
(51–76)
(42–63)
(43–58)
(43–58)
(42–57)
(28–68)
(38–54)
(40–53)
(40–53)
(37–49)
(36–47)
(35–46)
(56–73)
(47–60)
(36–46)
(24–31)
(21–28)
(20–25)
(19–24)
(4.9–6)
(4.4–5.6)
(3.8–4.9)
(3.5–4.5)
(3.7–4.8)
(3.7–4.9)
(3.8–5)
(20–25)
(19–24)
(14–18)
(9.5–12)
(7.3–9.6)
(6.7–8.5)
(5.9–7.7)
(6.7–8.7)
(9.1–12)
(11–14)
(6.8–9)
(6–7.7)
(5.6–7.1)
(5.3–6.8)
(26–34)
(45–58)
(56–73)
(36–46)
(30–39)
(27–35)
(22–28)
INCIDENCE HIV-POSITIVE
NUMBER
(THOUSANDS)
NOTIFIED NEW AND RELAPSEa
RATEb
<0.01
<0.01
0.02
0.024
0.028
0.029
0.031
<0.01
0.012
0.022
0.035
0.035
0.029
0.021
0.011
0.018
0.038
0.079
0.11
0.12
0.14
<0.01
0.019
0.069
0.15
0.21
0.23
0.25
0.027
0.059
0.077
0.074
0.063
0.059
0.055
(<0.01–<0.01)
(<0.01–<0.01)
(0.012–0.031)
(0.014–0.036)
(0.016–0.043)
(0.017–0.045)
(0.017–0.049)
(<0.01–<0.01)
(<0.01–0.023)
(0.012–0.035)
(0.021–0.052)
(0.02–0.055)
(0.019–0.04)
(0.013–0.031)
(<0.01–0.024)
(<0.01–0.034)
(0.015–0.073)
(0.042–0.13)
(0.059–0.18)
(0.066–0.2)
(0.074–0.22)
(<0.01–<0.01)
(<0.01–0.039)
(0.039–0.11)
(0.087–0.22)
(0.17–0.25)
(0.17–0.3)
(0.2–0.31)
(0.012–0.047)
(0.032–0.093)
(0.045–0.12)
(0.055–0.095)
(0.048–0.08)
(0.037–0.085)
(0.033–0.081)
<1
<1
<1
<1
<1
<1
1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
1.2
1.4
1.5
<1
<1
<1
1.5
2.2
2.4
2.6
<1
<1
<1
<1
<1
<1
<1
(<1–<1)
(<1–<1)
(<1–1)
(<1–1.2)
(<1–1.4)
(<1–1.5)
(<1–1.6)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–1.5)
(<1–2)
(<1–2.2)
(<1–2.4)
(<1–<1)
(<1–<1)
(<1–1.1)
(<1–2.3)
(1.8–2.6)
(1.8–3.1)
(2–3.3)
(<1–<1)
(<1–<1)
(<1–1.2)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.011)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.012)
(<0.01–0.01)
(<0.01–0.011)
(<0.01–<0.01)
(<0.01–0.011)
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.016
0.014
0.018
0.017
0.015
<0.01
<0.01
0.038
0.038
0.049
0.042
0.034
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.011)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.014)
(<0.01–0.025)
(<0.01–0.022)
(<0.01–0.034)
(<0.01–0.028)
(<0.01–0.022)
(<0.01–<0.01)
(<0.01–0.013)
(0.024–0.054)
(0.026–0.053)
(0.037–0.064)
(0.03–0.057)
(0.025–0.044)
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
2.7
2.9
3.7
3.2
2.5
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(1.7–4)
(2–3.9)
(2.7–4.8)
(2.2–4.3)
(1.9–3.3)
a
Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
b
Rates are per 100 000 population.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 191
NUMBER
RATEb
653
641
604
506
427
435
431
23
20
20
20
16
13
14
13
44
12
10
4
8
7
590
1 157
1 333
2 206
1 655
1 560
1 410
1 521
1 481
1 185
928
19
13
5
10
8
17
36
43
72
54
51
46
20
19
15
11
441
358
2 620
1 630
5 187
6 034
6 417
7 301
6 390
3 039
4 854
6 799
5 308
5 126
5 250
5 003
1 577
1 380
1 278
1 076
811
806
810
4 073
2 132
2 476
2 111
1 713
1 725
1 321
2 256
3 245
3 349
3 225
2 944
2 683
2 412
2 576
2 114
1 630
1 050
980
832
688
29
36
33
34
42
43
44
1 937
1 834
1 414
973
807
638
641
350
448
587
395
330
294
295
423
624
791
479
401
361
283
5
4
36
21
64
70
72
81
70
30
47
68
54
53
54
52
16
14
13
10
8
8
8
95
64
67
56
45
46
35
26
39
42
42
39
36
32
57
45
36
24
22
19
16
4
4
3
3
4
4
4
19
18
14
10
8
6
6
7
9
11
7
6
5
5
27
43
58
36
30
27
21
CASE DETECTION RATEa
PERCENT
81
84
87
86
86
93
97
89
–
95
108
54
117
112
50
77
61
100
74
69
62
89
95
92
89
–
72
84
33
19
58
64
65
73
63
37
59
91
76
74
76
74
87
87
87
87
87
87
87
101
76
107
107
90
91
71
56
84
91
91
91
86
79
89
85
89
85
91
84
73
70
85
81
82
93
92
89
85
83
85
88
92
81
90
89
83
90
93
88
84
88
89
85
90
87
86
88
85
(61–114)
(71–101)
(74–103)
(74–102)
(74–102)
(80–110)
(83–114)
(78–102)
(83–110)
(93–127)
(50–58)
(99–139)
(95–132)
(34–83)
(64–95)
(51–75)
(83–123)
(61–91)
(58–85)
(52–76)
(78–101)
(83–110)
(81–106)
(78–102)
(65–80)
(75–96)
(22–54)
(16–24)
(48–72)
(53–79)
(54–80)
(61–90)
(53–77)
(25–61)
(49–72)
(79–106)
(62–94)
(61–91)
(63–95)
(61–92)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(68–166)
(63–93)
(89–131)
(89–132)
(78–105)
(79–107)
(61–83)
(37–91)
(71–101)
(79–105)
(79–105)
(79–105)
(75–99)
(70–92)
(78–101)
(76–97)
(78–101)
(76–97)
(80–104)
(74–95)
(64–83)
(63–78)
(75–97)
(72–92)
(73–93)
(81–107)
(80–105)
(79–102)
(75–96)
(74–95)
(75–97)
(77–100)
(81–106)
(72–91)
(79–103)
(78–102)
(74–94)
(79–104)
(81–107)
(78–100)
(75–96)
(78–101)
(79–102)
(75–96)
(79–103)
(77–99)
(76–98)
(78–101)
(76–97)
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
European Region
INCIDENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
191
05/10/11 09:03
7$%/($,QFLGHQFHQRWLILFDWLRQDQGFDVHGHWHFWLRQUDWHVDOOIRUPV±
INCIDENCE (INCLUDING HIV)
YEAR
Finland
France
Georgia
Germany
Greece
Hungary
Iceland
Ireland
Israel
Italy
Kazakhstan
Kyrgyzstan
Latvia
Lithuania
192
POPULATION
(MILLIONS)
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
5
5
5
5
5
5
5
57
58
59
61
62
62
63
5
5
5
4
4
4
4
79
82
82
83
82
82
82
10
11
11
11
11
11
11
10
10
10
10
10
10
10
<1
<1
<1
<1
<1
<1
<1
4
4
4
4
4
4
4
4
5
6
7
7
7
7
57
57
57
59
60
60
61
17
16
15
15
16
16
16
4
5
5
5
5
5
5
3
2
2
2
2
2
2
4
4
4
3
3
3
3
NUMBER
(THOUSANDS)
0.89
0.76
0.61
0.39
0.38
0.6
0.36
11
11
7.6
6.1
6.4
6
5.9
5.8
5.4
5.1
4.8
4.7
4.7
4.6
17
14
10
6.4
4.2
4.2
4
0.97
1.1
0.84
0.72
0.61
0.56
0.52
4.1
5
3.5
2.1
1.6
1.5
1.5
0.019
0.015
0.012
0.012
0.014
0.015
0.016
0.73
0.55
0.47
0.45
0.42
0.39
0.36
0.39
0.5
0.56
0.49
0.42
0.39
0.37
4.9
5.7
5.1
4.3
3.5
3.2
2.9
23
22
29
33
27
26
24
6.3
6.5
7.5
8
8.3
8.4
8.5
2.5
2.3
2.2
1.6
1.2
1
0.89
3.4
3.4
3
2.5
2.4
2.3
2.3
(0.78–1)
(0.67–0.86)
(0.53–0.69)
(0.34–0.44)
(0.33–0.43)
(0.52–0.68)
(0.31–0.41)
(11–12)
(10–11)
(7.1–8)
(5.7–6.4)
(6–6.8)
(5.6–6.4)
(5.5–6.2)
(3.5–8.7)
(4.4–6.5)
(4.3–5.9)
(4.2–5.4)
(4.2–5.2)
(4.1–5.2)
(4.1–5.2)
(15–19)
(12–16)
(9.1–12)
(5.6–7.2)
(3.7–4.8)
(3.7–4.8)
(3.5–4.5)
(0.85–1.1)
(0.94–1.2)
(0.74–0.94)
(0.63–0.82)
(0.54–0.69)
(0.49–0.63)
(0.46–0.6)
(3.6–4.7)
(4.4–5.6)
(3.1–4)
(1.8–2.4)
(1.4–1.9)
(1.3–1.7)
(1.3–1.7)
(0.016–0.022)
(0.014–0.017)
(0.011–0.014)
(0.011–0.014)
(0.013–0.015)
(0.013–0.017)
(0.013–0.02)
(0.64–0.82)
(0.48–0.62)
(0.41–0.53)
(0.4–0.51)
(0.37–0.47)
(0.34–0.44)
(0.32–0.41)
(0.36–0.43)
(0.45–0.56)
(0.49–0.64)
(0.43–0.54)
(0.37–0.47)
(0.34–0.45)
(0.32–0.42)
(4.3–5.5)
(4.9–6.5)
(4.6–5.6)
(3.7–4.9)
(3.1–4.1)
(2.9–3.6)
(2.6–3.3)
(14–34)
(18–27)
(25–34)
(27–39)
(23–32)
(22–30)
(20–28)
(3.8–9.3)
(5.3–7.9)
(6.2–8.9)
(6.5–9.6)
(6.7–10)
(6.9–10)
(7–10)
(1.5–3.7)
(1.9–2.8)
(1.9–2.6)
(1.4–1.8)
(1–1.3)
(0.89–1.2)
(0.78–1)
(2.1–5.1)
(2.7–4)
(2.6–3.5)
(2.2–2.9)
(2–2.8)
(2–2.7)
(2–2.7)
RATEb
18
15
12
7.4
7.2
11
6.7
20
19
13
9.9
10
9.6
9.3
107
107
107
107
107
107
107
21
17
13
7.7
5.1
5.1
4.8
9.6
10
7.6
6.4
5.4
4.9
4.6
40
48
35
21
16
15
15
7.4
5.7
4.4
4.1
4.5
4.8
5
21
15
12
11
9.6
8.8
8.1
8.7
9.5
9.4
7.4
5.9
5.4
4.9
8.6
10
8.9
7.3
5.9
5.4
4.9
139
139
196
215
175
163
151
143
143
151
158
159
159
159
92
93
92
69
51
45
39
92
92
86
74
71
70
69
(16–20)
(13–17)
(10–13)
(6.5–8.4)
(6.3–8.1)
(9.8–13)
(5.9–7.6)
(19–21)
(18–20)
(12–14)
(9.3–11)
(9.7–11)
(9–10)
(8.8–9.9)
(65–158)
(87–128)
(90–125)
(94–120)
(94–119)
(95–119)
(95–119)
(19–24)
(15–19)
(11–14)
(6.8–8.7)
(4.5–5.8)
(4.5–5.8)
(4.2–5.4)
(8.3–11)
(8.8–11)
(6.7–8.6)
(5.6–7.3)
(4.7–6.1)
(4.4–5.6)
(4–5.2)
(35–45)
(42–55)
(30–39)
(18–23)
(14–19)
(13–17)
(13–17)
(6.4–8.5)
(5.1–6.4)
(3.8–5.1)
(3.6–4.6)
(4.2–4.8)
(4.3–5.3)
(4.1–6.1)
(18–23)
(13–17)
(11–14)
(9.6–12)
(8.5–11)
(7.7–9.9)
(7.1–9.2)
(8–9.5)
(8.4–11)
(8.1–11)
(6.6–8.2)
(5.2–6.6)
(4.7–6.1)
(4.3–5.6)
(7.5–9.7)
(8.6–11)
(8–9.8)
(6.4–8.3)
(5.1–6.8)
(4.8–6)
(4.3–5.5)
(84–206)
(113–167)
(167–228)
(175–259)
(146–206)
(137–192)
(127–177)
(87–212)
(116–172)
(125–179)
(129–191)
(129–192)
(130–191)
(131–191)
(56–137)
(76–112)
(79–107)
(60–79)
(45–58)
(40–51)
(34–45)
(56–137)
(75–111)
(74–99)
(64–85)
(61–82)
(60–81)
(59–80)
INCIDENCE HIV-POSITIVE
NUMBER
(THOUSANDS)
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.5
0.46
0.37
0.35
0.38
0.37
0.36
<0.01
0.013
0.024
0.053
0.07
0.07
0.069
0.25
0.21
0.18
0.13
0.099
0.097
0.097
0.019
0.022
0.018
0.016
0.014
0.013
0.012
0.063
0.058
0.033
0.018
0.015
0.015
0.015
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.014
0.017
0.017
0.016
0.016
<0.01
0.017
0.027
0.026
0.021
0.02
0.018
0.25
0.3
0.29
0.25
0.21
0.19
0.18
<0.01
<0.01
0.028
0.19
0.25
0.29
0.33
<0.01
<0.01
0.011
0.059
0.15
0.11
0.24
<0.01
0.025
0.071
0.062
0.082
0.087
0.089
<0.01
<0.01
<0.01
<0.01
0.01
0.01
<0.01
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.011)
(<0.01–<0.01)
(0.32–0.74)
(0.3–0.66)
(0.24–0.53)
(0.23–0.49)
(0.25–0.54)
(0.24–0.51)
(0.24–0.51)
(<0.01–0.025)
(<0.01–0.034)
(<0.01–0.05)
(0.032–0.08)
(0.045–0.1)
(0.037–0.11)
(0.058–0.08)
(0.15–0.37)
(0.12–0.31)
(0.11–0.26)
(0.08–0.19)
(0.062–0.14)
(0.06–0.14)
(0.061–0.14)
(0.011–0.029)
(0.013–0.033)
(0.011–0.026)
(<0.01–0.023)
(<0.01–0.02)
(<0.01–0.019)
(<0.01–0.018)
(0.035–0.099)
(0.031–0.092)
(0.018–0.052)
(0.01–0.029)
(<0.01–0.024)
(<0.01–0.023)
(<0.01–0.024)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.015)
(<0.01–0.021)
(0.011–0.025)
(0.011–0.024)
(0.01–0.024)
(<0.01–0.023)
(<0.01–<0.01)
(<0.01–0.025)
(0.015–0.044)
(0.016–0.039)
(0.013–0.031)
(<0.01–0.035)
(0.016–0.02)
(0.13–0.41)
(0.15–0.48)
(0.2–0.39)
(0.16–0.36)
(0.12–0.31)
(0.13–0.27)
(0.11–0.25)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.058)
(0.15–0.24)
(0.2–0.3)
(0.23–0.34)
(0.27–0.4)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.017)
(0.021–0.11)
(0.11–0.19)
(0.083–0.14)
(0.19–0.29)
(<0.01–0.026)
(<0.01–0.054)
(0.044–0.11)
(0.044–0.083)
(0.061–0.11)
(0.066–0.11)
(0.069–0.11)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.014)
(<0.01–0.017)
(<0.01–0.017)
(<0.01–0.016)
NOTIFIED NEW AND RELAPSEa
RATEb
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
1.2
1.6
1.6
1.6
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
1.1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
1.3
1.6
1.8
2.1
<1
<1
<1
1.2
2.9
2.1
4.4
<1
1
3
2.7
3.6
3.9
3.9
<1
<1
<1
<1
<1
<1
<1
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–1.3)
(<1–1.1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–1)
(<1–1.8)
(1–2.3)
(<1–2.6)
(1.3–1.8)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–1.2)
(<1–1.6)
(<1–1.5)
(<1–1)
(<1–1.7)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–1.6)
(1.3–1.9)
(1.5–2.2)
(1.7–2.5)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–2.3)
(2.2–3.6)
(1.6–2.7)
(3.5–5.5)
(<1–<1)
(<1–2.2)
(1.8–4.4)
(1.9–3.6)
(2.7–4.7)
(2.9–4.9)
(3–4.9)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
a
Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
b
Rates are per 100 000 population.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 192
NUMBER
RATEb
772
661
527
339
331
519
312
9 030
8 723
6 122
4 887
3 355
2 890
2 906
1 537
1 625
4 397
4 501
4 412
4 732
4 674
14 653
12 198
9 064
5 539
3 664
3 659
3 436
877
939
703
626
535
465
466
3 588
4 339
3 073
1 808
1 428
1 315
1 313
18
12
13
10
6
11
22
624
458
386
387
337
340
319
234
398
537
371
322
347
340
4 246
5 627
3 501
3 828
3 414
2 541
1 721
10 969
11 310
25 843
25 512
23 140
20 508
19 703
2 306
3 393
6 205
6 329
6 628
5 765
5 652
906
1 541
1 982
1 409
1 046
951
913
1 471
2 362
2 657
2 114
2 095
1 895
1 750
15
13
10
6
6
10
6
16
15
10
8
5
5
5
28
32
93
101
100
108
107
19
15
11
7
4
4
4
9
9
6
6
5
4
4
35
42
30
18
14
13
13
7
4
5
3
2
3
7
18
13
10
9
8
8
7
5
7
9
6
5
5
5
7
10
6
7
6
4
3
66
71
173
168
148
129
123
52
74
125
126
127
109
106
34
62
83
61
46
42
41
40
65
76
62
62
57
53
CASE DETECTION RATEa
PERCENT
87
87
87
87
87
87
87
80
81
81
81
52
48
50
26
30
87
94
94
102
101
87
87
87
87
87
87
87
90
88
84
87
88
83
89
87
87
87
87
87
87
87
95
79
104
83
43
73
136
86
84
83
85
80
88
88
60
79
95
76
77
88
93
87
99
69
89
96
78
58
48
51
88
78
84
79
82
37
52
83
79
80
69
66
37
66
90
88
90
93
103
43
70
88
83
87
81
76
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(76–86)
(76–86)
(76–86)
(76–86)
(49–55)
(45–51)
(47–53)
(18–43)
(25–37)
(74–103)
(84–107)
(84–106)
(91–114)
(90–113)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(79–104)
(77–100)
(75–95)
(77–99)
(77–100)
(74–94)
(78–102)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(83–110)
(70–89)
(90–122)
(74–94)
(40–46)
(66–82)
(113–168)
(76–98)
(74–95)
(73–94)
(76–97)
(72–91)
(77–100)
(77–100)
(55–65)
(70–89)
(83–110)
(68–85)
(69–87)
(78–101)
(81–107)
(77–99)
(86–115)
(62–76)
(79–102)
(84–112)
(70–88)
(52–67)
(32–79)
(42–63)
(76–104)
(65–96)
(72–101)
(68–95)
(70–97)
(25–60)
(43–64)
(70–100)
(66–97)
(66–98)
(57–84)
(56–81)
(25–61)
(55–81)
(78–105)
(77–102)
(79–103)
(82–106)
(91–118)
(29–71)
(58–86)
(76–103)
(73–96)
(76–102)
(70–94)
(66–89)
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($,QFLGHQFHQRWLILFDWLRQDQGFDVHGHWHFWLRQUDWHVDOOIRUPV±
YEAR
Luxembourg
Malta
Monaco
Montenegro
Netherlands
Norway
Poland
Portugal
Republic of
Moldova
Romania
Russian
Federation
San Marino
Serbia
Serbia &
Montenegro
Slovakia
Slovenia
POPULATION
(MILLIONS)
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
2005
2008
2009
2010
1990
1995
2000
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
15
15
16
16
17
17
17
4
4
4
5
5
5
5
38
38
38
38
38
38
38
10
10
10
11
11
11
11
4
4
4
4
4
4
4
23
23
22
22
22
22
21
148
149
147
144
143
143
143
<1
<1
<1
<1
<1
<1
<1
10
10
10
10
10
11
11
5
5
5
5
5
5
5
2
2
2
2
2
2
2
RATEb
0.044
0.044
0.044
0.043
0.044
0.045
0.045
0.02
0.024
0.02
0.027
0.048
0.05
0.05
<0.01
<0.01
<0.01
(0.037–0.051)
(0.039–0.049)
(0.038–0.051)
(0.038–0.049)
(0.039–0.05)
(0.039–0.051)
(0.039–0.051)
(0.018–0.022)
(0.022–0.025)
(0.018–0.022)
(0.024–0.03)
(0.041–0.055)
(0.044–0.056)
(0.044–0.056)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
11
11
10
9.5
9.1
9
8.8
5.5
6.1
5
6.5
11
12
12
3.7
3.5
<1
0.17
0.14
0.13
0.12
1.5
1.9
1.5
1.3
1.1
1.2
1.2
0.34
0.27
0.28
0.32
0.31
0.3
0.3
19
18
13
9.5
8.7
8.7
8.8
7.1
6.4
4.9
3.8
3.2
3.1
3.1
5
4.9
5.6
6.2
6.3
6.4
6.5
33
33
37
36
29
27
25
160
160
180
150
150
150
150
<0.01
<0.01
<0.01
(0.16–0.2)
(0.13–0.17)
(0.12–0.15)
(0.1–0.14)
(1.3–1.7)
(1.7–2.2)
(1.4–1.7)
(1.1–1.5)
(1–1.3)
(1–1.4)
(1.1–1.4)
(0.3–0.38)
(0.24–0.3)
(0.25–0.31)
(0.28–0.36)
(0.27–0.35)
(0.26–0.34)
(0.26–0.33)
(16–21)
(16–21)
(11–14)
(8.3–11)
(7.6–9.8)
(7.6–9.9)
(7.7–10)
(6.3–8.1)
(5.6–7.3)
(4.3–5.5)
(3.3–4.3)
(2.8–3.7)
(2.7–3.5)
(2.7–3.6)
(3–7.4)
(4–5.9)
(4.6–6.7)
(5.1–7.4)
(5.2–7.7)
(5.2–7.7)
(5.3–7.8)
(20–49)
(26–39)
(30–45)
(29–43)
(24–35)
(22–32)
(20–30)
(97–240)
(130–190)
(140–220)
(130–180)
(130–180)
(130–180)
(130–180)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
27
23
21
19
10
13
9.6
8
6.9
7.2
7.3
8
6.2
6.2
6.9
6.4
6.2
6
49
48
33
25
23
23
23
72
63
47
36
30
29
29
114
114
136
164
175
178
182
143
143
167
164
134
125
116
107
107
122
107
107
106
106
4.8
9
4.3
3.4
3
2.1
1.8
6
5.8
4.3
1.7
1.8
1.2
0.8
0.63
0.53
0.44
0.83
0.6
0.42
0.31
0.24
0.21
0.21
(3.2–4.1)
(2.7–3.5)
(1.9–2.4)
(1.6–2.1)
(4–8.4)
(4.7–7)
(3.5–5.2)
(1.5–1.9)
(1.6–2.1)
(1–1.3)
(0.7–0.91)
(0.55–0.71)
(0.47–0.6)
(0.38–0.5)
(0.73–0.94)
(0.53–0.68)
(0.37–0.48)
(0.27–0.35)
(0.21–0.27)
(0.19–0.24)
(0.19–0.24)
34
31
21
18
59
53
40
32
34
22
15
12
9.7
8
43
31
21
15
12
11
11
(9.7–13)
(9.7–12)
(8.7–12)
(8.3–11)
(7.9–10)
(7.8–10)
(7.7–10)
(5–6.1)
(5.7–6.5)
(4.4–5.6)
(5.7–7.3)
(9.8–13)
(11–13)
(11–13)
(3.2–4.2)
(3–3.9)
(<1–<1)
(25–32)
(21–27)
(18–24)
(17–22)
(9–12)
(11–14)
(8.5–11)
(7–9.1)
(6–7.8)
(6.2–8.2)
(6.4–8.2)
(7–9)
(5.4–7)
(5.5–6.9)
(6.1–7.8)
(5.7–7.2)
(5.5–7)
(5.3–6.9)
(43–55)
(42–54)
(29–37)
(22–28)
(20–26)
(20–26)
(20–26)
(63–81)
(56–72)
(41–53)
(32–41)
(27–34)
(26–33)
(26–33)
(69–169)
(92–137)
(111–164)
(136–195)
(142–211)
(146–214)
(149–218)
(87–213)
(117–173)
(136–202)
(134–198)
(109–161)
(102–150)
(95–138)
(65–160)
(87–129)
(99–147)
(88–128)
(89–126)
(89–125)
(90–124)
(4.1–5.4)
(7.8–10)
(3.7–4.8)
(33–41)
(28–36)
(19–25)
(16–21)
(39–83)
(43–64)
(32–48)
(28–36)
(30–39)
(19–25)
(13–17)
(10–13)
(8.6–11)
(7–9.1)
(38–49)
(27–35)
(19–24)
(14–17)
(10–13)
(9.3–12)
(9.3–12)
INCIDENCE HIV-POSITIVE
NUMBER
(THOUSANDS)
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.012)
(<0.01–0.011)
(<0.01–0.013)
NOTIFIED NEW AND RELAPSEa
RATEb
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
1.2
1.3
1.4
NUMBER
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–1.2)
(<1–2.8)
(<1–2.7)
(<1–3.2)
<0.01
0.023
0.052
0.052
0.048
0.045
0.049
0.052
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.1
0.21
0.2
0.18
0.17
0.18
0.19
0.32
0.71
0.83
0.86
0.56
0.61
0.69
0.02
0.049
0.17
<0.01
0.32
0.33
0.38
0.15
0.41
0.74
0.82
0.63
0.58
0.53
<0.01
0.095
2.7
6.6
9.2
12
8.1
(<0.01–<0.01)
(0.011–0.038)
(0.029–0.081)
(0.032–0.076)
(0.028–0.072)
(0.027–0.069)
(0.036–0.063)
(0.037–0.07)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.011)
(<0.01–0.011)
(<0.01–0.011)
(<0.01–0.011)
(0.049–0.17)
(0.12–0.34)
(0.12–0.31)
(0.1–0.27)
(0.1–0.26)
(0.11–0.27)
(0.11–0.28)
(0.15–0.56)
(0.42–1.1)
(0.53–1.2)
(0.73–0.99)
(0.49–0.63)
(0.38–0.89)
(0.45–0.97)
(<0.01–0.068)
(0.017–0.097)
(0.11–0.26)
(<0.01–0.016)
(0.25–0.39)
(0.26–0.4)
(0.31–0.47)
(0.048–0.31)
(0.22–0.67)
(0.43–1.1)
(0.47–1.2)
(0.36–0.96)
(0.34–0.89)
(0.31–0.81)
(<0.01–<0.01)
(0.045–0.16)
(1.6–4)
(4.4–9.2)
(3.3–18)
(9.8–15)
(6.8–9.4)
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
3.3
7
8
8.1
5.3
5.7
6.4
<1
1.1
4.2
<1
8.8
9.1
11
<1
1.8
3.4
3.7
2.9
2.7
2.5
<1
<1
1.8
4.6
6.4
8.5
5.7
(<1–1.1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(1.5–5.6)
(4.1–11)
(5.2–11)
(7–9.3)
(4.6–5.9)
(3.6–8.3)
(4.2–9.1)
(<1–1.6)
(<1–2.2)
(2.6–6.3)
(<1–<1)
(6.9–11)
(7.2–11)
(8.6–13)
(<1–1.3)
(<1–3)
(1.9–5.2)
(2.2–5.7)
(1.7–4.4)
(1.6–4.1)
(1.4–3.8)
(<1–<1)
(<1–<1)
(1.1–2.7)
(3.1–6.4)
(2.3–13)
(6.8–10)
(4.8–6.6)
0.043
0.045
0.032
0.029
(0.024–0.067)
(0.024–0.071)
(0.017–0.051)
(0.015–0.046)
<1
<1
<1
<1
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
<1
<1
<1
<1
<1
<1
<1
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
13
8
10
8
0
24
13
11
16
21
48
41
20
1
1
0
5
4
3
4
5
12
10
5
3
3
0
1
156
131
113
110
1 369
1 619
1 244
1 127
964
1 111
1 029
285
236
221
269
252
258
261
16 136
15 958
10 931
8 203
7 421
7 645
7 002
6 214
5 577
4 227
3 303
2 817
2 723
2 728
1 728
2 925
2 935
5 141
4 442
4 347
4 122
16 256
23 271
27 470
26 104
21 724
20 868
18 379
50 641
84 980
140 677
127 930
128 263
126 227
118 641
1
2
1
3
25
21
18
17
9
10
8
7
6
7
6
7
5
5
6
5
5
5
42
42
29
21
19
20
18
63
55
41
31
26
26
26
40
67
71
136
122
121
115
70
103
124
120
101
97
86
34
57
96
89
90
88
83
4
8
4
3 208
2 714
1 879
2 326
4 194
2 798
2 864
1 448
1 540
1 010
710
559
438
386
722
525
368
269
208
186
169
33
28
19
24
41
26
27
27
29
19
13
10
8
7
37
27
19
13
10
9
8
a
Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
b
Rates are per 100 000 population.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 193
RATEb
48
32
44
37
0
CASE DETECTION RATEa
PERCENT
110
73
100
85
0
–
54
64
47
81
79
101
83
40
87
87
–
–
–
–
–
93
92
85
92
89
84
81
86
85
94
85
84
88
80
84
82
86
88
87
87
87
87
85
88
80
87
87
87
87
87
87
87
35
59
52
83
70
68
63
49
72
74
73
75
78
74
32
53
79
83
84
83
78
87
87
87
–
–
–
–
95
89
89
128
70
48
67
86
84
85
89
89
83
88
87
87
87
87
87
87
79
(94–130)
(65–81)
(86–116)
(76–97)
(47–62)
(58–70)
(44–50)
(72–91)
(71–89)
(88–118)
(74–94)
(36–45)
(77–100)
(77–100)
(77–100)
(77–99)
(74–97)
(81–105)
(79–102)
(74–95)
(72–92)
(76–98)
(75–97)
(82–108)
(75–96)
(75–96)
(78–100)
(71–90)
(75–95)
(73–93)
(76–98)
(78–101)
(77–99)
(77–99)
(77–99)
(77–99)
(76–97)
(77–100)
(70–91)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(23–57)
(49–73)
(44–64)
(70–100)
(58–86)
(56–83)
(53–77)
(33–80)
(59–88)
(61–91)
(61–90)
(62–92)
(65–95)
(62–90)
(21–52)
(44–65)
(65–97)
(69–101)
(71–101)
(71–99)
(67–93)
(77–100)
(77–100)
(77–100)
European Region
INCIDENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
(79–100)
(77–100)
(77–100)
(112–149)
(50–105)
(40–59)
(56–82)
(76–98)
(74–95)
(75–96)
(78–102)
(78–102)
(74–94)
(78–101)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(70–90)
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
193
05/10/11 09:03
7$%/($,QFLGHQFHQRWLILFDWLRQDQGFDVHGHWHFWLRQUDWHVDOOIRUPV±
INCIDENCE (INCLUDING HIV)
YEAR
Spain
Sweden
Switzerland
Tajikistan
The Former
Yugoslav Republic
of Macedonia
Turkey
Turkmenistan
Ukraine
United Kingdom of
Great Britain and
Northern Ireland
Uzbekistan
194
POPULATION
(MILLIONS)
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
39
39
40
43
45
46
46
9
9
9
9
9
9
9
7
7
7
7
8
8
8
5
6
6
6
7
7
7
2
2
2
2
2
2
2
54
59
64
68
71
72
73
4
4
5
5
5
5
5
52
51
49
47
46
46
45
57
58
59
60
61
62
62
21
23
25
26
27
27
27
NUMBER
(THOUSANDS)
8.7
10
9.2
8.4
7.8
7.7
7.3
0.63
0.62
0.49
0.57
0.54
0.58
0.63
1.5
0.95
0.66
0.59
0.53
0.58
0.58
4.9
5.3
7.7
12
13
14
14
1.5
1.1
0.83
0.6
0.5
0.46
0.43
31
34
29
23
21
21
21
2.4
2.2
4.2
3.3
3.3
3.3
3.3
21
27
41
47
47
46
46
6.6
7
6.9
8.9
7.9
7.7
7.9
26
29
32
33
34
35
35
(7.7–9.9)
(8.8–11)
(8.1–10)
(7.3–9.5)
(6.8–8.8)
(6.7–8.7)
(6.4–8.3)
(0.55–0.71)
(0.54–0.71)
(0.43–0.55)
(0.5–0.65)
(0.47–0.61)
(0.51–0.66)
(0.56–0.72)
(1.3–1.7)
(0.84–1.1)
(0.58–0.74)
(0.52–0.67)
(0.47–0.6)
(0.51–0.65)
(0.51–0.66)
(3–7.3)
(4.3–6.4)
(6.4–9.2)
(9.7–15)
(11–16)
(11–17)
(12–17)
(0.94–2.3)
(0.92–1.4)
(0.68–1)
(0.54–0.67)
(0.43–0.57)
(0.4–0.53)
(0.37–0.5)
(22–43)
(28–41)
(24–35)
(19–27)
(17–26)
(17–25)
(17–25)
(1.9–2.9)
(1.9–2.5)
(3.7–4.6)
(2.9–3.7)
(2.7–4)
(2.7–4)
(2.7–4)
(15–29)
(22–32)
(33–49)
(39–56)
(38–56)
(38–55)
(38–55)
(6.2–7.1)
(6.5–7.4)
(6.5–7.4)
(8.3–9.5)
(7.4–8.4)
(7.2–8.3)
(7.4–8.4)
(16–39)
(24–35)
(26–38)
(27–40)
(28–41)
(28–42)
(29–42)
RATEb
22
26
23
19
17
17
16
7.3
7.1
5.5
6.3
5.8
6.2
6.8
22
14
9.2
8
7
7.6
7.6
93
91
125
187
202
204
206
81
58
41
30
24
23
21
58
58
46
33
30
29
28
64
52
92
70
68
67
66
41
52
84
101
102
101
101
12
12
12
15
13
13
13
128
128
128
128
128
128
128
(20–25)
(22–29)
(20–26)
(17–22)
(15–20)
(15–19)
(14–18)
(6.4–8.3)
(6.2–8)
(4.9–6.2)
(5.5–7.3)
(5.1–6.6)
(5.5–7.1)
(5.9–7.7)
(19–25)
(12–15)
(8–10)
(7–9)
(6.1–7.9)
(6.6–8.6)
(6.7–8.6)
(56–138)
(74–110)
(103–149)
(150–227)
(165–243)
(167–245)
(169–247)
(49–120)
(47–70)
(34–50)
(27–33)
(21–28)
(19–26)
(18–24)
(40–79)
(47–70)
(38–56)
(28–40)
(25–36)
(24–35)
(23–34)
(50–80)
(45–61)
(82–103)
(61–79)
(55–82)
(54–81)
(54–80)
(28–56)
(43–62)
(68–101)
(83–120)
(83–122)
(83–121)
(84–121)
(11–12)
(11–13)
(11–13)
(14–16)
(12–14)
(12–13)
(12–14)
(78–190)
(104–154)
(104–154)
(104–154)
(104–154)
(105–153)
(105–153)
INCIDENCE HIV-POSITIVE
NUMBER
(THOUSANDS)
0.87
1.3
1.2
1.1
0.99
1
0.95
<0.01
0.011
<0.01
0.014
0.013
0.015
0.016
0.047
0.04
0.031
0.032
0.032
0.034
0.036
<0.01
0.041
0.12
0.23
0.31
0.34
0.37
(0.57–1.2)
(0.87–1.8)
(0.77–1.6)
(0.72–1.5)
(0.85–1.1)
(0.68–1.4)
(0.64–1.3)
(<0.01–0.011)
(<0.01–0.017)
(<0.01–0.015)
(<0.01–0.021)
(<0.01–0.02)
(<0.01–0.022)
(<0.01–0.025)
(0.026–0.074)
(0.024–0.059)
(0.019–0.046)
(0.02–0.048)
(0.02–0.046)
(0.021–0.05)
(0.022–0.053)
(<0.01–<0.01)
(0.021–0.068)
(0.078–0.17)
(0.13–0.37)
(<0.01–1.9)
(0.28–0.4)
(0.28–0.47)
NOTIFIED NEW AND RELAPSEa
RATEb
2.2
3.3
2.9
2.5
2.2
2.2
2.1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
1.9
3.6
4.7
5
5.3
(1.5–3.2)
(2.2–4.6)
(1.9–4)
(1.7–3.4)
(1.9–2.5)
(1.5–3.1)
(1.4–2.9)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–1.1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–1.2)
(1.3–2.7)
(2–5.7)
(<1–28)
(4.2–5.9)
(4.1–6.8)
<0.01
0.013
0.029
0.039
0.049
0.051
0.054
(<0.01–<0.01)
(<0.01–0.024)
(0.014–0.05)
(0.019–0.066)
(0.025–0.082)
(0.026–0.084)
(0.027–0.09)
<1
<1
<1
<1
<1
<1
<1
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
0.3
0.94
3.2
4.6
4.3
5.1
6
0.077
0.093
0.14
0.27
0.28
0.29
0.31
<0.01
<0.01
<0.01
0.17
0.45
0.58
0.71
(0.083–0.65)
(0.52–1.5)
(2.1–4.5)
(3.1–6.3)
(3.5–5.2)
(4.2–6.1)
(5–7.1)
(0.042–0.12)
(0.053–0.14)
(0.082–0.2)
(0.17–0.4)
(0.19–0.4)
(0.18–0.43)
(0.19–0.45)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.014)
(0.14–0.21)
(0.37–0.55)
(0.46–0.71)
(0.56–0.87)
<1
1.8
6.6
9.7
9.4
11
13
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
1.7
2.1
2.6
(<1–1.3)
(1–2.9)
(4.4–9.2)
(6.6–13)
(7.7–11)
(9.2–13)
(11–16)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(1.4–2.1)
(1.7–2.6)
(2.1–3.2)
a
Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
b
Rates are per 100 000 population.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 194
NUMBER
RATEb
7 600
8 764
7 993
7 281
6 769
6 687
6 377
557
564
417
539
457
515
552
1 278
830
544
508
319
333
323
2 460
2 029
2 779
5 460
6 396
6 125
6 297
20
22
20
17
15
15
14
7
6
5
6
5
6
6
19
12
8
7
4
4
4
46
35
45
85
96
90
92
786
641
598
450
450
384
24 468
22 981
18 038
19 744
17 600
16 757
15 879
2 325
1 939
4 038
3 191
3 757
3 157
3 230
16 465
21 459
32 945
39 608
37 832
36 075
33 857
5 908
6 176
6 220
8 173
6 586
7 008
7 219
9 414
9 866
15 750
21 513
17 040
17 540
16 883
40
32
29
22
22
19
45
39
28
29
25
23
22
63
46
90
67
76
63
64
32
42
67
84
82
79
74
10
11
11
14
11
11
12
46
43
64
83
64
65
62
CASE DETECTION RATEa
PERCENT
87
87
87
87
87
87
87
89
90
85
94
85
89
87
87
87
83
86
60
58
55
50
38
36
45
47
44
44
–
69
77
99
91
97
89
78
67
61
87
82
80
77
99
88
97
96
113
94
96
78
81
80
84
81
78
73
89
89
90
92
84
91
91
36
34
50
65
50
51
48
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(78–102)
(80–104)
(75–97)
(82–109)
(75–96)
(78–101)
(77–99)
(77–99)
(77–99)
(73–95)
(76–98)
(53–69)
(51–66)
(49–63)
(34–82)
(32–47)
(30–44)
(37–56)
(39–58)
(37–54)
(37–54)
(57–85)
(64–95)
(90–110)
(79–105)
(84–112)
(77–104)
(57–113)
(56–83)
(51–76)
(73–105)
(68–101)
(67–98)
(65–94)
(80–126)
(76–104)
(87–109)
(85–110)
(93–138)
(78–117)
(80–119)
(57–113)
(68–98)
(67–99)
(70–102)
(68–99)
(65–95)
(62–89)
(83–95)
(83–95)
(84–96)
(86–98)
(79–89)
(85–97)
(86–98)
(24–59)
(28–41)
(41–61)
(54–80)
(41–61)
(42–62)
(40–58)
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($&DVHQRWLILFDWLRQV±
YEAR
Albania
• 20
13 •
Andorra
• 44
8•
Armenia
• 17
46 •
Austria
• 20
4•
Azerbaijan
• 36
70 •
Belarus
• 30
52 •
Belgium
• 16
8•
Bosnia and
Herzegovina
• 95
35 •
Bulgaria
• 26
32 •
Croatia
• 57
16 •
Cyprus
•4
4•
Czech Republic
• 19
6•
Denmark
•7
5•
Estonia
• 27
a
21 •
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
NEW AND
RELAPSEa
653
641
604
506
427
435
431
23
12
10
4
8
7
590
1 157
1 333
2 206
1 655
1 560
1 410
1 521
1 481
1 185
928
441
358
2 620
1 630
5 187
6 034
6 417
7 301
6 390
3 039
4 854
6 799
5 308
5 126
5 250
5 003
1 577
1 380
1 278
1 076
811
806
810
4 073
2 132
2 476
2 111
1 713
1 725
1 321
2 256
3 245
3 349
3 225
2 944
2 683
2 412
2 576
2 114
1 630
1 050
980
832
688
29
36
33
34
42
43
44
1 937
1 834
1 414
973
807
638
641
350
448
587
395
330
294
295
423
624
791
479
401
361
283
SMEAR- SMEAR-NEGATIVE/
POSITIVE
UNKNOWN
EXTRAPULMONARY
OTHER RELAPSE
139
171
196
170
171
145
223
188
134
87
109
105
226
234
167
145
136
165
1
5
3
2
0
9
1
1
4
4
2
4
0
1
3
436
621
581
487
440
339
451
505
1 049
724
725
639
75
153
365
296
299
351
467
324
234
765
652
519
249
209
175
90
76
268
213
34
69
669
890
1 561
1 409
1 487
1 997
620
3 978
2 508
2 728
3 124
2 275
93
245
651
993
1 261
965
1 845
2 547
1 235
1 060
1 201
1 269
2 148
2 985
3 710
3 074
3 002
2 647
518
442
363
500
430
429
400
409
380
311
280
534
454
406
287
294
366
326
290
213
107
865
759
640
509
609
441
997
1 287
1 106
919
862
529
140
261
258
235
188
161
1 087
2 524
1 214
1 020
894
806
1 709
0
1 511
1 121
892
748
449
442
376
687
443
747
1 204
0
372
328
302
183
703
165
42
575
515
410
382
103
101
81
87
0
36
39
36
6
4
9
6
14
11
10
13
28
15
13
17
12
7
3
487
420
308
249
218
1 026
679
461
432
322
300
290
204
126
54
128
171
129
106
101
186
244
145
140
125
128
144
121
83
25
369
255
162
144
135
99
124
320
217
180
175
134
60
67
46
30
18
17
RE-TREAT EXCL. TOTAL
HISTORY
RELAPSE
RETREAT UNKNOWN
0
53
11
9
25
19
16
8
34
7
2
9
53
19
43
32
21
25
0
10
0
0
0
0
0
0
0
1
0
0
0
0
1
0
0
0
0
2
0
0
0
0
0
0
0
38
54
211
148
96
81
22
116
470
446
370
38
76
327
618
542
451
0
0
0
0
0
30
26
30
26
45
0
4
0
21
29
25
29
245
301
0
47
74
1 314
1 287
1 429
1 153
0
1 886
2 446
955
844
47
74
3 200
3 733
2 384
1 997
1 215
2 161
1 160
0
1 049
357
261
456
343
825
1 049
849
878
1 114
95
0
0
68
67
80
89
68
67
0
0
158
130
169
107
50
66
32
24
49
17
47
69
130
193
156
67
113
101
0
6
0
0
10
297
0
383
124
106
157
111
0
77
207
215
237
383
201
313
372
348
0
13
0
0
343
825
0
492
617
658
80
89
0
125
128
214
42
23
7
94
36
62
43
0
0
0
1
2
3
2
1
0
0
3
3
3
21
25
0
0
0
34
61
21
25
34
61
1
37
6
28
0
0
6
0
29
37
4
6
28
29
37
10
0
41
0
3
0
71
116
54
47
30
33
0
40
43
50
46
71
116
94
90
80
79
0
0
0
9
0
44
94
6
11
0
64
0
% SMEARPOS AMONG
NEW PULM
–
38
48
59
66
61
58
–
–
10
83
75
33
0
–
49
55
36
40
38
35
–
38
33
31
–
25
26
–
52
18
38
34
32
47
–
46
46
25
26
29
32
–
43
47
48
52
49
–
–
46
37
37
36
41
45
–
39
100
45
48
50
52
–
63
–
39
39
42
32
–
35
29
41
18
48
–
–
32
38
40
37
40
–
–
41
41
47
43
45
–
–
75
44
43
44
44
42
European Region
NEW CASES
NEW AND RELAPSE
NOTIFICATION RATEa
1990–2010
Rates are per 100 000 population. Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 195
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
195
05/10/11 09:03
7$%/($&DVHQRWLILFDWLRQV±
NEW CASES
NEW AND RELAPSE
NOTIFICATION RATEa
1990–2010
YEAR
Finland
• 15
6•
France
• 16
5•
Georgia
• 28
107 •
Germany
• 19
4•
Greece
•9
4•
Hungary
• 35
13 •
Iceland
•7
7•
Ireland
• 18
7•
Israel
•5
5•
Italy
•7
3•
Kazakhstan
• 66
123 •
Kyrgyzstan
• 52
106 •
Latvia
• 34
41 •
Lithuania
• 40
a
196
53 •
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
NEW AND
RELAPSEa
772
661
527
339
331
519
312
9 030
8 723
6 122
4 887
3 355
2 890
2 906
1 537
1 625
4 397
4 501
4 412
4 732
4 674
14 653
12 198
9 064
5 539
3 664
3 659
3 436
877
939
703
626
535
465
466
3 588
4 339
3 073
1 808
1 428
1 315
1 313
18
12
13
10
6
11
22
624
458
386
387
337
340
319
234
398
537
371
322
347
340
4 246
5 627
3 501
3 828
3 414
2 541
1 721
10 969
11 310
25 843
25 512
23 140
20 508
19 703
2 306
3 393
6 205
6 329
6 628
5 765
5 652
906
1 541
1 982
1 409
1 046
951
913
1 471
2 362
2 657
2 114
2 095
1 895
1 750
SMEAR- SMEAR-NEGATIVE/
POSITIVE
UNKNOWN
EXTRAPULMONARY
OTHER RELAPSE
244
205
130
104
93
82
193
136
114
104
198
146
224
157
95
123
114
84
0
114
0
3 449
1 815
1 941
1 222
1 019
2 969
1 364
1 557
1 115
1 038
2 305
1 665
1 389
967
439
51
394
221
601
1 509
1 868
2 055
2 140
1 087
2 213
1 524
1 063
1 119
1 088
121
1 324
1 261
1 217
1 283
1 155
3 852
0
1 379
954
1 025
946
6 473
1 873
2 801
1 797
1 765
1 614
235
197
80
198
RE-TREAT EXCL. TOTAL
HISTORY
RELAPSE
RETREAT UNKNOWN
29
0
0
0
22
19
29
22
19
0
15
15
0
0
14
0
0
0
0
371
379
0
371
379
116
2 078
0
0
0
196
259
207
264
275
291
422
1 945
1 413
291
1 118
196
681
2 152
1 677
566
1 409
2
11
955
4
1 211
801
353
773
9
402
17
148
103
114
86
345
338
138
195
493
441
252
281
161
472
635
671
339
322
374
196
81
107
80
44
0
26
48
0
1
1
74
83
2
48
74
84
3
67
51
121
796
412
423
346
363
3 292
2 361
1 137
896
800
251
221
117
79
51
0
16
79
131
107
85
292
216
178
126
371
347
285
211
0
7
2
1
2
2
3
6
3
7
3
1
3
12
7
4
5
3
2
4
0
2
0
0
1
0
0
1
0
0
1
0
0
0
0
1
1
0
1
0
0
1
0
138
130
123
95
84
150
156
124
119
122
96
99
81
60
112
8
59
1
2
2
1
7
20
38
40
9
31
22
40
41
16
31
36
93
139
78
216
142
95
119
103
213
168
147
130
162
100
55
76
89
74
0
0
0
0
0
8
6
4
9
1
0
1
0
0
3
8
7
4
9
4
0
0
0
0
0
1 413
687
1 275
938
885
578
2 700
891
1 506
1 576
863
759
1 514
522
1 047
900
408
384
0
385
0
269
0
0
356
293
292
625
293
292
0
3 022
8 903
6 911
6 193
5 213
4 769
5 966
11 324
14 472
10 737
9 319
8 745
1 002
2 555
920
2 754
2 278
2 127
832
1 296
1 972
1 712
1 609
1 645
1 685
2 929
2 141
2 036
2 267
2 028
749
1 683
1 805
1 585
1 558
1 635
504
637
536
400
367
339
693
793
554
400
377
400
226
285
148
118
47
86
979
776
964
884
742
719
1 049
1 051
793
744
702
633
206
503
357
264
158
221
71
71
16
712
1 336
703
1 320
3 061
3 209
3 456
3 698
4 062
2 032
11 800
5 773
5 673
5 151
1 320
5 093
15 009
9 229
9 371
9 213
3 117
0
4 397
3 696
0
127
297
411
398
331
344
258
436
358
427
643
127
555
847
756
758
987
0
39
0
118
267
171
128
121
88
108
34
24
26
21
118
375
205
152
147
109
0
0
75
0
128
327
0
203
218
177
182
460
154
186
187
128
509
460
357
404
364
1
0
0
0
897
0
141
166
0
1
% SMEARPOS AMONG
NEW PULM
–
56
60
53
50
32
36
–
54
57
55
52
50
–
–
17
21
50
64
65
66
–
37
–
33
35
37
37
–
–
41
38
18
50
–
–
19
15
27
28
31
–
–
40
13
40
67
50
33
–
–
48
45
50
44
41
–
–
50
46
39
48
39
–
34
44
46
37
51
43
–
34
44
32
37
36
35
–
33
31
48
46
42
45
–
42
45
49
50
49
46
–
48
42
55
54
51
53
Rates are per 100 000 population. Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 196
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($&DVHQRWLILFDWLRQV±
YEAR
Luxembourg
• 13
5•
Malta
•4
5•
Monaco
•3
3•
Montenegro
• 25
17 •
Netherlands
•9
6•
Norway
•7
5•
Poland
• 42
18 •
Portugal
• 63
26 •
Republic of
Moldova
• 40
115 •
Romania
• 70
86 •
Russian
Federation
• 34
83 •
San Marino
•4
–
Serbia
• 33
Serbia (without Kosovo)
24 •
Kosovo
Serbia &
Montenegro
• 41
34 •
Slovakia
• 27
a
7•
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
1990
1995
2000
1990
1995
2000
2005
2008
2009
2010
NEW AND
RELAPSEa
48
32
44
37
0
24
13
11
16
21
48
41
20
1
1
0
1
156
131
113
110
1 369
1 619
1 244
1 127
964
1 111
1 029
285
236
221
269
252
258
261
16 136
15 958
10 931
8 203
7 421
7 645
7 002
6 214
5 577
4 227
3 303
2 817
2 723
2 728
1 728
2 925
2 935
5 141
4 442
4 347
4 122
16 256
23 271
27 470
26 104
21 724
20 868
18 379
50 641
84 980
140 677
127 930
128 263
126 227
118 641
1
2
1
3 208
2 714
1 879
2 326
2 146
1 722
1 625
1 442
1 062
992
254
884
4 194
2 798
2 864
1 448
1 540
1 010
710
559
438
386
SMEAR- SMEAR-NEGATIVE/
POSITIVE
UNKNOWN
EXTRAPULMONARY
21
14
0
19
20
0
0
3
0
0
18
6
5
5
5
15
12
4
4
9
10
19
11
6
2
2
6
12
6
10
0
0
0
64
65
53
39
66
38
43
49
1
13
20
12
14
575
289
237
189
203
176
1 522
528
491
371
392
370
513
427
385
388
499
463
62
37
48
53
42
57
103
119
91
125
89
79
102
108
37
6 955
3 180
2 823
2 650
2 658
2 484
7 285
6 392
4 591
3 835
4 047
3 625
647
477
789
576
408
501
2 019
1 863
1 302
1 053
1 043
1 531
1 005
974
953
826
1 759
1 178
905
631
405
665
651
1 696
1 533
1 318
1 267
1 958
1 788
2 237
1 942
2 015
2 073
154
122
568
476
471
405
10 469
10 202
10 801
9 511
8 987
7 951
8 303
10 180
8 038
6 093
5 681
5 113
37 512
27 467
32 605
33 949
33 351
31 416
OTHER RELAPSE
RE-TREAT EXCL. TOTAL
HISTORY
RELAPSE
RETREAT UNKNOWN
0
4
0
0
0
0
4
0
0
0
0
0
0
28
27
5
0
0
1
5
2
3
0
0
1
7
2
3
1
0
1
9
0
0
0
13
8
5
8
14
2
6
4
27
10
11
12
0
1
0
0
14
16
17
16
70
30
33
29
27
70
44
49
46
43
0
20
17
28
2
0
0
10
14
27
28
12
14
27
0
155
0
1 071
882
0
360
377
392
0
1 077
660
311
507
1 071
882
1 077
1 020
688
899
66
326
268
177
122
114
123
304
228
178
148
268
481
350
292
271
0
0
0
148
374
640
491
543
377
0
1 137
1 374
1 120
1 311
148
374
1 777
1 865
1 663
1 688
3 422
3 474
3 568
3 170
2 486
2 899
0
712
0
1 077
3 614
3 697
2 950
3 002
2 416
156
3 241
3 062
2 399
2 699
1 077
3 770
6 938
6 012
5 401
5 115
42 241
102 228
74 301
75 775
72 931
67 894
5 227
5 313
12 320
3 769
10 945
3 513
7 342
0
7 081
5 669
8 704
7 428
9 000
8 737
12 478
26 449
86 642
23 569
37 243
18 147
35 153
94 070
32 569
45 980
1
0
0
0
0
0
1 105
1 172
1 055
977
873
848
801
690
232
324
254
287
1 584
920
488
700
988
519
488
431
596
401
479
434
197
501
245
211
197
202
234
223
40
188
139
148
40
144
139
119
260
92
64
52
260
92
64
52
300
280
203
200
300
236
203
171
44
44
269
299
29
29
1 497
0
930
2 486
173
175
198
203
0
198
203
788
236
162
126
121
112
555
469
356
285
202
190
177
203
134
99
61
59
20
102
58
49
32
25
18
50
49
47
30
20
120
108
98
79
55
0
12
0
0
0
0
0
4
0
54
0
0
0
0
0
0
0
22
0
0
0
0
2
7
45
105
0
280
0
5
0
22
124
11
2
0
0
0
6 426
6 669
0
7
652
7
0
7
652
7
25
21
23
% SMEARPOS AMONG
NEW PULM
–
–
53
41
–
–
0
–
56
36
33
44
52
40
–
–
–
–
–
–
–
49
63
55
44
–
27
35
33
34
34
32
–
52
26
29
37
25
–
–
49
33
38
41
40
41
–
57
65
57
52
56
–
–
25
27
43
44
40
38
–
56
50
57
61
61
61
–
47
21
30
31
31
32
–
–
100
–
–
–
–
41
56
68
58
47
62
62
62
28
45
–
52
–
62
0
–
59
33
31
31
37
37
European Region
NEW CASES
NEW AND RELAPSE
NOTIFICATION RATEa
1990–2010
Rates are per 100 000 population. Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 197
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
197
05/10/11 09:03
7$%/($&DVHQRWLILFDWLRQV±
NEW CASES
NEW AND RELAPSE
NOTIFICATION RATEa
1990–2010
YEAR
Slovenia
• 37
8•
Spain
• 20
14 •
Sweden
•7
6•
Switzerland
• 19
4•
Tajikistan
• 46
92 •
The Former
Yugoslav Republic
of Macedonia
–
19 •
Turkey
• 45
22 •
Turkmenistan
• 63
64 •
Ukraine
• 32
74 •
United Kingdom of
Great Britain and
Northern Ireland
• 10
12 •
Uzbekistan
• 46
a
198
62 •
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
NEW AND
RELAPSEa
722
525
368
269
208
186
169
7 600
8 764
7 993
7 281
6 769
6 687
6 377
557
564
417
539
457
515
552
1 278
830
544
508
319
333
323
2 460
2 029
2 779
5 460
6 396
6 125
6 297
786
641
598
450
450
384
24 468
22 981
18 038
19 744
17 600
16 757
15 879
2 325
1 939
4 038
3 191
3 757
3 157
3 230
16 465
21 459
32 945
39 608
37 832
36 075
33 857
5 908
6 176
6 220
8 173
6 586
7 008
7 219
9 414
9 866
15 750
21 513
17 040
17 540
16 883
SMEAR- SMEAR-NEGATIVE/
POSITIVE
UNKNOWN
EXTRAPULMONARY
303
145
109
81
85
64
83
133
110
83
70
67
109
59
30
33
13
30
2 605
3 423
2 511
2 333
2 236
2 076
6 159
4 446
3 880
2 855
2 879
2 621
124
890
1 581
1 572
1 680
102
118
134
97
107
117
235
147
208
161
180
226
216
152
197
199
228
209
185
118
108
64
73
82
515
287
249
156
163
150
126
139
151
99
97
91
1 042
434
1 745
2 057
1 972
2 290
617
1 918
2 175
2 284
2 208
2 038
427
1 417
1 774
1 684
1 631
319
167
178
188
198
141
376
308
236
133
103
135
4 383
4 315
7 450
6 993
6 007
5 375
OTHER RELAPSE
RE-TREAT EXCL. TOTAL
HISTORY
RELAPSE
RETREAT UNKNOWN
0
12
0
30
31
20
11
6
8
16
9
5
2
3
30
47
29
16
8
11
0
0
0
0
0
1 078
461
0
1 078
461
0
0
324
324
0
11
0
0
0
40
30
37
11
40
30
37
0
0
52
52
0
5
0
0
0
102
118
54
5
102
118
54
41
41
0
123
246
261
338
2 066
1 600
272
647
2 189
1 846
533
985
1 085
697
66
150
141
106
116
92
0
0
0
25
16
43
23
33
16
0
60
33
23
36
25
16
103
56
56
52
0
0
0
17 534
8 544
5 944
4 325
4 289
4 191
1 064
4 371
5 359
5 442
5 647
5 617
0
0
0
808
991
840
814
696
1 559
849
631
643
808
2 550
1 689
1 445
1 339
3
14
29
544
1 017
995
1 331
1 370
1 153
1 327
2 709
1 498
1 293
1 223
1 248
1
241
656
611
564
473
393
67
71
42
129
1 894
100
152
67
1 965
142
281
82
82
8 263
10 738
9 793
17 258
1 514
1 739
1 889
3 210
0
1 889
3 210
14 574
13 632
9 976
17 505
15 934
17 599
3 660
3 858
3 355
365
2 093
2 651
2 562
2 826
2 552
2 093
5 477
5 114
1 204
1 821
1 286
1 256
1 201
4 162
2 037
2 752
2 221
2 462
2 551
2 014
2 478
3 600
3 033
3 262
3 443
46
28
24
0
0
0
0
460
413
0
460
413
576
576
1 656
2 032
688
2 735
3 825
5 695
5 117
4 959
4 711
5 798
10 142
7 857
6 640
6 943
6 735
1 333
1 760
6 324
4 214
4 667
4 288
324
7 378
4 018
1 480
3 447
347
9 015
5 087
2 451
4 596
136
2 433
0
0
370
35
274
0
0
23
1 637
1 069
971
1 149
0
0
984
905
388
58
112
71
143
221
185
370
% SMEARPOS AMONG
NEW PULM
–
78
52
50
49
55
49
–
30
43
39
45
44
44
–
30
45
39
38
37
34
–
26
29
30
29
31
35
–
63
18
45
47
47
53
–
46
35
43
59
66
51
–
20
34
56
62
58
56
–
29
27
40
51
53
48
–
46
38
–
45
46
36
–
–
37
40
37
34
32
–
32
27
42
44
42
41
Rates are per 100 000 population. Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 198
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($7UHDWPHQWRXWFRPHVQHZVPHDUSRVLWLYHFDVHV±
% OF COHORT
YEAR
Albania
–
89 •
Andorra
–
100 •
Armenia
• 55
73 •
• 82
66 •
Austria
Azerbaijan
• 65
62 •
–
64 •
Belarus
Belgium
–
–
Bosnia and
Herzegovina
• 97
99 •
Bulgaria
–
85 •
Croatia
–
63 •
Cyprus
• 100
–
Czech Republic
• 60
–
Denmark
–
–
Estonia
–
59 •
–
68 •
–
–
Finland
France
Georgia
• 58
a
75 •
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
NUMBER
NOTIFIED
139
171
196
165
170
171
1
5
2
3
2
436
621
581
497
487
440
467
324
234
189
90
669
890
1 561
1 356
1 409
1 487
1 845
2 547
1 235
1 051
1 060
1 201
400
409
380
322
311
280
865
759
640
737
509
609
1 087
2 524
1 214
1 080
1 020
894
1 204
0
372
382
328
302
6
4
9
8
6
14
487
420
308
267
249
218
128
171
129
135
106
101
369
255
162
168
144
135
244
205
130
85
104
93
3 449
1 815
1 941
1 921
1 222
1 019
221
601
1 509
1 867
1 868
2 055
SIZE OF
COHORT
196
181
170
171
2
5
2
3
3
507
447
581
490
487
440
383
298
230
380
226
538
890
1 561
1 356
1 392
1 480
1 987
1 902
2 160
358
304
503
502
865
756
1 035
1 267
757
852
1 342
1 233
1 193
1 055
391
637
602
234
6
8
12
487
396
315
459
470
110
128
213
200
257
162
302
259
240
181
170
227
221
807
1 489
1 975
2 196
2 352
COHORT AS
% NOTIFIED
–
–
100
110
100
100
–
200
100
100
100
150
116
72
100
99
100
100
82
92
98
–
–
251
80
100
100
100
99
100
–
–
–
189
179
180
–
88
80
156
161
–
100
100
162
172
149
140
–
–
111
114
117
118
–
–
105
167
184
77
100
–
89
–
200
–
100
94
102
172
189
–
–
64
99
158
189
–
–
101
100
180
180
178
–
–
–
213
163
244
–
–
–
–
–
–
100
134
99
106
118
114
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
43
50
52
64
35
35
39
25
4
4
4
2
2
2
1
1
5
4
2
4
11
5
4
4
80
100
33
33
52
81
59
55
62
60
2
0
17
50
0
0
67
67
2
6
13
15
11
12
81
73
58
0
0
0
0
8
4
3
6
5
7
10
9
7
0
0
0
0
36
3
5
11
6
3
0
0
0
50
0
0
0
0
1
7
14
12
10
8
7
6
7
0
20
0
0
0
0
0
4
1
7
10
1
11
11
7
8
58
89
48
49
48
47
40
59
7
0
11
8
8
15
10
9
1
4
3
3
3
13
0
12
2
4
2
2
7
9
8
19
3
12
11
10
16
21
16
4
4
22
27
29
12
67
68
64
7
3
0
9
9
10
10
7
4
2
3
1
6
10
20
25
21
16
20
41
45
52
55
10
10
8
7
1
0
4
17
0
9
9
6
24
15
4
97
77
93
93
87
97
1
18
3
4
5
2
0
1
1
1
4
0
1
1
0
1
1
0
1
2
0
1
1
0
1
1
2
1
1
0
82
77
79
78
3
2
5
7
4
7
6
9
2
0
2
2
7
8
6
4
1
6
1
1
40
49
46
48
100
7
12
11
15
0
7
13
18
26
0
0
0
3
0
0
1
1
2
3
0
45
24
19
7
0
0
38
25
13
33
25
8
0
25
17
17
57
59
62
69
67
3
11
10
3
1
0
17
6
19
21
3
1
0
1
3
2
1
2
7
6
35
11
20
1
2
37
44
26
16
49
39
53
25
5
6
5
1
0
1
1
1
0
2
1
1
9
8
13
57
67
70
60
59
58
2
2
2
1
1
11
8
14
15
15
1
1
1
18
2
6
10
10
6
6
12
10
15
1
18
43
46
33
27
26
34
19
16
17
1
6
0
1
1
1
9
5
14
41
38
60
60
53
57
18
25
13
17
20
19
8
3
3
2
3
3
3
9
5
6
12
12
29
25
13
9
8
7
2
0
7
6
4
3
European Region
TREATMENT SUCCESS (%)a
1995–2009
TREATMENT SUCCESS = percent cured + percent completed then rounded to the nearest digit.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 199
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
199
05/10/11 09:03
7$%/($7UHDWPHQWRXWFRPHVQHZVPHDUSRVLWLYHFDVHV±
% OF COHORT
TREATMENT SUCCESS (%)a
1995–2009
YEAR
Germany
–
69 •
Greece
–
–
Hungary
–
–
Iceland
• 100
75 •
Ireland
–
66 •
Israel
–
86 •
Italy
• 80
–
Kazakhstan
–
62 •
Kyrgyzstan
–
82 •
• 61
75 •
Latvia
Lithuania
–
76 •
Luxembourg
• 100
–
Malta
• 100
80 •
Monaco
–
–
Montenegro
• 30
86 •
Netherlands
• 72
80 •
• 77
–
Norway
Poland
–
a
200
67 •
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
NUMBER
NOTIFIED
SIZE OF
COHORT
3 852
0
1 379
1 183
954
1 025
454
1 199
2 416
2 126
2 227
235
197
257
80
198
796
412
423
381
346
363
2
1
2
2
2
3
0
651
412
612
602
2
2
2
7
5
4
138
130
135
123
95
73
107
185
188
186
216
142
126
95
119
1 413
687
1 275
979
938
885
3 022
8 903
6 911
6 195
6 193
5 213
832
1 296
1 972
1 720
1 712
1 609
504
637
536
478
400
367
979
776
964
925
884
742
336
227
242
178
202
295
223
0
8 781
6 884
6 140
6 167
5 355
1 233
1 897
1 718
1 640
1 543
475
637
536
772
1 471
592
776
958
1 209
1 764
1 033
37
21
14
0
0
0
5
5
5
8
15
12
5
4
5
12
20
10
0
64
41
65
53
575
289
237
187
189
203
62
37
48
38
53
42
6 955
3 180
2 823
2 827
2 650
2 658
63
76
65
78
715
301
208
411
467
454
87
37
47
122
105
214
2 823
4 510
4 228
4 391
COHORT AS
% NOTIFIED
–
–
87
204
223
217
–
–
–
0
–
–
–
158
97
161
174
–
100
200
100
350
250
133
–
53
82
137
153
196
–
156
160
192
187
170
21
32
–
0
–
–
–
99
100
99
100
103
–
95
96
100
96
96
94
100
100
162
368
161
–
100
99
131
200
139
–
–
0
–
–
–
100
80
100
150
133
83
–
–
–
–
–
–
98
185
100
147
124
104
88
220
247
224
140
100
98
321
198
–
–
7
100
160
160
165
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
61
39
37
33
29
16
32
40
34
40
16
9
11
12
11
1
0
0
7
0
2
2
1
2
1
4
18
10
11
18
–
–
–
–
–
–
28
32
31
32
36
13
20
21
10
13
12
11
3
12
14
20
12
9
6
7
11
20
17
9
0
0
0
14
0
0
0
0
0
0
0
0
0
0
0
0
0
100
100
100
71
80
75
0
0
0
0
0
0
14
20
25
33
3
0
7
0
51
62
70
69
66
12
9
5
7
9
0
3
0
0
4
1
2
2
1
0
22
23
15
24
65
69
64
78
72
73
37
18
15
16
11
14
6
36
15
11
12
10
10
3
1
0
0
0
0
0
2
0
0
3
2
1
1
11
9
1
2
5
1
3
4
16
–
–
–
–
–
–
76
70
69
64
62
3
1
0
0
0
5
5
4
4
4
10
12
20
26
30
3
5
5
4
3
3
8
3
2
2
73
81
81
80
79
61
68
72
80
32
72
9
4
4
5
4
0
4
1
2
0
3
3
3
3
3
3
9
12
11
7
4
9
4
5
4
6
4
3
3
1
0
5
1
5
5
6
5
6
21
7
7
4
2
5
6
2
2
2
4
7
7
8
7
57
11
73
70
70
51
76
100
0
0
31
0
0
10
11
12
7
10
0
4
3
1
3
2
0
12
11
7
7
9
0
2
6
10
0
4
0
–
–
–
–
–
–
80
0
0
0
0
0
0
0
15
0
0
0
0
0
0
0
0
8
0
20
100
100
75
60
80
0
0
0
0
0
17
25
20
10
17
52
49
17
23
9
17
14
11
43
49
62
54
62
21
62
32
37
55
53
75
62
71
69
34
22
30
25
22
3
5
8
8
6
7
5
7
9
14
14
2
2
6
0
0
0
0
1
3
0
0
4
0
2
4
5
3
1
2
1
3
8
3
4
0
70
18
9
3
15
15
8
14
7
8
0
11
2
19
7
50
65
62
54
48
22
12
14
20
19
11
5
6
7
5
6
1
0
0
0
6
9
10
10
10
5
8
7
9
17
0
0
0
TREATMENT SUCCESS = percent cured + percent completed then rounded to the nearest digit.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 200
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($7UHDWPHQWRXWFRPHVQHZVPHDUSRVLWLYHFDVHV±
% OF COHORT
YEAR
Portugal
• 69
–
Republic of
Moldova
–
53 •
• 51
85 •
• 65
55 •
Romania
Russian
Federation
San Marino
–
–
Serbia
• 85
85 •
Serbia &
Montenegro
Slovakia
• 64
82 •
• 90
87 •
Slovenia
Spain
–
–
Sweden
–
85 •
–
–
Switzerland
Tajikistan
• 88
81 •
• 70
90 •
The Former
Yugoslav Republic
of Macedonia
Turkey
–
91 •
• 73
84 •
• 83
60 •
Turkmenistan
Ukraine
United Kingdom of
Great Britain and
Northern Ireland
–
–
Uzbekistan
• 78
a
81 •
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
2005
2007
2008
2009
1995
2000
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
NUMBER
NOTIFIED
SIZE OF
COHORT
COHORT AS
% NOTIFIED
2 019
1 863
1 302
1 173
1 053
1 043
665
651
1 696
1 610
1 533
1 318
10 469
10 202
10 801
9 425
9 511
8 987
37 512
27 467
32 605
33 103
33 949
33 351
1 240
1 924
1 393
1 694
1 683
651
1 690
1 599
1 533
1 318
11 597
10 158
10 929
11 245
10 082
10 737
54
3 616
25 692
31 857
32 356
32 316
1
1
1 105
1 146
1 172
1 055
1 497
0
788
236
162
176
126
121
303
145
109
90
81
85
2 605
3 423
2 511
2 317
2 333
2 236
102
118
134
96
97
107
185
118
108
95
64
73
1 042
434
1 745
2 228
2 057
1 972
319
167
178
200
188
198
4 383
4 315
7 450
7 527
6 993
6 007
544
1 017
995
1 378
1 331
1 370
8 263
10 738
1 154
1 145
1 391
1 137
1 956
267
807
238
158
304
498
174
270
145
109
148
159
149
61
103
107
144
160
–
–
100
100
99
100
100
111
100
101
119
106
119
0
13
79
96
95
97
–
100
–
–
–
–
104
100
119
108
131
–
102
101
98
173
395
144
89
100
100
164
196
175
–
–
–
0
–
–
–
95
99
247
228
238
–
–
–
–
–
–
33
153
99
93
99
100
70
91
101
99
100
101
–
80
100
100
100
100
100
100
100
93
100
100
116
–
–
100
99
96
–
–
74
138
506
–
95
27
94
100
100
100
11 028
14 574
13 632
1 204
1 821
1 639
1 286
1 256
2 735
3 825
5 695
6 326
5 117
4 959
0
112
133
237
221
255
348
665
1 729
2 073
2 044
1 972
222
152
179
197
188
199
3 461
7 450
7 510
6 993
6 007
544
1 017
995
1 288
1 331
1 375
9 564
11 068
14 407
13 111
1 348
2 266
6 510
2 598
1 030
5 336
6 326
5 117
4 959
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
45
9
13
12
11
23
71
76
75
77
4
6
6
5
4
0
0
0
3
4
5
4
3
2
19
9
2
5
7
1
60
54
54
49
38
28
71
72
72
72
54
64
55
55
54
52
62
2
8
7
5
13
42
11
13
13
14
11
4
3
3
3
3
0
9
10
11
10
6
4
5
4
5
4
15
6
13
12
12
11
0
11
16
8
17
7
8
4
4
4
4
6
13
14
16
18
20
0
11
11
12
14
6
8
6
5
5
6
11
9
11
10
9
8
37
7
0
8
6
31
9
4
3
2
1
4
4
4
5
4
5
0
0
100
0
0
0
72
77
80
81
34
82
64
81
66
86
47
82
64
33
47
27
38
24
13
7
6
4
18
7
1
2
2
1
3
0
0
26
0
46
0
26
51
38
55
42
63
5
6
7
7
2
4
16
14
6
12
5
14
4
8
12
11
15
9
1
0
0
1
0
2
0
0
0
1
1
5
4
4
5
10
6
4
2
1
2
1
2
1
5
1
3
2
1
4
3
2
2
33
1
16
1
1
1
0
2
3
3
3
5
2
3
–
–
–
–
–
–
0
0
0
0
79
74
66
87
85
11
6
7
6
6
0
1
0
1
0
2
1
1
1
1
8
18
26
4
8
69
74
74
78
76
75
61
51
62
74
81
85
18
3
9
5
7
6
9
35
22
13
7
5
7
15
4
5
4
4
13
4
2
10
7
4
3
8
6
6
7
8
9
2
0
2
1
2
2
0
7
5
5
5
9
7
14
1
2
5
0
0
0
2
1
1
0
1
0
0
1
0
0
45
60
59
61
55
79
70
79
83
83
83
73
44
32
33
30
18
2
14
5
1
1
3
2
3
3
3
11
9
6
5
6
5
6
0
0
1
1
1
7
6
4
6
6
6
7
6
5
3
3
2
2
3
5
5
5
5
19
3
2
2
3
7
1
1
1
1
1
4
54
56
52
5
6
7
14
12
13
12
12
16
10
9
8
5
5
3
0
0
68
77
78
7
7
4
0
0
1
1
1
24
16
16
78
27
72
72
75
77
0
53
9
7
6
5
9
3
6
7
6
6
7
6
6
6
6
5
4
5
7
6
4
5
3
6
1
2
3
3
European Region
TREATMENT SUCCESS (%)a
1995–2009
TREATMENT SUCCESS = percent cured + percent completed then rounded to the nearest digit.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 201
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
201
05/10/11 09:03
7$%/($7UHDWPHQWRXWFRPHVUHWUHDWPHQWFDVHV±
% OF COHORT
TREATMENT SUCCESS (%)a
1995–2009
YEAR
Albania
–
76 •
Andorra
–
100 •
Armenia
• 50
63 •
Austria
–
41 •
Azerbaijan
–
53 •
–
42 •
Belarus
Belgium
–
–
Bosnia and
Herzegovina
–
84 •
Bulgaria
–
70 •
Croatia
–
50 •
Cyprus
–
–
Czech Republic
–
–
Denmark
–
–
Estonia
–
51 •
Finland
–
36 •
France
–
–
Georgia
• 32
a
202
60 •
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
NUMBER
NOTIFIED
SIZE OF
COHORT
53
19
43
25
32
21
30
25
28
21
0
0
1
0
2
38
76
327
596
618
542
1
0
2
6
54
327
590
534
542
30
26
63
25
47
74
3 200
2 903
3 733
2 384
343
825
1 049
884
849
878
80
89
68
73
67
130
193
156
183
67
113
383
201
309
313
372
42
10
27
11
37
74
1 314
1 081
3 084
1 687
862
815
616
55
47
72
42
122
106
156
77
116
198
301
500
384
94
98
36
62
0
0
3
1
3
3
21
25
34
81
61
92
22
2
5
38
31
76
56
6
28
29
36
37
10
71
116
94
78
90
80
15
22
36
32
59
89
79
88
82
29
22
14
19
15
14
14
0
371
385
379
196
681
2 152
1 845
1 677
566
298
470
2 037
1 847
1 542
1 521
COHORT AS
% NOTIFIED
–
–
70
100
88
100
–
–
–
100
–
100
16
71
100
99
86
100
–
33
104
–
–
148
–
100
41
37
83
71
–
–
–
98
96
70
–
62
69
99
63
–
–
63
68
85
115
103
–
–
99
97
160
103
–
–
98
–
–
35
–
–
67
–
167
–
–
152
91
94
92
–
–
54
76
100
86
–
–
51
95
101
98
103
–
–
–
107
74
–
–
–
–
–
–
–
152
69
95
100
92
269
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
37
24
39
38
37
60
36
38
3
4
14
10
0
8
4
0
10
4
4
10
13
0
4
5
0
–
0
50
52
13
12
15
9
100
–
100
0
15
28
34
36
54
0
–
0
0
7
7
11
8
8
0
–
0
17
7
12
12
15
4
0
–
0
33
19
37
30
21
15
0
–
0
0
0
4
2
5
10
0
11
80
56
0
11
0
0
0
11
20
11
9
3
27
38
9
5
36
0
30
18
24
59
28
32
18
39
7
9
12
32
14
5
6
5
4
6
11
6
6
6
9
14
13
15
23
19
4
38
29
17
13
30
29
38
32
30
4
9
9
13
18
8
7
5
3
1
6
20
37
16
17
15
7
45
21
19
48
13
19
8
10
0
0
14
15
0
6
19
11
43
51
2
79
85
85
70
52
15
8
7
5
32
3
4
3
22
5
1
1
2
1
3
2
2
2
1
3
0
1
1
0
5
57
22
16
32
10
37
7
38
7
16
4
12
11
1
3
5
14
12
5
8
2
12
65
5
20
13
9
1
1
57
27
23
36
5
5
5
0
0
0
0
100
40
20
53
16
39
46
11
39
37
16
8
3
12
21
3
0
27
27
11
16
60
64
39
44
7
5
17
54
21
37
36
34
2
20
15
10
17
33
36
29
8
23
19
23
20
26
0
40
0
3
7
5
26
39
5
5
0
0
0
5
3
3
7
0
31
38
3
3
8
9
15
0
4
4
23
6
3
26
18
20
9
37
25
19
1
20
13
21
7
7
21
0
0
0
0
0
47
21
64
24
31
35
33
29
34
12
10
7
9
6
5
9
8
10
11
23
17
45
29
23
15
14
15
2
0
6
9
7
3
5
TREATMENT SUCCESS = percent cured + percent completed then rounded to the nearest digit.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 202
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($7UHDWPHQWRXWFRPHVUHWUHDWPHQWFDVHV±
% OF COHORT
YEAR
Germany
–
59 •
Greece
–
–
Hungary
–
–
Iceland
–
100 •
Ireland
–
60 •
Israel
–
67 •
Italy
• 48
–
Kazakhstan
–
48 •
Kyrgyzstan
–
71 •
Latvia
–
45 •
Lithuania
–
35 •
Luxembourg
–
–
Malta
–
50 •
Monaco
–
–
Montenegro
• 20
73 •
Netherlands
–
71 •
Norway
–
–
Poland
–
a
62 •
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
NUMBER
NOTIFIED
493
533
441
252
48
74
70
84
3
SIZE OF
COHORT
63
432
489
190
316
0
371
347
328
285
211
0
1
1
2
0
1
122
333
319
126
22
40
51
41
16
10
14
50
51
52
8
7
8
4
9
8
7
8
4
9
31
26
625
293
1 772
292
1 320
5 093
15 009
14 143
9 229
9 371
127
555
847
1 040
756
758
118
375
205
176
152
147
128
509
460
426
357
404
1
2
1
1
0
2 901
4 085
18 722
8 662
9 392
278
845
1 035
897
924
205
205
176
293
148
282
455
426
354
404
4
0
0
0
0
0
1
1
7
2
1
1
0
4
2
0
27
22
10
11
10
23
10
11
70
44
44
49
46
28
12
14
24
27
18
28
55
47
49
1 071
882
1 077
1 047
1 020
688
3
9
25
28
56
985
1 038
720
942
COHORT AS
% NOTIFIED
–
–
88
92
43
125
–
–
–
0
–
–
–
33
96
97
44
–
–
100
–
100
–
100
–
45
35
98
124
325
–
100
100
100
100
100
–
4
–
0
–
–
–
57
27
132
94
100
–
50
100
100
119
122
–
55
100
100
193
101
–
55
99
100
99
100
–
–
–
–
–
–
–
–
100
0
57
100
–
–
–
–
–
–
37
105
100
100
–
26
64
125
96
107
–
25
64
104
104
–
–
6
91
99
71
137
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
51
30
27
30
19
21
36
41
29
40
16
9
13
8
13
3
0
1
9
0
5
7
5
5
5
5
18
13
18
22
–
–
–
–
–
–
16
12
11
29
20
37
39
14
15
13
15
10
9
8
10
28
11
11
8
9
30
18
17
10
0
100
0
0
0
0
0
0
0
0
0
50
100
100
0
0
0
50
0
0
40
7
0
6
0
0
57
62
45
60
10
7
16
6
8
10
0
0
0
40
0
2
2
0
0
29
20
41
33
13
71
75
0
56
42
31
25
14
25
75
11
6
15
63
14
0
0
11
26
4
0
0
0
0
0
10
12
0
0
0
25
0
13
8
0
0
0
0
22
3
31
–
–
–
–
–
–
62
46
24
24
22
4
1
29
18
27
10
13
9
10
9
14
14
25
32
34
5
6
9
7
6
5
19
4
8
3
59
40
34
36
28
15
31
34
34
43
8
8
8
6
7
8
9
8
10
6
6
11
13
9
7
4
1
4
4
9
39
50
54
28
43
2
1
4
0
1
19
10
9
7
14
3
1
1
13
0
8
9
11
2
14
29
29
22
50
28
45
27
30
40
35
0
2
0
21
25
28
22
24
8
4
5
18
4
22
22
21
19
22
5
19
17
1
15
0
0
–
0
0
0
–
0
0
–
0
0
–
0
100
100
–
50
50
0
0
0
0
0
–
50
50
4
70
45
20
52
10
27
20
13
10
9
0
0
0
0
10
0
60
30
0
18
28
11
5
6
4
22
68
67
32
67
6
4
4
6
2
0
0
4
0
6
7
0
2
4
39
11
20
53
22
33
44
28
29
0
33
28
43
67
22
8
7
0
0
0
14
0
0
0
0
0
36
7
64
22
35
43
30
13
31
31
21
32
14
6
7
7
5
0
0
0
1
0
4
32
18
16
14
5
9
8
12
18
European Region
TREATMENT SUCCESS (%)a
1995–2009
TREATMENT SUCCESS = percent cured + percent completed then rounded to the nearest digit.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 203
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
203
05/10/11 09:03
7$%/($7UHDWPHQWRXWFRPHVUHWUHDWPHQWFDVHV±
% OF COHORT
TREATMENT SUCCESS (%)a
1995–2009
YEAR
Portugal
• 55
–
Republic of
Moldova
–
33 •
Romania
–
57 •
Russian
Federation
• 58
34 •
San Marino
–
–
Serbia
• 73
74 •
Serbia &
Montenegro
Slovakia
–
82 •
Slovenia
–
88 •
Spain
–
–
Sweden
–
69 •
Switzerland
–
–
Tajikistan
–
72 •
The Former
Yugoslav Republic
of Macedonia
–
79 •
Turkey
–
73 •
Turkmenistan
–
–
Ukraine
–
47 •
United Kingdom of
Great Britain and
Northern Ireland
–
–
Uzbekistan
–
a
204
69 •
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
2005
2007
2008
2009
1995
2000
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
NUMBER
NOTIFIED
SIZE OF
COHORT
COHORT AS
% NOTIFIED
268
481
350
307
292
271
148
374
1 777
2 201
1 865
1 663
1 077
3 770
6 938
6 239
6 012
5 401
133
209
293
305
178
50
43
84
99
61
–
–
0
96
98
100
100
–
69
97
95
77
100
–
9
31
19
19
51
–
–
–
–
–
–
95
113
110
101
–
10
–
38
94
99
173
100
–
51
93
100
138
100
–
–
–
0
–
–
–
23
53
113
76
–
–
–
–
–
–
–
–
–
80
100
102
304
–
–
94
103
100
100
–
–
62
100
100
101
–
25
100
33
262
–
–
–
–
91
342
190
–
–
32
99
–
–
–
220
44
100
99
100
18 147
35 153
96 557
94 070
32 569
1
1 713
2 167
1 865
1 663
2 605
6 737
5 930
4 656
5 391
12
1 694
10 855
18 527
18 070
16 726
0
300
314
280
203
198
203
20
120
108
97
98
79
30
47
29
18
16
8
284
355
309
205
21
46
101
96
170
79
24
27
18
22
8
0
1 078
420
461
0
11
40
30
32
37
9
16
36
28
45
5
102
118
53
54
370
2 189
2 003
1 846
533
25
16
103
69
56
56
808
2 550
1 885
1 689
1 445
67
1 965
142
351
281
1 762
1 995
1 881
1 618
97
71
56
56
1 593
1 885
1 692
1 459
495
142
116
737
1 889
3 210
5 752
2 093
5 477
5 240
7 152
10 424
0
460
436
413
147
433
347
9 015
4 617
5 087
2 451
764
3 999
4 617
5 046
2 451
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
38
10
8
8
7
17
66
66
64
69
6
4
10
7
6
0
1
0
5
9
7
9
9
7
24
14
6
12
12
0
22
18
16
29
0
19
18
18
4
0
13
14
18
15
100
16
29
12
26
0
17
20
20
19
0
13
1
16
8
24
39
36
40
38
42
25
33
33
33
31
20
13
16
10
19
17
24
4
3
3
3
9
10
11
10
10
25
10
16
14
13
13
20
10
12
14
12
8
21
26
28
29
32
17
14
15
17
16
8
9
16
15
14
12
11
14
11
8
4
0
11
5
7
7
9
46
46
49
60
26
27
27
14
10
8
10
9
2
2
1
0
12
15
7
12
3
3
6
4
67
10
10
0
14
0
78
50
40
28
34
0
38
47
20
48
11
7
4
5
14
2
0
1
1
1
4
3
3
1
0
4
3
5
46
3
29
44
44
5
13
46
41
39
32
75
4
4
17
9
0
0
0
0
14
0
13
4
0
0
8
7
0
41
13
–
–
–
–
–
–
0
0
0
0
0
6
4
13
0
0
0
7
0
11
0
3
0
78
75
67
75
69
7
11
25
25
14
11
29
33
32
29
47
42
43
43
9
9
9
11
8
7
8
10
6
8
6
6
1
1
2
1
24
27
34
39
33
38
38
39
7
17
11
7
2
4
2
2
32
7
13
11
2
7
4
2
24
34
30
29
46
42
44
44
5
6
4
3
2
2
2
2
12
10
9
9
11
6
10
13
66
42
41
63
9
26
1
18
7
13
17
7
11
10
16
7
6
9
23
5
1
0
3
0
20
31
18
35
10
29
13
16
14
14
21
22
11
13
12
7
8
5
0
0
57
71
4
8
0
0
3
2
36
19
20
28
18
24
30
55
41
57
48
39
8
9
8
10
11
8
7
4
7
7
9
14
9
9
9
0
1
3
3
5
TREATMENT SUCCESS = percent cured + percent completed then rounded to the nearest digit.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 204
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($+,9WHVWLQJDQGSURYLVLRQRI&37$57DQG,37 –
YEAR
Albania
• 15
42 •
Andorra
–
0•
Armenia
• 12
70 •
Austria
–
–
–
–
Azerbaijan
Belarus
–
93 •
Belgium
• 82
–
Bosnia and
Herzegovina
–
–
Bulgaria
•1
67 •
Croatia
–
–
Cyprus
•0
–
Czech Republic
• 19
–
Denmark
–
–
Estonia
• 94
90 •
Finland
•1
–
–
–
France
Georgia
• 10
30 •
Germany
–
–
–
–
Greece
Hungary
–
–
Iceland
• 91
–
Ireland
•6
16 •
• 85
90 •
Israel
Italy
–
–
Kazakhstan
• 77
84 •
Kyrgyzstan
–
104 •
Latvia
• 85
80 •
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
% OF TB
NUMBER OF TB
PATIENTS WITH PATIENTS WITH
KNOWN HIV
KNOWN HIV
STATUS
STATUS
15
41
47
42
–
0
0
0
12
16
26
70
–
–
–
–
–
59
–
–
–
95
95
93
82
91
91
–
–
–
0
–
1
23
40
67
–
–
–
–
0
72
–
–
19
20
23
–
–
48
61
–
94
90
92
90
1
1
–
–
–
–
–
–
10
25
22
30
–
–
–
–
–
–
–
–
–
–
0
–
91
83
58
–
6
19
26
16
85
88
83
90
–
–
–
–
77
98
97
84
–
91
104
104
85
85
85
80
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 205
81
177
211
186
0
0
0
270
335
521
1 242
5 945
5 227
5 227
5 153
937
913
930
0
23
732
1 155
1 773
0
36
189
174
161
177
207
0
490
401
380
295
3
5
674
1 482
1 289
1 723
0
10
5
7
28
89
125
68
316
283
288
308
31 187
28 237
29 597
23 854
6 508
6 617
6 569
1 226
910
830
748
PATIENTS
NOTIFIED
(NEW AND
RETREAT)
540
434
447
440
10
4
9
7
2 322
2 125
2 006
1 780
954
707
688
7 920
10 078
10 417
8 394
6 357
5 483
5 511
5 554
1 144
1 006
1 020
2 160
1 736
1 772
1 390
3 302
3 151
2 911
2 649
1 144
980
855
695
37
50
55
NUMBER OF HIV- % OF TESTED
POSITIVE TB
TB PATIENTS
PATIENTS
HIV-POSITIVE
1
4
6
0
0
0
0
6
12
17
17
139
156
190
187
52
56
43
1
0
0
0
1
2
0
1
2
1 007
868
702
2
7
5
424
367
339
8
11
9
0
33
42
40
34
3
6
6
4
519
444
411
329
361
350
533
327
5 374
5 812
2 890
6 448
5 836
5 978
5 796
6 045
4 474
4 432
4 302
767
669
588
2 024
1 606
1 448
11
6
12
22
461
470
488
428
372
322
347
343
4 137
4 418
3 877
2 495
40 429
28 913
30 578
28 550
6 765
7 127
6 358
6 295
1 443
1 070
977
934
13
20
33
30
2
2
1
1
1
0
11
18
11
12
17
12
22
13
183
238
325
333
117
88
183
53
72
73
71
1
2
3
0
–
–
–
–
2
4
3
1
–
–
–
–
–
–
–
–
–
3
4
4
6
6
5
–
–
–
–
–
–
0
0
0
–
–
–
–
–
6
–
–
1
4
3
–
–
6
4
–
7
10
11
12
100
120
–
–
–
–
–
–
2
1
3
2
–
–
–
–
–
–
–
–
–
–
–
–
10
20
0
–
39
20
9
18
5
4
8
4
–
–
–
–
1
1
1
1
–
2
1
3
4
8
9
9
% OF HIV% OF HIVNUMBER OF HIVPOSITIVE
POSITIVE TB POSITIVE TB
PEOPLE
PATIENTS ON PATIENTS ON
PROVIDED IPT
CPT
ART
–
100
67
–
–
–
–
–
83
67
53
47
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
0
–
–
–
–
0
0
–
–
–
–
–
50
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
54
85
55
73
–
–
–
–
–
–
–
–
–
–
–
–
100
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
41
15
11
26
–
–
100
70
–
–
–
–
–
100
100
–
–
–
–
–
33
8
35
41
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
100
–
–
–
–
0
100
–
–
–
–
–
50
–
–
–
–
–
–
–
–
–
–
–
33
58
47
–
–
–
–
–
–
–
–
100
85
55
73
–
–
–
–
–
–
–
–
–
–
–
–
100
–
–
–
–
–
–
–
–
100
36
–
–
–
–
–
8
12
7
8
–
–
22
37
55
29
60
76
2
3
5
0
0
1
0
62
257
0
0
9
1
0
0
0
301
0
European Region
% OF TB PATIENTS WITH
KNOWN HIV STATUS
2005–2010
0
656
1 027
1 063
58
0
0
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
205
05/10/11 09:03
7$%/($+,9WHVWLQJDQGSURYLVLRQRI&37$57DQG,37 –
% OF TB PATIENTS WITH
KNOWN HIV STATUS
2005–2010
YEAR
Lithuania
–
–
–
–
Luxembourg
Malta
•4
81 •
Monaco
–
–
Montenegro
•5
74 •
• 22
34 •
Netherlands
Norway
–
–
Poland
–
0•
Portugal
• 70
–
Republic of
Moldova
• 103
93 •
Romania
• 37
34 •
• 55
123 •
Russian
Federation
San Marino
–
–
Serbia
•0
1•
• 95
96 •
• 38
76 •
Slovakia
Slovenia
Spain
–
–
–
–
–
–
Sweden
Switzerland
Tajikistan
•9
53 •
•0
9•
–
4•
–
100 •
–
95 •
–
0•
The Former
Yugoslav Republic
of Macedonia
Turkey
Turkmenistan
Ukraine
United Kingdom of
Great Britain and
Northern Ireland
Uzbekistan
• 124
206
100 •
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
% OF TB
NUMBER OF TB
PATIENTS WITH PATIENTS WITH
KNOWN HIV
KNOWN HIV
STATUS
STATUS
–
–
–
–
–
–
–
–
4
85
86
81
–
–
–
–
5
55
76
74
22
29
33
34
–
–
–
–
–
0
0
0
70
88
53
–
103
89
91
93
37
25
28
34
55
103
131
123
–
–
–
–
0
0
0
1
95
85
99
96
38
62
71
76
–
49
47
–
–
–
–
–
–
–
–
–
9
49
50
53
0
20
9
9
–
0
0
4
–
–
–
100
–
94
86
95
–
–
–
0
124
100
100
100
1
45
38
26
8
73
91
84
252
285
380
370
2 574
2 250
2 081
1 938
37
28
27
29
23
53
44
32
1
170
133
120
114
1 157
997
1 160
1 073
290
324
363
NUMBER OF HIV- % OF TESTED
POSITIVE TB
TB PATIENTS
PATIENTS
HIV-POSITIVE
7
21
14
19
5
4
3
0
0
0
1
61
39
42
47
35
27
22
2 485
2 648
1 520
9 280
8 081
8 236
7 509
3 536
2 995
2 871
35
27
22
571
442
349
6 469
5 171
5 107
5 068
10 860
6 123
6 443
7 121
85 537
221 889
204 624
199 445
6 278
5 838
5 591
5 444
29 347
24 786
23 267
21 078
154 379
214 905
156 222
162 553
9
260
260
300
160
202
214
229
3 533
6 083
9 253
10 617
3
5
5
12
720
537
500
420
107
131
134
130
3 468
2 813
2 595
2 385
760
633
506
439
278
213
188
172
8 359
8 214
7 592
7 089
569
552
627
675
626
516
554
549
7 526
7 996
7 482
7 641
658
483
473
420
21 303
18 452
17 402
16 551
3 291
3 909
3 157
3 230
39 608
37 832
38 901
36 409
8 633
8 655
9 040
8 483
28 891
21 194
21 453
20 330
3
5
5
12
1
0
1
1
0
0
0
1
3 991
3 599
670
3 949
3 714
4 049
2
99
43
38
0
1
581
3 230
35 739
33 424
34 621
0
35 801
21 194
21 453
20 330
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 206
PATIENTS
NOTIFIED
(NEW AND
RETREAT)
508
425
1
48
49
100
2
2
0
0
1
14
0
0
1 526
3 375
3 771
4 501
553
0
147
256
357
427
–
–
–
–
–
–
–
–
–
11
11
12
–
–
–
–
0
0
0
1
24
14
11
13
–
–
–
–
–
100
100
100
23
17
23
–
0
5
5
6
1
3
3
3
4
3
5
5
–
–
–
–
100
100
100
100
0
0
0
0
0
0
0
1
–
13
12
–
–
–
–
–
–
–
–
–
0
1
1
2
100
2
0
0
–
–
100
2
–
–
–
0
–
9
11
13
–
–
–
–
0
1
2
2
% OF HIV% OF HIVNUMBER OF HIVPOSITIVE
POSITIVE TB POSITIVE TB
PEOPLE
PATIENTS ON PATIENTS ON
PROVIDED IPT
CPT
ART
–
–
–
–
–
–
–
–
–
60
–
–
–
–
–
–
–
–
–
0
–
54
–
–
–
–
–
–
–
–
–
–
–
99
–
–
–
–
–
10
–
–
38
43
–
–
–
–
–
–
–
–
433
–
–
–
0
–
0
0
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
0
–
0
23
0
0
–
–
–
–
–
36
–
–
–
–
–
63
57
–
–
–
–
–
0
35
25
92
–
–
–
–
–
–
–
–
–
100
–
–
–
–
–
–
–
–
–
100
–
249
–
–
–
–
–
–
–
–
–
–
–
100
100
–
–
28
–
32
–
80
82
88
–
23
77
82
–
–
–
–
400
100
–
–
100
–
100
100
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
0
35
45
42
100
100
–
–
–
–
–
64
–
–
–
–
–
36
32
50
–
–
–
–
0
30
10
37
0
0
0
0
90
54
21
0
188
188
133
6 933
10 451
0
4
0
0
0
23
0
0
0
0
0
2 763
4 980
5 029
1 046
1 056
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($7HVWLQJIRU0'57%DQGQXPEHURIFRQILUPHGFDVHVRI0'57%±
Albania
Andorra
Armenia
Austria
Azerbaijan
Belarus
Belgium
Bosnia and
Herzegovina
Bulgaria
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Finland
France
Georgia
Germany
Greece
Hungary
Iceland
Ireland
Israel
Italy
Kazakhstan
Kyrgyzstan
a
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
NEW CASES
NOTIFIED
NUMBER OF
% OF NOTIFIED
NUMBER OF
NOTIFIED TESTED TESTED FOR CONFIRMED CASES
FOR MDR-TB
MDR-TB
OF MDR-TB
1
2
0
2
0
0
0
0
162
128
156
177
13
497
402
416
415
10
4
7
7
1 995
1 507
1 464
1 329
928
161
192
119
186
9
3
2
4
576
417
480
471
570
22
15
800
265
240
453
923
1 342
1 576
11
22
10
437
358
4 720
5 130
5 872
5 237
5 308
4 634
4 633
4 345
1 076
811
806
11
12
2
2
47
32
43
56
6
4
7
0
1
1
4
2 004
1 663
1 659
1 289
3 101
2 838
2 526
2 301
1 050
944
793
652
34
41
41
1 035
757
854
600
482
833
716
801
586
13
11
8
973
807
638
562
483
413
5
2
2
395
330
288
307
253
209
79
74
86
63
3
1
6
6
24
27
30
425
354
331
250
339
331
519
312
4 887
3 355
2 890
316
272
245
197
198
238
295
239
1 291
1 313
2 890
195
481
369
359
105
45
61
43
12
799
1 685
1 777
1 987
3 094
2 360
2 343
2 138
497
14
4 294
4 148
4 457
4 383
5 391
3 561
3 545
3 350
626
534
464
26
16
20
1 677
1 321
1 230
442
509
486
0
1
0
0
3
3
0
2
16
13
6
12
10
6
10
22
385
336
333
319
365
318
338
339
3 828
3 414
2 541
1 721
22 303
19 684
16 810
15 641
5 918
6 230
5 434
5 308
7
5
6
19
200
114
162
176
259
226
258
245
552
3 676
3 644
7 387
989
269
785
566
PREVIOUSLY TREATED CASES
801
1 802
2 071
1 972
588
630
621
476
16
29
27
140
5 605
4 140
5 214
837
484
677
225
32
48
29
45
90
75
29
57
29
28
33
35
61
–
61
67
10
–
–
15
–
39
45
45
55
78
77
–
52
46
51
47
16
29
28
35
56
–
60
–
47
71
66
–
58
60
65
–
78
77
73
–
74
77
74
79
58
72
57
77
26
39
100
–
19
41
40
45
57
66
66
64
79
–
30
–
26
39
40
–
70
83
60
86
52
34
49
55
71
71
76
72
–
–
–
–
–
28
25
33
14
8
12
4
NOTIFIED
0
1
0
1
0
0
0
0
86
60
80
59
11
43
32
21
25
0
0
2
0
327
618
542
451
26
5
5
270
25
29
3 200
3 733
2 384
1 997
1 049
849
878
1 114
68
67
93
301
464
507
7
15
4
4
3
0
1
22
14
12
16
3
4
7
NUMBER OF NOTIFIED
TESTED FOR MDR-TB
12
22
9
19
0
1
0
182
190
200
220
16
23
16
366
960
1 230
1 754
1 697
41
48
56
156
67
113
101
201
313
372
348
94
36
62
43
3
3
3
106
77
66
47
691
105
128
165
61
7
10
5
34
61
20
37
39
5
0
1
29
37
10
18
28
33
42
42
54
36
2
1
6
5
14
16
13
94
90
80
79
22
19
71
75
62
61
22
9
7
8
112
104
106
1
0
4
54
190
183
188
57
16
39
27
12
15
371
379
41
0
3
4
515
720
594
558
251
219
151
130
0
9
2 152
1 677
566
1 409
493
441
252
281
74
84
3
13
8
16
347
285
211
88
102
55
0
1
0
0
1
2
0
2
14
12
4
12
1
0
1
0
40
41
16
31
7
4
9
4
293
292
1
0
1
0
10
8
12
21
6
3
8
2
1 384
981
1 408
169
97
225
225
71
15 009
9 229
9 371
9 213
847
756
758
987
% OF NOTIFIED
NUMBER OF
TESTED FOR CONFIRMED CASES
MDR-TB
OF MDR-TB
14
4 474
4 413
4 655
152
325
263
264
28
69
43
76
–
–
50
–
56
31
37
49
62
–
92
55
11
–
–
48
–
145
200
152
60
72
–
–
68
115
58
47
344
34
34
47
65
–
66
–
0
100
133
–
59
61
–
–
62
76
330
–
76
83
78
77
100
47
–
53
30
27
–
–
24
43
105
40
51
50
60
46
0
–
467
–
25
36
26
–
100
–
100
–
25
20
75
68
86
75
89
50
–
–
–
–
–
48
47
51
18
43
35
27
1
1
0
1
0
0
0
76
68
76
118
2
8
3
58
459
516
840
1 021
3
6
3
7
9
2
1
25
18
31
40
3
0
0
1
0
6
1
3
0
0
1
37
32
32
27
1
0
1
8
10
14
141
290
185
171
31
24
16
8
0
4
13
8
4
European Region
YEAR
TOTAL
CONFIRMED
CASES OF
MDR-TBa
0
0
0
1
0
0
2
1
2
0
1 950
2 329
2 099
96
172
161
264
TOTAL CONFIRMED CASES OF MDR-TB includes cases with unknown previous treatment history (i.e. not included under NEW CASES or PREVIOUSLY TREATED CASES).
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 207
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
207
05/10/11 09:03
7$%/($7HVWLQJIRU0'57%DQGQXPEHURIFRQILUPHGFDVHVRI0'57%±
YEAR
Latvia
Lithuania
Luxembourg
Malta
Monaco
Montenegro
Netherlands
Norway
Poland
Portugal
Republic of
Moldova
Romania
Russian
Federation
San Marino
Serbia
Slovakia
Slovenia
Spain
Sweden
Switzerland
Tajikistan
The Former
Yugoslav Republic
of Macedonia
Turkey
Turkmenistan
Ukraine
United Kingdom of
Great Britain and
Northern Ireland
Uzbekistan
a
208
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
TOTAL
CONFIRMED
CASES OF
MDR-TBa
160
129
131
87
338
276
322
310
0
NEW CASES
NOTIFIED
NUMBER OF
% OF NOTIFIED
NUMBER OF
NOTIFIED TESTED TESTED FOR CONFIRMED CASES
FOR MDR-TB
MDR-TB
OF MDR-TB
1 238
918
830
825
2 114
1 892
1 677
1 573
37
0
873
684
618
613
1 293
1 259
1 074
998
36
0
0
0
1
0
1
24
21
46
41
20
17
11
22
17
11
2
0
1
0
7
13
20
11
3
4
8
1
143
123
108
102
1 113
948
1 094
1 013
269
252
258
1
82
75
80
61
709
696
720
741
193
180
210
72
52
0
30
28
28
22
8 203
7 061
7 268
6 610
3 181
2 703
2 600
5 409
3 758
338
1 048
1 069
1 015
530
816
435
501
4 501
3 951
3 804
3 745
22 407
18 774
17 866
15 963
119 226
120 835
117 227
109 904
536
1 212
1 284
1 234
1 594
3 025
2 226
3 336
6 960
14 686
13 692
9
16
39
38
3 168
2 526
1 740
2 178
652
510
406
361
249
197
180
161
7 281
6 769
6 687
6 377
539
457
515
552
508
319
333
323
5 337
6 150
5 864
5 959
555
427
417
368
18 753
16 760
15 943
15 183
3 149
3 628
3 157
3 148
3 482
5 336
39
53
58
60
86
342
654
1 023
35 739
33 424
31 295
8 173
6 586
7 008
7 219
19 876
15 971
16 569
15 734
9
8
4
1
1
1
2
1
0
76
56
49
4
12
13
18
5
5
9
319
333
4
2
1
7
191
263
222
250
PREVIOUSLY TREATED CASES
3 229
1 407
1 496
1 391
36 249
36 888
35 862
1 112
923
248
300
191
185
217
182
167
146
1 080
1 147
1 009
425
349
424
440
326
258
269
270
833
160
106
130
191
153
3 237
4 212
3 714
4 342
164
81
12 007
9 194
3 428
3 749
3 957
3 970
0
274
571
2 845
71
75
74
74
61
67
64
63
97
–
–
71
52
48
41
55
–
–
–
100
57
61
74
60
64
73
66
73
72
71
81
–
66
53
–
49
44
55
54
–
12
31
34
33
7
16
12
21
–
30
31
33
–
–
–
–
35
37
–
–
38
59
47
51
87
92
93
91
–
16
17
16
79
76
82
80
64
81
81
84
–
–
14
3
19
30
46
42
17
25
23
29
–
–
5
3
–
–
36
29
42
57
56
55
0
2
3
18
NOTIFIED
NUMBER OF NOTIFIED
TESTED FOR MDR-TB
94
83
83
63
127
113
114
128
0
205
152
147
109
460
357
404
364
0
0
182
144
134
102
440
356
404
364
0
0
0
0
0
0
1
7
2
3
0
0
0
0
0
5
11
16
10
3
1
8
27
10
11
12
44
49
46
43
14
27
14
9
9
12
30
32
30
29
8
14
20
18
0
13
12
19
13
68
300
289
314
95
130
91
96
5 061
5 816
6 218
4
6
4
1
0
0
1
1
0
31
6
20
2
7
8
11
2
3
1
62
92
0
0
0
2
101
125
99
110
21
19
1 437
1 492
23
38
37
42
0
52
115
430
1 077
1 020
688
899
350
292
271
1 777
1 865
1 663
1 688
6 938
6 012
5 401
5 115
35 153
94 070
32 569
45 980
300
280
203
200
108
98
79
55
29
16
8
11
1 078
461
324
30
37
52
118
54
41
2 189
1 846
533
985
103
56
56
52
2 550
1 689
1 445
1 339
142
281
82
2 093
5 477
5 114
460
413
576
9 015
5 087
2 451
4 596
% OF NOTIFIED
NUMBER OF
TESTED FOR CONFIRMED CASES
MDR-TB
OF MDR-TB
3
0
2
607
468
172
145
148
652
1 227
1 129
1 077
1 300
2 522
1 641
2 004
6 404
6 798
13 405
121
130
56
62
36
32
28
13
8
9
174
383
110
17
30
35
30
30
34
41
33
580
223
19
17
28
28
508
740
599
615
111
63
6 348
4 840
271
186
364
247
435
470
732
1 180
89
95
91
94
96
100
100
100
–
–
–
–
–
43
0
67
–
–
–
–
52
90
82
100
68
65
65
67
57
52
–
–
–
60
–
52
49
50
55
–
37
66
68
64
19
42
30
39
–
7
21
29
–
–
–
–
40
46
–
–
52
63
46
58
97
81
100
82
–
38
–
34
57
81
–
58
25
63
–
80
–
–
109
23
18
30
50
54
20
44
41
46
–
–
–
77
–
–
116
95
59
45
–
43
5
9
30
26
66
46
48
24
209
162
208
181
0
0
0
1
2
0
1
0
1
2
3
1
0
2
0
34
0
17
16
9
9
270
748
780
701
435
686
344
405
1 899
2 314
6 169
5
10
4
2
1
1
1
1
0
0
23
45
13
2
4
4
7
2
1
3
257
174
4
2
1
5
90
138
123
140
18
19
2 045
3 844
7
7
12
11
86
290
539
593
TOTAL CONFIRMED CASES OF MDR-TB includes cases with unknown previous treatment history (i.e. not included under NEW CASES or PREVIOUSLY TREATED CASES).
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 208
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($1HZVPHDUSRVLWLYHFDVHQRWLILFDWLRQE\DJHDQGVH[±
Albania
Andorra
Armenia
Austria
Azerbaijan
Belarus
Belgium
Bosnia and
Herzegovina
Bulgaria
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Finland
France
Georgia
Germany
Greece
Hungary
Iceland
Ireland
Israel
Italy
Kazakhstan
Kyrgyzstan
FEMALE
15–24
25–34
35–44
45–54
55–64
65+
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
0
2
0
0
0
19
26
28
0
21
21
17
0
14
16
14
19
24
31
16
40
19
20
16
30
16
37
15
0
0
0
1
2
3
0
4
1
1
0
0
0
77
0
0
0
0
18
152
170
36
37
17
32
4
13
9
109
328
1
1
0
16
130
104
75
95
30
23
4
29
24
297
371
0
1
0
11
131
83
49
82
59
22
12
14
33
215
267
0
0
0
10
63
84
68
89
42
41
13
6
42
209
280
0
0
0
8
26
30
27
71
23
24
8
4
30
187
30
0
0
0
1
21
24
15
73
41
30
10
1
0
88
27
0
3
3
1
71
65
23
20
26
180
173
49
57
50
273
224
63
39
32
287
293
52
55
27
118
163
54
32
15
62
58
102
56
47
0
4
1
1
15
56
22
27
61
82
58
37
90
99
61
34
140
66
78
61
139
58
44
46
100
77
80
51
0
9
1
6
13
98
40
38
16
150
115
97
20
195
143
210
3
195
133
132
9
150
90
178
10
136
65
141
1
0
0
24
10
1
27
19
1
48
18
0
72
38
1
47
25
1
34
24
2
0
0
0
1
0
0
0
0
0
0
0
9
15
3
11
13
14
20
9
16
13
10
7
0
2
5
2
7
16
11
13
15
5
8
14
13
4
6
9
0
0
0
1
0
0
0
36
18
16
9
6
3
1
1
3
3
138
108
104
11
11
5
6
5
4
2
226
127
134
14
8
3
7
3
1
4
176
89
82
2
1
4
5
17
8
49
109
135
115
17
37
105
118
251
UNKNOWN
0–14
15–24
25–34
35–44
45–54
55–64
65+
0
3
0
2
1
11
3
11
0
10
9
7
0
8
5
6
13
8
5
3
20
5
5
2
16
11
18
8
0
0
0
0
1
1
3
1
6
1
0
1
0
0
90
3
1
0
1
24
27
24
22
11
13
5
5
3
64
141
1
0
7
27
21
17
52
22
11
4
18
3
98
100
1
0
2
24
10
4
32
12
8
2
0
6
47
57
0
0
1
8
11
7
21
11
3
2
0
3
32
73
0
0
1
8
4
8
18
6
5
5
0
0
24
9
0
0
0
0
4
7
8
59
22
10
6
0
0
24
18
0
1
3
6
2
25
28
12
15
27
53
52
24
15
31
50
56
32
19
15
43
37
17
4
12
11
28
10
13
4
62
91
34
27
23
1
0
0
4
2
0
40
30
35
27
67
46
39
19
64
29
33
16
49
29
28
10
77
48
28
18
23
124
130
94
0
9
3
10
11
90
42
50
14
111
59
57
7
59
43
57
3
29
23
38
4
37
15
60
6
70
34
130
1
1
0
12
3
1
18
8
1
15
4
1
11
2
2
6
1
0
56
30
1
0
0
0
0
19
7
5
88
57
28
0
3
7
3
2
8
5
0
11
11
3
4
4
0
1
90
46
56
4
6
6
10
6
6
2
92
43
38
10
8
3
65
49
20
11
365
155
180
17
33
58
62
167
18
17
46
52
89
7
10
17
28
104
5
5
47
41
397
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
1
1
1
0
1
2
0
0
10
7
8
22
31
24
83
52
57
88
89
55
53
61
45
90
59
46
0
5
0
7
10
12
16
20
12
28
24
18
18
16
23
9
11
9
11
14
7
0
0
0
1
0
1
0
30
10
12
6
9
3
1
3
5
10
156
136
127
31
25
7
10
8
4
6
431
248
212
53
19
21
25
22
3
8
502
247
222
56
40
25
28
19
14
9
414
211
196
35
12
12
24
28
11
8
297
125
134
15
7
8
61
53
25
18
496
244
205
2
4
0
5
14
20
76
226
340
179
30
111
272
529
453
25
113
268
341
539
40
63
207
264
460
18
45
76
143
442
12
28
60
77
625
6
1
59
49
113
94
171
99
167
147
92
89
167
146
0
0
4
3
51
45
104
69
73
61
43
36
37
30
103
75
0
0
1
1
10
14
22
25
32
22
24
14
19
12
46
23
5
0
0
2
13
9
18
10
8
5
7
6
2
25
17
0
0
0
8
6
24
24
85
67
104
117
58
67
27
39
0
1
1
7
5
17
13
19
11
22
22
10
15
30
33
0
0
0
0
0
0
0
1
0
0
0
1
0
0
0
1
1
0
0
3
0
0
1
0
0
0
0
0
0
1
0
1
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
1
0
10
6
8
7
10
18
7
21
4
6
10
12
4
7
5
12
6
11
0
0
0
0
0
13
9
7
8
10
7
13
3
2
6
3
3
7
0
2
15
8
5
0
0
0
1
1
9
12
8
15
20
4
13
59
63
93
38
26
15
28
202
96
191
70
23
18
12
157
75
137
69
23
15
8
94
58
101
39
13
5
4
124
54
61
30
38
26
6
289
112
115
71
3
0
0
7
6
3
16
10
6
1
52
38
80
27
16
14
8
93
58
145
47
6
7
10
57
33
56
45
3
7
2
40
13
25
29
3
5
0
51
19
19
17
32
19
10
168
39
70
58
36
31
15
3
4
1
5
1 057
917
675
109
128
247
261
1 409
1 142
754
171
227
303
260
1 379
983
595
165
205
269
188
923
795
511
65
115
194
141
439
274
251
38
52
66
64
218
175
127
30
46
84
48
84
46
33
1
6
15
5
999
751
566
70
128
215
223
1 079
767
520
94
146
236
199
599
436
263
34
100
141
98
275
286
205
18
41
70
71
202
121
122
15
30
33
40
204
187
132
19
29
98
42
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 209
UNKNOWN
0–14
0
0
0
0
0
0
0
0
0
24
5
0
0
0
0
0
0
0
0
0
0
0
0
0
9
2
0
0
0
0
MALE/FEMALE
RATIO
1.8
2.1
3.4
2.7
–
–
0.7
–
5.0
5.5
6.0
3.9
2.1
2.5
3.5
2.0
2.9
9.2
3.1
3.2
–
–
4.1
3.3
2.6
2.6
1.7
–
1.7
1.4
1.2
1.4
–
1.6
2.3
2.7
2.0
–
2.1
2.7
1.0
–
7.0
–
2.2
2.7
3.2
–
2.3
1.4
1.7
–
–
3.3
2.2
3.3
1.6
2.0
1.9
2.6
2.1
2.1
1.8
–
2.0
2.9
2.9
3.9
2.4
–
1.9
2.0
–
2.7
1.8
–
–
2.9
3.2
–
1.0
0.0
–
2.0
–
0.7
1.8
2.2
–
2.0
1.4
2.3
2.0
2.3
1.8
1.4
–
1.6
1.7
1.6
2.3
1.6
1.4
1.4
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
European Region
MALE
YEAR
209
05/10/11 09:03
7$%/($1HZVPHDUSRVLWLYHFDVHQRWLILFDWLRQE\DJHDQGVH[±
MALE
Latvia
Lithuania
Luxembourg
Malta
Monaco
Montenegro
Netherlands
Norway
Poland
Portugal
Republic of
Moldova
Romania
Russian
Federation
San Marino
Serbia
Serbia &
Montenegro
Slovakia
Slovenia
Spain
Sweden
Switzerland
Tajikistan
The Former
Yugoslav Republic
of Macedonia
Turkey
Turkmenistan
Ukraine
United Kingdom of
Great Britain and
Northern Ireland
Uzbekistan
210
FEMALE
YEAR
0–14
15–24
25–34
35–44
45–54
55–64
65+
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
2005
2010
1995
2000
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
0
0
1
0
4
1
0
1
20
53
22
20
46
38
42
34
44
106
71
44
132
97
118
75
71
124
104
65
225
145
186
128
70
111
117
71
176
155
187
157
40
64
55
39
90
74
108
89
30
34
34
15
77
68
67
54
0
0
0
0
0
0
0
0
0
1
1
0
2
0
0
0
1
3
2
0
1
1
1
0
1
0
0
1
1
0
1
0
0
0
1
0
2
0
0
1
0
0
0
0
22
0
0
0
0
0
0
3
1
79
34
23
22
4
1
9
5
1
119
63
42
29
8
9
4
7
4
75
41
23
22
6
3
6
15
4
28
25
26
20
3
6
4
4
7
9
10
14
9
5
2
4
8
1
10
21
19
17
12
4
3
3
1
3
3
11
8
5
122
99
109
70
215
147
85
295
303
199
205
363
375
227
795
812
389
310
328
349
284
565
782
639
574
200
208
181
369
361
292
393
173
140
90
377
434
310
237
164
140
93
0
2
2
0
387
46
36
21
55
52
211
119
1 662
832
752
669
115
31
337
243
2 322
1 508
1 511
865
166
36
345
244
3 608
1 799
1 786
1 336
95
13
313
248
2 587
1 684
1 999
1 293
65
13
106
113
1 751
916
952
895
15
6
31
21
784
533
638
567
1
295
526
596
402
151
54
8
2 228
6 276
5 571
5 361
2 787
920
UNKNOWN
0–14
15–24
25–34
35–44
45–54
55–64
65+
0
2
0
0
5
0
1
1
22
25
17
6
6
20
25
20
49
41
31
19
53
37
41
36
55
27
31
25
45
39
57
31
47
28
23
12
32
32
49
43
27
7
18
10
16
22
23
18
29
15
12
13
42
48
54
32
0
0
0
0
0
0
0
0
2
0
1
1
0
0
1
0
0
1
0
1
0
0
2
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
1
24
4
3
1
0
1
0
0
3
56
29
14
9
4
3
4
7
3
50
22
19
14
7
1
7
3
2
13
16
11
13
2
4
3
10
9
9
5
0
1
8
8
7
10
4
11
8
5
3
0
0
2
0
1
8
5
1
4
3
2
0
4
1
3
2
7
5
7
129
99
95
59
139
114
67
163
158
142
118
172
154
109
225
211
112
82
87
87
66
111
170
151
104
33
41
29
107
82
63
82
42
25
11
414
421
316
245
85
64
42
4
0
2
1
3
6
355
53
55
40
42
16
97
47
1 352
701
758
503
38
32
92
90
1 240
766
780
477
31
45
57
46
871
484
493
400
19
23
61
47
479
341
374
275
10
14
23
23
396
207
219
172
12
6
18
20
417
321
442
438
1
43
73
74
38
31
44
0
28
1 247
2 554
1 719
1 182
745
790
0
0
0
6
5
11
69
66
127
76
74
167
55
46
133
49
39
83
22
34
158
149
164
275
0
0
5
0
0
0
0
0
0
0
23
16
5
1
1
7
3
4
1
90
17
9
8
6
24
9
4
5
129
22
7
9
7
11
3
6
2
64
24
5
5
2
9
4
5
4
39
33
4
6
3
5
3
4
1
34
159
54
27
11
42
20
16
3
98
10
14
0
1
1
2
1
1
0
0
142
130
10
9
10
9
13
9
6
7
252
251
13
8
15
16
20
12
11
15
151
151
5
10
12
11
9
8
8
6
63
54
5
2
5
4
1
2
3
4
24
23
4
2
3
2
2
1
2
1
108
76
14
15
13
3
15
6
4
3
2
0
26
23
2
1
2
0
225
320
32
15
17
9
185
272
30
14
13
12
151
111
20
17
10
7
89
109
11
5
7
7
43
87
17
5
5
4
53
82
17
10
13
6
0
0
50
33
2
19
3
2
21
41
699
485
15
73
100
112
314
487
474
384
146
140
101
112
380
590
243
193
0
76
72
74
327
447
175
141
47
31
46
46
182
298
166
101
25
34
27
38
185
218
213
203
0
17
8
25
280
405
95
115
110
114
163
131
60
80
81
31
39
42
31
28
40
67
83
58
1
0
261
538
365
547
597
512
288
375
308
213
288
248
112
217
239
111
367
350
0
0
0
0
0
0
0
0
0
0
5
0
0
0
0
0
0
0
0
0
0
0
1
0
0
2
0
1
3
2
10
62
76
108
96
70
204
118
93
317
156
116
296
112
83
350
132
109
386
4
2
0
1
1
0
0
0
22
18
6
3
7
13
3
4
4
132
44
15
13
7
39
11
10
7
337
123
31
16
18
63
36
16
10
242
108
50
25
17
36
22
15
9
150
63
16
25
17
26
14
11
6
112
152
32
20
15
27
17
14
12
228
13
6
1
0
0
1
0
0
1
0
166
139
5
9
7
10
12
5
10
6
394
306
12
10
21
28
23
18
9
12
367
291
8
12
16
8
26
10
13
9
230
286
5
11
10
5
23
7
12
6
140
146
4
4
5
5
13
5
2
5
230
184
27
25
16
13
27
8
7
8
2
1
8
12
2
5
2
0
308
398
15
8
14
6
279
366
42
14
20
19
164
214
45
20
23
24
104
129
33
19
20
24
54
93
29
20
18
12
48
74
24
14
13
11
0
0
33
23
1
16
2
1
10
21
1 148
631
11
103
148
130
385
693
1 295
779
188
185
181
212
1 076
1 552
1 028
703
0
144
146
183
2 064
2 385
963
778
79
127
97
141
1 515
2 007
534
514
30
31
51
51
1 087
1 062
429
407
0
21
13
26
437
532
8
9
7
86
135
132
130
200
169
96
166
135
87
95
108
75
95
60
138
124
108
0
0
9
14
15
6
25
8
351
596
487
749
831
574
510
723
529
346
522
479
213
263
293
107
313
297
0
11
40
22
0
0
0
0
0
0
0
0
1
0
0
0
0
7 417
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 210
UNKNOWN
0
0
0
0
0
0
0
0
0
0
0
0
0
2 559
MALE/FEMALE
RATIO
1.2
3.4
3.1
3.0
3.8
2.9
2.8
3.0
–
–
1.6
–
0.3
–
–
3.0
–
–
–
–
1.9
0.9
2.0
2.0
2.4
2.1
1.6
2.1
1.8
–
2.2
2.4
2.2
2.6
2.6
2.8
2.9
–
3.3
1.1
3.8
3.5
2.6
2.5
2.5
2.4
–
6.7
–
2.8
–
–
–
–
1.6
1.3
1.8
–
1.9
1.8
1.8
2.7
2.1
2.5
1.8
3.0
2.6
–
2.1
1.9
1.2
1.5
1.3
1.5
2.0
1.4
1.6
1.3
–
–
1.3
1.3
1.5
1.5
1.7
2.1
–
–
2.7
2.5
1.3
1.6
1.8
1.8
3.9
3.3
–
2.9
–
1.5
1.6
1.5
–
1.5
1.4
1.3
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 211
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
211
05/10/11 09:03
2.7
16
2.2
7.3
12
2.0
11
0.7
0.5
0.6
1.2
2.2
1.1
31
7.5
8.9
9.0
10
12
424
7.9
11
10
11
2.9
2.3
0.7
0.4
0.2
0.2
8.5
0.2
0.3
0.4
0.2
<0.1
0.5
1.4
6.0
16
15
13
0.1
0.3
0.3
0.3
6.4
7.4
2.3
12
0.7
0.3
0.1
0.1
0.9
7.5
10
0.2
0.4
0.2
5.6
23
53
15
20
1.1
0.1
0.5
1.7
0.6
1.6
471
1.6
0.5
9.4
1.4
In country
In country
0.6
0.4
In country
No
In country
Out of country
In and out of cty
In and out of cty
In country
In country
In country
Out of country
In and out of cty
In country
In country
No
In and out of cty
In country
In and out of cty
Out of country
Out of country
Out of country
Out of country
In country
In and out of cty
In country
In country
In country
In country
In country
Out of country
Out of country
In country
In and out of cty
In country
In country
In country
Out of country
Out of country
No
In country
In country
SECOND-LINE
DST
AVAILABLE
4.7
1.0
5.1
2.4
2.7
6.5
0.7
1.8
2.5
5.6
10
7.9
0.3
3.1
6.1
6.9
2.8
2.2
9.0
10
0
3.5
0
3.4
1.3
1.1
4.4
0.9
7.5
1.9
6.5
5.3
14
1.6
471
1.6
DST LABS
PER 5M
POPULATION
LABORATORIES
CULTURE LABS
PER 5M
POPULATION
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No
Yes
Yes
Yes
Yes
No
No
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
NRLa
Yes, all suspects
Yes, all suspects
Yes, all suspects
If TB is confirmed
Yes, all suspects
If TB is confirmed
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
No
If TB is confirmed
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
If TB is confirmed
No
Yes, all suspects
Yes, all suspects
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
If TB is confirmed
Yes, all suspects
Yes, all suspects
Yes
Yes
Yes
FIRST-LINE DRUGS
If TB is confirmed
Yes, all suspects
Yes, all suspects
TB DIAGNOSIS
FREE THROUGH NTP
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
RIFAMPICIN USED
THROUGHOUT
TREATMENT
European Region
100
0
100
70
96
10
100
100
0
95
80
0
0
90
50
98
0
99
0
95
90
100
60
80
60
0
92
0
100
100
85
% OF PATIENTS
TREATED WITH FDCb
DRUG MANAGEMENT
a NRL = national reference laboratory
b FDC = fixed-dose combination
c NURSES (Registered Nurses, Registered Midwives, Enrolled Nurses, Enrolled Midwives); HEALTH ASSISTANTS (Medical Assistants, Clinical Officers); LABORATORY TECHNICIANS (Microscopists)
Albania
Andorra
Armenia
Austria
Azerbaijan
Belarus
Belgium
Bosnia and Herzegovina
Bulgaria
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Finland
France
Georgia
Germany
Greece
Hungary
Iceland
Ireland
Israel
Italy
Kazakhstan
Kyrgyzstan
Latvia
Lithuania
Luxembourg
Malta
Monaco
Montenegro
Netherlands
Norway
Poland
Portugal
Republic of Moldova
Romania
Russian Federation
San Marino
Serbia
Slovakia
Slovenia
Spain
Sweden
Switzerland
Tajikistan
The Former Yugoslav
Republic of Macedonia
Turkey
Turkmenistan
Ukraine
United Kingdom of Great
Britain and Northern
Ireland
Uzbekistan
SMEAR LABS
PER 100K
POPULATION
7$%/($/DERUDWRULHV173VHUYLFHVGUXJPDQDJHPHQWKXPDQUHVRXUFHVDQGLQIHFWLRQFRQWURO
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No
No
No
Yes
Yes
No
No
Yes
Yes
Yes
Yes
No
Yes
Yes
No
No
Yes
Yes
Yes
No
Yes
No
Yes
No
No
No
No
No
No
No
Yes
No
PAEDIATRIC
FORMULATIONS
PROCURED
7
22
62
0
2
14
3
0
0
1
6
95
65
70
95
100
30
80
5
NURSES
100
100
70
18
MEDICAL
OFFICERS
0
0
0
0
0
0
0
100
0
70
HEALTH
ASSISTANTS
18
15
0
0
2
51
0
100
100
70
12
LABORATORY
TECHNICIANS
% OF STAFF TRAINED BY THE NTP (IN 2010)c
37
64
125
53
497
2038
15
0
TB NOTIFICATION
RATE PER 100 000
HEALTH-CARE
WORKERS
1109_0319_P_111_246 212
05/10/11 09:03
South-East Asia Region
Table A3.1 Estimates of the burden of disease caused by TB, 1990–2010
215
Table A3.2 Incidence, notification and case detection rates, all forms, 1990–2010
216
Table A3.3 Case notifications, 1990–2010
217
Table A3.4 Treatment outcomes, new smear-positive cases, 1995–2009
218
Table A3.5 Treatment outcomes, retreatment cases, 1995–2009
219
Table A3.6 HIV testing and provision of CPT, ART and IPT, 2005–2010
220
Table A3.7 Testing for MDR-TB and number of confirmed cases of MDR-TB, 2005–2010
221
Table A3.8 New smear-positive case notification by age and sex, 1995–2010
222
Table A3.9 Laboratories, NTP services, drug management, human resources and
infection control, 2010
223
1109_0319_P_111_246 213
05/10/11 09:03
Estimates of mortality, prevalence and incidence
Estimated values are shown as best estimates followed by lower and upper bounds. The lower and upper bounds are
defi ned as the 2.5th and 97.5th centiles of outcome distributions produced in simulations. See ANNEX 1 for further
details.
Estimated numbers are shown rounded to two significant figures. Estimated rates are shown rounded to three
significant figures unless the value is under 100, in which case rates are shown rounded to two significant figures.
Estimates for all years are recalculated as new information becomes available and techniques are refi ned, so they
may differ from those published in previous reports in this series. Estimates published in previous global TB control
reports should no longer be used.
Data source
Data shown in this annex are taken from the WHO global TB database on 2 September 2011. Data shown in the main
part of the report were taken from the database on 21 June 2011. As a result, data in this annex may differ slightly from
those in the main part of the report.
Data can be downloaded from www.who.int/tb/data.
South-East Asia
India
Estimates for India have not yet been officially approved by the Ministry of Health and Family Welfare, Government of
India and should therefore be considered provisional.
214
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 214
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($(VWLPDWHVRIWKHEXUGHQRIGLVHDVHFDXVHGE\7%±
Bangladesh
Bhutan
Democratic
People's Republic
of Korea
India
Indonesia
Maldives
Myanmar
Nepal
Sri Lanka
Thailand
Timor-Leste
a
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
2005
2008
2009
2010
POPULATION
(MILLIONS)
105
117
130
141
145
147
149
<1
<1
<1
<1
<1
<1
<1
20
22
23
24
24
24
24
874
964
1 054
1 140
1 191
1 208
1 225
184
199
213
227
235
237
240
<1
<1
<1
<1
<1
<1
<1
39
42
45
46
47
48
48
19
22
24
27
29
29
30
17
18
19
20
20
21
21
57
60
63
67
68
69
69
1
1
1
1
NUMBER
(THOUSANDS)
62
69
72
69
64
64
64
0.26
0.18
0.17
0.14
0.096
0.063
0.067
19
21
19
15
8.4
6.3
5.7
340
370
410
410
360
340
320
93
110
110
71
64
63
64
0.069
0.023
0.027
0.019
0.011
0.011
0.011
43
44
43
27
23
22
20
7.3
6
5.1
5.5
6.1
6.2
6.2
2
2.3
1.9
1.9
1.9
1.9
1.9
11
11
14
12
12
11
11
0.64
0.74
0.63
0.52
(35–96)
(54–86)
(56–91)
(51–89)
(46–85)
(47–85)
(47–85)
(0.12–0.5)
(0.11–0.29)
(0.1–0.27)
(0.084–0.22)
(0.061–0.16)
(0.05–0.076)
(0.054–0.081)
(11–30)
(17–26)
(14–24)
(10–20)
(5.2–13)
(4.3–10)
(4.1–9.4)
(210–480)
(230–540)
(250–580)
(290–550)
(230–530)
(220–500)
(210–470)
(54–140)
(88–130)
(84–130)
(49–99)
(42–93)
(41–92)
(42–91)
(0.033–0.12)
(0.015–0.037)
(0.017–0.041)
(0.011–0.03)
(<0.01–0.017)
(<0.01–0.018)
(<0.01–0.017)
(31–57)
(33–56)
(34–54)
(19–36)
(16–32)
(15–30)
(12–31)
(3.9–12)
(4.2–8.3)
(3.1–7.7)
(3.4–8.5)
(3.8–9.3)
(3.9–9.3)
(3.9–9.3)
(0.87–3.7)
(1.7–3.1)
(1.3–2.8)
(1.2–2.8)
(1.2–2.8)
(1.2–2.8)
(1.2–2.8)
(4.9–22)
(7.4–16)
(10–19)
(7.7–17)
(8.5–18)
(7.5–17)
(7–16)
(0.38–1)
(0.45–1.1)
(0.36–1)
(0.31–0.89)
RATEa
58
59
56
49
44
44
43
47
35
29
21
14
8.8
9.2
96
97
81
61
35
26
23
38
38
38
36
31
29
26
51
55
50
31
27
27
27
31
9.2
9.9
6.5
3.5
3.6
3.4
110
104
96
57
49
46
41
38
28
21
20
21
21
21
11
13
10
9.5
9.4
9.1
9.1
20
19
22
18
18
17
16
63
68
57
46
(33–91)
(46–73)
(43–70)
(37–63)
(32–58)
(32–58)
(32–57)
(22–89)
(22–55)
(18–47)
(13–33)
(8.7–23)
(7.1–11)
(7.4–11)
(55–150)
(76–120)
(61–104)
(42–85)
(22–55)
(18–42)
(17–39)
(24–55)
(24–55)
(24–55)
(25–48)
(19–44)
(18–42)
(17–39)
(29–78)
(44–68)
(39–62)
(21–43)
(18–40)
(17–39)
(18–38)
(15–55)
(5.9–15)
(6.1–15)
(3.9–10)
(2.3–5.4)
(2.3–5.7)
(2.1–5.4)
(80–145)
(79–133)
(75–121)
(40–78)
(33–69)
(32–64)
(24–65)
(21–63)
(19–38)
(13–32)
(12–31)
(13–32)
(13–32)
(13–31)
(5–21)
(9.1–17)
(6.9–15)
(6.1–14)
(6.1–14)
(5.9–13)
(5.9–13)
(8.5–38)
(12–27)
(16–30)
(12–26)
(12–26)
(11–24)
(10–23)
(38–100)
(42–104)
(33–94)
(28–79)
PREVALENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
520
580
620
620
600
610
610
2.8
2.2
2
1.7
1.4
1.2
1.3
160
170
160
140
110
100
97
4000
4500
4900
4100
3500
3300
3100
780
890
890
720
690
690
690
0.48
0.077
0.15
0.098
0.033
0.04
0.04
350
370
370
300
270
260
250
64
60
58
64
70
71
71
20
22
20
20
21
21
21
120
110
130
130
130
130
130
7.4
8.2
7.7
7.2
(210–990)
(260–950)
(290–1000)
(290–1000)
(270–990)
(280–1000)
(280–1000)
(1–5.4)
(0.84–3.8)
(0.77–3.5)
(0.64–3)
(0.44–2.5)
(0.29–2.1)
(0.32–2.3)
(62–310)
(77–290)
(74–260)
(64–240)
(38–190)
(28–170)
(24–170)
(3600–4500)
(3900–5000)
(4300–5500)
(3300–5000)
(2500–4700)
(2200–4600)
(2000–4600)
(310–1500)
(390–1500)
(410–1500)
(320–1200)
(300–1200)
(290–1100)
(300–1200)
(0.14–1.1)
(0.012–0.22)
(0.046–0.32)
(0.028–0.22)
(<0.01–0.091)
(<0.01–0.11)
(<0.01–0.11)
(150–610)
(160–630)
(170–620)
(140–490)
(120–430)
(190–320)
(180–310)
(26–120)
(27–99)
(23–99)
(25–110)
(29–120)
(29–120)
(29–120)
(7.3–39)
(10–36)
(8.7–34)
(8.6–34)
(8.8–35)
(8.7–35)
(8.8–35)
(44–230)
(54–190)
(63–220)
(58–210)
(61–220)
(57–210)
(55–210)
(2.8–13)
(3.3–14)
(2.8–14)
(2.3–13)
RATE
493
494
479
440
414
412
411
500
432
357
260
202
171
181
792
793
706
603
459
412
399
459
462
466
358
294
275
256
423
445
418
315
294
289
289
220
31
55
33
11
13
13
894
881
831
647
564
544
525
335
278
238
235
242
241
238
114
121
108
103
103
101
101
204
193
212
193
196
188
182
733
760
703
643
(199–937)
(225–810)
(221–783)
(206–718)
(189–681)
(188–677)
(188–671)
(180–972)
(161–740)
(135–616)
(97–449)
(63–351)
(41–301)
(44–318)
(307–1519)
(354–1313)
(325–1157)
(271–999)
(158–790)
(115–718)
(100–698)
(407–515)
(409–519)
(412–522)
(288–436)
(209–393)
(185–382)
(161–373)
(168–804)
(196–738)
(190–687)
(141–523)
(127–493)
(123–484)
(123–484)
(62–500)
(4.6–88)
(17–118)
(9.5–75)
(1.7–30)
(2.5–34)
(2.4–34)
(381–1555)
(380–1496)
(376–1377)
(301–1052)
(253–913)
(396–667)
(381–643)
(136–644)
(126–458)
(96–405)
(93–403)
(99–409)
(98–409)
(96–405)
(42–227)
(56–198)
(47–180)
(43–173)
(43–172)
(42–171)
(42–170)
(77–404)
(90–317)
(100–349)
(87–321)
(89–320)
(83–310)
(80–300)
(281–1266)
(305–1302)
(251–1233)
(202–1138)
INCIDENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
240
260
290
320
330
330
330
1.7
1.6
1.4
1.2
1.2
1.1
1.1
69
75
79
82
83
84
84
1900
2100
2300
2400
2300
2300
2300
350
380
400
430
440
450
450
0.33
0.26
0.2
0.15
0.13
0.12
0.11
150
170
190
190
190
180
180
31
35
40
45
47
48
49
11
12
12
13
14
14
14
78
82
86
91
93
94
94
5
5.4
5.5
5.6
(140–350)
(210–320)
(240–350)
(260–380)
(270–390)
(270–400)
(270–400)
(1.1–2.4)
(1.3–1.9)
(1.2–1.7)
(1–1.5)
(0.97–1.4)
(0.94–1.3)
(0.92–1.3)
(42–100)
(61–90)
(64–95)
(67–99)
(71–96)
(71–97)
(72–97)
(1600–2200)
(1800–2400)
(2000–2500)
(2100–2600)
(2100–2600)
(2100–2500)
(2000–2500)
(210–520)
(310–450)
(330–490)
(350–520)
(360–540)
(370–540)
(370–540)
(0.2–0.49)
(0.22–0.3)
(0.16–0.24)
(0.12–0.18)
(0.11–0.15)
(0.1–0.14)
(0.098–0.13)
(110–200)
(130–210)
(150–220)
(160–220)
(160–210)
(160–210)
(160–210)
(19–46)
(29–42)
(32–48)
(36–54)
(38–57)
(39–58)
(40–58)
(7.1–17)
(9.8–15)
(10–15)
(11–16)
(11–16)
(11–16)
(11–17)
(49–110)
(66–98)
(70–100)
(74–110)
(76–110)
(77–110)
(78–110)
(4–6)
(4.3–6.5)
(4.5–6.6)
(4.6–6.7)
RATE
225
225
225
225
225
225
225
308
308
253
187
165
158
151
344
344
344
344
344
345
345
216
216
216
209
196
190
185
189
189
189
189
189
189
189
150
105
74
52
42
39
36
393
404
412
403
393
388
384
163
163
163
163
163
163
163
66
66
66
66
66
66
66
137
137
137
137
137
137
137
498
498
498
498
(137–334)
(183–271)
(183–271)
(183–271)
(183–271)
(184–270)
(184–269)
(203–433)
(254–366)
(206–305)
(155–223)
(138–194)
(132–185)
(127–177)
(210–512)
(280–415)
(280–415)
(280–415)
(293–400)
(295–399)
(295–398)
(181–255)
(189–246)
(194–240)
(188–231)
(176–217)
(171–211)
(167–205)
(115–281)
(154–228)
(154–228)
(154–228)
(154–228)
(154–227)
(155–226)
(91–223)
(90–122)
(60–89)
(42–62)
(37–47)
(34–45)
(31–42)
(288–515)
(312–508)
(332–500)
(338–474)
(336–453)
(334–446)
(328–445)
(99–243)
(133–197)
(133–197)
(133–197)
(133–197)
(133–196)
(134–195)
(41–97)
(54–80)
(54–80)
(54–80)
(54–80)
(54–79)
(54–79)
(86–199)
(111–165)
(111–165)
(111–165)
(111–165)
(112–164)
(112–163)
(399–598)
(399–598)
(406–601)
(407–598)
South-East Asia Region
MORTALITY (EXCLUDING HIV)
YEAR
Rates are per 100 000 population.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 215
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
215
05/10/11 09:03
7$%/($,QFLGHQFHQRWLILFDWLRQDQGFDVHGHWHFWLRQUDWHVDOOIRUPV±
INCIDENCE (INCLUDING HIV)
YEAR
Bangladesh
Bhutan
Democratic
People's Republic
of Korea
India
Indonesia
Maldives
Myanmar
Nepal
Sri Lanka
Thailand
Timor-Leste
216
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
2005
2008
2009
2010
POPULATION
(MILLIONS)
105
117
130
141
145
147
149
<1
<1
<1
<1
<1
<1
<1
20
22
23
24
24
24
24
874
964
1 054
1 140
1 191
1 208
1 225
184
199
213
227
235
237
240
<1
<1
<1
<1
<1
<1
<1
39
42
45
46
47
48
48
19
22
24
27
29
29
30
17
18
19
20
20
21
21
57
60
63
67
68
69
69
1
1
1
1
NUMBER
(THOUSANDS)
240
260
290
320
330
330
330
1.7
1.6
1.4
1.2
1.2
1.1
1.1
69
75
79
82
83
84
84
1900
2100
2300
2400
2300
2300
2300
350
380
400
430
440
450
450
0.33
0.26
0.2
0.15
0.13
0.12
0.11
150
170
190
190
190
180
180
31
35
40
45
47
48
49
11
12
12
13
14
14
14
78
82
86
91
93
94
94
5
5.4
5.5
5.6
(140–350)
(210–320)
(240–350)
(260–380)
(270–390)
(270–400)
(270–400)
(1.1–2.4)
(1.3–1.9)
(1.2–1.7)
(1–1.5)
(0.97–1.4)
(0.94–1.3)
(0.92–1.3)
(42–100)
(61–90)
(64–95)
(67–99)
(71–96)
(71–97)
(72–97)
(1600–2200)
(1800–2400)
(2000–2500)
(2100–2600)
(2100–2600)
(2100–2500)
(2000–2500)
(210–520)
(310–450)
(330–490)
(350–520)
(360–540)
(370–540)
(370–540)
(0.2–0.49)
(0.22–0.3)
(0.16–0.24)
(0.12–0.18)
(0.11–0.15)
(0.1–0.14)
(0.098–0.13)
(110–200)
(130–210)
(150–220)
(160–220)
(160–210)
(160–210)
(160–210)
(19–46)
(29–42)
(32–48)
(36–54)
(38–57)
(39–58)
(40–58)
(7.1–17)
(9.8–15)
(10–15)
(11–16)
(11–16)
(11–16)
(11–17)
(49–110)
(66–98)
(70–100)
(74–110)
(76–110)
(77–110)
(78–110)
(4–6)
(4.3–6.5)
(4.5–6.6)
(4.6–6.7)
RATEb
225
225
225
225
225
225
225
308
308
253
187
165
158
151
344
344
344
344
344
345
345
216
216
216
209
196
190
185
189
189
189
189
189
189
189
150
105
74
52
42
39
36
393
404
412
403
393
388
384
163
163
163
163
163
163
163
66
66
66
66
66
66
66
137
137
137
137
137
137
137
498
498
498
498
(137–334)
(183–271)
(183–271)
(183–271)
(183–271)
(184–270)
(184–269)
(203–433)
(254–366)
(206–305)
(155–223)
(138–194)
(132–185)
(127–177)
(210–512)
(280–415)
(280–415)
(280–415)
(293–400)
(295–399)
(295–398)
(181–255)
(189–246)
(194–240)
(188–231)
(176–217)
(171–211)
(167–205)
(115–281)
(154–228)
(154–228)
(154–228)
(154–228)
(154–227)
(155–226)
(91–223)
(90–122)
(60–89)
(42–62)
(37–47)
(34–45)
(31–42)
(288–515)
(312–508)
(332–500)
(338–474)
(336–453)
(334–446)
(328–445)
(99–243)
(133–197)
(133–197)
(133–197)
(133–197)
(133–196)
(134–195)
(41–97)
(54–80)
(54–80)
(54–80)
(54–80)
(54–79)
(54–79)
(86–199)
(111–165)
(111–165)
(111–165)
(111–165)
(112–164)
(112–163)
(399–598)
(399–598)
(406–601)
(407–598)
INCIDENCE HIV-POSITIVE
NUMBER
(THOUSANDS)
<0.01
0.03
0.055
0.26
0.46
0.56
0.66
<0.01
<0.01
0.014
0.015
0.034
0.043
0.053
(<0.01–0.017)
(0.013–0.053)
(<0.01–0.18)
(0.11–0.47)
(0.23–0.76)
(0.28–0.92)
(0.33–1.1)
(<0.01–0.012)
(<0.01–0.013)
(<0.01–0.025)
(<0.01–0.03)
(0.018–0.055)
(0.022–0.071)
(0.026–0.09)
NOTIFIED NEW AND RELAPSEa
RATEb
<1
<1
<1
<1
<1
<1
<1
<1
1.3
2.5
2.3
4.9
6.1
7.3
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–2.2)
(<1–2.5)
(1.1–4.4)
(<1–4.6)
(2.6–7.9)
(3.1–9.9)
(3.6–12)
17
76
130
140
120
120
110
<0.01
0.019
0.4
7.9
14
16
18
(9–27)
(48–110)
(89–180)
(91–190)
(81–170)
(78–170)
(75–160)
(<0.01–0.015)
(<0.01–0.042)
(0.19–0.69)
(4–13)
(7.6–22)
(8.8–25)
(9.9–29)
1.9
7.9
13
12
10
9.8
9.2
<1
<1
<1
3.5
6
6.8
7.6
(1–3.1)
(5–11)
(8.4–17)
(8–17)
(6.8–14)
(6.5–14)
(6.1–13)
(<1–<1)
(<1–<1)
(<1–<1)
(1.8–5.8)
(3.2–9.5)
(3.7–11)
(4.1–12)
7.7
19
27
28
20
26
37
0.34
0.62
0.87
0.98
1
0.94
0.87
<0.01
<0.01
0.034
0.057
0.066
0.092
0.13
10
18
17
16
15
15
15
(4.4–12)
(12–28)
(18–39)
(18–39)
(11–32)
(17–36)
(21–57)
(0.16–0.58)
(0.38–0.92)
(0.54–1.3)
(0.62–1.4)
(0.63–1.5)
(0.57–1.4)
(0.49–1.3)
(<0.01–<0.01)
(<0.01–0.01)
(0.015–0.061)
(0.028–0.098)
(0.031–0.11)
(0.052–0.14)
(0.067–0.21)
(6–16)
(12–25)
(12–24)
(10–22)
(12–19)
(13–18)
(13–18)
20
45
60
60
43
54
77
1.8
2.9
3.6
3.6
3.5
3.2
2.9
<1
<1
<1
<1
<1
<1
<1
18
31
28
23
22
22
22
(11–30)
(27–66)
(39–86)
(40–83)
(24–67)
(37–75)
(43–120)
(<1–3)
(1.8–4.3)
(2.2–5.2)
(2.3–5.2)
(2.2–5)
(1.9–4.8)
(1.6–4.5)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–1)
(10–28)
(21–42)
(19–38)
(16–33)
(18–27)
(18–27)
(18–27)
NUMBER
48 673
56 437
75 557
123 118
151 062
160 875
153 892
1 154
1 299
1 140
1 007
961
1 125
1 311
46
48
58
88
104
109
103
207
250
200
153
137
158
181
34 131
42 722
72 541
76 336
84 648
1 519 182
1 218 183
1 115 718
1 156 248
1 332 267
1 351 913
1 339 866
74 470
35 529
84 591
254 601
296 514
292 754
300 659
152
231
132
122
120
100
95
12 416
18 229
30 840
107 009
124 037
128 343
131 590
10 142
19 804
29 519
33 448
32 909
34 888
35 114
6 666
5 956
8 413
9 249
9 290
9 314
9 547
46 510
45 428
34 187
57 895
55 252
63 975
66 397
3 767
3 285
4 748
4 854
149
180
301
315
348
174
126
106
101
112
112
109
40
18
40
112
126
123
125
69
93
48
41
39
32
30
32
43
69
231
263
270
274
53
92
121
123
114
119
117
38
33
45
47
45
45
46
81
76
54
87
81
93
96
373
304
432
432
a
Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
b
Rates are per 100 000 population.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 216
RATEb
CASE DETECTION RATEa
PERCENT
21
21
26
39
46
49
46
67
81
79
81
83
100
120
–
–
43
52
87
91
101
80
58
49
49
57
59
59
21
9
21
59
67
65
66
46
88
65
80
93
82
83
8
11
17
57
67
69
71
33
56
74
75
70
73
72
58
49
68
70
69
68
69
60
56
40
64
59
68
70
75
61
87
87
(14–34)
(18–26)
(22–32)
(32–48)
(38–57)
(41–60)
(38–56)
(48–102)
(69–98)
(65–97)
(68–99)
(71–100)
(85–119)
(102–142)
(36–53)
(43–64)
(75–103)
(79–107)
(87–118)
(68–96)
(51–67)
(44–54)
(44–54)
(52–64)
(53–65)
(53–65)
(14–35)
(8–12)
(17–26)
(49–73)
(55–82)
(54–80)
(55–81)
(31–76)
(76–104)
(54–80)
(66–98)
(82–106)
(72–95)
(72–97)
(6–11)
(9–14)
(14–21)
(49–68)
(58–78)
(60–81)
(62–84)
(22–54)
(47–69)
(62–91)
(62–92)
(58–86)
(61–89)
(60–87)
(40–94)
(41–61)
(56–83)
(58–87)
(57–84)
(57–83)
(58–84)
(41–95)
(46–68)
(33–49)
(53–78)
(49–73)
(57–83)
(59–85)
(62–93)
(51–76)
(72–106)
(72–106)
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($&DVHQRWLILFDWLRQV±
YEAR
Bangladesh
• 46
103 •
Bhutan
• 207
181 •
Democratic
People's Republic
of Korea
–
348 •
India
• 174
109 •
Indonesia
• 40
125 •
Maldives
• 69
30 •
Myanmar
• 32
274 •
Nepal
• 53
117 •
Sri Lanka
• 38
46 •
Thailand
• 81
96 •
Timor-Leste
• 311
a
432 •
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
2005
2008
2009
2010
NEW AND
RELAPSEa
48 673
56 437
75 557
123 118
151 062
160 875
153 892
1 154
1 299
1 140
1 007
961
1 125
1 311
34 131
42 722
72 541
76 336
84 648
1 519 182
1 218 183
1 115 718
1 156 248
1 332 267
1 351 913
1 339 866
74 470
35 529
84 591
254 601
296 514
292 754
300 659
152
231
132
122
120
100
95
12 416
18 229
30 840
107 009
124 037
128 343
131 590
10 142
19 804
29 519
33 448
32 909
34 888
35 114
6 666
5 956
8 413
9 249
9 290
9 314
9 547
46 510
45 428
34 187
57 895
55 252
63 975
66 397
3 767
3 285
4 748
4 854
SMEAR- SMEAR-NEGATIVE/
POSITIVE
UNKNOWN
EXTRAPULMONARY
20 524
38 484
84 848
106 373
109 402
105 772
19 297
29 396
23 076
22 192
25 375
21 625
2 060
5 914
11 318
18 359
21 999
23 506
367
347
308
351
434
457
657
430
272
146
285
275
265
363
387
418
355
518
16 440
17 796
28 026
29 366
31 240
13 801
18 123
31 444
32 491
36 285
3 787
5 381
10 914
12 232
13 715
264 515
349 374
508 890
615 977
624 617
630 165
880 589
650 345
399 066
390 356
384 113
366 381
68 979
98 006
171 838
219 946
233 026
231 121
31 768
52 338
158 640
166 376
169 213
183 366
34
15 035
85 373
116 850
108 616
101 247
0
833
6 142
9 673
11 215
11 659
114
65
66
53
45
41
89
31
23
32
13
20
18
32
29
35
41
33
8 681
17 254
36 541
41 248
41 357
42 318
7 058
8 659
35 601
44 034
50 919
56 840
653
2 304
30 252
34 447
31 509
27 976
8 591
13 683
14 617
14 640
15 442
15 569
2 769
3 049
4 314
4 868
4 683
4 764
4 635
7 938
9 074
9 474
9 298
9 794
9 718
3 241
1 677
2 261
2 198
2 146
1 996
2 145
2 489
4 955
7 013
6 527
7 054
7 210
656
982
1 561
1 917
2 167
2 358
2 548
20 273
17 754
29 762
28 788
32 810
33 450
1 035
867
1 206
22 606
12 439
18 837
16 933
20 058
20 927
2 142
1 996
3 095
1 419
2 953
7 501
7 815
9 143
10 135
554
399
406
OTHER RELAPSE
0
729
1 763
3 876
4 138
4 099
2 989
0
0
0
RE-TREAT EXCL. TOTAL
HISTORY
RELAPSE
RETREAT UNKNOWN
4 806
729
1 763
3 876
6 991
4 099
7 795
0
10
36
40
46
51
61
11
24
25
21
10
36
51
70
76
82
0
0
0
103
1 364
2 157
2 247
3 408
7 752
12 013
12 329
11 650
103
9 116
14 170
14 576
15 058
0
1 381
1 774
1 796
1 508
690
17 993
75 073
104 214
108 361
110 691
80 072
148 580
185 071
181 395
182 281
690
98 065
223 653
289 285
289 756
292 972
0
0
0
106
1 448
4 446
3 615
3 710
4 387
1 815
1 978
2 202
106
1 448
4 446
5 430
5 688
6 589
0
0
0
0
0
10
4
4
0
1
1
0
1
2
4
2
10
4
5
2
5
3
0
0
0
0
1 837
2 623
4 615
4 308
4 558
4 456
982
4 701
5 159
5 813
1 837
2 623
5 597
9 009
9 717
10 269
786
1 807
2 344
2 444
2 598
2 617
629
510
519
495
786
1 807
2 973
2 954
3 117
3 112
0
372
244
192
213
161
248
649
510
394
409
380
202
132
261
387
2 240
1 965
1 111
16
12
11
1 130
1 041
1 795
3 956
3 929
2 996
52
35
52
0
58
0
0
0
0
0
92
0
0
0
0
248
277
266
202
196
219
1 130
1 041
1 795
1 716
1 964
1 885
36
23
41
2 853
0
731
0
0
% SMEARPOS AMONG
NEW PULM
–
52
57
79
83
81
83
–
36
45
53
71
60
62
–
–
54
50
47
47
46
–
23
35
56
61
62
63
–
100
78
65
59
61
64
–
56
68
74
62
78
67
–
55
67
51
48
45
43
–
52
60
61
61
61
62
46
65
66
69
69
70
68
–
47
59
61
63
62
62
33
30
28
–
South-East Asia Region
NEW CASES
NEW AND RELAPSE
NOTIFICATION RATEa
1990–2010
Rates are per 100 000 population. Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 217
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
217
05/10/11 09:03
7$%/($7UHDWPHQWRXWFRPHVQHZVPHDUSRVLWLYHFDVHV±
% OF COHORT
TREATMENT SUCCESS (%)a
1995–2009
YEAR
Bangladesh
• 71
92 •
• 97
92 •
Bhutan
Democratic
People's Republic
of Korea
–
89 •
• 25
88 •
• 91
91 •
• 97
47 •
• 67
85 •
• 73
90 •
• 79
86 •
• 64
86 •
• 81
–
India
Indonesia
Maldives
Myanmar
Nepal
Sri Lanka
Thailand
Timor-Leste
a
218
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
2005
2007
2008
2009
NUMBER
NOTIFIED
SIZE OF
COHORT
20 524
38 484
84 848
104 296
106 373
109 402
367
347
308
328
351
434
10 867
38 484
84 848
104 296
106 089
109 075
433
347
340
331
354
434
16 440
17 796
23 575
28 026
29 366
264 515
349 374
508 890
592 587
615 977
624 617
31 768
52 338
158 640
160 617
166 376
169 213
114
65
66
59
53
45
8 681
17 254
36 541
42 588
41 248
41 357
8 591
13 683
14 617
14 355
14 640
15 442
3 049
4 314
4 868
4 528
4 683
4 764
20 273
17 754
29 762
28 487
28 788
32 810
1 035
1 021
867
1 206
14 571
17 796
23 575
28 026
29 366
264 722
349 328
507 204
592 414
615 977
624 617
3 018
52 338
158 640
160 617
166 376
169 213
114
59
70
60
53
45
7 872
16 792
36 652
42 773
41 247
41 811
8 053
12 992
14 617
14 355
14 640
15 468
3 058
4 314
4 841
4 477
4 646
4 754
20 273
23 061
29 919
29 588
33 078
27 597
1 035
1 021
867
COHORT AS
% NOTIFIED
53
100
100
100
100
100
118
100
110
101
101
100
–
89
100
100
100
100
100
100
100
100
100
100
10
100
100
100
100
100
100
91
106
102
100
100
91
97
100
100
100
101
94
95
100
100
100
100
100
100
99
99
99
100
100
130
101
104
115
84
100
100
100
–
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
66
77
91
91
90
91
78
75
84
91
89
86
5
4
1
1
2
1
20
15
7
2
2
6
5
4
4
3
4
4
0
4
5
3
3
3
2
1
1
1
1
1
0
3
3
3
3
3
10
9
2
2
2
2
1
3
1
0
0
2
12
5
2
3
2
2
1
0
0
1
3
0
73
84
82
83
85
1
31
83
84
85
85
73
70
83
82
83
84
96
97
86
68
45
47
53
73
77
77
78
77
56
79
87
86
86
87
75
75
83
84
81
83
36
65
70
77
76
81
61
69
73
9
5
5
6
5
25
4
2
2
2
2
18
17
8
9
8
7
2
0
0
0
3
2
3
2
2
0
1
5
5
4
4
2
2
2
2
2
2
3
2
6
3
4
2
4
5
6
5
6
6
3
5
5
5
4
4
3
4
5
5
6
6
2
8
8
9
7
7
5
4
5
7
4
4
4
4
0
1
2
2
2
2
0
1
1
1
1
1
0
0
0
0
5
2
3
2
2
0
7
7
6
6
6
6
4
4
4
4
4
0
0
3
10
11
4
18
9
5
5
5
5
18
7
3
3
3
3
13
15
6
7
7
4
9
7
7
5
4
3
11
8
7
3
2
3
2
2
75
57
1
1
1
1
1
5
2
2
2
2
0
2
6
18
40
44
7
2
2
2
2
2
6
2
2
3
3
2
4
2
1
1
1
3
24
15
9
2
4
2
2
4
3
0
14
9
7
8
8
8
17
5
1
2
3
3
4
4
3
3
4
3
28
3
5
6
7
5
21
15
12
2
4
2
3
3
3
3
2
1
1
1
1
1
0
1
1
1
2
2
0
2
2
2
2
1
1
0
0
TREATMENT SUCCESS = percent cured + percent completed then rounded to the nearest digit.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 218
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($7UHDWPHQWRXWFRPHVUHWUHDWPHQWFDVHV±
% OF COHORT
YEAR
Bangladesh
• 75
81 •
Bhutan
• 59
82 •
Democratic
People's Republic
of Korea
–
83 •
• 70
75 •
• 32
72 •
India
Indonesia
Maldives
–
0•
Myanmar
• 64
73 •
Nepal
–
85 •
Sri Lanka
–
73 •
Thailand
–
68 •
–
–
Timor-Leste
a
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
2005
2007
2008
2009
NUMBER
NOTIFIED
SIZE OF
COHORT
729
1 763
3 876
3 788
6 991
4 099
10
36
51
54
70
76
1 179
1 815
3 876
3 788
103
9 116
11 234
14 170
14 576
690
98 065
223 653
276 542
289 285
289 756
106
1 448
4 446
4 382
5 430
5 688
10
4
5
3
2
5
1 837
2 623
5 597
9 131
9 009
9 717
786
1 807
2 973
2 748
2 954
3 117
248
649
510
438
394
409
1 130
1 041
1 795
1 665
3 956
3 929
52
44
35
52
1 285
9 116
11 234
14 170
14 576
551
48 133
224 143
193 364
289 285
289 756
76
2 530
4 812
4 382
5 430
5 687
6 637
22
52
46
70
76
5
5
0
0
1
1 443
3 001
6 556
9 167
8 631
9 540
2 047
2 973
2 748
1 954
3 063
521
504
432
393
408
2 285
2 562
3 468
2 542
56
44
35
COHORT AS
% NOTIFIED
162
103
100
100
–
162
220
–
102
85
100
100
–
1 248
100
100
100
100
80
49
100
70
100
100
72
175
108
100
100
100
–
125
100
0
0
20
79
114
117
100
96
98
–
113
100
100
66
98
–
80
99
99
100
100
–
–
127
154
88
65
108
100
100
–
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
71
70
73
74
3
2
6
5
5
4
4
4
8
2
2
2
11
7
5
5
2
14
9
10
66
50
16
9
6
0
2
23
5
14
6
5
65
80
76
70
10
11
3
12
6
4
3
8
8
2
16
7
2
0
1
3
10
2
1
1
75
70
69
75
74
64
55
47
63
45
45
22
50
63
60
50
53
11
6
8
8
9
6
15
24
2
29
29
9
22
15
17
21
20
2
3
4
3
2
4
7
7
8
7
7
0
3
3
4
4
4
4
12
13
10
11
3
5
4
5
4
4
0
3
4
3
3
3
2
5
3
3
2
13
16
16
15
13
13
1
7
8
11
14
12
5
4
3
2
2
9
2
1
7
2
1
67
15
7
5
7
8
100
80
–
–
0
55
65
58
44
46
44
20
–
–
0
8
9
14
9
27
28
0
–
–
0
4
7
10
8
12
11
0
–
–
0
4
4
6
4
5
5
0
–
–
0
19
12
7
5
7
7
0
0
–
–
100
9
3
5
30
3
4
73
81
80
71
82
3
2
2
4
3
4
4
5
10
6
8
6
3
5
3
7
4
3
5
4
4
3
7
5
3
44
67
68
64
66
20
5
5
7
7
6
5
7
8
8
1
2
2
2
1
26
18
16
15
13
3
3
2
5
5
52
61
54
58
96
59
57
6
9
12
10
0
16
14
12
11
9
11
2
2
11
5
6
4
5
0
7
6
7
9
7
7
2
9
11
18
3
14
9
0
7
0
South-East Asia Region
TREATMENT SUCCESS (%)a
1995–2009
TREATMENT SUCCESS = percent cured + percent completed then rounded to the nearest digit.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 219
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
219
05/10/11 09:03
7$%/($+,9WHVWLQJDQGSURYLVLRQRI&37$57DQG,37 –
% OF TB PATIENTS WITH
KNOWN HIV STATUS
2005–2010
YEAR
Bangladesh
•0
1•
Bhutan
• 25
–
–
–
Democratic
People's Republic
of Korea
India
•2
32 •
Indonesia
–
–
–
0•
•2
3•
Maldives
Myanmar
Nepal
–
–
Sri Lanka
–
10 •
–
77 •
Thailand
Timor-Leste
•0
220
–
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
% OF TB
NUMBER OF TB
PATIENTS WITH PATIENTS WITH
KNOWN HIV
KNOWN HIV
STATUS
STATUS
0
0
1
1
25
7
12
–
–
0
0
–
2
2
17
32
–
0
1
–
–
–
0
0
2
3
3
3
–
–
–
–
–
1
19
10
–
78
75
77
0
0
2
–
0
37
1 446
1 778
250
68
136
0
0
29 488
34 225
258 037
480 752
367
2 782
0
0
2 109
4 292
4 174
4 362
123
1 897
1 015
45 000
49 657
52 753
0
1
108
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 220
PATIENTS
NOTIFIED
(NEW AND
RETREAT)
123 118
153 915
160 875
158 698
1 018
985
1 150
1 332
50 474
84 554
88 665
96 298
1 304 828
1 517 338
1 533 308
1 522 147
254 601
298 329
294 732
302 861
123
122
104
97
107 991
128 738
133 502
137 403
34 077
33 419
35 407
35 609
9 695
9 614
9 788
10 095
57 895
57 492
65 940
68 239
3 783
3 297
4 759
NUMBER OF HIV- % OF TESTED
POSITIVE TB
TB PATIENTS
PATIENTS
HIV-POSITIVE
37
1
4
1
2
2
0
0
6 411
6 039
36 483
41 476
107
479
0
0
611
4 200
1 015
961
2
0
8 215
8 109
8 544
1
0
–
100
0
0
0
3
1
–
–
–
–
–
22
18
14
9
–
29
17
–
–
–
–
–
29
98
24
22
–
–
–
–
–
–
0
–
–
18
16
16
–
100
0
–
% OF HIV% OF HIVNUMBER OF HIVPOSITIVE
POSITIVE TB POSITIVE TB
PEOPLE
PATIENTS ON PATIENTS ON
PROVIDED IPT
CPT
ART
–
57
100
100
0
0
0
–
–
–
–
–
–
68
89
90
–
–
–
–
–
–
–
–
50
26
97
100
–
–
–
–
0
–
–
–
–
69
72
71
–
100
–
–
–
59
100
0
0
100
100
–
–
–
–
–
–
41
50
57
–
–
42
–
–
–
–
–
31
28
67
94
–
–
–
–
0
–
–
–
–
39
50
53
–
100
–
–
64
0
0
0
0
0
0
0
0
333
514
2
5
3
206
127
0
2
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($7HVWLQJIRU0'57%DQGQXPEHURIFRQILUPHGFDVHVRI0'57%±
YEAR
Bangladesh
Bhutan
Democratic
People's Republic
of Korea
India
Indonesia
Maldives
Myanmar
Nepal
Sri Lanka
Thailand
339
2
7
8
17
34
308
1 660
2 967
446
182
3
0
508
815
192
76
69
229
32
8
4
11
358
3
4
NEW CASES
NOTIFIED
119 242
146 924
156 776
150 903
967
915
1 074
1 250
41 358
70 384
74 089
81 240
1 081 175
1 228 053
1 243 552
1 229 175
250 155
292 899
289 044
296 272
118
120
99
94
102 394
119 729
123 785
127 134
31 104
30 465
32 290
32 497
8 983
9 088
9 118
9 328
56 100
53 536
62 011
64 512
3 731
3 262
4 707
PREVIOUSLY TREATED CASES
NUMBER OF
% OF NOTIFIED
NUMBER OF
NOTIFIED TESTED TESTED FOR CONFIRMED CASES
FOR MDR-TB
MDR-TB
OF MDR-TB
2
7
7
108
0
0
0
136
130
126
659
759
813
839
0
0
–
–
–
–
0
1
1
9
–
–
–
–
–
0
–
–
–
–
–
0
–
–
–
0
–
–
–
–
–
0
0
0
7
8
9
9
–
–
–
–
–
0
0
–
2
7
3
5
0
0
0
12
7
9
7
3
0
5
0
0
NOTIFIED
3 876
6 991
4 099
7 795
51
70
76
82
9 116
14 170
14 576
15 058
223 653
289 285
289 756
292 972
4 446
5 430
5 688
6 589
5
2
5
3
5 597
9 009
9 717
10 269
2 973
2 954
3 117
3 112
510
394
409
380
1 795
3 956
3 929
2 996
52
35
52
NUMBER OF NOTIFIED
TESTED FOR MDR-TB
% OF NOTIFIED
NUMBER OF
TESTED FOR CONFIRMED CASES
MDR-TB
OF MDR-TB
339
3
0
8
30
1 511
3 454
324
0
680
962
300
220
193
417
323
419
378
9
6
–
–
–
4
6
0
11
37
–
–
–
–
–
1
1
–
–
–
–
5
–
–
–
0
–
8
10
–
–
10
7
6
82
82
102
99
–
–
–
–
–
26
12
–
339
0
0
4
10
308
1 660
182
0
508
815
54
51
168
25
5
4
6
0
4
South-East Asia Region
Timor-Leste
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
TOTAL
CONFIRMED
CASES OF
MDR-TBa
a
TOTAL CONFIRMED CASES OF MDR-TB includes cases with unknown previous treatment history (i.e. not included under NEW CASES or PREVIOUSLY TREATED CASES).
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 221
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
221
05/10/11 09:03
7$%/($1HZVPHDUSRVLWLYHFDVHQRWLILFDWLRQE\DJHDQGVH[±
MALE
Bangladesh
Bhutan
Democratic
People's Republic
of Korea
India
Indonesia
Maldives
Myanmar
Nepal
Sri Lanka
Thailand
Timor-Leste
222
FEMALE
YEAR
0–14
15–24
25–34
35–44
45–54
55–64
65+
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
2005
2010
29
256
524
365
2
6
1
505
3 640
8 170
10 460
42
65
47
108
983
5 643
10 443
12 535
65
41
58
50
1 001
5 750
11 423
11 409
36
30
26
25
748
4 718
11 038
12 758
35
24
23
12
648
3 667
8 476
11 176
24
12
14
26
424
2 837
7 453
11 536
11
2
12
13
293
167
447
16
1 588
3 185
4 871
6
928
1 409
2 524
334
20 963
62 620
78 278
203
1 508
2 422
4 046
391
31 090
74 678
82 757
297
2 927
2 688
4 849
287
30 829
76 870
90 440
306
2 519
2 040
4 061
216
24 230
64 843
81 210
302
1 167
1 185
2 629
123
15 308
43 038
60 766
228
651
485
1 153
68
8 534
24 726
38 442
109
846
714
1
0
0
0
42
88
132
106
15 215
16 501
28
9
9
8
713
1 459
3 401
3 043
20 906
24 645
11
10
8
6
1 423
2 636
5 877
6 578
18 401
21 090
10
2
5
0
1 401
2 781
5 888
6 688
17 847
20 977
8
5
6
4
977
2 161
4 585
5 607
13 509
17 329
10
5
6
5
677
1 235
2 557
3 632
6 390
7 910
6
3
5
6
298
836
1 764
2 308
170
148
165
10
25
9
14
59
27
44
55
8
1 904
1 946
2 110
163
266
341
268
1 191
859
1 344
1 506
136
1 763
1 685
1 832
361
459
520
539
2 936
2 570
3 814
3 695
149
1 713
1 722
1 724
519
695
724
602
2 948
2 380
4 393
5 253
116
1 491
1 806
1 856
521
793
918
884
2 434
2 117
4 003
5 042
119
1 294
1 759
1 857
365
484
657
683
2 607
1 908
2 831
3 625
52
772
820
1 126
261
360
424
448
2 346
2 213
3 407
4 189
47
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 222
UNKNOWN
0
0
0
0
0
0–14
15–24
25–34
35–44
45–54
55–64
65+
64
495
751
653
12
7
9
17
309
3 029
6 776
9 221
43
57
45
104
546
3 238
6 785
8 279
44
34
38
45
360
2 247
5 538
6 185
25
31
13
18
236
1 315
3 960
5 458
12
23
11
18
132
778
2 281
3 484
9
3
9
10
38
370
1 230
2 250
8
2
2
9
167
166
407
32
2 250
6 292
8 544
16
683
1 127
1 493
179
14 495
45 136
53 415
160
1 121
1 756
2 461
169
17 287
45 629
49 425
244
2 004
1 890
2 910
80
11 768
28 577
34 035
282
1 524
1 381
2 276
49
7 516
17 042
22 719
192
591
764
1 347
30
4 594
10 513
15 527
90
357
336
637
11
2 697
5 408
9 735
33
946
816
1
0
1
1
58
72
147
196
13 916
14 800
13
11
10
2
535
1 040
2 376
2 452
16 393
17 838
8
4
7
3
729
1 592
3 047
3 454
13 022
14 629
4
5
1
4
729
1 397
2 563
2 752
10 927
13 142
6
4
2
1
450
987
2 101
2 525
7 539
9 524
6
5
2
0
343
592
1 218
1 838
2 783
3 451
2
2
4
1
154
378
885
1 139
176
195
192
15
23
19
15
52
32
57
82
8
1 267
1 208
1 177
207
312
295
255
741
624
907
1 087
127
1 078
1 111
1 036
206
264
261
233
888
1 035
1 662
1 930
90
833
797
819
142
176
189
171
782
780
1 334
1 749
76
575
658
681
122
202
200
183
936
873
1 367
1 467
60
419
532
642
81
144
154
186
1 175
1 016
1 259
1 494
18
228
230
352
56
113
130
154
1 178
1 321
1 938
2 276
29
UNKNOWN
0
0
0
0
0
MALE/FEMALE
RATIO
2.6
2.3
2.1
2.0
1.4
1.1
1.4
1.1
–
1.6
1.4
1.7
2.6
2.2
2.2
2.3
1.4
–
1.4
1.5
1.9
1.1
1.4
2.4
1.8
1.8
2.0
1.9
–
2.0
2.1
2.2
2.7
2.5
2.9
2.9
2.5
2.1
2.3
2.3
1.5
–
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 223
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
223
05/10/11 09:03
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
No
<0.1
0.1
0
0.2
0.3
0.2
1.1
In country
In country
Out of country
Out of country
In country
No
In country
<0.1
0.9
16
0.2
0.5
0.5
4.7
1.2
1.1
2.1
22
0.9
1.6
0.9
1.6
NRLa
Yes
Yes
<0.1
6.9
SECOND-LINE
DST
AVAILABLE
Out of country
Out of country
0.1
6.9
0.7
4.4
DST LABS
PER 5M
POPULATION
LABORATORIES
CULTURE LABS
PER 5M
POPULATION
Yes, all suspects
Yes (other criteria)
If TB is confirmed
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
If TB is confirmed
TB DIAGNOSIS
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
FIRST-LINE DRUGS
FREE THROUGH NTP
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
RIFAMPICIN USED
THROUGHOUT
TREATMENT
South-East Asia Region
0
100
95
100
100
90
25
100
100
100
% OF PATIENTS
TREATED WITH FDCb
DRUG MANAGEMENT
a NRL = national reference laboratory
b FDC = fixed-dose combination
c NURSES (Registered Nurses, Registered Midwives, Enrolled Nurses, Enrolled Midwives); HEALTH ASSISTANTS (Medical Assistants, Clinical Officers); LABORATORY TECHNICIANS (Microscopists)
Bangladesh
Bhutan
Democratic People's Republic
of Korea
India
Indonesia
Maldives
Myanmar
Nepal
Sri Lanka
Thailand
Timor-Leste
SMEAR LABS
PER 100K
POPULATION
7$%/($/DERUDWRULHV173VHUYLFHVGUXJPDQDJHPHQWKXPDQUHVRXUFHVDQGLQIHFWLRQFRQWURO
Yes
Yes
No
Yes
Yes
Yes
No
Yes
Yes
No
PAEDIATRIC
FORMULATIONS
PROCURED
85
0
70
20
97
100
29
25
MEDICAL
OFFICERS
71
0
88
6
85
100
25
0
NURSES
0
84
24
25
0
HEALTH
ASSISTANTS
85
0
72
26
100
62
100
LABORATORY
TECHNICIANS
% OF STAFF TRAINED BY THE NTP (IN 2010)c
0
TB NOTIFICATION
RATE PER 100 000
HEALTH-CARE
WORKERS
1109_0319_P_111_246 224
05/10/11 09:03
Western Pacific
Pacific Region
Table A3.1 Estimates of the burden of disease caused by TB, 1990–2010
227
Table A3.2 Incidence, notification and case detection rates, all forms, 1990–2010
230
Table A3.3 Case notifications, 1990–2010
233
Table A3.4 Treatment outcomes, new smear-positive cases, 1995–2009
236
Table A3.5 Treatment outcomes, retreatment cases, 1995–2009
238
Table A3.6 HIV testing and provision of CPT, ART and IPT, 2005–2010
240
Table A3.7 Testing for MDR-TB and number of confirmed cases of MDR-TB, 2005–2010
242
Table A3.8 New smear-positive case notification by age and sex, 1995–2010
244
Table A3.9 Laboratories, NTP services, drug management, human resources and
infection control, 2010
246
1109_0319_P_111_246 225
05/10/11 09:03
Estimates of mortality, prevalence and incidence
Estimated values are shown as best estimates followed by lower and upper bounds. The lower and upper bounds are
defi ned as the 2.5th and 97.5th centiles of outcome distributions produced in simulations. See ANNEX 1 for further
details.
Estimated numbers are shown rounded to two significant figures. Estimated rates are shown rounded to three
significant figures unless the value is under 100, in which case rates are shown rounded to two significant figures.
Estimates for all years are recalculated as new information becomes available and techniques are refi ned, so they
may differ from those published in previous reports in this series. Estimates published in previous global TB control
reports should no longer be used.
Data source
Data shown in this annex are taken from the WHO global TB database on 2 September 2011. Data shown in the main
part of the report were taken from the database on 21 June 2011. As a result, data in this annex may differ slightly from
those in the main part of the report.
Data can be downloaded from www.who.int/tb/data.
226
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 226
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($(VWLPDWHVRIWKHEXUGHQRIGLVHDVHFDXVHGE\7%±
American Samoa
1990
1995
2000
2005
2008
2009
2010
Australia
1990
1995
2000
2005
2008
2009
2010
Brunei
1990
Darussalam
1995
2000
2005
2008
2009
2010
Cambodia
1990
1995
2000
2005
2008
2009
2010
China
1990
1995
2000
2005
2008
2009
2010
China, Hong Kong 1990
SAR
1995
2000
2005
2008
2009
2010
China, Macao
1990
SAR
1995
2000
2005
2008
2009
2010
Cook Islands
1990
1995
2000
2005
2008
2009
2010
Fiji
1990
1995
2000
2005
2008
2009
2010
French Polynesia 1990
1995
2000
2005
2008
2009
2010
Guam
1990
1995
2000
2005
2008
2009
2010
Japan
1990
1995
2000
2005
2008
2009
2010
Kiribati
1990
1995
2000
2005
2008
2009
2010
Lao People's
1990
Democratic
1995
Republic
2000
2005
2008
2009
2010
Malaysia
1990
1995
2000
2005
2008
2009
2010
a
POPULATION
(MILLIONS)
<1
<1
<1
<1
<1
<1
<1
17
18
19
20
22
22
22
<1
<1
<1
<1
<1
<1
<1
10
11
12
13
14
14
14
1 145
1 214
1 269
1 308
1 328
1 335
1 341
6
6
7
7
7
7
7
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
122
124
126
126
127
127
127
<1
<1
<1
<1
<1
<1
<1
4
5
5
6
6
6
6
18
21
23
26
28
28
28
NUMBER
(THOUSANDS)
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.036
0.039
0.035
0.039
0.042
0.043
0.045
<0.01
<0.01
0.016
<0.01
<0.01
0.012
0.011
15
13
13
10
9.1
8.8
8.6
220
160
110
86
56
55
54
0.58
0.55
0.53
0.5
0.49
0.45
0.43
0.031
0.036
0.04
0.032
0.032
0.026
0.033
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.039
0.031
0.026
0.022
0.022
0.023
0.031
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
4.3
3.6
2.8
2.4
2.3
2.3
2
<0.01
0.049
0.039
0.054
0.056
0.039
0.046
0.68
1
0.83
0.64
0.64
0.67
0.71
4.3
3.7
2.9
2.8
2.5
2.4
2.4
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.031–0.044)
(0.033–0.046)
(0.035–0.035)
(0.034–0.047)
(0.037–0.051)
(0.038–0.053)
(0.039–0.053)
(<0.01–<0.01)
(<0.01–<0.01)
(0.016–0.017)
(<0.01–<0.01)
(<0.01–<0.01)
(0.012–0.013)
(<0.01–0.013)
(9.8–20)
(9.8–18)
(10–16)
(7.6–13)
(6.7–12)
(6.3–12)
(6.2–12)
(190–240)
(130–200)
(80–140)
(84–89)
(54–58)
(53–57)
(52–56)
(0.5–0.7)
(0.48–0.66)
(0.46–0.64)
(0.43–0.6)
(0.42–0.59)
(0.39–0.55)
(0.38–0.52)
(0.026–0.037)
(0.033–0.041)
(0.035–0.049)
(0.027–0.038)
(0.028–0.039)
(0.024–0.03)
(0.028–0.04)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.024–0.06)
(0.018–0.051)
(0.016–0.04)
(0.013–0.035)
(0.014–0.033)
(0.014–0.037)
(0.018–0.049)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.011)
(<0.01–0.011)
(3.7–5.2)
(3.1–4.3)
(2.8–2.8)
(2.4–2.4)
(2.3–2.3)
(2.3–2.3)
(1.7–2.4)
(<0.01–0.011)
(0.029–0.078)
(0.022–0.065)
(0.031–0.088)
(0.033–0.089)
(0.022–0.068)
(0.027–0.074)
(0.39–1.1)
(0.71–1.4)
(0.55–1.2)
(0.38–0.99)
(0.39–1)
(0.42–1)
(0.44–1.1)
(3.6–5.2)
(3–4.5)
(2.3–3.6)
(2.3–3.4)
(2–3.1)
(1.9–3)
(1.9–3.1)
RATEa
4.8
2.7
<1
2
<1
1.1
<1
<1
<1
<1
<1
<1
<1
<1
2.5
2.5
4.9
1.9
2.2
3.1
2.7
153
120
105
75
66
63
61
19
13
8.7
6.6
4.2
4.1
4.1
10
8.9
7.8
7.3
7.1
6.5
6.1
8.6
9.1
9.3
6.6
6.2
4.9
6.1
<1
2.7
<1
<1
1.1
1.2
<1
5.3
4
3.2
2.7
2.6
2.7
3.6
2.5
3.7
2.8
2.1
1.9
1.7
1.4
3.8
5.6
3
3.5
4.5
5.2
4.9
3.5
2.9
2.3
1.9
1.8
1.8
1.5
8.5
63
46
59
58
40
47
16
21
16
11
11
11
11
24
18
12
11
9.1
8.6
8.5
(3.3–6.6)
(2–3.5)
(<1–1.2)
(1.3–2.9)
(<1–1.1)
(<1–1.7)
(<1–1.5)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(2.2–3)
(2.1–3)
(4.9–5.2)
(1.7–2.3)
(2.2–2.3)
(3.1–3.2)
(2.3–3.2)
(103–214)
(88–158)
(82–130)
(57–95)
(48–86)
(45–84)
(44–82)
(17–21)
(11–16)
(6.3–11)
(6.4–6.8)
(4.1–4.4)
(4–4.3)
(3.9–4.2)
(8.6–12)
(7.7–11)
(6.8–9.4)
(6.3–8.8)
(6.1–8.6)
(5.6–7.8)
(5.3–7.3)
(7.4–10)
(8.3–10)
(8–11)
(5.6–7.9)
(5.3–7.5)
(4.5–5.7)
(5.2–7.3)
(<1–<1)
(1.8–3.7)
(<1–1.5)
(<1–1.2)
(<1–2)
(<1–2.2)
(<1–<1)
(3.2–8.3)
(2.3–6.5)
(2–4.9)
(1.6–4.2)
(1.6–3.9)
(1.6–4.3)
(2.1–5.7)
(2.1–3.1)
(3.2–4.4)
(2.5–3.3)
(1.9–2.5)
(1.6–2.2)
(1.4–2)
(1.2–1.6)
(3.3–4.6)
(4.7–6.7)
(2.7–3.6)
(2.9–4.2)
(3.7–5.5)
(4.4–6.2)
(4.2–6)
(3.1–4.3)
(2.5–3.5)
(2.3–2.3)
(1.9–1.9)
(1.8–1.8)
(1.8–1.8)
(1.3–1.9)
(5.6–16)
(37–101)
(26–77)
(34–95)
(34–93)
(23–69)
(27–74)
(9.4–26)
(15–29)
(10–22)
(6.7–17)
(6.5–17)
(6.8–17)
(7.1–17)
(20–29)
(15–22)
(9.6–15)
(8.6–13)
(7.2–11)
(6.7–11)
(6.6–11)
PREVALENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
0.022
0.012
<0.01
0.013
<0.01
<0.01
<0.01
1.4
1.5
1.5
1.5
1.7
1.7
1.8
0.2
0.23
0.44
0.21
0.33
0.3
0.36
120
120
110
100
96
94
93
2500
2400
2200
1800
1600
1500
1500
9.8
9
8.7
8.3
8.4
7.5
7.1
0.52
0.55
0.67
0.53
0.56
0.4
0.58
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.46
0.38
0.32
0.26
0.25
0.28
0.35
0.083
0.13
0.11
0.087
0.082
0.077
0.059
0.085
0.15
0.076
0.11
0.14
0.16
0.15
77
64
58
40
35
35
35
0.099
0.57
0.45
0.65
0.64
0.51
0.55
6.6
8.7
8.1
7.3
7.6
7.8
8.1
41
37
32
32
30
30
30
(<0.01–0.036)
(<0.01–0.021)
(<0.01–<0.01)
(<0.01–0.022)
(<0.01–0.01)
(<0.01–0.014)
(<0.01–0.014)
(0.5–2.5)
(0.49–2.6)
(0.48–2.5)
(0.5–2.6)
(0.55–2.8)
(0.58–2.9)
(0.62–3)
(0.063–0.35)
(0.075–0.4)
(0.16–0.75)
(0.055–0.37)
(0.11–0.56)
(0.087–0.51)
(0.13–0.61)
(51–210)
(52–190)
(54–190)
(46–160)
(43–150)
(42–150)
(42–150)
(2300–2600)
(2100–2600)
(1800–2500)
(1600–2100)
(1400–1800)
(1300–1700)
(1300–1700)
(3.4–17)
(2.8–15)
(2.8–15)
(2.8–14)
(3–14)
(2.4–13)
(2.2–12)
(0.19–0.88)
(0.13–0.96)
(0.22–1.1)
(0.19–0.9)
(0.21–0.93)
(0.098–0.7)
(0.22–0.96)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.18–0.78)
(0.14–0.66)
(0.12–0.54)
(0.1–0.44)
(0.099–0.42)
(0.1–0.48)
(0.14–0.6)
(0.029–0.14)
(0.046–0.23)
(0.041–0.19)
(0.027–0.15)
(0.028–0.14)
(0.027–0.13)
(0.016–0.1)
(0.028–0.15)
(0.068–0.25)
(0.023–0.13)
(0.046–0.18)
(0.053–0.23)
(0.056–0.27)
(0.047–0.25)
(27–130)
(21–110)
(20–98)
(13–68)
(12–60)
(12–59)
(11–59)
(0.025–0.18)
(0.22–0.99)
(0.17–0.8)
(0.24–1.1)
(0.25–1.1)
(0.17–0.89)
(0.21–0.95)
(2.8–12)
(3.9–15)
(3.6–14)
(2.9–13)
(3–13)
(3.1–13)
(3.3–14)
(19–65)
(17–58)
(15–50)
(14–49)
(13–48)
(13–48)
(13–49)
RATE
46
24
9.2
21
8.1
12
11
8.4
8.3
7.7
7.4
7.7
7.8
8
81
80
136
59
85
76
91
1258
1032
923
746
692
673
660
215
195
170
140
119
112
108
169
146
128
122
121
107
100
146
137
155
111
108
76
106
3.1
29
15
8.7
15
14
5.5
63
49
39
31
29
32
40
43
62
48
34
31
29
22
64
106
49
64
79
88
81
63
51
46
32
28
27
27
138
741
541
703
666
515
550
157
182
152
128
126
128
130
227
178
136
121
110
108
107
(21–77)
(11–39)
(3–16)
(8.9–35)
(2.6–15)
(4.9–21)
(4.1–20)
(2.9–14)
(2.7–14)
(2.5–13)
(2.4–13)
(2.6–13)
(2.6–13)
(2.8–14)
(25–139)
(26–137)
(50–230)
(15–103)
(29–145)
(22–130)
(33–153)
(532–2238)
(469–1735)
(433–1488)
(348–1191)
(314–1110)
(301–1088)
(296–1070)
(201–230)
(175–215)
(145–196)
(120–160)
(103–136)
(97–127)
(93–123)
(59–286)
(46–250)
(41–219)
(41–208)
(43–205)
(35–183)
(31–172)
(52–246)
(31–241)
(52–266)
(39–188)
(40–180)
(18–132)
(40–176)
(<1–5.5)
(12–48)
(4.4–25)
(2.9–16)
(4.5–27)
(4.9–26)
(1.2–9.7)
(24–107)
(18–85)
(15–67)
(12–54)
(12–49)
(12–56)
(16–70)
(15–72)
(21–106)
(17–79)
(11–59)
(11–53)
(10–49)
(5.8–37)
(21–109)
(47–172)
(15–84)
(27–104)
(30–133)
(32–149)
(26–140)
(22–107)
(17–87)
(16–78)
(11–54)
(9.3–47)
(9.1–47)
(9.1–47)
(35–248)
(284–1284)
(201–951)
(264–1225)
(255–1162)
(177–912)
(208–952)
(66–282)
(81–311)
(67–257)
(50–219)
(50–216)
(51–217)
(53–221)
(107–356)
(84–278)
(62–215)
(55–189)
(49–174)
(46–171)
(46–171)
INCIDENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
0.012
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
1.1
1.2
1.2
1.2
1.3
1.4
1.4
0.17
0.18
0.33
0.2
0.25
0.25
0.27
55
59
61
62
62
62
62
1700
1600
1400
1200
1100
1100
1000
7.5
7.1
6.9
6.5
6.4
5.9
5.7
0.4
0.49
0.52
0.4
0.4
0.37
0.41
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.32
0.27
0.22
0.17
0.16
0.19
0.23
0.063
0.1
0.086
0.071
0.064
0.058
0.05
0.066
0.099
0.062
0.072
0.1
0.12
0.12
60
50
45
31
28
27
27
0.084
0.39
0.31
0.45
0.43
0.4
0.37
3.7
4.1
4.5
5
5.3
5.4
5.6
23
22
22
22
23
23
23
(<0.01–0.015)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.99–1.3)
(1.1–1.4)
(1–1.3)
(1.1–1.4)
(1.2–1.5)
(1.2–1.6)
(1.2–1.6)
(0.15–0.19)
(0.16–0.21)
(0.28–0.37)
(0.17–0.22)
(0.22–0.28)
(0.22–0.29)
(0.24–0.31)
(38–74)
(46–74)
(51–72)
(53–71)
(53–71)
(53–71)
(53–72)
(1400–2200)
(1300–1900)
(1200–1600)
(1000–1400)
(970–1300)
(940–1200)
(910–1200)
(6.6–8.5)
(6.3–8.1)
(6.1–7.8)
(5.7–7.4)
(5.6–7.2)
(5.2–6.7)
(5–6.4)
(0.35–0.45)
(0.43–0.55)
(0.46–0.59)
(0.35–0.45)
(0.34–0.45)
(0.33–0.42)
(0.36–0.47)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.26–0.38)
(0.22–0.33)
(0.19–0.27)
(0.13–0.21)
(0.13–0.19)
(0.15–0.23)
(0.18–0.28)
(0.055–0.072)
(0.09–0.12)
(0.077–0.095)
(0.062–0.08)
(0.057–0.072)
(0.05–0.066)
(0.044–0.056)
(0.058–0.075)
(0.086–0.11)
(0.054–0.07)
(0.063–0.082)
(0.09–0.12)
(0.1–0.13)
(0.1–0.13)
(52–67)
(43–56)
(39–51)
(28–36)
(24–31)
(24–31)
(24–31)
(0.066–0.1)
(0.32–0.47)
(0.25–0.38)
(0.36–0.54)
(0.35–0.53)
(0.33–0.48)
(0.3–0.45)
(2.6–4.9)
(3.1–5.3)
(3.5–5.7)
(4–6.1)
(4.3–6.4)
(4.5–6.5)
(4.6–6.7)
(20–26)
(20–25)
(20–24)
(20–24)
(21–25)
(21–25)
(21–25)
RATE
26
12
6.9
13
6
7.9
7.8
6.6
6.7
6.1
6
6.2
6.3
6.3
66
63
100
55
65
65
68
574
529
492
461
446
442
437
153
129
109
92
83
80
78
129
116
102
96
92
85
80
110
123
121
83
76
70
76
<1
19
12
6.4
12
9.3
3.5
43
35
28
21
19
22
27
32
48
36
28
24
22
18
50
68
40
43
58
66
65
49
40
36
25
22
22
21
116
505
372
488
450
408
370
88
86
85
87
88
89
90
127
108
95
86
83
83
82
(21–31)
(9.3–14)
(5.6–8.4)
(10–15)
(4.9–7.3)
(6.4–9.6)
(6.3–9.5)
(5.8–7.5)
(5.8–7.6)
(5.4–7)
(5.3–6.8)
(5.4–7.1)
(5.5–7.1)
(5.6–7.1)
(58–74)
(55–71)
(87–114)
(48–61)
(57–74)
(57–73)
(59–77)
(398–781)
(411–662)
(411–579)
(397–529)
(384–513)
(378–510)
(373–506)
(120–189)
(105–155)
(92–127)
(80–105)
(73–94)
(70–91)
(68–88)
(113–146)
(102–132)
(89–115)
(84–108)
(81–104)
(74–96)
(71–91)
(96–125)
(108–138)
(106–137)
(73–94)
(66–87)
(62–79)
(67–87)
(<1–1.2)
(16–22)
(11–14)
(5–7.8)
(9–14)
(6.8–12)
(<1–7)
(35–52)
(28–42)
(23–33)
(16–25)
(16–23)
(18–27)
(21–33)
(28–37)
(42–54)
(32–40)
(24–31)
(22–27)
(19–25)
(16–21)
(44–56)
(59–77)
(35–45)
(38–49)
(51–66)
(58–75)
(57–73)
(43–55)
(35–45)
(31–40)
(22–28)
(19–25)
(19–24)
(19–24)
(92–144)
(409–611)
(295–458)
(394–591)
(360–549)
(334–488)
(297–452)
(62–118)
(64–111)
(67–106)
(70–105)
(72–106)
(73–107)
(74–107)
(112–142)
(97–120)
(86–104)
(79–94)
(76–91)
(75–90)
(75–89)
Western Pacific Region
MORTALITY (EXCLUDING HIV)
YEAR
Rates are per 100 000 population.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 227
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
227
05/10/11 09:03
7$%/($(VWLPDWHVRIWKHEXUGHQRIGLVHDVHFDXVHGE\7%±
MORTALITY (EXCLUDING HIV)
Marshall Islands
Micronesia
(Federated
States of)
Mongolia
Nauru
New Caledonia
New Zealand
Niue
Northern Mariana
Islands
Palau
Papua New
Guinea
Philippines
Republic of Korea
Samoa
Singapore
Solomon Islands
a
228
YEAR
POPULATION
(MILLIONS)
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
2
2
2
3
3
3
3
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
3
4
4
4
4
4
4
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
4
5
5
6
7
7
7
62
69
77
86
90
92
93
43
45
46
47
48
48
48
<1
<1
<1
<1
<1
<1
<1
3
3
4
4
5
5
5
<1
<1
<1
<1
<1
<1
<1
NUMBER
(THOUSANDS)
0.014
0.015
0.032
0.028
0.038
0.041
0.044
0.024
0.07
0.07
0.056
0.038
0.034
0.033
0.42
0.27
0.19
0.1
0.12
0.13
0.14
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.013
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.012
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
3.2
3.1
2
2.5
2.6
2.8
2.9
29
33
34
35
34
32
31
5.4
5
4.5
3.7
3
2.8
2.6
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.13
0.14
0.13
0.084
0.11
0.11
0.12
0.22
0.19
0.16
0.12
0.096
0.096
0.092
(<0.01–0.052)
(<0.01–0.053)
(0.016–0.054)
(<0.01–0.095)
(<0.01–0.11)
(<0.01–0.12)
(<0.01–0.16)
(0.016–0.031)
(0.028–0.14)
(0.044–0.1)
(0.029–0.092)
(0.011–0.097)
(0.011–0.086)
(<0.01–0.088)
(0.35–0.5)
(0.22–0.33)
(0.16–0.23)
(0.079–0.13)
(0.099–0.15)
(0.11–0.16)
(0.11–0.17)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.011–0.016)
(<0.01–0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.01)
(<0.01–0.011)
(0.012–0.012)
(<0.01–<0.01)
(<0.01–0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(2–4.9)
(1.7–5)
(0.88–4.1)
(1.1–5)
(1.1–5.2)
(1.2–5.5)
(1.3–5.8)
(15–44)
(21–44)
(34–34)
(24–47)
(23–46)
(22–44)
(21–43)
(5.2–5.6)
(4.8–5.2)
(4.4–4.5)
(3.6–3.7)
(3–3)
(2.8–2.8)
(2.5–2.7)
(<0.01–0.011)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.11–0.15)
(0.12–0.17)
(0.13–0.13)
(0.083–0.084)
(0.095–0.14)
(0.099–0.14)
(0.1–0.14)
(0.11–0.37)
(0.14–0.24)
(0.12–0.21)
(0.079–0.16)
(0.064–0.14)
(0.064–0.14)
(0.062–0.13)
RATEa
30
30
62
54
71
76
81
25
65
65
51
34
31
29
19
12
7.8
4
4.6
4.9
5
14
5.7
6.6
19
7.3
6.1
3.8
7.7
4.6
3.1
1.9
1.7
1.7
1.7
<1
<1
<1
<1
<1
<1
<1
<1
3.6
<1
<1
<1
<1
<1
6.9
8.7
11
8.9
5.6
6
5.7
4.2
14
25
9.5
9.3
15
15
78
65
37
41
40
42
43
47
47
44
40
37
35
33
13
11
9.7
7.8
6.3
5.8
5.4
4.4
3.2
2.7
1.4
2.2
1.8
1.3
4.1
4
3.2
2
2.3
2.3
2.3
71
52
40
25
19
18
17
(3.5–109)
(6.8–103)
(31–103)
(13–183)
(17–215)
(18–225)
(17–295)
(17–32)
(26–127)
(41–95)
(27–84)
(10–88)
(9.8–78)
(8.9–79)
(16–23)
(9.6–14)
(6.4–9.4)
(3.1–5.2)
(3.7–5.6)
(4–5.9)
(4.2–6)
(8.4–21)
(3.3–9.2)
(3.8–11)
(12–30)
(4–12)
(3.5–10)
(2.2–6.5)
(6.6–9.2)
(4–5.5)
(2.7–3.9)
(1.6–2.2)
(1.5–2.1)
(1.5–2.1)
(1.5–2)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(2.9–4.3)
(<1–1.2)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(5.5–9)
(6.9–11)
(8.5–15)
(7–12)
(4.6–7.1)
(4.6–8)
(4.6–7.5)
(2.4–7.3)
(8–24)
(16–37)
(5.9–14)
(5.4–16)
(8.9–25)
(8.7–24)
(47–117)
(36–106)
(16–76)
(18–82)
(17–79)
(18–82)
(19–84)
(24–71)
(30–64)
(44–44)
(28–55)
(26–51)
(24–49)
(22–46)
(12–13)
(11–12)
(9.7–9.7)
(7.7–7.8)
(6.3–6.3)
(5.8–5.9)
(5.1–5.6)
(2.5–7.1)
(1.7–5.8)
(1.4–5.1)
(<1–2.6)
(1.7–2.9)
(1.2–2.7)
(<1–2.1)
(3.6–4.9)
(3.4–4.9)
(3.2–3.3)
(1.9–2)
(2–2.8)
(2–2.8)
(2–2.8)
(35–120)
(39–68)
(29–52)
(17–34)
(12–27)
(12–26)
(11–24)
PREVALENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
0.13
0.16
0.28
0.3
0.39
0.41
0.45
0.42
0.65
0.61
0.51
0.39
0.37
0.36
20
14
11
7.7
8.4
8.8
9.1
0.014
<0.01
<0.01
0.022
<0.01
<0.01
<0.01
0.22
0.15
0.11
0.068
0.069
0.071
0.069
0.46
0.5
0.49
0.49
0.49
0.44
0.41
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.055
0.088
0.14
0.11
0.061
0.068
0.061
<0.01
0.033
0.05
0.021
0.025
0.037
0.037
27
28
23
28
29
31
32
620
630
600
540
490
480
470
96
90
85
79
75
74
73
0.084
0.068
0.059
0.038
0.041
0.036
0.029
2.3
2.7
2.5
1.9
2.1
2.2
2.2
1.9
1.7
1.5
1.1
1
0.99
0.96
(0.017–0.46)
(0.031–0.49)
(0.11–0.55)
(0.059–0.91)
(0.084–1.1)
(0.092–1.1)
(0.078–1.5)
(0.088–0.7)
(0.23–1.4)
(0.27–1.1)
(0.21–0.97)
(0.1–0.95)
(0.098–0.87)
(0.088–0.88)
(9.1–32)
(6.7–22)
(5–17)
(2.9–12)
(3.5–13)
(3.8–14)
(3.9–14)
(<0.01–0.024)
(<0.01–0.012)
(<0.01–0.013)
(<0.01–0.037)
(<0.01–0.015)
(<0.01–0.013)
(<0.01–<0.01)
(0.079–0.37)
(0.053–0.25)
(0.033–0.19)
(0.02–0.12)
(0.022–0.12)
(0.022–0.12)
(0.021–0.12)
(0.14–0.79)
(0.15–0.86)
(0.14–0.85)
(0.16–0.83)
(0.19–0.8)
(0.15–0.75)
(0.13–0.7)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.021–0.096)
(0.032–0.16)
(0.052–0.24)
(0.043–0.19)
(0.021–0.11)
(0.026–0.12)
(0.022–0.11)
(<0.01–0.015)
(0.01–0.058)
(0.022–0.084)
(<0.01–0.036)
(<0.01–0.045)
(0.014–0.065)
(0.014–0.064)
(11–50)
(11–52)
(7.5–47)
(9.5–55)
(9.9–58)
(11–61)
(11–63)
(470–790)
(480–800)
(470–740)
(460–630)
(440–550)
(420–540)
(410–530)
(77–110)
(73–110)
(68–100)
(63–94)
(60–90)
(59–89)
(58–88)
(0.031–0.15)
(0.023–0.12)
(0.019–0.11)
(0.011–0.068)
(0.019–0.066)
(0.015–0.06)
(0.011–0.05)
(0.73–3.9)
(0.93–4.6)
(0.87–4.2)
(0.66–3.3)
(0.73–3.6)
(0.74–3.7)
(0.77–3.8)
(0.75–3.8)
(0.78–2.8)
(0.68–2.4)
(0.51–1.9)
(0.44–1.7)
(0.43–1.7)
(0.42–1.6)
INCIDENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
RATE
269
314
540
581
739
773
831
433
606
570
463
358
333
320
910
611
442
301
316
326
331
155
68
71
214
83
74
52
131
78
51
30
28
29
28
14
14
13
12
11
10
9.3
<1
68
19
<1
<1
<1
<1
125
154
201
163
97
110
100
58
188
259
104
126
180
179
659
588
437
454
449
460
465
1003
904
775
633
548
520
502
223
203
184
167
157
154
151
52
41
33
21
23
20
16
77
77
63
46
45
44
44
625
472
360
245
198
189
178
(37–980)
(60–957)
(212–1058)
(113–1743)
(159–2086)
(173–2120)
(145–2724)
(91–730)
(213–1280)
(250–1015)
(189–883)
(95–861)
(88–786)
(80–796)
(417–1466)
(292–964)
(207–692)
(115–490)
(132–506)
(139–517)
(142–522)
(62–267)
(25–118)
(29–126)
(86–370)
(31–148)
(27–129)
(16–92)
(47–220)
(28–131)
(15–89)
(8.6–51)
(9.1–48)
(9.1–50)
(8.2–48)
(4.2–23)
(4.2–23)
(3.6–22)
(3.8–20)
(4.4–19)
(3.5–17)
(2.9–16)
(<1–<1)
(15–120)
(4.2–33)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(48–217)
(55–272)
(76–353)
(63–284)
(34–168)
(42–195)
(35–176)
(18–102)
(59–335)
(113–437)
(43–180)
(40–224)
(68–318)
(67–314)
(274–1214)
(243–1103)
(140–866)
(155–900)
(151–882)
(160–913)
(161–925)
(765–1277)
(687–1149)
(614–957)
(542–731)
(484–612)
(456–584)
(438–566)
(179–267)
(163–242)
(148–220)
(134–200)
(126–189)
(124–185)
(121–182)
(19–91)
(13–74)
(11–62)
(6.1–38)
(10–36)
(8.3–33)
(5.9–27)
(24–131)
(27–131)
(22–107)
(16–77)
(15–76)
(15–75)
(15–75)
(244–1234)
(218–777)
(166–592)
(110–407)
(86–332)
(83–318)
(78–298)
0.065
0.097
0.14
0.19
0.23
0.25
0.27
0.36
0.35
0.3
0.26
0.24
0.23
0.23
8.9
7.2
6.1
5.7
5.9
6.1
6.2
<0.01
<0.01
<0.01
0.014
<0.01
<0.01
<0.01
0.17
0.11
0.087
0.056
0.055
0.056
0.057
0.37
0.41
0.42
0.39
0.36
0.35
0.33
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.038
0.062
0.092
0.074
0.045
0.045
0.044
<0.01
0.025
0.03
0.013
0.019
0.025
0.025
13
14
16
18
20
20
21
240
250
250
260
260
260
260
70
46
36
41
44
46
47
0.058
0.05
0.041
0.031
0.024
0.022
0.02
1.9
2.1
2
1.6
1.7
1.8
1.8
0.97
0.86
0.75
0.67
0.62
0.6
0.58
(<0.01–0.2)
(0.022–0.23)
(0.083–0.2)
(0.046–0.43)
(0.067–0.5)
(0.071–0.54)
(0.046–0.69)
(0.093–0.82)
(0.19–0.55)
(0.21–0.4)
(0.17–0.37)
(0.1–0.44)
(0.11–0.41)
(0.095–0.42)
(7.5–10)
(6.3–8.2)
(5.5–6.8)
(5.3–6.2)
(5.5–6.4)
(5.6–6.5)
(5.7–6.6)
(<0.01–0.011)
(<0.01–<0.01)
(<0.01–<0.01)
(0.011–0.017)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.15–0.19)
(0.1–0.13)
(0.074–0.1)
(0.05–0.064)
(0.048–0.061)
(0.048–0.064)
(0.05–0.064)
(0.33–0.43)
(0.35–0.47)
(0.37–0.47)
(0.34–0.44)
(0.32–0.4)
(0.3–0.39)
(0.29–0.38)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.03–0.046)
(0.05–0.076)
(0.073–0.11)
(0.059–0.09)
(0.037–0.053)
(0.036–0.056)
(0.036–0.053)
(<0.01–<0.01)
(0.02–0.031)
(0.024–0.036)
(0.011–0.016)
(0.016–0.023)
(0.02–0.031)
(0.02–0.031)
(8.2–18)
(9.3–20)
(11–23)
(12–26)
(13–28)
(13–29)
(14–29)
(150–360)
(200–300)
(210–310)
(210–310)
(210–310)
(210–310)
(210–310)
(61–80)
(40–52)
(33–40)
(36–47)
(39–50)
(40–51)
(41–53)
(0.047–0.071)
(0.038–0.063)
(0.03–0.054)
(0.025–0.038)
(0.021–0.028)
(0.018–0.027)
(0.016–0.024)
(1.7–2.1)
(1.9–2.4)
(1.7–2.2)
(1.4–1.8)
(1.5–1.9)
(1.6–2)
(1.6–2)
(0.59–1.4)
(0.7–1)
(0.61–0.91)
(0.54–0.8)
(0.5–0.74)
(0.49–0.72)
(0.48–0.7)
RATE
137
190
263
363
441
471
502
379
325
279
240
219
212
206
405
314
254
225
222
224
224
102
47
45
139
55
51
40
99
59
41
24
22
23
23
11
11
11
9.5
8.4
8
7.6
74
57
40
23
13
9.9
6.5
86
109
135
110
71
74
72
45
147
156
67
95
125
124
303
303
303
303
303
303
303
393
360
329
301
285
280
275
163
102
79
88
93
95
97
36
30
23
17
13
12
11
62
61
50
37
36
36
35
312
240
185
142
121
115
108
(11–417)
(42–445)
(158–393)
(89–826)
(126–949)
(134–1014)
(85–1279)
(96–850)
(181–510)
(198–374)
(156–341)
(94–395)
(98–370)
(86–377)
(344–471)
(273–357)
(227–281)
(206–244)
(206–239)
(208–240)
(208–240)
(82–124)
(38–57)
(35–57)
(111–170)
(42–69)
(41–63)
(32–48)
(87–111)
(53–66)
(35–48)
(22–28)
(20–25)
(19–26)
(20–26)
(9.6–13)
(9.5–13)
(9.5–12)
(8.3–11)
(7.4–9.4)
(7–9)
(6.6–8.7)
(<1–148)
(<1–114)
(<1–81)
(<1–47)
(<1–27)
(<1–20)
(<1–13)
(69–104)
(87–133)
(107–166)
(88–134)
(60–84)
(58–92)
(58–87)
(36–55)
(118–178)
(126–190)
(54–81)
(77–116)
(100–151)
(100–150)
(197–430)
(197–430)
(197–430)
(197–430)
(197–430)
(197–430)
(197–430)
(239–585)
(293–434)
(268–396)
(245–362)
(232–343)
(229–336)
(226–329)
(142–186)
(89–117)
(72–86)
(76–100)
(82–105)
(83–107)
(85–110)
(29–44)
(23–37)
(17–30)
(14–21)
(12–15)
(9.8–15)
(8.9–13)
(55–70)
(53–69)
(44–57)
(32–41)
(31–41)
(31–40)
(31–40)
(190–464)
(195–290)
(150–223)
(116–171)
(99–146)
(94–138)
(89–130)
Rates are per 100 000 population.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 228
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($(VWLPDWHVRIWKHEXUGHQRIGLVHDVHFDXVHGE\7%±
MORTALITY (EXCLUDING HIV)
YEAR
1990
1995
2000
2005
2008
2009
2010
Tonga
1990
1995
2000
2005
2008
2009
2010
Tuvalu
1990
1995
2000
2005
2008
2009
2010
Vanuatu
1990
1995
2000
2005
2008
2009
2010
Viet Nam
1990
1995
2000
2005
2008
2009
2010
Wallis and Futuna 1990
Islands
1995
2000
2005
2008
2009
2010
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
67
74
79
83
86
87
88
<1
<1
<1
<1
<1
<1
<1
NUMBER
(THOUSANDS)
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.012
<0.01
0.026
0.028
0.023
0.023
0.014
29
32
27
28
29
29
29
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.016)
(<0.01–0.016)
(<0.01–0.012)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.023)
(<0.01–<0.01)
(0.015–0.041)
(0.018–0.04)
(0.014–0.035)
(0.014–0.035)
(<0.01–0.027)
(20–41)
(21–45)
(16–41)
(17–42)
(17–44)
(18–44)
(19–43)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
RATEa
6.6
2.5
<1
<1
<1
<1
<1
6.1
4.6
3.7
3
2.3
3
2.9
94
60
71
57
35
35
33
8.2
4.1
14
13
10
9.7
5.8
44
43
35
33
33
34
34
12
6.1
6.6
5
4.2
4.8
4.8
(3.8–12)
(2–3.1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(4.3–8.4)
(3.1–6.7)
(2.1–6.2)
(1.8–4.8)
(1.4–3.6)
(2.4–3.7)
(2.1–3.9)
(42–174)
(19–169)
(35–123)
(30–94)
(12–84)
(12–88)
(12–75)
(5.9–15)
(3.3–5)
(8.2–22)
(8.8–19)
(6.2–15)
(6–15)
(2.8–11)
(29–62)
(29–61)
(21–52)
(20–51)
(20–51)
(21–51)
(21–49)
(11–12)
(5.4–7)
(5.5–7.9)
(4.2–5.9)
(3.7–4.7)
(4.5–5.2)
(4.5–5.2)
PREVALENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.06
0.049
0.041
0.034
0.028
0.031
0.03
0.084
0.062
0.063
0.052
0.038
0.038
0.036
0.21
0.13
0.3
0.29
0.26
0.26
0.19
270
290
270
280
290
290
290
0.024
0.015
0.023
0.014
<0.01
<0.01
<0.01
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.027–0.098)
(0.02–0.081)
(0.016–0.074)
(0.013–0.06)
(0.011–0.049)
(0.015–0.05)
(0.014–0.049)
(0.031–0.17)
(0.015–0.16)
(0.025–0.12)
(0.021–0.097)
(0.011–0.086)
(0.01–0.088)
(0.011–0.078)
(0.049–0.38)
(0.029–0.23)
(0.12–0.52)
(0.13–0.48)
(0.1–0.44)
(0.1–0.44)
(0.071–0.34)
(120–460)
(130–500)
(120–470)
(120–490)
(120–500)
(130–500)
(130–510)
(<0.01–0.043)
(<0.01–0.025)
(0.011–0.036)
(<0.01–0.022)
(<0.01–0.016)
(<0.01–0.018)
(<0.01–0.017)
RATE
93
49
<1
<1
<1
<1
<1
63
51
42
34
28
30
29
930
674
666
534
391
385
366
145
78
161
136
113
109
78
396
393
345
336
333
334
334
175
109
161
96
68
72
72
(27–168)
(11–86)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(28–103)
(21–85)
(16–75)
(13–59)
(11–47)
(14–48)
(13–48)
(347–1847)
(161–1684)
(261–1296)
(219–1003)
(110–874)
(105–901)
(109–795)
(33–256)
(17–139)
(62–279)
(60–228)
(45–193)
(44–186)
(30–142)
(179–682)
(176–675)
(148–601)
(143–587)
(144–579)
(145–580)
(147–576)
(39–309)
(45–175)
(73–249)
(43–154)
(23–114)
(16–128)
(16–128)
INCIDENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.036
0.032
0.027
0.023
0.02
0.019
0.017
0.048
0.04
0.034
0.028
0.025
0.024
0.023
0.19
0.11
0.2
0.17
0.17
0.17
0.17
140
150
160
170
170
170
180
0.012
0.011
<0.01
<0.01
<0.01
<0.01
<0.01
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.03–0.042)
(0.026–0.037)
(0.021–0.034)
(0.018–0.028)
(0.016–0.023)
(0.016–0.021)
(0.015–0.021)
(0.031–0.07)
(0.016–0.076)
(0.021–0.048)
(0.019–0.039)
(0.013–0.041)
(0.012–0.042)
(0.013–0.037)
(0.15–0.23)
(0.085–0.13)
(0.16–0.25)
(0.14–0.21)
(0.14–0.2)
(0.14–0.2)
(0.14–0.2)
(100–180)
(110–190)
(120–210)
(130–220)
(130–220)
(130–220)
(130–220)
(0.011–0.013)
(0.01–0.012)
(<0.01–0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
RATE
72
39
13
<1
<1
<1
<1
38
33
28
22
19
18
17
536
437
357
291
258
247
237
127
63
110
83
74
72
69
204
204
205
204
201
200
199
85
77
68
60
54
53
51
(56–90)
(12–82)
(<1–26)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(32–45)
(28–39)
(22–35)
(18–28)
(16–23)
(16–20)
(14–20)
(343–772)
(174–819)
(228–514)
(196–404)
(133–423)
(118–423)
(133–371)
(103–155)
(50–76)
(88–133)
(67–100)
(61–90)
(59–86)
(57–83)
(153–262)
(154–262)
(154–263)
(154–261)
(152–258)
(152–255)
(152–253)
(78–93)
(71–83)
(66–70)
(53–67)
(50–59)
(43–63)
(42–61)
Western Pacific Region
Tokelau
POPULATION
(MILLIONS)
a
Rates are per 100 000 population.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 229
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
229
05/10/11 09:03
7$%/($,QFLGHQFHQRWLILFDWLRQDQGFDVHGHWHFWLRQUDWHVDOOIRUPV±
INCIDENCE (INCLUDING HIV)
YEAR
American Samoa
Australia
Brunei
Darussalam
Cambodia
China
China, Hong Kong
SAR
China, Macao
SAR
Cook Islands
Fiji
French Polynesia
Guam
Japan
Kiribati
Lao People's
Democratic
Republic
230
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
POPULATION
(MILLIONS)
<1
<1
<1
<1
<1
<1
<1
17
18
19
20
22
22
22
<1
<1
<1
<1
<1
<1
<1
10
11
12
13
14
14
14
1 145
1 214
1 269
1 308
1 328
1 335
1 341
6
6
7
7
7
7
7
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
122
124
126
126
127
127
127
<1
<1
<1
<1
<1
<1
<1
4
5
5
6
6
6
6
NUMBER
(THOUSANDS)
0.012
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
1.1
1.2
1.2
1.2
1.3
1.4
1.4
0.17
0.18
0.33
0.2
0.25
0.25
0.27
55
59
61
62
62
62
62
1700
1600
1400
1200
1100
1100
1000
7.5
7.1
6.9
6.5
6.4
5.9
5.7
0.4
0.49
0.52
0.4
0.4
0.37
0.41
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.32
0.27
0.22
0.17
0.16
0.19
0.23
0.063
0.1
0.086
0.071
0.064
0.058
0.05
0.066
0.099
0.062
0.072
0.1
0.12
0.12
60
50
45
31
28
27
27
0.084
0.39
0.31
0.45
0.43
0.4
0.37
3.7
4.1
4.5
5
5.3
5.4
5.6
(<0.01–0.015)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.99–1.3)
(1.1–1.4)
(1–1.3)
(1.1–1.4)
(1.2–1.5)
(1.2–1.6)
(1.2–1.6)
(0.15–0.19)
(0.16–0.21)
(0.28–0.37)
(0.17–0.22)
(0.22–0.28)
(0.22–0.29)
(0.24–0.31)
(38–74)
(46–74)
(51–72)
(53–71)
(53–71)
(53–71)
(53–72)
(1400–2200)
(1300–1900)
(1200–1600)
(1000–1400)
(970–1300)
(940–1200)
(910–1200)
(6.6–8.5)
(6.3–8.1)
(6.1–7.8)
(5.7–7.4)
(5.6–7.2)
(5.2–6.7)
(5–6.4)
(0.35–0.45)
(0.43–0.55)
(0.46–0.59)
(0.35–0.45)
(0.34–0.45)
(0.33–0.42)
(0.36–0.47)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.26–0.38)
(0.22–0.33)
(0.19–0.27)
(0.13–0.21)
(0.13–0.19)
(0.15–0.23)
(0.18–0.28)
(0.055–0.072)
(0.09–0.12)
(0.077–0.095)
(0.062–0.08)
(0.057–0.072)
(0.05–0.066)
(0.044–0.056)
(0.058–0.075)
(0.086–0.11)
(0.054–0.07)
(0.063–0.082)
(0.09–0.12)
(0.1–0.13)
(0.1–0.13)
(52–67)
(43–56)
(39–51)
(28–36)
(24–31)
(24–31)
(24–31)
(0.066–0.1)
(0.32–0.47)
(0.25–0.38)
(0.36–0.54)
(0.35–0.53)
(0.33–0.48)
(0.3–0.45)
(2.6–4.9)
(3.1–5.3)
(3.5–5.7)
(4–6.1)
(4.3–6.4)
(4.5–6.5)
(4.6–6.7)
RATEb
26
12
6.9
13
6
7.9
7.8
6.6
6.7
6.1
6
6.2
6.3
6.3
66
63
100
55
65
65
68
574
529
492
461
446
442
437
153
129
109
92
83
80
78
129
116
102
96
92
85
80
110
123
121
83
76
70
76
<1
19
12
6.4
12
9.3
3.5
43
35
28
21
19
22
27
32
48
36
28
24
22
18
50
68
40
43
58
66
65
49
40
36
25
22
22
21
116
505
372
488
450
408
370
88
86
85
87
88
89
90
(21–31)
(9.3–14)
(5.6–8.4)
(10–15)
(4.9–7.3)
(6.4–9.6)
(6.3–9.5)
(5.8–7.5)
(5.8–7.6)
(5.4–7)
(5.3–6.8)
(5.4–7.1)
(5.5–7.1)
(5.6–7.1)
(58–74)
(55–71)
(87–114)
(48–61)
(57–74)
(57–73)
(59–77)
(398–781)
(411–662)
(411–579)
(397–529)
(384–513)
(378–510)
(373–506)
(120–189)
(105–155)
(92–127)
(80–105)
(73–94)
(70–91)
(68–88)
(113–146)
(102–132)
(89–115)
(84–108)
(81–104)
(74–96)
(71–91)
(96–125)
(108–138)
(106–137)
(73–94)
(66–87)
(62–79)
(67–87)
(<1–1.2)
(16–22)
(11–14)
(5–7.8)
(9–14)
(6.8–12)
(<1–7)
(35–52)
(28–42)
(23–33)
(16–25)
(16–23)
(18–27)
(21–33)
(28–37)
(42–54)
(32–40)
(24–31)
(22–27)
(19–25)
(16–21)
(44–56)
(59–77)
(35–45)
(38–49)
(51–66)
(58–75)
(57–73)
(43–55)
(35–45)
(31–40)
(22–28)
(19–25)
(19–24)
(19–24)
(92–144)
(409–611)
(295–458)
(394–591)
(360–549)
(334–488)
(297–452)
(62–118)
(64–111)
(67–106)
(70–105)
(72–106)
(73–107)
(74–107)
INCIDENCE HIV-POSITIVE
NUMBER
(THOUSANDS)
0.03
0.029
0.03
0.039
0.047
0.05
0.052
(0.017–0.048)
(0.017–0.045)
(0.017–0.046)
(0.024–0.058)
(0.028–0.072)
(0.031–0.073)
(0.032–0.077)
RATEb
<1
<1
<1
<1
<1
<1
<1
<1 (<1–2.1)
<0.01
<0.01
2.1
5.7
6.1
4.8
4.2
4
4
0.79
10
12
16
18
18
18
(<0.01–<0.01)
(<0.01–<0.01)
(0.79–4.1)
(3.4–8.6)
(3.9–8.8)
(3.1–6.9)
(2.6–6.2)
(2.2–6.2)
(3.4–4.7)
(0.23–1.7)
(4.2–18)
(6–19)
(9.4–25)
(11–28)
(10–28)
(10–28)
<1
<1
22
51
49
36
30
28
29
<1
<1
<1
1.3
1.4
1.3
1.4
(<1–1.9)
(<1–1.4)
(8.3–43)
(30–77)
(32–71)
(23–52)
(19–45)
(16–44)
(24–33)
(<1–<1)
(<1–1.5)
(<1–1.5)
(<1–1.9)
(<1–2.1)
(<1–2.1)
(<1–2.1)
0.054
0.032
0.057
0.042
(0.036–0.076)
(<0.01–0.078)
(0.039–0.079)
(0.027–0.06)
<1
<1
<1
<1
(<1–1.1)
(<1–1.1)
(<1–1.1)
(<1–<1)
<0.01
<0.01
<0.01
<0.01
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
<1
<1
<1
<1
(<1–1.1)
(<1–1)
(<1–<1)
(<1–1.6)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.012)
<0.01 (<0.01–0.011)
<0.01
0.17
0.14
0.14
0.11
0.1
0.1
0.1
<0.01
<0.01
<0.01
<0.01
0.014
0.088
0.17
0.21
0.24
(<0.01–<0.01)
(0.086–0.27)
(0.074–0.24)
(0.069–0.22)
(0.057–0.17)
(0.053–0.17)
(0.055–0.16)
(0.055–0.17)
(<0.01–0.016)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.037)
(0.042–0.15)
(0.097–0.27)
(0.11–0.33)
(0.13–0.38)
<1
<1
<1
<1
<1
<1
<1
NUMBER
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–1.3)
19
3
6
3
4
4
1 016
1 073
1 043
1 046
1 213
1 217
1 187
143
5
10
5
6
6
6
6
5
5
6
6
5
57
307
163
223
213
237
6 501
14 603
18 891
35 535
38 927
39 202
40 460
375 481
515 764
454 372
894 428
975 821
965 257
908 399
6 510
6 212
6 015
5 660
5 544
5 160
4 935
343
402
449
355
359
308
368
0
2
1
1
2
2
0
226
203
144
132
106
144
189
59
94
45
58
54
59
68
131
152
266
282
280
286
33
42
36
68
73
72
68
112
101
89
83
80
74
70
95
101
104
74
69
58
68
0
11
6
5
10
10
0
31
26
18
16
13
17
22
30
62
63
50
53
41
26
25
19
20
15
54
63
89
102
101
51 821
43 078
39 384
27 194
24 181
23 631
22 693
68
35
37
51
57
56
42
35
31
22
19
19
18
95
252
332
335
278
286
1 826
830
2 227
3 699
4 045
3 848
3 999
300
361
347
284
287
44
17
42
64
67
63
64
2 (<1–6.3)
1
<1
<1
<1
<1
<1
<1
<1
5
2.6
<1
<1
<1
1.5
2.9
3.4
3.9
(<1–5)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–16)
(1.8–3.5)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–2.6)
(1.6–4.5)
(1.9–5.4)
(2.2–6.2)
a
Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
b
Rates are per 100 000 population.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 230
RATEb
9
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
<0.01 (<0.01–<0.01)
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
NOTIFIED NEW AND RELAPSEa
CASE DETECTION RATEa
PERCENT
75
–
75
75
75
75
75
90
89
89
85
90
88
84
86
–
94
82
89
84
88
12
25
31
58
63
64
65
21
33
33
74
88
90
87
87
87
87
87
87
87
87
87
82
86
89
91
82
89
0
58
46
81
87
107
0
72
76
64
78
66
76
82
93
–
72
89
78
92
82
–
–
87
87
87
87
87
87
87
88
87
87
87
84
81
–
81
74
77
70
78
50
20
49
74
76
71
72
(62–93)
(62–93)
(62–93)
(62–93)
(62–93)
(62–93)
(79–103)
(78–102)
(78–102)
(75–97)
(80–104)
(78–101)
(75–96)
(76–99)
(82–108)
(73–93)
(78–102)
(75–96)
(78–101)
(9–17)
(20–32)
(26–37)
(50–67)
(55–73)
(55–74)
(57–77)
(17–27)
(27–40)
(28–39)
(65–86)
(78–101)
(79–103)
(77–100)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(73–93)
(76–98)
(78–101)
(80–104)
(73–93)
(78–102)
(50–68)
(41–53)
(66–102)
(69–111)
(82–147)
(59–88)
(62–94)
(54–77)
(64–98)
(56–80)
(62–94)
(66–104)
(82–108)
(65–80)
(78–102)
(70–88)
(81–106)
(73–93)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(77–99)
(78–101)
(77–99)
(77–100)
(77–99)
(74–96)
(66–103)
(65–102)
(61–92)
(63–96)
(58–85)
(64–97)
(37–70)
(16–27)
(39–63)
(61–92)
(63–93)
(59–86)
(60–88)
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($,QFLGHQFHQRWLILFDWLRQDQGFDVHGHWHFWLRQUDWHVDOOIRUPV±
YEAR
Malaysia
Marshall Islands
Micronesia
(Federated
States of)
Mongolia
Nauru
New Caledonia
New Zealand
Niue
Northern Mariana
Islands
Palau
Papua New
Guinea
Philippines
Republic of Korea
Samoa
POPULATION
(MILLIONS)
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
18
21
23
26
28
28
28
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
2
2
2
3
3
3
3
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
3
4
4
4
4
4
4
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
4
5
5
6
7
7
7
62
69
77
86
90
92
93
43
45
46
47
48
48
48
<1
<1
<1
<1
<1
<1
<1
23
22
22
22
23
23
23
0.065
0.097
0.14
0.19
0.23
0.25
0.27
0.36
0.35
0.3
0.26
0.24
0.23
0.23
8.9
7.2
6.1
5.7
5.9
6.1
6.2
<0.01
<0.01
<0.01
0.014
<0.01
<0.01
<0.01
0.17
0.11
0.087
0.056
0.055
0.056
0.057
0.37
0.41
0.42
0.39
0.36
0.35
0.33
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.038
0.062
0.092
0.074
0.045
0.045
0.044
<0.01
0.025
0.03
0.013
0.019
0.025
0.025
13
14
16
18
20
20
21
240
250
250
260
260
260
260
70
46
36
41
44
46
47
0.058
0.05
0.041
0.031
0.024
0.022
0.02
(20–26)
(20–25)
(20–24)
(20–24)
(21–25)
(21–25)
(21–25)
(<0.01–0.2)
(0.022–0.23)
(0.083–0.2)
(0.046–0.43)
(0.067–0.5)
(0.071–0.54)
(0.046–0.69)
(0.093–0.82)
(0.19–0.55)
(0.21–0.4)
(0.17–0.37)
(0.1–0.44)
(0.11–0.41)
(0.095–0.42)
(7.5–10)
(6.3–8.2)
(5.5–6.8)
(5.3–6.2)
(5.5–6.4)
(5.6–6.5)
(5.7–6.6)
(<0.01–0.011)
(<0.01–<0.01)
(<0.01–<0.01)
(0.011–0.017)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.15–0.19)
(0.1–0.13)
(0.074–0.1)
(0.05–0.064)
(0.048–0.061)
(0.048–0.064)
(0.05–0.064)
(0.33–0.43)
(0.35–0.47)
(0.37–0.47)
(0.34–0.44)
(0.32–0.4)
(0.3–0.39)
(0.29–0.38)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.03–0.046)
(0.05–0.076)
(0.073–0.11)
(0.059–0.09)
(0.037–0.053)
(0.036–0.056)
(0.036–0.053)
(<0.01–<0.01)
(0.02–0.031)
(0.024–0.036)
(0.011–0.016)
(0.016–0.023)
(0.02–0.031)
(0.02–0.031)
(8.2–18)
(9.3–20)
(11–23)
(12–26)
(13–28)
(13–29)
(14–29)
(150–360)
(200–300)
(210–310)
(210–310)
(210–310)
(210–310)
(210–310)
(61–80)
(40–52)
(33–40)
(36–47)
(39–50)
(40–51)
(41–53)
(0.047–0.071)
(0.038–0.063)
(0.03–0.054)
(0.025–0.038)
(0.021–0.028)
(0.018–0.027)
(0.016–0.024)
RATEb
127
108
95
86
83
83
82
137
190
263
363
441
471
502
379
325
279
240
219
212
206
405
314
254
225
222
224
224
102
47
45
139
55
51
40
99
59
41
24
22
23
23
11
11
11
9.5
8.4
8
7.6
74
57
40
23
13
9.9
6.5
86
109
135
110
71
74
72
45
147
156
67
95
125
124
303
303
303
303
303
303
303
393
360
329
301
285
280
275
163
102
79
88
93
95
97
36
30
23
17
13
12
11
(112–142)
(97–120)
(86–104)
(79–94)
(76–91)
(75–90)
(75–89)
(11–417)
(42–445)
(158–393)
(89–826)
(126–949)
(134–1014)
(85–1279)
(96–850)
(181–510)
(198–374)
(156–341)
(94–395)
(98–370)
(86–377)
(344–471)
(273–357)
(227–281)
(206–244)
(206–239)
(208–240)
(208–240)
(82–124)
(38–57)
(35–57)
(111–170)
(42–69)
(41–63)
(32–48)
(87–111)
(53–66)
(35–48)
(22–28)
(20–25)
(19–26)
(20–26)
(9.6–13)
(9.5–13)
(9.5–12)
(8.3–11)
(7.4–9.4)
(7–9)
(6.6–8.7)
(<1–148)
(<1–114)
(<1–81)
(<1–47)
(<1–27)
(<1–20)
(<1–13)
(69–104)
(87–133)
(107–166)
(88–134)
(60–84)
(58–92)
(58–87)
(36–55)
(118–178)
(126–190)
(54–81)
(77–116)
(100–151)
(100–150)
(197–430)
(197–430)
(197–430)
(197–430)
(197–430)
(197–430)
(197–430)
(239–585)
(293–434)
(268–396)
(245–362)
(232–343)
(229–336)
(226–329)
(142–186)
(89–117)
(72–86)
(76–100)
(82–105)
(83–107)
(85–110)
(29–44)
(23–37)
(17–30)
(14–21)
(12–15)
(9.8–15)
(8.9–13)
INCIDENCE HIV-POSITIVE
NUMBER
(THOUSANDS)
0.36
1.5
2.1
2.6
2.8
2.6
2.3
(0.15–0.66)
(0.97–2.2)
(1.4–2.9)
(2.4–2.9)
(2.6–3.1)
(2.3–2.8)
(2.1–2.5)
RATEb
2
7.4
8.8
10
10
9.2
8
9.6 (<1–37)
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<1
<1
<1
<1
<1
<1
<1
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.015
0.077
0.3
0.64
0.76
0.79
0.83
0.016
0.068
0.19
0.42
0.73
0.88
1
0.13
0.099
0.11
0.26
0.28
0.3
0.33
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–0.012)
(<0.01–0.052)
(0.015–0.19)
(0.14–0.51)
(0.36–1)
(0.37–1.3)
(0.46–1.2)
(0.48–1.3)
(<0.01–0.032)
(0.026–0.13)
(0.028–0.51)
(0.15–0.82)
(0.36–1.2)
(0.42–1.5)
(0.51–1.8)
(0.041–0.28)
(0.032–0.2)
(0.065–0.16)
(0.14–0.41)
(0.15–0.45)
(0.16–0.48)
(0.17–0.52)
<1
<1
<1
<1
<1
<1
<1
<1
1.6
5.5
11
12
12
12
<1
<1
<1
<1
<1
<1
1.1
<1
<1
<1
<1
<1
<1
<1
NUMBER
RATEb
11 702
11 778
15 057
15 342
17 144
17 341
18 517
64
57
64
59
62
62
65
34
111
125
135
190
367
172
91
98
164
148
160
1 659
2 780
3 109
4 601
4 490
4 481
4 458
7
65
213
236
253
352
381
160
85
90
149
134
144
76
121
129
181
168
165
162
76
4
11
5
4
3
143
87
94
47
44
54
49
348
391
344
332
292
298
301
0
0
0
0
0
0
0
28
48
75
57
28
38
32
40
109
49
39
29
84
46
44
20
18
22
20
10
11
9
8
7
7
7
0
0
0
0
0
0
0
64
83
110
85
45
62
53
19
110
10
50
19
19
2 497
8 041
10 520
12 564
13 984
12 306
14 531
317 008
119 186
119 914
137 100
139 603
146 565
166 323
63 904
42 117
21 782
38 290
36 847
38 741
41 889
44
45
43
24
12
16
14
93
93
60
171
196
206
214
184
212
514
172
155
160
155
160
178
149
94
47
81
77
81
87
27
27
24
13
7
9
8
(<1–3.6)
(4.7–11)
(5.8–12)
(9.1–11)
(9.4–11)
(8.4–10)
(7.3–8.7)
<0.01 (<0.01–0.02)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
NOTIFIED NEW AND RELAPSEa
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–1.2)
(<1–4)
(2.6–9.6)
(5.9–17)
(5.6–20)
(6.8–18)
(7–19)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–1.4)
(<1–1.6)
(<1–1.9)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–1)
(<1–1.1)
a
Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
b
Rates are per 100 000 population.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 231
CASE DETECTION RATEa
PERCENT
51
53
68
68
75
75
80
–
–
25
59
54
54
70
101
49
30
37
68
63
70
19
38
51
80
76
74
72
75
–
88
78
89
76
73
85
77
108
83
81
97
86
93
96
83
85
82
86
90
0
0
0
0
0
0
0
74
77
81
77
63
84
73
–
75
–
75
–
75
75
20
56
65
68
71
61
70
131
48
47
53
54
57
65
91
92
60
93
83
85
90
76
90
104
78
49
73
71
(45–57)
(47–59)
(62–75)
(63–75)
(69–82)
(69–82)
(73–87)
(17–41)
(26–240)
(25–188)
(25–189)
(27–412)
(45–396)
(31–88)
(23–43)
(26–57)
(38–158)
(36–137)
(38–168)
(16–22)
(34–44)
(46–57)
(74–88)
(70–82)
(69–80)
(67–78)
(62–93)
(70–114)
(64–98)
(71–116)
(63–95)
(61–91)
(76–97)
(69–86)
(93–127)
(74–94)
(72–91)
(85–113)
(76–98)
(81–107)
(84–112)
(73–94)
(75–96)
(73–92)
(76–98)
(79–104)
(61–92)
(63–96)
(66–103)
(63–96)
(53–75)
(68–107)
(60–90)
(62–93)
(62–93)
(62–93)
(62–93)
(14–30)
(40–86)
(45–99)
(48–104)
(50–108)
(43–93)
(49–107)
(88–215)
(40–59)
(39–58)
(44–66)
(45–67)
(48–70)
(54–79)
(80–105)
(81–106)
(55–65)
(81–107)
(74–94)
(75–97)
(79–103)
(62–94)
(71–117)
(80–141)
(64–97)
(43–57)
(60–89)
(59–86)
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
Western Pacific Region
INCIDENCE (INCLUDING HIV)
NUMBER
(THOUSANDS)
231
05/10/11 09:03
7$%/($,QFLGHQFHQRWLILFDWLRQDQGFDVHGHWHFWLRQUDWHVDOOIRUPV±
INCIDENCE (INCLUDING HIV)
YEAR
Singapore
Solomon Islands
Tokelau
Tonga
Tuvalu
Vanuatu
Viet Nam
Wallis and Futuna
Islands
232
POPULATION
(MILLIONS)
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
3
3
4
4
5
5
5
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
67
74
79
83
86
87
88
<1
<1
<1
<1
<1
<1
<1
NUMBER
(THOUSANDS)
1.9
2.1
2
1.6
1.7
1.8
1.8
0.97
0.86
0.75
0.67
0.62
0.6
0.58
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
0.036
0.032
0.027
0.023
0.02
0.019
0.017
0.048
0.04
0.034
0.028
0.025
0.024
0.023
0.19
0.11
0.2
0.17
0.17
0.17
0.17
140
150
160
170
170
170
180
0.012
0.011
<0.01
<0.01
<0.01
<0.01
<0.01
(1.7–2.1)
(1.9–2.4)
(1.7–2.2)
(1.4–1.8)
(1.5–1.9)
(1.6–2)
(1.6–2)
(0.59–1.4)
(0.7–1)
(0.61–0.91)
(0.54–0.8)
(0.5–0.74)
(0.49–0.72)
(0.48–0.7)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(0.03–0.042)
(0.026–0.037)
(0.021–0.034)
(0.018–0.028)
(0.016–0.023)
(0.016–0.021)
(0.015–0.021)
(0.031–0.07)
(0.016–0.076)
(0.021–0.048)
(0.019–0.039)
(0.013–0.041)
(0.012–0.042)
(0.013–0.037)
(0.15–0.23)
(0.085–0.13)
(0.16–0.25)
(0.14–0.21)
(0.14–0.2)
(0.14–0.2)
(0.14–0.2)
(100–180)
(110–190)
(120–210)
(130–220)
(130–220)
(130–220)
(130–220)
(0.011–0.013)
(0.01–0.012)
(<0.01–0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
(<0.01–<0.01)
RATEb
62
61
50
37
36
36
35
312
240
185
142
121
115
108
72
39
13
<1
<1
<1
<1
38
33
28
22
19
18
17
536
437
357
291
258
247
237
127
63
110
83
74
72
69
204
204
205
204
201
200
199
85
77
68
60
54
53
51
(55–70)
(53–69)
(44–57)
(32–41)
(31–41)
(31–40)
(31–40)
(190–464)
(195–290)
(150–223)
(116–171)
(99–146)
(94–138)
(89–130)
(56–90)
(12–82)
(<1–26)
(<1–<1)
(<1–<1)
(<1–<1)
(<1–<1)
(32–45)
(28–39)
(22–35)
(18–28)
(16–23)
(16–20)
(14–20)
(343–772)
(174–819)
(228–514)
(196–404)
(133–423)
(118–423)
(133–371)
(103–155)
(50–76)
(88–133)
(67–100)
(61–90)
(59–86)
(57–83)
(153–262)
(154–262)
(154–263)
(154–261)
(152–258)
(152–255)
(152–253)
(78–93)
(71–83)
(66–70)
(53–67)
(50–59)
(43–63)
(42–61)
INCIDENCE HIV-POSITIVE
NUMBER
(THOUSANDS)
0.026
0.083
0.09
0.073
0.079
0.081
0.081
0.05
0.39
1.4
3.5
6.2
7.1
7.3
7.6
(0.016–0.04)
(0.043–0.14)
(0.051–0.14)
(0.044–0.11)
(0.045–0.12)
(0.059–0.11)
(0.059–0.11)
(0.026–0.078)
(0.11–0.85)
(0.7–2.3)
(2.1–5.3)
(3.8–9.3)
(4–11)
(4.5–11)
(4.6–11)
NOTIFIED NEW AND RELAPSEa
RATEb
<1
2.4
2.3
1.7
1.6
1.6
1.6
21
<1
1.9
4.5
7.5
8.3
8.4
8.6
(<1–1.3)
(1.2–3.9)
(1.3–3.6)
(1–2.6)
(<1–2.6)
(1.2–2.2)
(1.2–2.1)
(11–33)
(<1–1.3)
(<1–3.2)
(2.7–6.7)
(4.5–11)
(4.7–13)
(5.2–13)
(5.2–13)
a
Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
b
Rates are per 100 000 population.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 232
NUMBER
RATEb
1 591
1 889
1 728
1 356
1 548
1 525
1 560
382
352
302
397
387
366
338
1
2
0
0
0
0
0
23
20
24
18
13
8
11
23
36
16
12
17
18
14
140
79
152
76
103
134
116
50 203
55 739
89 792
94 916
97 772
95 036
94 867
53
54
44
32
32
31
31
123
99
74
85
76
70
63
62
132
0
0
0
0
0
24
21
25
18
13
8
11
255
390
170
124
174
184
142
95
47
82
36
45
57
48
75
75
114
114
114
109
108
6
42
7
49
9
9
66
66
CASE DETECTION RATEa
PERCENT
85
89
88
87
91
86
87
40
41
40
60
63
61
58
86
335
0
–
–
–
–
64
63
88
79
66
43
63
48
89
48
43
67
74
60
75
75
75
44
61
80
70
37
37
56
56
56
55
54
–
55
–
83
–
125
129
(75–96)
(78–101)
(77–100)
(77–99)
(80–104)
(76–98)
(77–99)
(27–65)
(34–51)
(33–49)
(49–73)
(52–77)
(51–75)
(48–71)
(69–111)
(160–1098)
(54–77)
(54–76)
(70–113)
(65–100)
(56–80)
(39–49)
(54–76)
(33–75)
(48–224)
(33–74)
(31–63)
(41–131)
(43–155)
(38–107)
(62–93)
(62–93)
(62–93)
(36–54)
(50–75)
(66–98)
(58–85)
(29–49)
(29–49)
(43–74)
(44–74)
(44–75)
(43–72)
(43–71)
(51–60)
(73–94)
(105–151)
(108–157)
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($&DVHQRWLILFDWLRQV±
YEAR
American Samoa
• 19
6•
Australia
•6
5•
Brunei
Darussalam
• 57
59 •
Cambodia
• 68
286 •
China
• 33
68 •
China, Hong Kong
SAR
• 112
70 •
China, Macao
SAR
• 95
68 •
•0
0•
Cook Islands
Fiji
• 31
22 •
French Polynesia
• 30
15 •
Guam
–
56 •
Japan
• 42
18 •
Kiribati
• 95
287 •
Lao People's
Democratic
Republic
• 44
a
64 •
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
NEW AND
RELAPSEa
9
3
6
3
4
4
1 016
1 073
1 043
1 046
1 213
1 217
1 187
143
SMEAR- SMEAR-NEGATIVE/
POSITIVE
UNKNOWN
EXTRAPULMONARY
0
0
0
0
0
0
0
0
17
16
31
41
41
27
12
20
24
17
43
43
61
65
2
77
70
8
6
13
15
5
12
0
5
0
0
0
0
15
5
12
0
5
0
0
0
0
0
0
0
605
814
718
542
432
466
588
893
997
1 168
605
814
1 306
1 435
1 429
1 634
0
0
0
42 845
35 546
34 169
6 325
2 863
0
0
18 693
19 664
49 707
43 701
42 537
39 307
53 480
90 780
58 378
17 046
14 909
18 693
73 144
140 487
102 079
59 583
54 216
5 301
0
0
0
3 115
3 179
2 981
2 673
2 352
772
701
728
722
792
0
0
0
0
188
219
376
321
316
594
500
185
188
197
782
719
561
509
513
0
0
0
0
141
160
136
139
116
123
0
2
0
1
2
1
0
84
68
62
63
78
83
89
94
180
162
150
130
175
0
0
1
0
0
1
0
105
99
42
29
5
21
45
70
50
43
49
45
49
0
0
0
0
0
0
0
37
34
40
40
19
38
45
0
0
0
0
0
0
0
0
0
0
0
49
12
14
21
17
21
0
0
0
0
0
0
0
17
17
28
39
0
0
0
0
0
0
0
49
12
31
38
45
60
0
0
0
0
0
0
0
2
0
0
0
2
0
0
0
0
4
2
10
0
0
2
4
2
12
0
0
0
62
63
50
53
41
29
21
20
17
13
19
25
18
17
18
10
14
10
14
6
0
0
0
1
3
2
5
4
0
0
0
0
1
3
2
5
4
0
0
0
0
54
63
89
102
101
51 821
43 078
39 384
27 194
24 181
23 631
22 693
68
43
27
31
31
39
5
26
50
60
51
6
9
8
10
9
0
0
0
0
1
1
0
1
2
1
1
0
0
1
2
1
1
2
0
0
0
0
14 367
11 853
10 931
8 995
8 853
8 237
25 172
19 118
10 056
8 856
8 591
8 630
2 803
7 046
5 340
5 073
4 975
4 632
0
736
1 367
867
1 257
1 212
1 194
1 125
579
539
568
736
1 367
1 992
1 836
1 751
1 762
54
124
147
145
118
47
79
71
70
91
106
126
107
59
71
0
0
0
3
3
10
4
6
7
7
0
8
3
10
17
4
14
0
0
0
478
1 526
2 801
3 075
3 034
3 119
404
457
484
519
368
394
95
180
275
298
292
323
2
64
139
153
154
163
41
26
30
22
2
64
180
179
184
185
67
78
52
62
252
332
335
278
286
1 826
830
2 227
3 699
4 045
3 848
3 999
0
2
3
2
3
1
0
0
2
1
0
0
0
0
0
1
0
0
0
251
241
299
267
274
362
339
409
391
410
369
450
473
511
457
1
7
5
84
101
132
140
146
166
30
28
18
30
42
27
43
49
43
11 101
14 822
21 001
19 860
17 863
17 454
1 465
1 108
7 057
7 847
8 378
8 301
1 428
2 147
6 759
10 678
12 529
14 239
134 488
204 765
472 719
462 596
449 152
429 899
203 088
229 943
329 157
431 115
439 399
432 868
0
1 940
1 561
1 459
1 444
1 475
RE-TREAT EXCL. TOTAL
HISTORY
RELAPSE
RETREAT UNKNOWN
0
1
0
0
0
307
163
223
213
237
6 501
14 603
18 891
35 535
38 927
39 202
40 460
375 481
515 764
454 372
894 428
975 821
965 257
908 399
6 510
6 212
6 015
5 660
5 544
5 160
4 935
343
402
449
355
359
308
368
0
2
1
1
2
2
0
226
203
144
132
106
144
189
59
2
3
0
0
0
OTHER RELAPSE
1 560
0
0
0
43
35
35
26
0
0
0
0
0
0
0
% SMEARPOS AMONG
NEW PULM
–
–
100
60
0
0
0
–
–
41
42
42
41
40
–
–
34
77
83
89
83
–
88
93
75
72
68
68
–
40
47
59
52
51
50
–
–
38
33
33
35
39
–
60
47
46
48
47
41
–
100
0
100
100
50
–
44
41
60
68
94
80
66
–
–
60
46
53
50
42
–
–
90
51
38
34
43
–
36
38
52
50
51
49
–
–
53
61
67
67
56
–
54
77
85
86
89
89
Western Pacific Region
NEW CASES
NEW AND RELAPSE
NOTIFICATION RATEa
1990–2010
Rates are per 100 000 population. Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 233
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
233
05/10/11 09:03
7$%/($&DVHQRWLILFDWLRQV±
NEW CASES
NEW AND RELAPSE
NOTIFICATION RATEa
1990–2010
YEAR
Malaysia
• 64
65 •
Marshall Islands
–
352 •
Micronesia
(Federated
States of)
• 381
144 •
Mongolia
• 76
162 •
Nauru
• 76
29 •
New Caledonia
• 84
20 •
New Zealand
• 10
7•
Niue
•0
0•
Northern Mariana
Islands
• 64
53 •
Palau
–
93 •
Papua New
Guinea
• 60
212 •
Philippines
• 514
178 •
Republic of Korea
• 149
87 •
Samoa
• 27
a
234
8•
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
NEW AND
RELAPSEa
11 702
11 778
15 057
15 342
17 144
17 341
18 517
SMEAR- SMEAR-NEGATIVE/
POSITIVE
UNKNOWN
EXTRAPULMONARY
0
0
0
0
0
0
0
0
4
5
0
2
18
4
19
30
38
25
1 330
732
897
640
726
701
976
862
1 620
1 745
1 683
1 675
4
0
2
1
1
0
11
2
1
1
0
0
2
1
21
20
16
9
15
20
81
15
15
22
26
16
9
29
15
10
13
13
0
0
0
78
74
83
101
90
86
222
133
114
91
90
68
34
130
95
92
102
134
29
2
11
6
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14
27
15
13
16
17
26
37
35
12
16
13
8
11
7
3
6
2
0
0
0
0
0
0
0
0
0
0
0
2
0
0
0
0
0
2
0
0
0
0
0
0
19
9
6
4
0
10
3
6
1
0
0
0
19
19
2 497
8 041
10 520
12 564
13 984
12 306
14 531
317 008
119 186
119 914
137 100
139 603
146 565
166 323
63 904
42 117
21 782
38 290
36 847
38 741
41 889
44
45
43
24
12
16
14
6
9
9
10
4
0
0
0
0
0
0
0
1 652
1 933
1 805
2 323
2 238
2 584
3 767
4 405
5 105
5 340
4 768
5 907
2 349
3 227
4 198
4 522
4 826
5 798
914
1 582
273
955
1 456
1 799
1 388
1 824
94 768
67 056
81 647
85 025
88 806
89 198
140 712
52 858
50 347
49 916
52 041
72 440
8
8
1 149
2 085
2 745
1 610
0
0
0
0
3 957
2 577
2 973
3 075
6 289
6 602
8 066
3 957
8 866
9 575
11 141
0
0
0
11 754
8 216
11 638
11 048
11 285
11 596
19 360
11 304
18 460
17 292
17 634
18 660
5 171
5 813
6 923
8 795
0
0
0
0
2 082
2 262
3 021
2 694
2 899
2 838
4 077
3 616
3 981
4 038
2 082
2 262
7 098
6 310
6 880
6 876
4 602
3 707
4 577
2 174
15
13
11
6
8
6
30
18
8
5
5
5
6
12
5
1
3
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4
11
5
4
3
143
87
94
47
44
54
49
348
391
344
332
292
298
301
0
0
0
0
0
0
0
28
48
75
57
28
38
32
4 021
5 517
4 862
3 814
4 596
4 338
1 069
1 384
1 702
2 197
2 344
2 545
11
48
28
52
59
25
31
62
71
64
9
28
30
12
65
9
15
32
38
61
53
0
455
1 389
1 868
1 838
1 809
1 837
79
69
35
89
47
79
RE-TREAT EXCL. TOTAL
HISTORY
RELAPSE
RETREAT UNKNOWN
210
0
332
692
420
499
34
111
125
135
190
367
172
91
98
164
148
160
1 659
2 780
3 109
4 601
4 490
4 481
4 458
7
6 688
8 156
8 446
10 441
9 981
11 135
OTHER RELAPSE
651
362
761
820
210
0
983
1 054
1 181
1 319
73
0
0
0
1
2
2
8
0
5
7
2
10
0
0
6
3
5
4
0
0
2
3
7
3
2
3
14
2
7
10
2
3
21
5
9
13
0
0
4
0
0
0
0
82
126
216
267
263
245
125
277
306
343
82
126
341
544
569
588
0
0
0
0
2
0
0
3
0
0
0
0
0
6
1
9
8
4
4
7
4
9
8
0
6
0
0
0
8
5
4
4
4
7
19
11
9
11
0
0
0
0
1
0
0
4
4
1
3
0
4
7
11
6
5
7
0
0
0
0
273
955
1 456
1 799
474
242
8
0
0
0
0
0
% SMEARPOS AMONG
NEW PULM
–
62
60
63
73
68
72
–
–
31
61
31
42
48
–
10
18
48
30
56
40
–
25
65
68
74
71
72
–
–
100
0
50
50
50
–
21
57
52
29
37
56
–
26
36
42
53
50
56
–
0
–
–
–
–
–
–
35
42
30
52
50
57
–
60
–
33
–
40
47
–
30
30
26
30
32
30
–
40
56
62
63
63
55
–
38
42
39
39
39
38
–
33
42
58
55
62
55
Rates are per 100 000 population. Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 234
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($&DVHQRWLILFDWLRQV±
NEW CASES
NEW AND RELAPSE
NOTIFICATION RATEa
1990–2010
YEAR
Singapore
• 53
31 •
Solomon Islands
• 123
63 •
Tokelau
• 62
0•
Tonga
• 24
11 •
Tuvalu
• 255
142 •
Vanuatu
• 95
48 •
Viet Nam
• 75
108 •
Wallis and Futuna
Islands
66 •
SMEAR- SMEAR-NEGATIVE/
POSITIVE
UNKNOWN
EXTRAPULMONARY
OTHER RELAPSE
455
248
552
525
552
530
1 187
869
570
672
655
735
127
165
174
240
235
213
109
109
169
140
138
133
133
128
161
136
86
98
97
65
62
97
140
105
1
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
9
15
11
11
6
6
2
5
3
0
1
3
9
3
4
2
1
2
6
0
5
9
8
5
13
7
3
5
0
2
16
7
4
3
10
7
0
0
0
30
63
35
45
47
44
27
56
21
19
24
33
21
28
17
39
62
35
37 550
53 169
55 492
53 484
51 291
52 145
8 379
17 993
16 429
19 056
18 612
18 237
6 194
13 137
16 670
18 610
18 333
17 651
6
3
2
0
7
1
6
9
9
2
7
0
0
0
0
0
120
55
60
111
83
82
0
0
0
0
13
0
5
14
2
2
0
0
0
0
0
0
0
0
0
0
RE-TREAT EXCL. TOTAL
HISTORY
RELAPSE
RETREAT UNKNOWN
93
40
49
48
120
55
153
151
132
130
20
13
0
0
0
0
0
3
13
0
5
14
2
5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
1
0
0
0
0
0
0
1
0
0
0
1
0
0
0
3
2
0
0
3
2
0
0
0
0
0
0
0
0
3
1
5
3
0
1
1
5
1
2
0
1
5
8
1
3
1
0
0
0
0
0
0
0
0
3 616
5 493
6 325
6 622
6 800
6 834
976
912
1 331
1 574
3 616
5 493
7 301
7 534
8 131
8 408
0
0
1 825
2 581
1
0
0
1
0
0
0
% SMEARPOS AMONG
NEW PULM
–
28
22
49
44
46
42
–
45
46
51
51
62
58
–
50
–
–
–
–
–
–
82
75
79
100
86
67
–
32
0
63
64
100
71
–
53
53
63
70
66
57
–
82
75
77
74
73
74
–
60
–
14
–
22
–
Western Pacific Region
–
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
1990
1995
2000
2005
2008
2009
2010
NEW AND
RELAPSEa
1 591
1 889
1 728
1 356
1 548
1 525
1 560
382
352
302
397
387
366
338
1
2
0
0
0
0
0
23
20
24
18
13
8
11
23
36
16
12
17
18
14
140
79
152
76
103
134
116
50 203
55 739
89 792
94 916
97 772
95 036
94 867
a
Rates are per 100 000 population. Where notification data from a country had not been received by 2 September, the notification rate was assumed to be the same as for 2009 (in italics ).
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 235
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
235
05/10/11 09:03
7$%/($7UHDWPHQWRXWFRPHVQHZVPHDUSRVLWLYHFDVHV±
% OF COHORT
TREATMENT SUCCESS (%)a
1995–2009
YEAR
American Samoa
• 100
100 •
Australia
–
80 •
Brunei
Darussalam
–
71 •
• 91
95 •
Cambodia
China
• 93
95 •
China, Hong Kong
SAR
–
70 •
China, Macao
SAR
–
88 •
Cook Islands
• 100
–
Fiji
• 86
94 •
French Polynesia
• 67
89 •
Guam
–
96 •
Japan
–
52 •
Kiribati
• 87
97 •
• 70
93 •
• 69
78 •
Lao People's
Democratic
Republic
Malaysia
Marshall Islands
• 25
84 •
• 80
88 •
• 74
88 •
Micronesia
(Federated
States of)
Mongolia
a
236
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
NUMBER
NOTIFIED
SIZE OF
COHORT
2
3
0
0
0
4
2
4
0
0
3
251
241
281
299
267
238
241
498
587
606
84
101
136
132
140
11 101
14 822
21 001
19 421
19 860
17 863
134 488
204 765
472 719
465 877
462 596
449 152
0
1 940
1 561
1 501
1 459
1 444
141
160
136
138
139
116
2
0
1
84
101
136
164
164
4 363
14 775
21 001
19 429
19 811
17 863
131 413
213 766
472 719
465 877
464 151
449 039
1 940
1 561
1 481
1 448
1 441
160
136
251
246
115
2
1
2
2
0
73
62
68
78
82
79
33
62
18
26
28
18
2
1
68
62
63
52
78
83
29
21
19
20
17
43
27
5
31
31
14 367
11 853
10 931
9 433
8 995
8 853
54
124
103
147
145
478
1 526
2 801
3 080
3 075
3 034
6 688
8 156
8 446
9 578
10 441
9 981
11
48
19
28
52
9
15
32
47
38
61
455
1 389
1 868
1 856
1 838
1 809
43
27
36
31
47
10 348
10 931
9 421
8 999
8 772
31
54
123
100
146
144
343
1 588
2 802
3 080
3 075
3 034
13 398
7 915
8 446
10 236
9 757
9 981
163
11
47
27
35
58
10
14
20
52
59
60
455
1 389
1 868
1 855
1 838
1 809
COHORT AS
% NOTIFIED
–
100
133
–
–
–
–
95
100
177
196
227
–
100
100
100
124
117
39
100
100
100
100
100
98
104
100
100
100
100
–
100
100
99
99
100
–
100
100
182
177
99
100
–
100
–
100
0
107
100
108
150
105
95
–
214
86
137
140
106
–
100
100
720
100
152
–
87
100
100
100
99
–
100
99
97
99
99
72
104
100
100
100
100
200
97
100
107
93
100
–
100
98
142
125
112
111
93
63
111
155
98
100
100
100
100
100
100
COMPLETED
100
0
75
–
–
0
0
100
0
0
0
0
0
0
–
–
100
–
–
0
–
–
0
–
–
0
0
0
25
–
–
0
27
12
7
7
6
45
68
77
73
73
9
10
6
6
3
0
0
1
0
3
2
2
1
1
16
8
7
12
16
42
66
63
64
63
83
88
89
91
92
92
72
93
92
93
92
93
21
5
13
23
8
8
4
4
3
3
3
22
2
2
2
2
17
7
4
8
9
2
4
3
3
2
2
2
1
2
1
1
1
0
0
0
0
0
1
0
0
0
0
0
1
2
1
1
1
1
4
2
2
1
0
4
4
2
1
1
1
1
1
1
1
1
1
17
20
18
4
20
2
1
2
2
2
1
3
3
3
3
3
2
55
60
59
58
59
5
3
7
10
11
5
5
11
17
15
6
9
14
0
0
4
3
6
4
3
24
20
3
11
12
81
93
49
89
86
100
8
0
42
0
2
0
6
4
6
5
3
0
0
0
0
0
0
0
4
1
1
1
2
0
1
3
2
4
7
0
100
0
100
0
–
8
5
0
0
0
0
0
–
0
0
0
96
89
0
–
7
5
10
5
6
4
3
2
11
12
4
6
0
0
0
2
0
0
0
0
50
–
3
8
10
10
1
1
21
0
0
4
0
6
0
0
0
–
4
2
9
4
2
1
9
0
0
0
0
0
93
85
89
90
96
0
0
0
0
0
7
11
6
6
2
0
0
0
0
0
0
0
0
0
0
0
4
6
3
2
30
38
17
18
21
45
83
62
79
93
84
62
68
85
91
92
91
69
0
69
67
78
78
3
64
85
93
91
71
80
93
75
25
39
65
66
83
82
85
84
84
15
22
29
30
31
42
7
31
14
3
13
8
9
5
2
1
2
0
78
1
5
1
1
21
27
2
4
6
14
0
0
5
40
8
23
7
4
6
4
3
4
5
11
18
19
19
13
7
7
7
4
3
6
7
5
6
5
4
6
8
9
8
8
9
7
0
2
0
0
9
10
7
10
8
2
3
8
3
3
2
3
2
4
3
1
1
1
1
1
5
4
4
2
0
0
0
0
2
0
1
0
0
1
2
0
0
0
0
0
0
0
0
1
0
0
0
19
9
3
1
1
2
8
10
5
5
4
4
67
9
2
4
3
3
10
0
0
4
2
0
10
4
3
2
2
2
44
26
30
28
24
0
0
0
0
0
0
4
7
1
0
0
1
14
4
16
15
11
9
1
0
9
0
0
3
0
0
5
21
49
7
2
3
2
0
1
0
50
–
78
81
71
81
82
89
67
0
9
5
0
97
89
85
DIED
FAILED
0
0
0
0
0
5
2
0
2
6
3
5
6
7
7
DEFAULTED
NOT
EVALUATED
CURED
TREATMENT SUCCESS = percent cured + percent completed then rounded to the nearest digit.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 236
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($7UHDWPHQWRXWFRPHVQHZVPHDUSRVLWLYHFDVHV±
% OF COHORT
YEAR
Nauru
–
–
New Caledonia
• 75
93 •
New Zealand
–
76 •
Niue
–
–
Northern Mariana
Islands
–
81 •
Palau
• 67
75 •
Papua New
Guinea
• 56
72 •
• 60
89 •
• 76
83 •
• 80
90 •
• 86
82 •
Philippines
Republic of Korea
Samoa
Singapore
Solomon Islands
• 65
88 •
Tokelau
–
–
Tonga
• 75
83 •
Tuvalu
–
88 •
• 85
96 •
• 89
92 •
Vanuatu
Viet Nam
Wallis and Futuna
Islands
–
a
–
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
NUMBER
NOTIFIED
4
0
3
2
1
21
20
16
12
9
15
78
74
83
81
101
90
0
0
0
0
0
0
14
27
15
14
13
16
9
3
5
6
1 652
1 933
1 805
2 087
2 323
2 238
94 768
67 056
81 647
86 566
85 025
88 806
11 754
8 216
11 638
10 927
11 048
11 285
15
13
11
6
8
455
248
552
504
525
552
109
109
169
142
140
138
1
0
0
0
0
0
9
15
11
14
11
6
6
0
5
12
9
8
30
63
35
41
45
47
37 550
53 169
55 492
54 457
53 484
51 291
3
SIZE OF
COHORT
4
3
2
3
0
32
45
16
13
11
15
73
84
84
98
92
0
0
0
27
15
13
13
16
9
3
0
8
4 904
422
1 292
2 087
2 259
2 584
90 297
50 196
81 125
86 566
85 025
88 806
11 675
3 231
3 752
3 987
4 056
3 813
15
13
11
13
7
10
122
242
548
859
951
937
368
109
169
142
140
138
0
20
15
11
14
11
6
7
6
16
9
8
13
26
42
42
43
47
38 189
53 169
55 492
54 457
53 482
51 387
1
1
3
2
COHORT AS
% NOTIFIED
–
100
–
67
150
0
152
225
100
108
122
100
–
99
101
104
97
102
–
–
–
–
–
–
–
100
100
93
100
100
100
–
100
–
–
133
297
22
72
100
97
115
95
75
99
100
100
100
99
39
32
36
37
34
100
100
100
–
117
125
27
98
99
170
181
170
338
100
100
100
100
100
–
–
–
–
–
–
222
100
100
100
100
100
–
–
120
133
100
100
43
41
120
102
96
100
102
100
100
100
100
100
–
–
–
–
–
–
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
25
0
0
33
67
100
67
33
0
0
0
0
0
0
0
0
75
0
0
0
75
33
88
69
9
0
56
6
8
73
93
13
9
6
23
9
0
0
0
9
0
3
2
0
0
0
7
9
0
0
0
0
0
5
0
0
0
25
60
86
73
76
23
6
7
8
7
0
0
0
1
1
3
1
47
33
6
15
16
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
81
73
0
0
56
0
0
92
77
81
11
0
0
0
8
0
0
0
0
0
0
0
0
0
0
0
0
0
11
19
27
8
15
19
22
100
0
0
0
0
0
–
63
73
56
75
82
67
–
13
56
24
14
6
7
13
6
15
7
10
8
7
2
2
2
1
2
2
67
8
0
8
0
0
15
71
83
19
19
17
65
7
30
17
11
22
–
25
4
2
4
1
4
4
1
2
2
2
2
2
2
2
1
1
1
1
20
8
9
0
29
10
2
14
14
16
16
15
6
5
8
6
2
4
–
0
0
0
1
2
2
2
1
1
1
1
1
1
3
1
1
1
0
1
0
0
0
8
0
0
0
0
0
0
0
0
0
0
0
0
0
1
–
0
15
26
19
6
16
16
5
6
4
4
4
4
5
3
4
4
3
3
0
0
0
0
0
0
11
14
2
1
0
1
4
4
4
1
1
3
–
0
25
9
5
51
13
6
34
3
3
3
5
4
14
12
11
12
12
12
0
0
0
0
0
0
0
0
1
1
2
2
26
11
2
1
3
3
75
93
73
93
100
83
0
0
0
0
0
0
10
0
18
7
0
17
5
7
0
0
0
0
0
0
0
0
0
0
10
0
9
0
0
0
100
56
67
88
38
77
64
81
63
81
84
90
90
89
90
90
86
0
19
11
0
46
12
17
12
28
15
5
2
2
2
2
2
0
13
11
0
15
8
10
2
5
4
3
3
3
3
3
3
0
0
0
0
0
0
7
0
2
0
2
1
1
1
1
1
14
0
6
11
0
0
4
2
0
2
0
4
2
1
2
2
2
0
0
6
0
13
0
0
0
5
0
0
2
2
2
2
2
2
100
0
0
0
0
0
39
57
33
58
58
54
73
82
79
80
82
74
81
81
81
82
81
13
85
91
85
71
90
71
62
62
65
Western Pacific Region
TREATMENT SUCCESS (%)a
1995–2009
TREATMENT SUCCESS = percent cured + percent completed then rounded to the nearest digit.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 237
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
237
05/10/11 09:03
7$%/($7UHDWPHQWRXWFRPHVUHWUHDWPHQWFDVHV±
% OF COHORT
TREATMENT SUCCESS (%)a
1995–2009
YEAR
American Samoa
–
–
Australia
–
66 •
Brunei
Darussalam
–
–
Cambodia
• 85
79 •
• 92
90 •
China
China, Hong Kong
SAR
–
65 •
China, Macao
SAR
–
78 •
Cook Islands
–
–
Fiji
–
80 •
French Polynesia
• 50
100 •
Guam
–
100 •
Japan
–
48 •
Kiribati
–
100 •
Lao People's
Democratic
Republic
• 100
89 •
Malaysia
–
61 •
Marshall Islands
–
88 •
• 100
19 •
• 61
73 •
Micronesia
(Federated
States of)
Mongolia
a
238
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
NUMBER
NOTIFIED
SIZE OF
COHORT
0
1
0
0
0
1
0
0
0
17
43
47
43
61
11
43
55
50
65
15
5
12
12
0
605
814
1 306
1 542
1 435
1 429
18 693
73 144
140 487
112 816
102 079
59 583
5
12
12
0
436
827
1 306
711
597
1 429
54 052
43 252
89 239
70 163
64 023
59 853
782
719
572
561
509
49
12
31
46
38
45
0
0
0
218
716
555
526
481
0
0
2
0
0
0
37
37
46
38
46
0
0
1
4
2
0
5
2
1
3
2
2
5
1
2
2
1
1
736
1 367
1 992
1 685
1 836
1 751
4
4
4
5
2
1
0
1
1 169
1 992
1 423
1 547
1 452
3
10
24
17
4
2
64
180
149
179
184
210
0
983
1 147
1 054
1 181
9
3
5
17
6
1
64
181
149
153
184
1 056
1 362
1 171
1 181
0
5
11
7
2
2
3
21
5
5
9
82
126
341
609
544
569
20
16
2
8
9
20
9
8
5
16
23
126
443
609
385
380
COHORT AS
% NOTIFIED
–
–
100
–
–
–
–
65
100
117
116
107
–
–
100
100
100
–
72
102
100
46
42
100
289
59
64
62
63
100
–
28
100
97
94
94
–
308
119
100
100
102
–
–
–
–
–
–
–
–
–
–
0
250
–
–
133
200
200
100
–
–
100
50
0
100
–
86
100
84
84
83
–
300
30
21
100
150
50
100
101
100
85
100
–
–
107
119
111
100
–
–
400
145
29
400
450
667
43
160
100
178
28
100
130
100
71
67
CURED
COMPLETED
DIED
FAILED
DEFAULTED
NOT
EVALUATED
–
–
–
100
–
–
–
–
–
–
–
–
–
–
–
–
0
–
–
–
9
16
7
4
6
73
56
69
62
60
9
5
5
12
3
0
0
0
2
0
5
4
2
8
9
19
15
20
22
40
75
50
–
59
85
49
77
74
34
90
86
85
84
85
86
40
25
33
–
26
5
27
6
5
45
2
2
5
5
4
4
20
0
8
–
5
6
9
6
7
3
2
1
3
2
2
2
0
0
0
–
3
1
2
4
5
1
3
1
3
2
2
2
0
0
0
–
3
4
3
2
3
1
1
1
1
1
1
1
0
0
8
–
4
0
11
5
6
15
1
8
4
5
5
4
27
40
0
21
26
26
18
61
45
38
4
4
6
13
15
17
9
8
0
0
18
7
5
5
6
8
22
19
16
14
68
51
37
55
43
16
24
35
26
35
11
11
13
3
11
0
0
0
0
0
5
0
0
3
7
0
14
15
13
4
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
40
50
–
40
0
–
20
50
–
0
0
–
0
0
–
0
0
75
75
100
25
50
0
0
0
0
0
0
25
0
0
0
0
0
50
100
–
100
0
0
0
50
–
0
–
0
–
0
–
0
0
0
–
0
31
29
14
14
15
15
16
24
30
32
5
8
13
16
15
6
2
1
1
1
1
2
9
8
6
41
43
39
31
31
89
100
100
53
83
100
41
75
83
86
85
0
11
0
0
0
24
17
0
8
12
3
3
3
0
12
0
0
11
6
7
9
8
0
0
0
0
8
2
5
1
2
0
12
0
0
11
5
3
0
1
0
0
0
0
0
0
22
1
0
1
0
46
23
36
33
9
18
26
27
8
7
11
9
1
2
1
1
9
27
5
6
27
22
22
23
60
13
0
13
100
25
11
0
40
0
61
57
39
43
51
60
10
63
50
75
0
60
89
25
20
19
0
14
34
33
22
13
13
50
0
0
5
0
0
0
0
10
13
0
13
0
0
75
20
75
9
8
9
6
6
4
0
0
0
13
8
11
12
16
17
0
0
0
13
7
4
5
4
4
50
0
30
0
0
0
0
0
0
0
20
6
4
6
3
1
1
2
TREATMENT SUCCESS = percent cured + percent completed then rounded to the nearest digit.
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 238
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($7UHDWPHQWRXWFRPHVUHWUHDWPHQWFDVHV±
% OF COHORT
YEAR
Nauru
–
100 •
New Caledonia
• 100
89 •
New Zealand
–
67 •
Niue
–
–
Northern Mariana
Islands
–
–
Palau
–
–
Papua New
Guinea
–
58 •
Philippines
–
61 •
• 40
71 •
Republic of Korea
Samoa
–
–
Singapore
–
76 •
Solomon Islands
–
100 •
–
–
Tokelau
Tonga
• 100
–
Tuvalu
–
–
Vanuatu
–
100 •
Viet Nam
• 81
73 •
Wallis and Futuna
Islands
–
a
–
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
1995
2000
2005
2007
2008
2009
NUMBER
NOTIFIED
SIZE OF
COHORT
0
1
3
0
4
4
7
4
4
9
4
7
19
17
11
9
0
0
0
0
0
0
0
2
0
0
0
0
0
273
955
1 456
1 277
1 799
1 388
8
3 957
5 075
8 866
9 575
2 082
2 262
7 098
6 583
6 310
6 880
0
0
0
0
0
120
55
153
149
151
132
13
0
5
9
14
2
0
0
0
0
0
0
0
1
0
0
0
1
3
1
2
0
1
5
8
0
1
3
3 616
5 493
7 301
7 658
7 534
8 131
1
0
1
0
1
4
7
2
5
9
23
18
17
11
9
0
0
0
0
2
0
0
0
0
0
68
65
530
4 101
3 819
4 362
2 004
131
3 331
2 698
2 476
2 420
0
1
0
0
149
116
149
130
5
9
14
2
0
9
1
0
0
0
0
0
0
0
0
5
0
0
1
3
2 384
8 806
7 374
7 659
7 534
357
0
0
0
COHORT AS
% NOTIFIED
–
–
–
100
0
–
100
–
100
50
125
100
–
329
95
100
100
100
–
–
–
–
–
–
–
–
–
–
0
–
–
–
–
–
–
–
–
7
4
–
–
38
–
–
–
81
43
46
96
6
47
41
39
35
–
–
–
–
–
–
–
–
97
78
99
98
–
–
100
100
100
100
–
–
–
–
–
–
–
100
–
–
–
–
–
–
0
0
0
–
–
100
0
–
100
100
66
160
101
100
100
4
–
–
–
–
–
–
DIED
FAILED
DEFAULTED
NOT
EVALUATED
CURED
COMPLETED
–
0
–
100
100
–
100
–
–
0
–
–
0
–
–
0
–
–
0
–
0
0
86
100
0
0
0
0
40
89
14
0
40
0
0
0
20
0
0
0
0
0
0
0
0
11
0
0
0
0
30
67
65
91
67
4
0
24
0
11
0
0
0
0
0
0
65
33
12
9
22
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
0
–
–
–
100
–
–
–
0
–
–
–
0
–
–
–
0
–
–
–
0
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
29
42
35
14
4
15
1
6
21
20
9
3
36
22
5
5
29
3
53
56
48
39
59
72
70
74
69
18
15
13
1
2
3
2
2
3
4
4
4
1
3
2
1
1
2
6
4
4
2
3
0
1
1
1
7
7
5
3
12
6
6
6
5
11
14
26
53
21
18
20
16
21
–
100
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
0
–
–
71
40
37
79
11
30
39
15
15
22
20
0
1
0
0
5
3
3
1
1
0
5
3
20
78
79
50
40
22
21
50
20
0
0
0
20
0
0
0
0
0
0
0
0
0
0
0
100
100
–
–
–
–
0
0
0
0
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
0
0
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
100
–
–
0
100
80
74
79
79
80
67
0
–
–
0
0
2
5
4
3
3
6
0
–
–
100
0
5
6
5
6
5
8
0
–
–
0
0
8
5
6
5
5
2
0
–
–
0
0
2
3
3
4
3
10
0
–
–
0
0
4
7
3
3
3
7
–
–
–
–
–
–
Western Pacific Region
TREATMENT SUCCESS (%)a
1995–2009
TREATMENT SUCCESS = percent cured + percent completed then rounded to the nearest digit.
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 239
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
239
05/10/11 09:03
7$%/($+,9WHVWLQJDQGSURYLVLRQRI&37$57DQG,37 –
% OF TB PATIENTS WITH
KNOWN HIV STATUS
2005–2010
YEAR
American Samoa
•0
100 •
• 42
44 •
• 100
100 •
Australia
Brunei
Darussalam
Cambodia
•3
77 •
–
16 •
• 68
74 •
• 91
94 •
China
China, Hong Kong
SAR
China, Macao
SAR
Cook Islands
•0
–
Fiji
• 100
82 •
• 48
24 •
• 72
61 •
–
52 •
• 13
54 •
–
38 •
• 73
91 •
• 77
68 •
•6
50 •
•0
89 •
•0
0•
• 40
0•
• 41
58 •
French Polynesia
Guam
Japan
Kiribati
Lao People's
Democratic
Republic
Malaysia
Marshall Islands
Micronesia
(Federated
States of)
Mongolia
Nauru
New Caledonia
New Zealand
Niue
–
–
Northern Mariana
Islands
• 98
100 •
• 90
100 •
Palau
Papua New
Guinea
–
240
7•
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
% OF TB
NUMBER OF TB
PATIENTS WITH PATIENTS WITH
KNOWN HIV
KNOWN HIV
STATUS
STATUS
0
100
100
100
42
36
49
44
100
100
100
100
3
54
70
77
–
8
6
16
68
72
74
74
91
91
90
94
0
0
0
–
100
98
48
82
48
32
23
24
72
66
63
61
–
56
51
52
13
5
54
54
–
13
17
38
73
88
84
91
77
100
69
68
6
39
46
50
0
27
83
89
0
0
0
0
40
–
–
0
41
46
46
58
–
–
–
–
98
117
87
100
90
–
100
100
–
4
7
7
0
3
4
4
448
440
648
564
163
223
213
237
1 044
21 523
28 264
32 236
81 682
63 227
145 919
4 209
4 121
3 953
3 805
378
376
335
407
0
0
0
0
132
104
69
157
30
16
12
10
46
59
64
62
13 777
12 429
12 098
44
16
151
159
557
686
1 537
11 661
15 337
15 192
17 577
86
127
98
137
7
64
72
87
1
1 296
3 993
4 256
0
0
0
0
21
0
140
136
140
178
0
0
0
56
35
33
32
9
18
19
19
582
888
1 112
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 240
PATIENTS
NOTIFIED
(NEW AND
RETREAT)
6
3
4
4
1 073
1 227
1 314
1 281
163
223
213
237
36 123
39 820
40 199
41 628
990 509
1 034 199
982 303
923 308
6 160
5 729
5 348
5 132
415
411
371
433
1
2
2
0
132
106
144
191
63
50
53
41
64
90
102
101
28 319
24 760
24 170
23 261
339
342
278
294
3 807
4 149
3 930
4 083
16 066
17 506
18 102
19 337
112
127
143
201
112
166
155
174
4 726
4 767
4 787
4 801
11
7
4
3
53
51
63
57
340
297
302
305
0
0
0
0
57
30
38
32
10
19
19
12 564
13 984
13 220
16 113
NUMBER OF HIV- % OF TESTED
POSITIVE TB
TB PATIENTS
PATIENTS
HIV-POSITIVE
0
0
0
22
17
23
28
2
0
2
1
86
3 309
3 597
2 112
2 848
2 511
4 542
35
48
38
28
1
1
1
3
0
0
0
0
1
0
3
0
0
0
0
0
2
0
1
67
52
53
2
0
2
0
221
179
181
1 468
1 819
1 644
1 628
0
0
2
0
0
0
0
1
1
0
2
0
0
0
0
0
0
8
8
3
2
0
0
0
0
0
0
0
0
0
0
91
130
–
0
0
0
5
4
4
5
1
0
1
0
8
15
13
7
–
3
4
3
1
1
1
1
0
0
0
1
–
–
–
–
1
–
0
2
0
0
0
0
0
3
0
2
–
0
0
0
5
0
1
0
–
40
26
12
13
12
11
9
0
0
2
0
–
0
0
0
100
0
0
0
–
–
–
–
0
–
–
–
6
6
2
1
–
–
–
–
0
0
0
0
0
–
0
0
–
–
10
12
% OF HIV% OF HIVNUMBER OF HIVPOSITIVE
POSITIVE TB POSITIVE TB
PEOPLE
PATIENTS ON PATIENTS ON
PROVIDED IPT
CPT
ART
–
–
–
–
9
12
–
–
0
–
100
100
–
39
30
65
–
54
87
–
49
35
29
14
0
0
0
0
–
–
–
–
–
–
–
100
–
–
–
–
–
50
–
100
–
–
–
–
0
–
100
–
–
98
89
83
–
–
10
22
–
–
0
–
–
–
–
–
100
100
–
100
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
59
–
–
0
–
100
100
–
22
15
45
–
20
43
45
54
33
26
25
100
100
0
0
–
–
–
–
–
–
–
100
–
–
–
–
–
50
–
0
–
–
–
–
0
–
0
–
–
59
–
–
–
43
10
22
–
–
100
–
–
–
–
–
100
100
–
100
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
0
0
0
2
66
66
491
75
78
0
1
0
0
0
0
0
0
1
0
0
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
47
135
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($+,9WHVWLQJDQGSURYLVLRQRI&37$57DQG,37 –
% OF TB PATIENTS WITH
KNOWN HIV STATUS
2005–2010
YEAR
Philippines
–
1•
–
–
Republic of Korea
Samoa
•8
50 •
–
74 •
•0
11 •
Singapore
Solomon Islands
Tokelau
–
–
–
73 •
–
0•
•0
0•
• 15
43 •
Tonga
Tuvalu
Vanuatu
Viet Nam
Wallis and Futuna
Islands
–
–
1
1
1
–
–
–
–
8
0
13
50
–
–
71
74
0
0
0
11
–
–
–
–
–
100
100
73
–
89
0
0
0
16
8
0
15
11
36
43
–
–
100
–
1 069
1 136
1 356
2
0
2
7
1 121
1 187
0
0
0
39
0
0
0
13
8
8
17
0
0
0
17
11
0
14 128
11 332
34 907
42 356
4
9
PATIENTS
NOTIFIED
(NEW AND
RETREAT)
NUMBER OF HIV- % OF TESTED
POSITIVE TB
TB PATIENTS
PATIENTS
HIV-POSITIVE
137 100
145 892
153 167
174 389
46 969
44 170
47 299
48 101
24
12
16
14
1 469
1 601
1 574
1 608
397
387
366
341
0
0
0
0
18
13
8
11
15
19
18
14
81
104
136
116
95 892
98 684
98 192
99 022
7
0
0
0
0
0
0
0
595
2 210
5 934
3 515
0
9
0
0
1
0
96
138
0
0
0
0
52
53
0
0
0
0
0
0
0
0
0
0
–
0
0
0
–
–
–
–
0
–
0
0
–
–
5
4
–
–
–
0
–
–
–
–
–
0
0
0
–
0
–
–
–
0
0
–
4
20
17
8
–
–
0
–
% OF HIV% OF HIVNUMBER OF HIVPOSITIVE
POSITIVE TB POSITIVE TB
PEOPLE
PATIENTS ON PATIENTS ON
PROVIDED IPT
CPT
ART
–
–
0
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
78
89
62
–
–
–
–
–
–
0
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
32
6
43
–
–
–
–
1
16
0
0
0
0
0
0
0
0
0
0
0
500
1 500
1 317
0
Western Pacific Region
–
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
% OF TB
NUMBER OF TB
PATIENTS WITH PATIENTS WITH
KNOWN HIV
KNOWN HIV
STATUS
STATUS
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 241
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
241
05/10/11 09:03
7$%/($7HVWLQJIRU0'57%DQGQXPEHURIFRQILUPHGFDVHVRI0'57%±
YEAR
American Samoa
Australia
Brunei
Darussalam
Cambodia
China
China, Hong Kong
SAR
China, Macao
SAR
Cook Islands
Fiji
French Polynesia
Guam
Japan
Kiribati
Lao People's
Democratic
Republic
Malaysia
Marshall Islands
Micronesia
(Federated
States of)
Mongolia
Nauru
New Caledonia
New Zealand
Niue
Northern Mariana
Islands
Palau
Papua New
Guinea
a
242
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
TOTAL
CONFIRMED
CASES OF
MDR-TBa
0
0
12
21
31
33
0
0
31
2
31
474
2 792
41
18
21
28
9
7
3
6
0
0
0
0
0
0
0
0
1
0
1
2
68
1
0
2
1
56
55
64
2
1
1
1
4
3
1
0
115
168
187
0
0
0
0
4
0
7
4
0
0
2
0
0
0
0
0
5
NEW CASES
NOTIFIED
5
3
4
4
1 030
1 182
1 176
1 146
158
211
213
232
34 817
38 385
38 770
39 994
844 721
932 120
922 720
869 092
5 441
5 168
4 839
4 619
341
338
291
347
1
2
2
0
132
102
142
179
60
48
48
37
62
89
101
99
26 327
22 924
22 419
21 499
329
325
274
280
3 560
3 892
3 694
3 836
15 010
16 452
16 921
18 018
107
120
135
188
91
161
146
157
4 385
4 223
4 218
4 213
11
4
4
3
46
41
54
49
321
286
293
294
0
0
0
0
57
28
38
32
10
19
19
11 108
12 185
11 832
14 289
PREVIOUSLY TREATED CASES
NUMBER OF
% OF NOTIFIED
NUMBER OF
NOTIFIED TESTED TESTED FOR CONFIRMED CASES
FOR MDR-TB
MDR-TB
OF MDR-TB
0
0
868
164
181
11
5
3 271
2 443
2 056
1 897
265
243
201
221
0
0
0
4
46
42
27
39
37
50
56
7 684
1
0
15 010
52
40
68
35
40
48
50
0
75
121
40
0
41
43
20
247
231
237
24
21
17
3
11
–
–
0
0
–
–
–
76
–
–
77
78
–
0
–
0
–
–
–
–
60
47
42
41
78
72
69
64
–
–
0
–
–
–
0
2
–
96
88
73
63
42
50
57
–
–
–
36
0
–
–
0
–
–
–
–
100
–
–
–
49
–
30
36
38
25
33
32
0
2
3
1
–
–
0
–
–
100
80
41
77
81
81
–
–
–
–
–
42
–
55
53
30
–
–
58
–
–
–
–
0
0
21
0
0
3
1
12
229
28
8
15
18
6
5
3
4
0
0
0
0
0
0
0
0
1
0
1
2
41
0
1
2
1
1
0
4
3
1
0
1
3
18
0
0
0
0
1
0
6
NOTIFIED
1
0
0
0
43
43
61
65
5
12
0
5
1 306
1 435
1 429
1 634
140 487
102 079
59 583
54 216
719
561
509
513
31
38
45
60
0
0
0
0
4
2
12
3
2
5
4
2
1
1
2
1 992
1 836
1 751
1 762
10
17
4
14
180
179
184
185
983
1 054
1 181
1 319
5
7
2
10
21
5
9
13
341
544
569
588
3
0
0
7
4
9
8
19
11
9
11
NUMBER OF NOTIFIED
TESTED FOR MDR-TB
% OF NOTIFIED
NUMBER OF
TESTED FOR CONFIRMED CASES
MDR-TB
OF MDR-TB
0
0
48
13
5
91
93
163
310
234
211
19
25
27
39
0
0
2
4
3
2
4
4
0
0
1
2
694
0
1 056
3
1
3
21
3
2
3
16
334
508
561
0
4
1
0
14
6
8
0
2
0
0
0
0
0
0
0
2
0
0
0
0
0
1 456
1 799
1 388
1 824
1
0
0
0
0
–
–
–
–
–
–
–
74
–
–
–
100
–
6
–
6
–
–
–
–
23
55
46
41
61
66
60
65
–
–
–
–
–
–
100
33
100
100
80
100
0
0
100
100
–
–
–
39
–
–
–
0
–
–
–
–
107
–
–
–
60
–
50
30
100
60
22
23
5
61
89
95
–
–
–
–
–
100
11
0
74
55
89
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
0
0
11
0
0
28
30
367
1 669
13
10
6
10
3
2
0
2
0
0
0
0
0
0
0
0
0
0
0
0
27
0
0
0
0
1
0
0
0
0
114
165
169
0
0
0
0
3
0
1
0
0
0
0
0
0
TOTAL CONFIRMED CASES OF MDR-TB includes cases with unknown previous treatment history (i.e. not included under NEW CASES or PREVIOUSLY TREATED CASES).
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 242
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($7HVWLQJIRU0'57%DQGQXPEHURIFRQILUPHGFDVHVRI0'57%±
YEAR
Philippines
Republic of Korea
Samoa
Singapore
Solomon Islands
Tokelau
Tonga
Tuvalu
Vanuatu
Viet Nam
274
929
1 073
522
450
0
3
4
3
3
0
0
0
0
0
0
0
0
217
101
NEW CASES
NOTIFIED
133 143
137 026
143 592
163 248
35 269
34 153
35 842
39 051
24
12
16
14
1 296
1 437
1 442
1 478
392
373
364
336
0
0
0
0
18
13
8
11
12
17
18
14
73
103
133
115
88 591
91 150
88 236
88 033
7
PREVIOUSLY TREATED CASES
NUMBER OF
% OF NOTIFIED
NUMBER OF
NOTIFIED TESTED TESTED FOR CONFIRMED CASES
FOR MDR-TB
MDR-TB
OF MDR-TB
4
74
1 242
3
0
895
919
915
923
5
1
0
0
0
0
0
9
0
0
1
0
–
–
–
–
–
–
–
0
69
64
63
62
–
–
1
0
–
–
–
–
–
–
–
0
–
–
0
0
–
–
0
–
–
–
–
–
–
–
–
–
4
14
1 050
2
103
0
2
1
3
2
0
0
0
0
0
0
0
NOTIFIED
3 957
8 866
9 575
11 141
7 098
6 310
6 880
6 876
0
0
0
0
153
151
132
130
5
14
2
5
0
0
0
0
0
0
0
3
2
0
0
8
1
3
1
7 301
7 534
8 131
8 408
NUMBER OF NOTIFIED
TESTED FOR MDR-TB
% OF NOTIFIED
NUMBER OF
TESTED FOR CONFIRMED CASES
MDR-TB
OF MDR-TB
138
1 305
36
297
0
105
103
85
79
15
1
0
0
0
0
0
0
3
15
0
3
–
–
–
–
–
–
–
–
69
68
64
61
–
–
750
20
–
–
–
–
–
–
–
–
–
–
–
–
–
–
0
–
–
–
–
–
–
–
–
–
119
729
23
232
347
0
1
3
0
1
0
0
0
0
0
0
0
Western Pacific Region
Wallis and Futuna
Islands
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
2005
2008
2009
2010
TOTAL
CONFIRMED
CASES OF
MDR-TBa
a
TOTAL CONFIRMED CASES OF MDR-TB includes cases with unknown previous treatment history (i.e. not included under NEW CASES or PREVIOUSLY TREATED CASES).
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 243
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
243
05/10/11 09:03
7$%/($1HZVPHDUSRVLWLYHFDVHQRWLILFDWLRQE\DJHDQGVH[±
MALE
YEAR
American Samoa
Australia
Brunei
Darussalam
Cambodia
China
China, Hong Kong
SAR
China, Macao
SAR
Cook Islands
Fiji
French Polynesia
Guam
Japan
Kiribati
Lao People's
Democratic
Republic
Malaysia
Marshall Islands
Micronesia
(Federated
States of)
Mongolia
Nauru
New Caledonia
New Zealand
Niue
Northern Mariana
Islands
Palau
Papua New
Guinea
Philippines
244
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
0–14
15–24
25–34
35–44
FEMALE
45–54
55–64
1
1
65+
0
0
0
0
0
0
0
3
0
2
16
32
42
35
27
33
25
23
22
24
11
25
19
12
9
49
30
27
0
0
0
161
26
49
39
1 102
1 131
1 416
759
6
9
17
453
519
894
750
12 791
19 111
43 005
42 851
4
19
15
1 244
1 323
1 600
1 564
18 306
29 399
49 558
38 880
15
19
13
1 147
1 618
2 349
1 760
15 487
25 206
55 400
50 246
5
12
18
1 253
1 456
2 043
2 105
13 105
25 593
54 872
52 925
7
9
7
1 257
1 373
1 964
1 531
13 489
21 429
53 822
56 754
15
0
18
707
1 058
1 811
1 599
10 130
21 771
69 779
64 514
4
3
2
0
0
3
0
0
0
0
0
0
0
7
1
78
76
52
7
10
6
17
0
0
1
0
8
8
9
7
102
84
84
19
8
9
5
0
0
0
0
10
6
18
15
160
108
99
20
25
21
7
0
0
0
0
9
13
18
11
211
200
184
13
22
23
22
0
0
0
0
4
5
14
6
236
168
166
12
9
17
20
1
0
0
0
2
4
16
2
578
453
413
16
17
22
11
0
0
0
0
3
2
6
4
1
0
0
3
2
3
3
2
1
4
2
0
4
0
1
4
4
1
3
2
1
2
0
0
15
2
9
1
1
2
2
342
246
197
128
6
4
3
627
572
488
252
6
4
5
995
676
605
382
9
2
5
1 847
1 494
868
469
6
2
7
2 059
1 509
1 418
911
9
4
3
4 089
3 816
3 867
3 326
2
3
3
6
7
13
8
59
32
244
129
9
15
27
56
92
136
157
640
694
1 179
884
3
15
13
71
128
223
254
879
1 138
2 218
1 438
3
12
10
68
166
296
287
775
1 177
2 277
1 599
3
17
9
78
201
373
416
788
908
1 980
1 453
8
4
6
90
177
300
385
374
814
1 427
967
2
1
2
55
176
352
380
1 072
891
1 507
981
3
2
0
0
0
5
4
10
1
2
4
4
1
0
0
1
5
4
3
1
3
6
6
1
0
5
1
6
0
0
3
1
2
0
1
3
37
6
7
3
8
99
181
271
285
1
111
260
253
255
2
68
171
232
231
4
19
68
147
154
4
13
38
52
50
0
15
23
36
40
0–14
15–24
25–34
35–44
45–54
0
2
2
0
1
5
8
6
6
0
2
3
3
4
7
10
5
5
0
3
4
0
3
7
7
10
11
55–64
65+
UNKNOWN
0
0
0
1
0
0
1
2
0
0
0
0
0
0
2
4
15
18
36
19
26
43
12
11
12
15
10
2
5
6
5
14
14
12
0
0
0
2
123
38
45
60
1 169
1 420
1 864
926
4
9
7
388
457
790
752
10 890
14 536
31 180
27 064
6
11
15
1 133
1 157
1 413
1 321
13 250
18 496
27 759
21 022
9
8
12
1 435
1 649
2 089
1 303
8 376
12 377
24 728
20 422
6
3
8
1 426
1 798
2 323
1 732
5 679
9 899
19 889
16 075
3
2
4
1 180
1 459
2 058
1 607
4 579
7 102
18 203
17 441
4
0
10
578
892
1 573
1 331
2 841
6 296
21 244
20 020
0
5
3
3
0
0
0
0
0
0
0
0
1
0
7
1
65
67
49
9
10
5
7
0
0
0
0
10
7
7
11
115
81
101
18
4
9
6
0
0
0
0
9
5
9
12
86
92
76
12
6
7
10
0
0
0
0
2
7
6
5
44
57
64
4
6
8
5
1
0
0
0
3
1
4
1
45
34
49
5
3
1
7
0
0
0
0
4
4
6
8
211
135
133
6
13
5
6
0
0
0
0
3
0
5
5
0
1
0
0
4
2
1
1
3
1
0
0
0
1
1
3
0
1
0
0
3
1
0
0
1
14
5
5
6
3
3
0
258
222
187
89
1
1
4
476
464
428
232
2
1
3
298
213
249
194
5
2
3
476
292
224
155
2
0
0
637
384
309
183
2
2
3
2 234
1 958
2 077
1 909
2
5
5
3
10
7
13
58
41
208
152
5
22
15
49
59
101
133
446
464
1 044
704
6
12
7
49
95
186
152
448
564
1 061
881
3
7
4
69
131
205
215
345
424
947
592
4
7
8
54
122
244
269
316
367
816
542
1
3
5
52
91
192
225
149
356
586
425
3
1
4
26
71
178
225
339
286
572
388
7
1
5
0
4
7
9
9
0
3
3
2
2
1
1
0
4
2
0
1
2
3
4
0
0
2
4
8
0
1
0
2
0
1
1
5
30
32
15
12
8
70
200
320
296
9
78
213
270
246
3
33
113
145
112
4
15
41
63
83
2
9
26
32
42
0
25
17
25
28
1
1
0
3
3
2
0
2
0
6
5
0
0
2
0
1
2
4
1
3
0
0
0
0
0
0
0
0
0
0
0
1
0
3
1
0
0
0
0
4
0
0
2
1
2
1
4
6
6
6
0
3
3
1
2
3
5
10
13
0
4
4
0
3
3
6
6
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
0
0
0
1
4
0
2
2
3
8
1
0
3
5
9
3
0
0
10
9
4
3
2
3
3
1
3
1
3
2
2
0
0
0
0
0
0
0
0
10
0
2
0
2
17
0
0
0
6
7
1
1
0
4
3
1
3
1
1
1
1
2
0
1
1
1
1
0
0
1
2
2
1
1
1
1
1
8
28
37
2
87
183
279
43
70
205
260
56
30
108
196
61
21
94
135
46
12
48
87
47
5
12
27
26
482
511
7 358
9 320
11 275
12 224
13 253
13 716
12 531
13 651
7 646
8 923
4 279
4 742
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 244
UNKNOWN
0
0
0
0
0
0
0
2
1
0
0
1
1
1
2
0
1
8
1
1
2
6
11
12
0
1
1
2
0
3
6
9
7
1
3
1
1
1
4
5
6
6
0
1
4
4
3
4
10
2
6
1
0
1
1
0
0
0
6
38
64
1
77
200
313
20
45
204
292
32
21
124
191
26
15
65
97
20
5
35
52
19
1
2
9
11
374
454
3 710
4 825
5 268
5 489
5 565
5 301
4 603
4 643
3 274
3 329
2 029
2 070
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
MALE/FEMALE
RATIO
–
2.0
0.0
–
–
2.1
1.6
1.4
–
1.6
2.1
1.5
1.0
1.0
1.0
1.2
1.8
2.0
2.3
2.5
–
2.4
2.3
2.1
1.6
2.2
2.9
2.0
1.0
–
–
–
1.1
1.6
2.0
1.1
–
3.1
1.2
1.2
–
2.6
2.0
1.8
2.3
2.4
2.1
2.0
–
1.3
1.2
1.5
1.4
1.6
1.5
1.5
2.2
2.3
2.1
2.0
–
1.1
0.9
1.0
2.5
0.4
–
0.7
1.4
1.2
1.1
1.2
–
0.5
–
0.0
1.7
0.9
0.6
2.3
1.6
1.3
1.3
1.1
–
–
–
–
1.9
0.9
2.8
0.9
8.0
–
–
2.3
–
1.4
1.0
1.0
2.2
–
2.3
2.4
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
7$%/($1HZVPHDUSRVLWLYHFDVHQRWLILFDWLRQE\DJHDQGVH[±
MALE
Republic of Korea
Samoa
Singapore
Solomon Islands
Tokelau
Tonga
Tuvalu
Vanuatu
Viet Nam
0–14
15–24
25–34
35–44
45–54
55–64
65+
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
1995
2000
2005
2010
27
19
22
22
0
0
0
1 131
821
687
537
1
3
4
1
9
8
8
11
14
13
14
16
1 613
1 085
1 171
705
1
1
0
1
40
9
25
21
6
4
18
18
1 425
988
1 326
1 049
1
1
1
1 207
853
1 336
1 496
0
1
1
1 225
901
1 669
1 997
2
1
0
60
34
61
38
5
8
9
16
62
51
94
105
7
8
15
8
1 307
731
1 005
1 029
3
2
0
1
70
26
96
86
9
10
12
3
0
0
1
1
0
1
0
0
1
0
1
0
0
0
0
0
1
0
1
2
2
0
0
2
0
0
0
1
1
1
1
1
0
2
5
0
3
0
0
0
2
1
4
1
6
7
4
6
0
2
5
5
3
0
5
1
5
1
1
1
3
10
0
5
1
2
4
5
4
2
0
0
2
1
0
51
54
59
2 367
3 408
3 205
6 147
7 105
7 036
8 209
8 738
7 851
6 713
8 606
8 564
5 150
4 958
5 790
7 712
7 573
6 248
0
1
0
0
2
3
4
4
0
0
UNKNOWN
0–14
15–24
25–34
35–44
45–54
55–64
65+
0
46
25
27
23
1
0
0
908
546
590
472
2
2
2
863
544
842
686
2
1
0
296
220
370
487
0
0
0
8
9
5
15
17
15
23
19
18
8
20
21
11
13
21
17
408
295
373
368
1
0
1
1
19
5
20
21
13
5
9
4
867
795
1 729
2 216
1
0
0
1
1
0
1
3
8
9
4
431
393
491
509
0
1
2
2
21
7
33
26
7
7
12
11
0
0
0
1
1
1
0
1
0
1
1
0
0
0
0
0
0
0
0
0
0
1
2
0
1
0
1
0
0
2
1
2
0
1
0
1
1
0
0
0
0
0
0
5
0
3
1
0
5
3
5
5
1
0
15
1
3
0
2
7
2
3
0
3
3
4
5
2
0
0
3
1
3
0
0
1
2
1
0
0
64
47
53
1 334
1 747
1 870
2 320
2 293
2 454
2 754
2 116
1 681
2 594
2 298
1 864
2 847
2 023
1 863
4 907
4 604
3 751
0
3
94
64
118
120
3
6
11
3
0
0
0
0
22
9
29
21
12
7
11
5
UNKNOWN
0
3
31
16
43
44
0
2
1
5
0
0
0
0
MALE/FEMALE
RATIO
2.1
1.9
1.6
1.4
1.1
2.3
1.2
1.0
2.8
3.5
2.7
2.6
0.7
0.9
1.0
1.0
–
–
–
–
0.8
2.0
1.2
5.0
1.0
–
0.7
4.0
2.0
0.9
1.3
0.9
–
2.2
2.7
2.9
–
–
–
–
Western Pacific Region
Wallis and Futuna
Islands
FEMALE
YEAR
Data can be downloaded from www.who.int/tb/data
1109_0319_P_111_246 245
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
245
05/10/11 09:03
246
WHO REPORT 2011 | GLOBAL TUBERCULOSIS CONTROL
1109_0319_P_111_246 246
Data can be downloaded from www.who.int/tb/data
05/10/11 09:03
0
1.8
40
82
244
0.4
52
0
0
0
0
0
1.3
1.3
0.8
1.6
4.9
2.1
1.0
1.1
1.7
1.0
10.2
4.6
0.9
5.6
93
2.5
5.6
3.6
0
2.4
2.0
5.8
37
111
0.5
1.1
2.2
2.5
13
1.1
3.3
14
9.2
0.3
1.5
0.2
0.4
1.5
0
0
0
0.1
0
0.1
0.7
82
244
40
1.8
0
0.5
93
0
0
0
37
111
13
0.4
0.7
2.1
9.2
DST LABS
PER 5M
POPULATION
LABORATORIES
CULTURE LABS
PER 5M
POPULATION
In country
Out of country
Out of country
Out of country
Out of country
Out of country
In country
In country
In country
In country
Out of country
No
In country
Out of country
Out of country
Out of country
No
In country
Out of country
Out of country
In country
In country
No
Out of country
In country
In country
In country
Out of country
Out of country
No
Out of country
In country
Out of country
SECOND-LINE
DST
AVAILABLE
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No
Yes
Yes
Yes
No
Yes
No
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
No
NRLa
Yes, all suspects
Yes, all suspects
If TB is confirmed
No
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
If TB is confirmed
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
Yes, all suspects
If TB is confirmed
Yes, all suspects
Yes, all suspects
Yes (other criteria)
For certain income groups
Yes, all suspects
TB DIAGNOSIS
Yes
Yes
Yes
No
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
FIRST-LINE DRUGS
FREE THROUGH NTP
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
RIFAMPICIN USED
THROUGHOUT
TREATMENT
100
0
100
0
100
100
100
0
100
100
100
100
0
100
50
15
98
99
0
0
0
100
15
5
0
0
0
100
0
0
100
% OF PATIENTS
TREATED WITH FDCb
DRUG MANAGEMENT
a NRL = national reference laboratory
b FDC = fixed-dose combination
c NURSES (Registered Nurses, Registered Midwives, Enrolled Nurses, Enrolled Midwives); HEALTH ASSISTANTS (Medical Assistants, Clinical Officers); LABORATORY TECHNICIANS (Microscopists)
American Samoa
Australia
Brunei Darussalam
Cambodia
China
China, Hong Kong SAR
China, Macao SAR
Cook Islands
Fiji
French Polynesia
Guam
Japan
Kiribati
Lao People's Democratic
Republic
Malaysia
Marshall Islands
Micronesia (Federated States
of)
Mongolia
Nauru
New Caledonia
New Zealand
Niue
Northern Mariana Islands
Palau
Papua New Guinea
Philippines
Republic of Korea
Samoa
Singapore
Solomon Islands
Tokelau
Tonga
Tuvalu
Vanuatu
Viet Nam
Wallis and Futuna Islands
SMEAR LABS
PER 100K
POPULATION
7$%/($/DERUDWRULHV173VHUYLFHVGUXJPDQDJHPHQWKXPDQUHVRXUFHVDQGLQIHFWLRQFRQWURO
Yes
No
Yes
No
No
No
Yes
Yes
No
No
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
No
Yes
No
No
Yes
No
Yes
No
Yes
Yes
No
No
Yes
No
Yes
Yes
PAEDIATRIC
FORMULATIONS
PROCURED
60
100
100
0
80
100
100
75
5
8
0
30
0
100
75
60
70
100
20
50
100
80
50
90
5
5
0
20
30
100
85
2
50
4
100
100
60
NURSES
100
100
100
50
MEDICAL
OFFICERS
40
50
100
0
50
100
50
90
10
0
0
45
4
100
90
0
0
100
100
50
HEALTH
ASSISTANTS
60
100
100
0
50
100
20
90
0
22
0
5
50
100
100
100
4
100
100
60
LABORATORY
TECHNICIANS
% OF STAFF TRAINED BY THE NTP (IN 2010)c
0
0
111
192
0
200
233
0
1049
0
98
0
0
92
0
15
79
TB NOTIFICATION
RATE PER 100 000
HEALTH-CARE
WORKERS
1109_0319_P_001_248 247
23/09/11 07:20
1109_0319_P_001_248 248
23/09/11 07:20
The World Health Organization monitors
the global tuberculosis epidemic in support
of national TB control programmes.
For further information about tuberculosis contact:
Information Resource Centre HTM/STB
World Health Organization
20 Avenue Appia, 1211–Geneva–27, Switzerland
Email: [email protected]
Web site: www.who.int/tb
ISBN 978 92 4 156438 0